,CID,name,smiles,7.1-Drug Indication,8.1-Pharmacodynamics,8.2-MeSH Pharmacological Classification,"8.5-Absorption, Distribution and Excretion",8.6-Metabolism/Metabolites,8.7-Biological Half-Life
0,20001,Trimethyl-[2-[2-(2-oxopyrrolidin-1-yl)ethoxy]ethyl]azanium,C[N+](C)(C)CCOCCN1CCCC1=O,,,,,,
1,20002,2-Pentynyltrimethylammonium iodide,CCC#CC[N+](C)(C)C.[I-],,,,,,
2,20003,Trimethyl(pent-2-ynyl)azanium,CCC#CC[N+](C)(C)C,,,,,,
3,20004,(2-(2-Oxo-1-pyrrolidinylmethoxy)ethyl)trimethylammonium iodide,C[N+](C)(C)CCOCN1CCCC1=O.[I-],,,,,,
4,20005,Trimethyl-[2-[(2-oxopyrrolidin-1-yl)methoxy]ethyl]azanium,C[N+](C)(C)CCOCN1CCCC1=O,,,,,,
5,20006,Dimethylamphetamine,CC(CC1=CC=CC=C1)N(C)C,,,"['A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)']",,,
6,20007,CID 20007,C(C(CS(=O)(=O)[O-])S)S.[Na+],,,,,,
7,20008,4-Methylbenzo[c]phenanthrene,CC1=C2C=CC3=C(C2=CC=C1)C4=CC=CC=C4C=C3,,,,,,
8,20009,"1-Aziridinepropionic acid, ethyl ester",CCOC(=O)CCN1CC1,,,,,,
9,20010,"2-Propyn-1-amine, N,N-diethyl-",CCN(CC)CC#C,,,,,,
10,20011,Quaternium 15,C1N2CN3CN1C[N+](C2)(C3)CC=CCl.[Cl-],['Quaternium-15 is approved for use within allergenic epicutaneous patch tests which are indicated for use as an aid in the diagnosis of allergic contact dermatitis (ACD) in persons 6 years of age and older.'],,,,,
11,20012,"1-(3-Chloroallyl)-3,5,7-triaza-1-azoniaadamantane",C1N2CN3CN1C[N+](C2)(C3)CC=CCl,,,,,,
12,20013,Dodecanedihydrazide,C(CCCCCC(=O)NN)CCCCC(=O)NN,,,,,,
13,20014,"o-CRESOL, alpha,alpha'-(HEXAMETHYLENEDINITRILO)DI-",C1=CC=C(C(=C1)CN=CCCCCC=NCC2=CC=CC=C2O)O,,,,,,
14,20015,"Hexahydro-alpha,alpha-diphenyl-beta-methyl-1H-azepine-1-propanol",CC(CN1CCCCCC1)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
15,20016,"3,4-Dihydro-alpha,alpha-diphenyl-gamma-methyl-2(1H)-isoquinolinepropanol",CC(CC(C1=CC=CC=C1)(C2=CC=CC=C2)O)N3CCC4=CC=CC=C4C3,,,,,,
16,20017,Methyl nonacosanoate,CCCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)OC,,,,,,
17,20018,"1,3-Diethylthiomethylimidazolidine dihydrochloride",CCSC[NH+]1CC[NH+](C1)CSCC.[Cl-].[Cl-],,,,,,
18,20019,"1,3-Bis[(ethylthio)methyl]imidazolidine",CCSCN1CCN(C1)CSCC,,,,,,
19,20020,"2H-1,4-Benzodiazepin-2-one, 1,3,4,5-tetrahydro-7-chloro-1-(3-(dimethylamino)propyl)-5-(o-fluorophenyl)-, dihydrochloride",C[NH+](C)CCCN1C(=O)C[NH2+]C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F.[Cl-].[Cl-],,,,,,
20,20021,"7-chloro-1-[3-(dimethylamino)propyl]-5-(2-fluorophenyl)-4,5-dihydro-3H-1,4-benzodiazepin-2-one",CN(C)CCCN1C(=O)CNC(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F,,,,,,
21,20022,"2H-1,4-Benzodiazepin-2-one, 1,3,4,5-tetrahydro-7-chloro-1-(3-(diethylamino)propyl)-5-(o-fluorophenyl)-, dihydrochloride",CC[NH+](CC)CCCN1C(=O)C[NH2+]C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F.[Cl-].[Cl-],,,,,,
22,20023,"7-chloro-1-[3-(diethylamino)propyl]-5-(2-fluorophenyl)-4,5-dihydro-3H-1,4-benzodiazepin-2-one",CCN(CC)CCCN1C(=O)CNC(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F,,,,,,
23,20024,2-Buten-1-ol,CC=CCO,,,,,,
24,20025,N-Vinylacetanilide,CC(=O)N(C=C)C1=CC=CC=C1,,,,,,
25,20026,3-Chloro-2-butanone,CC(C(=O)C)Cl,,,,,,
26,20027,"Carbonic acid, dithio-, anhydrosulfide, O,O-dibutyl ester",CCCCOC(=S)SC(=S)OCCCC,,,,,,
27,20028,N-Benzoyl-3-(p-(bis(2-fluoroethyl)amino)phenyl)alanine,C1=CC=C(C=C1)C(=O)NC(CC2=CC=C(C=C2)N(CCF)CCF)C(=O)O,,,,,,
28,20029,"BUTYRIC ACID, 4-(p-((2-CHLOROETHYL)(2-FLUOROETHYL)AMINO)PHENYL)-",C1=CC(=CC=C1CCCC(=O)O)N(CCF)CCCl,,,,,,
29,20030,"BUTYRIC ACID, 4-(p-(BIS(2-FLUOROETHYL)AMINO)PHENYL)-",C1=CC(=CC=C1CCCC(=O)O)N(CCF)CCF,,,,,,
30,20031,4-(p-((2-Fluoroethyl)amino)phenyl)butyric acid methyl ester hydrochloride,COC(=O)CCCC1=CC=C(C=C1)[NH2+]CCF.[Cl-],,,,,,
31,20032,Methyl 4-[4-(2-fluoroethylamino)phenyl]butanoate,COC(=O)CCCC1=CC=C(C=C1)NCCF,,,,,,
32,20033,3-[4-[2-Chloroethyl(2-fluoroethyl)amino]phenyl]prop-2-enoic acid,C1=CC(=CC=C1C=CC(=O)O)N(CCF)CCCl,,,,,,
33,20034,"HYDROCINNAMIC ACID, p-(BIS(2-FLUOROETHYL)AMINO)-",C1=CC(=CC=C1CCC(=O)O)N(CCF)CCF,,,,,,
34,20035,3-[4-[Bis(2-fluoroethyl)amino]phenyl]prop-2-enoic acid,C1=CC(=CC=C1C=CC(=O)O)N(CCF)CCF,,,,,,
35,20036,"1-Methylethyl 1,2,2-trichloroethyl disulfide",CC(C)SSC(C(Cl)Cl)Cl,,,,,,
36,20037,Phenarsazine oxide,C1=CC=C2C(=C1)NC3=CC=CC=C3[As]2O[As]4C5=CC=CC=C5NC6=CC=CC=C64,,,,,,
37,20038,1-Phenylpiperidine,C1CCN(CC1)C2=CC=CC=C2,,,,,,
38,20039,"2',3'-Dideoxyadenosine",C1C[C@@H](O[C@@H]1CO)N2C=NC3=C(N=CN=C32)N,,,"['Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)', 'Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Antimetabolites.)']",,,
39,20040,"2,6-Dinitro-4-octylphenol",CCCCCCCCC1=CC(=C(C(=C1)[N+](=O)[O-])O)[N+](=O)[O-],,,,,,
40,20041,Dinosam,CCCC(C)C1=C(C(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])O,,,,,,
41,20042,"4-tert-Butyl-2,6-dinitrophenol",CC(C)(C)C1=CC(=C(C(=C1)[N+](=O)[O-])O)[N+](=O)[O-],,,,,,
42,20043,"4-Hydroxy-3,5-dinitrobiphenyl",C1=CC=C(C=C1)C2=CC(=C(C(=C2)[N+](=O)[O-])O)[N+](=O)[O-],,,,,,
43,20044,"4-Cyclohexyl-2,6-dinitrophenol",C1CCC(CC1)C2=CC(=C(C(=C2)[N+](=O)[O-])O)[N+](=O)[O-],,,,,,
44,20045,"2-Isocyanato-1-(isocyanatomethyl)-1,5,5-trimethylcyclohexane",CC1(CCC(C(C1)(C)CN=C=O)N=C=O)C,,,,,,
45,20046,"Cyclopentanol, 1,2-dimethyl-3-(1-methylethenyl)-",CC1C(CCC1(C)O)C(=C)C,,,,,,
46,20047,Desacetylcinobufotalin,C[C@]12CCC3C([C@@]14[C@H](O4)[C@@H]([C@@H]2C5=COC(=O)C=C5)O)CC[C@]6([C@@]3(CC[C@@H](C6)O)C)O,,,,,,
47,20048,2-(Aminoethyl)cysteine monohydrochloride,C(CSC[C@@H](C(=O)O)N)[NH3+].[Cl-],,,,,,
48,20049,S-(2-aminoethyl)cysteine,C(CSCC(C(=O)O)N)N,,,"['Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)']",,,
49,20050,"2-Hexyl-4,6-dinitrophenol",CCCCCCC1=C(C(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])O,,,,,,
50,20051,Methylsuccinic anhydride,CC1CC(=O)OC1=O,,,,,,
51,20052,"1,2-Dibromodecane",CCCCCCCCC(CBr)Br,,,,,,
52,20053,1-(4-Hydroxycyclohexyl)-5-octylbarbituric acid,CCCCCCCCC1C(=O)NC(=O)N(C1=O)C2CCC(CC2)O,,,,,,
53,20054,5-Cyclohexyl-1-(4-hydroxycyclohexyl)barbituric acid,C1CCC(CC1)C2C(=O)NC(=O)N(C2=O)C3CCC(CC3)O,,,,,,
54,20055,2-(3-amino-5-chlorophenyl)-N-methylacetamide,CNC(=O)CC1=CC(=CC(=C1)Cl)N,,,,,,
55,20056,Phosacetim,CC(=NP(=S)(OC1=CC=C(C=C1)Cl)OC2=CC=C(C=C2)Cl)N,,,,"['Organophosphorus pesticides are rapidly absorbed into the body through the mucous membrane of the digestive tract, the respiratory system, & the skin, and are conveyed by the blood to various body tissues. /Organophosphorus pesticides/']",,
56,20057,"Cyclohexene, 3-(2-methylpropyl)-",CC(C)CC1CCCC=C1,,,,,,
57,20058,Uridine triacetate,CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=O)NC2=O)OC(=O)C)OC(=O)C,"['Marketed as the product Xuriden (FDA), uridine triacetate is indicated for the treatment of hereditary orotic aciduria.  Marketed as the product Vistogard (FDA), uridine triacetate is indicated for the emergency treatment of adult and pediatric patients in the following situations: following a fluorouracil or capecitabine overdose regardless of the presence of symptoms; or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration.']",,,"['Maximum concentrations of uridine in plasma following oral administration are generally achieved within 2 to 3 hours.', 'Uridine can be excreted via the kidneys, but is also metabolized by normal pyrimidine catabolic pathways present in most tissues.', 'Circulating uridine is taken up into mammalian cells via specific nucleoside transporters, and also crosses the blood brain barrier.']","['Following oral administration, uridine triacetate is deacetylated by nonspecific esterases present throughout the body, yielding uridine in the circulation.']",['2 to 2.5 hours']
58,20059,"N,N'-Bis(alpha-methylphenethyl)ethylenediamine dihydrochloride",CC(CC1=CC=CC=C1)[NH2+]CC[NH2+]C(C)CC2=CC=CC=C2.[Cl-].[Cl-],,,,,,
59,20060,"N,N'-bis(1-phenylpropan-2-yl)ethane-1,2-diamine",CC(CC1=CC=CC=C1)NCCNC(C)CC2=CC=CC=C2,,,,,,
60,20061,3-Aminodibenzofuran,C1=CC=C2C(=C1)C3=C(O2)C=C(C=C3)N,,,,,,
61,20062,"3,5-Dinitrobenzonitrile",C1=C(C=C(C=C1[N+](=O)[O-])[N+](=O)[O-])C#N,,,,,,
62,20063,Ethyl propyl sulfide,CCCSCC,,,,,,
63,20064,Ethyl carbazate,CCOC(=O)NN,,,,,,
64,20065,2-Chloro-N-methyl-3-oxobutanamide,CC(=O)C(C(=O)NC)Cl,,,,,,
65,20066,"2,8-Decadiyne",CC#CCCCCC#CC,,,,,,
66,20067,"[(8S)-11-amino-5-benzoyl-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate",CC1=C(C(=O)C2=C(C1=O)N3CC4C(C3([C@@H]2COC(=O)N)OC)N4C(=O)C5=CC=CC=C5)N,,,,,,
67,20068,"[(7R,8S)-11-(ethylamino)-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate",CCNC1=C(C(=O)C2=C(C1=O)[C@H]([C@@]3(N2CC4C3N4)OC)COC(=O)N)C,,,,,,
68,20069,"[(7R,8S)-7-methoxy-12-methyl-11-(methylamino)-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate",CC1=C(C(=O)C2=C(C1=O)N3CC4C([C@@]3([C@@H]2COC(=O)N)OC)N4)NC,,,,,,
69,20070,"[6-(Aziridin-1-yl)-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl hydrogen carbonimidate",CC1=C(C(=O)C2=C(C1=O)N3CC4C([C@@]3([C@@H]2COC(=O)N)OC)N4)N5CC5,,,,,,
70,20071,Isopropyl mandelate,CC(C)OC(=O)C(C1=CC=CC=C1)O,,,,,,
71,20072,2-Acetamidophenanthrene,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C=C2,,,,,,
72,20073,N-3-Phenanthrenylacetamide,CC(=O)NC1=CC2=C(C=CC3=CC=CC=C32)C=C1,,,,,,
73,20074,Benzyl butyl adipate,CCCCOC(=O)CCCCC(=O)OCC1=CC=CC=C1,,,,,,
74,20075,Dinonyl sebacate,CCCCCCCCCOC(=O)CCCCCCCCC(=O)OCCCCCCCCC,,,,,,
75,20076,1-(2-(2-Methylindol-2-yl)ethyl)-4-phenylpiperazine,CC1=C(C2=CC=CC=C2N1)CCN3CCN(CC3)C4=CC=CC=C4,,,,,,
76,20077,"1,3,5-Triazin-2-amine",C1=NC=NC(=N1)N,,,,,,
77,20078,"N-ethyl-1,3,5-triazin-2-amine",CCNC1=NC=NC=N1,,,,,,
78,20079,Trichloroacetic anhydride,C(=O)(C(Cl)(Cl)Cl)OC(=O)C(Cl)(Cl)Cl,,,,,,
79,20080,CID 20080,C(COC(=O)C=CC(=O)OCC[NH3+])[NH3+].[Cl-].[Cl-],,,,,,
80,20081,CID 20081,C(COC(=O)C=CC(=O)OCCN)N,,,,,,
81,20082,Methylcycloheptane,CC1CCCCCC1,,,,,,
82,20083,2-Octanol,CCCCCCC(C)O,,,,,,
83,20084,"1,3-Diisopropylurea",CC(C)NC(=O)NC(C)C,,,,,,
84,20085,p-Acetamidoazobenzene,CC(=O)NC1=CC=C(C=C1)N=NC2=CC=CC=C2,,,,,,
85,20086,"1-Aziridinepropionic acid, ethylene ester",C1CN1CCC(=O)OCCOC(=O)CCN2CC2,,,,,,
86,20087,"2,6-Di-tert-butyl-4-ethylphenol",CCC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C,,,,,,
87,20088,Stearic acid hydrazide,CCCCCCCCCCCCCCCCCC(=O)NN,,,,,,
88,20089,CID 20089,C1CN(CCN1)CCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O,,,,,,
89,20090,"7-chloro-5-phenyl-1-(2-piperazin-1-ylethyl)-3H-1,4-benzodiazepin-2-one",C1CN(CCN1)CCN2C(=O)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4,,,,,,
90,20091,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-1-(3-(dimethylamino)propyl)-5-(o-fluorophenyl)-, dihydrochloride",CN(C)CCCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F.Cl.Cl,,,,,,
91,20092,"7-Chloro-1-(3-dimethylaminopropyl)-5-(2-fluorophenyl)-1H-1,4-benzodiazepin-2(3H)-one",CN(C)CCCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F,,,,,,
92,20093,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-1-(3-(diethylamino)propyl)-5-(o-fluorophenyl)-, dihydrochloride",CCN(CC)CCCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F.Cl.Cl,,,,,,
93,20094,"7-chloro-1-[3-(diethylamino)propyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one",CCN(CC)CCCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F,,,,,,
94,20095,"N-(1,1-Dimethylethyl)-4-nitrobenzenamine",CC(C)(C)NC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
95,20096,"6-Benzofuraldehyde, 4,7-dimethoxy-2,3-dimethyl-",CC1=C(OC2=C(C(=CC(=C12)OC)C=O)OC)C,,,,,,
96,20097,"Ethyl 3,5-dihydroxybenzoate hemihydrate",CCOC(=O)C1=CC(=CC(=C1)O)O.CCOC(=O)C1=CC(=CC(=C1)O)O.O,,,,,,
97,20098,"Ethyl 3,5-dihydroxybenzoate",CCOC(=O)C1=CC(=CC(=C1)O)O,,,,,,
98,20099,"(17-but-2-ynyl-17-hydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl) acetate",CC#CCC1(CCC2C1(CCC3C2CCC4=C3C=CC(=C4)OC(=O)C)C)O,,,,,,
99,20100,"Estra-1(10),2,4-triene-1,3,17-triol",CC12CCC3C(C1CC[C@@H]2O)CCC4=C3C(=CC(=C4)O)O,,,,,,
100,20101,"1,4-Dihydroxyestra-1,3,5(10)-trien-17-one diacetate",CC(=O)OC1=CC2=C(C3CCC4(C(C3CC2)CCC4=O)C)C(=C1)OC(=O)C,,,,,,
101,20102,"17-(Methylsulfanyl)estra-1(10),2,4,16-tetraen-3-ol",CC12CCC3C(C1CC=C2SC)CCC4=C3C=CC(=C4)O,,,,,,
102,20103,"17-Hydroxy-3-oxoestra-1,4-dien-10-yl acetate",CC(=O)O[C@]12C=CC(=O)C=C1CCC3C2CCC4(C3CC[C@@H]4O)C,,,,,,
103,20104,"3,17-Dioxoestra-1,4-dien-10-yl acetate",CC(=O)OC12C=CC(=O)C=C1CCC3C2CCC4(C3CCC4=O)C,,,,,,
104,20105,Dipropetryn,CCSC1=NC(=NC(=N1)NC(C)C)NC(C)C,,,,,,
105,20106,"2,4-Bis(trichloromethyl)-6-vinyl-1,3,5-triazine",C=CC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
106,20107,Lykurim,CS(=O)(=O)OCCNCC(C(CNCCOS(=O)(=O)C)O)O,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
107,20108,"s-Triazine, 2,4-bis(ethylamino)-",CCNC1=NC(=NC=N1)NCC,,,,,,
108,20109,"4,6-Bis(4-methylphenoxy)-1,3,5-triazin-2-amine",CC1=CC=C(C=C1)OC2=NC(=NC(=N2)N)OC3=CC=C(C=C3)C,,,,,,
109,20110,"[(7R,8S)-7-methoxy-12-methyl-10,13-dioxo-11-piperidin-1-yl-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate",CC1=C(C(=O)C2=C(C1=O)N3CC4C([C@@]3([C@@H]2COC(=O)N)OC)N4)N5CCCCC5,,,,,,
110,20111,4-Butoxybutan-1-ol,CCCCOCCCCO,,,,,,
111,20112,4-Hydroxypentan-2-one,CC(CC(=O)C)O,,,,,,
112,20113,"4,4'-Isopropylidenebis[2-(2,6-dibromophenoxy)ethanol]",CC(C)(C1=CC(=C(C(=C1)Br)OCCO)Br)C2=CC(=C(C(=C2)Br)OCCO)Br,,,,,,
113,20114,"(1R,9S,10R)-17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol",C1CC[C@@]23CCN([C@H]([C@@H]2C1)CC4=C3C=C(C=C4)O)CC5CC5,,,,,,
114,20115,"Methyl 2,4,5-trichlorophenyl sulfone",CS(=O)(=O)C1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
115,20116,"ANILINE, p-ARSENOSO-N,N-DIETHYL-",CCN(CC)C1=CC=C(C=C1)[As]=O,,,,,,
116,20117,"ANILINE, p-ARSENOSO-N,N-BIS(2-CHLOROETHYL)-",C1=CC(=CC=C1N(CCCl)CCCl)[As]=O,,,,,,
117,20118,2-(Phenethylamino)-1-phenylethanol,C1=CC=C(C=C1)CCNCC(C2=CC=CC=C2)O,,,,,,
118,20119,2-(Isopropylamino)-1-phenylethanol,CC(C)NCC(C1=CC=CC=C1)O,,,,,,
119,20120,Dimethylnitramine,CN(C)[N+](=O)[O-],,,,,,
120,20121,N-Nitrodibutylamine,CCCCN(CCCC)[N+](=O)[O-],,,,,,
121,20122,N-Nitromorpholine,C1COCCN1[N+](=O)[O-],,,,,,
122,20123,"Ethylenediamine, N,N'-dimethyl-N,N'-dinitro-",CN(CCN(C)[N+](=O)[O-])[N+](=O)[O-],,,,,,
123,20124,"1,4-Dinitropiperazine",C1CN(CCN1[N+](=O)[O-])[N+](=O)[O-],,,,,,
124,20125,2-Ethylhexanamide,CCCCC(CC)C(=O)N,,,,,,
125,20126,2-Ethylheptanamide,CCCCCC(CC)C(=O)N,,,,,,
126,20127,(1-Ethyl-1-propenyl)benzene,CCC(=CC)C1=CC=CC=C1,,,,,,
127,20128,"1,4-Dioxaspiro[4.5]decan-2-ylmethanol",C1CCC2(CC1)OCC(O2)CO,,,,,,
128,20129,2-Phenoxypropanol,CC(CO)OC1=CC=CC=C1,,,,,,
129,20130,"Ammonium, dimethyl((o-tolylcarbamoyl)methyl)((2,6-xylylcarbamoyl)methyl)-, chloride",CC1=C(C(=CC=C1)C)NC(=O)C[N+](C)(C)CC(=O)NC2=CC=CC=C2C.[Cl-],,,,,,
130,20131,"[2-(2,6-Dimethylanilino)-2-oxoethyl]-dimethyl-[2-(2-methylanilino)-2-oxoethyl]azanium",CC1=C(C(=CC=C1)C)NC(=O)C[N+](C)(C)CC(=O)NC2=CC=CC=C2C,,,,,,
131,20132,"Dimethyl(1-(2,6-xylylcarbamoyl)ethyl)((2,6-xylylcarbamoyl)methyl)ammonium chloride",CC1=C(C(=CC=C1)C)NC(=O)C[N+](C)(C)C(C)C(=O)NC2=C(C=CC=C2C)C.[Cl-],,,,,,
132,20133,"[2-(2,6-Dimethylanilino)-2-oxoethyl]-[1-(2,6-dimethylanilino)-1-oxopropan-2-yl]-dimethylazanium",CC1=C(C(=CC=C1)C)NC(=O)C[N+](C)(C)C(C)C(=O)NC2=C(C=CC=C2C)C,,,,,,
133,20134,"Dimethyl((2,4-xylylcarbamoyl)methyl)((2,6-xylylcarbamoyl)methyl)ammonium chloride",CC1=CC(=C(C=C1)NC(=O)C[N+](C)(C)CC(=O)NC2=C(C=CC=C2C)C)C.[Cl-],,,,,,
134,20135,"[2-(2,4-Dimethylanilino)-2-oxoethyl]-[2-(2,6-dimethylanilino)-2-oxoethyl]-dimethylazanium",CC1=CC(=C(C=C1)NC(=O)C[N+](C)(C)CC(=O)NC2=C(C=CC=C2C)C)C,,,,,,
135,20136,"(1,1-Diethylpropyl)benzene",CCC(CC)(CC)C1=CC=CC=C1,,,,,,
136,20137,2-Chlorobutyric acid,CCC(C(=O)O)Cl,,,,,,
137,20138,But-2-enal,CC=CC=O,,,,,,
138,20139,"2,4,6-Trimethylbenzyl alcohol",CC1=CC(=C(C(=C1)C)CO)C,,,,,,
139,20140,Valnoctamide,CCC(C)C(CC)C(=O)N,,,,,,
140,20141,3-(Dimethylamino)-2-hydroxypropyl p-(propylamino)benzoate hydrochloride,CCCNC1=CC=C(C=C1)C(=O)OCC(C[NH+](C)C)O.[Cl-],,,,,,
141,20142,Hydroxycaine,CCCNC1=CC=C(C=C1)C(=O)OCC(CN(C)C)O,,,,,,
142,20143,"1,3-Dimethylindan",CC1CC(C2=CC=CC=C12)C,,,,,,
143,20144,2-(4-Phenyl-1-piperazinyl)bicyclo(3.3.1)nonan-9-ol,C1CC2CCC(C(C1)C2O)N3CCN(CC3)C4=CC=CC=C4,,,,,,
144,20145,"BICYCLO(3.3.1)NONAN-9-ONE, 2-(4-PHENYL-1-PIPERAZINYL)-, exo-",C1CC2CCC(C(C1)C2=O)N3CCN(CC3)C4=CC=CC=C4,,,,,,
145,20146,2-(4-Phenyl-1-piperazinyl)bicyclo(3.2.1)octan-8-one,C1CC2C(CCC1C2=O)N3CCN(CC3)C4=CC=CC=C4,,,,,,
146,20147,4-Methyl-2-(4-nitroanilino)pentanamide,CC(C)CC(C(=O)N)NC1=CC=C(C=C1)[N+](=O)[O-],,,,,,
147,20148,"4-(2,3-Dihydroxypropoxy)benzoic acid",C1=CC(=CC=C1C(=O)O)OCC(CO)O,,,,,,
148,20149,Tetracontane,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,,,,,,
149,20150,Diethanolnitramine dinitrate,C(CO[N+](=O)[O-])N(CCO[N+](=O)[O-])[N+](=O)[O-],,,,,,
150,20151,Allyltriethylammonium iodide,CC[N+](CC)(CC)CC=C.[I-],,,,,,
151,20152,Triethyl(prop-2-enyl)azanium,CC[N+](CC)(CC)CC=C,,,,,,
152,20153,1-Ethyl-1-methylpiperidinium iodide,CC[N+]1(CCCCC1)C.[I-],,,,,,
153,20154,"Piperidinium, 1-ethyl-1-methyl-, bromide",CC[N+]1(CCCCC1)C,,,,,,
154,20155,1-Phenyl-2-propyn-1-ol,C#CC(C1=CC=CC=C1)O,,,,,,
155,20156,"Butyric acid, 2-ethyl-, 2,2,2-trichloroethyl ester",CCC(CC)C(=O)OCC(Cl)(Cl)Cl,,,,,,
156,20157,"Isoquinoline, 1,2,3,4-tetrahydro-2-(3,3-diphenylallyl)-",C1CN(CC2=CC=CC=C21)CC=C(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
157,20158,Acetyl cinobufotalin,CC(=O)O[C@H]1CC[C@@]2(C3CC[C@@]4([C@H]([C@H]([C@@H]5[C@@]4(C3CC[C@@]2(C1)O)O5)OC(=O)C)C6=COC(=O)C=C6)C)C,,,,,,
158,20159,"3-[7-chloro-5-(2-fluorophenyl)-2-oxo-4,5-dihydro-3H-1,4-benzodiazepin-4-ium-1-yl]propyl-methylazanium dichloride",C[NH2+]CCCN1C(=O)C[NH2+]C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F.[Cl-].[Cl-],,,,,,
159,20160,"7-chloro-5-(2-fluorophenyl)-1-[3-(methylamino)propyl]-4,5-dihydro-3H-1,4-benzodiazepin-2-one",CNCCCN1C(=O)CNC(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F,,,,,,
160,20161,Isopropyl 4-hydroxybenzoate,CC(C)OC(=O)C1=CC=C(C=C1)O,,,,,,
161,20162,1-Cyclohexyl-5-hexylbarbituric acid,CCCCCCC1C(=O)NC(=O)N(C1=O)C2CCCCC2,,,,,,
162,20163,Indium citrate,C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O.[In+3],,,,,,
163,20164,Ethyl 2-(2-dimethoxyphosphoryloxyprop-1-enylsulfanyl)acetate,CCOC(=O)CSC=C(C)OP(=O)(OC)OC,,,,,,
164,20165,"2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(3-(methylamino)propyl)-, dihydrochloride",CNCCCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F.Cl.Cl,,,,,,
165,20166,"7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1-[3-(methylamino)propyl]-2H-1,4-benzodiazepine-2-one",CNCCCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F,,,,,,
166,20167,Pentaerythritol tetrabenzoate,C1=CC=C(C=C1)C(=O)OCC(COC(=O)C2=CC=CC=C2)(COC(=O)C3=CC=CC=C3)COC(=O)C4=CC=CC=C4,,,,,,
167,20168,Trimethylolethyl tribenzoate,CC(COC(=O)C1=CC=CC=C1)(COC(=O)C2=CC=CC=C2)COC(=O)C3=CC=CC=C3,,,,,,
168,20169,Neopentyl glycol dibenzoate,CC(C)(COC(=O)C1=CC=CC=C1)COC(=O)C2=CC=CC=C2,,,,,,
169,20170,Biebrich scarlet,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C=C(C=C3)N=NC4=CC=C(C=C4)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+],,,,,,
170,20171,2-[(2-Hydroxynaphthalen-1-yl)diazenyl]-5-[(4-sulfophenyl)diazenyl]benzene-1-sulfonic acid,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C=C(C=C3)N=NC4=CC=C(C=C4)S(=O)(=O)O)S(=O)(=O)O)O,,,,,,
171,20172,Chromotrope 2R,C1=CC=C(C=C1)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)[O-])S(=O)(=O)[O-])O)O.[Na+].[Na+],,,,,,
172,20173,"4,5-Dihydroxy-3-(phenyldiazenyl)naphthalene-2,7-disulfonic acid",C1=CC=C(C=C1)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)O)O,,,,,,
173,20174,C.I. Direct blue 10,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C(C=C4C=C3S(=O)(=O)[O-])S(=O)(=O)[O-])O)O)OC)N=NC5=C(C6=C(C=C(C=C6C=C5S(=O)(=O)[O-])S(=O)(=O)[O-])O)O.[Na+].[Na+].[Na+].[Na+],,,,,,
174,20175,"3,3'-[(3,3'-Dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis(diazene-2,1-diyl)]bis(4,5-dihydroxynaphthalene-2,7-disulfonic acid)",COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C(C=C4C=C3S(=O)(=O)O)S(=O)(=O)O)O)O)OC)N=NC5=C(C6=C(C=C(C=C6C=C5S(=O)(=O)O)S(=O)(=O)O)O)O,,,,,,
175,20176,"3,5-Dimethyl-4-hydroxybenzonitrile",CC1=CC(=CC(=C1O)C)C#N,,,,,,
176,20177,Aminoacetic anhydride,C(C(=O)OC(=O)CN)N,,,,,,
177,20178,Carbanthrene Red G 2B,CCN1C2=C3C(=CC(=CC3=N1)C4=CC5=NN(C6=C5C(=C4)C(=O)C7=CC=CC=C76)CC)C(=O)C8=CC=CC=C82,,,,,,
178,20179,Clonidine hydrochloride,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,['Sedation'],,"['Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)', 'Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)', 'Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']",,,
179,20180,"3,7-Bis(2-methoxyethyl)-1,5-diphenyl-3,7-diazabicyclo(3.3.1)nonan-9-one",COCCN1CC2(CN(CC(C1)(C2=O)C3=CC=CC=C3)CCOC)C4=CC=CC=C4,,,,,,
180,20181,"3,7-Bis(3-methoxypropyl)-1,5-diphenyl-3,7-diazabicyclo(3.3.1)nonan-9-one",COCCCN1CC2(CN(CC(C1)(C2=O)C3=CC=CC=C3)CCCOC)C4=CC=CC=C4,,,,,,
181,20182,"3,7-Diazabicyclo(3.3.1)nonan-9-one, 3,7-bis(1,1-dimethyl-2-hydroxyethyl)-1,5-diphenyl-",CC(C)(CO)N1CC2(CN(CC(C1)(C2=O)C3=CC=CC=C3)C(C)(C)CO)C4=CC=CC=C4,,,,,,
182,20183,(p-Chlorophenoxy)acetic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)COC1=CC=C(C=C1)Cl.[Cl-],,,,,,
183,20184,"Acetic acid, (p-chlorophenoxy)-, 2-(diethylamino)ethyl ester",CCN(CC)CCOC(=O)COC1=CC=C(C=C1)Cl,,,,,,
184,20185,"1,2-Dihydro-4-(p-(2,3-epoxypropoxy)phenyl)-7-methoxy-3-phenylnaphthalene",COC1=CC2=C(C=C1)C(=C(CC2)C3=CC=CC=C3)C4=CC=C(C=C4)OCC5CO5,,,,,,
185,20186,Isopropyl N-acetoxy-N-phenylcarbamate,CC(C)OC(=O)N(C1=CC=CC=C1)OC(=O)C,,,,,,
186,20187,Malononitrile mustard,C1=CC(=CC=C1C=C(C#N)C#N)N(CCCl)CCCl,,,,,,
187,20188,[(1R)-2-[4-[bis(2-chloroethyl)amino]phenyl]-1-carboxyethyl]azanium;chloride,C1=CC(=CC=C1C[C@H](C(=O)O)[NH3+])N(CCCl)CCCl.[Cl-],,,,,,
188,20189,Medphalan,C1=CC(=CC=C1C[C@H](C(=O)O)N)N(CCCl)CCCl,,,"['A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) (See all compounds classified as Antineoplastic Agents, Alkylating.)', 'Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION. (See all compounds classified as Myeloablative Agonists.)']",,,
189,20190,"3-(m-(Bis(beta-chloroethyl)amino)phenyl)-D,L-alanine hydrochloride",C1=CC(=CC(=C1)N(CCCl)CCCl)CC(C(=O)O)[NH3+].[Cl-],,,,,,
190,20191,Azo-mustard,CC1=C(C=CC(=C1)N(CCCl)CCCl)N=NC2=CC=CC=C2C(=O)O,,,,,,
191,20192,"N,N-Bis(2-chloroethyl)-2,3-dimethoxyaniline",COC1=CC=CC(=C1OC)N(CCCl)CCCl,,,,,,
192,20193,Quinacrine mustard,CC(CCCN(CCCl)CCCl)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC.Cl.Cl,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
193,20194,"1,4-Pentanediamine, N1,N1-bis(2-chloroethyl)-N4-(6-chloro-2-methoxy-9-acridinyl)-",CC(CCCN(CCCl)CCCl)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC,,,"['Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. (See all compounds classified as Fluorescent Dyes.)']",,,
194,20195,Bromacrylide,C=CC(=O)NCNC(=O)CCBr,,,,,,
195,20196,"3',5-Dichlorosalicylanilide",C1=CC(=CC(=C1)Cl)NC(=O)C2=C(C=CC(=C2)Cl)O,,,,,,
196,20197,"Benzene, 1-ethyl-4-(1-methylethyl)-",CCC1=CC=C(C=C1)C(C)C,,,,,,
197,20198,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-1-(3-(dimethylamino)propyl)-7-nitro-5-phenyl-, monohydrochloride",C[NH+](C)CCCN1C(=O)CN=C(C2=C1C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3.[Cl-],,,,,,
198,20199,"7-Nitro-1-(3-dimethylaminopropyl)-5-(phenyl)-1H-1,4-benzodiazepin-2(3H)-one",CN(C)CCCN1C(=O)CN=C(C2=C1C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3,,,,,,
199,20200,Hex-3-enoic acid,CCC=CCC(=O)O,,,,,,
200,20201,2-Hydroxyethyl palmitate,CCCCCCCCCCCCCCCC(=O)OCCO,,,,,,
201,20202,4-Propanoylbenzoic acid,CCC(=O)C1=CC=C(C=C1)C(=O)O,,,,,,
202,20203,"1,5-Diphenyl-2,2-dimethyl-1-dimethylaminopentane hydrochloride",CC(C)(CCCC1=CC=CC=C1)C(C2=CC=CC=C2)[NH+](C)C.[Cl-],,,,,,
203,20204,"N,N,2,2-tetramethyl-1,5-diphenylpentan-1-amine",CC(C)(CCCC1=CC=CC=C1)C(C2=CC=CC=C2)N(C)C,,,,,,
204,20205,5-Hydroxypentanal,C(CCO)CC=O,,,,,,
205,20206,"n-(5,5-Dimethylhexyl)acrylamide",CC(C)(C)CCCCNC(=O)C=C,,,,,,
206,20207,Ethylene glycol butyl vinyl ether,CCCCOCCOC=C,,,,,,
207,20208,2-Hydroxy-5-methoxy-4-methylacetophenone,CC1=CC(=C(C=C1OC)C(=O)C)O,,,,,,
208,20209,6-Chlorohexanoic acid,C(CCC(=O)O)CCCl,,,,,,
209,20210,6-Bromohexanoic acid,C(CCC(=O)O)CCBr,,,,,,
210,20211,"Benzimidazole, 4,6-dichloro-2-(trifluoromethyl)-",C1=C(C=C(C2=C1NC(=N2)C(F)(F)F)Cl)Cl,,,,,,
211,20212,"Benzimidazole, 4,7-dichloro-2-(trifluoromethyl)-",C1=CC(=C2C(=C1Cl)NC(=N2)C(F)(F)F)Cl,,,,,,
212,20213,"Benzimidazole, 4-chloro-6-nitro-2-(trifluoromethyl)-",C1=C(C=C(C2=C1NC(=N2)C(F)(F)F)Cl)[N+](=O)[O-],,,,,,
213,20214,"Benzimidazole, 4-bromo-5,6,7-trichloro-2-(trifluoromethyl)-",C12=C(C(=C(C(=C1Br)Cl)Cl)Cl)N=C(N2)C(F)(F)F,,,,,,
214,20215,"Benzimidazole, 4,7-dibromo-2-(trifluoromethyl)-",C1=CC(=C2C(=C1Br)NC(=N2)C(F)(F)F)Br,,,,,,
215,20216,"Hydrazine, (2-phenoxyethyl)-, hydrochloride",C1=CC=C(C=C1)OCCN[NH3+].[Cl-],,,,,,
216,20217,(2-Phenoxyethyl)hydrazine,C1=CC=C(C=C1)OCCNN,,,,,,
217,20218,"1,7,7-Trimethylbicyclo[2.2.1]heptane-2,5-dione",CC1(C2CC(=O)C1(CC2=O)C)C,,,,,,
218,20219,Allyl octanoate,CCCCCCCC(=O)OCC=C,,,,,,
219,20220,"11H-DIBENZO(b,e)(1,4)DIAZEPIN-11-ONE, 5,10-DIHYDRO-10-(3-(DIMETHYLAMINO)PROPYL)-",CN(C)CCCN1C2=CC=CC=C2NC3=CC=CC=C3C1=O,,,,,,
220,20221,"11H-DIBENZO(b,e)(1,4)DIAZEPIN-11-ONE, 5,10-DIHYDRO-10-(3-(DIETHYLAMINO)PROPYL)-",CCN(CC)CCCN1C2=CC=CC=C2NC3=CC=CC=C3C1=O,,,,,,
221,20222,alpha-(Ethylaminomethyl)-p-hydroxybenzyl alcohol,CCNCC(C1=CC=C(C=C1)O)O,,,,,,
222,20223,p-Hydroxy-alpha-(propylaminomethyl)benzyl alcohol,CCCNCC(C1=CC=C(C=C1)O)O,,,,,,
223,20224,"2,4-Dinitrophenyl acetate",CC(=O)OC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-],,,,,,
224,20225,"16-Hydroxy-17-oxoestra-1(10),2,4-triene-1,3-diyl diacetate",CC(=O)OC1=CC2=C(C3CCC4(C(C3CC2)CC(C4=O)O)C)C(=C1)OC(=O)C,,,,,,
225,20226,Kelevan,CCOC(=O)CCC(=O)CC1(C2(C3(C4(C1(C5(C2(C3(C(C45Cl)(Cl)Cl)Cl)Cl)Cl)Cl)Cl)Cl)Cl)O,,,,,,
226,20227,9-Phenanthrylacetamide,CC(=O)NC1=CC2=CC=CC=C2C3=CC=CC=C31,,,,,,
227,20228,"HYDROCINNAMIC ACID, p-((2-CHLOROETHYL)(2-FLUOROETHYL)AMINO)-",C1=CC(=CC=C1CCC(=O)O)N(CCF)CCCl,,,,,,
228,20229,Choline methyl ether iodide,C[N+](C)(C)CCOC.[I-],,,,,,
229,20230,(2-Methoxyethyl)trimethylaminium,C[N+](C)(C)CCOC,,,,,,
230,20231,"Nicotinonitrile, 2-hydroxy-6-methyl-5-phenyl-",CC1=C(C=C(C(=O)N1)C#N)C2=CC=CC=C2,,,,,,
231,20232,2-Fluoroethyl (4-nitrophenyl)acetate,C1=CC(=CC=C1CC(=O)OCCF)[N+](=O)[O-],,,,,,
232,20233,2-Fluoroethyldiphenyl acetate,C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)OCCF,,,,,,
233,20234,2-Fluoroethyl 3-phenylprop-2-enoate,C1=CC=C(C=C1)C=CC(=O)OCCF,,,,,,
234,20235,2-Fluoroethyl (4-methoxyphenyl)acetate,COC1=CC=C(C=C1)CC(=O)OCCF,,,,,,
235,20236,"ANILINE, m-CHLORO-N-METHYL-N-NITROSO-",CN(C1=CC(=CC=C1)Cl)N=O,,,,,,
236,20237,1-Methyl-3-nitroguanidine,CN=C(N)N[N+](=O)[O-],,,,,,
237,20238,CID 20238,CCN(C(=N[N+](=O)[O-])N)N=O,,,,,,
238,20239,"4,7,10-Trioxa-1,13-tridecanediamine",C(CN)COCCOCCOCCCN,,,,,,
239,20240,Isobutyl 4-hydroxybenzoate,CC(C)COC(=O)C1=CC=C(C=C1)O,,,,,,
240,20241,"1,2,6,7-Diepoxyheptane",C1C(O1)CCCC2CO2,,,,,,
241,20242,"ESTRA-1,3,5(10)-TRIENE-1,3,17-beta-TRIOL, TRIACETATE",CC(=O)O[C@H]1CCC2C1(CCC3C2CCC4=C3C(=CC(=C4)OC(=O)C)OC(=O)C)C,,,,,,
242,20243,Cyanoketone,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC=C4[C@@]3(C[C@H](C(=O)C4(C)C)C#N)C,,,,,,
243,20244,"1,9-Nonanediol, dimethanesulfonate",CS(=O)(=O)OCCCCCCCCCOS(=O)(=O)C,,,,,,
244,20245,Nonacosanoic acid,CCCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)O,,,,,,
245,20246,"HYDROCINNAMIC ACID, m-(BIS(2-CHLOROETHYL)AMINO)-",C1=CC(=CC(=C1)N(CCCl)CCCl)CCC(=O)O,,,,,,
246,20247,"Carbanilic acid, 4-(3-(methoxycarbonyl)propyl)-, benzyl ester",COC(=O)CCCC1=CC=C(C=C1)NC(=O)OCC2=CC=CC=C2,,,,,,
247,20248,N-Benzoyl-3-(p-((2-chloroethyl)(2-fluoroethyl)amino)phenyl)alanine,C1=CC=C(C=C1)C(=O)NC(CC2=CC=C(C=C2)N(CCF)CCCl)C(=O)O,,,,,,
248,20249,3-(p-(Bis(2-fluoroethyl)amino)phenyl)alanine,C1=CC(=CC=C1CC(C(=O)O)N)N(CCF)CCF,,,,,,
249,20250,"2,2',4'-Trichloroacetophenone",C1=CC(=C(C=C1Cl)Cl)C(=O)CCl,,,,,,
250,20251,"3,5-Diiodo-4-methoxybenzoic acid",COC1=C(C=C(C=C1I)C(=O)O)I,,,,,,
251,20252,Dipropyl sulfoxide,CCCS(=O)CCC,,,,,,
252,20253,Aletamine hydrochloride,C=CCC(CC1=CC=CC=C1)N.Cl,,,,,,
253,20254,Aletamine,C=CCC(CC1=CC=CC=C1)N,,,,,,
254,20255,1-Cyclohexyl-5-octylbarbituric acid,CCCCCCCCC1C(=O)NC(=O)N(C1=O)C2CCCCC2,,,,,,
255,20256,5-Allyl-1-(4-hydroxycyclohexyl)barbituric acid,C=CCC1C(=O)NC(=O)N(C1=O)C2CCC(CC2)O,,,,,,
256,20257,"1,2,3,4-Tetrahydro-1,2-diphenyl-6-methoxy-1-naphthol",COC1=CC2=C(C=C1)C(C(CC2)C3=CC=CC=C3)(C4=CC=CC=C4)O,,,,,,
257,20258,"6-Methoxy-2-phenyl-1-(p-tolyl)-1,2,3,4-tetrahydro-1-naphthol",CC1=CC=C(C=C1)C2(C(CCC3=C2C=CC(=C3)OC)C4=CC=CC=C4)O,,,,,,
258,20259,"Naphthalene, 1,2-dihydro-3,4-diphenyl-7-methoxy-",COC1=CC2=C(C=C1)C(=C(CC2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
259,20260,"NAPHTHALENE, 1,2-DIHYDRO-7-METHOXY-3-PHENYL-4-(p-TOLYL)-",CC1=CC=C(C=C1)C2=C(CCC3=C2C=CC(=C3)OC)C4=CC=CC=C4,,,,,,
260,20261,"N,N'-Bis(trichloroacetyl)-o-phenylenediamine",C1=CC=C(C(=C1)NC(=O)C(Cl)(Cl)Cl)NC(=O)C(Cl)(Cl)Cl,,,,,,
261,20262,9-Benzyladenine,C1=CC=C(C=C1)CN2C=NC3=C(N=CN=C32)N,,,,,,
262,20263,2-Methylbenzofuran,CC1=CC2=CC=CC=C2O1,,,,,,
263,20264,"ACETIC ACID, (sec-BUTYLIDENEDITHIO)DI-",CCC(C)(SCC(=O)O)SCC(=O)O,,,,,,
264,20265,"2,4-Dichloro-6-isothiocyanato-1,3,5-triazine",C(=NC1=NC(=NC(=N1)Cl)Cl)=S,,,,,,
265,20266,Tybamate,CCCCNC(=O)OCC(C)(CCC)COC(=O)N,,,,"['...WELL ABSORBED FROM GI TRACT... MEPROBAMATE IS QUITE UNIFORMLY DISTRIBUTED IN BODY, & ABOUT 10% OF DRUG IS EXCRETED IN UNCHANGED FORM IN URINE. /MEPROBAMATE/', 'ABSORPTION OF [(14)C]-TYBAMATE...FROM GI TRACT WAS FAIRLY RAPID IN RATS RECEIVING ORAL DOSE. 67% OF (14)C REMAINED THERE 2 HR LATER, WHEREAS ONLY 21% REMAINED 4 HR LATER. 21% WAS EXCRETED IN 2-HR URINE. 24 HR AFTER IP DOSE, RATS HAD EXCRETED 87% OF (14)C IN URINE, 5% IN FECES...3% WAS PRESENT IN INTESTINAL CONTENTS.', 'IN PREGNANT MICE, TYBAMATE SLOWLY CROSSED PLACENTA, & LEVELS OF (14)C WERE LOWER IN FETUS THAN IN MOTHER. 30 MIN AFTER RECTAL ADMIN...MUCH (14)C WAS PRESENT IN LIVER & INTESTINES. RAPID PENETRATION...INTO BRAIN & ADIPOSE TISSUE WOULD BE EXPECTED FOR THIS LIPID-SOL DRUG.', 'WHOLE-BODY AUTORADIOGRAPHY OF MICE RECEIVING IV DOSES...SHOWED THAT (14)C WAS PRESENT IN CNS WITHIN 50 SEC, & LEVELS WERE ALSO HIGH IN ADIPOSE TISSUE, MYOCARDIUM, SALIVARY GLANDS, & KIDNEYS. AFTER 10 MIN...(14)C IN BRAIN HAD DECR, BUT WERE HIGH IN LIVER, INTESTINES, & KIDNEYS, ORGANS CONCERNED WITH EXCRETION OF TYBAMATE.']",,['...TYBAMATE...HAS T/2 OF 3 HR... BRIEF ACTION OF TYBAMATE IS ADVANTAGE IN SOME SITUATIONS.']
266,20267,4-Amino-9-fluorenone,C1=CC=C2C(=C1)C3=C(C2=O)C=CC=C3N,,,,,,
267,20268,2-(2-Chloro-4-nitrophenylazo)-5-methoxy-p-toluidine,CC1=CC(=C(C=C1OC)N)N=NC2=C(C=C(C=C2)[N+](=O)[O-])Cl,,,,,,
268,20269,"Ethanamine, 2-bromo-N-(2-bromoethyl)-N-methyl-",CN(CCBr)CCBr,,,,,,
269,20270,"2,2'-Thiodiethanol diacetate",CC(=O)OCCSCCOC(=O)C,,,,,,
270,20271,1-Bromoeicosane,CCCCCCCCCCCCCCCCCCCCBr,,,,,,
271,20272,1-Acetyl-2-(alpha-ethylbenzyl)hydrazine,CCC(C1=CC=CC=C1)NNC(=O)C,,,,,,
272,20273,"2,5-Thiophenedicarboxylic acid",C1=C(SC(=C1)C(=O)O)C(=O)O,,,,,,
273,20274,1-Iodoheptane,CCCCCCCI,,,,,['1-iodoheptane has known human metabolites that include heptyl-glutathione.'],
274,20275,1-Iodononane,CCCCCCCCCI,,,,,,
275,20276,1-Iodoundecane,CCCCCCCCCCCI,,,,,,
276,20277,5-Butyl-5-ethyl-1-methylbarbituric acid,CCCCC1(C(=O)NC(=O)N(C1=O)C)CC,,,,,,
277,20278,"2-Biphenylol, 5-nitro-",C1=CC=C(C=C1)C2=C(C=CC(=C2)[N+](=O)[O-])O,,,,,,
278,20279,Cladribine,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,"[""For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.""]","['Cladribine is a synthetic purine nucleoside that acts as an antineoplastic agent with immunosuppressive effects. Cladribine differs structurally from deoxyadenosine only by the presence of a chlorine atom at position 2 of the purine ring, which results in resistance to enzymatic degradation by adenosine deaminase. Due to this resistance, cladribine exhibits a more prolonged cytotoxic effect than deoxyadenosine against resting and proliferating lymphocytes. Cladribine is one of a group of chemotherapy drugs known as the anti-metabolites.&nbsp;Anti-metabolites stop cells from making and repairing DNA, which are processes that are necessary for cancer cells to grow and multiply.']","['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)']","['Oral bioavailability is 34 to 48%.', '4.5 Â± 2.8 L/kg [patients with hematologic malignancies]', '978 +/- 422 mL/h/kg', 'Cladribine is bound approximately 20% to plasma proteins.', 'It is not known whether cladribine is distributed into breast milk.', 'It is not known whether cladribine is removed from circulation by dialysis or hemofiltration.', 'Cladribine penetrates into cerebrospinal fluid. One report indicates that concentrations are approximately 25% of those in plasma.', 'For more Absorption, Distribution and Excretion (Complete) data for CLADRIBINE (9 total), please visit the HSDB record page.']","[""Metabolized in all cells with deoxycytidine kinase activity to 2-chloro-2'-deoxyadenosine-5'-triphosphate"", ""Metabolized in all cells with deoxycytidine kinase activity to 2-chloro-2'-deoxyadenosine-5'-triphosphate.""]","['5.4 hours', 'Cladribine plasma concentration after intravenous administration declines multi-exponentially with an average half-life of 6.7 +/-2.5 hours.', '... The terminal half-life varies from 5.7 to 19.7 hours ...', '... The terminal phase half-life in 22 patients ranged from 14.3-25.8 hr, with a mean (SD) of 19.7 (3.4) hr. ...']"
279,20280,Cocamidopropyl betaine,CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(=O)[O-],,,"['Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)']",,,
280,20281,3-(Dodecanoylamino)propyl(carboxymethyl)dimethylammonium,CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(=O)O,,,,,,
281,20282,1-Iodododecane,CCCCCCCCCCCCI,,,,,,
282,20283,Hexylcyclohexane,CCCCCCC1CCCCC1,,,,,,
283,20284,Pentylcyclohexane,CCCCCC1CCCCC1,,,,,,
284,20285,5-Fluorocytosine arabinoside,C1=C(C(=NC(=O)N1[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O)N)F,,,,,,
285,20286,Plastoquinone 9,CC1=C(C(=O)C(=CC1=O)CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C,,,,,,
286,20287,Sulfisoxazole diolamine,CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N.C(CO)NCCO,,,['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)'],,,
287,20288,Fluenetil,C1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)OCCF,,,,,,
288,20289,Truxicurium iodide,CC[N+](C)(CC)CCCOC(=O)C1C(C(C1C2=CC=CC=C2)C(=O)OCCC[N+](C)(CC)CC)C3=CC=CC=C3.[I-].[I-],,,,,,
289,20290,Truxicurium,CC[N+](C)(CC)CCCOC(=O)C1C(C(C1C2=CC=CC=C2)C(=O)OCCC[N+](C)(CC)CC)C3=CC=CC=C3,,,,,,
290,20291,"3,4,5-Trimethoxybenzoic acid 2-(diethylamino)ethyl ester hydrochloride",CC[NH+](CC)CCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC.[Cl-],,,,,,
291,20292,"2-Diethylaminoethyl 3,4,5-trimethoxybenzoate",CCN(CC)CCOC(=O)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
292,20293,"2-Thiophenemethanaminium, N,N-dimethyl-N-(2-phenoxyethyl)-, 4-chlorobenzenesulfonate (1:1)",C[N+](C)(CCOC1=CC=CC=C1)CC2=CC=CS2.C1=CC(=CC=C1OS(=O)[O-])Cl,,,,,,
293,20294,Thenium,C[N+](C)(CCOC1=CC=CC=C1)CC2=CC=CS2,,,,,,
294,20295,4-Chlorophenyl hydrogen sulfite,C1=CC(=CC=C1OS(=O)O)Cl,,,,,,
295,20296,"2-Hexanone, 6-(acetyloxy)-",CC(=O)CCCCOC(=O)C,,,,,,
296,20297,"Calcium;7-(4-carbamoyloxy-3-hydroxy-5-methoxy-6,6-dimethyloxan-2-yl)oxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-8-methyl-2-oxochromen-4-olate",CC1=C(C=CC2=C1OC(=O)C(=C2[O-])NC(=O)C3=CC(=C(C=C3)O)CC=C(C)C)OC4C(C(C(C(O4)(C)C)OC)OC(=O)N)O.[Ca+2],,,,,,
297,20298,Tridihexethyl chloride,CC[N+](CC)(CC)CCC(C1CCCCC1)(C2=CC=CC=C2)O.[Cl-],,,,,,
298,20299,Tridihexethyl,CC[N+](CC)(CC)CCC(C1CCCCC1)(C2=CC=CC=C2)O,['Used as an adjunct in the treatment of peptic ulcer disease and in Acquired nystagmus'],"['Tridihexethyl is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. Tridihexethyl is an antimuscarinic, anticholinergic drug.']",,,,
299,20300,"1,2,3,4-Tetrahydro-1-(p-fluorophenyl)-6-methoxy-2-phenyl-1-naphthol",COC1=CC2=C(C=C1)C(C(CC2)C3=CC=CC=C3)(C4=CC=C(C=C4)F)O,,,,,,
300,20301,"NAPHTHALENE, 1,2-DIHYDRO-4-(p-FLUOROPHENYL)-7-METHOXY-3-PHENYL-",COC1=CC2=C(C=C1)C(=C(CC2)C3=CC=CC=C3)C4=CC=C(C=C4)F,,,,,,
301,20302,"BENZ(c)ACRIDINE, 7-(2-(2-CHLOROETHYLETHYLAMINO)ETHYLAMINO)-, DIHYDROCHLORIDE",CC[NH+](CC[NH2+]C1=C2C=CC3=CC=CC=C3C2=NC4=CC=CC=C41)CCCl.[Cl-].[Cl-],,,,,,
302,20303,"N-benzo[c]acridin-7-yl-N'-(2-chloroethyl)-N'-ethylethane-1,2-diamine",CCN(CCNC1=C2C=CC3=CC=CC=C3C2=NC4=CC=CC=C41)CCCl,,,,,,
303,20304,Hedaquinium chloride,C1=CC=C2C=[N+](C=CC2=C1)CCCCCCCCCCCCCCCC[N+]3=CC4=CC=CC=C4C=C3.[Cl-].[Cl-],,,,,,
304,20305,Hedaquinium,C1=CC=C2C=[N+](C=CC2=C1)CCCCCCCCCCCCCCCC[N+]3=CC4=CC=CC=C4C=C3,,,,,,
305,20306,CID 20306,C(=CCl)C(=O)[O-].[Na+],,,,,,
306,20307,"Hepta-2,4-dienal",CCC=CC=CC=O,,,,,,
307,20308,"N,N,2-trimethyl-4-[(4-nitrophenyl)diazenyl]aniline",CC1=C(C=CC(=C1)N=NC2=CC=C(C=C2)[N+](=O)[O-])N(C)C,,,,,,
308,20309,"N,N-Dimethyl-4-((m-nitrophenyl)azo)-o-toluidine",CC1=C(C=CC(=C1)N=NC2=CC(=CC=C2)[N+](=O)[O-])N(C)C,,,,,,
309,20310,4-Methylphthalic acid,CC1=CC(=C(C=C1)C(=O)O)C(=O)O,,,,,,
310,20311,"Benzene, 1-methoxy-4-(trimethoxymethyl)-",COC1=CC=C(C=C1)C(OC)(OC)OC,,,,,,
311,20312,"4,6-Dichloro-5-nitropyrimidine",C1=NC(=C(C(=N1)Cl)[N+](=O)[O-])Cl,,,,,,
312,20313,Amitriptylinoxide,C[N+](C)(CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31)[O-],,,,,,
313,20314,"2,5-Diaminopyridine",C1=CC(=NC=C1N)N,,,,,,
314,20315,4-Aminomorpholine,C1COCCN1N,,,,,,
315,20316,Thiazinamium chloride,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)[N+](C)(C)C.[Cl-],,,,,,
316,20317,Modumate,C(CC(C(=O)O)N)CN=C(N)N.C(CC(=O)O)C(C(=O)O)N,,,,,,
317,20318,CID 20318,C1=CC=C2C(=C1)C(=O)C(=C(O2)O)C(C3=CC=CC=C3Cl)C4=C(OC5=CC=CC=C5C4=O)O,,,,,,
318,20319,CID 20319,C1=CC=C2C(=C1)C(=O)C(=C(O2)O)C(C3=CC=C(C=C3)Cl)C4=C(OC5=CC=CC=C5C4=O)O,,,,,,
319,20320,"4-Hydroxycyclohexa-2,5-dien-1-one",C1=CC(=O)C=CC1O,,,,,,
320,20321,Hexoprenaline hydrochloride,C1=CC(=C(C=C1C(C[NH2+]CCCCCC[NH2+]CC(C2=CC(=C(C=C2)O)O)O)O)O)O.[Cl-].[Cl-],,,,,,
321,20322,p-Nitrophenylbiguanide,C1=CC(=CC=C1N=C(N)N=C(N)N)[N+](=O)[O-],,,,,,
322,20323,"1-(4,6-Dimethyl-2-pyrimidinyl)-3-(p-nitrophenyl)guanidine",CC1=CC(=NC(=N1)N=C(N)NC2=CC=C(C=C2)[N+](=O)[O-])C,,,,,,
323,20324,"5-sec-Butyl-1,5-dimethylbarbituric acid",CCC(C)C1(C(=O)NC(=O)N(C1=O)C)C,,,,,,
324,20325,1-Phenylphenanthrene,C1=CC=C(C=C1)C2=CC=CC3=C2C=CC4=CC=CC=C43,,,,,,
325,20326,Ethoxychlor,CCOC1=CC=C(C=C1)C(C2=CC=C(C=C2)OCC)C(Cl)(Cl)Cl,,,,,,
326,20327,"1,1,1-Trichloro-2,2-bis(p-propoxyphenyl)ethane",CCCOC1=CC=C(C=C1)C(C2=CC=C(C=C2)OCCC)C(Cl)(Cl)Cl,,,,,,
327,20328,"m,p'-DDT",C1=CC(=CC(=C1)Cl)C(C2=CC=C(C=C2)Cl)C(Cl)(Cl)Cl,,,,,,
328,20329,1H-Benzimidazol-4-amine,C1=CC(=C2C(=C1)NC=N2)N,,,,,,
329,20330,4-Methylcyclohexanecarboxylic acid,CC1CCC(CC1)C(=O)O,,,,,,
330,20331,3-(5-Nitro-2-furanyl)-1-phenyl-2-propen-1-one,C1=CC=C(C=C1)C(=O)C=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
331,20332,CID 20332,C1=CC=C(C=C1)N2C(=O)C(N=C2S)CC3=CC=C(C=C3)O,,,,,,
332,20333,CID 20333,COC1=CC=C(C=C1)C(=O)C=CC2=C(C=CO2)[N+](=O)[O-],,,,,,
333,20334,"1,3-Dimethylimidazolium iodide",CN1C=C[N+](=C1)C.[I-],,,,,,
334,20335,"1,3-Dimethylimidazolium",CN1C=C[N+](=C1)C,,,,,,
335,20336,CID 20336,COC1=CC=CC=C1C=NN=C(N)S,,,,,,
336,20337,CID 20337,C1=CC(=NN=C2C=CC(=O)C=C2)C=CC1=C3C=CC(=NN=C4C(=CC5=C(C4=O)C(=N)C(=NNC6=CC=C(C=C6)N(O)O)C(=C5)S(=O)(=O)[O-])S(=O)(=O)[O-])C=C3.[Na+].[Na+],,,,,,
337,20338,CID 20338,C1=CC(=NN=C2C=CC(=O)C=C2)C=CC1=C3C=CC(=NN=C4C(=CC5=C(C4=O)C(=N)C(=NNC6=CC=C(C=C6)N(O)O)C(=C5)S(=O)(=O)O)S(=O)(=O)O)C=C3,,,,,,
338,20339,"2-Methoxy-3,3,5-trimethyl-2,3-dihydro-1,2-oxaphosphole 2-oxide",CC1=CC(P(=O)(O1)OC)(C)C,,,,,,
339,20340,"1,5-Dimethyl-5-isopropylbarbituric acid",CC(C)C1(C(=O)NC(=O)N(C1=O)C)C,,,,,,
340,20341,Deglucocheirotoxin,CC1[C@H](C(C([C@@H](O1)O[C@H]2CC[C@@]3(C4CC[C@@]5([C@H](CC[C@@]5(C4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)C=O)O)O)O,,,,,,
341,20342,Mono(2-ethylhexyl) adipate,CCCCC(CC)COC(=O)CCCCC(=O)O,,,,,,
342,20343,"Ethanol, 2-amino-, benzoate (salt)",C1=CC=C(C=C1)C(=O)[O-].C(CO)[NH3+],,,,,,
343,20344,CID 20344,C(CS)N=C([NH3+])N.[Br-],,,,,,
344,20345,Kinetin riboside,C1=COC(=C1)CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O,,,,,,
345,20346,"Carbanilide, 2,2'-diethylthio-",CCN(C1=CC=CC=C1)C(=S)N(CC)C2=CC=CC=C2,,,,,,
346,20347,3-Methyl-1-hexyn-3-ol,CCCC(C)(C#C)O,,,,,,
347,20348,CID 20348,C1=COC(=C1)C(=C(C2=CC=CO2)O)N=O,,,,,,
348,20349,p-Chloroazobenzene,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)Cl,,,,,,
349,20350,4-Methylcyclohex-3-ene-1-carboxylic acid,CC1=CCC(CC1)C(=O)O,,,,,,
350,20351,"11H-DIBENZO(b,e)(1,4)DIAZEPIN-11-ONE, 5,10-DIHYDRO-10-(2-(DIETHYLAMINO)ETHYL)-",CCN(CC)CCN1C2=CC=CC=C2NC3=CC=CC=C3C1=O,,,,,,
351,20352,4-Butoxyaniline,CCCCOC1=CC=C(C=C1)N,,,,,,
352,20353,Vitamin e succinate,CC1=C(C(=C(C2=C1O[C@](CC2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C)OC(=O)CCC(=O)O)C,"[""The primary health-related use for which alpha-tocopherol succinate is formally indicated is as a dietary supplement for patients who demonstrate a genuine vitamin E deficiency. At the same time, vitamin E deficiency is generally quite rare but may occur in premature babies of very low birth weight (< 1500 grams), individuals with fat-malabsorption disorders (as fat is required for the digestive tract to absorb vitamin E), or individuals with abetalipoproteinemia - a rare, inherited disorder that causes poor absorption of dietary fat - who require extremely large doses of supplemental vitamin E daily (around 100 mg/kg or 5-10 g/day). In all such cases, alpha-tocopherol is largely the preferred form of vitamin E to be administered.  Elsewhere, vitamin E's chemical profile as a fat-soluble antioxidant that is capable of neutralizing free radicals in the body continues to generate ongoing interest and study regarding how and whether or not the vitamin can help prevent or delay various chronic diseases associated with free radicals or other potential biological effects that vitamin E possesses like cardiovascular diseases, diabetes, ocular conditions, immune illnesses, cancer, and more. None of these ongoing studies have yet to elucidate any formally significant evidence, however.  Similarly, more effective clinical trials are necessary to confirm what has only been accrued as preliminary data when it comes to studies proposing the demonstration of alpha-tocopherol succinate's capability to act as an anti-cancer therapy or as a regulator of inflammation.""]","['Of the eight separate variants of vitamin E, alpha-tocopherol is the predominant form of vitamin E in human and animal tissues, and it has the highest bioavailability. This is because the liver preferentially resecretes only alpha-tocopherol by way of the hepatic alpha-tocopherol transfer protein (alpha-TTP); the liver metabolizes and excretes all the other vitamin E variants, which is why blood and cellular concentrations of other forms of vitamin E other than alpha-tocopherol are ultimately lower.  Furthermore, the term alpha-tocopherol generally refers to a group of eight possible stereoisomers which is often called all-rac-tocopherol for being a racemic mixture of all eight stereoisomers. Of the eight stereoisomers, the RRR-alpha-tocopherol - or sometimes referred to as the d-alpha-tocopherol - stereoisomer is the naturally occurring form of alpha-tocopherol that is perhaps best recognized by the alpha-TTP and has been reported to demonstrate approximately twice the systemic availability of all-rac-tocopherol.  As a result, often times (but certainly not always) the discussion of vitamin E - at least within the context of using the vitamin for health-related indications - is generally in reference to the use of RRR- or d-alpha-tocopherol.  Subsequently, without further evidence to suggest otherwise, alpha-tocpherol succinate is generally believed to undergo a logical de-esterification in the gastrointestinal tract before being subsequently absorbed as free tocopherol.']","['Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)', 'Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body. (See all compounds classified as Vitamins.)']","[""_In addition to any following information, owing to alpha-Tocopherol succinate's closely related chemical nature with alpha-Tocopherol acetate, please also refer to the drug information page for alpha-Tocopherol acetate for further data._  It is generally believed that alpha-tocopherol succinate is ultimately de-esterified or cleaved to provide alpha-tocopherol once administered to the human body. It is consequently expected that pharmacodynamics and pharmacokinetics similar to that of alpha-tocopherol to be followed.   50 to 80% absorbed from gastrointestinal tract."", ""_In addition to any following information, owing to alpha-Tocopherol succinate's closely related chemical nature with alpha-Tocopherol acetate, please also refer to the drug information page for alpha-Tocopherol acetate for further data._  It is generally believed that alpha-tocopherol succinate is ultimately de-esterified or cleaved to provide alpha-tocopherol once administered to the human body. It is consequently expected that pharmacodynamics and pharmacokinetics similar to that of alpha-tocopherol to be followed."", ""_In addition to any following information, owing to alpha-Tocopherol succinate's closely related chemical nature with alpha-Tocopherol acetate, please also refer to the drug information page for alpha-Tocopherol acetate for further data._  It is generally believed that alpha-tocopherol succinate is ultimately de-esterified or cleaved to provide alpha-tocopherol once administered to the human body. It is consequently expected that pharmacodynamics and pharmacokinetics similar to that of alpha-tocopherol to be followed."", ""_In addition to any following information, owing to alpha-Tocopherol succinate's closely related chemical nature with alpha-Tocopherol acetate, please also refer to the drug information page for alpha-Tocopherol acetate for further data._  It is generally believed that alpha-tocopherol succinate is ultimately de-esterified or cleaved to provide alpha-tocopherol once administered to the human body. It is consequently expected that pharmacodynamics and pharmacokinetics similar to that of alpha-tocopherol to be followed.""]","[""_In addition to any following information, owing to alpha-Tocopherol succinate's closely related chemical nature with alpha-Tocopherol acetate, please also refer to the drug information page for alpha-Tocopherol acetate for further data._  It is generally believed that alpha-tocopherol succinate is ultimately de-esterified or cleaved to provide alpha-tocopherol once administered to the human body. It is consequently expected that pharmacodynamics and pharmacokinetics similar to that of alpha-tocopherol to be followed.  Hepatic.""]","[""_In addition to any following information, owing to alpha-Tocopherol succinate's closely related chemical nature with alpha-Tocopherol acetate, please also refer to the drug information page for alpha-Tocopherol acetate for further data._  It is generally believed that alpha-tocopherol succinate is ultimately de-esterified or cleaved to provide alpha-tocopherol once administered to the human body. It is consequently expected that pharmacodynamics and pharmacokinetics similar to that of alpha-tocopherol to be followed.""]"
353,20354,Phenyl butyrate,CCCC(=O)OC1=CC=CC=C1,,,,,,
354,20355,"[(7R,8S)-7-methoxy-12-methyl-10,13-dioxo-11-pyrrolidin-1-yl-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate",CC1=C(C(=O)C2=C(C1=O)N3CC4C([C@@]3([C@@H]2COC(=O)N)OC)N4)N5CCCC5,,,,,,
355,20356,"3-(p-(3,4-Dihydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy)-1,2-propanediol cyclic carbonate",COC1=CC2=C(C=C1)C(=C(CC2)C3=CC=CC=C3)C4=CC=C(C=C4)OCC5COC(=O)O5,,,,,,
356,20357,"2-Hexyl-4-methyl-1,3-dioxolane",CCCCCCC1OCC(O1)C,,,,,,
357,20358,Cyclohexyl formate,C1CCC(CC1)OC=O,,,,,,
358,20359,"2-Methyl-2-pentyl-1,3-dioxolane",CCCCCC1(OCCO1)C,,,,,,
359,20360,"2-Methyl-2-propyl-1,3-dioxolane",CCCC1(OCCO1)C,,,,,,
360,20361,"4-Methyl-2-(trichloromethyl)-1,3-dioxolane",CC1COC(O1)C(Cl)(Cl)Cl,,,,,,
361,20362,"Isoquinolinium, 2-(3-(trimethylammonio)propyl)-, dibromide",C[N+](C)(C)CCC[N+]1=CC2=CC=CC=C2C=C1.[Br-].[Br-],,,,,,
362,20363,3-Isoquinolin-2-ium-2-ylpropyl(trimethyl)azanium,C[N+](C)(C)CCC[N+]1=CC2=CC=CC=C2C=C1,,,,,,
363,20364,Cyclohexanehexanol,C1CCC(CC1)CCCCCCO,,,,,,
364,20365,2-Cyclohexylidenemalononitrile,C1CCC(=C(C#N)C#N)CC1,,,,,,
365,20366,"2,4-Dioxo-3-azaspiro[5.5]undecane-1,5-dicarbonitrile",C1CCC2(CC1)C(C(=O)NC(=O)C2C#N)C#N,,,,,,
366,20367,"(9R,14R,18R)-13-ethyl-8-methyl-8,15-diazahexacyclo[14.2.1.01,9.02,7.010,15.012,17]nonadeca-2,4,6-triene-14,18-diol",CCC1[C@H](N2C3CC1C4C2CC5([C@H]3N(C6=CC=CC=C65)C)[C@@H]4O)O,,,,,,
367,20368,CID 20368,C1=CC=C(C=C1)C=CC[NH3+].[Cl-],,,,,,
368,20369,3-Phenylprop-2-en-1-amine,C1=CC=C(C=C1)C=CCN,,,,,,
369,20370,"2-Methyl-2-pentyl-1,3-dioxolane-4-methanol",CCCCCC1(OCC(O1)CO)C,,,,,,
370,20371,"2-Methyl-2-phenyl-1,3-dioxolane-4-methanol",CC1(OCC(O1)CO)C2=CC=CC=C2,,,,,,
371,20372,"2-Methyl-2-propyl-1,3-dioxolane-4-methanol",CCCC1(OCC(O1)CO)C,,,,,,
372,20373,"2-Methyl-2-(2-thienyl)-1,3-dioxolane-4-methanol",CC1(OCC(O1)CO)C2=CC=CS2,,,,,,
373,20374,"4-(Chloromethyl)-2,2-dimethyl-1,3-dioxolane",CC1(OCC(O1)CCl)C,,,,,,
374,20375,"4-(Chloromethyl)-2-(trichloromethyl)-1,3-dioxolane",C1C(OC(O1)C(Cl)(Cl)Cl)CCl,,,,,,
375,20376,3-Hydroxy-4-aminobiphenyl,C1=CC=C(C=C1)C2=CC(=C(C=C2)N)O,,,,,,
376,20377,"Azetidine, 1-ethyl-3-phenyl-",CCN1CC(C1)C2=CC=CC=C2,,,,,,
377,20378,"(3,3-Dimethoxypropen-1-yl)benzene",COC(C=CC1=CC=CC=C1)OC,,,,,,
378,20379,1-(4-Chlorophenyl)-2-[4-[2-(diethylamino)ethylamino]-6-methylpyrimidin-2-yl]guanidine,CCN(CC)CCNC1=NC(=NC(=C1)C)N=C(N)NC2=CC=C(C=C2)Cl,,,,,,
379,20380,"1-Phenyl-2-(p-tolylazo)-1,3-butanedione",CC1=CC=C(C=C1)N=NC(C(=O)C)C(=O)C2=CC=CC=C2,,,,,,
380,20381,CID 20381,CCN(C1=CC=CC2=CC=CC=C21)C(=N)S,,,,,,
381,20382,"(1R,5R,6R,7S,9R,11S,13S,14S)-3-amino-14-(hydroxymethyl)-8,10-dioxa-2,4-diazatetracyclo[7.3.1.17,11.01,6]tetradec-3-ene-5,9,12,13,14-pentol",C([C@@]1([C@@H]2[C@@H]3[C@H](N=C(N[C@]34[C@@H]([C@@](O2)(O[C@H]1C4O)O)O)N)O)O)O,,,"['Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)', 'Substances which, when ingested, inhaled, or absorbed, or when applied to, injected into, or developed within the body in relatively small amounts may, by their chemical action, cause damage to structure or disturbance of function. (From Dorland, 27th ed) (See all compounds classified as Poisons.)', 'A class of drugs that act by inhibition of sodium influx through cell membranes. Blockade of sodium channels slows the rate and amplitude of initial rapid depolarization, reduces cell excitability, and reduces conduction velocity. (See all compounds classified as Sodium Channel Blockers.)']","['Twenty-three specimens of a tree-frog Polypedates sp. were collected from two locations (Mymensingh and Barisal) of Bangladesh in 1999, and assayed for their toxicity scores and toxin principle. Among the tissues, only the skin of the Mymensingh specimens was found to be toxic in mouse test, with the toxicity scores of 31-923 ug/g. The toxin isolated from the skin was analyzed by high-performance liquid chromatography, electrospray ionization-time of flight mass spectrometry and proton nuclear magnetic resonance, and characterized as tetrodotoxin, a toxin principle.', 'Tetrodotoxin (TTX) and its analogs (TTXs), widely distributed among marine as well as terrestrial animals, induce dangerous intoxications. These highly potential toxins are also known as the causative agent of puffer fish poisoning. ... TTX, anhydrotetrodotoxin, 11-deoxytetrodotoxin and trideoxytetrodotoxin were determined in separated tissues of Bangladeshi marine puffers, Takifugu oblongus. TTX was predominant in skin, muscle and liver, whereas trideoxytetrodotoxin preponderated in the ovary. The toxicity of the various tissues was determined by a mouse bioassay.', 'To investigate the relationship between the toxicity of puffer fish and the distribution of tetrodotoxin-producing bacteria in puffer fish Fugu rubripes collected from the Bohai Sea of China, bacteria were isolated from each organ (ovaries, livers, intestines and gallbladders) and screened for tetrodotoxin (TTX) production. 20 out of 36 isolated strains were found to produce TTX in vitro. In the organs of ovaries and livers whose toxicity is more potent than other organs, the number and toxicity of TTX-producing strains was greater than that of others. Most TTX-producing bacterial strains were identified as Bacillus spp. (19 strains) and Actinomycete spp. (1 strain) based on the morphological observation, physiological and biochemical characteristics and G+C content of DNA. The purified toxin was identified to be TTX by high performance liquid chromatography assay, thin-layer chromatography assay and electrospray ionization mass spectrometry analysis. Our results suggested that TTX-producing bacteria are closely related to the toxification of the puffer fish. More research is needed to elucidate the mechanism of TTX synthesis and the role of TTX in bacteria.', 'The liver homogenate of puffer fish was fractionated into blood cell, nuclear, mitochondrial, microsomal and cytosol fractions by the differential centrifugation method. ... Analyses by HPLC and LC-FABMS demonstrated that tetrodotoxin is the major toxic principle in each fraction. These results reveal that tetrodotoxin is widely distributed in organelles in liver cells, though predominantly in the cytosol fraction.', 'For more Absorption, Distribution and Excretion (Complete) data for Tetrodotoxin (9 total), please visit the HSDB record page.']","['The metabolic source of tetrodotoxin is uncertain. No algal source has been identified, and until recently tetrodotoxin was assumed to be a metabolic product of the host. However, recent reports of the production of tetrodotoxin/anhydrotetrodotoxin by several bacterial species, including strains of the family Vibrionaceae, Pseudomonas sp., and Photobacterium phosphoreum, point toward a bacterial origin of this family of toxins.', 'To investigate the genes related to the biosynthesis or accumulation of tetrodotoxin (TTX) in pufferfish, mRNA expression patterns in the liver from pufferfish, akamefugu Takifugu chrysops and kusafugu Takifugu niphobles, were compared by mRNA arbitrarily primed reverse transcription-polymerase chain reaction (RAP RT-PCR) with fish bearing different concentrations of TTX and its derivatives. RAP RT-PCR provided a 383 bp cDNA fragment and its transcripts were higher in toxic than non-toxic pufferfish liver. Its deduced amino acid sequence was similar to those of fibrinogen-like proteins reported for other vertebrates. Northern blot analysis and rapid amplification of cDNA ends (RACE) revealed that the cDNA fragment of 383 bp was composed of at least three fibrinogen-like protein (flp) genes, flp-1, flp-2 and flp-3. Relative mRNA levels of flp-1, flp-2 and flp-3 showed a linear correlation with toxicity of the liver for two pufferfish species.']",
382,20383,"2,4-Diamino-6-diethylamino-5-(4-carbethoxyphenylazo)pyrimidine",CCN(CC)C1=NC(=NC(=C1N=NC2=CC=C(C=C2)C(=O)OCC)N)N,,,,,,
383,20384,Myfadol hydrochloride,CC1C(CCCN1CC(=O)C2=CC=CC=C2)(C)C3=CC(=CC=C3)O.Cl,,,,,,
384,20385,Myfadol,CC1C(CCCN1CC(=O)C2=CC=CC=C2)(C)C3=CC(=CC=C3)O,,,,,,
385,20386,"2,3-Dimethoxy-5-methyl-6-(3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl)cyclohexa-2,5-diene-1,4-dione",CC1=C(C(=O)C(=C(C1=O)OC)OC)CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C,,,,,,
386,20387,"[1,1'-Biphenyl]-2,2',4,4'-tetrol",C1=CC(=C(C=C1O)O)C2=C(C=C(C=C2)O)O,,,,,,
387,20388,Dibromofluorescein,C1=CC=C2C(=C1)C(=O)OC23C4=C(C(=C(C=C4)[O-])Br)OC5=C3C=CC(=C5Br)[O-].[Na+].[Na+],,,,,,
388,20389,Decylmalonic acid,CCCCCCCCCCC(C(=O)O)C(=O)O,,,,,,
389,20390,Pyridoxine tripalmitate,CCCCCCCCCCCCCCCC(=O)OCC1=CN=C(C(=C1COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C,,,,,,
390,20391,Pyridoxine trilaurate,CCCCCCCCCCCC(=O)OCC1=CN=C(C(=C1COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)C,,,,,,
391,20392,2-(Methoxycarbonyl)benzoic acid,COC(=O)C1=CC=CC=C1C(=O)O,,,,,,
392,20393,2-(((2-Ethylhexyl)oxy)carbonyl)benzoic acid,CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)O,,,,,,
393,20394,2-(Chloromethyl)quinoline,C1=CC=C2C(=C1)C=CC(=N2)CCl,,,,,,
394,20395,Fenbutrazate,CCC(C1=CC=CC=C1)C(=O)OCCN2CCOC(C2C)C3=CC=CC=C3,,,,,,
395,20396,"2-Methyl-2-(o-tolyl)-1,3-dioxolane-4-methanol",CC1=CC=CC=C1C2(OCC(O2)CO)C,,,,,,
396,20397,"2-Phenyl-2-propyl-1,3-dioxolane-4-methanol",CCCC1(OCC(O1)CO)C2=CC=CC=C2,,,,,,
397,20398,1-Aminobiurea,C(=O)(N)NNC(=O)NN,,,,,,
398,20399,Dihydrorobinetin,C1=CC2=C(C=C1O)OC(C(C2=O)O)C3=CC(=C(C(=C3)O)O)O,,,,,,
399,20400,"1H-Indol-5-OL, 3-(2-(dimethylamino)ethyl)-, bioxalate",C[NH+](C)CCC1=CNC2=C1C=C(C=C2)O.C(=O)(C(=O)[O-])O,,,,,,
400,20401,5-Methoxyindole-2-carboxylic acid,COC1=CC2=C(C=C1)NC(=C2)C(=O)O,,,,,,
401,20402,4-Hydroxy-5-isopropyl-2-methylbenzyl alcohol,CC1=CC(=C(C=C1CO)C(C)C)O,,,,,,
402,20403,"Acetic acid, (2-naphthyloxy)-, 2-fluoroethyl ester",C1=CC=C2C=C(C=CC2=C1)OCC(=O)OCCF,,,,,,
403,20404,2-Isopropyl-5-methylhexanoic acid,CC(C)CCC(C(C)C)C(=O)O,,,,,,
404,20405,CID 20405,C(=N)(S)[S-].[Na+],,,,,,
405,20406,"Acetamide, N-(tetrahydro-5,5-diethyl-4-oxo-2H-1,3-thiazin-2-ylidene)-",CCC1(CSC(=NC1=O)NC(=O)C)CC,,,,,,
406,20407,"N-(Tetrahydro-4-oxo-5-phenyl-2H-1,3-thiazin-2-ylidene)acetamide",CC(=O)NC1=NC(=O)C(CS1)C2=CC=CC=C2,,,,,,
407,20408,CID 20408,C1=CC=C(C(=C1)C2=C3C=C(C(=O)C=C3OC4=C(C(=C(C=C24)I)O)[Hg])I)S(=O)(=O)[O-].O.[Na+],,,,,,
408,20409,"[3-Hydroxy-2,7-diiodo-6-oxo-9-(2-sulfophenyl)xanthen-4-yl]mercury",C1=CC=C(C(=C1)C2=C3C=C(C(=O)C=C3OC4=C(C(=C(C=C24)I)O)[Hg])I)S(=O)(=O)O,,,,,,
409,20410,Fourneau 2268,CC1OCC(O1)C[N+](C)(C)C.[I-],,,,,,
410,20411,"N,N,N,2-Tetramethyl-1,3-dioxolane-4-methanaminium",CC1OCC(O1)C[N+](C)(C)C,,,,,,
411,20412,Bis(2-oxoethyl)mercury,C(C=O)[Hg]CC=O,,,,,,
412,20413,2-Hydroxy-6-isopropyl-3-methylbenzoic acid,CC1=C(C(=C(C=C1)C(C)C)C(=O)O)O,,,,,,
413,20414,"2,2,4,4,6,8,8-Heptamethylnonane",CC(CC(C)(C)C)CC(C)(C)CC(C)(C)C,,,,,,
414,20415,"2-[(3,4-Dimethylphenyl)amino]nicotinic acid",CC1=C(C=C(C=C1)NC2=C(C=CC=N2)C(=O)O)C,,,,,,
415,20416,"Phosphoric acid, bis(2-chloroethyl) 4-methyl-2-oxo-2H-1-benzopyran-7-yl ester",CC1=CC(=O)OC2=C1C=CC(=C2)OP(=O)(OCCCl)OCCCl,,,,,,
416,20417,4-Morpholinecarboxaldehyde,C1COCCN1C=O,,,,,,
417,20418,CID 20418,C1=CC=C2C(=C1)C(=C3C=CC=C(C3=C2O)N=C4C=CC5=C6C=CC7=C8C6=C(C=CC8=C9C=CC1=C(C9=N7)C(=O)C2=CC=CC=C2C1=O)C(=O)C5=C4)O,,,,,,
418,20419,"9,10-Anthracenedione, 1-amino-4-(phenylamino)-",C1=CC=C(C=C1)NC2=C3C(=C(C=C2)N)C(=O)C4=CC=CC=C4C3=O,,,,,,
419,20420,"Benzene, 2-chloro-1-methyl-4-(1-methylethyl)-",CC1=C(C=C(C=C1)C(C)C)Cl,,,,,,
420,20421,"p-CYMENE, 3-CHLORO-",CC1=CC(=C(C=C1)C(C)C)Cl,,,,,,
421,20422,Decahydroazecine,C1CCCCNCCCC1,,,,,,
422,20423,"Benzilic acid, 2-(1-pyrrolidinyl)ethyl ester",C1CCN(C1)CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
423,20424,Phenylacetic acid alpha-(2-morpholinoethyl)benzyl ester hydrochloride,C1COCC[NH+]1CCC(C2=CC=CC=C2)OC(=O)CC3=CC=CC=C3.[Cl-],,,,,,
424,20425,(3-Morpholin-4-yl-1-phenylpropyl) 2-phenylacetate,C1COCCN1CCC(C2=CC=CC=C2)OC(=O)CC3=CC=CC=C3,,,,,,
425,20426,"Ethane, 2,2-bis(4-chlorophenyl)-1,1,1-tribromo-",C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)C(Br)(Br)Br)Cl,,,,,,
426,20427,Direct Blue 71,C1=CC=C2C(=C1)C(=CC=C2N=NC3=CC4=C(C=CC=C4S(=O)(=O)[O-])C(=C3)S(=O)(=O)[O-])N=NC5=C6C=CC(=CC6=C(C=C5)N=NC7=C(C=C8C=C(C=CC8=C7O)N)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],,,,,,
427,20428,Direct Blue 71 parent,C1=CC=C2C(=C1)C(=CC=C2N=NC3=CC4=C(C=CC=C4S(=O)(=O)O)C(=C3)S(=O)(=O)O)N=NC5=C6C=CC(=CC6=C(C=C5)N=NC7=C(C=C8C=C(C=CC8=C7O)N)S(=O)(=O)O)S(=O)(=O)O,,,,,,
428,20429,"Ethanone, 1-oxiranyl-",CC(=O)C1CO1,,,,,,
429,20430,"4-butoxy-6-chloro-N-ethyl-1,3,5-triazin-2-amine",CCCCOC1=NC(=NC(=N1)NCC)Cl,,,,,,
430,20431,Acid Green 25,CC1=CC(=C(C=C1)NC2=C3C(=C(C=C2)NC4=C(C=C(C=C4)C)S(=O)(=O)[O-])C(=O)C5=CC=CC=C5C3=O)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
431,20432,"Benzenesulfonic acid, 2,2'-[(9,10-dihydro-9,10-dioxo-1,4-anthracenediyl)diimino]bis[5-methyl-",CC1=CC(=C(C=C1)NC2=C3C(=C(C=C2)NC4=C(C=C(C=C4)C)S(=O)(=O)O)C(=O)C5=CC=CC=C5C3=O)S(=O)(=O)O,,,,,,
432,20433,Indole-1-acetamidoxime,C1=CC=C2C(=C1)C=CN2CC(=NO)N,,,,,,
433,20434,"2-Methyl-2-isopropyl-1,3-dioxolane",CC(C)C1(OCCO1)C,,,,,,
434,20435,"17-(Cyclopropylmethyl)-7-(2-hydroxypropan-2-yl)-6-methoxy-4,5-epoxy-6,14-ethenomorphinan-3-ol",CC(C)(C1CC23C=CC1([C@@H]4[C@]25CCN([C@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O,,,,,,
435,20436,Isobutyranilide,CC(C)C(=O)NC1=CC=CC=C1,,,,,,
436,20437,"s-Triazine, 2,4-bis(methylthio)-6-chloro-",CSC1=NC(=NC(=N1)Cl)SC,,,,,,
437,20438,"2-Azido-4,6-bis(methylsulfanyl)-1,3,5-triazine",CSC1=NC(=NC(=N1)N=[N+]=[N-])SC,,,,,,
438,20439,"2-Chloro-4-methoxy-6-(methylthio)-1,3,5-triazine",COC1=NC(=NC(=N1)Cl)SC,,,,,,
439,20440,"4-chloro-6-methoxy-N-propyl-1,3,5-triazin-2-amine",CCCNC1=NC(=NC(=N1)Cl)OC,,,,,,
440,20441,N-Methyliminodiacetic acid,CN(CC(=O)O)CC(=O)O,,,,,,
441,20442,Propylenediamine tetra-acetic acid,CC(CN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O,,,,,,
442,20443,Di(2-thienyl)acetic acid,C1=CSC(=C1)C(C2=CC=CS2)C(=O)O,,,,,,
443,20444,(Cyclohexylmethyl)benzene,C1CCC(CC1)CC2=CC=CC=C2,,,,,,
444,20445,"6,6'-Dimethyl-2,2'-bipyridine",CC1=NC(=CC=C1)C2=CC=CC(=N2)C,,,,,,
445,20446,"Benzeneacetaldehyde, alpha-ethylidene-",CC=C(C=O)C1=CC=CC=C1,,,,,,
446,20447,3-Methyl-2-phenylbut-2-enoic acid,CC(=C(C1=CC=CC=C1)C(=O)O)C,,,,,,
447,20448,Mucochloric anhydride,C1(C(=C(C(=O)O1)Cl)Cl)OC2C(=C(C(=O)O2)Cl)Cl,,,,,,
448,20449,3-Furanmethanol,C1=COC=C1CO,,,,,,
449,20450,Coumarylpyrone,C1=CC(=O)OC2=CC3=C(C=CC(=O)O3)C=C21,,,,,,
450,20451,"Ethane, 1-butoxy-2-ethoxy-",CCCCOCCOCC,,,,,,
451,20452,Methylchlor,CC1=CC=C(C=C1)C(C2=CC=C(C=C2)C)C(Cl)(Cl)Cl,,,,,,
452,20453,"Phosphonic acid, (2,2,2-trichloro-1-hydroxyethyl)-, dimethyl ester, isobutyrate",CC(C)C(=O)OC(C(Cl)(Cl)Cl)P(=O)(OC)OC,,,,,,
453,20454,"Dodecanoic acid, 2,2,2-trichloro-1-(dimethoxyphosphinyl)ethyl ester",CCCCCCCCCCCC(=O)OC(C(Cl)(Cl)Cl)P(=O)(OC)OC,,,,,,
454,20455,2-(Cyanomethyl)benzimidazole,C1=CC=C2C(=C1)NC(=N2)CC#N,,,,,,
455,20456,2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl 3-naphthalen-1-ylprop-2-enoate,C1CN(CCN1CCOC(=O)C=CC2=CC=CC3=CC=CC=C32)C4=CC=C(C=C4)Cl,,,,,,
456,20457,2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl 3-(furan-2-yl)prop-2-enoate,C1CN(CCN1CCOC(=O)C=CC2=CC=CO2)C3=CC=C(C=C3)Cl,,,,,,
457,20458,2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl 3-(1H-indol-3-yl)prop-2-enoate,C1CN(CCN1CCOC(=O)C=CC2=CNC3=CC=CC=C32)C4=CC=C(C=C4)Cl,,,,,,
458,20459,"2-Chloro-4-ethylamino-6-propoxy-1,3,5-triazine",CCCOC1=NC(=NC(=N1)NCC)Cl,,,,,,
459,20460,"2-Chloro-4-propoxy-6-propylamino-1,3,5-triazine",CCCNC1=NC(=NC(=N1)Cl)OCCC,,,,,,
460,20461,"4-chloro-N-propan-2-yl-6-propan-2-yloxy-1,3,5-triazin-2-amine",CC(C)NC1=NC(=NC(=N1)Cl)OC(C)C,,,,,,
461,20462,"2-Allyloxy-4-chloro-6-ethylamino-1,3,5-triazine",CCNC1=NC(=NC(=N1)Cl)OCC=C,,,,,,
462,20463,"4-chloro-6-prop-2-enoxy-N-prop-2-enyl-1,3,5-triazin-2-amine",C=CCNC1=NC(=NC(=N1)Cl)OCC=C,,,,,,
463,20464,"Butyramide, N-antipyrinyl-",CCCC(=O)NC1=C(N(N(C1=O)C2=CC=CC=C2)C)C,,,,,,
464,20465,"2,3-Epoxy-3-methylbutyramide",CC1(C(O1)C(=O)N)C,,,,,,
465,20466,CID 20466,CC1=CC(=O)C(=C(O1)[O-])C(=O)C.[Na+],,,,,,
466,20467,5-Aminotetrazole,C1(=NNN=N1)N,,,,,,
467,20468,Chlorbisan,CC1=CC(=CC(=C1SC2=C(C=C(C=C2C)Cl)O)O)Cl,,,,,,
468,20469,Beclomethasone,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)Cl)C,,,"['Drugs that are used to treat asthma. (See all compounds classified as Anti-Asthmatic Agents.)', 'A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)', 'Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)']",,,
469,20470,"Pyrrolidine, 1-valeryl-",CCCCC(=O)N1CCCC1,,,,,,
470,20471,CID 20471,CC[NH2+]CC.C1=CC=C(C(=C1)C(=O)[O-])O,,,,,,
471,20472,"2-Oxaspiro(4,5)decan-1-one",C1CCC2(CC1)CCOC2=O,,,,,,
472,20473,(3-Mercaptopropyl)trimethoxysilane,CO[Si](CCCS)(OC)OC,,,,,,
473,20474,2-Ethylcyclohexanone,CCC1CCCCC1=O,,,,,,
474,20475,"(1S,5aR)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,8,9,9b,10,11-dodecahydroindeno[5,4-f]chromen-7-one",C[C@@]1(CCC2C1(CCC3C2CC[C@@H]4C3(CCC(=O)O4)C)C)O,,,,,,
475,20476,9H-fluoren-9-yl 3-(diethylamino)propanoate,CCN(CC)CCC(=O)OC1C2=CC=CC=C2C3=CC=CC=C13,,,,,,
476,20477,"Fluorene-9,9-dipropionic acid",C1=CC=C2C(=C1)C3=CC=CC=C3C2(CCC(=O)O)CCC(=O)O,,,,,,
477,20478,"Fluorene-9,9-dipropionitrile",C1=CC=C2C(=C1)C3=CC=CC=C3C2(CCC#N)CCC#N,,,,,,
478,20479,Butylboronic acid,B(CCCC)(O)O,,,,,,
479,20480,"4-Methyl-1,3,2-dioxathiane 2,2-dioxide",CC1CCOS(=O)(=O)O1,,,,,,
480,20481,"4-Methyl-1,3,2-dioxathiane 2-oxide",CC1CCOS(=O)O1,,,,,,
481,20482,"1,2,2-Triphenylethanol",C1=CC=C(C=C1)C(C2=CC=CC=C2)C(C3=CC=CC=C3)O,,,,,,
482,20483,"2,2'-Trithiobisethanol",C(CSSSCCO)O,,,,,,
483,20484,Fructosamine,C1[C@H]([C@H]([C@@H]([C@](O1)(CN)O)O)O)O,,,,,,
484,20485,Tabersonine,CC[C@]12CC(=C3[C@@]4([C@H]1N(CC4)CC=C2)C5=CC=CC=C5N3)C(=O)OC,,,,,,
485,20486,Chlorophenol red,C1=CC=C2C(=C1)C(OS2(=O)=O)(C3=CC(=C(C=C3)O)Cl)C4=CC(=C(C=C4)O)Cl,,,,,,
486,20487,Octahydro-2H-1-benzopyran-2-one,C1CCC2C(C1)CCC(=O)O2,,,,,,
487,20488,"Arsine, ethylenebis(diphenyl-",C1=CC=C(C=C1)[As](CC[As](C2=CC=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
488,20489,"5,8-Dihydroxy-7-methoxyflavone",COC1=C(C2=C(C(=C1)O)C(=O)C=C(O2)C3=CC=CC=C3)O,,,,,,
489,20490,(Cyclopentylmethyl)cyclohexane,C1CCC(CC1)CC2CCCC2,,,,,,
490,20491,2-Morpholino-1-phenylethanol,C1COCCN1CC(C2=CC=CC=C2)O,,,,,,
491,20492,"3,4-Dimethylbiphenyl",CC1=C(C=C(C=C1)C2=CC=CC=C2)C,,,,,,
492,20493,2-Ethylacetoacetic acid,CCC(C(=O)C)C(=O)O,,,,,,
493,20494,"[5-Hydroxy-6-[2-hydroxy-3-[[4-[[2-hydroxy-7-[3-hydroxy-5-methoxy-6,6-dimethyl-4-(5-methyl1H-pyrrole-2-carbonyl)oxyoxan-2-yl]oxy-8-methyl-4-oxochromen-3-yl]carbamoyl]-3-methyl1H-pyrrole-2-carbonyl]amino]-8-methyl-4-oxochromen-7-yl]oxy-3-methoxy-2,2-dimethyloxan-4-yl] 5-methyl-1H-pyrrole-2-carboxylate",CC1=CC=C(N1)C(=O)OC2C(C(OC(C2OC)(C)C)OC3=C(C4=C(C=C3)C(=O)C(=C(O4)O)NC(=O)C5=CNC(=C5C)C(=O)NC6=C(OC7=C(C6=O)C=CC(=C7C)OC8C(C(C(C(O8)(C)C)OC)OC(=O)C9=CC=C(N9)C)O)O)C)O,,,,,,
494,20495,Clothixamide,CNC(=O)CCN1CCN(CC1)CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl,,,,,,
495,20496,1-Bromononadecane,CCCCCCCCCCCCCCCCCCCBr,,,,,,
496,20497,"1,2,3-Butanetriol",CC(C(CO)O)O,,,,,,
497,20498,3-Methoxybutyl acetate,CC(CCOC(=O)C)OC,,,,,,
498,20499,Difurfuryl disulfide,C1=COC(=C1)CSSCC2=CC=CO2,,,,,,
499,20500,9-Iminofluorene,C1=CC=C2C(=C1)C3=CC=CC=C3C2=N,,,,,,
500,20501,Stipitatic acid,C1=C(C=C(C(=CC1=O)O)O)C(=O)O,,,,,,
501,20502,"1,4-Butanedione, 1,4-diphenyl-2,3-epoxy-",C1=CC=C(C=C1)C(=O)C2C(O2)C(=O)C3=CC=CC=C3,,,,,,
502,20503,"(5beta)-12,beta,14-Dihydroxy-3-oxocard-20(22)-enolide",C[C@]12CCC(=O)C[C@H]1CCC3C2C[C@H]([C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)O,,,,,,
503,20504,Butamoxane,CCCCNCC1COC2=CC=CC=C2O1,,,,,,
504,20505,Isobutylaminomethylbenzodioxan,CC(C)CNCC1COC2=CC=CC=C2O1,,,,,,
505,20506,"N-Pentyl-1,4-benzodioxan-2-methylamine",CCCCCNCC1COC2=CC=CC=C2O1,,,,,,
506,20507,"1,3-Benzodioxole-2-acetic acid, 2-methyl-",CC1(OC2=CC=CC=C2O1)CC(=O)O,,,,,,
507,20508,2-Cyclohexylethanol,C1CCC(CC1)CCO,,,,,,
508,20509,2-Cyclohexylethylamine,C1CCC(CC1)CCN,,,,,,
509,20510,CID 20510,C1=CC=C(C=C1)C2=CC(=C3C(=CC(=O)C(=C3O2)O)O)O,,,,,,
510,20511,"Cyclohexane, eicosyl-",CCCCCCCCCCCCCCCCCCCCC1CCCCC1,,,,,,
511,20512,"Eicosane, 9-cyclohexyl-",CCCCCCCCCCCC(CCCCCCCC)C1CCCCC1,,,,,,
512,20513,Diethylbutylamine,CCCCN(CC)CC,,,,,,
513,20514,Octadecylcyclohexane,CCCCCCCCCCCCCCCCCCC1CCCCC1,,,,,,
514,20515,"2-Chloro-4-isopropylamino-6-methoxy-1,3,5-triazine",CC(C)NC1=NC(=NC(=N1)Cl)OC,,,,,,
515,20516,"4-chloro-6-methoxy-N-prop-2-enyl-1,3,5-triazin-2-amine",COC1=NC(=NC(=N1)NCC=C)Cl,,,,,,
516,20517,Solypertine,COC1=CC=CC=C1N2CCN(CC2)CCC3=CNC4=CC5=C(C=C43)OCO5,,,,,,
517,20518,"(3'R,3'aS,6aS,6bS,7'aR,9R,11aS)-3',6',10,11b-tetramethylspiro[2,3,4,6,6a,6b,7,8,11,11a-decahydro-1H-benzo[a]fluorene-9,2'-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridine]-3-ol",C[C@@H]1[C@H]2[C@@H](CC(CN2)C)O[C@]13CC[C@H]4[C@@H]5CC=C6CC(CCC6([C@H]5CC4=C3C)C)O,,,,,,
518,20519,p-Nitrobenzyl tosylate,CC1=CC=C(C=C1)S(=O)(=O)OCC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
519,20520,Nile Blue 2B,CC[N+](=C1C=CC2=NC3=C(C=C(C4=CC=CC=C43)NCC5=CC=CC=C5)OC2=C1)CC.[Cl-],,,,,,
520,20521,[5-(Benzylamino)benzo[a]phenoxazin-9-ylidene]-diethylazanium,CC[N+](=C1C=CC2=NC3=C(C=C(C4=CC=CC=C43)NCC5=CC=CC=C5)OC2=C1)CC,,,,,,
521,20522,2-Phenylethyl 4-methylbenzenesulfonate,CC1=CC=C(C=C1)S(=O)(=O)OCCC2=CC=CC=C2,,,,,,
522,20523,"N,N'-Diphenyladipamide",C1=CC=C(C=C1)NC(=O)CCCCC(=O)NC2=CC=CC=C2,,,,,,
523,20524,"3-Methyl-1,5-pentanediol",CC(CCO)CCO,,,,,,
524,20525,"2,4,5-Trimethoxybenzaldehyde",COC1=CC(=C(C=C1C=O)OC)OC,,,,,,
525,20526,Chlorobutene,CCC=CCl,,,,,,
526,20527,N-Hydroxy-4-acetylaminobiphenyl,CC(=O)N(C1=CC=C(C=C1)C2=CC=CC=C2)O,,,,,,
527,20528,"9,10-Anthracenedione, 1-[(2-hydroxyethyl)amino]-",C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=CC=C3)NCCO,,,,,,
528,20529,Cytoxyl alcohol cyclohexylamine salt,C1CCC(CC1)N.C(CNP(=O)(N(CCCl)CCCl)O)CO,,,,,,
529,20530,Cytoxal alcohol,C(CNP(=O)(N(CCCl)CCCl)O)CO,,,,,,
530,20531,"10-(3-(Methylamino)propyl)-5,10-dihydro-11H-dibenzo(b,e)(1,4)diazepin-11-one hydrochloride",C[NH2+]CCCN1C2=CC=CC=C2NC3=CC=CC=C3C1=O.[Cl-],,,,,,
531,20532,"5-[3-(methylamino)propyl]-11H-benzo[b][1,4]benzodiazepin-6-one",CNCCCN1C2=CC=CC=C2NC3=CC=CC=C3C1=O,,,,,,
532,20533,"2-Methyl-4-oxo-3-(2-penten-1-yl)-2-cyclopenten-1-yl 2,2-dimethyl-3-(2-methyl-1-propen-1-yl)cyclopropanecarboxylate",CCC=CCC1=C(C(CC1=O)OC(=O)C2C(C2(C)C)C=C(C)C)C,,,,,,
533,20534,2-Butylfuran,CCCCC1=CC=CO1,,,,,,
534,20535,N'-Isopropylacetohydrazide,CC(C)NNC(=O)C,,,,,,
535,20536,Benzo[c]phenanthrene-5-carbaldehyde,C1=CC=C2C(=C1)C=CC3=C2C4=CC=CC=C4C(=C3)C=O,,,,,,
536,20537,"1,2,3,4-Tetramethylphenanthrene",CC1=C(C(=C2C(=C1C)C=CC3=CC=CC=C32)C)C,,,,,,
537,20538,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-bromo-1-(3-(dimethylamino)propyl)-5-(2-pyridyl)-, dihydrochloride",C[NH+](C)CCCN1C(=O)C[NH+]=C(C2=C1C=CC(=C2)Br)C3=CC=CC=N3.[Cl-].[Cl-],,,,,,
538,20539,"7-bromo-1-[3-(dimethylamino)propyl]-5-pyridin-2-yl-3H-1,4-benzodiazepin-4-ium-2-one",CN(C)CCCN1C(=O)C[NH+]=C(C2=C1C=CC(=C2)Br)C3=CC=CC=N3,,,,,,
539,20540,3-Chloro-7-hydroxy-4-methylcoumarin bis(3-chloropropyl) phosphate,CC1=C(C(=O)OC2=C1C=CC(=C2)OP(=O)(OCCCCl)OCCCCl)Cl,,,,,,
540,20541,"5H-Dibenzo(a,d)cycloheptene, 10,11-dihydro-5-(3-(4-methylpiperazinyl)propylidene)-, dihydrochloride",C[NH+]1CC[NH+](CC1)CCC=C2C3=CC=CC=C3CCC4=CC=CC=C42.[Cl-].[Cl-],,,,,,
541,20542,"1-Methyl-4-[3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propyl]piperazine",CN1CCN(CC1)CCC=C2C3=CC=CC=C3CCC4=CC=CC=C42,,,,,,
542,20543,Pleo zinc,C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O.[Zn],,,,,,
543,20544,Acetylthiocholine,CC(=O)SCC[N+](C)(C)C,,,,,,
544,20545,3-(p-Methoxybenzyl)-4-(p-methoxyphenyl)hexane,CCC(CC1=CC=C(C=C1)OC)C(CC)C2=CC=C(C=C2)OC,,,,,,
545,20546,3-Phenylhexane,CCCC(CC)C1=CC=CC=C1,,,,,,
546,20547,2-Phenylacetoacetonitrile,CC(=O)C(C#N)C1=CC=CC=C1,,,,,,
547,20548,2-(2-Ethylbutoxy)ethanol,CCC(CC)COCCO,,,,,,
548,20549,"1,4-Bis[(2-hydroxyethyl)amino]anthraquinone",C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3C2=O)NCCO)NCCO,,,,,,
549,20550,"2-Chloro-4,6-dimethylpyrimidine",CC1=CC(=NC(=N1)Cl)C,,,,,,
550,20551,Acid blue 80,CC1=CC(=C(C(=C1NC2=C3C(=C(C=C2)NC4=C(C(=C(C=C4C)C)S(=O)(=O)[O-])C)C(=O)C5=CC=CC=C5C3=O)C)S(=O)(=O)[O-])C.[Na+].[Na+],,,,,,
551,20552,Acid Anthraquinone Brilliant Blue,CC1=CC(=C(C(=C1NC2=C3C(=C(C=C2)NC4=C(C(=C(C=C4C)C)S(=O)(=O)O)C)C(=O)C5=CC=CC=C5C3=O)C)S(=O)(=O)O)C,,,,,,
552,20553,2-Hydroxybutanenitrile,CCC(C#N)O,,,,,,
553,20554,4-Piperidinobutyrophenone,C1CCN(CC1)CCCC(=O)C2=CC=CC=C2,,,,,,
554,20555,"Benzene, 2-bromo-4-methyl-1-(1-methylethyl)-",CC1=CC(=C(C=C1)C(C)C)Br,,,,,,
555,20556,"3,7-Bis(3-hydroxypropyl)-1,5-diphenyl-3,7-diazabicyclo(3.3.1)nonan-9-one hydrochloride",C1C2(CN(CC(C2=O)(CN1CCCO)C3=CC=CC=C3)CCCO)C4=CC=CC=C4.[Cl-],,,,,,
556,20557,"3,7-Bis(3-hydroxypropyl)-1,5-diphenyl-3,7-diazabicyclo[3.3.1]nonan-9-one",C1C2(CN(CC(C2=O)(CN1CCCO)C3=CC=CC=C3)CCCO)C4=CC=CC=C4,,,,,,
557,20558,"3,3-Dimethyl-2-acetyloxirane",CC(=O)C1C(O1)(C)C,,,,,,
558,20559,(1-Isothiocyanatoethyl)benzene,CC(C1=CC=CC=C1)N=C=S,,,,,,
559,20560,Senecioic acid amide,CC(=CC(=O)N)C,,,,,,
560,20561,2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl 3-phenylprop-2-enoate,C1CN(CCN1CCOC(=O)C=CC2=CC=CC=C2)C3=CC=C(C=C3)Cl,,,,,,
561,20562,2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl 3-(2-hydroxyphenyl)prop-2-enoate,C1CN(CCN1CCOC(=O)C=CC2=CC=CC=C2O)C3=CC=C(C=C3)Cl,,,,,,
562,20563,CID 20563,C=CC[N-]C1=NC(=NC(=N1)N[N+]#N)OCC=C,,,,,,
563,20564,CID 20564,C=CCNC1=NC(=NC(=N1)OCC=C)N[N+]#N,,,,,,
564,20565,Fenuron tca,C[NH+](C)C(=O)NC1=CC=CC=C1.C(=O)(C(Cl)(Cl)Cl)[O-],,,,,,
565,20566,"Phosphoric acid, 3-chloro-4-methyl-2-oxo-2H-1-benzopyran-7-yl bis(2-chloropropyl) ester",CC1=C(C(=O)OC2=C1C=CC(=C2)OP(=O)(OCC(C)Cl)OCC(C)Cl)Cl,,,,,,
566,20567,"Ethanol, 2-(methoxymethoxy)-",COCOCCO,,,,,,
567,20568,Dodecyltrichlorosilane,CCCCCCCCCCCC[Si](Cl)(Cl)Cl,,,,,['... Chlorosilanes will be rapidly hydrolyzed upon contact with tissue fluids to release hydrochloric acid. /Chlorosilanes/'],
568,20569,CID 20569,[Li+].CCCCCCCCCCCCCCCCCC(=O)[O-],,,,,,
569,20570,"p,p'-Amino-DDT",C1=CC(=CC=C1C(C2=CC=C(C=C2)N)C(Cl)(Cl)Cl)N,,,,,,
570,20571,"[1,1'-Binaphthalene]-2,2'-diamine",C1=CC=C2C(=C1)C=CC(=C2C3=C(C=CC4=CC=CC=C43)N)N,,,,,,
571,20572,(3-Methyl-2-butenyl)benzene,CC(=CCC1=CC=CC=C1)C,,,,,,
572,20573,"[(2R,3R,5S,8R,10R,17S)-8-acetyloxy-11-ethyl-5,14-dihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] benzoate",CCN1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5C[C@@]6(C(C[C@]4([C@H]5C6OC(=O)C7=CC=CC=C7)OC(=O)C)OC)O)C(CC2O)OC)OC)COC,,,,,,
573,20574,"2,2-Dimethyl-2-azoniabicyclo(2.2.1)heptane iodide",C[N+]1(CC2CCC1C2)C.[I-],,,,,,
574,20575,"2,2-Dimethyl-2-azoniabicyclo[2.2.1]heptane",C[N+]1(CC2CCC1C2)C,,,,,,
575,20576,2-Ethyl-2-azabicyclo(2.2.1)heptane,CCN1CC2CCC1C2,,,,,,
576,20577,"Carbamic acid, phenyl-, 2-(trimethylammonio)ethyl ester, iodide",C[N+](C)(C)CCOC(=O)NC1=CC=CC=C1.[I-],,,,,,
577,20578,Trimethyl-[2-(phenylcarbamoyloxy)ethyl]azanium,C[N+](C)(C)CCOC(=O)NC1=CC=CC=C1,,,,,,
578,20579,"1H-Azepino(5,4,3-cd)indole-2-carboxylic acid, 3,4-dihydro-9-chloro-6-methyl-, ethyl ester, hydrochloride",CCOC(=O)C1=C2CC[NH+]=C(C3=C2C(=C(C=C3)Cl)N1)C.[Cl-],,,,,,
579,20580,"3,4-Dihydro-9-chloro-6-methyl-1H-azepino[5,4,3-cd]indole-2-carboxylic acid ethyl ester",CCOC(=O)C1=C2CCN=C(C3=C2C(=C(C=C3)Cl)N1)C,,,,,,
580,20581,"6-Methyl-3,4,5,6-tetrahydro-1H-azepino(5,4,3-cd)indole hydrochloride",CC1C2=C3C(=CNC3=CC=C2)CC[NH2+]1.[Cl-],,,,,,
581,20582,"3,4,5,6-Tetrahydro-6-methyl-1H-azepino[5,4,3-cd]indole",CC1C2=C3C(=CNC3=CC=C2)CCN1,,,,,,
582,20583,"3,4-Dihydro-9-chloro-1,6-dimethyl-1H-azepino(5,4,3-cd)indole hydrochloride",CC1=NCCC2=C[NH+](C3=C(C=CC1=C23)Cl)C.[Cl-],,,,,,
583,20584,"9-chloro-1,6-dimethyl-3,4-dihydro-1H-azepino[5,4,3-cd]indole",CC1=NCCC2=CN(C3=C(C=CC1=C23)Cl)C,,,,,,
584,20585,"1,3-dimethyl-7H-purine-2,6-dione;2-hydroxyethyl(trimethyl)azanium",CN1C2=C(C(=O)N(C1=O)C)NC=N2.C[N+](C)(C)CCO,,,,,,
585,20586,Tetrapropylammonium hydroxide,CCC[N+](CCC)(CCC)CCC.[OH-],,,,,,
586,20587,"Ethanol, 2,2'-(cyclohexylimino)bis-",C1CCC(CC1)N(CCO)CCO,,,,,,
587,20588,"2-Ethyl-5-hydroxyisoquinolinium, bromide",CC[N+]1=CC2=C(C=C1)C(=CC=C2)O.[Br-],,,,,,
588,20589,2-Ethylisoquinolin-2-ium-5-ol,CC[N+]1=CC2=C(C=C1)C(=CC=C2)O,,,,,,
589,20590,"1-(2,2,3-Trimethylcyclopent-3-en-1-yl)ethanone",CC1=CCC(C1(C)C)C(=O)C,,,,,,
590,20591,2'-Amino-3'-hydroxyacetophenone,CC(=O)C1=C(C(=CC=C1)O)N,,,,,,
591,20592,1-(4-Hydroxyphenyl)-2-aminoethanol hydrochloride,C1=CC(=CC=C1C(C[NH3+])O)O.[Cl-],,,,,,
592,20593,Doxepinol,CN(C)CCCC1(C2=CC=CC=C2COC3=CC=CC=C31)O,,,,,,
593,20594,"3-Methyl-1,2,4-cyclopentanetrione",CC1C(=O)CC(=O)C1=O,,,,,,
594,20595,"1,2-Dihydro-1,5,8-trimethylnaphthalene",CC1CC=CC2=C(C=CC(=C12)C)C,,,,,,
595,20596,"3-(9,10-Dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thien-4-ylidene)-N-methyl-1-propanamine",CNCCC=C1C2=C(CCC3=CC=CC=C31)SC=C2,,,,,,
596,20597,"6-Oxa-3-thiabicyclo[3.1.0]hexane 3,3-dioxide",C1C2C(O2)CS1(=O)=O,,,,,,
597,20598,"Indole, 3-(2-(hexahydro-1H-azepin-1-YL)ethyl)-2-phenyl-",C1CCCN(CC1)CCC2=C(NC3=CC=CC=C32)C4=CC=CC=C4,,,,,,
598,20599,Agn-PC-0jkfdt,CC(C(=O)[O-])O.C1CCC2C(C1)CC3CCCCC3[I+]2,,,,,,
599,20600,"2-Iodoniatricyclo[8.4.0.03,8]tetradecane",C1CCC2C(C1)CC3CCCCC3[I+]2,,,,,,
600,20601,"5,6-Diphenyl-1,2,4-triazin-3(2H)-one",C1=CC=C(C=C1)C2=NC(=O)NN=C2C3=CC=CC=C3,,,,,,
601,20602,"2-Ethyl-5-hydroxy-1,2,3,4-tetrahydroisoquinoline, hydrobromide",CC[NH+]1CCC2=C(C1)C=CC=C2O.[Br-],,,,,,
602,20603,"2-ethyl-3,4-dihydro-1H-isoquinolin-5-ol",CCN1CCC2=C(C1)C=CC=C2O,,,,,,
603,20604,"5-(3,4,5-Trimethoxybenzoyloxy)-2-ethyl-1,2,3,4-tetrahydro-isoquinoline hydrobromide",CC[NH+]1CCC2=C(C1)C=CC=C2OC(=O)C3=CC(=C(C(=C3)OC)OC)OC.[Br-],,,,,,
604,20605,"(2-ethyl-3,4-dihydro-1H-isoquinolin-5-yl) 3,4,5-trimethoxybenzoate",CCN1CCC2=C(C1)C=CC=C2OC(=O)C3=CC(=C(C(=C3)OC)OC)OC,,,,,,
605,20606,5-Hydroxy-2-ethyl-decahydroisoquinoline hydrobromide,CC[NH+]1CCC2C(C1)CCCC2O.[Br-],,,,,,
606,20607,"2-ethyl-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-5-ol",CCN1CCC2C(C1)CCCC2O,,,,,,
607,20608,"Benzoic acid, 3,4,5-trimethoxy-, 2-ethyldecahydro-5-isoquinolyl ester, hydrobromide",CC[NH+]1CCC2C(C1)CCCC2OC(=O)C3=CC(=C(C(=C3)OC)OC)OC.[Br-],,,,,,
608,20609,Niosh/DH9900000,CCN1CCC2C(C1)CCCC2OC(=O)C3=CC(=C(C(=C3)OC)OC)OC,,,,,,
609,20610,2-Cyanoethyl methacrylate,CC(=C)C(=O)OCCC#N,,,,,,
610,20611,12-Methylbenzo[a]pyrene,CC1=CC2=C3C(=CC4=CC=CC=C42)C=CC5=C3C1=CC=C5,,,,,,
611,20612,"6-(4-Chlorophenyl)-1,3,5-triazine-2,4-diamine",C1=CC(=CC=C1C2=NC(=NC(=N2)N)N)Cl,,,,,,
612,20613,"4,6-Dibromo-1,3,5-triazin-2-amine",C1(=NC(=NC(=N1)Br)Br)N,,,,,,
613,20614,N-Nitrosopipecolic acid,C1CCN(C(C1)C(=O)O)N=O,,,,,,
614,20615,"1,1,3-Trimethylcyclopentane",CC1CCC(C1)(C)C,,,,,,
615,20616,5-Acenaphthylenamine,C1=CC2=C3C(=CC=C(C3=C1)N)C=C2,,,,,,
616,20617,"2-Bromo-4,6-dichlorophenol",C1=C(C=C(C(=C1Cl)O)Br)Cl,,,,,,
617,20618,2-Methyl-2-azabicyclo[2.2.1]heptane,CN1CC2CCC1C2,,,,,,
618,20619,Benzyltrimethylammonium iodide,C[N+](C)(C)CC1=CC=CC=C1.[I-],,,"['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)', 'Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)']",,,
619,20620,2-Chlorophenyl acetate,CC(=O)OC1=CC=CC=C1Cl,,,,,,
620,20621,"2,4-Dibromo-6-chlorophenol",C1=C(C=C(C(=C1Cl)O)Br)Br,,,,,,
621,20622,"2-Prop-1-enyl-1,3-dioxolane",CC=CC1OCCO1,,,,,,
622,20623,2-Nitroethyl nitrate,C(CO[N+](=O)[O-])[N+](=O)[O-],,,,,,
623,20624,"2-[(4,4-Diphenylcyclohexyl)-(2-hydroxyethyl)amino]ethanol",C1CC(CCC1N(CCO)CCO)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
624,20625,1-Methyl-4-nitro-1H-imidazol-5-amine,CN1C=NC(=C1N)[N+](=O)[O-],,,,,,
625,20626,5-(4-Chlorophenylazo)-6-hydroxynaphthalene-2-sulfonic acid,C1=CC(=CC=C1N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)O)O)Cl,,,,,,
626,20627,3-Nitro-N-phenylbenzenamine,C1=CC=C(C=C1)NC2=CC(=CC=C2)[N+](=O)[O-],,,,,,
627,20628,Nitracrine,CN(C)CCCNC1=C2C(=NC3=CC=CC=C31)C=CC=C2[N+](=O)[O-],,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Compounds that inhibit cell production of DNA or RNA. (See all compounds classified as Nucleic Acid Synthesis Inhibitors.)']",,,
628,20629,"2-(12-Fluoro-5-hydroxy-4a,6a,8,8-tetramethyl-2-oxo-2,4a,4b,5,6,6a,9a,10,10a,10b,11,12-dodecahydro-6bH,8H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-6b-yl)-2-oxoethyl acetate",CC(=O)OCC(=O)[C@@]12[C@@H](CC3C1(CC([C@H]4C3C[C@@H](C5=CC(=O)C=CC45C)F)O)C)OC(O2)(C)C,,,,,,
629,20630,2-Chloro-5-nitrobenzenesulfonyl chloride,C1=CC(=C(C=C1[N+](=O)[O-])S(=O)(=O)Cl)Cl,,,,,,
630,20631,4-Chloro-2-nitrobenzenesulfonyl chloride,C1=CC(=C(C=C1Cl)[N+](=O)[O-])S(=O)(=O)Cl,,,,,,
631,20632,"Benzene, (1-pentyloctyl)-",CCCCCCCC(CCCCC)C1=CC=CC=C1,,,,,,
632,20633,"Benzene, (1-butylnonyl)-",CCCCCCCCC(CCCC)C1=CC=CC=C1,,,,,,
633,20634,"Benzene, (1-propyldecyl)-",CCCCCCCCCC(CCC)C1=CC=CC=C1,,,,,,
634,20635,"Benzene, (1-ethylundecyl)-",CCCCCCCCCCC(CC)C1=CC=CC=C1,,,,,,
635,20636,2-Phenyltridecane,CCCCCCCCCCCC(C)C1=CC=CC=C1,,,,,,
636,20637,7-Phenyltetradecane,CCCCCCCC(CCCCCC)C1=CC=CC=C1,,,,,,
637,20638,6-Phenyltetradecane,CCCCCCCCC(CCCCC)C1=CC=CC=C1,,,,,,
638,20639,5-Phenyltetradecane,CCCCCCCCCC(CCCC)C1=CC=CC=C1,,,,,,
639,20640,4-Phenyltetradecane,CCCCCCCCCCC(CCC)C1=CC=CC=C1,,,,,,
640,20641,3-Phenyltetradecane,CCCCCCCCCCCC(CC)C1=CC=CC=C1,,,,,,
641,20642,2-Phenyltetradecane,CCCCCCCCCCCCC(C)C1=CC=CC=C1,,,,,,
642,20643,N-(2-Chloroethyl)dicyclohexylamine hydrochloride,C1CCC(CC1)[NH+](CCCl)C2CCCCC2.[Cl-],,,,,,
643,20644,N-(2-chloroethyl)-N-cyclohexylcyclohexanamine,C1CCC(CC1)N(CCCl)C2CCCCC2,,,,,,
644,20645,N-(2-Chloroethyl)dipropylamine hydrochloride,CCC[NH+](CCC)CCCl.[Cl-],,,,,,
645,20646,"1-Propanamine, N-(2-chloroethyl)-N-propyl-",CCCN(CCC)CCCl,,,,,,
646,20647,"Ethanamine, 2-chloro-N-ethyl-, hydrochloride",CC[NH2+]CCCl.[Cl-],,,,,,
647,20648,"Ethanamine, 2-chloro-N-ethyl-",CCNCCCl,,,,,,
648,20649,Methyl-ethyl-beta-chloroethylamine hydrochloride,CC[NH+](C)CCCl.[Cl-],,,,,,
649,20650,2-Chloroethylethylmethylamine,CCN(C)CCCl,,,,,,
650,20651,2-Chloroethyl(methyl)ammonium chloride,C[NH2+]CCCl.[Cl-],,,,,,
651,20652,"Ethanamine, 2-chloro-N-methyl-",CNCCCl,,,,,,
652,20653,2-Methylhexanoic acid,CCCCC(C)C(=O)O,,,,,,
653,20654,"Benzene, (1-propyloctyl)-",CCCCCCCC(CCC)C1=CC=CC=C1,,,,,,
654,20655,3-Phenylundecane,CCCCCCCCC(CC)C1=CC=CC=C1,,,,,,
655,20656,"Benzene, (1-methyldecyl)-",CCCCCCCCCC(C)C1=CC=CC=C1,,,,,,
656,20657,"Benzene, (1-butylhexyl)-",CCCCCC(CCCC)C1=CC=CC=C1,,,,,,
657,20658,"Benzene, (1-propylheptyl)-",CCCCCCC(CCC)C1=CC=CC=C1,,,,,,
658,20659,2-Phenyldecane,CCCCCCCCC(C)C1=CC=CC=C1,,,,,,
659,20660,6-Phenylundecane,CCCCCC(CCCCC)C1=CC=CC=C1,,,,,,
660,20661,5-Phenylundecane,CCCCCCC(CCCC)C1=CC=CC=C1,,,,,,
661,20662,2-Cyanoethylene oxide,C1C(O1)C#N,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,['Cyanoethylene oxide is a known human metabolite of acrylonitrile.'],
662,20663,"Ethanol, 2,2'-[[3-chloro-4-[(4-nitrophenyl)azo]phenyl]imino]bis-",C1=CC(=CC=C1N=NC2=C(C=C(C=C2)N(CCO)CCO)Cl)[N+](=O)[O-],,,,,,
663,20664,1-Bromo-3-chloropropan-2-ol,C(C(CBr)O)Cl,,,,,,
664,20665,4-(Hexyloxy)-1-butanol,CCCCCCOCCCCO,,,,,,
665,20666,4-Morpholineethanethiol,C1COCCN1CCS,,,,,,
666,20667,Dodecyl ether,CCCCCCCCCCCCOCCCCCCCCCCCC,,,,,,
667,20668,2-(2-Phenylacetamido)acetohydroxamic acid,C1=CC=C(C=C1)CC(=O)NCC(=O)NO,,,,,,
668,20669,4-(Butylamino)butan-1-ol,CCCCNCCCCO,,,,,,
669,20670,"Benzilic acid, (2-morpholinoethyl) ester, hydrochloride",C1COCC[NH+]1CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O.[Cl-],,,,,,
670,20671,"2-Morpholin-4-ylethyl 2-hydroxy-2,2-diphenylacetate",C1COCCN1CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
671,20672,2-(1-Pyrrolidinyl)ethyl benzilate hydrochloride,C1CC[NH+](C1)CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O.[Cl-],,,,,,
672,20673,Offterror,C1CC[NH+](CC1)CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O.[Cl-],,,,,,
673,20674,Piperilate,C1CCN(CC1)CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
674,20675,"ACETIC ACID, (4-BUTOXY-m-TOLYL)-",CCCCOC1=C(C=C(C=C1)CC(=O)O)C,,,,,,
675,20676,Flunidazole,C1=CC(=CC=C1C2=NC=C(N2CCO)[N+](=O)[O-])F,,,,,,
676,20677,"1,9-Dibromononane",C(CCCCBr)CCCCBr,,,,,,
677,20678,N-Nitrosomethylvinylamine,CN(C=C)N=O,,,,,,
678,20679,N-Nitroso-N-methylallylamine,CN(CC=C)N=O,,,,,,
679,20680,N-Ethyl-N-nitrosobutylamine,CCCCN(CC)N=O,,,,,,
680,20681,CID 20681,CC1=CC=CC=C1[O-].[Na+],,,,,,
681,20682,"1,3-Pentadiene, 3-methyl-",CC=C(C)C=C,,,,,,
682,20683,Fenalamide,CCC(C1=CC=CC=C1)(C(=O)NCCN(CC)CC)C(=O)OCC,,,,,,
683,20684,2-(1H-Purin-6-ylamino)ethanol,C1=NC2=C(N1)C(=NC=N2)NCCO,,,,,,
684,20685,Busatin,CCCCN(CCCC)C(=S)N=NC1=C(N(C2=CC=CC=C21)C)O,,,,,,
685,20686,2-Methylglutaronitrile,CC(CCC#N)C#N,,,,,,
686,20687,Brown HT,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])NN=C3C=C(C(=O)C(=NNC4=CC=C(C5=CC=CC=C54)S(=O)(=O)[O-])C3=O)CO.[Na+].[Na+],,,,,,
687,20688,"3,5-Bis(4-sulfo-1-naphthylazo)-2,4-dihydroxybenzenemethanol",C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)O)NN=C3C=C(C(=O)C(=NNC4=CC=C(C5=CC=CC=C54)S(=O)(=O)O)C3=O)CO,,,,,,
688,20689,Butyrylthiocholine,CCCC(=O)SCC[N+](C)(C)C,,,,,,
689,20690,CID 20690,C1=CN=CC=C1S,,,,,,
690,20691,Tetrabutylurea,CCCCN(CCCC)C(=O)N(CCCC)CCCC,,,,,,
691,20692,"1,3,5-Tris(cyanomethyl)hexahydro-s-triazine",C1N(CN(CN1CC#N)CC#N)CC#N,,,,,,
692,20693,"Butyl 1,2,2-trichloroethyl disulfide",CCCCSSC(C(Cl)Cl)Cl,,,,,,
693,20694,alpha-Phenyl-beta-aminoethanol hydrochloride,C1=CC=C(C=C1)C(C[NH3+])O.[Cl-],,,,,,
694,20695,4-Hydroxypyrimidine,C1=CN=CNC1=O,,,,,,
695,20696,"N,N-Dihexyl-4-hexyloxy-1-naphthamidine hydrochloride",CCCCCC[NH+](CCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCCCCCC.[Cl-],,,,,,
696,20697,"4-hexoxy-N,N-dihexylnaphthalene-1-carboximidamide",CCCCCCN(CCCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCCCCCC,,,,,,
697,20698,CID 20698,C[C@@H]1C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O[C@@H](CC2C(O2)C=CC1=O)C)OC(=O)C)OC)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C)O[C@H]4C[C@@]([C@H]([C@@H](O4)C)OC(=O)CC(C)C)(C)O)N(C)C)O)CC=O,,,,,,
698,20699,"BENZO(b)NAPHTHO(2,1-d)THIOPHENE, 1-METHYL-",CC1=C2C(=CC=C1)C=CC3=C2SC4=CC=CC=C34,,,,,,
699,20700,"BENZO(b)NAPHTHO(2,1-d)THIOPHENE, 6-METHYL-",CC1=CC2=CC=CC=C2C3=C1C4=CC=CC=C4S3,,,,,,
700,20701,"Octadecanoic acid, compd. with 2,2',2''-nitrilotris[ethanol] (1:1)",CCCCCCCCCCCCCCCCCC(=O)[O-].C(CO)[NH+](CCO)CCO,,,,,,
701,20702,"p-Hydroxyphenyl 2,5-dimethyl-3-furyl ketone",CC1=CC(=C(O1)C)C(=O)C2=CC=C(C=C2)O,,,,,,
702,20703,"Ketone, 3,5-diiodo-4-hydroxyphenyl 2-furyl",C1=COC=C1C(=O)C2=CC(=C(C(=C2)I)O)I,,,,,,
703,20704,CID 20704,CCC1=CC=CO1.CC(=O)C1=CC(=C(C(=C1)I)O)I,,,,,,
704,20705,"1-(4-Hydroxy-3,5-diiodophenyl)ethanone",CC(=O)C1=CC(=C(C(=C1)I)O)I,,,,,,
705,20706,2-Phenylthiazolidine,C1CSC(N1)C2=CC=CC=C2,,,,,,
706,20707,2-Aminobenzoxazole,C1=CC=C2C(=C1)N=C(O2)N,,,,,,
707,20708,Tetradecyltrimethylammonium chloride,CCCCCCCCCCCCCC[N+](C)(C)C.[Cl-],,,"['Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)', 'Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)']",,,
708,20709,Atropine N-oxide hydrochloride,C[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)[O-].Cl,,,,,,
709,20710,Genatropin,C[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)[O-],,,,,,
710,20711,"6-(2-Bromoethyl)-1,3,5-triazine-2,4-diamine",C(CBr)C1=NC(=NC(=N1)N)N,,,,,,
711,20712,Adenosine Phosphate Disodium,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)([O-])[O-])O)O)N.[Na+].[Na+],,,,,,
712,20713,2-Tert-butylcyclobutan-1-one,CC(C)(C)C1CCC1=O,,,,,,
713,20714,5-((p-Chlorophenoxy)methyl)-5-phenylhydantoin,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)COC3=CC=C(C=C3)Cl,,,,,,
714,20715,CID 20715,CC1(C(=NC(=N1)S)S)COC2=CC=C(C=C2)Cl,,,,,,
715,20716,5-((p-Chlorophenoxy)methyl)-5-methylhydantoin,CC1(C(=O)NC(=O)N1)COC2=CC=C(C=C2)Cl,,,,,,
716,20717,2-Chloroethyldimethylammonium chloride,C[NH+](C)CCCl.[Cl-],,,,,,
717,20718,3-Bromotropolone,C1=CC(=C(C(=O)C=C1)O)Br,,,,,,
718,20719,CID 20719,CC[N-]C1=NC(=NC(=N1)N[N+]#N)OC,,,,,,
719,20720,CID 20720,CCNC1=NC(=NC(=N1)OC)N[N+]#N,,,,,,
720,20721,"KETONE, m-(BIS(2-CHLOROETHYL)AMINO)PHENYL MORPHOLINO",C1COCCN1C(=O)C2=CC(=CC=C2)N(CCCl)CCCl,,,,,,
721,20722,"2,4,6-Trinitrophenyl nitramine",C1=C(C=C(C(=C1[N+](=O)[O-])N[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
722,20723,Dibutyldichlorogermane,CCCC[Ge](CCCC)(Cl)Cl,,,,,,
723,20724,3-Phenylbutyric acid,CC(CC(=O)O)C1=CC=CC=C1,,,,,,
724,20725,"6,7-Dimethoxy-1-methylisoquinoline",CC1=NC=CC2=CC(=C(C=C12)OC)OC,,,,,,
725,20726,"1,3-Dibenzyl-2-phenylimidazolidine",C1CN(C(N1CC2=CC=CC=C2)C3=CC=CC=C3)CC4=CC=CC=C4,,,,,,
726,20727,2-(Methylamino)pyridine,CNC1=CC=CC=N1,,,,,,
727,20728,"4-[(17-acetyl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy]-4-oxobutanoic acid",CC(=O)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)CCC(=O)O)C)C,,,,,,
728,20729,"11H-Indeno(2,1-A)phenanthren-11-one",C1=CC=C2C(=C1)C=CC3=C2C=CC4=C3C(=O)C5=CC=CC=C45,,,,,,
729,20730,"13H-Dibenzo(A,H)fluoren-13-one",C1=CC=C2C(=C1)C=CC3=C2C(=O)C4=CC5=CC=CC=C5C=C34,,,,,,
730,20731,4-Amino-2-(hexyloxy)thiobenzoic acid S-(2-(diethylamino)ethyl) ester hydrochloride,CCCCCCOC1=C(C=CC(=C1)N)C(=O)SCC[NH+](CC)CC.[Cl-],,,,,,
731,20732,4-Amino-2-(hexyloxy)thiobenzoic acid S-[2-(diethylamino)ethyl] ester,CCCCCCOC1=C(C=CC(=C1)N)C(=O)SCCN(CC)CC,,,,,,
732,20733,Hyoscyamine hydrobromide,CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3.Br,,,"['Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (See all compounds classified as Adjuvants, Anesthesia.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Agents that dilate the pupil. They may be either sympathomimetics or parasympatholytics. (See all compounds classified as Mydriatics.)', 'Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)']",,,
733,20734,"2,3-Dimethylfluorene",CC1=CC2=C(C=C1C)C3=CC=CC=C3C2,,,,,,
734,20735,"meso-2,3-Diphenylbutane",CC(C1=CC=CC=C1)C(C)C2=CC=CC=C2,,,,,,
735,20736,Methyl 2-acetylacetoacetate,CC(=O)C(C(=O)C)C(=O)OC,,,,,,
736,20737,"2,4,6-Tribromo-3-methylphenol",CC1=C(C(=C(C=C1Br)Br)O)Br,,,,,,
737,20738,"3-(Benzoyloxy)-2,4-pentanedione",CC(=O)C(C(=O)C)OC(=O)C1=CC=CC=C1,,,,,,
738,20739,4-Isopropylcyclohexanol,CC(C)C1CCC(CC1)O,,,,,,
739,20740,3-Phenyldecane,CCCCCCCC(CC)C1=CC=CC=C1,,,,,,
740,20741,CID 20741,C1=CC(=CN=C1)C(=N)S,,,,,,
741,20742,"2,4-Dichloro-6-dodecoxy-1,3,5-triazine",CCCCCCCCCCCCOC1=NC(=NC(=N1)Cl)Cl,,,,,,
742,20743,CID 20743,C1=CC(=CC=C1C(=O)[O-])N=NC2=C(N=C(N=C2N)N)N.[Na+],,,,,,
743,20744,4-[2-(4-Nitrophenyl)ethenyl]aniline,C1=CC(=CC=C1C=CC2=CC=C(C=C2)[N+](=O)[O-])N,,,,,,
744,20745,6-Methylhept-5-en-2-ol,CC(CCC=C(C)C)O,,,,,,
745,20746,3-Methyl-9H-carbazole,CC1=CC2=C(C=C1)NC3=CC=CC=C32,,,,,,
746,20747,"4-(4-Phenylpiperazin-1-yl)butyl 3,4,5-trimethoxybenzoate",COC1=CC(=CC(=C1OC)OC)C(=O)OCCCCN2CCN(CC2)C3=CC=CC=C3,,,,,,
747,20748,Methyl cyclohexanecarboxylate,COC(=O)C1CCCCC1,,,,,,
748,20749,Prifinium bromide,CC[N+]1(CCC(=C(C2=CC=CC=C2)C3=CC=CC=C3)C1C)CC.[Br-],,,,,,
749,20750,CID 20750,CC=CCC#N,,,,,,
750,20751,"2,4,6-Cycloheptatrien-1-one, 4-hydroxy-",C1=CC(=O)C=CC(=C1)O,,,,,,
751,20752,"N,N'-Dibenzylformamidine",C1=CC=C(C=C1)CNC=NCC2=CC=CC=C2,,,,,,
752,20753,4-(Hydroxyamino)quinoline 1-oxide,C1=CC=C2C(=C1)C(=NO)C=CN2O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)']",,,
753,20754,"KETONE, 1-AZIRIDINYL m-(BIS(2-CHLOROETHYL)AMINO)PHENYL",C1CN1C(=O)C2=CC(=CC=C2)N(CCCl)CCCl,,,,,,
754,20755,(-)-cis-Chrysanthemic acid,CC(=C[C@@H]1[C@@H](C1(C)C)C(=O)O)C,,,,,,
755,20756,Hept-2-en-4-one,CCCC(=O)C=CC,,,,,,
756,20757,Dicyclohexyl ether,C1CCC(CC1)OC2CCCCC2,,,,,,
757,20758,"cis-1,2-Indandiol",C1[C@@H]([C@@H](C2=CC=CC=C21)O)O,,,,,,
758,20759,"1H-Indene-1,2-diol, 2,3-dihydro-, trans-",C1[C@@H]([C@H](C2=CC=CC=C21)O)O,,,,,,
759,20760,"1,3-Dioxo-2-phenylisoindoline-5-carboxylic acid",C1=CC=C(C=C1)N2C(=O)C3=C(C2=O)C=C(C=C3)C(=O)O,,,,,,
760,20761,"6-Bromo-1,3,5-triazine-2,4-diamine",C1(=NC(=NC(=N1)Br)N)N,,,,,,
761,20762,"CYTOSINE, 5-(p-AMINOPHENYL)-",C1=CC(=CC=C1C2=C(NC(=O)N=C2)N)N,,,,,,
762,20763,"4-[(3R,5S)-3-hydroxy-10,13-dimethyl-7-oxo-1,2,3,4,5,6,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid",CC(CCC(=O)O)C1CCC2C1(CCC3C2C(=O)C[C@H]4C3(CC[C@H](C4)O)C)C,,,,,,
763,20764,"Indole, 3-(2-(benzylmethylamino)ethyl)-5-(benzyloxy)-",CN(CCC1=CNC2=C1C=C(C=C2)OCC3=CC=CC=C3)CC4=CC=CC=C4,,,,,,
764,20765,"3,3'-Oxybis[2-propenal]",C(=COC=CC=O)C=O,,,,,,
765,20766,3-Methoxyprop-2-enal,COC=CC=O,,,,,,
766,20767,"4-chloro-N-ethyl-6-methoxy-1,3,5-triazin-2-amine",CCNC1=NC(=NC(=N1)Cl)OC,,,,,,
767,20768,"N''-[(2-Chlorophenyl)methyl]-N,N-dimethylguanidine",CN(C)C(=NCC1=CC=CC=C1Cl)N,,,,,,
768,20769,Isopropyl methacrylate,CC(C)OC(=O)C(=C)C,,,,,,
769,20770,Diphenylarsinic acid,C1=CC=C(C=C1)[As](=O)(C2=CC=CC=C2)O,,,,,,
770,20771,"3H-Indolium, 1,3,3-trimethyl-2-[2-(1-methyl-2-phenyl-1H-indol-3-yl)ethenyl]-, chloride (1:1)",CC1(C2=CC=CC=C2[N+](=C1C=CC3=C(N(C4=CC=CC=C43)C)C5=CC=CC=C5)C)C.[Cl-],,,,,,
771,20772,"1,3,3-Trimethyl-2-[2-(1-methyl-2-phenyl-1H-indol-3-yl)ethenyl]-3H-indolium",CC1(C2=CC=CC=C2[N+](=C1C=CC3=C(N(C4=CC=CC=C43)C)C5=CC=CC=C5)C)C,,,,,,
772,20773,1-(Hydroxymethyl)-3-[(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2-thione,C1CN(C(=S)N1CO)N=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
773,20774,Quadrosilan,C[Si]1(O[Si](O[Si](O[Si](O1)(C)C2=CC=CC=C2)(C)C)(C)C3=CC=CC=C3)C,,,,,,
774,20775,"4,6-dibromo-N-butan-2-yl-1,3,5-triazin-2-amine",CCC(C)NC1=NC(=NC(=N1)Br)Br,,,,,,
775,20776,CID 20776,CC[N-]C1=NC(=NC(=N1)N[N+]#N)SC,,,,,,
776,20777,CID 20777,CCNC1=NC(=NC(=N1)SC)N[N+]#N,,,,,,
777,20778,CID 20778,CC(C)[N-]C1=NC(=NC(=N1)N[N+]#N)SC,,,,,,
778,20779,CID 20779,CC(C)NC1=NC(=NC(=N1)SC)N[N+]#N,,,,,,
779,20780,"N-butan-2-yl-4-chloro-6-methylsulfanyl-1,3,5-triazin-2-amine",CCC(C)NC1=NC(=NC(=N1)Cl)SC,,,,,,
780,20781,"2,3,6-Trichlorobenzaldehyde",C1=CC(=C(C(=C1Cl)C=O)Cl)Cl,,,,,,
781,20782,"(13-ethyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl) decanoate",CCCCCCCCCC(=O)OC1CCC2C1(CCC3C2CCC4=CC(=O)CCC34)CC,,,,,,
782,20783,1-Methyl-4-phenyl-4-hydroxy-3-benzoylpiperidine hydrochloride,CN1CCC(C(C1)C(=O)C2=CC=CC=C2)(C3=CC=CC=C3)O.Cl,,,,,,
783,20784,3-Benzoyl-4-hydroxy-1-methyl-4-phenylpiperidine,CN1CCC(C(C1)C(=O)C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
784,20785,Furidarone,CC1=CC(=C(O1)C)C(=O)C2=CC(=C(C(=C2)I)O)I,,,,,,
785,20786,Diphenylstyrylcarbinol,C1=CC=C(C=C1)C=CC(C2=CC=CC=C2)(C3=CC=CC=C3)O,,,,,,
786,20787,Buramate,C1=CC=C(C=C1)CNC(=O)OCCO,,,,,,
787,20788,"Carbamic acid, phenethyl-, 2-hydroxyethyl ester",C1=CC=C(C=C1)CCNC(=O)OCCO,,,,,,
788,20789,(beta-Methylphenethyl)carbamic acid 2-hydroxyethyl ester,CC(CNC(=O)OCCO)C1=CC=CC=C1,,,,,,
789,20790,2-(2-Benzothiazolylthio)ethanol,C1=CC=C2C(=C1)N=C(S2)SCCO,,,,,,
790,20791,2-Hydrazinylacetamide hydrochloride,C(C(=O)N)NN.Cl,,,,,,
791,20792,2-Hydrazinylacetamide,C(C(=O)N)NN,,,,,,
792,20793,"Butyramide, 4-piperidino-",C1CCN(CC1)CCCC(=O)N,,,,,,
793,20794,4-(Piperidin-1-yl)butanoic acid,C1CCN(CC1)CCCC(=O)O,,,,,,
794,20795,CID 20795,CCCOP(=O)O,,,,,,
795,20796,Ethylene dimethanesulfonate,CS(=O)(=O)OCCOS(=O)(=O)C,,,,,,
796,20797,Nookatone,CC1CC(=O)C=C2C1(CC(CC2)C(=C)C)C,,,,,,
797,20798,2-(1-Methylpiperidin-4-yl)-5-pyridin-4-ylpyrazol-3-amine,CN1CCC(CC1)N2C(=CC(=N2)C3=CC=NC=C3)N,,,,,,
798,20799,2-Methylbut-2-en-1-ol,CC=C(C)CO,,,,,,
799,20800,"Ammonium, (((6-chloro-o-tolyl)carbamoyl)methyl)dimethyl((2,6-xylylcarbamoyl)methyl)-, bromide",CC1=C(C(=CC=C1)C)NC(=O)C[N+](C)(C)CC(=O)NC2=C(C=CC=C2Cl)C.[Br-],,,,,,
800,20801,"[2-(2-Chloro-6-methylanilino)-2-oxoethyl]-[2-(2,6-dimethylanilino)-2-oxoethyl]-dimethylazanium",CC1=C(C(=CC=C1)C)NC(=O)C[N+](C)(C)CC(=O)NC2=C(C=CC=C2Cl)C,,,,,,
801,20802,CID 20802,CC1(C(=O)NC(=N1)S)COC2=CC=C(C=C2)Cl,,,,,,
802,20803,Guinea green B,CCN(CC1=CC(=CC=C1)S(=O)(=O)[O-])C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)[O-])C=C3)C5=CC=CC=C5.[Na+],,,,"['Studies in rats involving oral administration showed that only small amounts of the dye (< 5%) are absorbed and excreted unchanged in the bile. Following its iv injection in rats, about 75% of the dye was excreted in the bile within 4 hr.']",,
803,20804,C.I. Acid green 3,CCN(CC1=CC(=CC=C1)S(=O)(=O)O)C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)O)C=C3)C5=CC=CC=C5,,,,"['Studies in rats involving oral administration showed that only small amounts of the dye (< 5%) are absorbed and excreted unchanged in the bile. Following its iv injection in rats, about 75% of the dye was excreted in the bile within 4 hr.']",,
804,20805,"Acetic acid, mercaptophenyl-, 2-fluoroethyl ester, S-ester with O,O-diethyl phosphorodithioate",CCOP(=S)(OCC)SC(C1=CC=CC=C1)C(=O)OCCF,,,,,,
805,20806,Trichodermin,CC1=C[C@@H]2[C@](CC1)([C@]3([C@@H](C[C@H]([C@@]34CO4)O2)OC(=O)C)C)C,,,,,,
806,20807,"2,4-Dichloro-6-phenoxy-1,3,5-triazine",C1=CC=C(C=C1)OC2=NC(=NC(=N2)Cl)Cl,,,,,,
807,20808,2-Furyl p-hydroxyphenyl ketone,C1=COC(=C1)C(=O)C2=CC=C(C=C2)O,,,,,,
808,20809,"Ketone, 3-(2-aminoethyl)indol-5-YL methyl, hydrochloride",CC(=O)C1=CC2=C(C=C1)NC=C2CCN.Cl,,,,,,
809,20810,Acetryptine,CC(=O)C1=CC2=C(C=C1)NC=C2CCN,,,,,,
810,20811,Octamoxin,CCCCCCC(C)NN,['For the treatment of depression.'],,,,,
811,20812,6-Chloropicolinic acid,C1=CC(=NC(=C1)Cl)C(=O)O,,,,,,
812,20813,Furyltriazine,C1=COC(=C1)C2=NC(=NC(=N2)N)N,,,,,,
813,20814,CID 20814,CC[NH+](CC)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.[Cl-],,,,,,
814,20815,"5H-Dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine, 10,11-dihydro-N,N-diethyl-",CCN(CC)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,,,,,,
815,20816,"5H-Dibenzo(a,d)cycloheptene, 10,11-dihydro-5-(3-(1,2,5,6-tetrahydropyridino)propylidene)-",C1CNCC(=C1)CCC=C2C3=CC=CC=C3CCC4=CC=CC=C42,,,,,,
816,20817,CID 20817,C1=CC=C(C=C1)COS(=O)(=O)[O-].[Na+],,,,,,
817,20818,Benzyl sulfate,C1=CC=C(C=C1)COS(=O)(=O)O,,,,,,
818,20819,CID 20819,C1=NC(=O)C2=C(N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)([O-])[O-])O)O.[Na+].[Na+],,,,,,
819,20820,"Acetoacetamide, N-(2-benzothiazolyl)-",CC(=O)CC(=O)NC1=NC2=CC=CC=C2S1,,,,,,
820,20821,5-Nitroisatoic anhydride,C1=CC2=C(C=C1[N+](=O)[O-])C(=O)OC(=O)N2,,,,,,
821,20822,"Octanoic acid, barium salt",CCCCCCCC(=O)[O-].CCCCCCCC(=O)[O-].[Ba+2],,,,,,
822,20823,Ticarcillin (sodium),CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CSC=C3)C(=O)[O-])C(=O)[O-])C.[Na+].[Na+],,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
823,20824,Carbenicillin,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)O)C(=O)O)C,['For the treatment of acute and chronic infections of the upper and lower urinary tract and in asymptomatic bacteriuria due to susceptible strains of bacteria.'],"['Carbenicillin is a semisynthetic penicillin. Though carbenicillin provides substantial <i>in vitro</i> activity against a variety of both gram-positive and gram-negative microorganisms, the most important aspect of its profile is in its antipseudomonal and antiproteal activity. Because of the high urine levels obtained following administration, carbenicillin has demonstrated clinical efficacy in urinary infections due to susceptible strains of: <i>Escherichia coli</i>, <i>Proteus mirabilis</i>, <i>Proteus vulgaris</i>, <i>Morganella morganii</i>, <i>Pseudomonas</i> species, <i>Providencia rettgeri</i>, <i>Enterobacter</i> species, and <i>Enterococci</i> (<i>S. faecalis</i>).']",['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],"['Rapidly absorbed from the small intestine following oral administration. Oral bioavailability is 30 to 40%.', 'CARBENICILLIN IS NOT ABSORBED FROM GI TRACT &, THEREFORE MUST BE GIVEN PARENTERALLY. ... IM INJECTION OF 1 G PRODUCES PEAK PLASMA CONCN OF 15-20 UG/ML IN 1/2-2 HR... MAX PLASMA CONCN ARE ABOUT 4 TIMES HIGHER AFTER IV THAN AFTER IM ADMIN... IV INFUSION...1 G/HR RESULTS IN AVG PLASMA CONCN OF APPROX 150 UG/ML.', 'ABOUT 50% OF ANTIBIOTIC IN PLASMA IS PROTEIN BOUND. ...CARBENICILLIN IS EXCRETED PRIMARILY BY RENAL TUBULES. ABOUT 75-80%...IS RECOVERABLE IN ACTIVE FORM IN URINE IN 9 HR.', 'Carbenicillin is not stable in acids nor does it resist penicillinases; thus it is administered parenterally because of poor absorption following oral administration. A parenteral dose of 50-200 mg/kg is divided for administration every 4-6 hr.', 'Although carbenicillin is eliminated from the bovine mammary gland within 72 hr posttreatment, mastitis produced by P. aeruginosa is not effectively treated; resistant organisms are recovered 24-48 hr postinfusion.', 'For more Absorption, Distribution and Excretion (Complete) data for CARBENICILLIN (11 total), please visit the HSDB record page.']",['Minimal.'],"['1 hour', '...T 1/2...IN INDIVIDUALS WITH NORMAL RENAL FUNCTION IS ABOUT 1 HR...PROLONGED TO ABOUT 2 HR IN PRESENCE OF HEPATIC DYSFUNCTION.']"
824,20825,N-Phthaloylglycine,C1=CC=C2C(=C1)C(=O)N(C2=O)CC(=O)O,,,,,,
825,20826,"9,10-Anthracenedione, 4,8-diamino-1,5-dihydroxy-2-(4-methoxyphenyl)-",COC1=CC=C(C=C1)C2=CC(=C3C(=C2O)C(=O)C4=C(C=CC(=C4C3=O)O)N)N,,,,,,
826,20827,"3-Bromo-1,2-propanediol",C(C(CBr)O)O,,,,,,
827,20828,CID 20828,COC1=CC=C(C=C1)C=CC2=CC=C(C=C2)OC,,,,,,
828,20829,"p-Aminobenzoic acid 2-(2-octylamino)-2,2-dimethylethyl ester",CCCCCCC(C)NC1=C(C=CC(=C1)N)C(=O)OCC(C)C,,,,,,
829,20830,2-Piperidinomethyl-1-tetralone,C1CCN(CC1)CC2CCC3=CC=CC=C3C2=O,,,,,,
830,20831,2-Tetradecanol,CCCCCCCCCCCCC(C)O,,,,,,
831,20832,"Benzene, 2,4-dimethyl-1-(1-methylethyl)-",CC1=CC(=C(C=C1)C(C)C)C,,,,,,
832,20833,5-Isopropyl-m-xylene,CC1=CC(=CC(=C1)C(C)C)C,,,,,,
833,20834,"2,4-Dihydroxy-6-propylbenzoic acid",CCCC1=C(C(=CC(=C1)O)O)C(=O)O,,,,,,
834,20835,2-(4-Cyclohexenyl)bicyclo(2.2.1)hept-5-ene,C1CC(CC=C1)C2CC3CC2C=C3,,,,,,
835,20836,Butan-1-(2H)ol,[2H]OCCCC,,,,,,
836,20837,2-Butanol (D),[2H]OC(C)CC,,,,,,
837,20838,(2-Chloro-2-phenylethyl)benzene,C1=CC=C(C=C1)CC(C2=CC=CC=C2)Cl,,,,,,
838,20839,"2-[4,6-Bis(2-hydroxyethyl)-1,3,5-triazinan-2-yl]ethanol",C(CO)C1NC(NC(N1)CCO)CCO,,,,,,
839,20840,CID 20840,CC1=NC(=O)N=C(N1)N,,,,,,
840,20841,CID 20841,C1=CC=C(C=C1)C2=NC(=O)N=C(N2)N,,,,,,
841,20842,Grayanotoxin I,CC(=O)O[C@@H]1C2CC[C@@H]3C1(C[C@H]([C@]4([C@H]([C@]3(C)O)C[C@@H](C4(C)C)O)O)O)C[C@@]2(C)O,,,"['Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs that interrupt transmission at the skeletal neuromuscular junction by causing sustained depolarization of the motor end plate. These agents are primarily used as adjuvants in surgical anesthesia to cause skeletal muscle relaxation. (See all compounds classified as Neuromuscular Depolarizing Agents.)']",,,
842,20843,"3,4-Dihydro-1-methyl-6,7-isoquinolinediol hydrochloride",CC1=[NH+]CCC2=CC(=C(C=C12)O)O.[Cl-],,,,,,
843,20844,"1,2-Dehydrosalsolinol",CC1=NCCC2=CC(=C(C=C12)O)O,,,,,,
844,20845,"2-Methyl-1,4-dioxaspiro[4.5]decane",CC1COC2(O1)CCCCC2,,,,,,
845,20846,2-Dimethylaminoethyl-2-methyl-benzhydryl ether citrate,CC1=CC=CC=C1C(C2=CC=CC=C2)OCC[NH+](C)C.C(C(=O)O)C(CC(=O)[O-])(C(=O)O)O,,,,,,
846,20847,Clamoxyquin hydrochloride,CCN(CC)CCCNCC1=CC(=C2C=CC=NC2=C1O)Cl.Cl.Cl,,,,,,
847,20848,Nitralin,CCCN(CCC)C1=C(C=C(C=C1[N+](=O)[O-])S(=O)(=O)C)[N+](=O)[O-],,,,"['NITRALIN IS NOT ABSORBED BY PLANT FOLIAGE & THEREFORE IS NOT A POSTEMERGENCE HERBICIDE. ABSORPTION BY SEED OR ROOTS OF PLANTS IS MEDIATED BY IMBIBITION OF WATER.', 'Nitralin, as the (14)C-ring-labeled cmpd, has been studied in soybeans, peanuts, peas, and carrots grown under modified field conditions in which the herbicide was soil incorporated at 0.6, 0.75, and 1.0 lb/acre, respectively. In soybeans, the whole plant contained 0.02 ppm equivalents of nitralin. The seeds contained less than 0.01 ppm equivalents of nitralin. Similarly, whole plant parts from peanuts and peas contained an equivalent of 0.03 ppm equivalents of nitralin, with the seeds in a range similar to that of soybeans. Carrots were grown...under greenhouse conditions 11 wk after the initial incorporation study with soybeans. Six wk after planting, carrots were harvested and the roots were divided into peel and cores for analysis. The roots contained 0.006 ppm equivalents of nitralin with 78 and 22% of the radioactivity residing in the peel and cores, respectively.', '(14)C-ring-labeled nitralin fed to rats was rapidly excreted, with 52% of the radioactivity being in the urine and 47% in the feces. No (14)CO2 was observed in an expt run in a metabolism cage. Multiple metabolic products were observed. Guernsey cows were fed nitralin at 50 ppm in their ration. Exam of milk revealed no detectable residues of nitralin or its degradation products 4-methylsulfonyl-2,6-dinitro-N-propylaniline, 4-methylsulfonyl-2,6-dinitrophenol and 4-methylsulfonyl-2,6-dinitroaniline. Analyses of various tissues, feces, and urine showed no detectable residues of nitralin or 4-methylsulfonyl-2,-6-dinitrophenol.']","['PLANAVIN WAS FED TO A CATHETERIZED LACTATING COW AT 5 PPM IN THE FEED RATION FOR 4 DAYS. PLANAVIN OR POSSIBLE SULFUR-CONTAINING METABOLITES WERE NOT DETECTED IN MILK, URINE OR FECES BY ELECTRON AFFINITY & SULFUR-FLAME PHOTOMETRIC GAS CHROMATOGRAPHIC ANALYSIS. THE SULFUR DETECTOR SHOWED THAT THE HERBICIDE RAPIDLY (15 MIN) DECOMPOSED IN FRESH RUMEN FLUID WITH PRODUCTION OF THREE SULFUR-CONTAINING /SRP: METABOLITES NOT DEFINATELY IDENTIFIED/.', 'Plant metabolites are 2,6-dinitro-4-methylsulfonyl-N-propylaniline, 2,6-dinitro-4-methyl-sulphonylaniline /and/ 2,6-dinitro-4-methylsulfonylphenol.', '(14)C-Nitralin was dosed orally to rats 150 mg/kg). The radioactivity was quantitatively (199.8%) between 0-72 hr after dosing. Most of this was distributed equally between the urine and feces; 1.5% was found in the carcass skin and intestines. Structural analysis of the urinary metabolites showed that the metabolism proceeded via a complex multistep series of biotransformations involving nitro-group reduction side-chain oxidation and removal and the subsequent formation of a variety of heterocyclic ring structures. A major metabolite was 7-amino-2-ethyl-5-methylsulfonyl-1-propylbenzimidazole; this accounted for only 3-4% of the ingested radioactivity and was 1 of 5 metabolites produced in this yield. Seven other metabolites were identified none of which was derived from single-step biotransformation of nitralin. The latter simpler metabolites were detected on the incubation of nitralin with rat liver enzymes of the type used in microbial mutagenicity testing. Two pathways nitro-reduction and N-dealkylation) were observed under aerobic conditions but the former greatly predominated under anaerobic conditions.']",
848,20849,Adipimide,C1CCC(=O)NC(=O)C1,,,,,,
849,20850,"N-Allyl-1,5-dimethyl-4-hexenylamine",CC(CCC=C(C)C)NCC=C,,,,,,
850,20851,Trioctylphosphine,CCCCCCCCP(CCCCCCCC)CCCCCCCC,,,,,,
851,20852,"(16alpha)-9,11-Dichloro-17,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione",C[C@@H]1CC2C3CCC4=CC(=O)C=CC4([C@]3(C(CC2([C@]1(C(=O)CO)O)C)Cl)Cl)C,,,,,,
852,20853,1-Naphthaleneethylamine,C1=CC=C2C(=C1)C=CC=C2CCN,,,,,,
853,20854,"(4R,9'R)-9',11'-dichloro-2,2,10',13'-tetramethylspiro[1,3-dioxane-4,17'-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene]-3',5-dione",CC1(OCC(=O)[C@@]2(O1)CCC3C2(CC([C@]4(C3CCC5=CC(=O)C=CC54C)Cl)Cl)C)C,,,,,,
854,20855,"Carbamodithioic acid, diethyl-, ethyl ester",CCN(CC)C(=S)SCC,,,,,,
855,20856,Dianisylneopentane,CC(C)(C)C(C1=CC=C(C=C1)OC)C2=CC=C(C=C2)OC,,,,,,
856,20857,"2-Chloro-4-ethoxy-6-ethylamino-1,3,5-triazine",CCNC1=NC(=NC(=N1)Cl)OCC,,,,,,
857,20858,"1,1-Diethoxypropane",CCC(OCC)OCC,,,,,,
858,20859,"1,1-Dimethoxypropane",CCC(OC)OC,,,,,,
859,20860,"8-Methyl-1,5-dioxaspiro(5.5)undecan-3-ol",CC1CCCC2(C1)OCC(CO2)O,,,,,,
860,20861,4-Ethylbenzaldehyde,CCC1=CC=C(C=C1)C=O,,,,,,
861,20862,"3,3,3-Trichloro-2-methyl-1-propene",CC(=C)C(Cl)(Cl)Cl,,,,,,
862,20863,"2-(2,6-Diethylphenylamino)-2-imidazoline hydrochloride",CCC1=C(C(=CC=C1)CC)NC2=[NH+]CCN2.[Cl-],,,"['Drugs that selectively bind to and activate alpha adrenergic receptors. (See all compounds classified as Adrenergic alpha-Agonists.)', 'Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. (See all compounds classified as Parasympathomimetics.)']",,,
863,20864,"N-(2,6-Diethylphenyl)-4,5-dihydro-1H-imidazol-2-amine",CCC1=C(C(=CC=C1)CC)NC2=NCCN2,,,"['Drugs that selectively bind to and activate alpha adrenergic receptors. (See all compounds classified as Adrenergic alpha-Agonists.)', 'Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. (See all compounds classified as Parasympathomimetics.)']",,,
864,20865,N-(4-Chlorophenyl)benzenesulfonamide,C1=CC=C(C=C1)S(=O)(=O)NC2=CC=C(C=C2)Cl,,,,,,
865,20866,"1-Naphthylamine, N-(2-imidazolin-2-YL)-",C1CN=C(N1)NC2=CC=CC3=CC=CC=C32,,,,,,
866,20867,CID 20867,C1=CC(=CC=C1CN=C(N)N=C([NH3+])N)Cl.[Cl-],,,,,,
867,20868,2-[(4-Chlorophenyl)methyl]-1-(diaminomethylidene)guanidine,C1=CC(=CC=C1CN=C(N)N=C(N)N)Cl,,,,,,
868,20869,"BENZAMIDE, p-(3-AMIDINOGUANIDINO)-N-METHYL-, MONOHYDROCHLORIDE",CNC(=O)C1=CC=C(C=C1)N=C(N)[NH2+]C(=N)N.[Cl-],,,,,,
869,20870,4-[[amino-(diaminomethylideneamino)methylidene]amino]-N-methylbenzamide,CNC(=O)C1=CC=C(C=C1)N=C(N)N=C(N)N,,,,,,
870,20871,"BENZAMIDE, p-(3-AMIDINOGUANIDINO)-N,N-DIMETHYL-, MONOHYDROCHLORIDE",CN(C)C(=O)C1=CC=C(C=C1)N=C(N)[NH2+]C(=N)N.[Cl-],,,,,,
871,20872,"4-[[amino-(diaminomethylideneamino)methylidene]amino]-N,N-dimethylbenzamide",CN(C)C(=O)C1=CC=C(C=C1)N=C(N)N=C(N)N,,,,,,
872,20873,"BENZAMIDE, p-(3-AMIDINOGUANIDINO)-N-ETHYL-, MONOHYDROCHLORIDE",CCNC(=O)C1=CC=C(C=C1)N=C(N)[NH2+]C(=N)N.[Cl-],,,,,,
873,20874,4-[[amino-(diaminomethylideneamino)methylidene]amino]-N-ethylbenzamide,CCNC(=O)C1=CC=C(C=C1)N=C(N)N=C(N)N,,,,,,
874,20875,"BENZAMIDE, p-(3-AMIDINOGUANIDINO)-N,N-DIETHYL-, MONOHYDROCHLORIDE",CCN(CC)C(=O)C1=CC=C(C=C1)N=C(N)[NH2+]C(=N)N.[Cl-],,,,,,
875,20876,"4-[[amino-(diaminomethylideneamino)methylidene]amino]-N,N-diethylbenzamide",CCN(CC)C(=O)C1=CC=C(C=C1)N=C(N)N=C(N)N,,,,,,
876,20877,CID 20877,CC1=CC=CC=C1N=C(N)N=C([NH3+])N.[Cl-],,,,,,
877,20878,CID 20878,CC1=CC(=C(C=C1)N=C(N)N=C([NH3+])N)C.[Cl-],,,,,,
878,20879,"1-(2,4-Xylyl)biguanide",CC1=CC(=C(C=C1)N=C(N)N=C(N)N)C,,,,,,
879,20880,CID 20880,C1=CC(=CC=C1N=C(N)N=C([NH3+])N)[N+](=O)[O-].[Cl-],,,,,,
880,20881,CID 20881,C1=CC(=CC(=C1)[N+](=O)[O-])N=C(N)N=C([NH3+])N.[Cl-],,,,,,
881,20882,N-(3-nitrophenyl)imidodicarbonimidic diamide,C1=CC(=CC(=C1)[N+](=O)[O-])N=C(N)N=C(N)N,,,,,,
882,20883,Clodazon,CN(C)CCCN1C2=C(C=C(C=C2)Cl)N(C1=O)C3=CC=CC=C3,,,,,,
883,20884,Ethyl chloroglyoxylate,CCOC(=O)C(=O)Cl,,,,,,
884,20885,2-(2-Hydroxy-4-methoxybenzoyl)benzoic acid,COC1=CC(=C(C=C1)C(=O)C2=CC=CC=C2C(=O)O)O,,,,,,
885,20886,CID 20886,CC1(C2=CCC=CC2N(C3=CC=CC=C31)CCCN(C)C)C,,,,,,
886,20887,"2-Imidazolidinone, 1,3-dibutyl-",CCCCN1CCN(C1=O)CCCC,,,,,,
887,20888,CID 20888,C(=NC(=N)N)([NH3+])N.[Cl-],,,,,,
888,20889,(N'-carbamimidoylcarbamimidoyl)-propan-2-ylazanium;chloride,CC(C)[NH2+]C(=NC(=N)N)N.[Cl-],,,,,,
889,20890,Isopropylbiguanide,CC(C)N=C(N)N=C(N)N,,,,,,
890,20891,CID 20891,CCC(C)N=C(N)N=C([NH3+])N.[Cl-],,,,,,
891,20892,2-Butan-2-yl-1-(diaminomethylidene)guanidine,CCC(C)N=C(N)N=C(N)N,,,,,,
892,20893,CID 20893,CC(C)(C)N=C(N)N=C([NH3+])N.[Cl-],,,,,,
893,20894,(E)-2-(tert-butyl)-1-(diaminomethylene)guanidine,CC(C)(C)N=C(N)N=C(N)N,,,,,,
894,20895,CID 20895,CCCCC[NH2+]C(=NC(=N)N)N.[Cl-],,,,,,
895,20896,1-Pentylbiguanide,CCCCCN=C(N)N=C(N)N,,,,,,
896,20897,CID 20897,C1CCC(CC1)N=C(N)N=C([NH3+])N.[Cl-],,,,,,
897,20898,1-Cyclohexyl-biguanide,C1CCC(CC1)N=C(N)N=C(N)N,,,,,,
898,20899,"N,N-dimethyl-3-(3,4,5-trimethoxyphenyl)prop-2-enamide",CN(C)C(=O)C=CC1=CC(=C(C(=C1)OC)OC)OC,,,,,,
899,20900,1-(5-nitro-1H-indol-3-yl)ethanone,CC(=O)C1=CNC2=C1C=C(C=C2)[N+](=O)[O-],,,,,,
900,20901,"1-Benzyl-2-(2,2-diphenyl-1,3-dioxolan-4-yl)piperidine",C1CCN(C(C1)C2COC(O2)(C3=CC=CC=C3)C4=CC=CC=C4)CC5=CC=CC=C5,,,,,,
901,20902,3-Chloro-2-nitrobenzoic acid,C1=CC(=C(C(=C1)Cl)[N+](=O)[O-])C(=O)O,,,,,,
902,20903,3-Cyclohexene-1-carboxylic acid,C1CC(CC=C1)C(=O)O,,,,,,
903,20904,Ethyl diethylphosphinate,CCOP(=O)(CC)CC,,,,,,
904,20905,6-Methylpiperidin-2-one,CC1CCCC(=O)N1,,,,,,
905,20906,Fluorosalan,C1=CC(=CC(=C1)NC(=O)C2=C(C(=CC(=C2)Br)Br)O)C(F)(F)F,,,,,,
906,20907,Esbuphon,C1=CC(=CC(=C1)O)C(C[NH3+])O.[Cl-],,,,,,
907,20908,1-Naphthalenemethanol,C1=CC=C2C(=C1)C=CC=C2CO,,,,,['1-Nahthalenethanol is a known human metabolite of 1-Naphtaldehyde.'],
908,20909,"3-(4,6-Diamino-1,3,5-triazin-2-yl)propanenitrile",C(CC1=NC(=NC(=N1)N)N)C#N,,,,,,
909,20910,"2-Butene, 2-bromo-",CC=C(C)Br,,,,,,
910,20911,"Carbamic acid, methyl-, 2,3-dihydro-2,2,4-trimethyl-7-benzofuranyl ester",CC1=C2CC(OC2=C(C=C1)OC(=O)NC)(C)C,,,,,,
911,20912,Methallyl cyanide,CC(=C)CC#N,,,,,,
912,20913,But-2-enenitrile,CC=CC#N,,,,,,
913,20914,2-(2-Aminoethylmercapto)imidazoline bromide hydrobromide,C1CN=C([NH2+]1)SCC[NH3+].[Br-].[Br-],,,,,,
914,20915,2-[(2-Aminoethyl)thio]-2-imidazoline,C1CN=C(N1)SCCN,,,,,,
915,20916,2-(3-Aminopropyl thio)-2-imidazoline dihydrobromide,C1CN=C([NH2+]1)SCCC[NH3+].[Br-].[Br-],,,,,,
916,20917,2-[(3-Aminopropyl)thio]-2-imidazoline,C1CN=C(N1)SCCCN,,,,,,
917,20918,"1-Methoxy-4,9-cyclo-9,10-secoandrosta-1,3,5(10)-trien-17-ol",CC1=C(C=CC2=C1CCC3C2CCC4(C3CC[C@@H]4O)C)OC,,,,,,
918,20919,4-Methyl-2-phenylquinoline,CC1=CC(=NC2=CC=CC=C12)C3=CC=CC=C3,,,,,,
919,20920,"5,6-Bis(benzyloxy)-1H-indole",C1=CC=C(C=C1)COC2=C(C=C3C(=C2)C=CN3)OCC4=CC=CC=C4,,,,,,
920,20921,7-Benzofuranyl N-methylcarbamate,CNC(=O)OC1=CC=CC2=C1OC=C2,,,,,,
921,20922,"Carbamic acid, methyl-, 2,3-dihydro-7-benzofuranyl ester",CNC(=O)OC1=CC=CC2=C1OCC2,,,,,,
922,20923,"7-BENZOFURANOL, 2,3-DIHYDRO-2,2-DIMETHYL-, CARBAMATE (ester)",CC1(CC2=C(O1)C(=CC=C2)OC(=O)N)C,,,,,,
923,20924,"7-Benzofuranol, 2,3-dihydro-2,2-dimethyl-, dimethylcarbamate",CC1(CC2=C(O1)C(=CC=C2)OC(=O)N(C)C)C,,,,,,
924,20925,"4-Chloro-2,3-dihydro-2,2-dimethyl-7-benzofuranyl methylcarbamate",CC1(CC2=C(C=CC(=C2O1)OC(=O)NC)Cl)C,,,,,,
925,20926,Ethyl 5-methoxyindole-2-carboxylate,CCOC(=O)C1=CC2=C(N1)C=CC(=C2)OC,,,,,,
926,20927,"2,5-Cyclohexadienylbenzene",C1C=CC(C=C1)C2=CC=CC=C2,,,,,,
927,20928,1-Hexen-3-OL,CCCC(C=C)O,,,,,,
928,20929,4-Methyl-1-penten-3-OL,CC(C)C(C=C)O,,,,,,
929,20930,2-Hexene-4-ol,CCC(C=CC)O,,,,,,
930,20931,5-Methoxy-1-pentanol,COCCCCCO,,,,,,
931,20932,"Ethanol, 2-(1-phenylethoxy)-",CC(C1=CC=CC=C1)OCCO,,,,,,
932,20933,Carbenicillin disodium,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)[O-])C(=O)[O-])C.[Na+].[Na+],,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
933,20934,(2-Acetamidophenyl)azanium;chloride,CC(=O)NC1=CC=CC=C1[NH3+].[Cl-],,,,,,
934,20935,Piperidin-1-ol,C1CCN(CC1)O,,,,,,
935,20936,Dipentenedimercaptan,CC1CCC(CC1S)C(C)CS,,,,,,
936,20937,1-(2-Diethylaminoethyl)-3-(1-methyl-2-pyrrolidinyl)indole dihydrochloride,CC[NH+](CC)CCN1C=C(C2=CC=CC=C21)C3CCC[NH+]3C.[Cl-].[Cl-],,,,,,
937,20938,1-[2-(Diethylamino)ethyl]-3-(1-methyl-2-pyrrolidinyl)-1H-indole,CCN(CC)CCN1C=C(C2=CC=CC=C21)C3CCCN3C,,,,,,
938,20939,"2,4-Dichloro-6-diazomethyl-1,3,5-triazine",C(=[N+]=[N-])C1=NC(=NC(=N1)Cl)Cl,,,,,,
939,20940,"2-Diazomethyl-4,6-dimethoxy-1,3,5-triazine",COC1=NC(=NC(=N1)C=[N+]=[N-])OC,,,,,,
940,20941,"2,4,6-Tributyl-1,3,5-triazine",CCCCC1=NC(=NC(=N1)CCCC)CCCC,,,,,,
941,20942,"3-(9,11-Dihydroxy-8-methyl-5-oxo-5,10,11,11a-tetrahydro-1h-pyrrolo[2,1-c][1,4]benzodiazepin-2-yl)prop-2-enamide",CC1=C(C2=C(C=C1)C(=O)N3C=C(CC3C(N2)O)C=CC(=O)N)O,,,,,,
942,20943,"3,3-Dimethyl-7-oxo-6-[2-(phenylsulfanyl)acetamido]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC1(C(N2C(S1)C(C2=O)NC(=O)CSC3=CC=CC=C3)C(=O)O)C,,,,,,
943,20944,CID 20944,CCCC[SnH](CCCC)CCCC.CCCC[Sn+](CCCC)CCCC.[SH-],,,,,,
944,20945,"2,6-Dimethyl-4-nitropyridine 1-oxide",CC1=CC(=CC(=[N+]1[O-])C)[N+](=O)[O-],,,,,,
945,20946,3-Methyl-1-heptene,CCCCC(C)C=C,,,,,,
946,20947,"5H-Dibenzo(b,e)(1,4)diazepine, 10,11-dihydro-10-(3-(dimethylamino)propyl)-, hydrochloride",C[NH+](C)CCCN1CC2=CC=CC=C2NC3=CC=CC=C31.[Cl-],,,,,,
947,20948,"10-(3-Dimethylaminopropyl)-10,11-dihydro-(5H)-dibenzo-(b,E)(1,4)-diazepine",CN(C)CCCN1CC2=CC=CC=C2NC3=CC=CC=C31,,,,,,
948,20949,2-Isopropoxyphenol,CC(C)OC1=CC=CC=C1O,,,,,,
949,20950,3-Nitro-3-hexene,CCC=C(CC)[N+](=O)[O-],,,,,,
950,20951,2-Nitrobut-2-ene,CC=C(C)[N+](=O)[O-],,,,,,
951,20952,4-Nitro-4-nonene,CCCCC=C(CCC)[N+](=O)[O-],,,,,,
952,20953,2-Nitro-2-nonene,CCCCCCC=C(C)[N+](=O)[O-],,,,,,
953,20954,"3,6-Dimethyloctanoic acid",CCC(C)CCC(C)CC(=O)O,,,,,,
954,20955,CID 20955,C1=CN=CC=C1C(=O)C=CNN,,,,,,
955,20956,Cinnamaldehyde isonicotinoylhydrazone,C1=CC=C(C=C1)C=CC=NNC(=O)C2=CC=NC=C2,,,,,,
956,20957,"Isonicotinic acid, (diphenylmethylene)hydrazide",C1=CC=C(C=C1)C(=NNC(=O)C2=CC=NC=C2)C3=CC=CC=C3,,,,,,
957,20958,"1,4-Dipropylbenzene",CCCC1=CC=C(C=C1)CCC,,,,,,
958,20959,2-Pentylcyclopentanone,CCCCCC1CCCC1=O,,,,,,
959,20960,"3-Cyclohexen-1-ol, 4-methyl-1-(1-methylethyl)-, acetate",CC1=CCC(CC1)(C(C)C)OC(=O)C,,,,,,
960,20961,5-Methoxy-3-(2-methylaminopropyl)indole,CC(CC1=CNC2=C1C=C(C=C2)OC)NC,,,,,,
961,20962,"Acetonitrile, 2,2'-(cyclohexylimino)DI-",C1CCC(CC1)N(CC#N)CC#N,,,,,,
962,20963,2-Bromoethyl acrylate,C=CC(=O)OCCBr,,,,,,
963,20964,"4-Nitro-2,3,5,6-tetrachlorophenol",C1(=C(C(=C(C(=C1Cl)Cl)O)Cl)Cl)[N+](=O)[O-],,,,,,
964,20965,Bromophos-ethyl,CCOP(=S)(OCC)OC1=CC(=C(C=C1Cl)Br)Cl,,,,"['The rate of dermal absorption /of organophosphorus pesticides/ may be ... influenced by the solvent used. /Organophosphorus pesticides/', '... The organophosphorus insecticides are, in contrast to the chlorinated insecticides, rapidly metabolized & excreted and are not appreciably stored in body tissues. /Organophosphorus insecticides/', 'Many of the organophosphorus insecticides are excreted in the milk ... /Organophosphorus insecticides/', 'Following their absorption, most organophosphorus cmpd are excreted ... as hydrolysis products in the urine. /Anticholinesterase agents/', 'For more Absorption, Distribution and Excretion (Complete) data for BROMOPHOS-ETHYL (6 total), please visit the HSDB record page.']","['Plasma & tissue enzymes are responsible for hydrolysis /of organophosphorus compounds/ to the corresponding phosphoric & phosphonic acids. However, oxidative enzymes are also involved in the metabolism of some organophosphorus compounds. /Anticholinesterase agents/', 'The organophosphorus anticholinesterase agents are hydrolyzed in the body by a group of enzymes known as A-esterases or paroxonase. The enzymes are found in plasma and in the hepatic endoplasmic reticulum & can hydrolyze a large number of organophosphorus compounds ... by splitting the anhydride, P-F, P-CN, or ester bond. /Anticholinesterase agents/', 'Bromophos was enzymatically degraded to 4-bromo-2,5-dichlorophenyl phosphorothionate. This was the only product formed when hog or mouse liver preparations were used. Glutathione stimulated the reaction. When incubated with 4 molor sodium hydroxide, dimethyl phosphorothionate formed. No desmethyl bromophos was observed. When incubated with buffers of pH 10 and 11, the aryl phosphorothionate did form. /Bromophos/', 'The oxon of bromophos was hydrolyzed rather slowly by plasma of sheep, rabbit, rat, and chicken. /Bromophos/', 'Analyses of meat fats of animals from areas that use bromophos-ethyl dips and sprays to control cattle ticks have detected a residue identified as O,O-diethyl O-(2,5-dichlorophenyl)phosphorothionate.']",
965,20966,Ochratoxin B,C[C@@H]1CC2=C(C(=C(C=C2)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)O)C(=O)O1,,,,"['Methods for preparation of labelled ochratoxin A and B are described. The method for preparation of labelled ochratoxin B involves the synthesis of the azide of ochratoxin beta via the mixed anhydride and subsequent conjugation to labelled phenylalanine to yield (14)C-ochratoxin B. The labelled ochratoxins were injected into male Wistar rats and after different survival times they were sacrificed and subjected to whole body autoradiography. The distribution pattern of ochratoxin A in the rat did not differ from that earlier registered for mouse. The previously known, high susceptibility of rats (and not mice) to ochratoxin A-induced cancer could thus not be explained by an accumulation of the toxin in specific cells or organs. The distribution patterns of ochratoxin A and B were almost congruent--the only apparent difference being a much longer retention of the labelled ochratoxin A in the blood compared to ochratoxin B, which was much faster excreted. When analyzing tissue extracts for labelled metabolites only the extracts from the rats injected with ochratoxin B were found to contain easily detectable concentrations, while no metabolites of ochratoxin A were seen.', 'Mixture of ochratoxins A and B (0.38 and 0.13 mg/kg body wt) was fed to pigs daily for 8 days during early pregnancy. Ochratoxin B was poorly absorbed and preferentially hydrolyzed in intestinal tract.', '... Since little is known regarding biotransformation ... of OTB, the aim of this study was to investigate biotransformation of OTB in rats... Male F344 rats were administered either a single dose of OTB (10 mg/kg bw) or repeated doses (2 mg/kg bw, 5 days/week for 2 weeks) and euthanized 72 hr after the last dosing. ... Excretion of OTB and metabolites in urine and feces was analyzed using both HPLC with fluorescence detection and LC-MS/MS. Ochratoxin beta, which results from cleavage of the peptide bond, was the major metabolite excreted in urine in addition to small amounts of 4-hydroxy-OTB. In total, 19% of the administered dose was recovered as OTB and ochratoxin beta in urine and feces within 72 hr after a single dose. In contrast to OTA, no tissue-specific retention of OTB was evident after single and repeated administration. ... OTB is more extensively metabolized and more rapidly eliminated than OTA. ...']","['... Since little is known regarding biotransformation ... of OTB, the aim of this study was to investigate biotransformation of OTB in rats... Male F344 rats were administered either a single dose of OTB (10 mg/kg bw) or repeated doses (2 mg/kg bw, 5 days/week for 2 weeks) and euthanized 72 hr after the last dosing. ... Excretion of OTB and metabolites in urine and feces was analyzed using both HPLC with fluorescence detection and LC-MS/MS. Ochratoxin beta, which results from cleavage of the peptide bond, was the major metabolite excreted in urine in addition to small amounts of 4-hydroxy-OTB. In total, 19% of the administered dose was recovered as OTB and ochratoxin beta in urine and feces within 72 hr after a single dose. In contrast to OTA, no tissue-specific retention of OTB was evident after single and repeated administration. ... OTB is more extensively metabolized and more rapidly eliminated than OTA. ...', 'Ochratoxin B (0.13 mg/kg body wt) fed to pigs daily for 8 days was completely hydrolyzed to ochratoxin beta.', 'A metabolic product was formed from ochratoxin B by rat liver microsomal fractions in the presence of NADPH. It was isolated from the incubation mixture by extraction, thin-layer chromatography, high-pressure liquid chromatography, and crystallization. On the basis of mass and nuclear magnetic resonance spectroscopy, the structure is suggested to be 4-hydroxyochratoxin B. The Km for the formation of 4-hydroxyochratoxin B was determined, and the hydroxylation of ochratoxin A was not altered by the presence of ochratoxin B. Rats were given ochratoxin A or B, or a mixture of both intraperitoneally. The ratios of the three metabolites, ochratoxin A, (4R)-4-hydroxyochratoxin A, and ochratoxin alpha, excreted in the urine did not change in the presence of ochratoxin B. Ochratoxin B was metabolized to 4-hydroxyochratoxin B and ochratoxin beta, but in a different ratio than for the ochratoxin A metabolites. When given intraperitoneally, ochratoxin beta was excreted within 24 hr. In rats treated with ochratoxin A alone, the food intake was reduced by 50%, and histologically severe lesions, degeneration, and necrosis were observed in the proximal tubules. When ochratoxin A and B given in combination, the animals were clinically unaffected and histologically there was only slight damage of proximal tubules. These observations indicate that ochratoxin B considerably reduces the toxic effects of ochratoxin A.', 'The objectives of this study were to develop and evaluate procedures for the confirmation of ochratoxin A (OA), lactone opened OA (OP-OA), ochratoxin B (OB), hydroxy OA (OA-OH) and ochratoxin alpha (Oalpha) and metabolites formed in the rats from these toxins, and to demonstrate that many ochratoxin metabolites can be identified in the bile and urine of rats injected with the different ochratoxins. An esterification procedure in acidified methanol and a lactone hydrolysis procedure in strong base yielded two additional forms of most of the different ochratoxins. The esterification procedure provided a simple, fast and reliable method for the confirmation of the ochratoxins. A total of 20 different metabolites of OA, OP-OA, OB, OA-OH and Oalpha were detected in the urine and the bile of rats of which several were identified. Among these, OA and the recently discovered and toxic form of OA (OP-OA) were readily formed in vivo when either were injected. Procedures developed in this study can be used to confirm and isolate ochratoxins in biological samples and have shown that a new form of OA (OP-OA) along with many other metabolites are formed from OA and related ochratoxins in vivo.']",
966,20967,CID 20967,CCCCCCCCCC=CC=O,,,,,,
967,20968,Calcium phosphorylcholine chloride,C[N+](C)(C)CCOP(=O)([O-])[O-].[Cl-].[Ca+2],,,,,,
968,20969,"(6S,9R,16R)-9-chloro-6-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthren-3-one",C[C@@H]1CC2C3C[C@@H](C4=CC(=O)C=CC4([C@]3(C(CC2(C1C(=O)CO)C)O)Cl)C)F,,,,,,
969,20970,"1,3-Dithiolane",C1CSCS1,,,,,,
970,20971,1-Ethylindan,CCC1CCC2=CC=CC=C12,,,,,,
971,20972,"N,N'-Dibutyl-1,6-hexanediamine",CCCCNCCCCCCNCCCC,,,,,,
972,20973,2-(Methylthio)ethyl acrylate,CSCCOC(=O)C=C,,,,,,
973,20974,"2,4-Dinitrobenzyl alcohol",C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])CO,,,,,"['2,4-dinitrobenzylalcohol has known human metabolites that include Sulfuric acid 2,4-dinitrobenzyl ester.']",
974,20975,"Isoquinoline, 1,2,3,4-tetrahydro-2-amino-",C1CN(CC2=CC=CC=C21)N,,,,,,
975,20976,(N'-carbamimidoylcarbamimidoyl)-hexylazanium;chloride,CCCCCC[NH2+]C(=NC(=N)N)N.[Cl-],,,,,,
976,20977,Polihexanide,CCCCCCN=C(N)N=C(N)N,['Treatment of Acanthamoeba keratitis'],,"['Substances used on inanimate objects that destroy harmful microorganisms or inhibit their activity. Disinfectants are classed as complete, destroying SPORES as well as vegetative forms of microorganisms, or incomplete, destroying only vegetative forms of the organisms. They are distinguished from ANTISEPTICS, which are local anti-infective agents used on humans and other animals. (From Hawley&apos;s Condensed Chemical Dictionary, 11th ed) (See all compounds classified as Disinfectants.)']",,,
977,20978,"BENZAMIDE, p-(3-AMIDINOGUANIDINO)-N-BUTYL-, MONOHYDROCHLORIDE",CCCCNC(=O)C1=CC=C(C=C1)N=C(N)[NH2+]C(=N)N.[Cl-],,,,,,
978,20979,4-[[amino-(diaminomethylideneamino)methylidene]amino]-N-butylbenzamide,CCCCNC(=O)C1=CC=C(C=C1)N=C(N)N=C(N)N,,,,,,
979,20980,"BENZAMIDE, p-(3-AMIDINOGUANIDINO)-N,N-DIBUTYL-, MONOHYDROCHLORIDE",CCCCN(CCCC)C(=O)C1=CC=C(C=C1)N=C(N)[NH2+]C(=N)N.[Cl-],,,,,,
980,20981,"4-[[amino-(diaminomethylideneamino)methylidene]amino]-N,N-dibutylbenzamide",CCCCN(CCCC)C(=O)C1=CC=C(C=C1)N=C(N)N=C(N)N,,,,,,
981,20982,CID 20982,COC1=CC=C(C=C1)N=C(N)N=C([NH3+])N.[Cl-],,,,,,
982,20983,p-Methoxyphenylbiguanide,COC1=CC=C(C=C1)N=C(N)N=C(N)N,,,,,,
983,20984,"3,3-Dimethylglutaric acid",CC(C)(CC(=O)O)CC(=O)O,,,,,,
984,20985,Vinyl cyclohexanecarboxylate,C=COC(=O)C1CCCCC1,,,,,,
985,20986,Bicyclo[3.3.1]non-2-en-9-one,C1CC2CC=CC(C1)C2=O,,,,,,
986,20987,4-Formylmonomethylaminoazobenzene,CN(C=O)C1=CC=C(C=C1)N=NC2=CC=CC=C2,,,,,,
987,20988,CID 20988,C1=CC2=C(C=C1[N+](=O)[O-])SC(=N2)S,,,,,,
988,20989,"Benzoic acid, 4-(butylamino)-2-chloro-, 1-methyl-4-piperidyl ester",CCCCNC1=CC(=C(C=C1)C(=O)OC2CCN(CC2)C)Cl,,,,,,
989,20990,tert-butyl N-[3-(dimethylcarbamoylamino)phenyl]carbamate,CC(C)(C)OC(=O)NC1=CC=CC(=C1)NC(=O)N(C)C,,,,,,
990,20991,"10-(4-Methylpiperazino)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene",CN1CCN(CC1)C2CC3=CC=CC=C3CC4=CC=CC=C24,,,,,,
991,20992,"1,6-Bismaleimidohexane",C1=CC(=O)N(C1=O)CCCCCCN2C(=O)C=CC2=O,,,,,,
992,20993,1-Chlorohexadecane,CCCCCCCCCCCCCCCCCl,,,,,,
993,20994,Urea phosphate,C(=O)(N)N.OP(=O)(O)O,,,,,,
994,20995,2-Pentylthiophene,CCCCCC1=CC=CS1,,,,,,
995,20996,"Pentadecane, 1-chloro-",CCCCCCCCCCCCCCCCl,,,,,,
996,20997,Ochratoxin C,CCOC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=CC(=C3C[C@H](OC(=O)C3=C2O)C)Cl,,,,,"['The conversion of ochratoxin C to ochratoxin A was studied in rats after oral and intravenous administration. The concentration of ochratoxin A in the blood as a function of time was the same after oral administration of equivalent amounts of either ochratoxin C or ochratoxin A. The maximum ochratoxin A concentrations were measured 60 min after administration. Given intravenously, ochratoxin C was also converted to ochratoxin A. Maximum concentrations were reached after 90 min. It is concluded that ochratoxin C is readily converted to ochratoxin A after both oral and intravenous administration. There is reason to believe that a comparable toxicity of the two toxins is based upon this conversion and that only interference with the biotransformation mechanisms may cause a difference in their toxicity.', '...The metabolic profile of ochratoxin A (OA) /was studied/ in rats and in a culture of OA-producing Aspergillus ochraceus. Ochratoxin alpha (O alpha), ochratoxin beta (O beta), 4-R-hydroxyochratoxin A (4-R-OH OA), 4-R-hydroxyochratoxin B (4-R-OH OB), and 10-hydroxyochratoxin A (10-OH OA) were isolated from a culture of A. ochraceus and structurally characterized by 1H nuclear magnetic resonance spectroscopy, mass spectrometry and high-pressure liquid chromatography. 4-R-OH OA and O alpha were consistently produced and were the dominant biotransformed metabolites in the fungal culture and in rats treated with OA and ochratoxin C (OC), while the formation of 10-OH OA was conditional in the fungal system. Green fluorescent biomacromolecules were isolated by detergent extraction of the fungal culture followed by cold-acetone precipitation and gel filtration. Acid hydrolysis of the fluorescent macromolecules resulted in the release of several ochratoxins, including O alpha (80%), OA (2%), and OC (5%), and other unidentified fluorescent compounds but not OB and O beta. Cross-reactivity studies of the natural macromolecule conjugates of OA with anti-OA polyclonal antibodies indicated that they were covalently linked to the macromolecules via a group other than the carboxyl group. These studies demonstrated that a fungus can produce some of the same metabolites of OA as the rat and that O alpha, OA, and OC may be covalently linked to fungal macromolecules.']",
997,20998,"N-(2-methylbut-2-enylideneamino)-1,1-dioxo-1,2-benzothiazol-3-amine",CC=C(C)C=NNC1=NS(=O)(=O)C2=CC=CC=C21,,,,,,
998,20999,"Carbamic acid, isopropyl-, 4-pyridylmethyl ester",CC(C)NC(=O)OCC1=CC=NC=C1,,,,,,
999,21000,"CARBANILIC ACID, p-METHYL-, 4-PYRIDYLMETHYL ESTER",CC1=CC=C(C=C1)NC(=O)OCC2=CC=NC=C2,,,,,,
1000,21001,"CARBANILIC ACID, p-FLUORO-, 4-PYRIDYLMETHYL ESTER",C1=CC(=CC=C1NC(=O)OCC2=CC=NC=C2)F,,,,,,
1001,21002,2-Nitrothiophenol,C1=CC=C(C(=C1)[N+](=O)[O-])S,,,,,,
1002,21003,2-Cyclopentylcyclopentanone,C1CCC(C1)C2CCCC2=O,,,,,,
1003,21004,Dichloromethyl methyl ether,COC(Cl)Cl,,,,,,
1004,21005,Methyl m-tolyl sulfide,CC1=CC(=CC=C1)SC,,,,,,
1005,21006,Octyl hexanoate,CCCCCCCCOC(=O)CCCCC,,,,,,
1006,21007,Demeton-o sulfone,CCOP(=S)(OCC)OCCS(=O)(=O)CC,,,,,,
1007,21008,"2,4-Tolylene diisothiocyanate",CC1=C(C=C(C=C1)N=C=S)N=C=S,,,,,,
1008,21009,Methyl thiosalicylate,COC(=O)C1=CC=CC=C1S,,,,,,
1009,21010,5-Chloro-1-methyl-4-nitroimidazole,CN1C=NC(=C1Cl)[N+](=O)[O-],,,,,,
1010,21011,Chlomizole,CN1C=NC(=C1[N+](=O)[O-])Cl,,,,,,
1011,21012,"ANILINE, N,N-DIMETHYL-p-(6-METHOXY-2-PHENYL-3,4-DIHYDRO-1-NAPHTHYL)-",CN(C)C1=CC=C(C=C1)C2=C(CCC3=C2C=CC(=C3)OC)C4=CC=CC=C4,,,,,,
1012,21013,"2,3,4,5-Tetrachlorophenol",C1=C(C(=C(C(=C1Cl)Cl)Cl)Cl)O,,,,"['The compounds are readily absorbed from the gastroenteric tract and from parenteral sites of injection. /Chlorophenols/', 'Chlorophenols ... are readily absorbed from all routes including percutaneous and inhalation. /Chlorophenols/']","['The comparative formation of chlorophenol metabolites of hexachlorocyclohexane was investigated in rats and mice. Male Swiss mice and female Wistar rats were fed a diet containing 500 ppm hexachlorocyclohexane. Circulating concentrations of chlorophenols were determined after 24 hr in Wistar rats and Swiss mice given a single 200 mg/kg ip injection of hexachlorocyclohexane. Chlorophenol metabolites identified included 2,3,4,5-tetrachlorophenol. Species differences in the rate of chlorophenol metabolite formation in vitro were also measured in hepatic microsome fractions prepared from Aroclor 1254 pretreated animals.', 'The comparative formation of chlorophenol metabolites of hexachlorocyclohexane was investigated in rats and mice. Male Swiss mice and female Wistar rats were fed a diet containing 500 parts per million hexachlorocyclohexane. Animals were killed after 2 months and hepatic chlorophenol metabolites were determined using hig performance liquid chromatography. Circulating concentrations of chlorophenols were determined in Wistar rats and Swiss mice given a single 200 mg/kg intraperitoneal injection of hexachlorocyclohexane. After 24 hours blood was collected by heart puncture and chlorophenols assayed chromatographically. Species differences in the rate of chlorophenol metabolite formation in vitro were also measured in hepatic microsome fractions prepared from Aroclor 1254 pretreated animals. Chlorophenol metabolites identified were 2,6-dichlorophenol, 2,3,5-trichlorophenol, 2,3,6-trichlorophenol, 2,4,6-trichlorophenol, 2,3,4,5-tetrachlorophenol, 2,3,5,6-tetrachlorophenol, and pentachlorophenol. No qualitative species difference was detected in chromatographic profiles of chlorophenols extracted from mouse and rat liver after continuous 2 month administration of hexachlorocyclohexane. Only 2,6-dichlorophenol was significantly higher in mouse live than that observed in rat liver: 1292.5 ng/g in mouse and 140.0 ng/g in rat. No qualitative difference was observed in the chlorophenols of blood of mice and rats. However, the concentration of 2,6-dichlorophenol was 11.52 ug/ml compared to 1.65 ug/ml in mouse blood. In vitro, 647 picomoles/mg/hour 2,4,6-trichlorophenol were formed by rat liver microsomes, compared to 219 picomoles/mg/hour by mouse liver microsomes. It was concluded that hexachlorocyclohexane may be a tumor promoting agent which acts by facilitating the development of latent initiated cells of unknown origin. Differential plasma clearance of 2,6-dichlorophenol may account for species differences in its concentration; however it is unlikely that it plays a major role in the induction of liver tumors in mice.', 'The metabolism of tetrachlorobenzenes was investigated in the squirrel monkey and a comparison made of the interspecies metabolism of such compounds. Three groups of four male monkeys were given orally single doses of one of three tetrachlorobenzene isomers in corn oil twice per week for 3 weeks. The dose levels for 1,2,3,4-tetrachlorobenzene and 1,2,3,5-tetrachlorobenzene were 100 mg/kg, and the dose level for 1,2,4,5-tetrachlorobenzene was 50 mg/kg. Respective levels of fecal excretion at 48 hours were 38, 36, and 18% of the initial doses. No metabolism occurred for 1,2,4,5-tetrachlorobenzene in the squirrel monkey. Fecal metabolites of 1,2,3,5-tetrachlorobenzene included 2,3,4,5-tetrachlorophenol (2% of dose), 2,3,4,6-tetrachlorophenol (14%), 2,3,5,6-tetrachlorophenol (9%), and 2,3,5,6-tetrachlorophenyl-sulfinic-acid (15%). For animals dosed with either 1,2,3,4-tetrachlorobenzene or 1,2,3,5-tetrachlorobenzene, the fecal radioactivity demonstrated elimination of at least 50% unchanged compound. Fecal metabolites in monkeys dosed with 1,2,3,4-tetrachlorobenzene included 1,2,4,5-tetrachlorophenol (22 %), N-acetyl-S-(2,3,4,5-tetrachlorophenyl)cysteine (18%), 2,3,4,5-tetrachlorophenyl sulfinic acid (3%), 2,3,4-trichlorophenyl-methyl sulfide (0.6%), and 2,3,4,5-tetrachlorophenyl-methyl sulfide (0.2%). Different metabolic pathways were briefly compared for the squirrel monkey, the rat, and the rabbit. The authors conclude that the tetrachlorobenzenes studied are metabolized differently in different species and that different isomers are metabolized by different pathways.']",
1013,21014,CID 21014,C[C@@H]1CC2C3C=C(C4=CC5=C(CC4(C3C(CC2([C@]1(C(=O)COC(=O)C)O)C)O)C)C=NN5C6=CC=CC=C6)C,,,,,,
1014,21015,"8,11,14-Octadecatrienoic acid",CCCC=CCC=CCC=CCCCCCCC(=O)O,,,,,,
1015,21016,"Alanine, 3-ethylthiocarbamoyl-, L-",CCSNC(=O)CC(C(=O)O)N,,,,,,
1016,21017,"3,5-Diethyl-4-hydroxybenzonitrile",CCC1=CC(=CC(=C1O)CC)C#N,,,,,,
1017,21018,3-Bromo-5-tert-butyl-4-hydroxybenzonitrile,CC(C)(C)C1=C(C(=CC(=C1)C#N)Br)O,,,,,,
1018,21019,"2,3-Dimethyl-2-pentanol",CCC(C)C(C)(C)O,,,,,,
1019,21020,"beta-2-Methyl-2-phenyl-4-(2-piperidyl)-1,3-dioxolane hydrochloride",CC1(OCC(O1)C2CCCC[NH2+]2)C3=CC=CC=C3.[Cl-],,,,,,
1020,21021,"2-(2-Methyl-2-phenyl-1,3-dioxolan-4-yl)piperidine",CC1(OCC(O1)C2CCCCN2)C3=CC=CC=C3,,,,,,
1021,21022,Dehydroemetine,CCC1=C(C[C@H]2C3=CC(=C(C=C3CCN2C1)OC)OC)C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC,,,,,,
1022,21023,"3-[[2-[2-(3-Carboxy-2,4,6-triiodoanilino)-2-oxoethoxy]acetyl]amino]-2,4,6-triiodobenzoic acid;6-(methylamino)hexane-1,2,3,4,5-pentol",CNCC(C(C(C(CO)O)O)O)O.C1=C(C(=C(C(=C1I)NC(=O)COCC(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I)I)C(=O)O)I,,,,,,
1023,21024,"2,5-Dimethylhexa-1,3,5-triene",CC(=C)C=CC(=C)C,,,,,,
1024,21025,"4-((Dimethylamino)methyl)-2,6-diisopropylphenol",CC(C)C1=CC(=CC(=C1O)C(C)C)CN(C)C,,,,,,
1025,21026,3-Methyl-2-nitrophenol,CC1=C(C(=CC=C1)O)[N+](=O)[O-],,,,,,
1026,21027,2-Chloro-4-nitroanisole,COC1=C(C=C(C=C1)[N+](=O)[O-])Cl,,,,,,
1027,21028,"Pivalic acid, phenyl ester",CC(C)(C)C(=O)OC1=CC=CC=C1,,,,,,
1028,21029,"3,3',4,4'-Tetramethylbiphenyl",CC1=C(C=C(C=C1)C2=CC(=C(C=C2)C)C)C,,,,,,
1029,21030,"Benzene, 1-ethyl-3-(1-methylethyl)-",CCC1=CC(=CC=C1)C(C)C,,,,,,
1030,21031,8-Chlorocaffeine,CN1C2=C(N=C1Cl)N(C(=O)N(C2=O)C)C,,,,,,
1031,21032,CID 21032,C1=CC=C(C=C1)C(=O)N=C(NC2=CC=CC=C2)S,,,,,,
1032,21033,1-(2-(Diethylamino)ethyl)-2-((p-propylphenyl)thio)benzimidazole dipicrate,CCCC1=CC=C(C=C1)SC2=[N+](C3=CC=CC=C3N2)CC[NH+](CC)CC.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-].C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
1033,21034,"N,N-diethyl-2-[2-(4-propylphenyl)sulfanyl-3H-benzimidazol-1-ium-1-yl]ethanamine",CCCC1=CC=C(C=C1)SC2=[N+](C3=CC=CC=C3N2)CCN(CC)CC,,,,,,
1034,21035,"2,5-Dihydroxynaphthalene-1,4-dione",C1=CC2=C(C(=C1)O)C(=CC(=O)C2=O)O,,,,,,
1035,21036,"(1,1-Dimethylethyl)phenylphosphinic chloride",CC(C)(C)P(=O)(C1=CC=CC=C1)Cl,,,,,,
1036,21037,"3-Methyl-2-cyclobutene-1,2-dicarboxylic acid",CC1=C(C(C1)C(=O)O)C(=O)O,,,,,,
1037,21038,CID 21038,C[NH+](C)CCOC1CC2=CC=CC=C2OC3=CC=CC=C13.C(=CC(=O)[O-])C(=O)O,,,,,,
1038,21039,"2-(5,6-dihydrobenzo[b][1]benzoxepin-5-yloxy)-N,N-dimethylethanamine",CN(C)CCOC1CC2=CC=CC=C2OC3=CC=CC=C13,,,,,,
1039,21040,"1H-Benzimidazole, 5-chloro-2-phenyl-, hydrate",C1=CC=C(C=C1)C2=NC3=C(N2)C=C(C=C3)Cl.O,,,,,,
1040,21041,5-Chloro-2-phenyl-1H-benzo[d]imidazole,C1=CC=C(C=C1)C2=NC3=C(N2)C=C(C=C3)Cl,,,,,,
1041,21042,"2-methyl-5-nitroso-6a,7,8,9,10,12-hexahydro-6H-pyrido[2,1-c][1,4]benzodiazepine",CC1=CC2=C(C=C1)N(CC3CCCCN3C2)N=O,,,,,,
1042,21043,4-Diethylamino-4'-ethylazobenzene,CCC1=CC=C(C=C1)N=NC2=CC=C(C=C2)N(CC)CC,,,,,,
1043,21044,"Benzimidazole, 1-(2-(diethylamino)ethyl)-2-((p-ethoxyphenyl)thio)-, hydrochloride",CC[NH+](CC)CCN1C2=CC=CC=C2N=C1SC3=CC=C(C=C3)OCC.[Cl-],,,,,,
1044,21045,Etodesnitazene phenylthiol analogue,CCN(CC)CCN1C2=CC=CC=C2N=C1SC3=CC=C(C=C3)OCC,,,,,,
1045,21046,"Benzimidazole, 1-(2-(diethylamino)ethyl)-2-((p-(diethylamino)phenyl)thio)-, trihydrochloride, hydrate",CC[NH+](CC)CC[N+]1=C(NC2=CC=CC=C21)SC3=CC=C(C=C3)[NH+](CC)CC.[Cl-].[Cl-].[Cl-],,,,,,
1046,21047,"4-[[3-[2-(diethylamino)ethyl]-1H-benzimidazol-3-ium-2-yl]sulfanyl]-N,N-diethylaniline",CCN(CC)CC[N+]1=C(NC2=CC=CC=C21)SC3=CC=C(C=C3)N(CC)CC,,,,,,
1047,21048,"Benzimidazole, 1-(2-(diethylamino)ethyl)-2-((p-(ethylamino)phenyl)thio)-, trihydrochloride",CC[NH2+]C1=CC=C(C=C1)SC2=[N+](C3=CC=CC=C3N2)CC[NH+](CC)CC.[Cl-].[Cl-].[Cl-],,,,,,
1048,21049,4-[[3-[2-(diethylamino)ethyl]-1H-benzimidazol-3-ium-2-yl]sulfanyl]-N-ethylaniline,CCNC1=CC=C(C=C1)SC2=[N+](C3=CC=CC=C3N2)CCN(CC)CC,,,,,,
1049,21050,CID 21050,CN(C)C1=CC=C(C=C1)C=NNC(=O)NN=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
1050,21051,1-(Benzylideneamino)-3-[(5-nitrofuran-2-yl)methylideneamino]urea,C1=CC=C(C=C1)C=NNC(=O)NN=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
1051,21052,4-Amino-3-methylbenzophenone,CC1=C(C=CC(=C1)C(=O)C2=CC=CC=C2)N,,,,,,
1052,21053,2-Phthalimidoacetamide,C1=CC=C2C(=C1)C(=O)N(C2=O)CC(=O)N,,,,,,
1053,21054,CID 21054,CSCC1CN(C(=O)O1)N=CC2=CC=C(O2)[N+](=O)[O-],,,"['Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)', 'Agents used to treat trichomonas infections. (See all compounds classified as Antitrichomonal Agents.)']",,,
1054,21055,"Diethyl(2-mercaptoethyl)methylammonium bromide S-ester with S,S-dimethyl phosphorotrithioate",CC[N+](C)(CC)CCSP(=O)(SC)SC.[Br-],,,,,,
1055,21056,2-Bis(methylsulfanyl)phosphorylsulfanylethyl-diethyl-methylazanium,CC[N+](C)(CC)CCSP(=O)(SC)SC,,,,,,
1056,21057,1-Hepten-3-OL,CCCCC(C=C)O,,,,,,
1057,21058,"2,4,5-t Isobutyl ester",CC(C)COC(=O)COC1=CC(=C(C=C1Cl)Cl)Cl,,,,"['THE CHLOROPHENOXY COMPOUNDS ARE ABSORBED ACROSS THE GUT WALL, LUNG, & THE SKIN. THEY ARE NOT SIGNIFICANTLY FAT STORABLE. EXCRETION OCCURS WITHIN HOURS, OR AT MOST DAYS, PRIMARILY IN THE URINE. /CHLOROPHENOXY CMPD/', 'IN SHEEP GIVEN ORAL DOSE OF 25 MG/KG OF 2,4,5-T ESTER PEAK PLASMA CONCN OF 10 PPM ... FOUND 3-4 HR LATER; 86% OF ADMIN DOSE WAS RECOVERED FROM URINE IN UNALTERED FORM, & 1.4% AS FREE ACID, WITHIN 72 HR. THERE WAS LESS THAN 0.1 PPM OF 2,4,5-T IN TISSUES, BUT IN SHEEP POISONED BY REPEATED DOSES OF 2,4,5-T TISSUE LEVELS WERE 368 PPM. /2,4,5-T ESTERS/']",,['THESE HERBICIDES /CHLOROPHENOXY CMPD/ DO NOT ACCUM IN ANIMALS. THEY ARE NOT EXTENSIVELY METAB BUT ARE ACTIVELY EXCRETED INTO THE URINE ... THEIR PLASMA HALF-LIFE IN MAN IS ABOUT 1 DAY. /CHLOROPHENOXY HERBICIDES/']
1058,21059,Ethyl maltol,CCC1=C(C(=O)C=CO1)O,,,,,,
1059,21060,CID 21060,C1=CC=C(C=C1)C=C2C(=O)C(=C(O2)O)C3=CC=CC=C3,,,,,,
1060,21061,4-(Dimethylamino)thiophenol,CN(C)C1=CC=C(C=C1)S,,,,,,
1061,21062,"1-Anilino-2-methyl-9,10-anthraquinone",CC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)NC4=CC=CC=C4,,,,,,
1062,21063,"Ketone, 3-ethyl-2,2-dimethylcyclobutyl methyl (Z)-",CC[C@H]1C[C@H](C1(C)C)C(=O)C,,,,,,
1063,21064,"2,6,9,11-Dodecatetraenal, 2,6,10-trimethyl-",CC(=CCC=C(C)C=C)CCC=C(C)C=O,,,,,,
1064,21065,CID 21065,C1=CC(=C(C=C1O)C(=O)[O-])O.[Na+],,,,,,
1065,21066,1-Methyl-4-phenylisonipecotic acid ethyl ester 1-oxide hydrochloride,CCOC(=O)C1(CC[N+](CC1)(C)[O-])C2=CC=CC=C2.[Cl-],,,,,,
1066,21067,"Isonipecotic acid, 1-methyl-4-phenyl-, ethyl ester, 1-oxide",CCOC(=O)C1(CC[N+](CC1)(C)[O-])C2=CC=CC=C2,,,,,,
1067,21068,Strophanthidin 3-bromoacetate,C[C@]12CCC3C([C@]1(CC[C@@H]2C4=CC(=O)OC4)O)CC[C@]5([C@@]3(CC[C@@H](C5)OC(=O)CBr)C=O)O,,,,,,
1068,21069,"Dibenzo(b,f)(1,4)thiazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-, hydrochloride",CN1CC[NH+](CC1)C2=NC3=CC=CC=C3SC4=C2C=C(C=C4)Cl.[Cl-],,,,,,
1069,21070,Estradiol enanthate,CCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C,,,"['Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds. (See all compounds classified as Estrogens.)']",,,
1070,21071,Di-p-tolylmethane,CC1=CC=C(C=C1)CC2=CC=C(C=C2)C,,,,,,
1071,21072,"Bis(2,4,5-trimethylphenyl)methane",CC1=CC(=C(C=C1C)CC2=C(C=C(C(=C2)C)C)C)C,,,,,,
1072,21073,"Sulfamide, N-(2,4-dichlorobenzyl)-N-methyl-",CN(CC1=C(C=C(C=C1)Cl)Cl)S(=O)(=O)N,,,,,,
1073,21074,Diethylarsinic acid,CC[As](=O)(CC)O,,,,,,
1074,21075,"16alpha,17-(Isopropylidenedioxy)progesterone",CC(=O)C12C(CC3C1(CCC4C3CCC5=CC(=O)CCC45C)C)OC(O2)(C)C,,,,,,
1075,21076,"2(5H)-Furanone, 5-hydroxy-",C1=CC(=O)OC1O,,,,,,
1076,21077,2-cyano-N'-(phenylmethylene)acetohydrazide,C1=CC=C(C=C1)C=NNC(=O)CC#N,,,,,,
1077,21078,4-Biphenylglyoxal,C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)C=O,,,,,,
1078,21079,"N,N'-Dicyclohexyl-4-morpholinecarboxamidine",C1CCC(CC1)NC(=NC2CCCCC2)N3CCOCC3,,,,,,
1079,21080,"N,N-Dicyclohexyl-2-benzothiazolesulfenamide",C1CCC(CC1)N(C2CCCCC2)SC3=NC4=CC=CC=C4S3,,,,,,
1080,21081,3-(2-Carboxyethylsulfanyl)propanoic acid;dibutyltin,CCCC[Sn]CCCC.C(CSCCC(=O)O)C(=O)O,,,,,,
1081,21082,"9,10-Anthracenediol",C1=CC=C2C(=C1)C(=C3C=CC=CC3=C2O)O,,,,,,
1082,21083,"Cyclohexane, 1,4-bis(methylene)-",C=C1CCC(=C)CC1,,,,,,
1083,21084,"CARBANILIC ACID, p-METHOXY-, 4-PYRIDYLMETHYL ESTER",COC1=CC=C(C=C1)NC(=O)OCC2=CC=NC=C2,,,,,,
1084,21085,"3,7-Dimethyl-1-octene",CC(C)CCCC(C)C=C,,,,,,
1085,21086,Elronon,C[NH+](C)CCON=C1C2=CC=CC=C2CCC3=CC=CC=C31.[Cl-],,,"['Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)']",,,
1086,21087,Noxiptiline,CN(C)CCON=C1C2=CC=CC=C2CCC3=CC=CC=C31,,,"['Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)']",,,
1087,21088,N-(3-Aminopropyl)diethanolamine,C(CN)CN(CCO)CCO,,,,,,
1088,21089,N-Hydroxycytidine 5'-(Dihydrogen Phosphate),C1=CN(C(=O)N=C1NO)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)O)O)O,,,,,,
1089,21090,6-Chloro-6-deoxymannose,C(C(C(C(C(C=O)O)O)O)O)Cl,,,,,,
1090,21091,Pimetine,CN(C)CCN1CCC(CC1)CC2=CC=CC=C2,,,,,,
1091,21092,"o-CRESOL, alpha-(DIETHYLAMINO)-",CCN(CC)CC1=CC=CC=C1O,,,,,,
1092,21093,"(17S)-13-methyl-1,2,3,4,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,17-diol",CC12CCC3C(C1CC[C@@H]2O)CCC4=C3CCC(C4)O,,,,,,
1093,21094,"2-Indolinone, 3-(2-aminoethyl)-, hydrochloride",C1=CC=C2C(=C1)C(C(=O)N2)CC[NH3+].[Cl-],,,,,,
1094,21095,"3-(2-aminoethyl)-1,3-dihydro-2H-indol-2-one",C1=CC=C2C(=C1)C(C(=O)N2)CCN,,,,,,
1095,21096,4-Phenylcyclohexene,C1CC(CC=C1)C2=CC=CC=C2,,,,,,
1096,21097,Cyclohexylammonium chloride,C1CCC(CC1)[NH3+].[Cl-],,,,,,
1097,21098,CID 21098,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OS(=O)(=O)[O-].[Na+],,,,,,
1098,21099,CID 21099,C[C@]12CC[C@H]3[C@H](C1CCC2O)CCC4=C3C=CC(=C4)OS(=O)(=O)O,,,,,,
1099,21100,Metanephrine,CNCC(C1=CC(=C(C=C1)O)OC)O,,,,,,
1100,21101,"4-Biphenylacetic acid, 2'-fluoro-",C1=CC=C(C(=C1)C2=CC=C(C=C2)CC(=O)O)F,,,,,,
1101,21102,Benorilate,CC(=O)NC1=CC=C(C=C1)OC(=O)C2=CC=CC=C2OC(=O)C,,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']",,,
1102,21103,4-Methylphthalazin-1(2H)-one,CC1=NNC(=O)C2=CC=CC=C12,,,,,,
1103,21104,1-(Cyclohexylmethyl)hexahydro-1H-azepine hydrochloride,C1CCC[NH+](CC1)CC2CCCCC2.[Cl-],,,,,,
1104,21105,1-(Cyclohexylmethyl)azepane,C1CCCN(CC1)CC2CCCCC2,,,,,,
1105,21106,2'-Fluoro-alpha-methyl-4-biphenylacetic acid,CC(C1=CC=C(C=C1)C2=CC=CC=C2F)C(=O)O,,,,,,
1106,21107,6-chloro-4-oxo-4H-chromene-2-carboxylic acid,C1=CC2=C(C=C1Cl)C(=O)C=C(O2)C(=O)O,,,,,,
1107,21108,8-Nonen-2-one,CC(=O)CCCCCC=C,,,,,,
1108,21109,Trimetazidine,COC1=C(C(=C(C=C1)CN2CCNCC2)OC)OC,['Trimetazidine is indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies.'],"['Trimetazidine is indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies. Patients should be counselled regarding the risk of use with reduced renal or hepatic function, worsening of extrapyramidal symptoms or other movement disorders, and risk of falls.']",['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],"['In elderly patients, a 35 mg oral modified release tablet reaches a mean C<sub>max</sub> of 115 Âµg/L, with a T<sub>max</sub> of 2.0-5.0 hours, and a mean AUC<sub>0-12</sub> of 1104 h\\*Âµg/L. In young, healthy patients, the same dose reaches a mean C<sub>max</sub> of 91.2 Âµg/L, with a T<sub>max</sub> of 2.0-6.0 hours, and an AUC<sub>0-12h</sub> 720 h\\*Âµg/L.', 'Trimetazidine is 79-84% eliminated in the urine, with 60% as the unchanged parent compound. In a study of 4 healthy subjects, individual metabolites made up 0.01-1.4% of the dose recovered in urine. In the urine, 2-desmethyltrimetazidine made up 0-1.4% of the recovered dose, 3- and 4-desmethyltrimetazidine made up 0.039-0.071% each, N-methyltrimetazidine made up 0.015-0.11%, trimetazidine ketopiperazine made up 0.011-0.4%, N-formyltrimetazidine made up 0.035-0.42%, N-acetyltrimetazidine made up 0.016-0.19%, desmethyl trimetazidine O-sulphate made up 0.01-0.65%, and an unknown metabolite made up0.026-0.67%.', 'The volume of distribution of trimetazidine is 4.8 L/kg.', 'Trimetazidine clearance is strongly correlated with creatinine clearance. In eldery patients with a creatinine clearance of 72 Â± 8 mL/min, trimetazidine clearance was 15.69 L/h. In young, healthy patients with a creatinine clearance of 134 Â± 18 mL/min, trimetazidine clearance was 25.2 L/h.']","['Trimetazidine can be oxidized at the piperazine ring to form trimetazidine ketopiperazine. Trimetazidine can also be N-formylated, N-acetylated, or N-methylated at the piperazine ring to form N-formyltrimetazidine, N-acetyltrimetazidine, and N-methyltrimetazidine respectively. Alternatively, trimetazidine can be demethylated at the 2, 3, or 4 position of the 2,3,4-trimethoxybenzyl moiety to form 2-desmethyltrimetazidine, 3-desmethyltrimetazidine, or 4-desmethyltrimetazidine. The desmethyltrimetazidine metabolites can undergo sulfate conjugation or glucuronidation prior to elimination.']","['In young, healthy subjects, the half life of trimetazidine is 7.81 hours. In patients over 65, the half life increases to 11.7 hours.']"
1109,21110,"BENZOIC ACID, o-(2-(DIETHYLAMINO)ETHOXY)-, METHYL ESTER",CCN(CC)CCOC1=CC=CC=C1C(=O)OC,,,,,,
1110,21111,"Benzoic acid, 5-chloro-2-(2-(diethylamino)ethoxy)-, methyl ester",CCN(CC)CCOC1=C(C=C(C=C1)Cl)C(=O)OC,,,,,,
1111,21112,"Benzoic acid, 2-(2-(diethylamino)ethoxy)-3,5-dinitro-, methyl ester",CCN(CC)CCOC1=C(C=C(C=C1[N+](=O)[O-])[N+](=O)[O-])C(=O)OC,,,,,,
1112,21113,"3-Biphenylcarboxylic acid, 2-(2-(diethylamino)ethoxy)-, methyl ester",CCN(CC)CCOC1=C(C=CC=C1C(=O)OC)C2=CC=CC=C2,,,,,,
1113,21114,"1-[(16R,20S)-7-(4-fluorophenyl)-2,18,18,21-tetramethyl-17,19-dioxa-6,7-diazahexacyclo[11.10.0.02,10.04,8.014,21.016,20]tricosa-4(8),5,9-trien-20-yl]-2-hydroxyethanone",CC1(O[C@@H]2CC3C4CCC5=CC6=C(CC5(C4CCC3([C@@]2(O1)C(=O)CO)C)C)C=NN6C7=CC=C(C=C7)F)C,,,,,,
1114,21115,Methylprednisolone sodium phosphate,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)COP(=O)([O-])[O-])O.[Na+].[Na+],,,,,,
1115,21116,CID 21116,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(CC(C2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)COP(=O)(O)O)O,,,,,,
1116,21117,"(17-acetyl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl) 3-pyrrolidin-1-ylpropanoate",CC(=O)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC(=O)CCN5CCCC5)C)C,,,,,,
1117,21118,CID 21118,CSC(=NN=CC1=CC=C(O1)[N+](=O)[O-])S,,,,,,
1118,21119,"3-(5-Nitro-2-furyl)-4H-1,2,4-triazole",C1=C(OC(=C1)[N+](=O)[O-])C2=NC=NN2,,,,,,
1119,21120,N-Ethylphthalimide,CCN1C(=O)C2=CC=CC=C2C1=O,,,,,,
1120,21121,CID 21121,COC(=O)C1=CC=C(C=C1)[O-].[Na+],,,,,,
1121,21122,6-Methyl-1-heptene,CC(C)CCCC=C,,,,,,
1122,21123,"Carbamic acid, hydroxymethyl-, ethyl ester",CCOC(=O)NCO,,,,,,
1123,21124,alpha-(o-Chlorophenyl)-2-benzimidazolemethanol,C1=CC=C(C(=C1)C(C2=NC3=CC=CC=C3N2)O)Cl,,,,,,
1124,21125,(1H-Benzo[d]imidazol-2-yl)(4-chlorophenyl)methanol,C1=CC=C2C(=C1)NC(=N2)C(C3=CC=C(C=C3)Cl)O,,,,,,
1125,21126,"4,4,4-Trinitrobutanoic acid",C(CC([N+](=O)[O-])([N+](=O)[O-])[N+](=O)[O-])C(=O)O,,,,,,
1126,21127,Syringaldehyde oxime,COC1=CC(=CC(=C1O)OC)C=NO,,,,,,
1127,21128,"Carbanilic acid, 3,4,5-trimethoxy-, 4-pyridylmethyl ester",COC1=CC(=CC(=C1OC)OC)NC(=O)OCC2=CC=NC=C2,,,,,,
1128,21129,Indoxole,COC1=CC=C(C=C1)C2=C(NC3=CC=CC=C32)C4=CC=C(C=C4)OC,,,,,,
1129,21130,4-[bis(2-chloroethyl)aminodiazenyl]-4H-imidazole-5-carboxamide,C1=NC(C(=N1)C(=O)N)N=NN(CCCl)CCCl,,,,,,
1130,21131,1-(2-Hydroxyethyl)-3-{[(5-nitrofuran-2-YL)methylidene]amino}imidazolidin-2-one,C1CN(C(=O)N1CCO)N=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
1131,21132,1-(2-Chloroethyl)-3-[(5-nitrofuran-2-yl)methylideneamino]imidazolidin-2-one,C1CN(C(=O)N1CCCl)N=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
1132,21133,Isobutylammonium chloride,CC(C)C[NH3+].[Cl-],,,,,,
1133,21134,"3,5-Diaminonitrobenzene",C1=C(C=C(C=C1N)[N+](=O)[O-])N,,,,,,
1134,21135,trans-(+-)-2-Cyclohexyloxycyclopropylamine,C1CCC(CC1)O[C@H]2C[C@@H]2N,,,,,,
1135,21136,"N,N'-Di(alpha-(1-naphthyl)propionyloxy-2-ethyl)piperazine dihydrochloride",CC(C1=CC=CC2=CC=CC=C21)C(=O)OCCN3CCN(CC3)CCOC(=O)C(C)C4=CC=CC5=CC=CC=C54.Cl.Cl,,,,,,
1136,21137,Nafiverine,CC(C1=CC=CC2=CC=CC=C21)C(=O)OCCN3CCN(CC3)CCOC(=O)C(C)C4=CC=CC5=CC=CC=C54,,,,,,
1137,21138,Dexpropranolol,CC(C)NC[C@H](COC1=CC=CC2=CC=CC=C21)O,,,"['Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,"['Dexpropranolol (propranolol) has known human metabolites that include 4-Hydroxypropranolol, 5-Hydroxypropranolol, and N-Desisopropylpropranolol.']",
1138,21139,Nifurquinazol,C1=CC=C2C(=C1)C(=NC(=N2)C3=CC=C(O3)[N+](=O)[O-])N(CCO)CCO,,,,,,
1139,21140,"Indole-3-glyoxylic acid, hydrazide",C1=CC=C2C(=C1)C(=CN2)C(=O)C(=O)NN,,,,,,
1140,21141,"Indole-3-glyoxylic acid, dimethylhydrazide",CN(C)NC(=O)C(=O)C1=CNC2=CC=CC=C21,,,,,,
1141,21142,Dimethyl d-tartrate,COC(=O)[C@H]([C@@H](C(=O)OC)O)O,,,,,,
1142,21143,3-(4-Hydroxy-2-methylphenyl)-2-methyl-4(3H)-quinazolinone,CC1=C(C=CC(=C1)O)N2C(=NC3=CC=CC=C3C2=O)C,,,,,['Hydroxy-methaqualone is a known human metabolite of methaqualone.'],
1143,21144,(m-Phenylenebis(1-methylethylene))bis(trimethylammonium) dibromide,CC(C[N+](C)(C)C)C1=CC(=CC=C1)C(C)C[N+](C)(C)C.[Br-].[Br-],,,,,,
1144,21145,Trimethyl-[2-[3-[1-(trimethylazaniumyl)propan-2-yl]phenyl]propyl]azanium,CC(C[N+](C)(C)C)C1=CC(=CC=C1)C(C)C[N+](C)(C)C,,,,,,
1145,21146,"AMMONIUM, (m-PHENYLENEBIS(1-METHYLETHYLENE))BIS(BENZYLDIMETHYL-, DICHLORIDE",CC(C[N+](C)(C)CC1=CC=CC=C1)C2=CC(=CC=C2)C(C)C[N+](C)(C)CC3=CC=CC=C3.[Cl-].[Cl-],,,,,,
1146,21147,Benzyl-[2-[3-[1-[benzyl(dimethyl)azaniumyl]propan-2-yl]phenyl]propyl]-dimethylazanium,CC(C[N+](C)(C)CC1=CC=CC=C1)C2=CC(=CC=C2)C(C)C[N+](C)(C)CC3=CC=CC=C3,,,,,,
1147,21148,"(4R,8S,12R)-8-acetyl-11,12-dichloro-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one",CC(=O)[C@@]12[C@@H](CC3C1(CC([C@]4(C3CCC5=CC(=O)C=CC54C)Cl)Cl)C)OC(O2)(C)C,,,,,,
1148,21149,"2-Phenyl-1,2-butanediamine",CCC(CN)(C1=CC=CC=C1)N,,,,,,
1149,21150,1-(Aminomethyl)cyclohexan-1-amine,C1CCC(CC1)(CN)N,,,,,,
1150,21151,1-Aminomethylcycloheptylamine,C1CCCC(CC1)(CN)N,,,,,,
1151,21152,Trisodium nitrilotriacetate,C(C(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Na+].[Na+].[Na+],,,['Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)'],"['TRISODIUM AMINOTRIACETATE WAS WELL ABSORBED IN RATS AND DOGS, & EXCRETED UNCHANGED IN URINE. THE AMT (8 UG/G BONE), WHICH WAS INCORPORATED INTO RAT SKELETON IN COMBINATION WITH CA2+ REPRESENTED ONLY 0.007% OF THE 24 HR TURNOVER OF CALCIUM IN THAT TISSUE, AND WAS CONSIDERED UNLIKELY TO AFFECT DEVELOPMENT ADVERSELY.', 'RATS WERE GIVEN TRISODIUM NITRILOTRIACETATE AT DIETARY LEVELS OF 0.05, 0.1, 0.3, 0.5, 0.75, OR 2% FOR 42 & 30 DAYS. NITRILOTRIACETATE DID NOT ACCUMULATE IN BLADDER TISSUES TO ANY GREATER EXTENT THAN IN HEART AND LIVER, EVEN WHEN URINARY NTA LEVELS WERE EQUAL TO OR GREATER THAN 200 TIMES THOSE IN PLASMA.', 'In a whole body autoradiographic study, 0.93 Mg (1-(14)C-acetate) NTA, trisodium salt was administered intravenously to NMRI albino mice and the same amount orally to C57BI mice; heavy accumulation of radioactivity occurred in the skeleton, which persisted for 48 h, the longest interval studied.']",,
1152,21153,"Benzoic acid, 4-butylamino-2-chloro-, N-methyl-4-piperidyl ester, methanesulfonate",CCCCNC1=CC(=C(C=C1)C(=O)OC2CC[NH+](CC2)C)Cl.CS(=O)(=O)[O-],,,,,,
1153,21154,"(1,3-Dithiolan-2-ylidene)dimethylammonium bromide",C[N+](=C1SCCS1)C.[Br-],,,,,,
1154,21155,"1,3-Dithiolan-2-ylidene(dimethyl)azanium",C[N+](=C1SCCS1)C,,,,,,
1155,21156,3-Methoxybenzylamine,COC1=CC=CC(=C1)CN,,,,,,
1156,21157,Buthionine sulfoximine,CCCCS(=N)(=O)CCC(C(=O)O)N,,,"['Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military. (See all compounds classified as Radiation-Protective Agents.)', 'Antimetabolites that are useful in cancer chemotherapy. (See all compounds classified as Antimetabolites, Antineoplastic.)', 'Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Antimetabolites.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. (See all compounds classified as Radiation-Sensitizing Agents.)']",,,
1157,21158,"Oxirane, trimethyl-",CC1C(O1)(C)C,,,,,,
1158,21159,Tetramethyloxirane,CC1(C(O1)(C)C)C,,,,,,
1159,21160,"N,N'-Bis(1-indanyl)-1,4-bicyclo(2.2.2)octanebis(methylamine) dihydrochloride",C1CC2=CC=CC=C2C1[NH2+]CC34CCC(CC3)(CC4)C[NH2+]C5CCC6=CC=CC=C56.[Cl-].[Cl-],,,,,,
1160,21161,"N-[[4-[(2,3-dihydro-1H-inden-1-ylamino)methyl]-1-bicyclo[2.2.2]octanyl]methyl]-2,3-dihydro-1H-inden-1-amine",C1CC2=CC=CC=C2C1NCC34CCC(CC3)(CC4)CNC5CCC6=CC=CC=C56,,,,,,
1161,21162,Trimethyltin(1+),C[Sn+](C)C,,,,,,
1162,21163,"5,6-Dihydroxytryptamine",C1=C2C(=CC(=C1O)O)NC=C2CCN,,,"['Drugs used for their effects on serotonergic systems. Among these are drugs that affect serotonin receptors, the life cycle of serotonin, and the survival of serotonergic neurons. (See all compounds classified as Serotonin Agents.)']",,,
1163,21164,"4a,8a-Dimethyl-7-(propan-2-yl)octahydronaphthalen-1(2H)-one",CC(C)[C@@H]1CCC2(CCCC(=O)C2(C1)C)C,,,,,,
1164,21165,"Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-6-amino-8-(hydroxymethyl)-8a-methoxy-5-methyl-1-methylsulfonyl-, carbamate",CC1=C(C(=O)C2=C(C1=O)N3CC4C([C@@]3([C@@H]2COC(=O)N)OC)N4S(=O)(=O)C)N,,,,,,
1165,21166,5-Chloro-2-(2-(diethylamino)ethoxy)benzamide,CCN(CC)CCOC1=C(C=C(C=C1)Cl)C(=O)N,,,,,,
1166,21167,"3-Methyl-2-naphthylamine, hydrochloride",CC1=CC2=CC=CC=C2C=C1[NH3+].[Cl-],,,,,,
1167,21168,3-Methyl-2-naphthylamine,CC1=CC2=CC=CC=C2C=C1N,,,,,,
1168,21169,"6H-DIBENZO(b,d)PYRAN-6-ONE, 2-ACETAMIDO-",CC(=O)NC1=CC2=C(C=C1)OC(=O)C3=CC=CC=C32,,,,,,
1169,21170,"N-(2,4,6-Trimethylphenyl)acetamide",CC1=CC(=C(C(=C1)C)NC(=O)C)C,,,,,,
1170,21171,(S)-Canadine,COC1=C(C2=C(C[C@H]3C4=CC5=C(C=C4CCN3C2)OCO5)C=C1)OC,,,,,,
1171,21172,"1-(4,6-Dichloro-1,3,5-triazine-2-yl)-3-phenylurea",C1=CC=C(C=C1)NC(=O)NC2=NC(=NC(=N2)Cl)Cl,,,,,,
1172,21173,"3-(4,6-Dichloro-1,3,5-triazin-2-yl)-1,1-dimethylurea",CN(C)C(=O)NC1=NC(=NC(=N1)Cl)Cl,,,,,,
1173,21174,"1-(4,6-Dichloro-1,3,5-triazin-2-yl)-3-propan-2-ylurea",CC(C)NC(=O)NC1=NC(=NC(=N1)Cl)Cl,,,,,,
1174,21175,CID 21175,CC(C)N=C(NC1=NC(=NC(=N1)Cl)Cl)S,,,,,,
1175,21176,CID 21176,COC(=NC1=NC(=NC(=N1)Cl)Cl)S,,,,,,
1176,21177,Diethylaminophenylacetonitrile,CCN(CC)C(C#N)C1=CC=CC=C1,,,,,,
1177,21178,3-(2-Aminopropyl)-5-methylthioindole,CC(CC1=CNC2=C1C=C(C=C2)SC)N,,,,,,
1178,21179,"Indole, 3-(3-amino-2-butyl)-5-benzylthio-",CC(C1=CNC2=C1C=C(C=C2)SCC3=CC=CC=C3)C(C)N,,,,,,
1179,21180,5-Methylthiodimethyltryptamine,CN(C)CCC1=CNC2=C1C=C(C=C2)SC,,,,,,
1180,21181,5-Methylthio-3-(2-methylaminopropyl)indole,CC(CC1=CNC2=C1C=C(C=C2)SC)NC,,,,,,
1181,21182,5-Methylthio-3-(2-dimethylaminopropyl)indole,CC(CC1=CNC2=C1C=C(C=C2)SC)N(C)C,,,,,,
1182,21183,Hydrindantin,C1=CC=C2C(=C1)C(=O)C(C2=O)(C3(C(=O)C4=CC=CC=C4C3=O)O)O,,,,,,
1183,21184,4-(((Benzyloxy)carbonyl)amino)butanoic acid,C1=CC=C(C=C1)COC(=O)NCCCC(=O)O,,,,,,
1184,21185,"(16S,17R)-3-methoxy-13,16-dimethyl-7,8,9,11,12,14,15,17-octahydro-6H-cyclopenta[a]phenanthrene-16,17-diol",C[C@@]1(CC2C3CCC4=C(C3CCC2([C@H]1O)C)C=CC(=C4)OC)O,,,,,,
1185,21186,6-Methyl-2-pyridin-2-ylquinoline-4-carboxylic acid,CC1=CC2=C(C=C1)N=C(C=C2C(=O)O)C3=CC=CC=N3,,,,,,
1186,21187,6-Methyl-2-pyridin-3-ylquinoline-4-carboxylic acid,CC1=CC2=C(C=C1)N=C(C=C2C(=O)O)C3=CN=CC=C3,,,,,,
1187,21188,(2-Iodoethyl)trimethylammonium iodide,C[N+](C)(C)CCI.[I-],,,,,,
1188,21189,Iodocholine ion,C[N+](C)(C)CCI,,,,,,
1189,21190,CID 21190,C1=CC=C(C=C1)CN=C(S)[S-].[Na+],,,,,,
1190,21191,CID 21191,C1=CC=C(C=C1)CN=C(S)S,,,,,,
1191,21192,N-Acetyl-3-(o-boronophenyl)alanine,B(C1=CC=CC=C1CC(C(=O)O)NC(=O)C)(O)O,,,,,,
1192,21193,"1,1-Diethylselenourea",CCN(CC)C(=N)[SeH],,,,,,
1193,21194,alpha-Methyltryptamine acetate,CC(CC1=CNC2=CC=CC=C21)[NH3+].CC(=O)[O-],,,,,,
1194,21195,CID 21195,C[NH+](C)CCOC1CC2=CC=CC=C2SC3=C1C=CC=C3Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
1195,21196,"2-[(1-chloro-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)oxy]-N,N-dimethylethanamine",CN(C)CCOC1CC2=CC=CC=C2SC3=C1C=CC=C3Cl,,,,,,
1196,21197,CID 21197,C[NH+](C)CCOC1CC2=CC=CC=C2SC3=C1C=CC(=C3)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
1197,21198,"2-[(2-chloro-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)oxy]-N,N-dimethylethanamine",CN(C)CCOC1CC2=CC=CC=C2SC3=C1C=CC(=C3)Cl,,,,,,
1198,21199,CID 21199,CC1=C(COC1=O)C[C@H]([C@H](C)C2CCC3C2(CCC4C3C[C@@H]5[C@]6(C4(C(=O)C=C[C@@H]6O)C)O5)C)O,,,,,,
1199,21200,"N-benzyl-4-chloro-6-methyl-1,3,5-triazin-2-amine",CC1=NC(=NC(=N1)Cl)NCC2=CC=CC=C2,,,,,,
1200,21201,Disperse Yellow 42,C1=CC=C(C=C1)NC2=C(C=C(C=C2)S(=O)(=O)NC3=CC=CC=C3)[N+](=O)[O-],,,,,,
1201,21202,Bis(4-isocyanatocyclohexyl)methane,C1CC(CCC1CC2CCC(CC2)N=C=O)N=C=O,,,,,,
1202,21203,Anisacril,COC1=CC=CC=C1C(=C(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)O,,,,,,
1203,21204,Methyl 12-methyltridecanoate,CC(C)CCCCCCCCCCC(=O)OC,,,,,,
1204,21205,Methyl 14-methylpentadecanoate,CC(C)CCCCCCCCCCCCC(=O)OC,,,,,,
1205,21206,Methyl 12-methyltetradecanoate,CCC(C)CCCCCCCCCCC(=O)OC,,,,,,
1206,21207,Ditalimfos,CCOP(=S)(N1C(=O)C2=CC=CC=C2C1=O)OCC,,,,,,
1207,21208,4-Nitro-m-phenylenediamine,C1=CC(=C(C=C1N)N)[N+](=O)[O-],,,,,,
1208,21209,4-Chloro-M-phenylenediamine,C1=CC(=C(C=C1N)N)Cl,,,,,,
1209,21210,1-Butoxy-2-propanol,CCCCOCC(C)O,,,,,,
1210,21211,Methyl 9-acridinecarboxylate,COC(=O)C1=C2C=CC=CC2=NC3=CC=CC=C31,,,,,,
1211,21212,CID 21212,CC1=CC=C(O1)C[NH2+]C(=NC(=N)N)N.[Cl-],,,,,,
1212,21213,1-(5-Methylfurfuryl) Biguanide,CC1=CC=C(O1)CN=C(N)N=C(N)N,,,,,,
1213,21214,CID 21214,CC(C)NC1=NC(=NC(=N1)S)NC(C)C,,,,,,
1214,21215,1-Ethyl-alpha-((methylamino)methyl)indole-3-methanol,CCN1C=C(C2=CC=CC=C21)C(CNC)O,,,,,,
1215,21216,alpha-((Dimethylamino)methyl)-1-isopropylindole-3-methanol,CC(C)N1C=C(C2=CC=CC=C21)C(CN(C)C)O,,,,,,
1216,21217,alpha-((Dimethylamino)methyl)-1-ethylindole-3-methanol,CCN1C=C(C2=CC=CC=C21)C(CN(C)C)O,,,,,,
1217,21218,Methyltrioctylammonium chloride,CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC.[Cl-],,,,,,
1218,21219,Methyltricaprylylammonium,CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC,,,,,,
1219,21220,Sulfosuccinic acid,C(C(C(=O)O)S(=O)(=O)O)C(=O)O,,,,,,
1220,21221,CID 21221,C1=CC(=CC=C1S(=O)(=O)[O-])Cl.[Na+],,,,,,
1221,21222,Atheroline,COC1=C(C2=C3C(=C1)C=CN=C3C(=O)C4=CC(=C(C=C42)OC)O)OC,,,,,,
1222,21223,Light Green SF Yellowish,CCN(CC1=CC(=CC=C1)S(=O)(=O)[O-])C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)[O-])C=C3)C5=CC=C(C=C5)S(=O)(=O)[O-].[Na+].[Na+],,,,"['Light green SF exhibits high plasma binding.', 'Studies in rats and dog involving oral administration of light green SF indicate that only small amounts of the dye (<5%) are absorbed and excreted, mainly in the feces. Following its iv injection in rats, about 20% of the dye was excreted in the bile within four hours.']",,
1223,21224,C.I. Food Green 2,CCN(CC1=CC(=CC=C1)S(=O)(=O)O)C2=CC=C(C=C2)C(=C3C=CC(=[N+](CC)CC4=CC(=CC=C4)S(=O)(=O)O)C=C3)C5=CC=C(C=C5)S(=O)(=O)O,,,,,,
1224,21225,"4,5-Dihydro-2-(1-naphthylmethyl)-1H-imidazolium nitrate",C1CN=C([NH2+]1)CC2=CC=CC3=CC=CC=C32.[N+](=O)([O-])[O-],,,,,,
1225,21226,"1,10-Phenanthroline monohydrate",C1=CC2=C(C3=C(C=CC=N3)C=C2)N=C1.O,,,"['Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)', 'Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other. (See all compounds classified as Cross-Linking Reagents.)', 'Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. (See all compounds classified as Iron Chelating Agents.)', 'Agents that are capable of inserting themselves between the successive bases in DNA, thus kinking, uncoiling or otherwise deforming it and therefore preventing its proper functioning. They are used in the study of DNA. (See all compounds classified as Intercalating Agents.)', 'Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)', 'Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)']",,,
1226,21227,"3,5-Dimethyloxolan-2-one",CC1CC(OC1=O)C,,,,,,
1227,21228,Ethyl isopropyl sulfide,CCSC(C)C,,,,,,
1228,21229,CID 21229,C1=COC(=C1)CN=C(N)N=C([NH3+])N.[Cl-],,,,,,
1229,21230,Furfuryl Biguanide,C1=COC(=C1)CN=C(N)N=C(N)N,,,,,,
1230,21231,"3-Phenylthio-1,2-propanediol",C1=CC=C(C=C1)SCC(CO)O,,,,,,
1231,21232,3-(1-Benzofuran-2-yl)-3-oxopropanenitrile,C1=CC=C2C(=C1)C=C(O2)C(=O)CC#N,,,,,,
1232,21233,Metocurine,C[N+]1(CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)OC)O3)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)C,['Metocurine is a muscle relaxant.'],,"['Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. (See all compounds classified as Neuromuscular Nondepolarizing Agents.)']",,,
1233,21234,2-Methyl-3-amino-6-dimethylaminoacridine,CC1=CC2=C(C=C1N)N=C3C=C(C=CC3=C2)N(C)C,,,,,,
1234,21235,"13-Isopropylpodocarpa-8,11,13-trien-16-oic acid",CC(C)C1=CC2=C(C=C1)[C@]3(CCC[C@](C3CC2)(C)C(=O)O)C,,,,,,
1235,21236,L-Norleucine,CCCC[C@@H](C(=O)O)N,,,,,,
1236,21237,"GLYCOLURIL, 3a,6a-DIPHENYL-",C1=CC=C(C=C1)C23C(NC(=O)N2)(NC(=O)N3)C4=CC=CC=C4,,,,,,
1237,21238,Brilliant Red,CC1=CC(=C(C=C1Cl)S(=O)(=O)[O-])N=NC2=C(C=CC3=CC=CC=C32)O.CC1=CC(=C(C=C1Cl)S(=O)(=O)[O-])N=NC2=C(C=CC3=CC=CC=C32)O.[Ba+2],,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
1238,21239,2-Chloro-5-[(2-hydroxy-1-naphthyl)azo]toluene-4-sulphonic acid,CC1=CC(=C(C=C1Cl)S(=O)(=O)O)N=NC2=C(C=CC3=CC=CC=C32)O,,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],,,
1239,21240,"Benzene, 1-methyl-4-(2-methylpropyl)-",CC1=CC=C(C=C1)CC(C)C,,,,,,
1240,21241,4-Bromo-1-butene,C=CCCBr,,,,,,
1241,21242,"1,1-Diallylhydrazine",C=CCN(CC=C)N,,,,,,
1242,21243,3-Chloro-2-methyl-1-butene,CC(C(=C)C)Cl,,,,,,
1243,21244,5-Methyl-3-hexene-2-one,CC(C)C=CC(=O)C,,,,,,
1244,21245,"9H-Fluorene-2,7-diamine monohydrochloride",C1C2=C(C=CC(=C2)[NH3+])C3=C1C=C(C=C3)N.[Cl-],,,,,,
1245,21246,"2,6-Bis(1,1-dimethylethyl)-4-nitrobenzenamine",CC(C)(C)C1=CC(=CC(=C1N)C(C)(C)C)[N+](=O)[O-],,,,,,
1246,21247,3-[[4-(Methylcarbamoyl)pyridin-1-ium-1-yl]methyl]-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,CNC(=O)C1=CC=[N+](C=C1)CC2=C(N3C(CC2)C(C3=O)NC(=O)CC4=CC=CS4)C(=O)O,,,,,,
1247,21248,Disufene,C[N+](C)(C)CCNS(=O)(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)NCC[N+](C)(C)C.[I-].[I-],,,,,,
1248,21249,"N,N,N,N',N',N'-Hexamethyl[2,2'-[(1,1'-biphenyl-4,4'-diyl)bis(sulfonylimino)]bis(ethanaminium)]",C[N+](C)(C)CCNS(=O)(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)NCC[N+](C)(C)C,,,,,,
1249,21250,"p-ARSANILIC ACID, N,N-BIS(2-HYDROXYETHYL)-",C1=CC(=CC=C1N(CCO)CCO)[As](=O)(O)O,,,,,,
1250,21251,"p-ARSANILIC ACID, N,N-BIS(2-CHLOROETHYL)-",C1=CC(=CC=C1N(CCCl)CCCl)[As](=O)(O)O,,,,,,
1251,21252,[4-[2-Chloroethyl(methyl)amino]phenyl]arsonic acid,CN(CCCl)C1=CC=C(C=C1)[As](=O)(O)O,,,,,,
1252,21253,"p-ARSANILIC ACID, N,N-DIETHYL-",CCN(CC)C1=CC=C(C=C1)[As](=O)(O)O,,,,,,
1253,21254,"1,3,2-DITHIARSENOLANE, 2-(p-BIS(2-CHLOROETHYL)AMINOPHENYL)-",C1CS[As](S1)C2=CC=C(C=C2)N(CCCl)CCCl,,,,,,
1254,21255,"1,3,2-DITHIARSENOLANE, 2-(p-(DIETHYLAMINO)PHENYL)-",CCN(CC)C1=CC=C(C=C1)[As]2SCCS2,,,,,,
1255,21256,"ANILINE, p-ARSENOSO-N,N-BIS(2-HYDROXYETHYL)-",C1=CC(=CC=C1N(CCO)CCO)[As]=O,,,,,,
1256,21257,Chloro(trans-2-methoxycyclooctyl)mercury,COC1CCCCCCC1[Hg]Cl,,,,,,
1257,21258,4-Oxopentyl acetate,CC(=O)CCCOC(=O)C,,,,,,
1258,21259,"Benzene, 1,5-dimethyl-2,4-bis(1-methylethyl)-",CC1=CC(=C(C=C1C(C)C)C(C)C)C,,,,,,
1259,21260,Cyclofenil diphenol,C1CCC(=C(C2=CC=C(C=C2)O)C3=CC=C(C=C3)O)CC1,,,,,,
1260,21261,S-Diphenylmethyl-L-cysteine,C1=CC=C(C=C1)C(C2=CC=CC=C2)SC[C@@H](C(=O)O)N,,,,,,
1261,21262,4-(3-Methylbutoxy)aniline,CC(C)CCOC1=CC=C(C=C1)N,,,,,,
1262,21263,Pent-3-enoic acid,CC=CCC(=O)O,,,,,,
1263,21264,2-Ethyl-4-pentenal,CCC(CC=C)C=O,,,,,,
1264,21265,Prenyl benzoate,CC(=CCOC(=O)C1=CC=CC=C1)C,,,,,,
1265,21266,"1,2,3,4-Tetrahydro-6-methoxy-2-phenyl-1-(2-pyridyl)-1-naphthol",COC1=CC2=C(C=C1)C(C(CC2)C3=CC=CC=C3)(C4=CC=CC=N4)O,,,,,,
1266,21267,"1,2,3,4-Tetrahydro-6-methoxy-2-phenyl-1-(4-pyridyl)-1-naphthol",COC1=CC2=C(C=C1)C(C(CC2)C3=CC=CC=C3)(C4=CC=NC=C4)O,,,,,,
1267,21268,1'-Hydroxysafrole,C=CC(C1=CC2=C(C=C1)OCO2)O,,,,,"[""When 1'-hydroxysafrole was given orally or by ip injection to male rats, about 40% was excreted unchanged; this was not affected by phenobarbital or 3-methylcholanthrene admin. No 1'-hydroxysafrole was excreted in the bile."", ""The urinary metabolites of 1'-hydroxysafrole included 3'-hydroxyisosafrole, 3,4-methylenedioxyphenyl vinyl ketone, the dimethylamino & piperidyl mannich bases, & 3,4-methylenedioxyhippuric acid ..."", ""In men & rats, small oral doses of safrole were absorbed rapidly & then excreted almost entirely within 24 hr in the urine. 1'-hydroxysafrole, a proximate carcinogen of safrole, & 3'-hydroxyisosafrole were detected as conjugates in the urine of the rat; however, it was not possible to demonstrate their presence in man."", ""In the neutral extraction of urine from animals injected with 1'-hydroxysafrole, unmetabolized 1'-hydroxysafrole, 3'-hydroxyisosafrole, 3,4-methylenedioxyphenyl vinyl ketone & 2 unidentified metabolites (mol wt 180 & 226) were present. In the basic urine extraction, the dimethylamino & piperidyl mannich base metabolites were detected; the only acidic metabolite found was 3,4-methylenedioxyhippuric acid."", ""For more Metabolism/Metabolites (Complete) data for 1'-HYDROXYSAFROLE (8 total), please visit the HSDB record page.""]",
1268,21269,"(1R)-7-methoxy-11a-methyl-3,3a,3b,4,5,9b,10,11-octahydro-1H-naphtho[2,1-e][2]benzofuran-1-ol",CC12CCC3C(C1CO[C@H]2O)CCC4=C3C=CC(=C4)OC,,,,,,
1269,21270,"3-methoxy-13-methyl-17-(1,2,2-trifluoroethenyl)-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol",CC12CCC3C(C1CCC2(C(=C(F)F)F)O)CCC4=C3C=CC(=C4)OC,,,,,,
1270,21271,CID 21271,C=CCNC1=NC(=NC(=N1)S)NCC=C,,,,,,
1271,21272,Bis(beta-(2-methylaziridino)ethyl)sulfone,CC1CN1CCS(=O)(=O)CCN2CC2C,,,,,,
1272,21273,"(1,1'-Biphenyl)-3-carboxamide, 5-chloro-N-(3,4-dichlorophenyl)-2-hydroxy-",C1=CC=C(C=C1)C2=C(C(=CC(=C2)Cl)C(=O)NC3=CC(=C(C=C3)Cl)Cl)O,,,,,,
1273,21274,5-methyl-2-nitro-1H-imidazole,CC1=CN=C(N1)[N+](=O)[O-],,,,,,
1274,21275,"2,4-Dinitroimidazole",C1=C(NC(=N1)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1275,21276,"1-Methyl-2,4-dinitro-1H-imidazole",CN1C=C(N=C1[N+](=O)[O-])[N+](=O)[O-],,,,,,
1276,21277,4-Chlorobenzotrichloride,C1=CC(=CC=C1C(Cl)(Cl)Cl)Cl,,,,,,
1277,21278,"ETHANE, 1,2-BIS(p-CHLOROPHENYL)-",C1=CC(=CC=C1CCC2=CC=C(C=C2)Cl)Cl,,,,,,
1278,21279,"2-Chloro-4,6-bis(methoxyamino)-1,3,5-triazine",CONC1=NC(=NC(=N1)Cl)NOC,,,,,,
1279,21280,2-(4-Chlorophenyl)-3-oxobutanenitrile,CC(=O)C(C#N)C1=CC=C(C=C1)Cl,,,,,,
1280,21281,CID 21281,CCC1=C2C=CC(=O)C=C2OC(=C1C3=CC=C(C=C3)OC)O,,,,,,
1281,21282,"5,6,7,8,9,10-Hexahydro-cyclohepta[b]quinolin-11-one",C1CCC2=C(CC1)NC3=CC=CC=C3C2=O,,,,,,
1282,21283,"2,2-Diphenoxy-N-(morpholinopropyl)acetamide hydrochloride",C1COCC[NH+]1CCCNC(=O)C(OC2=CC=CC=C2)OC3=CC=CC=C3.[Cl-],,,,,,
1283,21284,"N-(3-morpholin-4-ylpropyl)-2,2-diphenoxyacetamide",C1COCCN1CCCNC(=O)C(OC2=CC=CC=C2)OC3=CC=CC=C3,,,,,,
1284,21285,N-(o-Chlorobenzyl)-N-methyl-2-propynylamine hydrochloride,C[NH+](CC#C)CC1=CC=CC=C1Cl.[Cl-],,,,,,
1285,21286,"Benzylamine, o-chloro-N-methyl-N-2-propynyl-",CN(CC#C)CC1=CC=CC=C1Cl,,,,,,
1286,21287,CID 21287,CC1=C(C=CC(=C1)Cl)OCC(=O)[O-].[K+],,,,,,
1287,21288,4-Acetamidopyridine,CC(=O)NC1=CC=NC=C1,,,,,,
1288,21289,Pyrimitate,CCOP(=S)(OCC)OC1=NC(=NC(=C1)C)N(C)C,,,,,,
1289,21290,CID 21290,CCCCC1=C(NC(=NC1=O)N(C)C)C,,,,,,
1290,21291,CID 21291,CC[PbH](CC)CC,,,,,,
1291,21292,CID 21292,CC=CCC(COCC[N+](C)(C)C)C1=CC=CC2=CC=CC=C21.[I-],,,,,,
1292,21293,CID 21293,CC=CCC(COCC[N+](C)(C)C)C1=CC=CC2=CC=CC=C21,,,,,,
1293,21294,"6H-Cyclohepta(b)quinoline, 11-(3-(dimethylamino)propoxy)-7,8,9,10-tetrahydro-, dihydrochloride",C[NH+](C)CCCOC1=C2CCCCCC2=[NH+]C3=CC=CC=C31.[Cl-].[Cl-],,,,,,
1294,21295,"N,N-dimethyl-3-(7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolin-11-yloxy)propan-1-amine",CN(C)CCCOC1=C2CCCCCC2=NC3=CC=CC=C31,,,,,,
1295,21296,"6H-Cyclohepta(b)quinoline, 11-(2-(diethylamino)ethoxy)-7,8,9,10-tetrahydro-, dihydrochloride",CC[NH+](CC)CCOC1=C2CCCCCC2=[NH+]C3=CC=CC=C31.[Cl-].[Cl-],,,,,,
1296,21297,"N,N-diethyl-2-(7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolin-11-yloxy)ethanamine",CCN(CC)CCOC1=C2CCCCCC2=NC3=CC=CC=C31,,,,,,
1297,21298,"6H-Cyclohepta(b)quinoline, 11-(2-(dimethylamino)-1-methylethoxy)-7,8,9,10-tetrahydro-, dihydrochloride",CC(C[NH+](C)C)OC1=C2CCCCCC2=[NH+]C3=CC=CC=C31.[Cl-].[Cl-],,,,,,
1298,21299,"N,N-dimethyl-2-(7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolin-11-yloxy)propan-1-amine",CC(CN(C)C)OC1=C2CCCCCC2=NC3=CC=CC=C31,,,,,,
1299,21300,"6H-Cyclohepta(b)quinoline, 2-chloro-11-(2-(dimethylamino)ethoxy)-7,8,9,10-tetrahydro-, dihydrochloride",C[NH+](C)CCOC1=C2CCCCCC2=[NH+]C3=C1C=C(C=C3)Cl.[Cl-].[Cl-],,,,,,
1300,21301,"2-[(2-chloro-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolin-11-yl)oxy]-N,N-dimethylethanamine",CN(C)CCOC1=C2CCCCCC2=NC3=C1C=C(C=C3)Cl,,,,,,
1301,21302,"6H-Cyclohepta(b)quinoline, 3-chloro-11-(2-(dimethylamino)-1-methylethoxy)-7,8,9,10-tetrahydro-, dihydrochloride",CC(C[NH+](C)C)OC1=C2CCCCCC2=[NH+]C3=C1C=CC(=C3)Cl.[Cl-].[Cl-],,,,,,
1302,21303,"2-[(3-chloro-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolin-11-yl)oxy]-N,N-dimethylpropan-1-amine",CC(CN(C)C)OC1=C2CCCCCC2=NC3=C1C=CC(=C3)Cl,,,,,,
1303,21304,Vidorosine,CCC12C=CCN3C1C4(CC3)C(C(C2OC(=O)C)O)N(C5=CC=CC(=C45)C(=O)OC)C,,,,,,
1304,21305,"2-Cyano-3,3-dicyclopropylacrylic acid ethyl ester",CCOC(=O)C(=C(C1CC1)C2CC2)C#N,,,,,,
1305,21306,N-(2-Acetylphenyl)acetamide,CC(=O)C1=CC=CC=C1NC(=O)C,,,,,,
1306,21307,Carboxin,CC1=C(SCCO1)C(=O)NC2=CC=CC=C2,,,"['Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. (See all compounds classified as Fungicides, Industrial.)']","['Carboxin and its sulfoxide are absorbed by germinating seeds and moved upward in the plant, traveling with transpiration system and moving into the lower stem and first leaves of the plant. Carboxin does not redistribute into new growth as the plant develops, and is not found in the seeds or upper leaves of crops grown from treated seed. Animals excrete carboxin and its degradation products rapidly, and no accumulation in tissues was indicated.', 'When carboxin was applied to bean plants (phaseolus vulgaris leguminatate ) ... most of fungicide residue in roots was in form of acetone-insol material. ... Barley plants formed carboxin-lignin complexes in the leaves.', 'When fed to dogs, carboxin is partially oxidized to oxycarboxin. Both compounds are excreted in urine.', 'Extensively metabolized in rats and eliminated mainly in urine and to a lesser extent feces.', 'Rats have been reported to excrete almost an entire dose within 24 hr, primarily in the urine.']","['In dogs fed carboxin, oxidation to sulfoxide occurred ... .', 'Rats and rabbits hydroxylated the phenyl ring of carboxin to give mainly para- and ortho-isomers. They were excreted in urine as glucuronides in rabbits (62 and 10%) and rats (26 and 6%); only traces of meta-isomer conjugate were detected. Variable amounts (1-15%) of the free para-isomer were found in feces of rats, but not of rabbits. A common minor urinary metabolite was identified tentatively as the sulfoxide of one of the phenols (1-3%). The remainder of the dose was unchanged carboxin in the feces (rat, 41%; rabbit, 10%) and in the urine (1-2%).', 'Extensively metabolized in rats... . Major metabolites in urine are p-hydroxylated carboxin sulfoxide, 4-acetamidophenol and its O-glucuronide.', '/In plants,/ undergoes oxidation to carboxin sulfoxide and carboxin sulfone.', 'For more Metabolism/Metabolites (Complete) data for CARBOXIN (7 total), please visit the HSDB record page.']",
1307,21308,2-Norbornanemethanol,C1CC2CC1CC2CO,,,,,,
1308,21309,3-(p-Chlorophenyl)-5-(2-piperidinoethyl)isoxazole hydrochloride,C1CC[NH+](CC1)CCC2=CC(=NO2)C3=CC=C(C=C3)Cl.[Cl-],,,,,,
1309,21310,"3-(4-Chlorophenyl)-5-(2-piperidin-1-ylethyl)-1,2-oxazole",C1CCN(CC1)CCC2=CC(=NO2)C3=CC=C(C=C3)Cl,,,,,,
1310,21311,"4-Ethoxy-N-ethyl-6-methyl-1,3,5-triazin-2-amine",CCNC1=NC(=NC(=N1)C)OCC,,,,,,
1311,21312,"1,3,5-Triazin-2-amine, 4-butoxy-N-ethyl-6-methyl-",CCCCOC1=NC(=NC(=N1)NCC)C,,,,,,
1312,21313,"N,4-Diethyl-6-methoxy-1,3,5-triazin-2-amine",CCC1=NC(=NC(=N1)OC)NCC,,,,,,
1313,21314,CID 21314,C[N-]C1=NC(=NC(=N1)N[N+]#N)Cl,,,,,,
1314,21315,CID 21315,CNC1=NC(=NC(=N1)Cl)N[N+]#N,,,,,,
1315,21316,"4-azido-6-chloro-N,N-dimethyl-1,3,5-triazin-2-amine",CN(C)C1=NC(=NC(=N1)N=[N+]=[N-])Cl,,,,,,
1316,21317,"2-Amino-4-azido-6-chloro-1,3,5-triazine",C1(=NC(=NC(=N1)Cl)N=[N+]=[N-])N,,,,,,
1317,21318,"4-Azido-6-methoxy-1,3,5-triazin-2-amine",COC1=NC(=NC(=N1)N=[N+]=[N-])N,,,,,,
1318,21319,Flucloxacillin,CC1=C(C(=NO1)C2=C(C=CC=C2Cl)F)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,['Used to treat bacterial infection by susceptible microorganisms.'],"['Flucloxacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name ""penicillin"" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Flucloxacillin has <i>in vitro</i> activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Flucloxacillin results from the inhibition of cell wall synthesis and is mediated through flucloxacillin binding to penicillin binding proteins (PBPs). Flucloxacillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.']",['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],['Bioavailability is 50â70% following oral administration.'],"['Hepatic.', 'Flucloxacillin has known human metabolites that include 6-[[3-(2-Chloro-6-fluorophenyl)-5-(hydroxymethyl)-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid.']",['0.75â1 hour']
1319,21320,"(9S,11S,14S,17R)-6-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-9,11,12,14,15,16-hexahydro-8H-cyclopenta[a]phenanthren-3-one",CC12C[C@@H]([C@H]3C([C@@H]1CC[C@@]2(C(=O)CO)O)C=C(C4=CC(=O)C=CC34C)Cl)O,,,,,,
1320,21321,Ammonium benzamidooxyacetate,C1=CC=C(C=C1)C(=O)NOCC(=O)[O-].[NH4+],,,,,,
1321,21322,Benzadox,C1=CC=C(C=C1)C(=O)NOCC(=O)O,,,,,,
1322,21323,"2-Imidazoline, 2-(1,2,3,4-tetrahydro-1-naphthylamino)-, hydrochloride",C1CC(C2=CC=CC=C2C1)NC3=[NH+]CCN3.[Cl-],,,,,,
1323,21324,"2-(1,2,3,4-Tetrahydro-1-naphthylamino)-2-imidazoline",C1CC(C2=CC=CC=C2C1)NC3=NCCN3,,,,,,
1324,21325,"2-Naphthalenecarboxamide, N-[2-[2-(acetylamino)phenyl]ethyl]-1-hydroxy-",CC(=O)NC1=CC=CC=C1CCNC(=O)C2=C(C3=CC=CC=C3C=C2)O,,,,,,
1325,21326,4-Methyl-5-thiazoleacetic acid,CC1=C(SC=N1)CC(=O)O,,,,,,
1326,21327,"1,2-Epoxy-3-(p-nitrophenoxy)propane",C1C(O1)COC2=CC=C(C=C2)[N+](=O)[O-],,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)', 'Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)']",,,
1327,21328,"6,8-Dioxabicyclo[3.2.1]octan-7-one",C1CC2C(=O)OC(C1)O2,,,,,,
1328,21329,"Benzenesulfonic acid, 2-methyl-5-nitro-, sodium salt",CC1=C(C=C(C=C1)[N+](=O)[O-])S(=O)(=O)[O-].[Na+],,,,,,
1329,21330,Oxycarboxin,CC1=C(S(=O)(=O)CCO1)C(=O)NC2=CC=CC=C2,,,,"['In plants carboxin and its metabolite, carboxin sulfoxide, are absorbed by germinating seeds /and/ moved upward in the plant, traveling with the transpiration system and moving into the lower stem and first leaves of the plant. Carboxin does not redistribute into new growth as the plant matures, and is not found in seeds or upper leaves of crops grown from treated seeds. Oxycarboxin is more stable in plants than carboxin but it is distributed in a similar manner.', '/Oxycarboxin is/ ... excreted in urine and feces.']","['The most prominent metabolites /of oxycarboxin/ result from the opening of the oxathiin ring.', 'When bean plants were exposed to oxycarboxin, four degradation products found in the plants and solution in which the plants were incubated were identified as: 2-(2-hydroxyethylsulfonyl)acetanilide, 4-phenyl-3-thiomorpholinone-1,1-dioxide, 2-(vinylsulfonyl)acetanilide.']",['The half-life of oxycarboxin in soil is 2-8 weeks with the most prominent metabolites resulting from the opening of the oxathiin ring.']
1330,21331,3-Ethyl-2-methylbenzoxazolium iodide,CC[N+]1=C(OC2=CC=CC=C21)C.[I-],,,,,,
1331,21332,"3-Ethyl-2-methyl-1,3-benzoxazol-3-ium",CC[N+]1=C(OC2=CC=CC=C21)C,,,,,,
1332,21333,"N1,N4-bis[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]terephthalamide",C1CN=C(N1)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)C(=O)NC4=CC=C(C=C4)C5=NCCN5.Cl.Cl,,,,,,
1333,21334,Bitpa,C1CN=C(N1)C2=CC=C(C=C2)NC(=O)C3=CC=C(C=C3)C(=O)NC4=CC=C(C=C4)C5=NCCN5,,,,,,
1334,21335,"4-Methoxy-1,3-dioxolo(4,5-g)isoquinoline hydrochloride",COC1=C2C=[NH+]C=CC2=CC3=C1OCO3.[Cl-],,,,,,
1335,21336,"4-Methoxy-[1,3]dioxolo[4,5-g]isoquinoline",COC1=C2C=NC=CC2=CC3=C1OCO3,,,,,,
1336,21337,"4-Methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolinium iodide",C[N+]1=CC2=C(C3=C(C=C2C=C1)OCO3)OC.[I-],,,,,,
1337,21338,"4-Methoxy-6-methyl-[1,3]dioxolo[4,5-g]isoquinolin-6-ium",C[N+]1=CC2=C(C3=C(C=C2C=C1)OCO3)OC,,,,,,
1338,21339,"Ammonium, (1,4-phenylenebis(oxyethylene))bis(triethyl-, diiodide",CC[N+](CC)(CC)CCOC1=CC=C(C=C1)OCC[N+](CC)(CC)CC.[I-].[I-].[I-],,,,,,
1339,21340,Triethyl-[2-[4-[2-(triethylazaniumyl)ethoxy]phenoxy]ethyl]azanium,CC[N+](CC)(CC)CCOC1=CC=C(C=C1)OCC[N+](CC)(CC)CC,,,,,,
1340,21341,1-Naphthyl (hydroxymethyl)carbamate,C1=CC=C2C(=C1)C=CC=C2OC(=O)NCO,,,,,['Carbaryl methylol is a known human metabolite of carbaryl.'],
1341,21342,4-Hydroxycarbaryl,CNC(=O)OC1=CC=C(C2=CC=CC=C21)O,,,,,['5-hydroxycarbaryl is a known human metabolite of carbaryl.'],
1342,21343,"5-Methyl-2,4-dinitroaniline",CC1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])N,,,,,,
1343,21344,3-Isonipecotylindole,C1CNCCC1C(=O)C2=CNC3=CC=CC=C32,,,,,,
1344,21345,3-(pyridin-3-ylmethyl)-1H-indole,C1=CC=C2C(=C1)C(=CN2)CC3=CN=CC=C3,,,,,,
1345,21346,3-(2-Piperidylmethyl)indole,C1CCNC(C1)CC2=CNC3=CC=CC=C32,,,,,,
1346,21347,"Indole, 3-(3-piperidylmethyl)-",C1CC(CNC1)CC2=CNC3=CC=CC=C32,,,,,,
1347,21348,2-Acetyl-5-nitrofuran,CC(=O)C1=CC=C(O1)[N+](=O)[O-],,,,,,
1348,21349,(1-Nitropropyl)benzene,CCC(C1=CC=CC=C1)[N+](=O)[O-],,,,,,
1349,21350,Piprotal,CCCCOCCOCCOC(C1=CC2=C(C=C1)OCO2)OCCOCCOCCCC,,,,"['When Tropital was fed to mice, rats or hamsters, degradation occurred primarily at the side chain with excretion of metabolites in the urine.', '... mice excreted 98% of ... /oral/ dose of Tropital in the urine ...', 'Methylenedioxphenyl synergists, piperonyl butoxide, Tropital and octachlorodipropyl ether are used as synergists for a variety of pesticides as well as functioning as inhibitors of the epoxidation of aldrin to dieldrin. the nature of the biliary and urinary metabolites following single i.v. administration of the synergists as well as their mode of separation and detection is illustrated. The rate of elimination of the biliary metabolites, although high, does not reach a rapid peak followed by a rapid decline, but suggests prolonged elimination of the metabolites from the body into the bile. ...']","['Methylenedioxphenyl synergists, piperonyl butoxide, Tropital and octachlorodipropyl ether are used as synergists for a variety of pesticides as well as functioning as inhibitors of the epoxidation of aldrin to dieldrin. the nature of the biliary and urinary metabolites following single i.v. administration of the synergists as well as their mode of separation and detection is illustrated. The rate of elimination of the biliary metabolites, although high, does not reach a rapid peak followed by a rapid decline, but suggests prolonged elimination of the metabolites from the body into the bile. ...', 'When Tropital was fed to mice, rats or hamsters, degradation occurred primarily at the side chain with excretion of metobolites in the urine. Some metabolism of the methylene dioxide to carbon dioxide also occurred. The glycine and glucuronate conjugates were found. Rats, mice and rabbits, admin Tropital orally, metabolized the Tropital to piperonal, piperonylic acid, N-piperonyglycine and two unidentified acid cmpd. When piperonylic acid was fed to mice, both the free acid and glycine conjugate were observed. After incubation of tropital with mouse liver microsomes and NADPH2, Tropital was degraded to piperonylic acid via piperonal.', 'The metabolism of methylenedioxyphenyl (MDP) compounds was studied in mammals. The purpose of the study was to investigate the mechanism and significance of demethylation of MDP and similar compounds in relation to the metabolism and mode of action of commercial synergist chemicals such as piperonyl-butoxide and tropital. Male Swiss-Webster-mice, Sprague-Dawley-rats, or hamsters were administered 13 carbon-14 labeled MDP compounds such as tropital, piperonal, piperonyl-alcohol, piperonylic-acid, safrole, dihydrosafrole, or piperonyl-butoxide. Urine, feces, and expired air were collected for 48 hours for carbon-14 assay. Carbon-14 activity in the intestine, liver, and carcass was determined. Urine samples were analyzed for metabolites. Compounds such as dihydrosafrole, safrole, myristicin, and piperonyl-butoxide were largely metabolized by oxidation of the methylene group of the MDP moiety to yield radiolabeled carbon-dioxide. The radiolabel ultimately appearing as carbon-dioxide was first liberated as radioactive formate. Carbon-dioxide was not an important route of elimination in the metabolism of piperonyl-alcohol, piperonal, piperonylic-acid, and tropital. Their metabolites were excreted primarily in the urine. No marked species difference was noted in carbon-14 tissue distribution after dosing with tropital and piperonyl-butoxide. Oxidation or conjugation of the side chain was the major metabolic pathway for tropital, piperonal, piperonyl-alcohol, and piperonylic-acid. Urinary metabolites of piperonyl-butoxide included many compounds lacking the MDP moiety and small amounts of 6-propyl-piperonylic-acid and its glycine conjugate. Urinary metabolites of tropital included glycine and glucuronic-acid conjugates of piperonylic-acid. In an in-vitro experiment, radiolabeled piperonyl-butoxide, tropital, safrole, and other MDP compounds were incubated with mouse liver microsomes and were assayed for metabolites. Metabolites such as formate and catechols were detected. The authors conclude that demethylation of the MDP moiety is the major metabolic pathway in mammals given piperonyl-butoxide, safrole, dihydrosafrole and myristicin.']",
1350,21351,CID 21351,CC[NH+](CCCC1=CC=C(C=C1)Cl)CC2=CC(=C(C=C2)OC)OC.C(=CC(=O)[O-])C(=O)O,,,,,,
1351,21352,"3-(4-chlorophenyl)-N-[(3,4-dimethoxyphenyl)methyl]-N-ethylpropan-1-amine",CCN(CCCC1=CC=C(C=C1)Cl)CC2=CC(=C(C=C2)OC)OC,,,,,,
1352,21353,Pentamethonium iodide,C[N+](C)(C)CCCCC[N+](C)(C)C.[I-].[I-],,,,,,
1353,21354,Octyltrichlorosilane,CCCCCCCC[Si](Cl)(Cl)Cl,,,,,['... Chlorosilanes will be rapidly hydrolyzed upon contact with tissue fluids to release hydrochloric acid. /Chlorosilanes/'],
1354,21355,Nonyltrichlorosilane,CCCCCCCCC[Si](Cl)(Cl)Cl,,,,,['... Chlorosilanes will be rapidly hydrolyzed upon contact with tissue fluids to release hydrochloric acid. /Chlorosilanes/'],
1355,21356,"5,6-Dichlorobenzoxazol-2(3H)-one",C1=C2C(=CC(=C1Cl)Cl)OC(=O)N2,,,,,,
1356,21357,Phenyl thiocyanate,C1=CC=C(C=C1)SC#N,,,,,,
1357,21358,Demeton-o sulfoxide,CCOP(=S)(OCC)OCCS(=O)CC,,,,,,
1358,21359,Prenisteine,CC(=CCSC[C@@H](C(=O)O)N)C,,,,,,
1359,21360,"6H-Cyclohepta(b)quinoline, 2-chloro-11-(2-(dimethylamino)-1-methylethoxy)-7,8,9,10-tetrahydro-, dihydrochloride",CC(C[NH+](C)C)OC1=C2CCCCCC2=[NH+]C3=C1C=C(C=C3)Cl.[Cl-].[Cl-],,,,,,
1360,21361,"2-[(2-chloro-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolin-11-yl)oxy]-N,N-dimethylpropan-1-amine",CC(CN(C)C)OC1=C2CCCCCC2=NC3=C1C=C(C=C3)Cl,,,,,,
1361,21362,Hydroxyecdysone,C[C@]12CC[C@H]3C(=CC(=O)[C@H]4[C@@]3(C[C@@H]([C@@H](C4)O)O)C)[C@@]1(CC[C@@H]2C(C)([C@@H](CCC(C)(C)O)O)O)O,,,,,,
1362,21363,Cyclohexylacetic acid,C1CCC(CC1)CC(=O)O,,,,,,
1363,21364,Dimethyl 2-nitroterephthalate,COC(=O)C1=CC(=C(C=C1)C(=O)OC)[N+](=O)[O-],,,,,,
1364,21365,"N-(1,2,4-triazol-4-yl)acetamide",CC(=O)NN1C=NN=C1,,,,,,
1365,21366,"p-DITHIIN-2,3-DICARBOXIMIDE, 5,6-DIHYDRO-N-(MORPHOLINOMETHYL)-",C1COCCN1CN2C(=O)C3=C(C2=O)SCCS3,,,,,,
1366,21367,3-Methoxy-N-methylanthranilic acid methyl ester hydrochloride,C[NH2+]C1=C(C=CC=C1OC)C(=O)OC.[Cl-],,,,,,
1367,21368,Damascenine,CNC1=C(C=CC=C1OC)C(=O)OC,,,,,,
1368,21369,5-(Bromomethyl)-3-(4-chlorophenyl)isoxazole,C1=CC(=CC=C1C2=NOC(=C2)CBr)Cl,,,,,,
1369,21370,2-((o-Chlorophenyl)dithio)ethylamine hydrochloride,C1=CC=C(C(=C1)SSCC[NH3+])Cl.[Cl-],,,,,,
1370,21371,2-[(2-Chlorophenyl)disulfanyl]ethanamine,C1=CC=C(C(=C1)SSCCN)Cl,,,,,,
1371,21372,Methyl propyl phosphorothioate,CCCOP(=O)(OCCC)SC,,,,,,
1372,21373,N-(4-((4-Hydroxyphenyl)azo)phenyl)acetamide,CC(=O)NC1=CC=C(C=C1)N=NC2=CC=C(C=C2)O,,,,,,
1373,21374,4'-Ethyl-4-dimethylaminoazobenzene,CCC1=CC=C(C=C1)N=NC2=CC=C(C=C2)N(C)C,,,,,,
1374,21375,CID 21375,C(C(C(=O)O)N)C(=O)C(=O)NO,,,,,,
1375,21376,"1,3,4-Oxadiazole, 2,5-bis(4-methoxy-3-nitrophenyl)-",COC1=C(C=C(C=C1)C2=NN=C(O2)C3=CC(=C(C=C3)OC)[N+](=O)[O-])[N+](=O)[O-],,,,,,
1376,21377,Acetyltrimethylammonium bromide,CC(=O)[N+](C)(C)C.[Br-],,,,,,
1377,21378,Acetyltrimethylammonium,CC(=O)[N+](C)(C)C,,,,,,
1378,21379,"2,5-Diaminoanisole",COC1=C(C=CC(=C1)N)N,,,,"['Skin absorption of a hair dye product with 2,5-DAA (1.9%, mixed 1:1 with H2O2) applied (27-32 min) on washed hair of 5 female volunteers was less than 0.102% of the amount applied, under hypothesis that distribution of the dye is equal in the whole body.', '(14)C-2,5-DAA.2HCl (aqueous solution) applied epicutaneously without hydrogen peroxide on HIM: OFA-Sprague-Dawley rats at 2 mg  (free base)/sq cm showed that 1.02% of the amount applied was absorbed. (14)C-2,5-DAA.2HCl in commercial preparation (1;1 with 6% H2O2) after epicutaneous applications on sq cm of clipped skin areas and 2 mg (free base)/sq cm on unclipped skin showed an absorption of 0.28% (clipped skin) and 0.07% (unclipped skin).']",,
1379,21380,CID 21380,C1=CC(=N)C(=CC1=N)N(O)O,,,,,,
1380,21381,CID 21381,CC(=NC)S,,,,,,
1381,21382,Clomacran,CN(C)CCCC1C2=CC=CC=C2NC3=C1C=C(C=C3)Cl,,,,,,
1382,21383,"s-Triazine, 2,4,6-tris(dichloromethyl)-",C1(=NC(=NC(=N1)C(Cl)Cl)C(Cl)Cl)C(Cl)Cl,,,,,,
1383,21384,"2,4-Bis(dichloromethyl)-6-methyl-1,3,5-triazine",CC1=NC(=NC(=N1)C(Cl)Cl)C(Cl)Cl,,,,,,
1384,21385,"2-(Dichloromethyl)-4,6-dimethoxy-1,3,5-triazine",COC1=NC(=NC(=N1)C(Cl)Cl)OC,,,,,,
1385,21386,"2,4-Dimethoxy-6-trichloromethyl-1,3,5-triazine",COC1=NC(=NC(=N1)C(Cl)(Cl)Cl)OC,,,,,,
1386,21387,1-Hydroxypyrene,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)O,,,['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)'],,,
1387,21388,Imidocarb hydrochloride,C1CN=C(N1)C2=CC(=CC=C2)NC(=O)NC3=CC=CC(=C3)C4=NCCN4.Cl.Cl,,,['Substances that are destructive to protozoans. (See all compounds classified as Antiprotozoal Agents.)'],,,
1388,21389,Imidocarb,C1CN=C(N1)C2=CC(=CC=C2)NC(=O)NC3=CC=CC(=C3)C4=NCCN4,,,['Substances that are destructive to protozoans. (See all compounds classified as Antiprotozoal Agents.)'],,,
1389,21390,"2-Amino-5-(methylthio)-1,3,4-thiadiazole",CSC1=NN=C(S1)N,,,,,,
1390,21391,"BENZIMIDAZOLE, 1-(2-(DIETHYLAMINO)ETHYL)-2-(p-METHOXYPHENYL)-",CCN(CC)CCN1C2=CC=CC=C2N=C1C3=CC=C(C=C3)OC,,,,,,
1391,21392,CID 21392,CCCCCCC(CC=CCCCCCCCC(=O)[O-])O.[Na+],,,,,,
1392,21393,"2,3-Dibromopropyl dihydrogen phosphate",C(C(CBr)Br)OP(=O)(O)O,,,,,,
1393,21394,"2,6-Dibromo-4-chlorophenol",C1=C(C=C(C(=C1Br)O)Br)Cl,,,,,,
1394,21395,"4,4-Diacetylheptanedinitrile",CC(=O)C(CCC#N)(CCC#N)C(=O)C,,,,,,
1395,21396,"2H-1,4-Benzothiazin-3(4H)-one",C1C(=O)NC2=CC=CC=C2S1,,,,,,
1396,21397,"1,5-Naphthalenedithiol",C1=CC2=C(C=CC=C2S)C(=C1)S,,,,,,
1397,21398,1-(4-Aminophenyl)-3-pyridin-2-ylprop-2-en-1-one,C1=CC=NC(=C1)C=CC(=O)C2=CC=C(C=C2)N,,,,,,
1398,21399,Ethyl 1-piperidinecarboxylate,CCOC(=O)N1CCCCC1,,,,,,
1399,21400,N-(4-(Diethylamino)phenyl)acetamide,CCN(CC)C1=CC=C(C=C1)NC(=O)C,,,,,,
1400,21401,Isopropyl furfurylcarbamate,CC(C)OC(=O)NCC1=CC=CO1,,,,,,
1401,21402,"1,4-Diaminoanthracene-9,10-diol",C1=CC=C2C(=C1)C(=C3C(=CC=C(C3=C2O)N)N)O,,,,,,
1402,21403,1-Ethoxynaphthalene,CCOC1=CC=CC2=CC=CC=C21,,,,,,
1403,21404,Copper 3-phenylsalicylate,C1=CC=C(C=C1)C2=C(C(=CC=C2)C(=O)[O-])[O-].[Cu+2],,,,,,
1404,21405,1-Methylpentylamine,CCCCC(C)N,,,,,,
1405,21406,2-(Hydroxymethyl)cyclohexanone,C1CCC(=O)C(C1)CO,,,,,,
1406,21407,N-Propylacetamide,CCCNC(=O)C,,,,,,
1407,21408,"1-Phenylpentane-1,3-dione",CCC(=O)CC(=O)C1=CC=CC=C1,,,,,,
1408,21409,"BENZYL ALCOHOL, alpha-(2-(DIMETHYLAMINO)-1-PHENOXYETHYL)-, HYDROCHLORIDE",C[NH+](C)CC(C(C1=CC=CC=C1)O)OC2=CC=CC=C2.[Cl-],,,,,,
1409,21410,3-(Dimethylamino)-2-phenoxy-1-phenylpropan-1-ol,CN(C)CC(C(C1=CC=CC=C1)O)OC2=CC=CC=C2,,,,,,
1410,21411,CID 21411,C1=CC2=C(C=C1Cl)N=C(S2)S,,,,,,
1411,21412,4-Bromobutyronitrile,C(CC#N)CBr,,,,,,
1412,21413,3-Bromoquinoline,C1=CC=C2C(=C1)C=C(C=N2)Br,,,,,,
1413,21414,2-Octyl-1-dodecanol,CCCCCCCCCCC(CCCCCCCC)CO,,,,,,
1414,21415,CID 21415,CC(C(C1[C@@H](C(C([C@H](O1)SCCOC(=O)C2=CC=CC=C2O)O)O)O)NC(=O)[C@@H]3CCC[NH+]3C)OC.C1=CC=C(C(=C1)C(=O)[O-])O,,,,,,
1415,21416,"2-[(2R,5R)-3,4,5-trihydroxy-6-[2-methoxy-1-[[(2S)-1-methylpyrrolidine-2-carbonyl]amino]propyl]oxan-2-yl]sulfanylethyl 2-hydroxybenzoate",CC(C(C1[C@@H](C(C([C@H](O1)SCCOC(=O)C2=CC=CC=C2O)O)O)O)NC(=O)[C@@H]3CCCN3C)OC,,,,,,
1416,21417,"BENZYL ALCOHOL, p-CHLORO-alpha-(TRICHLOROMETHYL)-",C1=CC(=CC=C1C(C(Cl)(Cl)Cl)O)Cl,,,,,,
1417,21418,Bis(2-chloroethyl) but-2-enedioate,C(CCl)OC(=O)C=CC(=O)OCCCl,,,,,,
1418,21419,"2,4-Dichloro-6-phenylphenol",C1=CC=C(C=C1)C2=C(C(=CC(=C2)Cl)Cl)O,,,,,,
1419,21420,"Urea, N,N'-bis(1,1-dimethylethyl)-",CC(C)(C)NC(=O)NC(C)(C)C,,,,,,
1420,21421,N-Nitrosodibenzylamine,C1=CC=C(C=C1)CN(CC2=CC=CC=C2)N=O,,,,,,
1421,21422,"2-Methyl-4,6-bis(methylsulfanyl)-1,3,5-triazine",CC1=NC(=NC(=N1)SC)SC,,,,,,
1422,21423,Trihexyl borate,B(OCCCCCC)(OCCCCCC)OCCCCCC,,,,,,
1423,21424,"Boric acid, tris(4-methyl-2-pentyl) ester",B(OC(C)CC(C)C)(OC(C)CC(C)C)OC(C)CC(C)C,,,,,,
1424,21425,Trioctadecyl borate,B(OCCCCCCCCCCCCCCCCCC)(OCCCCCCCCCCCCCCCCCC)OCCCCCCCCCCCCCCCCCC,,,,,,
1425,21426,Tris(octadec-9-enyl) borate,B(OCCCCCCCCC=CCCCCCCCC)(OCCCCCCCCC=CCCCCCCCC)OCCCCCCCCC=CCCCCCCCC,,,,,,
1426,21427,Tris(2-chlorophenyl) borate,B(OC1=CC=CC=C1Cl)(OC2=CC=CC=C2Cl)OC3=CC=CC=C3Cl,,,,,,
1427,21428,"2,6-Dimethylcyclohexanol",CC1CCCC(C1O)C,,,,,,
1428,21429,4'-Methylpropiophenone,CCC(=O)C1=CC=C(C=C1)C,,,,,,
1429,21430,"N,N-Bis(acetoxyethyl)acetamide",CC(=O)N(CCOC(=O)C)CCOC(=O)C,,,,,,
1430,21431,CID 21431,CCCCCCCCCCCCN=C([NH3+])N.[Br-],,,,,,
1431,21432,3-Methyl-3-octanol,CCCCCC(C)(CC)O,,,,,,
1432,21433,N-Benzylidene-m-nitroaniline,C1=CC=C(C=C1)C=NC2=CC(=CC=C2)[N+](=O)[O-],,,,,,
1433,21434,"3-Hexanimine, 5-(N,N-dimethylamino)methyl-4,4-diphenyl-, hydrochloride",CCC(=N)C(CC(C)[NH+](C)C)(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
1434,21435,"Hexylamine, 3,3-diphenyl-4-imino-N,N,1-trimethyl-",CCC(=N)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
1435,21436,1-(Piperidin-1-ylmethyl)naphthalen-2-ol,C1CCN(CC1)CC2=C(C=CC3=CC=CC=C32)O,,,,,,
1436,21437,"Naphtho[1,2-c]furan-1,3-dione",C1=CC=C2C(=C1)C=CC3=C2C(=O)OC3=O,,,,,,
1437,21438,CID 21438,C1=CC=C(C(=C1)N=C(N)S)Cl,,,,,,
1438,21439,2-Aminobenzyl alcohol,C1=CC=C(C(=C1)CO)N,,,,,['2-aminobenzylalcohol has known human metabolites that include (2-aminophenyl)methyl hydrogen sulfate.'],
1439,21440,3-(o-Nitrophenyl)-2-phenylacrylic acid,C1=CC=C(C=C1)C(=CC2=CC=CC=C2[N+](=O)[O-])C(=O)O,,,,,,
1440,21441,3-Chloro-4-methoxyaniline,COC1=C(C=C(C=C1)N)Cl,,,,,,
1441,21442,Thiocyanatoacetic acid butyl ester,CCCCOC(=O)CSC#N,,,,,,
1442,21443,"Malononitrile, (5-chloro-2-hydroxybenzylidene)-",C1=CC(=C(C=C1Cl)C=C(C#N)C#N)O,,,,,,
1443,21444,Thiocyanatoacetic acid propyl ester,CCCOC(=O)CSC#N,,,,,,
1444,21445,"Acetic acid, thiocyanato-, cyclohexyl ester",C1CCC(CC1)OC(=O)CSC#N,,,,,,
1445,21446,Thiocyanatoacetic acid ethyl ester,CCOC(=O)CSC#N,,,,,,
1446,21447,Di-sec-butylnitrosamine,CCC(C)N(C(C)CC)N=O,,,,,,
1447,21448,"2-Dimethylamino-3-chloro-1,4-naphthoquinone",CN(C)C1=C(C(=O)C2=CC=CC=C2C1=O)Cl,,,,,,
1448,21449,Benzyltrimethylammonium bromide,C[N+](C)(C)CC1=CC=CC=C1.[Br-],,,"['Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)', 'Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)']",,,
1449,21450,4-Aminobenzohydrazide,C1=CC(=CC=C1C(=O)NN)N,,,,,,
1450,21451,CID 21451,C1=CC=C(C=C1)N=C(NN)S,,,,,,
1451,21452,2-(9-Octadecenyloxy)ethanol,CCCCCCCCC=CCCCCCCCCOCCO,,,,,,
1452,21453,Diaveridine,COC1=C(C=C(C=C1)CC2=CN=C(N=C2N)N)OC,,,,,,
1453,21454,"Indole, 3-(piperidinomethyl)-",C1CCN(CC1)CC2=CNC3=CC=CC=C32,,,,,,
1454,21455,"Carbamic acid, (dimethylphenylsilyl)methyl ester",C[Si](C)(COC(=O)N)C1=CC=CC=C1,,,,,,
1455,21456,CID 21456,CCC(COC(=O)C(C)O)N,,,,,,
1456,21457,4-Methyl-3-pentenal,CC(=CCC=O)C,,,,,,
1457,21458,"2-Pentenal, 4-methyl-",CC(C)C=CC=O,,,,,,
1458,21459,1-(Ethenyloxy)pentane,CCCCCOC=C,,,,,,
1459,21460,Vinyl hexyl ether,CCCCCCOC=C,,,,,,
1460,21461,"6-Chloro-17-hydroxy-16-methylpregna-4,6-diene-3,20-dione",CC1CC2C3C=C(C4=CC(=O)CCC4(C3CCC2(C1(C(=O)C)O)C)C)Cl,,,,,,
1461,21462,"N-(2,6-Dimethylphenylcarbamoylmethyl)triethylammonium chloride",CC[N+](CC)(CC)CC(=O)NC1=C(C=CC=C1C)C.[Cl-],,,,,,
1462,21463,"Allyldiethyl((2,6-xylylcarbamoyl)methyl)ammonium chloride",CC[N+](CC)(CC=C)CC(=O)NC1=C(C=CC=C1C)C.[Cl-],,,,,,
1463,21464,"[2-(2,6-Dimethylanilino)-2-oxoethyl]-diethyl-prop-2-enylazanium",CC[N+](CC)(CC=C)CC(=O)NC1=C(C=CC=C1C)C,,,,,,
1464,21465,"AMMONIUM, p-PHENYLENEBIS(TRIMETHYL-, DIIODIDE",C[N+](C)(C)C1=CC=C(C=C1)[N+](C)(C)C.[I-].[I-],,,,,,
1465,21466,"1,4-Phenylenebis(trimethylaminium)",C[N+](C)(C)C1=CC=C(C=C1)[N+](C)(C)C,,,,,,
1466,21467,Mexiletine hydrochloride,CC1=C(C(=CC=C1)C)OCC(C)N.Cl,['Namuscla is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders.'],,"['Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)']",,,
1467,21468,"2,6-Diamino-4-butoxypyridine",CCCCOC1=CC(=NC(=C1)N)N,,,,,,
1468,21469,"Ethanol, 2-(3-methyl-1-phenyl-5-pyrazolyloxy)-",CC1=NN(C(=C1)OCCO)C2=CC=CC=C2,,,,,,
1469,21470,Thalicarpine,CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC(=C(C=C43)OC)OC5=CC(=C(C=C5C[C@H]6C7=CC(=C(C=C7CCN6C)OC)OC)OC)OC)OC)OC,,,,,,
1470,21471,N'-Hydroxy-4-methoxybenzenecarboximidamide,COC1=CC=C(C=C1)C(=NO)N,,,,,,
1471,21472,"4,5,6-Trimethoxytryptamine",COC1=C(C(=C2C(=C1)NC=C2CC[NH3+])OC)OC.[Cl-],,,,,,
1472,21473,"3-(2-Aminoethyl)-4,5,6-trimethoxy-1H-indole",COC1=C(C(=C2C(=C1)NC=C2CCN)OC)OC,,,,,,
1473,21474,Metomidate,CC(C1=CC=CC=C1)N2C=NC=C2C(=O)OC,,,['Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)'],,,
1474,21475,"1-(2,4-Dimethylphenyl)ethanol",CC1=CC(=C(C=C1)C(C)O)C,,,,,,
1475,21476,"3,5-Dimethylstyrene",CC1=CC(=CC(=C1)C=C)C,,,,,,
1476,21477,3-(Morpholinomethyl)indole,C1COCCN1CC2=CNC3=CC=CC=C32,,,,,,
1477,21478,"1H-Indole, 3-(1-pyrrolidinylmethyl)-",C1CCN(C1)CC2=CNC3=CC=CC=C32,,,,,,
1478,21479,Acetamidooxyacetic acid,CC(=O)NOCC(=O)O,,,,,,
1479,21480,"Dibenzo[a,e]fluoranthene",C1=CC=C2C(=C1)C=C3C4=CC=CC=C4C5=C3C2=CC6=CC=CC=C65,,,,,"['The production by dibenzo[a,e]fluoranthene (DBF) of DNA-protein cross-links in cultured mouse fibroblasts is probably mediated by the activation of proximate metabolites of DBF and not by the DBF molecule itself. In order to test this hypothesis, several agents that enhance or reduce production of the DBF metabolite putatively involved in cross-linking were tested. Increasing NADPH concentrations in the medium enhanced cross-link production; 1,2-epoxy-3,3,3-trichloropropane (TCPO), an inhibitor of epoxide hydrolases, slightly reduced DNA-protein cross-link formation at high concentrations; norharman (NH), an inhibitor of certain steps in the metabolism of DBF, totally blocked cross-linking. The possible involvement of DBF-bisdihydrodiol, a bifunctional metabolite identified in vitro, is discussed. Postincubation in DBF-free medium did not induce a significant reduction in cross-links, indicating that repair did not take place.', 'Dibenzo[a,e]fluoranthene, its 7-hydroxy, 3,4- and 12,13-dihydrodiol metabolic derivatives as well as three synthetic, structurally related hydrocarbons, were tested for mutagenicity towards Salmonella typhimurium TA100 strain in the presence of 3-methylcholanthrene-treated rat and mouse liver post-mitochondrial supernatants. Of these compounds, the 12,13-dihydrodiol showed the highest activity, being 6-10 times more mutagenic than the parent compound. Our data, in conjunction with those of previous studies on the liver microsomal metabolism and DNA binding of dibenzo[a,e]fluoranthene and its dihydrodiols, indicate that activation of dibenzo[a,e]fluoranthene to bacterial mutagens may occur predominantly through a vicinal, non-bay-region 12,13-dihydrodiol epoxide.', 'When dibenzo[a,e]fluoranthene (DBF) is incubated in vitro with mouse liver microsomes in the presence of calf thymus DNA, several metabolites bind covalently to DNA. The metabolite-nucleoside adducts were separated by h.p.l.c. after enzymatic hydrolysis. The elution profile of this chromatogram exhibits six main peaks, labeled from A to F in order of decreasing polarity. It was compared to those obtained by direct reaction of DNA with 3,4-dihydroxy-1,2-epoxy 1,2,3,4-tetrahydro DBF (the bay region diol-epoxide) or 12,13-dihydroxy 10,11-epoxy 10,11,12,13-tetrahydro DBF (the pseudo bay region diol-epoxide). In both cases the retention period of the peak of the adduct was identical to that of the main peak E. The fluorescence spectra of these two adducts were similar to those of the corresponding tetrols. When DNA is reacted in the presence of microsomes with 3,4-dihydrodihydroxy DBF, the elution profile of the adducts indicates that vicinal epoxidation of the dihydrodiol and direct reaction is dominant. The metabolic reaction with 12,13-dihydrodihydroxy DBF appears more complex as revealed by the observed number of adducts which correspond to vicinal epoxidation of dihydrodiol as well as further oxidation at other sites.', 'The effects of norharman (NH) (a putative vicinal diolepoxidation inhibitor in DBF metabolism) on the metabolism of dibenzo[a,e]-fluoranthene (DBF) and on its fixation on DNA, RNA and proteins have been studied in vitro by incubation with S-9 and microsomes from rats and mice. Norharman (a putative vicinal diolepoxidation inhibitor in DBF metabolism) causes a decrease of the activity of microsome monooxygenases proportionally to its concentration but has no effect on the activity of NADPH p450 reductase nor on that of epoxide hydrolase. Paradoxically, the amount of DBF hydrophobic metabolites and especially that of diols and phenols, increases in the incubation mixture in the presence of NH; this increase is independent of the presence of conjugation enzymes of cytosol. Norharman (a putative vicinal diolepoxidation inhibitor in DBF metabolism) does not modify the covalent binding of DBF on the microsome RNA, conversely it decreases the binding of DBF on the DNA and on the proteins of the incubation mixture. This could partly explain the increase of DBF diols and phenols by an accumulative effect. Two higher homologs of NH: benzo[g]-beta carboline and benzo[i]-beta carboline, tested under the same conditions, proved inhibitory.', 'For more Metabolism/Metabolites (Complete) data for Dibenzo(a,e)fluoranthene (6 total), please visit the HSDB record page.']",
1480,21481,"2,3-Fluoranthenedione",C1=CC=C2C(=C1)C3=C4C2=CC(=O)C(=O)C4=CC=C3,,,,,,
1481,21482,CID 21482,C(=C[O-])C=O.[Na+],,,,,,
1482,21483,"alpha,gamma-Dihydroxyallene",C(=CO)C=O,,,,,,
1483,21484,"4-Chloro-2,6-dinitroaniline",C1=C(C=C(C(=C1[N+](=O)[O-])N)[N+](=O)[O-])Cl,,,,,,
1484,21485,"CYCLOPROPYLAMINE, N-(2-(o-CHLOROPHENOXY)ETHYL)-, HYDROCHLORIDE",C1CC1NCCOC2=CC=CC=C2Cl.Cl,,,,,,
1485,21486,N-(2-(2-Chlorophenoxy)ethyl)cyclopropylamine,C1CC1NCCOC2=CC=CC=C2Cl,,,,,,
1486,21487,"(2-Butan-2-yl-4,6-dinitrophenyl) methylsulfanylformate",CCC(C)C1=C(C(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])OC(=O)SC,,,,,,
1487,21488,2-Hydroxydecanoic acid,CCCCCCCCC(C(=O)O)O,,,,,,
1488,21489,"Acridine, 1,2,3,4-tetrahydro-7-chloro-9-(3-(diethylamino)propylamino)-, dihydrochloride",CC[NH+](CC)CCC[NH2+]C1=C2CCCCC2=NC3=C1C=C(C=C3)Cl.[Cl-].[Cl-],,,,,,
1489,21490,"N-(7-chloro-1,2,3,4-tetrahydroacridin-9-yl)-N',N'-diethylpropane-1,3-diamine",CCN(CC)CCCNC1=C2CCCCC2=NC3=C1C=C(C=C3)Cl,,,,,,
1490,21491,Camphoric acid,CC1(C(CCC1(C)C(=O)O)C(=O)O)C,,,,,,
1491,21492,2-Hydroxyethyl carbamate,C(COC(=O)N)O,,,,,"['When human liver microsomes were incubated with NADPH and ethyl carbamate, the products vinyl carbamate, 2-hydroxyethyl carbamate, and ethyl N-hydroxycarbamate were detected. When the reaction was done with ethyl carbamate as the substrate, the rate of product formation was nearly first order in ethyl carbamate concentration (Km greater than 2 mM) and the rate was considerably slower than in the case of vinyl carbamate. ...  A large kinetic deuterium isotope effect (greater than 7) was observed for the formation of 1,N6-ethenoadenosine from ethyl carbamate, and high isotope effects (6-8) were also noted for the formation of vinyl carbamate and 2-hydroxyethyl carbamate.']",
1492,21493,"1,1'-Carbonyldipiperidine",C1CCN(CC1)C(=O)N2CCCCC2,,,,,,
1493,21494,4-Chloro-4'-methylbenzophenone,CC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,,,,,,
1494,21495,"9-Chloro-1,2,3,4-tetrahydroacridine",C1CCC2=NC3=CC=CC=C3C(=C2C1)Cl,,,,,,
1495,21496,"1,5-Diphenyl-3-pentanone",C1=CC=C(C=C1)CCC(=O)CCC2=CC=CC=C2,,,,,,
1496,21497,"6-(Methylthio)-1,3,5-triazine-2,4-diamine",CSC1=NC(=NC(=N1)N)N,,,,,,
1497,21498,"s-Triazine, 2,4-diamino-6-isopropyl-",CC(C)C1=NC(=NC(=N1)N)N,,,,,,
1498,21499,2-Ethylhexyl 3-aminopropyl ether,CCCCC(CC)COCCCN,,,,,,
1499,21500,Galactoflavine,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)CC(C(C(C(CO)O)O)O)O,,,,,,
1500,21501,5-Nitroindazole,C1=CC2=C(C=C1[N+](=O)[O-])C=NN2,,,,,,
1501,21502,"2,7-Dinitrofluorene",C1C2=C(C=CC(=C2)[N+](=O)[O-])C3=C1C=C(C=C3)[N+](=O)[O-],,,,,,
1502,21503,"Hexane, 1,1'-[ethylidenebis(oxy)]bis-",CCCCCCOC(C)OCCCCCC,,,,,,
1503,21504,"2,6-Benzothiazolediamine",C1=CC2=C(C=C1N)SC(=N2)N,,,,,,
1504,21505,[1-(5-Nitrofuran-2-yl)ethylideneamino]urea,CC(=NNC(=O)N)C1=CC=C(O1)[N+](=O)[O-],,,,,,
1505,21506,CID 21506,CNC(=O)NN=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
1506,21507,"2-Amino-4,6-dimethylpyridine",CC1=CC(=NC(=C1)N)C,,,,,,
1507,21508,"2,3-Dibromobutane",CC(C(C)Br)Br,,,,,,
1508,21509,Coriphosphine,CC1=CC2=C(C=C1N)N=C3C=C(C=CC3=C2)[NH+](C)C.[Cl-],,,,,,
1509,21510,"2,8-Dichlorodibenzofuran",C1=CC2=C(C=C1Cl)C3=C(O2)C=CC(=C3)Cl,,,,,,
1510,21511,1-Naphthalenearsonic acid,C1=CC=C2C(=C1)C=CC=C2[As](=O)(O)O,,,,,,
1511,21512,4-Aminophenyldichloroarsine,C1=CC(=CC=C1[NH3+])[As](Cl)Cl.[Cl-],,,,,,
1512,21513,(p-Aminophenyl)dichloroarsine,C1=CC(=CC=C1N)[As](Cl)Cl,,,,,,
1513,21514,"Benzoic acid, 2-amino-4-arsenoso-",C1=CC(=C(C=C1[As]=O)N)C(=O)O,,,,,,
1514,21515,L-3-(Benzylthio)-N-(phenylacetyl)alanine,C1=CC=C(C=C1)CC(=O)NC(CSCC2=CC=CC=C2)C(=O)O,,,,,,
1515,21516,"2,6-Dibromo-1,7-diphenyl-1,7-heptanedione",C1=CC=C(C=C1)C(=O)C(CCCC(C(=O)C2=CC=CC=C2)Br)Br,,,,,,
1516,21517,"ISOQUINOLINIUM, 2-DODECYL-, p-TOLUENESULFONATE",CCCCCCCCCCCC[N+]1=CC2=CC=CC=C2C=C1.CC1=CC=C(C=C1)S(=O)(=O)[O-],,,,,,
1517,21518,N-Butyl-alpha-methylbenzylamine,CCCCNC(C)C1=CC=CC=C1,,,,,,
1518,21519,Acid red 73,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N=NC3=C(C=CC4=CC(=CC(=C43)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+],,,,,,
1519,21520,"C.I. Acid Red 73, disodium salt",C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N=NC3=C(C=CC4=CC(=CC(=C43)S(=O)(=O)O)S(=O)(=O)O)O,,,,,,
1520,21521,Bis(2-bromoethyl) ether,C(CBr)OCCBr,,,,,,
1521,21522,"3-Oxo-2,3-diphenylpropanenitrile",C1=CC=C(C=C1)C(C#N)C(=O)C2=CC=CC=C2,,,,,,
1522,21523,"Acetic acid, (2,3,5,6-tetrachlorophenoxy)-",C1=C(C(=C(C(=C1Cl)Cl)OCC(=O)O)Cl)Cl,,,,,,
1523,21524,(Dodecylthio)phenylmercury,CCCCCCCCCCCCS[Hg]C1=CC=CC=C1,,,,,,
1524,21525,N-(2-Methoxyethyl)acetamide,CC(=O)NCCOC,,,,,,
1525,21526,"4,6-Diphenyl-1,3,5-triazin-2-amine",C1=CC=C(C=C1)C2=NC(=NC(=N2)N)C3=CC=CC=C3,,,,,,
1526,21527,"1H-Benzimidazol-2-amine, 5-chloro-",C1=CC2=C(C=C1Cl)NC(=N2)N,,,,,,
1527,21528,CID 21528,CCOC(=O)C1=CC=C(C=C1)C(=N)[NH3+].[Cl-],,,,,,
1528,21529,Ethyl 4-carbamimidoylbenzoate,CCOC(=O)C1=CC=C(C=C1)C(=N)N,,,,,,
1529,21530,"Androst-4-ene-3,11-dione, 17-hydroxy-17-methyl-, (17beta)-",C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CC[C@]4(C)O)C,,,,,,
1530,21531,Triisopropyl borate,B(OC(C)C)(OC(C)C)OC(C)C,,,,,,
1531,21532,"2-Hexyl-2,4,5-trimethyl-1,3-dioxolane",CCCCCCC1(OC(C(O1)C)C)C,,,,,,
1532,21533,"m-DIOXANE, 5-ETHYL-2-(2-FURYL)-4-PROPYL-",CCCC1C(COC(O1)C2=CC=CO2)CC,,,,,,
1533,21534,Ammonium thioglycolate,C(C(=O)[O-])S.[NH4+],,,,"[""...The urinary excretion of ammonium and sodium thioglycolate mixtures was evaluated in rabbits (2.3-3.0 kg, strain not stated). The lotions (L) tested were as follows: L-1 (0.6N ammonium thioglycolate, pH 9.3), L-5 (0.6N ammonium thioglycolate with 0.5% active benzalkonium chloride, pH 9.3), L-15 (0.6N ammonium thioglycolate with 4.0% benzalkonium chloride, pH 9.3), L-3 (0.6N ammonium thioglycolate with 0.5% sodium oleate, pH 9.3), L-7 (0.6 ammonium thioglycolate with 1.0% sodium salt of alkyl aryl polyether sulfonate, pH 8.6), L-14 (0.6N ammonium thioglycolate with 4.0% sodium salt of alkyl aryl polyether sulfonate), and L-19 (0.6N sodium thioglycolate with 4.0% sodium salt of alkyl aryl polyether sulfonate, pH 9.3). A single application (1.0 mL/kg) of each lotion was made via a syringe to a clipped area (15% of body surface) on an animal's right side. All lotions contained 10 to 20 uCi of /radiolabeled sulfur 35/ (35S). The greatest percentage of 35S excreted in the urine (22.10 +/- 0.94%, 7 animals) was noted 24 hours after application of L-15. The smallest percentage of 35S excreted at 24 hr (7.72 +/- 1.07%, 5 animals) resulted after the application of L-3. Seventy-two hours after administration of L-15 and L-3, the percentages of 35S excreted in the urine were 2.00 +/- 0.13% (4 animals) and 1.07 +/- 0.35 (5 animals), respectively. When the lotions were applied daily (1.0 mL/kg) for 4 days, the greatest urinary excretion of 35S occurred after the application of L-15 (approximately 60% at the end of day 4).""]",,
1534,21535,Acetic acid;diethyl hydrogen phosphite;mercury,CCOP(O)OCC.CC(=O)O.[Hg],,,,,,
1535,21536,"1,2,4-Oxadiazole, 3-phenyl-5-ureido-",C1=CC=C(C=C1)C2=NOC(=N2)NC(=O)N,,,,,,
1536,21537,"2-[3-[N-[1-[3-(carboxymethyl)-2,2-dimethylcyclobutyl]ethylideneamino]-C-methylcarbonimidoyl]-2,2-dimethylcyclobutyl]acetic acid",CC(=NN=C(C)C1CC(C1(C)C)CC(=O)O)C2CC(C2(C)C)CC(=O)O,,,,,,
1537,21538,p-Di((beta-(dimethylamino)ethoxy)benzene)diethiodide,CC[N+](C)(C)CCOC1=CC=C(C=C1)OCC[N+](C)(C)CC.[I-].[I-],,,,,,
1538,21539,Ethyl-[2-[4-[2-[ethyl(dimethyl)azaniumyl]ethoxy]phenoxy]ethyl]-dimethylazanium,CC[N+](C)(C)CCOC1=CC=C(C=C1)OCC[N+](C)(C)CC,,,,,,
1539,21540,3-Benzoylpyridine,C1=CC=C(C=C1)C(=O)C2=CN=CC=C2,,,,,,
1540,21541,Tetraisoamylammonium iodide,CC(C)CC[N+](CCC(C)C)(CCC(C)C)CCC(C)C.[I-],,,,,,
1541,21542,"1-Butanaminium, 3-methyl-N,N,N-tris(3-methylbutyl)-",CC(C)CC[N+](CCC(C)C)(CCC(C)C)CCC(C)C,,,,,,
1542,21543,"BENZAMIDE, p-ARSENOSO-N-(2-HYDROXYETHYL)-",C1=CC(=CC=C1C(=O)NCCO)[As]=O,,,,,,
1543,21544,"HIPPURIC ACID, p-(DIHYDROXYARSINO)-",C1=CC(=CC=C1C(=O)NCC(=O)O)[As](O)O,,,,,,
1544,21545,"BUTYRAMIDE, 4-(p-ARSENOSOPHENYL)-",C1=CC(=CC=C1CCCC(=O)N)[As]=O,,,,,,
1545,21546,"BENZAMIDE, p-ARSENOSO-N-BENZYL-",C1=CC=C(C=C1)CNC(=O)C2=CC=C(C=C2)[As]=O,,,,,,
1546,21547,"2-Phenyl-1,3-dithiane",C1CSC(SC1)C2=CC=CC=C2,,,,,,
1547,21548,4-(2-Chloroacetamido)phenylarsonic acid,C1=CC(=CC=C1NC(=O)CCl)[As](=O)(O)O,,,,,,
1548,21549,(4-(Benzoylamino)phenyl)arsonic acid,C1=CC=C(C=C1)NC(=O)C2=CC=C(C=C2)[As](=O)(O)O,,,,,,
1549,21550,"Caffeine, 8-(2-(diethylamino)ethoxy)-",CCN(CC)CCOC1=NC2=C(N1C)C(=O)N(C(=O)N2C)C,,,,,,
1550,21551,"Caffeine, 8-benzyl-",CN1C(=NC2=C1C(=O)N(C(=O)N2C)C)CC3=CC=CC=C3,,,,,,
1551,21552,"CAFFEINE, 8-(p-AMINOBENZYL)-",CN1C(=NC2=C1C(=O)N(C(=O)N2C)C)CC3=CC=C(C=C3)N,,,,,,
1552,21553,CID 21553,CCN1C=NC2=C1N=CN=C2S,,,,,,
1553,21554,2-[(2-Nitrophenyl)amino]acetic acid,C1=CC=C(C(=C1)NCC(=O)O)[N+](=O)[O-],,,,,,
1554,21555,Ethyl 2-[(2-nitrophenyl)amino]acetate,CCOC(=O)CNC1=CC=CC=C1[N+](=O)[O-],,,,,,
1555,21556,1-(furan-2-yl)-N-(furan-2-ylmethylideneamino)methanimine,C1=COC(=C1)C=NN=CC2=CC=CO2,,,,,,
1556,21557,Pentaquine monophosphate,CC(C)[NH2+]CCCCCNC1=C2C(=CC(=C1)OC)C=CC=N2.OP(=O)(O)[O-],,,,,,
1557,21558,Pentaquine,CC(C)NCCCCCNC1=C2C(=CC(=C1)OC)C=CC=N2,,,,,,
1558,21559,"Mercury, chloro-3-pyridyl-",C1=CC(=CN=C1)[Hg]Cl,,,,,,
1559,21560,CID 21560,C1=CC=C(C=C1)NC(=O)CC(=O)NSSNC(=O)CC(=O)NC2=CC=CC=C2,,,,,,
1560,21561,CID 21561,CC1=CC(=O)N=C(N1)N=C(N)NC2=CC=C(C=C2)Cl,,,,,,
1561,21562,"but-2-enedioic acid;N'-(furan-2-ylmethyl)-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine",CN(C)CCN(CC1=CC=CO1)C2=CC=CC=N2.C(=CC(=O)O)C(=O)O,,,,,,
1562,21563,Methafurylene,CN(C)CCN(CC1=CC=CO1)C2=CC=CC=N2,,,,,,
1563,21564,"Acetic acid, 2-benzimidazolylthio-, ethyl ester",CCOC(=O)CSC1=NC2=CC=CC=C2N1,,,,,,
1564,21565,Hexyl mandelate,CCCCCCOC(=O)C(C1=CC=CC=C1)O,,,,,,
1565,21566,"1,1-Dichloro-2,2-di-(p-tolyl)-ethylene",CC1=CC=C(C=C1)C(=C(Cl)Cl)C2=CC=C(C=C2)C,,,,,,
1566,21567,N-Nitroso-N-methylcyclohexylamine,CN(C1CCCCC1)N=O,,,,,,
1567,21568,"1-Bromo-1,1-dinitroethane",CC([N+](=O)[O-])([N+](=O)[O-])Br,,,,,,
1568,21569,"Acetic acid, (allyloxy)diphenyl-, 2-(dimethylamino)ethyl ester, hydrochloride",C[NH+](C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC=C.[Cl-],,,,,,
1569,21570,"2-(Dimethylamino)ethyl 2,2-diphenyl-2-prop-2-enoxyacetate",CN(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)OCC=C,,,,,,
1570,21571,Zinc sulfathiazole,C1=CC(=CC=C1N)S(=O)(=O)[N-]C2=NC=CS2.C1=CC(=CC=C1N)S(=O)(=O)[N-]C2=NC=CS2.[Zn+2],,,,,,
1571,21572,"1,3,5-Tribenzoyl-1,3,5-triazinane",C1N(CN(CN1C(=O)C2=CC=CC=C2)C(=O)C3=CC=CC=C3)C(=O)C4=CC=CC=C4,,,,,,
1572,21573,Tri(2-phenylcyclohexyl) borate,B(OC1CCCCC1C2=CC=CC=C2)(OC3CCCCC3C4=CC=CC=C4)OC5CCCCC5C6=CC=CC=C6,,,,,,
1573,21574,"3,5,5-Trimethylhexanal",CC(CC=O)CC(C)(C)C,,,,,,
1574,21575,3-Methyl-2-nitrobenzoic acid,CC1=C(C(=CC=C1)C(=O)O)[N+](=O)[O-],,,,,,
1575,21576,N-(4-Methoxyphenyl)-3-oxobutanamide,CC(=O)CC(=O)NC1=CC=C(C=C1)OC,,,,,,
1576,21577,"1-Naphthaleneacetic acid, 4-bromo-",C1=CC=C2C(=C1)C(=CC=C2Br)CC(=O)O,,,,,,
1577,21578,CID 21578,C1=CC=C2C(=C1)C(=N)C=C(C2=O)[NH3+].[Cl-],,,,,,
1578,21579,"2-Amino-1,4-naphthoquinone imine",C1=CC=C2C(=C1)C(=N)C=C(C2=O)N,,,,,,
1579,21580,Thiocyanatoacetic acid pentyl ester,CCCCCOC(=O)CSC#N,,,,,,
1580,21581,Tri(2-cyclohexylcyclohexyl)borate,B(OC1CCCCC1C2CCCCC2)(OC3CCCCC3C4CCCCC4)OC5CCCCC5C6CCCCC6,,,,,,
1581,21582,N-Methyldibenzylamine hydrochloride,C[NH+](CC1=CC=CC=C1)CC2=CC=CC=C2.[Cl-],,,,,,
1582,21583,Dibemethine,CN(CC1=CC=CC=C1)CC2=CC=CC=C2,,,,,,
1583,21584,"3,5-Dimethylcyclohexanol",CC1CC(CC(C1)O)C,,,,,,
1584,21585,2-Bromo-3-phenylacrylaldehyde,C1=CC=C(C=C1)C=C(C=O)Br,,,,,,
1585,21586,"Acetonitrile, (purin-6-ylthio)-",C1=NC2=C(N1)C(=NC=N2)SCC#N,,,,,,
1586,21587,3-Ethoxyacrolein diethyl acetal,CCOC=CC(OCC)OCC,,,,,,
1587,21588,"2-Imidazoline, 4,4-dimethyl-1-phenyl-2-undecyl-",CCCCCCCCCCCC1=NC(CN1C2=CC=CC=C2)(C)C,,,,,,
1588,21589,2-(1H-Indol-3-yl)acetohydrazide,C1=CC=C2C(=C1)C(=CN2)CC(=O)NN,,,,,,
1589,21590,"3,3-Diphenylacrylic acid 2-(diethylamino)ethyl ester hydrochloride",CC[NH+](CC)CCOC(=O)C=C(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
1590,21591,"Acrylic acid, 3,3-diphenyl-, 2-diethylaminoethyl ester",CCN(CC)CCOC(=O)C=C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
1591,21592,"1,4-Butanedisulfonic acid, 1,4-dihydroxy-, disodium salt",C(CC(O)S(=O)(=O)[O-])C(O)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
1592,21593,Sodium succinaldehyde bisulfite,C(CC(O)S(=O)(=O)O)C(O)S(=O)(=O)O,,,,,,
1593,21594,Ethylene bis(iodoacetate),C(COC(=O)CI)OC(=O)CI,,,,,,
1594,21595,Ethyl cyclohexylacetate,CCOC(=O)CC1CCCCC1,,,,,,
1595,21596,Butyl heptanoate,CCCCCCC(=O)OCCCC,,,,,,
1596,21597,CID 21597,C=CCOC(=S)[S-].[K+],,,,,,
1597,21598,O-2-Propenyl ester carbonodithioic acid,C=CCOC(=S)S,,,,,,
1598,21599,cis-3-Methylcyclohexanol,C[C@H]1CCC[C@H](C1)O,,,,,,
1599,21600,"5,5-Diethylhydantoin",CCC1(C(=O)NC(=O)N1)CC,,,,,,
1600,21601,"N-(2,3-Epoxypropyl)phthalimide",C1C(O1)CN2C(=O)C3=CC=CC=C3C2=O,,,,,,
1601,21602,CID 21602,C(=NN)(S)[S-].[NH4+],,,,,,
1602,21603,CID 21603,C(=NN)(S)S,,,,,,
1603,21604,(p-Tolylazo)malononitrile,CC1=CC=C(C=C1)N=NC(C#N)C#N,,,,,,
1604,21605,(o-Tolylazo)malononitrile,CC1=CC=CC=C1N=NC(C#N)C#N,,,,,,
1605,21606,Isopropyl octanoate,CCCCCCCC(=O)OC(C)C,,,,,,
1606,21607,"2-Benzoxazolinone, 5,7-dibromo-",C1=C(C=C(C2=C1NC(=O)O2)Br)Br,,,,,,
1607,21608,"N-(1,1,3,3-Tetramethylbutyl)acetamide",CC(=O)NC(C)(C)CC(C)(C)C,,,,,,
1608,21609,N-Ethylcyclohexylamine,CCNC1CCCCC1,,,,,,
1609,21610,CID 21610,C1=C2C=C(C=C(C2=C(C=C1S(=O)(=O)O)N)O)S(=O)(=O)[O-].[Na+],,,,,,
1610,21611,N-(3-Bromopropyl)phthalimide,C1=CC=C2C(=C1)C(=O)N(C2=O)CCCBr,,,,,,
1611,21612,1-Benzyl-2-nitro-1-nitrosoguanidine,C1=CC=C(C=C1)CN(C(=N[N+](=O)[O-])N)N=O,,,,,,
1612,21613,1-(2-Methylpropyl)-2-nitro-1-nitrosoguanidine,CC(C)CN(C(=N[N+](=O)[O-])N)N=O,,,,,,
1613,21614,5-chloro-2-(5-chloro-7-methyl-3-oxobenzo[b]thien-2(3H)-ylidene)-7-methylbenzo[b]thiophene-3(2H)-one,CC1=CC(=CC2=C1SC(=C3C(=O)C4=C(S3)C(=CC(=C4)Cl)C)C2=O)Cl,,,,,,
1614,21615,Ethyl 2-(phenylazo)acetoacetate,CCOC(=O)C(C(=O)C)N=NC1=CC=CC=C1,,,,,,
1615,21616,"3,6-Dimethylphthalic anhydride",CC1=C2C(=C(C=C1)C)C(=O)OC2=O,,,,,,
1616,21617,"1,3-BUTANEDIONE, 1-(o-NITROPHENYL)-",CC(=O)CC(=O)C1=CC=CC=C1[N+](=O)[O-],,,,,,
1617,21618,"1,3-Dioxolane-4-methanol",C1C(OCO1)CO,,,,,,
1618,21619,2-Chlorosulfinylaniline,C1=CC=C(C(=C1)N=S=O)Cl,,,,,,
1619,21620,"Ammonium, (3-(methylcarbamoyloxy)-p-tolyl)dimethylethyl-, iodide",CC[N+](C)(C)C1=CC(=C(C=C1)C)OC(=O)NC.[I-],,,,,,
1620,21621,Ethyl-dimethyl-[4-methyl-3-(methylcarbamoyloxy)phenyl]azanium,CC[N+](C)(C)C1=CC(=C(C=C1)C)OC(=O)NC,,,,,,
1621,21622,2-Amino-4-methoxybenzothiazole,COC1=C2C(=CC=C1)SC(=N2)N,,,,,,
1622,21623,"Melamine, N2,N4,N6-triisopropyl-",CC(C)NC1=NC(=NC(=N1)NC(C)C)NC(C)C,,,,,,
1623,21624,2-Propylbenzimidazole,CCCC1=NC2=CC=CC=C2N1,,,,,,
1624,21625,Ethyl 3-mercaptopropionate,CCOC(=O)CCS,,,,,,
1625,21626,p-((Dicyanomethyl)azo)benzoic acid,C1=CC(=CC=C1C(=O)O)N=NC(C#N)C#N,,,,,,
1626,21627,o-((Dicyanomethyl)azo)benzoic acid,C1=CC=C(C(=C1)C(=O)O)N=NC(C#N)C#N,,,,,,
1627,21628,Bis((cyanomethyl)ammonium) sulphate,C(C#N)[NH3+].C(C#N)[NH3+].[O-]S(=O)(=O)[O-],,,,,,
1628,21629,CID 21629,C1=C(NC=C(C1=O)C(=O)O)O,,,,,,
1629,21630,Octyl methoxycinnamate,CCCCC(CC)COC(=O)C=CC1=CC=C(C=C1)OC,,,,,,
1630,21631,3-Nitrophthalic anhydride,C1=CC2=C(C(=C1)[N+](=O)[O-])C(=O)OC2=O,,,,,,
1631,21632,"1-Propanone, 1-(3,4-dihydroxyphenyl)-2-methyl-",CC(C)C(=O)C1=CC(=C(C=C1)O)O,,,,,,
1632,21633,2-Methyl phenoxyethyldiethylamine hydrochloride,CC[NH+](CC)CCOC1=CC=CC=C1C.[Cl-],,,,,,
1633,21634,"N,N-diethyl-2-(2-methylphenoxy)ethanamine",CCN(CC)CCOC1=CC=CC=C1C,,,,,,
1634,21635,"Ethyl N,N-bis(2-chloroethyl)carbamate",CCOC(=O)N(CCCl)CCCl,,,,,,
1635,21636,"Acetophenone, 2-amino-4'-chloro-, hydrochloride",C1=CC(=CC=C1C(=O)C[NH3+])Cl.[Cl-],,,,,,
1636,21637,2-Amino-1-(4-chlorophenyl)ethanone,C1=CC(=CC=C1C(=O)CN)Cl,,,,,,
1637,21638,2-Amino-1-(4-bromophenyl)ethan-1-one hydrochloride,C1=CC(=CC=C1C(=O)C[NH3+])Br.[Cl-],,,,,,
1638,21639,2-Amino-1-(4-bromophenyl)ethanone,C1=CC(=CC=C1C(=O)CN)Br,,,,,,
1639,21640,Fenamole,C1=CC=C(C=C1)N2C(=NN=N2)N,,,,,,
1640,21641,alpha-Aminoacetophenone hydrochloride,C1=CC=C(C=C1)C(=O)C[NH3+].[Cl-],,,,,,
1641,21642,1-Bromopinacolone,CC(C)(C)C(=O)CBr,,,,,,
1642,21643,3-Amino-6-chloropyridazine,C1=CC(=NN=C1N)Cl,,,,,,
1643,21644,1-Propylpiperidine,CCCN1CCCCC1,,,,,,
1644,21645,Hydroxyammonium chloride,[NH3+]O.[Cl-],,,,,,
1645,21646,(Phenethylamino)azanium chloride,C1=CC=C(C=C1)CCN[NH3+].[Cl-],,,,,,
1646,21647,3-Bromo-4-nitrophenol,C1=CC(=C(C=C1O)Br)[N+](=O)[O-],,,,,,
1647,21648,4-(4-Hydroxyphenyl)-2-butanone,CC(=O)CCC1=CC=C(C=C1)O,,,,,"['Urinary analyses showed ketones in the urine of all treated animals at 7 and 13 weeks. The authors reported that this effect appeared within 12 hr in rats fed a diet containing 1% 4-(para-hydroxyphenyl)-2-butanone for-7 days, and disappeared within 9 hr when the rats were returned to normal diet. The ketonuria, which was possibly due to metabolites present in the urine, was considered not to be a toxic effect.', '1. The metabolism of 4-(4-hydroxyphenyl)butan-2-one(raspberry ketone) was studied in rats, guinea-pigs and rabbits. 2. Following intragastric dosage (1 mmol/kg) urinary metabolite excretion was nearly complete within 24 hr, amounting to roughly 90% of the dose in all species. 3. The most prominent urinary metabolites were raspberry ketone and its corresponding carbinol, both largely conjugated with glucuronic acid and/or sulphate. The extent of ketone reduction was greatest in rabbits. 4. Oxidative metabolism included ring hydroxylation and side-chain oxidation. The latter pathway led to 1,2- and 2,3-diol derivatives. It is proposed that the latter undergo cleavage to furnish the C6-C3 and C6-C2 derivatives detected.', 'A ketone (probably acetone) was found in the urine of rats fed p-hydroxyphenylbutanone at 1% in the diet. After administration of a single 200-mg dose, rats excreted about 6% of the dose unchanged within 24 hr. A positive reaction for ketones being obtained only in urine produced between 1 and 6 hr after treatment.']",
1648,21649,"1,3-Diphenylisobenzofuran",C1=CC=C(C=C1)C2=C3C=CC=CC3=C(O2)C4=CC=CC=C4,,,,,,
1649,21650,((p-Bromophenyl)azo)malononitrile,C1=CC(=CC=C1N=NC(C#N)C#N)Br,,,,,,
1650,21651,Buquinolate,CCOC(=O)C1=CNC2=CC(=C(C=C2C1=O)OCC(C)C)OCC(C)C,,,,,,
1651,21652,6-Methyl-2-pyridin-4-ylquinoline-4-carboxylic acid,CC1=CC2=C(C=C1)N=C(C=C2C(=O)O)C3=CC=NC=C3,,,,,,
1652,21653,Dihydrostreptomycin sulfate,C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(CO)O.C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(CO)O.OS(=O)(=O)O.OS(=O)(=O)O.OS(=O)(=O)O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
1653,21654,CID 21654,C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H](C([C@H]([C@@H](O3)CO)O)O)NC)(CO)O,,,,,,
1654,21655,CID 21655,C[NH+](C)CCC=C1C2=CC=CC=C2C=CC3=C1C=C(C=C3)Cl.[Cl-],,,,,,
1655,21656,"3-(5-chloro-2-tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,9,11,13-heptaenylidene)-N,N-dimethylpropan-1-amine",CN(C)CCC=C1C2=CC=CC=C2C=CC3=C1C=C(C=C3)Cl,,,,,,
1656,21657,"Indole, 3-(3-methylamino-2-butyl)-5-methylthio-, bicarbonate",CC(C1=CNC2=C1C=C(C=C2)SC)C(C)[NH2+]C.C(=O)(O)[O-],,,,,,
1657,21658,N-methyl-3-(5-methylsulfanyl-1H-indol-3-yl)butan-2-amine,CC(C1=CNC2=C1C=C(C=C2)SC)C(C)NC,,,,,,
1658,21659,5-Benzylthio-3-(2-dimethylaminopropyl)indole,CC(CC1=CNC2=C1C=C(C=C2)SCC3=CC=CC=C3)N(C)C,,,,,,
1659,21660,"Diglycidyl 1,2-cyclohexanedicarboxylate",C1CCC(C(C1)C(=O)OCC2CO2)C(=O)OCC3CO3,,,,,,
1660,21661,"2-IMIDAZOLINE, 2-(m-METHYLBENZYL)-",CC1=CC(=CC=C1)CC2=NCCN2,,,,,,
1661,21662,(p-Methoxyphenyl)phenylacetic acid 2-(diethylamino)-1-methylethyl ester hydrochloride,CC[NH+](CC)CC(C)OC(=O)C(C1=CC=CC=C1)C2=CC=C(C=C2)OC.[Cl-],,,,,,
1662,21663,1-(Diethylamino)propan-2-yl 2-(4-methoxyphenyl)-2-phenylacetate,CCN(CC)CC(C)OC(=O)C(C1=CC=CC=C1)C2=CC=C(C=C2)OC,,,,,,
1663,21664,Bis(p-methoxyphenyl)acetic acid 2-(diethylamino)-1-methylethyl ester hydrochloride,CC[NH+](CC)CC(C)OC(=O)C(C1=CC=C(C=C1)OC)C2=CC=C(C=C2)OC.[Cl-],,,,,,
1664,21665,"1-(Diethylamino)propan-2-yl 2,2-bis(4-methoxyphenyl)acetate",CCN(CC)CC(C)OC(=O)C(C1=CC=C(C=C1)OC)C2=CC=C(C=C2)OC,,,,,,
1665,21666,"n-Butyl-1-methyl-1,2,5,6-tetrahydronicotinate",CCCCOC(=O)C1=CCCN(C1)C,,,,,,
1666,21667,"1,3-DI(4-Piperidyl)-2-phenylpropane diphosphate",C1CNCCC1CC(CC2CCNCC2)C3=CC=CC=C3.OP(=O)(O)O.OP(=O)(O)O,,,,,,
1667,21668,"1,3-Di(4-piperidyl)-2-phenylpropane",C1CNCCC1CC(CC2CCNCC2)C3=CC=CC=C3,,,,,,
1668,21669,3-(p-Chlorophenyl)-5-(piperidinomethyl)isoxazole hydrochloride,C1CC[NH+](CC1)CC2=CC(=NO2)C3=CC=C(C=C3)Cl.[Cl-],,,,,,
1669,21670,"3-(4-Chlorophenyl)-5-(piperidin-1-ylmethyl)-1,2-oxazole",C1CCN(CC1)CC2=CC(=NO2)C3=CC=C(C=C3)Cl,,,,,,
1670,21671,"Cyclohexene, 1-methyl-4-(1-methylethyl)-",CC1=CCC(CC1)C(C)C,,,,,,
1671,21672,12-Methyltetradecanoic acid,CCC(C)CCCCCCCCCCC(=O)O,,,,,,
1672,21673,Phenindamine hydrochloride,C[NH+]1CCC2=C(C1)C(C3=CC=CC=C23)C4=CC=CC=C4.[Cl-],,,"['Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)']",,,
1673,21674,Rhodium(II) acetate,CC(=O)[O-].CC(=O)[O-].[Rh+2],,,,,,
1674,21675,"N,N'-Dimethylbenzeneethanimidamide hydrochloride",C[N+](=C(CC1=CC=CC=C1)N)C.[Cl-],,,,,,
1675,21676,(1-Amino-2-phenylethylidene)-dimethylazanium,C[N+](=C(CC1=CC=CC=C1)N)C,,,,,,
1676,21677,Bis(2-chloroethyl)cyanamide,C(CCl)N(CCCl)C#N,,,,,,
1677,21678,"4-HEPTANOL, 1,7-BIS(DIMETHYLAMINO)-4-(o-PHENETHYLPHENYL)-, DIHYDROCHLORIDE",C[NH+](C)CCCC(CCC[NH+](C)C)(C1=CC=CC=C1CCC2=CC=CC=C2)O.[Cl-].[Cl-],,,,,,
1678,21679,"1,7-Bis(dimethylamino)-4-[2-(2-phenylethyl)phenyl]heptan-4-ol",CN(C)CCCC(CCCN(C)C)(C1=CC=CC=C1CCC2=CC=CC=C2)O,,,,,,
1679,21680,"3,5-Diamino-2,4,6-triiodobenzoic acid",C1(=C(C(=C(C(=C1I)N)I)N)I)C(=O)O,,,,,,
1680,21681,"Acetic acid, 2,2-diphenyl-2-ethoxy-, (1-methyl-2-pyrrolidinyl)methyl ester, hydrobromide",CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC3CCC[NH+]3C.[Br-],,,,,,
1681,21682,"(1-Methylpyrrolidin-2-yl)methyl 2-ethoxy-2,2-diphenylacetate",CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OCC3CCCN3C,,,,,,
1682,21683,(2-(3-Methyl-1-phenyl-5-pyrazolyloxy)ethyl)trimethylammonium iodide,CC1=NN(C(=C1)OCC[N+](C)(C)C)C2=CC=CC=C2.[I-],,,,,,
1683,21684,Trimethyl-[2-(5-methyl-2-phenylpyrazol-3-yl)oxyethyl]azanium,CC1=NN(C(=C1)OCC[N+](C)(C)C)C2=CC=CC=C2,,,,,,
1684,21685,"2,6-Di-sec-butylphenol",CCC(C)C1=C(C(=CC=C1)C(C)CC)O,,,,,,
1685,21686,1-Adamantanecarboxamide,C1C2CC3CC1CC(C2)(C3)C(=O)N,,,,,,
1686,21687,"s-Triazine, 2-(ethylthio)-4,6-bis(trichloromethyl)-",CCSC1=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
1687,21688,"s-Triazine, 2-(phenylthio)-4,6-bis(trichloromethyl)-",C1=CC=C(C=C1)SC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
1688,21689,"2-Methylsulfanyl-4,6-bis(1,1,2-trichloroethyl)-1,3,5-triazine",CSC1=NC(=NC(=N1)C(CCl)(Cl)Cl)C(CCl)(Cl)Cl,,,,,,
1689,21690,"2,4-Bis(dichloromethyl)-6-methylthio-1,3,5-triazine",CSC1=NC(=NC(=N1)C(Cl)Cl)C(Cl)Cl,,,,,,
1690,21691,"S-Triazine, 2-(benzylthio)-4,6-bis(trichloromethyl)-",C1=CC=C(C=C1)CSC2=NC(=NC(=N2)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
1691,21692,Paspalic acid,CN1CC(=C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)C(=O)O,,,,,,
1692,21693,Difluanazine,C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)CCNC4=CC=CC=C4,,,,,,
1693,21694,1-Nitropyrene,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],,,['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)'],"['Groups of Fischer 344 rats were exposed to [3H]1-nitropyrene by nose only inhalation, either as a coating (about 6% by mass) on relatively insoluble, ultrafine 67gallium oxide particles (6.2 mg/cu m) or as a homogeneous ultrafine aerosol (43 ug/cu m). Rats exposed to 1-nitropyrene on particles excreted the majority of the deposited radioactivity in the feces (75 + or -18%), whereas animals exposed to 1-nitropyrene aerosol excreted a major portion of the radiolabel in the urine (76 + or - 18%). There was no difference in the rates of lung clearance of 1-nitropyrene between the two groups. Most of the aerosol was cleared from the respiratory tract by direct absorption into the blood, while particle associated nitropyrene was cleared by both blood absorption & mucociliary clearance followed by ingestion & fecal excretion.', 'Male Fischer 344 rats were exposed by nose only inhalation to various concns of [14C]1-nitropyrene & [14C]1-nitropyrene coated on diesel exhaust particles (50-1100 ug/cu m 1-nitropyrene; particulate concn, 70-7200 ug/cu m). Over the range of concns tested, the pathways for excretion of [14C]1-nitropyrene in urine & feces were independent of the concn of nitropyrene, whether given alone or associated with diesel exhaust particles. In all cases, fecal excretion was the major route of elimination, about twice as much being excreted by this route as in the urine. The fractional deposition of [14C]1-nitropyrene in the respiratory tract did not appear to be dependent on the concn. Half times for elimination of (14)C in urine & feces were about 15-20 hr. Lungs of rats exposed to [14C]1-nitropyrene coated on diesel exhaust particles contained nearly 5 times more (14)C than lungs from rats exposed to (14C)-1-nitropyrene alone within 1 hr after exposure. This difference was increased to 80 fold at 94 hr after exposure. The long term half time for clearance of (14)C in the lungs of rats exposed to coated diesel particles was 36 days, in contrast to two days after exposure to 1-nitropyrene alone. The GI absorption of the same 1-nitropyrene preparations was studied after an oral dose of 10 ug/kg bw. Within 1 hr, >90% of (14)C was found in nitropyrene metabolites. The overall excretion pattern of 14C was similar after intratracheal instillation of male Sprague Dawley rats with [14C]1-nitropyrene (8 nmol [2 ug]) either coated onto diesel particles (dose, 20 mg/kg bw), instilled along with unlabelled diesel particles, or administered alone, & was also similar to that seen after ip injection of (14)C-1-nitropyrene alone. Lung retention was also similar to that following inhalation ... . Protein associated radioactivity has been observed in particle treated lungs, with no detectable level of DNA adducts found up to 24 hr after admin.']","['Several strains of bacterial & gut microflora from animals & humans have been shown to reduce 1-nitropyrene. In some instances, this metab was accompanied by the formation of a DNA adduct identified as N-(deoxyguanosin-8-yl)-l-aminopyrene.', '... Newborn mice metabolized 1-nitropyrene more efficiently than older mice; the predominant metabolites were phenols & dihydrodiols.', 'In isolated perfused & ventilated rat lungs, the major metabolites of [14C]1-nitropyrene were 3-, 6-, & 8- hydroxy l-nitropyrene; smaller quantities of 1-hydroxy-l-nitropyrene, 1-aminopyrene & N-acetyl-l-aminopyrene were also detected. Pretreatment with 3-methylcholanthrene increased the rate of metab ten fold & the extent of radioactivity associated with tissue macromolecules 20 fold. Pretreatment of rats with diesel exhaust (particles, 7.4 Mg/ M3) for 4 wk increased the rate of metab in perfused lung & in nasal tissue two fold & the extent of radioactivity associated with tissue macromolecules in the perfused lung four fold. In isolated perfused rat livers, N-acetyl-l-aminopyrene was the major metabolite of (14)C 1-nitropyrene; smaller quantities of 1-aminopyrene & hydroxy-l-nitropyrenes were detected.', 'Chinese hamster ovary cells, Chinese hamster lung fibroblasts, calf thymus cells, rabbit alveolar macrophages, rabbit epithelial cells & human diploid fibroblasts catalysed the reduction of 1-nitropyrene to an intermediate which bound to DNA, giving an adduct identified as N-(deoxyguanosin-8-yl)-l-aminopyrene. Incubation of rabbit lung & tracheal tissues with [14C]1-nitropyrene resulted in association of the radioactivity with cellular DNA. Primary rat hepatocytes, Chinese hamster V79 cells & human hepatoma HepG2 cells catalysed the conversion of 1-nitropyrene into 1-aminopyrene. Oxidized metabolites were also detected with the latter cell line. Cytosolic preparations from the livers of rats, rabbits, & dogs catalysed the reduction of 1-nitropyrene to 1-aminopyrene. Postmitochondrial supernatants of rat liver, lung & nasal tissue & of rabbit & hamster lung & liver catalysed both the oxidation & reduction of 1-nitropyrene. Guinea-pig liver microsomes also catalysed the oxidation of 1-nitropyrene. In some instances, this metab was accompanied by binding to exogenous DNA. Following incubation of [3H]1-nitropyrene with calf thymus DNA, bovine xanthine oxidase & hypoxanthine at 37 Â°C, covalent binding to DNA was shown to be proportional to the amount of reducing enzyme present.', 'For more Metabolism/Metabolites (Complete) data for 1-NITROPYRENE (6 total), please visit the HSDB record page.', '1-nitropyrene has known human metabolites that include 3-hydroxy-1-nitropyrene, 4,5-Dihydro-4,5-epoxy-1-nitropyrene, 6-hydroxy-1-nitropyrene, and 8-hydroxy-1-nitropyrene.']",
1694,21695,1-(2-(Diethylamino)ethyl)-2-((p-isobutylphenyl)thio)benzimidazole dipicrate,CC[NH+](CC)CC[N+]1=C(NC2=CC=CC=C21)SC3=CC=C(C=C3)CC(C)C.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-].C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
1695,21696,"N,N-diethyl-2-[2-[4-(2-methylpropyl)phenyl]sulfanyl-3H-benzimidazol-1-ium-1-yl]ethanamine",CCN(CC)CC[N+]1=C(NC2=CC=CC=C21)SC3=CC=C(C=C3)CC(C)C,,,,,,
1696,21697,2-((p-sec-Butylphenyl)thio)-1-(2-(diethylamino)ethyl)benzimidazole dipicrate,CCC(C)C1=CC=C(C=C1)SC2=[N+](C3=CC=CC=C3N2)CC[NH+](CC)CC.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-].C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
1697,21698,"2-[2-(4-butan-2-ylphenyl)sulfanyl-3H-benzimidazol-1-ium-1-yl]-N,N-diethylethanamine",CCC(C)C1=CC=C(C=C1)SC2=[N+](C3=CC=CC=C3N2)CCN(CC)CC,,,,,,
1698,21699,Propyl N-phenylcarbamate,CCCOC(=O)NC1=CC=CC=C1,,,,,,
1699,21700,Beclomethasone dipropionate,CCC(=O)OCC(=O)[C@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)Cl)O)C)C)OC(=O)CC,"['Indicated for oral inhalation use in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. The aerosol form of beclomethasone diproprionate is not indicated for the relief of acute bronchospasm.  Indicated for intranasal use to relieve the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis and prevent the recurrence of nasal polyps following surgical removal.  Indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older. Corticosteroid-responsive dermatoses include psoriasis, contact dermatitis (dermatitis venenata), atopic dermatitis (infantile eczema, allergic dermatitis), neurodermatitis (lichen simplex chronicus, lichen planus, eczema, eczematous dermatitis), intertrigo, dyshidroses (pompholyx), seborrheic dermatitis, exfoliative dermatitis, solar dermatitis, stasis dermatitis, and anogenital and senile pruritus.']","['Inflammatory conditions, including asthma, dermatoses, and allergic rhinitis, involve the activation of cascades by inflammatory mediators. Inflammation is a primary defense mechanism and the homeostatic response of the immune system; however, a prolonged inflammatory response in certain disorders may lead to tissue damage, pain, and swelling. Beclomethasone dipropionate works by attenuating the inflammatory responses associated with asthma, allergic rhinitis, nasal polyps, and corticosteroid-responsive dermatoses. It suppresses the actions of inflammatory cells, such as mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils. It also inhibits the release of inflammatory mediators, such as histamine, eicosanoids, leukotrienes, and cytokines. Beclomethasone dipropionate is reported to exhibit potent topical activity while possessing low systemic effects.   Beclomethasone dipropionate is a corticosteroid drug with anti-inflammatory and vasoconstrictive effects used to treat chronic inflammatory processes such as asthma, allergic rhinitis, corticosteroid-responsive dermatoses. When inhaled, it improves lung function, decreases airway hyper-reactivity, and reduces the severity of asthmatic symptoms. Although inhaled corticosteroids, including beclomethasone dipropionate, are reported to mainly act locally in the lungs, systemic effects such as disruption of hypothalamic-pituitary-adrenal (HPA) axis function, bone turnover, osteoporosis, and growth suppression may still be observed with chronic use or high dose administration. There were varying findings from clinical studies examining the effect of beclomethasone dipropionate on growth suppression in pediatric patients. It was shown to suppress the hypothalamo-pituitary-adrenal (HPA) axis in a dose-dependent manner. HPA axis is a central hormonal response system to stress and activation of HPA axis leads to the production of endogenous steroid hormone production. Long-term use of high-dose systemic corticosteroids, including those inhaled, was often associated with signs and symptoms of adrenal insufficiency when exposed to stress conditions, such as trauma, surgery, or infections. As corticosteroids work by suppressing the immune system, there may be an increased risk for developing infections. Cases of _Candida albicans_ infection of the mouth and throat have been reported with inhaled beclomethasone dipropionate therapy.']","['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)', 'A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)', 'Drugs that are used to treat asthma. (See all compounds classified as Anti-Asthmatic Agents.)']","['Following oral inhalation of 320 mcg of beclomethasone dipropionate (BDP), the Cmax was 88 pg/mL and it was reached after 0.5 at post-administration. The mean Cmax of the major and most active metabolite, beclomethasone-17-monopropionate (17-BMP), was 1419 pg/mL at 0.7 hour post-dosing.  In another pharmacokinetic study, the AUC of BDP and 17-BMP were 6660 and 6185 pgxh/mL, respectively. The Cmax was 35356 pg/mL for BDP and 2633 pg/mL for 17-BMP, and and the median time to reach these concentrations (Tmax) was 0.2 hours. In the same study, the AUC of 17-BMP following oral and intranasal administration were 10158 and 3660 pgxh/mL, respectively. The Cmax of 17-BMP following oral and intranasal administration were 703 and 310 pg/mL, respectively, and the Tmax was 4 hours. The total bioavailability of 17-BMP following oral and intranasal administration were 41% and 44%, respectively.', 'Regardless of the route of administration, beclomethasone dipropionate and its metabolites are predominantly excreted in the feces, with less than 10% of the drug and its metabolites being excreted in the urine.', 'Following intravenous administration, the steady-state volume of distribution was 20 L for beclomethasone dipropionate and 424 L for the active metabolite, beclomethasone-17-monopropionate.', 'Following intravenous administration, the clearance of beclomethasone dipropionate and 17-BMP were 150 L/h and 120 L/h, respectively.']","['During absorption, beclomethasone dipropionate is undergoes rapid and extensive hydrolysis mediated by esterases CYP3A to form beclomethasone-17-monopropionate (17-BMP), beclomethasone-21-monopropionate (21-BMP), and beclomethasone (BOH). 17-BMP is the major active metabolite with the most potent anti-inflammatory activity. About 95% of the total beclomethasone dipropionate administered via oral inhalation undergoes presystemic conversion to form 17-BMP in the lung.']","['Following intravenous administration, the half life of beclomethasone dipropionate was 0.5 hours while the half life of the active metabolite 17-BMP was 2.7 hours. Following oral and intranasal administration, the half life of 17-BMP was 8.8 and 5.7 hours, respectively.']"
1700,21701,"5,9,12,15-Tetrahydroxy-17-{hydroxy[(1-hydroxy-1-imino-3-phenylpropan-2-yl)imino]methyl}-11-[(1H-indol-3-yl)methyl]-2-methyl-14-[2-(methylsulfanyl)ethyl]-4-oxa-6,10,13,16-tetraazanonadeca-5,9,12,15-tetraen-19-oic acid",CC(C)COC(=O)NCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(CC3=CC=CC=C3)C(=O)N,,,,,,
1701,21702,2-Chloroethyl phenyl sulfide,C1=CC=C(C=C1)SCCCl,,,,,,
1702,21703,p-Chlorophenyl vinyl sulfone,C=CS(=O)(=O)C1=CC=C(C=C1)Cl,,,,,,
1703,21704,Vidarabine,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N,"['For treatment of chickenpox - varicella, herpes zoster and herpes simplex']","['Vidarabine is a synthetic purine nucleoside analogue with <i>in vitro</i> and <i>in vivo</i> inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus (VZV). The inhibitory activity of Vidarabine is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts Vidarabine into Vidarabine monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. <i>In vitro</i>, Vidarabine triphosphate stops the DNA replication of herpes virus by being incorporated into the DNA strand and preventing the formation of phosphodiester bridges between bases. This ultimately leads to destabilization of the viral DNA strands.']","['Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Antimetabolites.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)']","['Systemetic absorption of vidarabine should not be expected to occur following ocular administration and swallowing lacrimal secretions.', 'Vira-A is rapidly deaminated to arabinosylhypoxanthine (Ara-Hx), the principal metabolite. ...Because of the low solubility of Vira-A, trace amounts of both Vira-A and Ara-Hx can be detected in the aqueous humor only if there is an epithelial defect in the cornea. If the cornea is normal, only trace amounts of Ara-Hx can be recovered from the aqueous humor.  Systemic absorption of Vira-A should not be expected to occur following ocular administration and swallowing lacrimal secretions.', 'Vidarabine is poorly absorbed following oral, im, or SC administration. Following iv administration of vidarabine, 75-87% of the dose is rapidly deaminated by adenosine deaminase to ara-hypoxanthine. Ara-hypoxanthine also possesses antiviral activity but substantially less than that of vidarabine. Following slow iv administration of vidarabine 10 mg/kg in adults, peak plasma concentrations of the drug range from 0.2-0.4 ug/mL and peak plasma concentrations of ara-hypoxanthine range from 3-6 ug/mL. Plasma concentrations of vidarabine and ara-hypoxanthine are higher and more prolonged in patients with renal impairment.', 'Vidarabine and ara-hypoxanthine are widely distributed into body tissues and fluids and readily cross the blood-brain barrier. In patients with normal meninges, ara-hypoxanthine concentrations in the CSF are about 33-35% of concurrent plasma concentrations. Vidarabine crosses the placenta in animals. It is not known if vidarabine is distributed into milk. ... Vidarabine is 20-30% bound and ara-hypoxanthine is 0-3% bound to plasma proteins.', 'Vidarabine and ara-hypoxanthine are excreted mainly by the kidneys. Within 24 hours following iv administration of vidarabine 15 mg/kg in patients with normal renal function, 1-3% of the dose is excreted in urine as vidarabine and 41-53% of the dose is excreted as ara-hypoxanthine. There is no evidence of fecal excretion of the drug or metabolite.']","['In laboratory animals, vidarabine is rapidly deaminated in the gastrointestinal tract to Ara-Hx.', 'In laboratory animals, Vira-A is rapidly deaminated in the gastrointestinal tract to arabinosylhypoxanthine (Ara-Hx).', 'Vidarabine is rapidly deaminated, possibly within the cornea, by adenosine deaminase to ara-hypoxanthine. Ara-hypoxanthine also possesses antiviral activity but substantially less than that of vidarabine.']","['The plasma half-life of vidarabine in adults with normal renal function is 1.5 hr, and the plasma half-life of ara-hypoxanthine is 3.3 hr.']"
1704,21705,CID 21705,CC(=C)C(=O)[O-].[Na+],,,,,,
1705,21706,Diadenosine tetraphosphate,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)N,,,"['Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)']",,,
1706,21707,"3-Indol-3-yl-2H-1,4-benzoxazin-2-one",C1=CC=C2C(=C1)C(=CN2)C3=NC4=CC=CC=C4OC3=O,,,,,,
1707,21708,CID 21708,CC(=O)CC(C1=CC=C(C=C1)I)C2=C(OC3=CC=CC=C3C2=O)O,,,,,,
1708,21709,"6H-Cyclohepta(b)quinoline, 4-chloro-11-(3-(dimethylamino)propoxy)-7,8,9,10-tetrahydro-, dihydrochloride",C[NH+](C)CCCOC1=C2CCCCCC2=[NH+]C3=C1C=CC=C3Cl.[Cl-].[Cl-],,,,,,
1709,21710,"3-[(4-chloro-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolin-11-yl)oxy]-N,N-dimethylpropan-1-amine",CN(C)CCCOC1=C2CCCCCC2=NC3=C1C=CC=C3Cl,,,,,,
1710,21711,Methyl 3-(1H-indol-3-yl)propanoate,COC(=O)CCC1=CNC2=CC=CC=C21,,,,,,
1711,21712,CID 21712,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)([O-])[O-])O)O)NC(=NC2=O)N.[Na+].[Na+],,,,,,
1712,21713,"2H-Azepin-2-one, hexahydro-N-lauroyl-",CCCCCCCCCCCC(=O)N1CCCCCC1=O,,,,,,
1713,21714,N-Benzyl-DL-aspartic acid,C1=CC=C(C=C1)CNC(CC(=O)O)C(=O)O,,,,,,
1714,21715,"Aspartic acid, N-ethyl-, DL-",CCNC(CC(=O)O)C(=O)O,,,,,,
1715,21716,1-(4-Hydroxy-3-thienyl)ethanone,CC(=O)C1=CSC=C1O,,,,,,
1716,21717,2-Phenylheptanoic acid,CCCCCC(C1=CC=CC=C1)C(=O)O,,,,,,
1717,21718,Alverine citrate,CCN(CCCC1=CC=CC=C1)CCCC2=CC=CC=C2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,,,['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)'],,,
1718,21719,Biphenamine hydrochloride,CCN(CC)CCOC(=O)C1=CC=CC(=C1O)C2=CC=CC=C2.Cl,,,,,,
1719,21720,Xenysalate,CCN(CC)CCOC(=O)C1=CC=CC(=C1O)C2=CC=CC=C2,,,,,,
1720,21721,Ethyl dibunate,CCOS(=O)(=O)C1=C2C=CC(=CC2=CC(=C1)C(C)(C)C)C(C)(C)C,,,,,,
1721,21722,Iprindole,CN(C)CCCN1C2=C(CCCCCC2)C3=CC=CC=C31,,,"['Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)']",,,
1722,21723,Teclozan,CCOCCN(CC1=CC=C(C=C1)CN(CCOCC)C(=O)C(Cl)Cl)C(=O)C(Cl)Cl,,,,,,
1723,21724,Bis(p-methoxyphenyl)acetic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)C(C1=CC=C(C=C1)OC)C2=CC=C(C=C2)OC.[Cl-],,,,,,
1724,21725,"2-(Diethylamino)ethyl 2,2-bis(4-methoxyphenyl)acetate",CCN(CC)CCOC(=O)C(C1=CC=C(C=C1)OC)C2=CC=C(C=C2)OC,,,,,,
1725,21726,5-Benzylthio-3-(2-methylaminopropyl)indole,CC(CC1=CNC2=C1C=C(C=C2)SCC3=CC=CC=C3)NC,,,,,,
1726,21727,"Ammonium, (1-(5-dimethylsulfonio-3-indolyl)-2-propyl)trimethyl-, diiodide, hydrate",CC(CC1=CNC2=C1C=C(C=C2)[S+](C)C)[N+](C)(C)C.[I-].[I-],,,,,,
1727,21728,1-(5-dimethylsulfonio-1H-indol-3-yl)propan-2-yl-trimethylazanium,CC(CC1=CNC2=C1C=C(C=C2)[S+](C)C)[N+](C)(C)C,,,,,,
1728,21729,"Indole, 3-(1-methylamino-2-propyl)-5-methylthio-",CC(CNC)C1=CNC2=C1C=C(C=C2)SC,,,,,,
1729,21730,"Indole, 3-(3-(dimethylamino)-2-butyl)-5-methylthio-",CC(C1=CNC2=C1C=C(C=C2)SC)C(C)N(C)C,,,,,,
1730,21731,"Indole, 3-(2-(methylamino)ethyl)-5-methylthio-",CNCCC1=CNC2=C1C=C(C=C2)SC,,,,,,
1731,21732,gamma-Chlordan,C1C2C(CC1(Cl)Cl)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']",,,
1732,21733,Pigment yellow 83,CC(=O)C(C(=O)NC1=CC(=C(C=C1OC)Cl)OC)N=NC2=C(C=C(C=C2)C3=CC(=C(C=C3)N=NC(C(=O)C)C(=O)NC4=CC(=C(C=C4OC)Cl)OC)Cl)Cl,,,,,,
1733,21734,2-((2-(Dimethylamino)ethyl)thio)-2-imidazoline dihydrobromide,CN(C)CCSC1=[NH+]CC[NH2+]1.[Br-].[Br-],,,,,,
1734,21735,"2-(4,5-dihydro-1H-imidazol-2-ylsulfanyl)-N,N-dimethylethanamine",CN(C)CCSC1=NCCN1,,,,,,
1735,21736,CID 21736,CCOC(=O)CC1=C(OC2=C(N1)C=CC(=O)C2=O)O,,,,,,
1736,21737,"N,N-Bis-(2-quinoxaloyl)-L-cystine",C1=CC=C2C(=C1)N=CC(=N2)C(=O)N[C@@H](CSSC[C@@H](C(=O)O)NC(=O)C3=NC4=CC=CC=C4N=C3)C(=O)O,,,,,,
1737,21738,"Glycine, N-(2-quinoxaloyl)-",C1=CC=C2C(=C1)N=CC(=N2)C(=O)NCC(=O)O,,,,,,
1738,21739,"Isoleucine, N-(2-quinoxaloyl)-, L-",CCC(C)[C@@H](C(=O)O)NC(=O)C1=NC2=CC=CC=C2N=C1,,,,,,
1739,21740,Potassium nitrazepate,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)[N+](=O)[O-])C(=O)[O-].[K+],,,,,,
1740,21741,"2,3-Dihydro-7-nitro-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid",C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)[N+](=O)[O-])C(=O)O,,,,,,
1741,21742,Mansonone C,CC1=C2C(=C(C=C1)C(C)C)C=C(C(=O)C2=O)C,,,,,,
1742,21743,Cefalonium,C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CS3)C(=O)[O-])C[N+]4=CC=C(C=C4)C(=O)N,,,,,,
1743,21744,"(6R,7R)-3-[(4-carbamoyl-1-pyridin-1-iumyl)methyl]-8-oxo-7-[(1-oxo-2-thiophen-2-ylethyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid",C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CS3)C(=O)O)C[N+]4=CC=C(C=C4)C(=O)N,,,,,,
1744,21745,CID 21745,C1=CC=C(C=C1)NC(=NC2=NC(=NC(=N2)Cl)Cl)S,,,,,,
1745,21746,2-Hydroxyethyl 10-oxodecanoate,C(CCCCC(=O)OCCO)CCCC=O,,,,,,
1746,21747,CID 21747,CCCC(C(C)CC)C(=O)NC(=O)N,,,,,,
1747,21748,Epinal; Epinephrine borate,B1(OC2=C(O1)C=C(C=C2)C(CNC)O)O,,,,,,
1748,21749,Bromchlorenone,C1=C2C(=CC(=C1Cl)Br)OC(=O)N2,,,,,,
1749,21750,"Hydrazinecarboxamide, 1-ethyl-2-((5-nitro-2-furanyl)methylene)-",CCN(C(=O)N)N=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
1750,21751,Iopydol,C1=C(C(=O)C(=CN1CC(CO)O)I)I,,,,,,
1751,21752,Iopydone,C1=C(C(=O)C(=CN1)I)I,,,,,,
1752,21753,Nifurmerone,C1=C(OC(=C1)[N+](=O)[O-])C(=O)CCl,,,,,,
1753,21754,"Bis(2-chloropropyl)carbamic acid, ethyl ester",CCOC(=O)N(CC(C)Cl)CC(C)Cl,,,,,,
1754,21755,"3,4-Dimethylbenzamide",CC1=C(C=C(C=C1)C(=O)N)C,,,,,,
1755,21756,"Indole, 3-(2-pyridylmethyl)-",C1=CC=C2C(=C1)C(=CN2)CC3=CC=CC=N3,,,,,,
1756,21757,"2,3,4,5-Tetrafluoroaniline",C1=C(C(=C(C(=C1F)F)F)F)N,,,,,,
1757,21758,5-Bromo-1-(tetrahydropyran-2-yl)cytosine,C1CCOC(C1)N2C=C(C(=NC2=O)N)Br,,,,,,
1758,21759,Amfecloral,CC(CC1=CC=CC=C1)N=CC(Cl)(Cl)Cl,['Used as an appetite suppressant.'],,,,,
1759,21760,Dimefadane,CN(C)C1CC(C2=CC=CC=C12)C3=CC=CC=C3,,,,,,
1760,21761,Metoclopramide dihydrochloride,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl.Cl.Cl,,,"['Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)', 'Compounds and drugs that bind to and inhibit or block the activation of DOPAMINE D2 RECEPTORS. (See all compounds classified as Dopamine D2 Receptor Antagonists.)']",,,
1761,21762,CID 21762,CN1C=NC(=C1SC2=NC(=N)N=C3C2=NC=N3)N(O)O,,,,,,
1762,21763,Propyl thioarsenite,CC(C)S[As](SC(C)C)SC(C)C,,,,,,
1763,21764,CID 21764,CC[GeH](CC)CC.CC[GeH](CC)CC.[TeH2],,,,,,
1764,21765,Hydrogen telluride,[TeH2],,,,,,
1765,21766,"1,3-Dioxolo(4,5-g)isoquinolinium, 7,8-dihydro-6-(7,8-dihydro-5-hydroxy-4-methoxy-1,3-dioxolo(4,5-g)isoquinolin-6(5H)-yl)-4-methoxy-, chloride",COC1=C2C=[N+](CCC2=CC3=C1OCO3)N4CCC5=CC6=C(C(=C5C4O)OC)OCO6.[Cl-],,,,,,
1766,21767,"4-methoxy-6-(4-methoxy-7,8-dihydro-[1,3]dioxolo[4,5-g]isoquinolin-6-ium-6-yl)-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-ol",COC1=C2C=[N+](CCC2=CC3=C1OCO3)N4CCC5=CC6=C(C(=C5C4O)OC)OCO6,,,,,,
1767,21768,"2,6-Octadienenitrile, 3,7-dimethyl-",CC(=CCCC(=CC#N)C)C,,,,,,
1768,21769,Benzindopyrine hydrochloride,C1=CC=C(C=C1)C[NH+]2C=C(C3=CC=CC=C32)CCC4=CC=NC=C4.[Cl-],,,,,,
1769,21770,Benzindopyrine,C1=CC=C(C=C1)CN2C=C(C3=CC=CC=C32)CCC4=CC=NC=C4,,,,,,
1770,21771,Evadene,CC(CC1C2=CC=CC=C2CCC3=CC=CC=C13)C[NH+](C)C.[Cl-],,,"['Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)', 'Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)']",,,
1771,21772,Butriptyline,CC(CC1C2=CC=CC=C2CCC3=CC=CC=C13)CN(C)C,,,"['Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)', 'Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)']",,,
1772,21773,(4-Hydroxy-4-phenylhexan-3-yl) carbamate,CCC(C(CC)(C1=CC=CC=C1)O)OC(=O)N,,,,,,
1773,21774,3-Hydroxy-3-phenylpentane-2-carbamate,CCC(C1=CC=CC=C1)(C(C)OC(=O)N)O,,,,,,
1774,21775,"1,6-Diisothiocyanatohexane",C(CCCN=C=S)CCN=C=S,,,,,,
1775,21776,Mefenorex hydrochloride,CC(CC1=CC=CC=C1)NCCCCl.Cl,,,['Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)'],,,
1776,21777,Mefenorex,CC(CC1=CC=CC=C1)NCCCCl,,,['Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)'],,,
1777,21778,"Pyrazinecarboxylic acid, 3,5-diamino-6-chloro-, 2-(aminoiminomethyl)hydrazide",C1(=C(N=C(C(=N1)Cl)N)N)C(=O)NN=C(N)N,,,,,,
1778,21779,Ampyrimine,C1=CC=C(C=C1)C2=C3C(=NC(=NC3=NC(=N2)N)N)N,,,,,,
1779,21780,"N-(2,5-Dimethylpyrrol-1-yl)isonicotinamide",CC1=CC=C(N1NC(=O)C2=CC=NC=C2)C,,,,,,
1780,21781,"4,5-Dibutoxy-2-imidazolidinone",CCCCOC1C(NC(=O)N1)OCCCC,,,,,,
1781,21782,Clodantoin,CCCCC(CC)C1C(=O)N(C(=O)N1)SC(Cl)(Cl)Cl,,,,,,
1782,21783,"3,4,5-Trimethoxycinnamamide",COC1=CC(=CC(=C1OC)OC)C=CC(=O)N,,,,,,
1783,21784,Clorprenaline HCl,CC(C)NCC(C1=CC=CC=C1Cl)O.O.Cl,,,,,,
1784,21785,Cypenamine hydrochloride,C1CC(C(C1)N)C2=CC=CC=C2.Cl,,,,,,
1785,21786,Cypenamine,C1CC(C(C1)N)C2=CC=CC=C2,,,,,,
1786,21787,"(1,1'-Bicyclohexyl)-1-carboxylic acid, 2-(1-piperidinyl)ethyl ester hydrochloride",C1CCC(CC1)C2(CCCCC2)C(=O)OCC[NH+]3CCCCC3.[Cl-],,,,,,
1787,21788,Dihexyverine,C1CCC(CC1)C2(CCCCC2)C(=O)OCCN3CCCCC3,,,,,,
1788,21789,Fenmetramide,CC1C(OCC(=O)N1)C2=CC=CC=C2,,,,,,
1789,21790,N-(2-Chloroethyl)ethylenediamine dihydrochloride,C(C[NH2+]CCCl)[NH3+].[Cl-].[Cl-],,,,,,
1790,21791,(2-Aminoethyl)(2-chloroethyl)amine,C(CNCCCl)N,,,,,,
1791,21792,"5H-DIBENZO(a,d)CYCLOHEPTENE, 10,11-DIHYDRO-5-(3-MORPHOLINOPROPYLIDENE)-",C1CC2=CC=CC=C2C(=CCCN3CCOCC3)C4=CC=CC=C41,,,,,,
1792,21793,Becanthone,CCN(CCNC1=C2C(=C(C=C1)C)SC3=CC=CC=C3C2=O)CC(C)(C)O,,,,,,
1793,21794,"(6S,9S,14S,16R,17S)-17-acetyl-6-chloro-10,13,16-trimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one",C[C@@H]1C[C@H]2C3C[C@@H](C4=CC(=O)CCC4([C@H]3CCC2([C@H]1C(=O)C)C)C)Cl,,,,,,
1794,21795,Iosefamic acid,CNC(=O)C1=C(C(=C(C(=C1I)NC(=O)CCCCCCCCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)C(=O)NC)I)I)C(=O)O)I,,,,,,
1795,21796,CID 21796,COC1=CC=CC=C1N2CCN(CC2)CCC3=CNC4=CC5=C(C=C43)OCO5.C(C(C(=O)O)O)(C(=O)O)O,,,,,,
1796,21797,Pyrroliphene,CC(CN1CCCC1)C(CC2=CC=CC=C2)(C3=CC=CC=C3)OC(=O)C,,,,,,
1797,21798,Anilamate,CNC(=O)OC1=CC=CC=C1C(=O)NC2=CC=CC=C2,,,,,,
1798,21799,"6H-CYCLOHEPTA(b)QUINOLINE, 7,8,9,10-TETRAHYDRO-11-AMINO-4-METHOXY-",COC1=CC=CC2=C(C3=C(CCCCC3)N=C21)N,,,,,,
1799,21800,Betamethasone dipropionate,CCC(=O)OCC(=O)[C@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)OC(=O)CC,,,['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)'],,,
1800,21801,Titanium tetrabutoxide,CCCC[O-].CCCC[O-].CCCC[O-].CCCC[O-].[Ti+4],,,,,,
1801,21802,"Indole, 3-(1-methyl-3-piperidylmethyl)-",CN1CCCC(C1)CC2=CNC3=CC=CC=C32,,,,,,
1802,21803,Chlorpyrifos-methyl,COP(=S)(OC)OC1=NC(=C(C=C1Cl)Cl)Cl,,,,"['The dermal absorption of Reldan 22 (224 g/L chlorpyrifos-methyl, solvent based) was assessed in vitro using full-thickness male Fischer 344 rat skin. Single (10 uL) 28 hr applications of (14)C-labelled test material (undiluted or 1% aqueous dilution) were made to the epidermal surface of skin discs held in occluded flow diffusion cells at 31 Â°C. Receptor fluid (tissue culture medium containing 6% polyethylene glycol 20 oleyl ether) was collected at 2 h intervals. The solubility of chlorpyrifosmethyl in the receptor fluid was confirmed to be higher than the applied dose. For the concentrate, total recovery of radioactivity was high (92.27-99.32%). A lag time for penetration of 4-6 hr was observed; this was followed by linear absorption over the following 24 hr. For the spray strength dilution, total recovery of radioactivity was also high (95.05-100.89%). Distribution of radioactivity was consistent for all of the six replicates. A lag time for penetration of 8-10 hr was observed; this was followed by linear absorption over the remainder of the study. The linear absorption rate was calculated to be 10.4 ug/sq cm per hour for the concentrate and 0.039 ug/sq cm per hour for the 1% dilution. Dermal penetration was low for both formulation types.', 'Two male Sprague-Dawley rats (approximately 200 g) were gavaged with (14)C-radiolabelled chlorpyrifos-methyl (purity >99%; 377 MBq/mmol; labelled at positions 2 and 6 on the pyridyl ring) at a dose level of 16 mg/kg bw (in corn oil). Urine, feces and expired carbon dioxide were collected for up to 72 hr. Blood samples were taken from the tail at intervals throughout the study period. Radioactivity levels were determined by liquid scintillation counting or combustion analysis (fecal samples). Urinary metabolites were identified by thin-layer chromatography (TLC) and autoradiography. Peak blood radioactivity levels were reported at 5 hr, at which point the amount of test material in the blood was calculated to be approximately 3.0% (2.4-3.7%; absolute levels not given) of the administered dose. Levels of radioactivity indicated rapid clearance from blood, and the peak level seen at 5 hr had declined by 50% at approximately 9 hr following administration, suggesting an initial half-life of approximately 4 hr. Excretion of radioactivity was found to be primarily in the urine and largely within 24 hr of administration. Radioactivity levels in expired air were minimal. Residual tissue radioactivity levels at 72 hr were low in all tissues (<1 part per million [ppm]), but varied markedly between the two animals.', 'When (14)C-bound residues were fed to male rats for 24 hours, the animals eliminated 75% of the radioactivity in urine, 7% in expired air and 8% in faeces after 3 days, indicating that the bound residues were highly bioavailable. A further ""bioavailable"" amount (4%) was found in selected organs.', 'Tissue distributions of dichlorvos, an organophosphate, and chlorpyrifos-methyl, an organophosphorothioate, were determined. Tiny amounts of dichlorvos, 0.067 and 0.027 mg/L, were detected in the vitreous humor and cerebrospinal fluid, respectively. Although dichlorvos (0.082-8.99 mg/L or mg/kg) was detected in the thoracic aortic blood, thoracic inferior vena caval blood, pericardial fluid, bile, and spleen, it was strongly suggested that it had diffused postmortem from the stomach, which contained 879 mg, because no dichlorvos was detected in the other blood samples and tissues tested. Substantial amounts (0.615-4.15 mg/L) of chlorpyrifos-methyl were detected in all blood samples, and the order of its concentrations was as follows: pulmonary vessel blood > thoracic inferior vena caval blood > blood in the right cardiac chambers > blood in the left cardiac chambers = thoracic aortic blood > right femoral venous blood. The total amount of chlorpyrifos-methyl in the stomach was 612 mg. However, it was strongly suggested that virtually no chlorpyrifos-methyl diffused from the stomach into surrounding fluids and tissues postmortem because no chlorpyrifos-methyl was detected in the bile and little was found in the pericardial fluids. Neither compound was detected in the urine. In vitro experiments showed that dichlorvos (10 mg/L) almost disappeared from fresh (pH 7.4) and acidified (pH 6.2) blood samples within 24 and 72 hr, respectively. However, 53 and 77% of the original amount of dichlorvos in 0.05M phosphate buffers at pH 7.4 and 6.2 were detected 72 hr later. Chlorpyrifos-methyl (1 mg/L) was very stable in blood samples, regardless of the pH, during the 72-hr study period, but in the pH 7.4 and 6.2 phosphate buffers, approximately 80% of the original amount had degraded after 72 hr. ... When sodium fluoride was added to blood samples, dichlorvos degraded completely within 15 min, and chlorpyrifos-methyl became very unstable. When analyzing samples to detect organophosphorus chemicals, this common preservative should not be added to fluid specimens.', 'For more Absorption, Distribution and Excretion (Complete) data for CHLORPYRIFOS-METHYL (6 total), please visit the HSDB record page.']","['Thyroid hormones are vital to a host of human physiological functions in both children and adults. Exposures to chemicals, including chlorpyrifos, have been found to modify thyroid signaling at environmentally relevant levels in animal studies. The aim of this study was to examine circulating T4 and TSH levels in relation to urinary concentrations of 3,5,6-trichloro-2-pyridinol (TCPY), a metabolite of the organophosphorus insecticides chlorpyrifos and chlorpyrifos-methyl, using data from individuals 12 years and older from the U.S. National Health and Nutrition Examination Surveys (NHANES). NHANES datasets from 1999 to 2000 and 2001-2002 were combined, and individuals with thyroid disease, those taking thyroid medications, and pregnant women were excluded (N = 3249). Multivariable linear regression models for relationships between log-transformed urinary TCPY and serum total T(4) or log (TSH) were constructed adjusting for important covariates. Models were stratified by sex and a categorical age variable (12-18, 18-40, 40-60, and >60 years). In male participants, an interquartile range (IQR) increase in urinary TCPY was associated with statistically significant increases in serum T(4) of 3.8% (95th CI 0.75 to 7.0) among those 12-18 years of age and 3.5% (95th CI 0.13 to 7.0) in the 18-40 year age group, relative to median T4 levels using unweighted models. An IQR increase in TCPY was also associated with decreases in TSH of 10.7% (-18.7-2.05) among men 18-40 years old and 20.0% (95th CI -28.9 to -9.86) among men >60 years old. Conversely, urinary TCPY was positively associated with TSH in females >60 years of age. /3,5,6-Trichloro-2-pyridinol (chlorpyrifos-methyl metabolite)/', 'The urinary metabolites of chlorpyrifos-methyl were investigated by TLC ... . The primary metabolite was identified by co-chromatography as 3,5,6-trichloro-2-pyridinol (TCP). Additional non-mobile material was stated to be conjugated TCP. Metabolites were not quantified, and fecal metabolites were not investigated.', 'The oxidative desulfuration of the three phosphorothionate insecticides -- chlorpyrifos, chlorpyrifos-methyl, and leptophos--was studied in rat brain and liver. Hepatic microsomes demonstrated activities of 4-28 nmol/g/min, with male activity 2- to 4-fold higher than female activity. Very low desulfuration activity of all three compounds was observed in both microsomal and crude mitochondrial fractions from brain (3-27 pmol/g/min). There were no sex differences in the brain. Although the liver displayed 140- to 2100-fold greater activity than brain on a wet-weight basis, the brain desulfuration activities of these three compounds as well as those of some previously reported phosphorothionates generally correlate well with the toxicity and may be important in determining the overall acute toxicity levels of phosphorothionate insecticides.', 'Urinary metabolites ... were identified by gas-liquid chromatography, TLC and mass spectrometry as 3,5,6-trichloro-2-pyridinol (TCP) (13.8%), its glucuronide conjugate (68.6%) and the desmethyl metabolite O-methyl-O-(3,5,6-trichloropyridyl) phosphorothioate (17.8%). Feces were not analysed, as they contained less than 5% of the administered radiolabel.', 'A normal metabolic reaction with phosphorothioates is oxidative desulfuration or isomerization to give the oxon form, which is the more potent inhibitor of acetylcholinesterase. Chlorpyrifosmethyl oxon was not identified in the rat metabolism studies with chlorpyrifos-methyl.']","['Two male Sprague-Dawley rats (approximately 200 g) were gavaged with (14)C-radiolabelled chlorpyrifos-methyl (purity >99%; 377 MBq/mmol; labelled at positions 2 and 6 on the pyridyl ring) at a dose level of 16 mg/kg bw (in corn oil). ... Levels of radioactivity indicated rapid clearance from blood, and the peak level seen at 5 hr had declined by 50% at approximately 9 hr following administration, suggesting an initial half-life of approximately 4 hr.']"
1803,21804,Chlorpyrifos oxon,CCOP(=O)(OCC)OC1=NC(=C(C=C1Cl)Cl)Cl,,,,,"['Chlorpyrifos-oxon has known human metabolites that include 3,5,6-Trichloro-2-pyridinol and Diethyl phosphorothioate.']",
1804,21805,Fospirate,COP(=O)(OC)OC1=NC(=C(C=C1Cl)Cl)Cl,,,,,,
1805,21806,Sodium aspartate,C([C@@H](C(=O)[O-])N)C(=O)[O-].[Na+].[Na+],,,,,,
1806,21807,"4,6-Diethyl-1,3,5-triazin-2-amine",CCC1=NC(=NC(=N1)N)CC,,,,,,
1807,21808,"2-Amino-4,6-di-p-tolyl-1,3,5-triazine",CC1=CC=C(C=C1)C2=NC(=NC(=N2)N)C3=CC=C(C=C3)C,,,,,,
1808,21809,"2,4-Dichloro-6-(2,3,4,5,6-pentachlorophenoxy)-1,3,5-triazine",C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)OC2=NC(=NC(=N2)Cl)Cl,,,,,,
1809,21810,2-Amino-4-chloro-6-methylpyrimidine,CC1=CC(=NC(=N1)N)Cl,,,,,,
1810,21811,"6H-Cyclohepta(b)quinoline, 3-chloro-11-(3-(dimethylamino)propoxy)-7,8,9,10-tetrahydro-, dihydrochloride",C[NH+](C)CCCOC1=C2CCCCCC2=[NH+]C3=C1C=CC(=C3)Cl.[Cl-].[Cl-],,,,,,
1811,21812,"3-[(3-chloro-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolin-11-yl)oxy]-N,N-dimethylpropan-1-amine",CN(C)CCCOC1=C2CCCCCC2=NC3=C1C=CC(=C3)Cl,,,,,,
1812,21813,8-Methyldecanoic acid,CCC(C)CCCCCCC(=O)O,,,,,,
1813,21814,"6H-Cyclohepta(b)quinoline, 2-chloro-11-(3-(dimethylamino)propoxy)-7,8,9,10-tetrahydro-, dihydrochloride",C[NH+](C)CCCOC1=C2CCCCCC2=[NH+]C3=C1C=C(C=C3)Cl.[Cl-].[Cl-],,,,,,
1814,21815,"3-[(2-chloro-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolin-11-yl)oxy]-N,N-dimethylpropan-1-amine",CN(C)CCCOC1=C2CCCCCC2=NC3=C1C=C(C=C3)Cl,,,,,,
1815,21816,"1,3,5-Triazine-2,4,6-triamine, N,N'-diethyl-",CCNC1=NC(=NC(=N1)N)NCC,,,,,,
1816,21817,"N,N'-Diphenyl-1,3,5-triazine-2,4,6-triamine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)N)NC3=CC=CC=C3,,,,,,
1817,21818,"2,4-Bis(diethylamino)-1,3,5-triazine-6-amine",CCN(CC)C1=NC(=NC(=N1)N)N(CC)CC,,,,,,
1818,21819,"2,4-Diamino-6-ethylamino-1,3,5-triazine",CCNC1=NC(=NC(=N1)N)N,,,,,,
1819,21820,"N2-phenyl-1,3,5-triazine-2,4,6-triamine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)N)N,,,,,,
1820,21821,1-Methylcarbamoyldiazepam,CNC(=O)C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,,,,,,
1821,21822,"(1,1'-Biphenyl)-3-carboxamide, 5-chloro-N-(2,5-dichlorophenyl)-2-hydroxy-",C1=CC=C(C=C1)C2=C(C(=CC(=C2)Cl)C(=O)NC3=C(C=CC(=C3)Cl)Cl)O,,,,,,
1822,21823,Securinin,C1CCN2[C@H](C1)[C@]34CC2C=CC3=CC(=O)O4,,,,,,
1823,21824,"Urea, N,N'-bis(3,5-bis(4,5-dihydro-1H-imidazol-2-yl)phenyl)-, tetrahydrochloride",C1C[NH+]=C(N1)C2=CC(=CC(=C2)NC(=O)NC3=CC(=CC(=C3)C4=[NH+]CCN4)C5=[NH+]CCN5)C6=[NH+]CCN6.[Cl-].[Cl-].[Cl-].[Cl-],,,,,,
1824,21825,"1,3-bis[3,5-bis(4,5-dihydro-1H-imidazol-2-yl)phenyl]urea",C1CN=C(N1)C2=CC(=CC(=C2)NC(=O)NC3=CC(=CC(=C3)C4=NCCN4)C5=NCCN5)C6=NCCN6,,,,,,
1825,21826,Triamcinolone hexacetonide,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)COC(=O)CC(C)(C)C)CCC5=CC(=O)C=C[C@@]53C)F)O,,,['Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)'],,,
1826,21827,Ethoxycyclopropane,CCOC1CC1,,,,,,
1827,21828,"2-Methyl-1,3-dithiolane",CC1SCCS1,,,,,,
1828,21829,"4-Methyl-2-phenyl-1,3-dithiolane",CC1CSC(S1)C2=CC=CC=C2,,,,,,
1829,21830,"2-Phenyl-1,3-dithiolane",C1CSC(S1)C2=CC=CC=C2,,,,,,
1830,21831,"2-(2-Phenylethenyl)-1,3-dithiolane",C1CSC(S1)C=CC2=CC=CC=C2,,,,,,
1831,21832,Heptylcyclohexane,CCCCCCCC1CCCCC1,,,,,,
1832,21833,"Benzophenone, 2',5-dichloro-2-methylamino-",CNC1=C(C=C(C=C1)Cl)C(=O)C2=CC=CC=C2Cl,,,,,,
1833,21834,CID 21834,CN(CC1=CN=C2C(=N1)C(=O)N=C(N2)N)C3=CC=C(C=C3)C(=O)O,,,,,,
1834,21835,"7H-Dibenz(DE,I)anthracen-7-one",C1=CC=C2C=C3C(=CC2=C1)C4=CC=CC5=C4C(=CC=C5)C3=O,,,,,,
1835,21836,1-Propenyl cyclopentane,CCC=C1CCCC1,,,,,,
1836,21837,CID 21837,C1=CC=C(C=C1)N2C(=O)C(N=C2S)CC(=O)O,,,,,,
1837,21838,CID 21838,C1=CC=C(C=C1)N2C(=O)C(N=C2S)CCC(=O)O,,,,,,
1838,21839,Dimorpholinomethane,C1COCCN1CN2CCOCC2,,,,,,
1839,21840,3-(6H-benzo[c][1]benzoxepin-11-ylidene)propan-1-amine,C1C2=CC=CC=C2C(=CCCN)C3=CC=CC=C3O1,,,,,,
1840,21841,"11,17-Dihydroxy-3,20-dioxopregna-1,4-dien-21-yl N,N-diethylglycinate",CCN(CC)CC(=O)OCC(=O)C1(CCC2C1(CC(C3C2CCC4=CC(=O)C=CC34C)O)C)O,,,,,,
1841,21842,Thiocarbanilic acid S-(2-hydroxyethyl) ester,C1=CC=C(C=C1)NC(=O)SCCO,,,,,,
1842,21843,"Aziridine, 1-ethenyl-",C=CN1CC1,,,,,,
1843,21844,"(7R,9S,14S,17R)-17-ethynyl-17-hydroxy-7,13-dimethyl-1,2,4,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one",C[C@@H]1CC2=C(CCC(=O)C2)[C@@H]3C1[C@@H]4CC[C@](C4(CC3)C)(C#C)O,,,,,,
1844,21845,1-Nitrosopiperazine,C1CN(CCN1)N=O,,,,,,
1845,21846,Benzetimide hydrochloride,C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC=CC=C3)CC4=CC=CC=C4.Cl,,,"['Agents used in the treatment of Parkinson&apos;s disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)', 'Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)']",,,
1846,21847,Benzetimide,C1CN(CCC1C2(CCC(=O)NC2=O)C3=CC=CC=C3)CC4=CC=CC=C4,,,"['Agents used in the treatment of Parkinson&apos;s disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)', 'Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)']",,,
1847,21848,"17-Hydroxy-6-methyl-16-methylenepregna-4,6-diene-3,20-dione",CC1=CC2C(CCC3(C2CC(=C)[C@@]3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C,,,,,,
1848,21849,"(5-Acetyloxy-4,4-diphenylheptan-2-yl)-methylazanium;chloride",CCC(C(CC(C)[NH2+]C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C.[Cl-],,,,,,
1849,21850,Ambuphylline,CC(C)(CO)N.CN1C2=C(C(=O)N(C1=O)C)NC=N2,,,"['Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)']",,,
1850,21851,Clorethate,C(C(Cl)(Cl)Cl)OC(=O)OCC(Cl)(Cl)Cl,,,,,,
1851,21852,Iodinated glycerol,CC(C1OCC(O1)CO)I,,,,,,
1852,21853,Tocamphyl,CC1=CC=C(C=C1)C(C)OC(=O)C2(CCC(C2(C)C)C(=O)O)C.C(CO)NCCO,,,,,,
1853,21854,"2,2,3-Trimethyl-3-[1-(4-methylphenyl)ethoxycarbonyl]cyclopentane-1-carboxylic acid",CC1=CC=C(C=C1)C(C)OC(=O)C2(CCC(C2(C)C)C(=O)O)C,,,,,,
1854,21855,Dimethindene,CC(C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C,"['Indicated as symptomatic treatment of allergic reactions: urticaria, allergies of the upper respiratory tract such as hey fever and perennial rhinitis, food and drug allergies; pruritus of various origins, except pruritus due to cholestasis; insect bites. Dimethindene is also indicated for pruritus in eruptive skin diseases such as chicken-pox. Dimethindene can also be used as an adjuvant in eczema and other pruriginous dermatoses of allergic origin.']","['Dimethindene occurs as a racemic mixture. The (S)-(+)-dimethindene is a potent M2-selective muscarinic receptor antagonist (with lower affinity for M1, M3, and M4 muscarinic receptors). The (R)-(-)-enantiomer is the eutomer (responsible for bioactivity) for histamine H1 receptor binding.']","['Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)', 'Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)', 'Agents, usually topical, that relieve itching (pruritus). (See all compounds classified as Antipruritics.)']",,,
1855,21856,"2,4,6-Tris(acetylamino)-1,3,5-triazine",CC(=O)NC1=NC(=NC(=N1)NC(=O)C)NC(=O)C,,,,,,
1856,21857,Cyanuric triazide,C1(=NC(=NC(=N1)N=[N+]=[N-])N=[N+]=[N-])N=[N+]=[N-],,,,,,
1857,21858,Tribenzoylmelamine,C1=CC=C(C=C1)C(=O)NC2=NC(=NC(=N2)NC(=O)C3=CC=CC=C3)NC(=O)C4=CC=CC=C4,,,,,,
1858,21859,16-Methylheptadecanoic acid,CC(C)CCCCCCCCCCCCCCC(=O)O,,,,,,
1859,21860,"2,3-Dihydroxyindole",C1=CC=C2C(=C1)C(=C(N2)O)O,,,,,,
1860,21861,4-Isopropyl-N-phenylaniline,CC(C)C1=CC=C(C=C1)NC2=CC=CC=C2,,,,,,
1861,21862,"2,3-Dimethoxybenzonitrile",COC1=CC=CC(=C1OC)C#N,,,,,,
1862,21863,N-(2-Furoyl)glycine,C1=COC(=C1)C(=O)NCC(=O)O,,,,,,
1863,21864,"2,3,4,5,5-Pentachloropenta-2,4-dienoic acid",C(=C(C(=O)O)Cl)(C(=C(Cl)Cl)Cl)Cl,,,,,,
1864,21865,"Carbamic acid, (3-hydroxypropyl)-, ethyl ester, carbanilate",CCOC(=O)NCCCOC(=O)NC1=CC=CC=C1,,,,,,
1865,21866,Ethyl (3-carbamoyloxypropyl)carbamate,CCOC(=O)NCCCOC(=O)N,,,,,,
1866,21867,"2-Heptyl-2-methyl-1,3-dioxolane-4-methanol",CCCCCCCC1(OCC(O1)CO)C,,,,,,
1867,21868,"2-Hexyl-2-methyl-1,3-dioxolane-4-methanol",CCCCCCC1(OCC(O1)CO)C,,,,,,
1868,21869,"2-Isobutyl-2-methyl-1,3-dioxolane-4-methanol",CC(C)CC1(OCC(O1)CO)C,,,,,,
1869,21870,CID 21870,C1COC(O1)C=CC2=CC=CC=C2,,,,,,
1870,21871,2-Octynenitrile,CCCCCC#CC#N,,,,,,
1871,21872,2-Octynoic acid,CCCCCC#CC(=O)O,,,,,,
1872,21873,Cyclohexylallene,C=C=CC1CCCCC1,,,,,,
1873,21874,Chlorcarvacrol,CC1=CC(=C(C=C1O)C(C)C)Cl,,,,,,
1874,21875,2-(2-((p-Chloro-alpha-phenylbenzyl)oxy)ethyl)-2-azabicyclo(2.2.2)octane,C1CC2CCC1CN2CCOC(C3=CC=CC=C3)C4=CC=C(C=C4)Cl,,,,,,
1875,21876,6-N-Hydroxylaminopurine,C1=NC2=C(N1)C(=NC=N2)NO,,,['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)'],,,
1876,21877,Dioxyline phosphate,CCOC1=C(C=C(C=C1)CC2=NC(=CC3=CC(=C(C=C32)OC)OC)C)OC.OP(=O)(O)O,,,,,,
1877,21878,Dimoxyline,CCOC1=C(C=C(C=C1)CC2=NC(=CC3=CC(=C(C=C32)OC)OC)C)OC,,,,,,
1878,21879,"(5R,17S)-17-amino-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-11-ol",CC12CCCC[C@@H]1CCC3C2C(CC4(C3CC[C@@H]4N)C)O,,,,,,
1879,21880,"2,2-Dimethyl-3-phenylpropanoic acid",CC(C)(CC1=CC=CC=C1)C(=O)O,,,,,,
1880,21881,2-Benzylbutanoic acid,CCC(CC1=CC=CC=C1)C(=O)O,,,,,,
1881,21882,3-Phenylpentanoic acid,CCC(CC(=O)O)C1=CC=CC=C1,,,,,,
1882,21883,"2-Butenoic acid, 3-[(diethoxyphosphinyl)oxy]-, ethyl ester, (E)-",CCOC(=O)C=C(C)OP(=O)(OCC)OCC,,,,,,
1883,21884,"2,5-Dimethylbenzoxazole",CC1=CC2=C(C=C1)OC(=N2)C,,,,,,
1884,21885,2-Dimethylaminopyridine,CN(C)C1=CC=CC=N1,,,,,,
1885,21886,"2,2-Dimethyl-1,3-oxathiolane",CC1(OCCS1)C,,,,,,
1886,21887,"2,8-Dinitro-6,12-diphenyldibenzo[b,f][1,5]diazocine",C1=CC=C(C=C1)C2=NC3=C(C=C(C=C3)[N+](=O)[O-])C(=NC4=C2C=C(C=C4)[N+](=O)[O-])C5=CC=CC=C5,,,,,,
1887,21888,"3,4,5-Trimethoxybenzylidenemalononitrile",COC1=CC(=CC(=C1OC)OC)C=C(C#N)C#N,,,,,,
1888,21889,"1,1,3,3-Tetramethyl-2-indanone",CC1(C2=CC=CC=C2C(C1=O)(C)C)C,,,,,,
1889,21890,"m-DIOXANE, 4-(p-METHOXYPHENYL)-5-METHYL-",CC1COCOC1C2=CC=C(C=C2)OC,,,,,,
1890,21891,"Bis(2,4,6-trimethylphenyl)diazene",CC1=CC(=C(C(=C1)C)N=NC2=C(C=C(C=C2C)C)C)C,,,,,,
1891,21892,4-((Diethoxyphosphinothioyl)oxy)benzoic acid ethyl ester,CCOC(=O)C1=CC=C(C=C1)OP(=S)(OCC)OCC,,,,,,
1892,21893,"2,2-Dimethyl-1,3-dithiolane-4-methanol",CC1(SCC(S1)CO)C,,,,,,
1893,21894,"1,3-Dioxolane, 2-dicyanomethylene-",C1COC(=C(C#N)C#N)O1,,,,,,
1894,21895,Phenylacetaldehyde glyceryl acetal,C1C(OC(O1)CC2=CC=CC=C2)CO,,,,,,
1895,21896,"2-Benzyl-2-methyl-1,3-dioxolane-4-methanol",CC1(OCC(O1)CO)CC2=CC=CC=C2,,,,,,
1896,21897,"2-Butyl-2-ethyl-1,3-dioxolane-4-methanol",CCCCC1(OCC(O1)CO)CC,,,,,,
1897,21898,"2-t-Butyl-2-isopropyl-1,3-dioxolane-4-methanol",CC(C)C1(OCC(O1)CO)C(C)(C)C,,,,,,
1898,21899,"2-Butyl-2-methyl-1,3-dioxolane-4-methanol",CCCCC1(OCC(O1)CO)C,,,,,,
1899,21900,"2-Cyclohexyl-2-methyl-1,3-dioxolane-4-methanol",CC1(OCC(O1)CO)C2CCCCC2,,,,,,
1900,21901,"2,2-Dibutyl-1,3-dioxolane-4-methanol",CCCCC1(OCC(O1)CO)CCCC,,,,,,
1901,21902,"2,2-Diethyl-1,3-dioxolane-4-methanol",CCC1(OCC(O1)CO)CC,,,,,,
1902,21903,"2,2-Diisobutyl-1,3-dioxolane-4-methanol",CC(C)CC1(OCC(O1)CO)CC(C)C,,,,,,
1903,21904,"2-Ethyl-2-isopentyl-1,3-dioxolane-4-methanol",CCC1(OCC(O1)CO)CCC(C)C,,,,,,
1904,21905,"2-(1-Ethylpentyl)-1,3-dioxolane-4-methanol",CCCCC(CC)C1OCC(O1)CO,,,,,,
1905,21906,CID 21906,CN1[C@H](CCC1=O)C2=CN=CC=C2.CN1[C@H](CCC1=O)C2=CN=CC=C2.C(=CC(=O)O)C(=O)O,,,,,,
1906,21907,R-(+)-Cotinine,CN1[C@H](CCC1=O)C2=CN=CC=C2,,,,,,
1907,21908,Methetoin,CCC1(C(=O)NC(=O)N1C)C2=CC=CC=C2,,,,,,
1908,21909,Butoxamine hydrochloride,CC(C(C1=C(C=CC(=C1)OC)OC)O)NC(C)(C)C.Cl,,,"['Drugs that bind to and block the activation of ADRENERGIC BETA-2 RECEPTORS. (See all compounds classified as Adrenergic beta-2 Receptor Antagonists.)', 'Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. (See all compounds classified as Hypolipidemic Agents.)', 'Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)', 'Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here. (See all compounds classified as Sympatholytics.)']",,,
1909,21910,Epipropidine,C1CN(CCC1C2CCN(CC2)CC3CO3)CC4CO4,,,,,,
1910,21911,CI 384 hydrochloride,CCCSC1=CC=CC=C1N2CC[NH+](CC2)CCCCCOC(=O)NCC.[Cl-],,,,,,
1911,21912,5-[4-(2-propylsulfanylphenyl)piperazin-1-yl]pentyl N-ethylcarbamate,CCCSC1=CC=CC=C1N2CCN(CC2)CCCCCOC(=O)NCC,,,,,,
1912,21913,CID 21913,C[C@@]1(CCC2(CC[C@@]3(C(=CC(=O)[C@H]4C3(CC[C@@H]5C4(CCC(C5(C)C)OC(=O)CCC(=O)O)C)C)C2C1)C)C)C(=O)O,,,,,,
1913,21914,"(2R,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9-trien-17-ol",C[C@]12CCC3C(C1CC[C@]2(C)O)CCC4=CC5=C(C[C@]34C)C=NN5,,,,,,
1914,21915,"2-((o-tert-Butyl-alpha-phenylbenzyl)oxy)-N,N-dimethyl-ethylamine hydrochloride",CC(C)(C)C1=CC=CC=C1C(C2=CC=CC=C2)OCC[NH+](C)C.[Cl-],,,,,,
1915,21916,Bufenadrine,CC(C)(C)C1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C,,,,,,
1916,21917,"17-acetyl-10,13-dimethyl-7,8,9,11,12,14,16,17-octahydro-6H-cyclopenta[a]phenanthrene-3,15-dione",CC(=O)C1CC(=O)C2C1(CCC3C2CCC4=CC(=O)C=CC34C)C,,,,,,
1917,21918,"Indole, 3-(2-quinuclidinylmethyl)-",C1CN2CCC1CC2CC3=CNC4=CC=CC=C43,,,,,,
1918,21919,Acetylpyruvic acid,CC(=O)CC(=O)C(=O)O,,,,,,
1919,21920,CID 21920,C1CCN=C(NC1)S,,,,,,
1920,21921,Ethylenediamine dihydroiodide,C(CN)N.I.I,,,,"['IN CATTLE NORMAL TOTAL SERUM IODINE CONCN RANGES FROM 5.6 TO 14 UG/100 ML... IN SHEEP NORMAL TOTAL SERUM IODINE CONCN IS ABOUT 2.3-4.6 UG/100 ML... IN CASES OF EDDI-INDUCED IODISM &...INFECTION...TOTAL SERUM IODINE CONCN.../REPORTED/ 10-100 OR MORE TIMES NORMAL.', 'IODIDES ARE READILY EXCRETED IN MILK /OF CATTLE/. ... IODIDES...ALSO SECRETED BY GLANDULAR CELLS IN RESP TRACT... SALIVARY & LACRIMAL GLANDS ALSO SECRETE IODIDES.']",,
1921,21922,"N-Cyclohexyl-1,2-ethanediamine",C1CCC(CC1)NCCN,,,,,,
1922,21923,"m-DIOXANE, 5-ETHYL-5-NITRO-2-PROPYL-",CCCC1OCC(CO1)(CC)[N+](=O)[O-],,,,,,
1923,21924,"1-Phenyl-2,3-dimethyl-4-benzoylamino-5-pyrazolone",CC1=C(C(=O)N(N1C)C2=CC=CC=C2)NC(=O)C3=CC=CC=C3,,,,,,
1924,21925,"(10,13-Dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) 2-phenylacetate",CC12CCC3C(C1CCC2OC(=O)CC4=CC=CC=C4)CCC5=CC(=O)CCC35C,,,,,,
1925,21926,[2-Hydroxy-2-(4-nitrophenyl)ethyl]-propan-2-ylazanium;chloride,CC(C)[NH2+]CC(C1=CC=C(C=C1)[N+](=O)[O-])O.[Cl-],,,,,,
1926,21927,CID 21927,C1=CC(=CC=C1C=NN=C(N)S)Cl,,,,,,
1927,21928,Phenylselenenyl chloride,C1=CC=C(C=C1)[Se]Cl,,,,,,
1928,21929,Drazoxolon,CC1=C(C(=O)ON1)N=NC2=CC=CC=C2Cl,,,,,,
1929,21930,Metazoxolon,CC1=C(C(=O)ON1)N=NC2=CC(=CC=C2)Cl,,,,,,
1930,21931,"Benzimidazole, 5,6-dimethyl-2-nitro-",CC1=CC2=C(C=C1C)N=C(N2)[N+](=O)[O-],,,,,,
1931,21932,4-Ethoxy-3-fluorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride,CC[NH+](CC)CCOC(=O)C1=CC(=C(C=C1)OCC)F.[Cl-],,,,,,
1932,21933,2-(Diethylamino)ethyl 4-ethoxy-3-fluorobenzoate,CCN(CC)CCOC(=O)C1=CC(=C(C=C1)OCC)F,,,,,,
1933,21934,4-Ethoxy-3-fluorobenzoic acid 3-(diethylamino)propyl ester hydrochloride,CC[NH+](CC)CCCOC(=O)C1=CC(=C(C=C1)OCC)F.[Cl-],,,,,,
1934,21935,3-(Diethylamino)propyl 4-ethoxy-3-fluorobenzoate,CCN(CC)CCCOC(=O)C1=CC(=C(C=C1)OCC)F,,,,,,
1935,21936,"delta(sup 2)-1,3,4-Oxadiazoline, 2-(o-chlorophenyl)-5-imino-, hydrochloride, hydrate",C1=CC=C(C(=C1)C2N=NC(=[NH2+])O2)Cl.[Cl-],,,,,,
1936,21937,"2-(2-chlorophenyl)-2H-1,3,4-oxadiazol-5-imine",C1=CC=C(C(=C1)C2N=NC(=N)O2)Cl,,,,,,
1937,21938,"5-[3-(Trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-amine",C1=CC(=CC(=C1)C(F)(F)F)C2=NN=C(O2)N,,,,,,
1938,21939,"5-Pyridin-2-yl-1,3,4-oxadiazol-2-amine",C1=CC=NC(=C1)C2=NN=C(O2)N,,,,,,
1939,21940,"5-(Pyridin-3-yl)-1,3,4-oxadiazol-2-amine",C1=CC(=CN=C1)C2=NN=C(O2)N,,,,,,
1940,21941,Acetophenazine-[d4] Dimaleate,CC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO.C(=CC(=O)O)C(=O)O,,,,,,
1941,21942,CID 21942,C1C(OC2=CC=CC=C2O1)CN=C([NH3+])N.C1C(OC2=CC=CC=C2O1)CN=C([NH3+])N.[O-]S(=O)(=O)[O-],,,,,,
1942,21943,Quindecamine,CC1=NC2=CC=CC=C2C(=C1)NCCCCCCCCCCNC3=CC(=NC4=CC=CC=C43)C,,,,,,
1943,21944,1-Prop-1-enoxybut-2-ene,CC=CCOC=CC,,,,,,
1944,21945,Methenamine hippurate,C1N2CN3CN1CN(C2)C3.C1=CC=C(C=C1)C(=O)NCC(=O)O,,,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. (See all compounds classified as Anti-Infective Agents, Urinary.)']",,,
1945,21946,"4-[(11,17-Dihydroxy-3,20-dioxopregna-1,4-dien-21-yl)oxy]-4-oxobutanoic acid--2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethan-1-ol (1/1)",CC12CC(C3C(C1CCC2(C(=O)COC(=O)CCC(=O)O)O)CCC4=CC(=O)C=CC34C)O.C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,,,,,,
1946,21947,Quinetolate,CCN(CC)C(=O)C1CC=CCC1C(=O)O.CCN(CC)C(=O)C1CC=CCC1C(=O)O.CN(C)CCNC1=C2C=C(C=CC2=NC=C1)OC,,,,,,
1947,21948,6-(Diethylcarbamoyl)cyclohex-3-ene-1-carboxylic acid,CCN(CC)C(=O)C1CC=CCC1C(=O)O,,,,,,
1948,21949,"N'-(6-Methoxy-4-quinolyl)-N,N-dimethyl-1,2-ethanediamine",CN(C)CCNC1=C2C=C(C=CC2=NC=C1)OC,,,,,,
1949,21950,Piminodine,CCOC(=O)C1(CCN(CC1)CCCNC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
1950,21951,Methyl 2-amino-3-mercaptopropanoate hydrochloride,COC(=O)C(CS)N.Cl,,,"['Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here. (See all compounds classified as Expectorants.)']",,,
1951,21952,Triclofenol piperazine,C1CNCCN1.C1=C(C(=CC(=C1Cl)Cl)Cl)O.C1=C(C(=CC(=C1Cl)Cl)Cl)O,,,,,,
1952,21953,Maleic hydrazide diethanolamine,C1=CC(=O)NNC1=O.C(CO)NCCO,,,,,,
1953,21954,Maleic hydrazide,C1=CC(=O)NNC1=O,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)', 'Any of the hormones produced naturally in plants and active in controlling growth and other functions. There are three primary classes: auxins, cytokinins, and gibberellins. (See all compounds classified as Plant Growth Regulators.)']","['...After oral doses of 100 mg/kg bw, rabbits excreted 43 to 62% maleic hydrazide unchanged in urine within 48 hr.', '(14)C Maleic hydrazide was administered orally to rats. After 3 days, very little (14)C activity was detected in tissues or blood and carbon dioxide accounted for only 0.2% of administered dose. Maleic hydrazide was rapidly excreted via urine unchanged (>90%) and as conjugate (6-8%).', 'Slowly absorbed over period of 24 hr by quackgrass. Rain within this period will reduce effectiveness. Rate of absorption is function of cell turgidity. Most effective absorption occurs when soil moisture is at field capacity and relative high humidity. Translocates more effectively downward. Once absorbed, maleic hydrazide is freely translocated to active growing points in plant. maleic hydrazide becomes fixed within the plant and is not metabolized.', 'In white ash and black locust seedlings, most of maleic hydrazide was translocated to leaves and stems of black locust seedlings within 1 day after treatment, but for white ash seedlings it remained in the stem tissue. After 30 days, the (14)C was concentrated in the leaves of the black locust seedlings, but only in the stem and at the injection point of white ash seedlings. Chromatography of the extracts showed no detectable metabolite in black locust seedlings, but 2 metabolites were detected in the white ash seedlings.', 'For more Absorption, Distribution and Excretion (Complete) data for MALEIC HYDRAZIDE (10 total), please visit the HSDB record page.']","['When applied to tea, Camelia sinensis, MH /(maleic hydrazine)/ was degraded to lactic acid, succinic acid, maleimide and hydrazine. Extracts of treated wheat seedlings... identified... beta-glycoside of MH. ...In presence of oxygen, MH undergoes photolysis to form succinic, maleic and nitric acid; and in absence of oxygen... succinic acid.', 'When applied to silver maple... and American sycamore... seedlings, maleic hydrazide translocated to all parts of the plant. In the plant tissue, a metabolite was formed. Hydrolysis products of the metabolite indicated a conjugate of maleic hydrazide and glucose. When applied to tobacco plants, (14)C maleic hydrazide was rapidly translocated to growing tissues. Translocation to roots also occurred. A small amount of (14)CO2 evolved. The major metabolite in foliar tissues was identified as the beta-D-glucoside of maleic hydrazide.', 'In one radio label experiment in rats, 77% of the administered radioactivity was recovered in urine within 6 days. 90% of the activity was found to be unaltered maleic hydrazide. The remainder was present as a conjugate of MH.', 'In rats, the urine and feces samples /collected following oral administration of 3,6-dione-labelled 14C-maleic hydrazide/ contained two peaks. Poor chromatographic separation and low levels of radiolabel in the fecal samples precluded reliable identification, but the peaks appeared to represent maleic hydrazide and possibly fumaric acid. The major peak in urine, representing 60% of the urinary radiolabel in males and 80% in females, co-chromatographed with maleic hydrazide. The minor urinary peak was initially found to co-chromatograph with maleimide, fumaric acid, or maleic diamide, depending on the solvent system, but subsequent investigation with deconjugation with a beta-glucuronidase containing sulfatase activity and HPLC showed this peak to be a maleic acid conjugate, probably a sulfate.', 'For more Metabolism/Metabolites (Complete) data for MALEIC HYDRAZIDE (7 total), please visit the HSDB record page.']",
1954,21955,alpha-((Butylamino)methyl)-p-hydroxybenzyl alcohol sulfate,CCCC[NH2+]CC(C1=CC=C(C=C1)O)O.CCCC[NH2+]CC(C1=CC=C(C=C1)O)O.[O-]S(=O)(=O)[O-],,,,,,
1955,21956,"Carbamic acid, methyl-, 5-hydroxy-1-naphthyl ester",CNC(=O)OC1=CC=CC2=C1C=CC=C2O,,,,,['4-hydroxycarbaryl is a known human metabolite of carbaryl.'],
1956,21957,2-Oxaspiro[4.4]nonan-3-one,C1CCC2(C1)CC(=O)OC2,,,,,,
1957,21958,"Pent-2-ene-1,4-dione",CC(=O)C=CC=O,,,,,,
1958,21959,3-Chloro-biphenyl-4-ylamine,C1=CC=C(C=C1)C2=CC(=C(C=C2)N)Cl,,,,,,
1959,21960,"4-Chloro-N,N,6-trimethylpyrimidin-2-amine",CC1=CC(=NC(=N1)N(C)C)Cl,,,,,,
1960,21961,Decafluorobenzhydryl bromide,C1(=C(C(=C(C(=C1F)F)F)F)F)C(C2=C(C(=C(C(=C2F)F)F)F)F)Br,,,,,,
1961,21962,"m-Cresol, 6-butyl-",CCCCC1=C(C=C(C=C1)C)O,,,,,,
1962,21963,4H-Cyclopenta[def]phenanthren-4-one,C1=CC2=C3C(=C1)C(=O)C4=CC=CC(=C43)C=C2,,,,,,
1963,21964,Methyl 4-hydroxy-4-methylpent-2-enoate,CC(C)(C=CC(=O)OC)O,,,,,,
1964,21965,"(2,4-Dichlorophenoxy)acetic acid isopropylamine salt",CC(C)[NH3+].C1=CC(=C(C=C1Cl)Cl)OCC(=O)[O-],,,,,,
1965,21966,Caffeine bromide,C[NH+]1C=NC2=C1C(=O)N(C(=O)N2C)C.[Br-],,,,,,
1966,21967,CID 21967,C([C@@H](C1C(=O)C(=C(O1)[O-])O)O)O.C([C@@H](C1C(=O)C(=C(O1)[O-])O)O)O.[Ca+2],,,,,,
1967,21968,CID 21968,C([C@@H](C1C(=O)C(=C(O1)O)O)O)O,,,,,,
1968,21969,Calcium borogluconate,B1(OC(C(O1)C(C(C(=O)[O-])O)O)CO)O.B1(OC(C(O1)C(C(C(=O)[O-])O)O)CO)O.[Ca+2],,,,,,
1969,21970,Borogluconate,B1(OC(C(O1)C(C(C(=O)O)O)O)CO)O,,,,,,
1970,21971,Tetradecahydrophenanthrene,C1CCC2C(C1)CCC3C2CCCC3,,,,,,
1971,21972,Perhydrofluorene,C1CCC2C(C1)CC3C2CCCC3,,,,,,
1972,21973,"3,4-Dimethoxy-alpha-((isopropylamino)methyl)benzyl alcohol",CC(C)NCC(C1=CC(=C(C=C1)OC)OC)O,,,,,,
1973,21974,"Stevane, 13-hydroxy-",CC1CC23CCC4C(CCCC4(C2CCC1(C3)O)C)(C)C,,,,,,
1974,21975,Carbasalate calcium,CC(=O)OC1=CC=CC=C1C(=O)[O-].CC(=O)OC1=CC=CC=C1C(=O)[O-].C(=O)(N)N.[Ca+2],,,"['Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']",,,
1975,21976,"(6S,9S,10S,12R,13S,14S,16R,19S,22S,23S,25R)-6,10,19-trimethyl-24-oxa-4-azoniaheptacyclo[12.12.0.02,11.04,9.015,25.018,23.019,25]hexacosane-10,12,13,14,16,22,23-heptol;chloride",C[C@H]1CC[C@H]2[C@@](C3[C@H]([C@@H]([C@@]4(C(C3C[NH+]2C1)C[C@@]56C4[C@@H](CC7[C@@]5(CC[C@@H]([C@]7(O6)O)O)C)O)O)O)O)(C)O.[Cl-],,,,,,
1976,21977,CID 21977,C[C@H]1CC[C@H]2[C@@](C3[C@H](C([C@@]4(C(C3CN2C1)C[C@@]56C4[C@@H](CC7[C@@]5(CC[C@@H]([C@]7(O6)O)O)C)O)O)O)O)(C)O,,,,,,
1977,21978,"Ethylenediamine, N,N,N',N'-tetraethylthiomethyl-",CCSCN(CCN(CSCC)CSCC)CSCC,,,,,,
1978,21979,"2,2-Dipropyl-1,3-dioxolane-4-methanol",CCCC1(OCC(O1)CO)CCC,,,,,,
1979,21980,"2-Ethyl-2-pentyl-1,3-dioxolane-4-methanol",CCCCCC1(OCC(O1)CO)CC,,,,,,
1980,21981,"Imidazolidine, 1,3-dinitro-",C1CN(CN1[N+](=O)[O-])[N+](=O)[O-],,,,,,
1981,21982,"s-Triazine, 2,4,6-tris(methylthio)-",CSC1=NC(=NC(=N1)SC)SC,,,,,,
1982,21983,Methylphenylphosphinic chloride,CP(=O)(C1=CC=CC=C1)Cl,,,,,,
1983,21984,(Ethylenedinitrilo)tetraacetonitrile,C(CN(CC#N)CC#N)N(CC#N)CC#N,,,,,,
1984,21985,"N,N'-Dicyanomethyl-N,N'-dimethylethylenediamine",CN(CCN(C)CC#N)CC#N,,,,,,
1985,21986,"Acetonitrile, 2,2'-((6-chloro-1,3,5-triazine-2,4-diyl)diimino)bis-",C(C#N)NC1=NC(=NC(=N1)Cl)NCC#N,,,,,,
1986,21987,"Acetonitrile, 2,2'-((6-amino-1,3,5-triazine-2,4-diyl)diimino)bis-",C(C#N)NC1=NC(=NC(=N1)N)NCC#N,,,,,,
1987,21988,N-Benzylideneanthranilic acid,C1=CC=C(C=C1)C=NC2=CC=CC=C2C(=O)O,,,,,,
1988,21989,2-Phenyl-2-piperidinoacetonitrile,C1CCN(CC1)C(C#N)C2=CC=CC=C2,,,,,,
1989,21990,"6H,13H-DIPYRIDAZINO(1,2-a:1',2'-d)-s-TETRAZINE, OCTAHYDRO-",C1CCN2CN3CCCCN3CN2C1,,,,,,
1990,21991,"o-CRESOL, alpha,alpha'-(TRIMETHYLENENITRILO)BIS(6-METHOXY-",COC1=CC=CC(=C1O)CN=CCC=NCC2=C(C(=CC=C2)OC)O,,,,,,
1991,21992,"2-Methyl-2-phenyl-1,3-dithiolane",CC1(SCCS1)C2=CC=CC=C2,,,,,,
1992,21993,"2-Phenyl-2-propyl-1,3-dithiolane",CCCC1(SCCS1)C2=CC=CC=C2,,,,,,
1993,21994,2-(5-Nitrofurylvinyl)quinoline-4-carboxylic acid,C1=CC=C2C(=C1)C(=CC(=N2)C=CC3=CC=C(O3)[N+](=O)[O-])C(=O)O,,,,,,
1994,21995,"p-PHENYLENEDIAMINE, N,N-DIETHYL-N',N'-DIMETHYL-",CCN(CC)C1=CC=C(C=C1)N(C)C,,,,,,
1995,21996,"2-Pyrazoline, 1,5-dimethyl-",CC1CC=NN1C,,,,,,
1996,21997,9-Amino-10-methylacridinium chloride,C[N+]1=C2C=CC=CC2=C(C3=CC=CC=C31)N.[Cl-],,,,,,
1997,21998,9-Amino-10-methylacridinium,C[N+]1=C2C=CC=CC2=C(C3=CC=CC=C31)N,,,,,,
1998,21999,10-Methylacridinium chloride,C[N+]1=C2C=CC=CC2=CC3=CC=CC=C31.[Cl-],,,,,,
1999,22000,10-Methylacridinium,C[N+]1=C2C=CC=CC2=CC3=CC=CC=C31,,,,,,
2000,22001,"11H-CYCLOHEPTA(b)QUINOLIN-11-ONE, 5,6,7,8,9,10-HEXAHYDRO-4-METHOXY-",COC1=CC=CC2=C1NC3=C(C2=O)CCCCC3,,,,,,
2001,22002,"11H-CYCLOHEPTA(b)QUINOLIN-11-ONE, 5,6,7,8,9,10-HEXAHYDRO-4-CHLORO-",C1CCC2=C(CC1)NC3=C(C2=O)C=CC=C3Cl,,,,,,
2002,22003,"11H-CYCLOHEPTA(b)QUINOLIN-11-ONE, 5,6,7,8,9,10-HEXAHYDRO-2-CHLORO-",C1CCC2=C(CC1)NC3=C(C2=O)C=C(C=C3)Cl,,,,,,
2003,22004,"6H-CYCLOHEPTA(b)QUINOLINE, 7,8,9,10-TETRAHYDRO-11-CHLORO-4-METHOXY-",COC1=CC=CC2=C1N=C3CCCCCC3=C2Cl,,,,,,
2004,22005,"6H-CYCLOHEPTA(b)QUINOLINE, 7,8,9,10-TETRAHYDRO-11-AMINO-2-METHYL-",CC1=CC2=C(C=C1)N=C3CCCCCC3=C2N,,,,,,
2005,22006,"6H-CYCLOHEPTA(b)QUINOLINE, 7,8,9,10-TETRAHYDRO-11-AMINO-",C1CCC2=C(C3=CC=CC=C3N=C2CC1)N,,,,,,
2006,22007,"2-methoxy-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolin-11-amine",COC1=CC2=C(C=C1)N=C3CCCCCC3=C2N,,,,,,
2007,22008,"6H-CYCLOHEPTA(b)QUINOLINE, 7,8,9,10-TETRAHYDRO-11-AMINO-4-METHYL-",CC1=C2C(=CC=C1)C(=C3CCCCCC3=N2)N,,,,,,
2008,22009,"6H-CYCLOHEPTA(b)QUINOLINE, 7,8,9,10-TETRAHYDRO-11-AMINO-4-CHLORO-",C1CCC2=C(CC1)N=C3C(=C2N)C=CC=C3Cl,,,,,,
2009,22010,"6H-CYCLOHEPTA(b)QUINOLINE, 7,8,9,10-TETRAHYDRO-11-AMINO-4-ETHYL-",CCC1=C2C(=CC=C1)C(=C3CCCCCC3=N2)N,,,,,,
2010,22011,CID 22011,CCN1C2=CC=CC=C2SC1=CC=CC3=[N+](C4=CC=CC=C4S3)CC.C1=C(C(=CC(=C1Cl)Cl)Cl)O.C1=C(C(=CC(=C1Cl)Cl)Cl)O.C1=C(C(=CC(=C1Cl)Cl)Cl)O,,,,,,
2011,22012,24-Ethylcholest-5-en-3beta-ol,CC[C@H](CC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CCC(C4)O)C)C)C(C)C,,,,,,
2012,22013,"2,4,5-Trimethylbenzaldehyde",CC1=CC(=C(C=C1C)C=O)C,,,,,,
2013,22014,"3,4'-Ace-1,2-benzanthracene",C1CC2=CC3=CC4=CC=CC=C4C=C3C5=CC=CC1=C25,,,,,,
2014,22015,"2,5-Dimethylbenzaldehyde",CC1=CC(=C(C=C1)C)C=O,,,,,,
2015,22016,"1,3-Benzodioxole-5-carboxaldehyde, 7-methoxy-",COC1=CC(=CC2=C1OCO2)C=O,,,,,,
2016,22017,Cycliramine,CN1CCC(=C(C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CC1,,,,,,
2017,22018,CID 22018,CCCC=COC1C(NC(=O)N1)OC=CCCC,,,,,,
2018,22019,"INDOLE, 2,3-BIS(p-METHOXYPHENYL)-1-(3-(DIETHYLAMINO)PROPYL)-",CCN(CC)CCCN1C2=CC=CC=C2C(=C1C3=CC=C(C=C3)OC)C4=CC=C(C=C4)OC,,,,,,
2019,22020,"INDOLE, 2,3-BIS(p-(2-(DIETHYLAMINO)ETHOXY)PHENYL)-",CCN(CC)CCOC1=CC=C(C=C1)C2=C(NC3=CC=CC=C32)C4=CC=C(C=C4)OCCN(CC)CC,,,,,,
2020,22021,"Acridine, 1,2,3,4-tetrahydro-9-piperidino-",C1CCN(CC1)C2=C3CCCCC3=NC4=CC=CC=C42,,,,,,
2021,22022,"6H-CYCLOHEPTA(b)QUINOLINE, 7,8,9,10-TETRAHYDRO-11-PYRROLIDINO-",C1CCC2=C(C3=CC=CC=C3N=C2CC1)N4CCCC4,,,,,,
2022,22023,"Acridine, 1,2,3,4-tetrahydro-9-(2-(3,4-dimethoxyphenyl)ethyl)amino-",COC1=C(C=C(C=C1)CCNC2=C3CCCCC3=NC4=CC=CC=C42)OC,,,,,,
2023,22024,"6H-CYCLOHEPTA(b)QUINOLINE, 7,8,9,10-TETRAHYDRO-11-(4-METHYL-1-PIPERAZINYL)-",CN1CCN(CC1)C2=C3CCCCCC3=NC4=CC=CC=C42,,,,,,
2024,22025,"6H-CYCLOHEPTA(b)QUINOLINE, 7,8,9,10-TETRAHYDRO-11-PIPERIDINO-",C1CCC2=C(C3=CC=CC=C3N=C2CC1)N4CCCCC4,,,,,,
2025,22026,"ANILINE, N-ETHYL-p-((p-NITROPHENYL)THIO)-",CCNC1=CC=C(C=C1)SC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
2026,22027,But-2-enedioic acid;2-piperazin-1-ylquinoline,C1CN(CCN1)C2=NC3=CC=CC=C3C=C2.C(=CC(=O)O)C(=O)O,,,,,,
2027,22028,Ohton hydrochloride,CC(C=C(C1=CC=CS1)C2=CC=CS2)[NH+](C)C.[Cl-],,,,,,
2028,22029,"2-Methylamino-heptane, hydrochloride",CCCCCC(C)[NH2+]C.[Cl-],,,,,,
2029,22030,CID 22030,CC(C1=CC=CC=C1)C(C)(C)[NH3+].C(=C(O)O)(C(=O)C(=O)[O-])O,,,,,,
2030,22031,Pentorex,CC(C1=CC=CC=C1)C(C)(C)N,,,,,,
2031,22032,Trimetamide,CC1=NC(=C(C=C1)CNC(=O)C2=CC(=C(C(=C2)OC)OC)OC)N,,,,,,
2032,22033,"2-Benzoxazolinone, 5-chloro-3-methyl-",CN1C2=C(C=CC(=C2)Cl)OC1=O,,,,,,
2033,22034,"2-Benzoxazolinone, 5-chloro-3-ethyl-",CCN1C2=C(C=CC(=C2)Cl)OC1=O,,,,,,
2034,22035,"6-Chloro-2-methyl-2H-1,4-benzoxazin-3(4H)-one",CC1C(=O)NC2=C(O1)C=CC(=C2)Cl,,,,,,
2035,22036,"D-Glucaric acid, calcium salt (1:1)",C(C(C(C(=O)[O-])O)O)(C(C(=O)[O-])O)O.[Ca+2],,,,,,
2036,22037,Calcium stearoyl-2-lactylate,CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C(=O)[O-].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C(=O)[O-].[Ca+2],,,,,,
2037,22038,Stearolac,CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C(=O)O,,,,,,
2038,22039,Calcium sulphidoacetate,C(C(=O)[O-])[S-].[Ca+2],,,,,,
2039,22040,Dopa hydrochloride,C1=CC(=C(C=C1CC(C(=O)O)[NH3+])O)O.[Cl-],,,,,,
2040,22041,Peroxypropionyl nitrate,CCC(=O)OO[N+](=O)[O-],,,,,,
2041,22042,CID 22042,C(C(=O)O)[NH+](CC(=O)[O-])CC(=O)[O-].C(C(=O)[O-])[NH+](CC(=O)[O-])CC(=O)[O-].O=[BiH].[Na+].[Na+].[Na+],,,,,,
2042,22043,Ethyl 4-bromobenzoate,CCOC(=O)C1=CC=C(C=C1)Br,,,,,,
2043,22044,Bromobenzyl cyanide,C1=CC=C(C=C1)C(C#N)Br,,,,,,
2044,22045,CID 22045,C1=CC(=C(C=C1Br)C(=O)NO)[O-].[Na+],,,,,,
2045,22046,5-Bromosalicylhydroxamic acid,C1=CC(=C(C=C1Br)C(=O)NO)O,,,,,,
2046,22047,Metiapine,CC1=CC2=C(C=C1)SC3=CC=CC=C3N=C2N4CCN(CC4)C,,,,,,
2047,22048,Methyl hexacosanoate,CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)OC,,,,,,
2048,22049,"1,3,6,8-Tetrahydroxy-2-(1-hydroxyhexyl)anthraquinone",CCCCCC(C1=C(C=C2C(=C1O)C(=O)C3=C(C2=O)C=C(C=C3O)O)O)O,,,,,,
2049,22050,CID 22050,CC[C@@H](C)[NH2+]C[C@H](C1=CC2=C(CCCC2)C=C1)O.[Cl-],,,,,,
2050,22051,"(1S)-2-[[(2R)-butan-2-yl]amino]-1-(5,6,7,8-tetrahydronaphthalen-2-yl)ethanol",CC[C@@H](C)NC[C@H](C1=CC2=C(CCCC2)C=C1)O,,,,,,
2051,22052,"Benzyl alcohol, 5-amino-2-(octyloxy)-",CCCCCCCCOC1=C(C=C(C=C1)N)CO,,,,,,
2052,22053,(2-Aminoethoxy)trimethylsilane,C[Si](C)(C)OCCN,,,,,,
2053,22054,1-Ethyl-2-methylbenzimidazole,CCN1C(=NC2=CC=CC=C21)C,,,,,,
2054,22055,Morpholinoacetonitrile,C1COCCN1CC#N,,,,,,
2055,22056,Dioxyline hydrochloride,CCOC1=C(C=C(C=C1)CC2=[NH+]C(=CC3=CC(=C(C=C32)OC)OC)C)OC.[Cl-],,,,,,
2056,22057,Dipropamine,CC[N+](C)(C)CCCOC1=CC=C(C=C1)OCCC[N+](C)(C)CC.[I-].[I-],,,,,,
2057,22058,Ethyl-[3-[4-[3-[ethyl(dimethyl)azaniumyl]propoxy]phenoxy]propyl]-dimethylazanium,CC[N+](C)(C)CCCOC1=CC=C(C=C1)OCCC[N+](C)(C)CC,,,,,,
2058,22059,1-Acetylhexahydro-1H-azepine,CC(=O)N1CCCCCC1,,,,,,
2059,22060,2-Hydroxy-3-butenenitrile,C=CC(C#N)O,,,,,,
2060,22061,"Ethane, 1,1-bis(2,4-xylyl)-2,2,2-trichloro-",CC1=CC(=C(C=C1)C(C2=C(C=C(C=C2)C)C)C(Cl)(Cl)Cl)C,,,,,,
2061,22062,"Phosphorodithioic acid, O,O-bis(2-ethylhexyl) ester",CCCCC(CC)COP(=S)(OCC(CC)CCCC)S,,,,,,
2062,22063,2-Thiophenecarboxamide,C1=CSC(=C1)C(=O)N,,,,,,
2063,22064,Tetramethylarsonium iodide,C[As+](C)(C)C.[I-],,,,,,
2064,22065,Tetramethylarsonium,C[As+](C)(C)C,,,,,,
2065,22066,"Benzylamine, N-(3-chloropropyl)-N-methyl-, hydrochloride",C[NH+](CCCCl)CC1=CC=CC=C1.[Cl-],,,,,,
2066,22067,N-benzyl-3-chloro-N-methylpropan-1-amine,CN(CCCCl)CC1=CC=CC=C1,,,,,,
2067,22068,"1,2-Diphenylpropane",CC(CC1=CC=CC=C1)C2=CC=CC=C2,,,,,,
2068,22069,"DL-3,3',5'-Triiodothyronine",C1=CC(=C(C=C1CC(C(=O)O)N)I)OC2=CC(=C(C(=C2)I)O)I,,,,,,
2069,22070,Bis(2-chloroethyl) sulfoxide,C(CCl)S(=O)CCCl,,,,,,
2070,22071,"Formamide, N-(5-amino-2-((5-(1,3-dioxoisoindolin-2-YL)pentyl)oxy)benzyl)-",C1=CC=C2C(=C1)C(=O)N(C2=O)CCCCCOC3=C(C=C(C=C3)N)CNC=O,,,,,,
2071,22072,"METHANE, BIS-(o-METHOXYPHENYL)-",COC1=CC=CC=C1CC2=CC=CC=C2OC,,,,,,
2072,22073,Bis-(5-dimethylaminomethyl-2-methoxyphenyl)methane dihydrochloride,C[NH+](C)CC1=CC(=C(C=C1)OC)CC2=C(C=CC(=C2)C[NH+](C)C)OC.[Cl-].[Cl-],,,,,,
2073,22074,"1-[3-[[5-[(dimethylamino)methyl]-2-methoxyphenyl]methyl]-4-methoxyphenyl]-N,N-dimethylmethanamine",CN(C)CC1=CC(=C(C=C1)OC)CC2=C(C=CC(=C2)CN(C)C)OC,,,,,,
2074,22075,"AMMONIUM, (m-HYDROXYPHENYL)TRIMETHYL-, METHYLSULFATE, DIETHYLPHOSPHATE",CCOP(=O)(OCC)OC1=CC=CC(=C1)[N+](C)(C)C.COS(=O)(=O)[O-],,,,,,
2075,22076,"3-[(Diethoxyphosphinyl)oxy]-N,N,N-trimethylbenzenaminium",CCOP(=O)(OCC)OC1=CC=CC(=C1)[N+](C)(C)C,,,,,,
2076,22077,"1,2,3,4,7-Pentachlorobicyclo[2.2.1]hept-2-ene",C1CC2(C(C1(C(=C2Cl)Cl)Cl)Cl)Cl,,,,,,
2077,22078,2-(3-Chlorophenoxy)propionamide,CC(C(=O)N)OC1=CC(=CC=C1)Cl,,,,,,
2078,22079,"Phosphorothioic acid, O,O-diethyl O-(2-propyl-4-methyl-6-pyrimidyl) ester",CCCC1=CC(=NC(=N1)C)OP(=S)(OCC)OCC,,,,,,
2079,22080,"N,N-Diethylthiocarbamyl O,O-diisopropyldithiophosphate",CCN(CC)C(=S)SP(=S)(OC(C)C)OC(C)C,,,,,,
2080,22081,"Carbamic acid, diethyldithio-, anhydrosulfide with O,O-dipropylphosphorodithioate, compd. with hydrogen sulfide (1:1)",CCCOP(=S)(OCCC)SC(=S)N(CC)CC.S,,,,,,
2081,22082,"dipropoxyphosphinothioyl N,N-diethylcarbamodithioate",CCCOP(=S)(OCCC)SC(=S)N(CC)CC,,,,,,
2082,22083,Aphidan,CCS(=O)CSP(=S)(OC(C)C)OC(C)C,,,,,,
2083,22084,"N,N-Dimethylhexanamide",CCCCCC(=O)N(C)C,,,,,,
2084,22085,"Ethyl bis(2,4-dinitrophenyl)acetate",CCOC(=O)C(C1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-])C2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
2085,22086,3-Amino-2-methoxydibenzofuran,COC1=C(C=C2C(=C1)C3=CC=CC=C3O2)N,,,,,,
2086,22087,"Acetamide, N-3-dibenzofuranyl-",CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3O2,,,,,,
2087,22088,alpha-Isopropyl-alpha-2-methylethylaminoethyl-1-naphthylacetic acid hydrochloride,CC[NH+](C)CCC(C1=CC=CC2=CC=CC=C21)(C(C)C)C(=O)O.[Cl-],,,,,,
2088,22089,2-[2-[Ethyl(methyl)amino]ethyl]-3-methyl-2-naphthalen-1-ylbutanoic acid,CCN(C)CCC(C1=CC=CC2=CC=CC=C21)(C(C)C)C(=O)O,,,,,,
2089,22090,CID 22090,CN(C)N=C(S)SSC(=NN(C)C)S,,,,,,
2090,22091,Acrolein phenylhydrazone,C=CC=NNC1=CC=CC=C1,,,,,,
2091,22092,"(1R,4aR)-7-ethenyl-1,4a,7-trimethyl-3,4,4b,5,6,8,10,10a-octahydro-2H-phenanthrene-1-carboxylic acid",C[C@]12CCC[C@@](C1CC=C3C2CCC(C3)(C)C=C)(C)C(=O)O,,,,,,
2092,22093,N-Dodecylguanidine acid phthalate,CCCCCCCCCCCCN=C(N)N.C1=CC=C(C(=C1)C(=O)O)C(=O)O,,,,,,
2093,22094,Chloropropylate,CC(C)OC(=O)C(C1=CC=C(C=C1)Cl)(C2=CC=C(C=C2)Cl)O,,,,"['In varying degrees, organochlorines are absorbed from the gut and also by the lung and across the skin. /Soild Organochlorines/', 'Metabolic studies extending over 10 days were performed on pairs of dogs (one male and one female) treated orally with technical chloropropylate at 12.8 or 64.1 mg/kg on five consecutive days. Urinary excretion accounted for 5.2 and 33.2% of the total dose in the urine of the males at low and high dose levels, the corresponding figures for the female being 3.2 and 33.7%. In the feces, 6.4 and 3.4% were detected in the male, at low and high doses respectively, and 16.9 and 7.3% in the female. No residues were detected in blood, brain, fat, liver, kidney or muscle at sacrifice. The method of analysis employed would not detect dichlorobenzilic acid conjugates. The presence of the probable metabolite, dichlorobenzilic acid has been demonstrated in dog urine, by thin layer chromatography.', 'When (14)carbon-labelled chloropropylate was administered orally to pairs of male and female rats at about 1.6 mg/kg the radioactivity was excreted in the urine and feces. No radioactive carbon dioxide was expired. The excretion pattern of the radioactivity differed between the two sexes, the male voiding 75% of the dose in the feces, and 6% in the urine, and the female 49% in the feces and 31% in the urine. Most of the radioactivity was eliminated in the first 48 hours. The total tissue residue of radioactivity 120 hours after administration was 0.9% and 1.0% in the male and female respectively. The majority of these residues were in the liver and fat.', 'When chloropropylate was fed to cow, major route of elimination was via urine (more than 80% of total dose). ... Chloropropylate was stable (up to 7 hr) in rumen fluid but decomposed in 10,000xg supernatant fraction of beef liver.', 'For more Absorption, Distribution and Excretion (Complete) data for CHLOROPROPYLATE (6 total), please visit the HSDB record page.']","[""When chloropropylate was fed to cow, major route of elimination was via urine (more than 80% of total dose). About 28% of material was identified as 4,4'-dichlorobenzilic acid and 55% as conjugates, not further identified. ... Spider mites and house flies ... metabolized chloropropylate to corresponding chlorine-containing analogs of benzilic acid, benzhydrol, benzophenone, and benzoic acid."", ""... Chlorobenzilate (CB), chloroprppylate (CP), orbromopropylate (BP). Samples were incubated aerobically for 4 hours in flasks in a water bath at 37 degrees-C. Major metabolites from degradation were identified by cochromatography. The metabolites were subjected to infrared analysis and mass spectrometry. CB, CP, and BP were degraded by the rat liver preparations; however, CB was metabolized appreciably more than the other two acaricides. The maximum activity with CB was associated with the nuclear supernatant and the microsomal fractions. The major degradation products were 4,4'-dichlorobenzophenone (DBP) and p-chlorobenzoic-acid (CBA). For CP, the nuclear and mitochondrial fractions were the most active. The major metabolite was DBP.  More than 93 percent of remained after 4 hours of incubation. p-Bromobenzoic-acid BP was the major metabolite."", '... Rats fed C-14 chloropropylate in a single dose at level simulating a dietary intake of 35 ppm were found to eliminate three radioactive components in the urine and feces. ... No respired radioactivity could be demonstrated. Analysis of internal organs resulted in the recovery of significant amounts of radioactivity in the kidney, liver, heart, stomach contents, and gastrointestinal tract.', ""... Three identified metabolites resulting from the degradation of /chloropropylate/, were 4,4'-dichlorobenzilic acid, 4,4'-dichlorobenzophenone, and carbon dioxide."", 'For more Metabolism/Metabolites (Complete) data for CHLOROPROPYLATE (6 total), please visit the HSDB record page.']",
2094,22095,CID 22095,C1CC(C2=CC=CC=C2C1)C3=C(OC4=CC=CC=C4C3=O)O,,,,,,
2095,22096,"Maleic anhydride, dihydroxy-, dipropionate",CCC(=O)OC1=C(C(=O)OC1=O)OC(=O)CC,,,,,,
2096,22097,Dihydroxymaleic anhydride bis(hydrocinnamate),C1=CC=C(C=C1)CCC(=O)OC2=C(C(=O)OC2=O)OC(=O)CCC3=CC=CC=C3,,,,,,
2097,22098,Dihydroxymaleic anhydride bis(3-chloropropionate),C(CCl)C(=O)OC1=C(C(=O)OC1=O)OC(=O)CCCl,,,,,,
2098,22099,"4-(4-Morpholinyl)-2,3-pentamethylenequinoline",C1CCC2=C(C3=CC=CC=C3N=C2CC1)N4CCOCC4,,,,,,
2099,22100,ethyl N-(2-dimethoxyphosphinothioylsulfanylethyl)carbamate,CCOC(=O)NCCSP(=S)(OC)OC,,,,,,
2100,22101,N-(p-Chloro-alpha-methylphenethyl)-N-methylfurfurylamine cyclohexanesulfamate,CC(CC1=CC=C(C=C1)Cl)[NH+](C)CC2=CC=CO2.C1CCC(CC1)NS(=O)(=O)[O-],,,,,,
2101,22102,1-(4-chlorophenyl)-N-(furan-2-ylmethyl)-N-methylpropan-2-amine,CC(CC1=CC=C(C=C1)Cl)N(C)CC2=CC=CO2,,,,,,
2102,22103,"Furfurylamine, N-methyl-N-(alpha-methyl-m-(trifluoromethyl)phenethyl)-, cyclohexanesulfamate (+-)-",CC(CC1=CC(=CC=C1)C(F)(F)F)[NH+](C)CC2=CC=CO2.C1CCC(CC1)NS(=O)(=O)[O-],,,,,,
2103,22104,N-(furan-2-ylmethyl)-N-methyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine,CC(CC1=CC(=CC=C1)C(F)(F)F)N(C)CC2=CC=CO2,,,,,,
2104,22105,Atropine octabromide,CCCCCCCC[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-],,,,,,
2105,22106,(8-Methyl-8-octyl-8-azoniabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate,CCCCCCCC[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C,,,,,,
2106,22107,Tiazesim,CN(C)CCN1C(=O)CC(SC2=CC=CC=C21)C3=CC=CC=C3,,,,,,
2107,22108,"2,5-Dichloro-4-nitrophenol",C1=C(C(=CC(=C1Cl)O)Cl)[N+](=O)[O-],,,,,,
2108,22109,2-Bromo-4-nitrophenol,C1=CC(=C(C=C1[N+](=O)[O-])Br)O,,,,,,
2109,22110,Acid Brown 14,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])NN=C3C=CC(=O)C(=NNC4=CC=C(C5=CC=CC=C54)S(=O)(=O)[O-])C3=O.[Na+].[Na+],,,,,,
2110,22111,"4-[2-[4,6-Dioxo-5-[(4-sulfonaphthalen-1-yl)hydrazinylidene]cyclohex-2-en-1-ylidene]hydrazinyl]naphthalene-1-sulfonic acid",C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)O)NN=C3C=CC(=O)C(=NNC4=CC=C(C5=CC=CC=C54)S(=O)(=O)O)C3=O,,,,,,
2111,22112,Acid red 41,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])N=NC3=C(C(=CC4=CC(=CC(=C43)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+].[Na+].[Na+],,,,,,
2112,22113,"7-Hydroxy-8-[(4-sulfo-1-naphthyl)azo]-1,3,6-naphthalenetrisulfonic acid",C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)O)N=NC3=C(C(=CC4=CC(=CC(=C43)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)O,,,,,,
2113,22114,CID 22114,C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC(=C(C=C3S(=O)(=O)[O-])Cl)Cl)O.[Na+],,,,,,
2114,22115,"4,5-Dichloro-2-[(2-hydroxynaphthalen-1-yl)diazenyl]benzenesulfonic acid",C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC(=C(C=C3S(=O)(=O)O)Cl)Cl)O,,,,,,
2115,22116,CID 22116,CC1=C(C=CC(=C1)S(=O)(=O)[O-])N=NC2=C(C=CC3=CC=CC=C32)O.[Na+],,,,,,
2116,22117,4-[(2-Hydroxy-1-naphthyl)azo]-m-toluenesulphonic acid,CC1=C(C=CC(=C1)S(=O)(=O)O)N=NC2=C(C=CC3=CC=CC=C32)O,,,,,,
2117,22118,CID 22118,CC1=CC(=C(C=C1Cl)N=NC2=C(C=CC3=CC=CC=C32)O)S(=O)(=O)[O-].[Na+],,,,,,
2118,22119,4-Chloro-2-[(2-hydroxy-1-naphthalenyl)azo]-5-methylbenzenesulfonic acid,CC1=CC(=C(C=C1Cl)N=NC2=C(C=CC3=CC=CC=C32)O)S(=O)(=O)O,,,,,,
2119,22120,"O,O-Diallyl dithiophosphate",C=CCOP(=S)(OCC=C)S,,,,,,
2120,22121,2-isopropyl-1H-benzo[d]imidazole,CC(C)C1=NC2=CC=CC=C2N1,,,,,,
2121,22122,2-Butyl-1H-benzimidazole,CCCCC1=NC2=CC=CC=C2N1,,,,,,
2122,22123,2-Pentyl-1H-benzimidazole,CCCCCC1=NC2=CC=CC=C2N1,,,,,,
2123,22124,(-)-Caulophylline methyl iodide,C[N+]1(CC2CC(C1)C3=CC=CC(=O)N3C2)C.[I-],,,,,,
2124,22125,"11,11-Dimethyl-6-oxo-7-aza-11-azoniatricyclo[7.3.1.0~2,7~]trideca-2,4-diene iodide",C[N+]1(CC2CC(C1)C3=CC=CC(=O)N3C2)C,,,,,,
2125,22126,"(1R)-1-[[(3R)-3-ethyl-9,10-dimethoxy-1,2,3,4,5,6,7,11b-octahydrobenzo[a]quinolizin-5-ium-2-yl]methyl]-7-methoxy-1,2,3,4-tetrahydroisoquinolin-2-ium-6-ol;dichloride",CC[C@H]1C[NH+]2CCC3=CC(=C(C=C3C2CC1C[C@@H]4C5=CC(=C(C=C5CC[NH2+]4)O)OC)OC)OC.[Cl-].[Cl-],,,,,,
2126,22127,"(1R)-1-[[(3R)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]methyl]-7-methoxy-1,2,3,4-tetrahydroisoquinolin-6-ol",CC[C@H]1CN2CCC3=CC(=C(C=C3C2CC1C[C@@H]4C5=CC(=C(C=C5CCN4)O)OC)OC)OC,,,,,,
2127,22128,CID 22128,C([C@@H](C(=O)O)N)N(N=O)O,,,,,,
2128,22129,2-Aminobutan-1-ol,CCC(CO)N,,,,,,
2129,22130,"2,3-Epoxy-p-menthane",CC1CCC(C2C1O2)C(C)C,,,,,,
2130,22131,2-Furylmercury chloride,C1=COC(=C1)[Hg]Cl,,,,,,
2131,22132,"Methyl 4,4,4-trinitrobutyrate",COC(=O)CCC([N+](=O)[O-])([N+](=O)[O-])[N+](=O)[O-],,,,,,
2132,22133,3-Amino-5-chloro-4-hydroxybenzenesulfonic acid,C1=C(C=C(C(=C1N)O)Cl)S(=O)(=O)O,,,,,,
2133,22134,Acid Red 17,C1=CC=C2C(=C1)C=CC=C2N=NC3=C4C=CC(=CC4=CC(=C3O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
2134,22135,Bordeaux Red,C1=CC=C2C(=C1)C=CC=C2N=NC3=C4C=CC(=CC4=CC(=C3O)S(=O)(=O)O)S(=O)(=O)O,,,,,,
2135,22136,CID 22136,COC1=CC=CC=C1N=NC2=C(C3=CC=CC=C3C(=C2)S(=O)(=O)[O-])O.[Na+],,,,,,
2136,22137,4-Hydroxy-3-[(2-methoxyphenyl)diazenyl]naphthalene-1-sulfonic acid,COC1=CC=CC=C1N=NC2=C(C3=CC=CC=C3C(=C2)S(=O)(=O)O)O,,,,,,
2137,22138,CID 22138,CC1=CC(=C(C=C1)N=NC2=C(C(=CC3=CC=CC=C32)C(=O)[O-])O)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
2138,22139,3-Hydroxy-4-[(4-methyl-2-sulphophenyl)azo]-2-naphthoic acid,CC1=CC(=C(C=C1)N=NC2=C(C(=CC3=CC=CC=C32)C(=O)O)O)S(=O)(=O)O,,,,,,
2139,22140,Acid red 25,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O-])N=NC3=C(C=CC4=C3C(=CC=C4)S(=O)(=O)[O-])O.[Na+].[Na+],,,,,,
2140,22141,7-Hydroxy-8-[(4-sulfonaphthalen-1-yl)diazenyl]naphthalene-1-sulfonic acid,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)O)N=NC3=C(C=CC4=C3C(=CC=C4)S(=O)(=O)O)O,,,,,,
2141,22142,"2,7-Naphthalenedisulfonic acid, 3-hydroxy-4-(phenylazo)-, disodium salt",C1=CC=C(C=C1)N=NC2=C3C=CC(=CC3=CC(=C2O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
2142,22143,"3-Hydroxy-4-(phenylazo)-2,7-naphthalenedisulfonic acid",C1=CC=C(C=C1)N=NC2=C3C=CC(=CC3=CC(=C2O)S(=O)(=O)O)S(=O)(=O)O,,,,,,
2143,22144,1-(4'-Nitrophenylazo)-2-hydroxy-6-sulfonaphthalene,C1=CC(=CC=C1N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)O)O)[N+](=O)[O-],,,,,,
2144,22145,6-Hydroxy-5-(p-tolylazo)-2-naphthalenesulfonic acid,CC1=CC=C(C=C1)N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)O)O,,,,,,
2145,22146,"2,6-Bis(chloromethyl)-4-methylphenol",CC1=CC(=C(C(=C1)CCl)O)CCl,,,,,,
2146,22147,"1,3-Dithiolane-4-methanol",C1C(SCS1)CO,,,,,,
2147,22148,"2,2,4-Trimethyl-1,3-dithiolane",CC1CSC(S1)(C)C,,,,,,
2148,22149,CI-628 citrate,COC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)[N+](=O)[O-])C3=CC=C(C=C3)OCCN4CCCC4.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,,,['Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. (See all compounds classified as Estrogen Antagonists.)'],,,
2149,22150,Nitromifene,COC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)[N+](=O)[O-])C3=CC=C(C=C3)OCCN4CCCC4,,,['Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. (See all compounds classified as Estrogen Antagonists.)'],,,
2150,22151,Acid Blue 15,CCN(CC)C1=CC(=C(C=C1)C(=C2C=CC(=[N+](CC)CC3=CC(=CC=C3)S(=O)(=O)[O-])C=C2)C4=CC=C(C=C4)N(CC)CC5=CC(=CC=C5)S(=O)(=O)[O-])C.[Na+],,,,,,
2151,22152,"(1E,4E)-4-{[4-(Diethylamino)-2-methylphenyl](4-{ethyl[(3-sulfophenyl)methyl]amino}phenyl)methylidene}-N-ethyl-N-[(3-sulfophenyl)methyl]cyclohexa-2,5-dien-1-iminium",CCN(CC)C1=CC(=C(C=C1)C(=C2C=CC(=[N+](CC)CC3=CC(=CC=C3)S(=O)(=O)O)C=C2)C4=CC=C(C=C4)N(CC)CC5=CC(=CC=C5)S(=O)(=O)O)C,,,,,,
2152,22153,CID 22153,CCN=C(N=C(N)S)S,,,,,,
2153,22154,"2,6-Naphthalenedisulfonic acid, 4-hydroxy-3-((2-methoxy-5-methylphenyl)azo)-, disodium salt",CC1=CC(=C(C=C1)OC)N=NC2=C(C=C3C=CC(=CC3=C2O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
2154,22155,"3-[2-(2-Methoxy-5-methylphenyl)hydrazinylidene]-4-oxo-3,4-dihydronaphthalene-2,6-disulfonic acid",CC1=CC(=C(C=C1)OC)N=NC2=C(C=C3C=CC(=CC3=C2O)S(=O)(=O)O)S(=O)(=O)O,,,,,,
2155,22156,"Aprphine, 1,2-dimethoxy-, (+-)-",CN1CCC2=CC(=C(C3=C2[C@@H]1CC4=CC=CC=C43)OC)OC,,,,,,
2156,22157,8-Aminofluoranthene,C1=CC2=C3C(=C1)C4=C(C3=CC=C2)C=C(C=C4)N,,,,,,
2157,22158,3-Oxo-2-(m-tolylazo)butyric acid ethyl ester,CCOC(=O)C(C(=O)C)N=NC1=CC=CC(=C1)C,,,,,,
2158,22159,3-Oxo-2-(p-tolylazo)butyric acid ethyl ester,CCOC(=O)C(C(=O)C)N=NC1=CC=C(C=C1)C,,,,,,
2159,22160,2-((m-Chlorophenyl)azo)-3-oxobutyric acid ethyl ester,CCOC(=O)C(C(=O)C)N=NC1=CC(=CC=C1)Cl,,,,,,
2160,22161,2-((p-Chlorophenyl)azo)-3-oxobutyric acid ethyl ester,CCOC(=O)C(C(=O)C)N=NC1=CC=C(C=C1)Cl,,,,,,
2161,22162,Cyclopentolate hydrochloride,CN(C)CCOC(=O)C(C1=CC=CC=C1)C2(CCCC2)O.Cl,,,"['Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)', 'Agents that dilate the pupil. They may be either sympathomimetics or parasympatholytics. (See all compounds classified as Mydriatics.)']",,,
2162,22163,"1,1,3-Triethoxybutane",CCOC(C)CC(OCC)OCC,,,,,,
2163,22164,Diethoxy(potassiooxy)phosphine sulfide,CCOP(=S)([O-])OCC.[K+],,,,,,
2164,22165,DL-N-Phenethylaspartic acid,C1=CC=C(C=C1)CCNC(CC(=O)O)C(=O)O,,,,,,
2165,22166,CID 22166,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C(=C(C=C4)N)O)C(=C3C(=O)[C@@]2(C(=O)C(=C(N)O)C1=O)O)O,,,,,,
2166,22167,"[2-(2,5-Dimethylphenyl)-2-hydroxyethyl]-propan-2-ylazanium;sulfate",CC1=CC(=C(C=C1)C)C(C[NH2+]C(C)C)O.CC1=CC(=C(C=C1)C)C(C[NH2+]C(C)C)O.[O-]S(=O)(=O)[O-],,,,,,
2167,22168,"1-(2,5-Dimethylphenyl)-2-[(propan-2-yl)amino]ethan-1-ol",CC1=CC(=C(C=C1)C)C(CNC(C)C)O,,,,,,
2168,22169,2-(3-Amino-4-propoxybenzoyl)oxyethyl-diethylazanium;chloride,CCCOC1=C(C=C(C=C1)C(=O)OCC[NH+](CC)CC)N.[Cl-],,,,,,
2169,22170,"1,11-Dodecadiene",C=CCCCCCCCCC=C,,,,,,
2170,22171,2-((1-Methyl-2-(phenylthio)ethyl)amino)ethanol,CC(CSC1=CC=CC=C1)NCCO,,,,,,
2171,22172,Methoxyacetone,CC(=O)COC,,,,,,
2172,22173,4-Dimethylaminophenol hydrochloride,CN(C)C1=CC=C(C=C1)O.Cl,,,['Agents counteracting or neutralizing the action of POISONS. (See all compounds classified as Antidotes.)'],,,
2173,22174,4-(Dimethylamino)phenol,CN(C)C1=CC=C(C=C1)O,,,['Agents counteracting or neutralizing the action of POISONS. (See all compounds classified as Antidotes.)'],,,
2174,22175,"3,4-Dihydro-6,7-dimethoxy-1-veratrylisoquinoline hydrochloride",COC1=C(C=C(C=C1)CC2=[NH+]CCC3=CC(=C(C=C32)OC)OC)OC.[Cl-],,,,,,
2175,22176,"3,4-Dihydropapaverine",COC1=C(C=C(C=C1)CC2=NCCC3=CC(=C(C=C32)OC)OC)OC,,,,,,
2176,22177,"3,4-Dihydro-6,7-dimethoxy-3-methylisoquinoline hydrochloride",CC1CC2=CC(=C(C=C2C=[NH+]1)OC)OC.[Cl-],,,,,,
2177,22178,"3-Methyl-6,7-dimethoxy-3,4-dihydroisoquinoline",CC1CC2=CC(=C(C=C2C=N1)OC)OC,,,,,,
2178,22179,Laurolitsine,COC1=C(C=C2C[C@H]3C4=C(C2=C1)C(=C(C=C4CCN3)O)OC)O,,,,,,
2179,22180,3-(Dibutylamino)propyl p-aminobenzoate monohydrochloride,CCCC[NH+](CCCC)CCCOC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
2180,22181,"3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione monohydrochloride",C[NH+]1C=NC2=C1C(=O)N(C(=O)N2C)C.[Cl-],,,,,,
2181,22182,Acamylophenine dihydrochloride,CC[NH+](CC)CC[NH2+]C(C1=CC=CC=C1)C(=O)OCCC(C)C.[Cl-].[Cl-],,,['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)'],,,
2182,22183,CID 22183,CC(=O)NC1=C(C=CC(=C1)[As](=O)(O)[O-])O.[Na+],,,,,,
2183,22184,Trichloro(hexadecyl)silane,CCCCCCCCCCCCCCCC[Si](Cl)(Cl)Cl,,,,,['... Chlorosilanes will be rapidly hydrolyzed upon contact with tissue fluids to release hydrochloric acid. /Chlorosilanes/'],
2184,22185,Octahydro-apo-beta-erythroidine,C1CC2CCN3C2C(C1)C4CC(=O)OCC4CC3,,,,,,
2185,22186,Cyclamate calcium dihydrate,C1CCC(CC1)NS(=O)(=O)[O-].C1CCC(CC1)NS(=O)(=O)[O-].O.O.[Ca+2],,,,,,
2186,22187,alpha-(alpha-Aminopropyl)benzyl alcohol,CCC(C(C1=CC=CC=C1)O)N,,,,,,
2187,22188,Terbacil,CC1=C(C(=O)N(C(=O)N1)C(C)(C)C)Cl,,,,,"['... Beagle dogs ... fed diets containing terbacil. ... Main metabolite /in urine/ was 3-tert-butyl-5-chloro-6-hydroxymethyluracil. ... Other/s/ ... observed: 6-chloro-2,3-dihydro-7-(hydroxymethyl)-3,3-dimethyl-5h-oxazolo- (3,2-a)pyrimidin-5-one; 6-chloro-2,3-dihydro-3,3,7-trimethyl- 5H-oxazolo(3,2-a)pyrimidin-5-one; 3-tert-butyl-6-hydroxymethyluracil /&/ 3-tert-butyl-6-formyluracil ... .', 'Terbacil is metabolized to 3-tert-butyl-5-chloro-6-(hydroxymethyl) uracil, excreted in dogs fed with a diet incorporating terbacil.', 'Oxidation of a methyl group and the tert-butyl group gives the oxidative products of terbacil, which are than cyclized to form an oxazolidine ring.', 'Orange seedlings were grown in solutions containing (14)C-terbacil. Analysis of plant tissues showed the presence of the 6-hydroxymethyl analog and a conjugate believed to be the beta-glucoside.', 'For more Metabolism/Metabolites (Complete) data for TERBACIL (7 total), please visit the HSDB record page.']",
2188,22189,"Acetic acid, chloro-, 2,4,5-trichlorophenyl ester",C1=C(C(=CC(=C1Cl)Cl)Cl)OC(=O)CCl,,,,,,
2189,22190,"Methylmercury;2,3,4,5,6-pentachlorophenol",C[Hg].C1(=C(C(=C(C(=C1Cl)Cl)Cl)Cl)Cl)O,,,,,,
2190,22191,"Mercury, (4,5,6,7,8,8-hexachloro-1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl)methyl-",C[Hg]N1C(=O)C2C(C1=O)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
2191,22192,O-n-Butyl-S-benzyl-xanthate,CCCCOC(=S)SCC1=CC=CC=C1,,,,,,
2192,22193,Calcium bis(methylarsonate),C[As](=O)([O-])[O-].C[As](=O)([O-])[O-].[Ca+2],,,,,,
2193,22194,Nissol,CN(C1=CC=CC2=CC=CC=C21)C(=O)CF,,,,,,
2194,22195,1-(Methoxymethyl)naphthalene,COCC1=CC=CC2=CC=CC=C21,,,,,,
2195,22196,"2,2'-Bifuran, 5,5'-dinitro-",C1=C(OC(=C1)[N+](=O)[O-])C2=CC=C(O2)[N+](=O)[O-],,,,,,
2196,22197,Ferrous lactate,CC(C(=O)[O-])O.CC(C(=O)[O-])O.[Fe+2],,,,"['Gastrointestinal absorption of iron is adequate and essentially equal from...ferrous...sulfate, fumarate, gluconate, succinate, glutamate, and lactate.']",,
2197,22198,1-Aminohomopiperidine,C1CCCN(CC1)N,,,,,,
2198,22199,Ethyl docosanoate,CCCCCCCCCCCCCCCCCCCCCC(=O)OCC,,,,,,
2199,22200,Ditridecylamine,CCCCCCCCCCCCCNCCCCCCCCCCCCC,,,,,,
2200,22201,"2,3-Dimethylpyrazine",CC1=NC=CN=C1C,,,,,,
2201,22202,3-Methylnonane,CCCCCCC(C)CC,,,,,,
2202,22203,"Coumarin, 7-(3-(dimethylamino)propoxy)-3-(4-pyridyl)-",CN(C)CCCOC1=CC=CC2=C1OC(=O)C(=C2)C3=CC=NC=C3,,,,,,
2203,22204,"Benzoic acid, 3,4,5-trimethoxy-, 4-(4-phenyl-1-piperazinyl)butyl ester, dihydrochloride",COC1=CC(=CC(=C1OC)OC)C(=O)OCCCCN2CCN(CC2)C3=CC=CC=C3.Cl.Cl,,,,,,
2204,22205,"13-Ethyl-3-methoxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-ol",CCC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)OC,,,,,,
2205,22206,Terbuthylazine,CCNC1=NC(=NC(=N1)Cl)NC(C)(C)C,,,"['Chemicals used to destroy pests of any sort. The concept includes fungicides (FUNGICIDES, INDUSTRIAL); INSECTICIDES; RODENTICIDES; etc. (See all compounds classified as Pesticides.)', 'Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['In a rat metabolism study, (14)C-terbuthylazine (3.6 mg) was administered orally to Wistar rats. Terbuthylazine was rapidly (50% excreted by 16-17 hrs) and completely metabolized and did not accumulate in tissues. Radioactivity was excreted equally in urine and feces in males, but in females about 66% of the radiolabel was excreted in the urine.', 'In mammals, following oral administration, 72-84% is eliminated in the urine and feces within 24 hr, and almost all within 48 hr.', 'Terbuthylazine (TBA) is an herbicide widely used in corn cultivation. Herein we evaluate the measurement of hair TBA as biomarkers of exposure. Five Sprague Dawley rats were gavaged with TBA for 3 days, and then the back hair was shaved and analyzed for TBA. In addition, head hair samples from 10 corn farmers, 9 rural residents, and 6 urban residents were collected at the end of the application season. Hair TBA was detected by liquid chromatography triple quadrupole mass spectrometry after solvent extraction. TBA was quantifiable in all rat samples with a mean concentration of 0.92 (+ or - 0.26)ng/mg, which corresponds to a 0.12% incorporation rate. TBA was quantifiable in all farmer samples (median: 0.67 ng/mg), in 75% of rural resident samples (0.01ng/mg) and in none of the urban resident samples (<0.01 ng/mg), with a statistical difference among groups (P<0.01). Our results suggest that TBA is incorporated in hair and prompt further investigation on the use of hair TBA as a potential biomarker of cumulative exposure.']","['Metabolism of terbuthylazine in rats is similar to other chloro-s-triazine herbicides. The major routes of metabolism are hydrolysis of the chlorine moiety and mono- or didealkylation. Hydroxylation of one or both of the dealkylated amine groups may also occur.', 'Urine and feces contained up to 25 and 15 identified metabolites, respectively, most of which were polar. Degradation of the triazine ring did not occur. Ammeline and ammelide, 2 dechlorinated and dealkylated/hydroxylated metabolites common to all triazines, were identified in low amounts in the feces.', 'In mammals, following oral administration, ...a de-ethyl metabolite forms rapidly, followed by conjugates of products formed by oxidation of one methyl group of the tert-butyl moiety. All are rapidly excreted.', '/Terbutylethylazine/ was rapidly metabolized to water soluble compounds in the leaves of corn, sorghum, and sugar cane and more slowly in susceptible barley, by displacement of the 2-chloro group with glutathione or gamma-glutamylcysteine.', 'The metabolism of atrazine (and three other triazine herbicides, terbuthylazine, ametryne, and tebutryne) has been investigated in vitro in liver microsomes from rats, pigs, and humans. The principal phase-1 reactions in all three species were N-monodealkylation, hydroxylation of the isopropyl or tert-butyl moiety and sulfoxidation of the substrate. Although all species produced the same type of metabolites, there were spiecies specific differences in the metabolite ratios. Subsequent studies have shown that cytochrome P450 1A2 is the major phase-1 enzyme involved in the metabolism of s-triazine in human liver micrsomes. /Triazine herbicides/', 'Terbuthylazine has known human metabolites that include 1-[[4-(tert-butylamino)-6-chloro-1,3,5-triazin-2-yl]amino]ethanol and 2-[[4-Chloro-6-(ethylamino)-1,3,5-triazin-2-yl]amino]-2-methylpropan-1-ol.']",
2206,22207,14-Methylhexadecanoic acid,CCC(C)CCCCCCCCCCCCC(=O)O,,,,,,
2207,22208,"1,3-Dihydroimidazol-2-one",C1=CNC(=O)N1,,,,,,
2208,22209,"6-Nonyl-1,3,5-triazine-2,4-diamine",CCCCCCCCCC1=NC(=NC(=N1)N)N,,,,,,
2209,22210,"1,1-Dibutoxybutane",CCCCOC(CCC)OCCCC,,,,,,
2210,22211,3-Phenylcarbazic acid 2-chloroethyl ester,C1=CC=C(C=C1)NNC(=O)OCCCl,,,,,,
2211,22212,(Chloromethyl)trimethoxysilane,CO[Si](CCl)(OC)OC,,,,,,
2212,22213,Hexyl glycidyl ether,CCCCCCOCC1CO1,,,,,,
2213,22214,Linadryl hydrochloride,C1COCCN1CCOC(C2=CC=CC=C2)C3=CC=CC=C3.Cl,,,,,,
2214,22215,"Morpholine, 4-(2-(diphenylmethoxy)ethyl)-",C1COCCN1CCOC(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
2215,22216,"3,4-Dibromo-1H-pyrazole",C1=NNC(=C1Br)Br,,,,,,
2216,22217,4-Nonanol,CCCCCC(CCC)O,,,,,,
2217,22218,"4,4-Dimethylhexanal",CCC(C)(C)CCC=O,,,,,,
2218,22219,4-Bromobenzohydrazide,C1=CC(=CC=C1C(=O)NN)Br,,,,,,
2219,22220,Ethyl 11-(4-iodophenyl)undecanoate,CCOC(=O)CCCCCCCCCCC1=CC=C(C=C1)I,,,,,,
2220,22221,"BENZAMIDE, 3,4-DIETHOXY-N-(p-(2-(METHYLAMINO)ETHOXY)BENZYL)-",CCOC1=C(C=C(C=C1)C(=O)NCC2=CC=C(C=C2)OCCNC)OCC,,,,,,
2221,22222,Methyl aminooxyacetate hydrochloride,COC(=O)CO[NH3+].[Cl-],,,,,,
2222,22223,Methyl 2-(aminooxy)acetate,COC(=O)CON,,,,,,
2223,22224,"3,3'-[(6-Methyl-1,3,5-triazine-2,4-diyl)diimino]di-1-propanol",CC1=NC(=NC(=N1)NCCCO)NCCCO,,,,,,
2224,22225,"2,2'-[(6-Methyl-1,3,5-triazine-2,4-diyl)diimino]diethanol",CC1=NC(=NC(=N1)NCCO)NCCO,,,,,,
2225,22226,Mexicanin E,C[C@@H]1C[C@@H]2[C@H](C[C@@H]3[C@H]1C=CC3=O)C(=C)C(=O)O2,,,,,,
2226,22227,(+)-Dihydrocarvone,C[C@@H]1CC[C@H](CC1=O)C(=C)C,,,,,,
2227,22228,(5-Ethenyl-1-azoniabicyclo[2.2.2]octan-2-yl)-quinolin-4-ylmethanol;sulfate,C=CC1C[NH+]2CCC1CC2C(C3=CC=NC4=CC=CC=C34)O.C=CC1C[NH+]2CCC1CC2C(C3=CC=NC4=CC=CC=C34)O.[O-]S(=O)(=O)[O-],,,,,,
2228,22229,CID 22229,C1=CC=C(C=C1)C2=NC3=CC=CC=C3C(=C2)C(=O)[O-].[Na+],,,,,,
2229,22230,Citric Acid Monohydrate,C(C(=O)O)C(CC(=O)O)(C(=O)O)O.O,,,"['Substances that bind to and sequester CALCIUM ions. (See all compounds classified as Calcium Chelating Agents.)', 'Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)']",,,
2230,22231,"Acridine, 9-amino-2-phenyl-",C1=CC=C(C=C1)C2=CC3=C(C4=CC=CC=C4N=C3C=C2)N,,,,,,
2231,22232,Hydrindantin dihydrate,C1=CC=C2C(=C1)C(=O)C(C2(O)O)(C3(C(=O)C4=CC=CC=C4C3(O)O)O)O,,,,,,
2232,22233,Diethylene glycol dicarbamate,C(COC(=O)N)OCCOC(=O)N,,,,,,
2233,22234,"1,3-Bis(carbamoyloxy)butane",CC(CCOC(=O)N)OC(=O)N,,,,,,
2234,22235,Chloracetophos,CC(=O)OC(C(Cl)(Cl)Cl)P(=O)(OC)OC,,,,,,
2235,22236,"Phosphonic acid, (2,2,2-trichloro-1-hydroxyethyl)-, diethyl ester, acetate",CCOP(=O)(C(C(Cl)(Cl)Cl)OC(=O)C)OCC,,,,,,
2236,22237,2-Chloro-4'-methylbenzophenone,CC1=CC=C(C=C1)C(=O)C2=CC=CC=C2Cl,,,,,,
2237,22238,But-2-enethiol,CC=CCS,,,,,,
2238,22239,"Acetophenone, 2-nitrilo-3',4',5'-trimethoxy-",COC1=CC(=CC(=C1OC)OC)C(=O)C#N,,,,,,
2239,22240,Ivasperine,CC12CC3C(C(=C)C1CCC([C@H]2O)O)C(=C)C(=O)O3,,,,,,
2240,22241,2-(diethylamino)-N-[[2-oxo-2-(4-phenylphenyl)ethylidene]amino]acetamide,CCN(CC)CC(=O)NN=CC(=O)C1=CC=C(C=C1)C2=CC=CC=C2,,,,,,
2241,22242,"BENZYL ALCOHOL, alpha-(alpha-AMINOBENZYL)-, HYDROCHLORIDE",C1=CC=C(C=C1)C(C(C2=CC=CC=C2)O)[NH3+].[Cl-],,,,,,
2242,22243,"2-Amino-1,2-diphenylethanol",C1=CC=C(C=C1)C(C(C2=CC=CC=C2)O)N,,,,,,
2243,22244,3-Amino-2-naphthoic acid,C1=CC=C2C=C(C(=CC2=C1)C(=O)O)N,,,,,,
2244,22245,"1-Naphthol, 4-amino-, hydrochloride",C1=CC=C2C(=C1)C(=CC=C2O)[NH3+].[Cl-],,,,,,
2245,22246,N-Methylnicotinium iodide,C[N+]1(CCCC1C2=CN=CC=C2)C.[I-],,,,,,
2246,22247,"3-(1,1-Dimethylpyrrolidin-1-ium-2-yl)pyridine",C[N+]1(CCCC1C2=CN=CC=C2)C,,,,,,
2247,22248,CID 22248,CCCCCCCCC=CCCCCCCCCC(=O)OC1C(COC1C(CC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC)O,,,,,,
2248,22249,3-Methyl-3-phenylazetidine,CC1(CNC1)C2=CC=CC=C2,,,,,,
2249,22250,4-Methoxy-N-methylaniline,CNC1=CC=C(C=C1)OC,,,,,,
2250,22251,"2-phenyl-3,4-dihydro-2H-thiochromene",C1CC2=CC=CC=C2SC1C3=CC=CC=C3,,,,,,
2251,22252,Butyroguanamine,CCCC1=NC(=NC(=N1)N)N,,,,,,
2252,22253,L-xylulose,C([C@@H]([C@H](C(=O)CO)O)O)O,,,,,,
2253,22254,"1,2-Dichloro-1,2-diphenylethane",C1=CC=C(C=C1)C(C(C2=CC=CC=C2)Cl)Cl,,,,,,
2254,22255,Sodium;ethylmercury(1+);(4-sulfidophenyl) sulfite,CC[Hg+].C1=CC(=CC=C1OS(=O)[O-])[S-].[Na+],,,,,,
2255,22256,(4-Sulfanylphenyl) hydrogen sulfite,C1=CC(=CC=C1OS(=O)O)S,,,,,,
2256,22257,CID 22257,CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4.O.Cl,,,,,,
2257,22258,"(4S,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one",CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=O)CC4,,,,,,
2258,22259,10-(2-Hexylcyclopropyl)decanamide,CCCCCCC1CC1CCCCCCCCCC(=O)N,,,,,,
2259,22260,N-(2-Chloroethyl)-N-ethyl-alpha-phenylbenzylamine hydrochloride,CC[NH+](CCCl)C(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
2260,22261,N-benzhydryl-2-chloro-N-ethylethanamine,CCN(CCCl)C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
2261,22262,Diisopromine,CC(C)N(CCC(C1=CC=CC=C1)C2=CC=CC=C2)C(C)C,,,,,,
2262,22263,"1,3-Bis(dimethylamino)-2-propanol",CN(C)CC(CN(C)C)O,,,,,,
2263,22264,Acetic acid;dibutyltin;hydrate,CCCC[Sn]CCCC.CCCC[Sn]CCCC.CC(=O)O.CC(=O)O.O,,,,,,
2264,22265,[1-Hydroxy-1-(3-hydroxyphenyl)propan-2-yl]azanium;chloride,CC(C(C1=CC(=CC=C1)O)O)[NH3+].[Cl-],,,,,,
2265,22266,Levomethadone hydrochloride,CCC(=O)C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2.Cl,,,,,,
2266,22267,Levomethadone,CCC(=O)C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
2267,22268,CID 22268,C[NH+]1CC[C@]23C4C(=CC=C2[C@@H]1CC5=C3C(=C(C=C5)OC)O4)OC.C1=C(C(=O)C(=CC1=[N+]([O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
2268,22269,CID 22269,CN1CC[C@]23C4C(=CC=C2[C@@H]1CC5=C3C(=C(C=C5)OC)O4)OC,,,,,,
2269,22270,2-(4-Aminobenzoyl)sulfanylethyl-diethylazanium;chloride,CC[NH+](CC)CCSC(=O)C1=CC=C(C=C1)N.[Cl-],,,,,,
2270,22271,Anthallan hydrochloride,CCCCN(CCCC)CC1C2=C(C(=C(C=C2C(=O)O1)O)O)O.Cl,,,,,,
2271,22272,Anthallan,CCCCN(CCCC)CC1C2=C(C(=C(C=C2C(=O)O1)O)O)O,,,,,,
2272,22273,Ferric cacodylate,C[As](=O)(C)[O-].C[As](=O)(C)[O-].C[As](=O)(C)[O-].[Fe+3],,,,"['... Observation of rats given oral administration of 59Fe-labeled cationic cacodylate ferric (59Fe-Cac) colloid, anionic citrate ferric (59Fe-Cit) colloid, cationic 59Fe-Cac complex and anionic 59Fe-Cit complex revealed that iron absorption was more efficient in the 59Fe-Cac colloid, moderate in the 59Fe-Cac complex, low in the 59Fe-Cit colloid, and lowest in the 59Fe- cases given 59Fe-Cac colloid and 59Fe-Cac complex, a very high ratio activity was found in the liver and in the erythrocyte or hemoglobin in circulating blood, while the blood plasma, bone marrow, and spleen were low in activity. Histochemical observations of rat jejunal mucosa exposed independently for 10 min to the Fe-Cac colloid, anionic Fe-Cit colloid, and Fe-Cac and Fe-Cit complexes revealed that the cationic Fe-Cac colloid and Fe-Cac complex adhered to the luminal surface of the mucosa covering the apical area of villi with some ferric iron in the capillaries, while the anionic Fe-Cit colloid and complex did not adhere to the epithelial cells and were found free in the jejunal lumen. Electron microscopy revealed that Fe-Cac colloid particles were taken into epithelial cells by pinocytosis at the webs of microvilli, moved to the Golgi area, exocytosed to the intercellular spaces, and then translocated into the basement membrane toward blood capillaries.']",,
2273,22274,"1,2,3-Propanetricarboxylic acid, 2-hydroxy-, manganese(3+) salt (1:1)",C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Mn+3],,,,,,
2274,22275,Phenpromethamine hydrochloride,CC(CNC)C1=CC=CC=C1.Cl,,,,,,
2275,22276,Phenpromethamine,CC(CNC)C1=CC=CC=C1,,,,,,
2276,22277,CID 22277,C1=CC=C(C(=C1)C(=O)[O-])O.[Hg],,,,,,
2277,22278,"3,4-Dimethylbenzaldehyde",CC1=C(C=C(C=C1)C=O)C,,,,,,
2278,22279,1-(3-Pyridinyl)ethanone oxime,CC(=NO)C1=CN=CC=C1,,,,,,
2279,22280,"Benzyl(4-(bis(p-(dimethylamino)phenyl)methylene)cyclohexa-2,5-dien-1-ylidene)methylammonium chloride",CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=C(C=C3)N(C)CC4=CC=CC=C4.[Cl-],,,,,,
2280,22281,"N-[4-[Bis[4-(dimethylamino)phenyl]methylene]-2,5-cyclohexadien-1-ylidene]-N-methylbenzenemethanaminium",CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=C(C=C3)N(C)CC4=CC=CC=C4,,,,,,
2281,22282,Bis(2-hydroxy-3-prop-2-enoxypropyl) but-2-enedioate,C=CCOCC(COC(=O)C=CC(=O)OCC(COCC=C)O)O,,,,,,
2282,22283,Ralgro,CC1CCCC(CCCCCC2=C(C(=CC(=C2)O)O)C(=O)O1)O,,,"['Non-steroidal compounds with estrogenic activity. (See all compounds classified as Estrogens, Non-Steroidal.)']",,,
2283,22284,"4-Hydroxy-3-methoxyestra-1,3,5(10)-trien-17-one",CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4O)OC,,,,,,
2284,22285,"Benzoic acid, 3-(bis(2-chloroethyl)amino)-4-ethyl-",CCC1=C(C=C(C=C1)C(=O)O)N(CCCl)CCCl,,,,,,
2285,22286,"(2R,17R)-2,17-diethynyl-13-methyl-1,3,4,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-2,17-diol",CC12CCC3C(C1CC[C@]2(C#C)O)CCC4=C3C[C@](CC4)(C#C)O,,,,,,
2286,22287,4-[[3-[2-[2-[4-[(4-Chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethoxycarbonyl]-2-hydroxynaphthalen-1-yl]methyl]-3-hydroxynaphthalene-2-carboxylic acid,C1CN(CCN1CCOCCOC(=O)C2=CC3=CC=CC=C3C(=C2O)CC4=C(C(=CC5=CC=CC=C54)C(=O)O)O)C(C6=CC=CC=C6)C7=CC=C(C=C7)Cl,,,,,,
2287,22288,Pigment yellow 16,CC1=C(C=CC(=C1)C2=CC(=C(C=C2)NC(=O)C(C(=O)C)N=NC3=C(C=C(C=C3)Cl)Cl)C)NC(=O)C(C(=O)C)N=NC4=C(C=C(C=C4)Cl)Cl,,,,,,
2288,22289,"3,5-Dichlorobenzamide",C1=C(C=C(C=C1Cl)Cl)C(=O)N,,,,,,
2289,22290,"2,5-Dichlorobenzamide",C1=CC(=C(C=C1Cl)C(=O)N)Cl,,,,,,
2290,22291,Hexedine,CCCCC(CC)CN1CC2(CN(CN2C1)CC(CC)CCCC)C,,,,,,
2291,22292,CID 22292,CC1=CC(=O)OC2=C1C=CC(=C2)[O-].[Na+],,,,,,
2292,22293,Chlorovinylmercury chloride,C(=C[Hg]Cl)Cl,,,,,,
2293,22294,"1,3,5-Trioxepane",C1COCOCO1,,,,,,
2294,22295,CID 22295,CCCCCCCCC=CCCCCCCCC(=O)O.CCN,,,,,,
2295,22296,Isometheptene bitartrate,CC(CCC=C(C)C)NC.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
2296,22297,Isometheptene,CC(CCC=C(C)C)NC,['Isometheptene is a sympathomimetic drug which causes vasoconstriction. It is used for treating migraines and tension headaches.'],"['Isometheptene Mucate is an indirect-acting sympathomimetic. Due to its vasoconstricting properties, Isometheptene Mucate is used for the treatment of acute migraine attacks, usually in combination with other analgeics. It can also displace catecholamines from vesicles inside the neuron leading to the sympathetic responses it is known for.']",,,,
2297,22298,Isonipecotic acid hydrochloride,C1CNCCC1C(=O)O.Cl,,,,,,
2298,22299,"2-Heptanamine, 6-methyl-, hydrochloride",CC(C)CCCC(C)[NH3+].[Cl-],,,,,,
2299,22300,Deoxyhydrastinine hydrochloride,C[NH+]1CCC2=CC3=C(C=C2C1)OCO3.[Cl-],,,,,,
2300,22301,Hydrohydrastinine,CN1CCC2=CC3=C(C=C2C1)OCO3,,,,,,
2301,22302,4-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol hydrochloride,C[NH2+]CC(C1=CC=C(C=C1)O)O.[Cl-],,,,,,
2302,22303,"2,6-Dimethylocta-5,7-dien-2-ol",CC(=CCCC(C)(C)O)C=C,,,,,,
2303,22304,Conjuncain,CCCCOC1=C(C=CC(=C1)C(=O)OCC[NH+](CC)CC)N.[Cl-],,,"['Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)']",,,
2304,22305,p-Aminobenzoic acid 2-(diisopropylamino)ethyl ester hydrochloride,CC(C)[NH+](CCOC(=O)C1=CC=C(C=C1)N)C(C)C.[Cl-],,,,,,
2305,22306,Isocaine-Schmitz,CC(C)N(CCOC(=O)C1=CC=C(C=C1)N)C(C)C,,,,,,
2306,22307,CID 22307,CC[C@H](C(C[C@H](C)[NH+](C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C.[Cl-],,,,,,
2307,22308,Alphacetylmethadol,CC[C@H](C(C[C@@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C,,,"['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)']",,['Alphacetylmethadol has known human metabolites that include norLAAM.'],
2308,22309,CID 22309,CC(=O)OC(C)(C)C=CC(=O)C(C)(C1[C@@H](CC2(C1(CC(=O)C3(C2CC=C4[C@H]3CC[C@@H](C4(C)C)O)CO)C)C)O)O,,,,,,
2309,22310,Linalyl oxide,CC1(CCC(O1)C(C)(C)O)C=C,,,,,,
2310,22311,Limonene,CC1=CCC(CC1)C(=C)C,,,,"['The data suggest that monoterpenes are poorly resorbed in the GI tract. The resorbed portion of hydrocarbons accumulates in the lipophilic body compartments and is metabolized and then excreted by the kidneys. /Monoterpenes/', 'Percutaneous absorption of radioactive limonene from foam bath was measured in animals. Maximum blood level reached after 10 min of exposure and the concentration was proportional to the skin exposed.', '...SKH-1 mice received topical or oral administration of limonene in the form of orange oil every day for 4 weeks ... Plasma and mammary pads were collected 4 hr after the final dosing. The mouse disposition study showed that topical and oral orange oil administration resulted in similar mammary tissue disposition of limonene with no clinical signs of toxicity ... Our studies showed that limonene is bio available in mammary tissue after topical orange oil application in mice ...']","['After oral administration, major metabolite in urine was perillic acid 8,9-diol in rats and rabbits, perillyl-beta-d-glucopyranosiduronic acid in hamsters, p-menth-1-ene-8,9-diol in dogs, and 8-hydroxy-p-menth-1-en-9-yl-beta-d-glucopyranosiduronic acid in guinea pigs and man.', '... A metabolite isolated from rabbit urine was identified as p-mentha-1,8-dien-10-ol. ...', 'Limonene given orally to humans yields the following major plasma metabolites: perillic acid, limonene-1,2-diol, limonene-8,9-diol, and dihydroperillic acid, probably derived from perillic acid. Limonene (unchanged) and perillic acid artifacts (methyl ester) were also detected as minor plasma metabolites. Peak plasma levels for all metabolites were achieved 4-6 hours after administration, with the exception of limonene-8,9-diol which reached its peak level one hour after administration. Phase II glucuronic acid conjugates have been identified in the urine of human volunteers for all major and minor metabolites. They include the glucuronic acid conjugates of perillic acid, dihydroperillic acid, limonene-8,9-diol, limonene-10- ol, limonene-6-ol, and limonene-7-ol (perillyl alcohol).']",
2311,22312,CID 22312,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)C(=O)[O-].[K+],,,,,,
2312,22313,"Benzimidazole, 2-((p-tert-butylphenyl)thio)-1-(2-(diethylamino)ethyl)-, dipicrate",CC[NH+](CC)CC[N+]1=C(NC2=CC=CC=C21)SC3=CC=C(C=C3)C(C)(C)C.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-].C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
2313,22314,"2-[2-(4-tert-butylphenyl)sulfanyl-3H-benzimidazol-1-ium-1-yl]-N,N-diethylethanamine",CCN(CC)CC[N+]1=C(NC2=CC=CC=C21)SC3=CC=C(C=C3)C(C)(C)C,,,,,,
2314,22315,"Gitoxigenin 3,16-diacetate",CC(=O)O[C@H]1CC[C@]2([C@@H](C1)CCC3C2CC[C@]4([C@@]3(C[C@@H]([C@@H]4C5=CC(=O)OC5)OC(=O)C)O)C)C,,,,,,
2315,22316,Glycine hydrochloride,C(C(=O)O)N.Cl,,,"['Substances used for their pharmacological actions on glycinergic systems. Glycinergic agents include agonists, antagonists, degradation or uptake inhibitors, depleters, precursors, and modulators of receptor function. (See all compounds classified as Glycine Agents.)']",,,
2316,22317,CID 22317,C(C(=O)[O-])N.[Na+],,,,,,
2317,22318,Sodium aurothiomalate,C(C(C(=O)[O-])[S-])C(=O)[O-].[Na+].[Na+].[Au+],['A disease-modifying antirheumatic drug (DMARD) indicated for the symptomatic treatment of arthritis.'],"['Unknown, may decrease prostaglandin synthesis or may alter cellular mechanisms by inhibiting sulfhydryl systems.']",['Drugs that are used to treat RHEUMATOID ARTHRITIS. (See all compounds classified as Antirheumatic Agents.)'],"['Gold sodium thiomalate solutions are rapidly absorbed following IM injection, with peak serum concentrations occurring in 3-6 hours.', 'The major route of elimination of an IV dose of gold sodium thiomalate is urinary excretion, with a mean of 35% of the dose found in the urine in ten days. Fecal elimination accounts for an additional 9.4% of the IV dose excreted in ten days, probably as a result of biliary secretion.', 'The apparent volume of distribution is 0.26 +/- 0.051 kg-1', '7.0 ml/ kg/day', 'Higher tissue levels occur with parenteral gold salts, with a mean steady state plasma level of 1 to 5 ug/ml. Drug is distributed widely throughout the body in lymph nodes, bone marrow, kidneys, liver, spleen, and tissues. About 85% to 90% is protein-bound.', 'Gold has been shown to cross the placenta in pregnant women receiving gold sodium thiomalate. Small amounts of gold have been shown to be distributed into milk in women receiving ... gold sodium thiomalate.', 'Gold sodium thiomalate solutions are rapidly absorbed following IM injection, with peak serum concentrations occurring in 3-6 hours.', 'Following single 10-mg doses of gold sodium thiomalate, serum gold concentrations showed a biphasic decline with a relatively rapid early phase (serum half-life about 43 hours) and a slow late phase (serum half-life about 6 days). The slow phase of decline may result from excretion and the rapid phase of decline may result from tissue distribution. The true potential of gold compounds, including ... gold sodium thiomalate, to cumulate has not been clearly defined, but it is clear that substantially larger amounts of gold are retained in the body during therapy with parenteral gold compounds than during therapy with auranofin.', 'For more Absorption, Distribution and Excretion (Complete) data for GOLD SODIUM THIOMALATE (8 total), please visit the HSDB record page.']","['No data available.', 'For a patient receiving gold sodium thiomalate the principal gold species in the urine is [Au(CN)2]-, which is also seen in a low molecular weight infiltrate of the blood']","['12.5 days', 'Following single 10-mg doses of gold sodium thiomalate, serum gold concentrations showed a biphasic decline with a relatively rapid early phase (serum half-life about 43 hours) and a slow late phase (serum half-life about 6 days).', '...Terminal log-linear phases corresponded to a mean disposition half-life of 25 days...', '... the mean alpha half-lives were 0.738 and 1.78 hr for the iv and im routes, respectively. The corresponding terminal (beta) half-lives were 54.1 and 63.0 hr...', 'Four normal male volunteers participated in a study designed to examine the disposition of gold given intramuscularly as gold sodium thiomalate. Blood samples were collected for 32 days following the administration of 10 mg of gold sodium thiomalate. .... Terminal log-linear phases corresponded to a mean disposition half-life of 25 days. ...']"
2318,22319,"disodium;[2-[(17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] phosphate",CC12CCC(=O)C=C1CCC3C2C(CC4(C3CC[C@@]4(C(=O)COP(=O)([O-])[O-])O)C)O.[Na+].[Na+],,,,,,
2319,22320,"Allylamine, N,N,2-trimethyl-",CC(=C)CN(C)C,,,,,,
2320,22321,Methyl 3-chloropropionate,COC(=O)CCCl,,,,,,
2321,22322,"[N'-[N'-(3,4-dichlorophenyl)carbamimidoyl]carbamimidoyl]-propan-2-ylazanium;chloride",CC(C)[NH2+]C(=NC(=NC1=CC(=C(C=C1)Cl)Cl)N)N.[Cl-],,,,,,
2322,22323,"1-[Amino-(3,4-dichloroanilino)methylidene]-2-propan-2-ylguanidine",CC(C)N=C(N)N=C(N)NC1=CC(=C(C=C1)Cl)Cl,,,,,"['1-[Amino-(3,4-dichloroanilino)methylidene]-2-propan-2-ylguanidine has known human metabolites that include 1-[amino-(3,4-dichloroanilino)methylidene]-2-(2-hydroxypropan-2-yl)guanidine.']",
2323,22324,Cetylpyridinium chloride monohydrate,CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1.O.[Cl-],,,,,,
2324,22325,"Tricyclo[5.2.1.01,7]decane",C1CCC23CCC2(C3)CC1,,,,,,
2325,22326,1-Cyclopentylethanone,CC(=O)C1CCCC1,,,,,,
2326,22327,Tridecylcyclohexane,CCCCCCCCCCCCCC1CCCCC1,,,,,,
2327,22328,Pentadecylcyclohexane,CCCCCCCCCCCCCCCC1CCCCC1,,,,,,
2328,22329,"2-Methyl-1,3-dithiane",CC1SCCCS1,,,,,,
2329,22330,"Thiophene, 2,5-dihydro-2-methyl-, 1,1-dioxide",CC1C=CCS1(=O)=O,,,,,,
2330,22331,"4-(Chloromethyl)-2,2-dimethyl-1,3-dithiolane",CC1(SCC(S1)CCl)C,,,,,,
2331,22332,"2,2-Dimethyl-1,3-dithiolane",CC1(SCCS1)C,,,,,,
2332,22333,"2-Ethyl-2-methyl-1,3-dithiolane",CCC1(SCCS1)C,,,,,,
2333,22334,"2-Ethyl-2-phenyl-1,3-dithiolane",CCC1(SCCS1)C2=CC=CC=C2,,,,,,
2334,22335,"1,3-Dithiolane, 2-(2-furyl)-",C1CSC(S1)C2=CC=CO2,,,,,,
2335,22336,"2(3H)-Benzofuranone, 3-(2-(diethylamino)ethyl)-3-phenyl-, hydrochloride",CC[NH+](CC)CCC1(C2=CC=CC=C2OC1=O)C3=CC=CC=C3.[Cl-],,,,,,
2336,22337,CID 22337,CC(CCC(=O)NCCS(=O)(=O)[O-])C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C.[Na+],,,,,,
2337,22338,"2-[4-(3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoylamino]ethanesulfonic acid",CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C,,,,,,
2338,22339,"Isonicotinamide, N-(2-(diethylamino)ethyl)-",CCN(CC)CCNC(=O)C1=CC=NC=C1,,,,,,
2339,22340,"Glycinonitrile, monohydrochloride",C(C#N)[NH3+].[Cl-],,,,,,
2340,22341,Iproniazid dihydrochloride,CC(C)NNC(=O)C1=CC=NC=C1.Cl.Cl,,,,,,
2341,22342,Etoxinol,CCOCC(C1=CC=C(C=C1)Cl)(C2=CC=C(C=C2)Cl)O,,,,,,
2342,22343,3-(p-Chlorophenyl)-5-methylrhodanine,CC1C(=O)N(C(=S)S1)C2=CC=C(C=C2)Cl,,,,,,
2343,22344,Tetrachlorothiophene,C1(=C(SC(=C1Cl)Cl)Cl)Cl,,,,,,
2344,22345,"(2Z)-2-Cyano-3-(2,4-dichlorophenyl)acrylic acid",C1=CC(=C(C=C1Cl)Cl)C=C(C#N)C(=O)O,,,,,,
2345,22346,CID 22346,C[C@]12CCC3C([C@]1(CC[C@@H]2C4=CC(=O)OC4)O)CC[C@]5([C@@]3(CC[C@@H](C5)O[C@H]6C(C([C@@H](C(O6)CO)O)O)O)C=O)O,,,,,,
2346,22347,(Phenylazo)malononitrile,C1=CC=C(C=C1)N=NC(C#N)C#N,,,,,,
2347,22348,2-Chlorophenylazomalononitrile,C1=CC=C(C(=C1)N=NC(C#N)C#N)Cl,,,,,,
2348,22349,((p-Iodophenyl)azo)malononitrile,C1=CC(=CC=C1N=NC(C#N)C#N)I,,,,,,
2349,22350,((p-Ethoxyphenyl)azo)malononitrile,CCOC1=CC=C(C=C1)N=NC(C#N)C#N,,,,,,
2350,22351,((4-Bromo-o-tolyl)azo)malononitrile,CC1=C(C=CC(=C1)Br)N=NC(C#N)C#N,,,,,,
2351,22352,((4-Iodo-o-tolyl)azo)malononitrile,CC1=C(C=CC(=C1)I)N=NC(C#N)C#N,,,,,,
2352,22353,((4-Bromo-m-tolyl)azo)malononitrile,CC1=C(C=CC(=C1)N=NC(C#N)C#N)Br,,,,,,
2353,22354,((2-Bromo-p-tolyl)azo)malononitrile,CC1=CC(=C(C=C1)N=NC(C#N)C#N)Br,,,,,,
2354,22355,((2-Bromo-4-ethoxyphenyl)azo)malononitrile,CCOC1=CC(=C(C=C1)N=NC(C#N)C#N)Br,,,,,,
2355,22356,"((3,5-Dibromophenyl)azo)malononitrile",C1=C(C=C(C=C1Br)Br)N=NC(C#N)C#N,,,,,,
2356,22357,((4-Bromo-2-chlorophenyl)azo)malononitrile,C1=CC(=C(C=C1Br)Cl)N=NC(C#N)C#N,,,,,,
2357,22358,((4-Bromo-3-chlorophenyl)azo)malononitrile,C1=CC(=C(C=C1N=NC(C#N)C#N)Cl)Br,,,,,,
2358,22359,"((2,4,6-Tribromophenyl)azo)malononitrile",C1=C(C=C(C(=C1Br)N=NC(C#N)C#N)Br)Br,,,,,,
2359,22360,((m-Nitrophenyl)azo)malononitrile,C1=CC(=CC(=C1)[N+](=O)[O-])N=NC(C#N)C#N,,,,,,
2360,22361,((4-Nitro-o-tolyl)azo)malononitrile,CC1=C(C=CC(=C1)[N+](=O)[O-])N=NC(C#N)C#N,,,,,,
2361,22362,((4-Nitro-m-tolyl)azo)malononitrile,CC1=C(C=CC(=C1)N=NC(C#N)C#N)[N+](=O)[O-],,,,,,
2362,22363,((4-Ethoxy-2-nitrophenyl)azo)malononitrile,CCOC1=CC(=C(C=C1)N=NC(C#N)C#N)[N+](=O)[O-],,,,,,
2363,22364,((3-Chloro-4-nitrophenyl)azo)malononitrile,C1=CC(=C(C=C1N=NC(C#N)C#N)Cl)[N+](=O)[O-],,,,,,
2364,22365,"Malononitrile, ((4-chloro-2-nitrophenyl)azo)-",C1=CC(=C(C=C1Cl)[N+](=O)[O-])N=NC(C#N)C#N,,,,,,
2365,22366,(1-Naphthylazo)malononitrile,C1=CC=C2C(=C1)C=CC=C2N=NC(C#N)C#N,,,,,,
2366,22367,CID 22367,C1=CC(=C(C=C1N)O)C(=O)[O-].[Na+],,,,,,
2367,22368,"1,2,5,6-Tetrahydro-1-methylnicotinic acid hydrochloride",C[NH+]1CCC=C(C1)C(=O)O.[Cl-],,,,,,
2368,22369,Unii-HM0PW39IN5,CC[NH2+]CC.C1=CC(=CC=C1C(=O)[O-])N,,,,,,
2369,22370,"1-Chloro-N'-(3,4-dichlorophenyl)-N,N-dimethylformamidine",CN(C)C(=NC1=CC(=C(C=C1)Cl)Cl)Cl,,,,,,
2370,22371,CID 22371,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)[O-].[K+],,,,,,
2371,22372,N-(9H-fluoren-2-yl)-N-oxidoacetamide,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)[O-],,,,,,
2372,22373,"4-chloro-6-methyl-N-phenyl-1,3,5-triazin-2-amine",CC1=NC(=NC(=N1)Cl)NC2=CC=CC=C2,,,,,,
2373,22374,CID 22374,CN1C=NC2=C1C(=O)N(C(=O)N2C)CC(=O)[O-].[Na+],,,,,,
2374,22375,1-Theobromineacetic acid,CN1C=NC2=C1C(=O)N(C(=O)N2C)CC(=O)O,,,,,,
2375,22376,CID 22376,CO[C@@H]1CC23[C@H]4CC(=O)OCC4CC[NH+]2CCC3C=C1.[Br-],,,,,,
2376,22377,2-((p-Methoxy-alpha-phenylbenzyl)oxy)ethyl(dimethyl)ammonium chloride,C[NH+](C)CCOC(C1=CC=CC=C1)C2=CC=C(C=C2)OC.[Cl-],,,,,,
2377,22378,Hostacaine,CCCC[NH2+]CC(=O)NC1=C(C=CC=C1Cl)C.[Cl-],,,,,,
2378,22379,Butanilicaine,CCCCNCC(=O)NC1=C(C=CC=C1Cl)C,,,,,,
2379,22380,"Benzyl alcohol, alpha-((methylamino)methyl)-, hydrochloride",C[NH2+]CC(C1=CC=CC=C1)O.[Cl-],,,,,,
2380,22381,"7-methoxy-1-methyl-4,9-dihydro-3H-pyrido[3,4-b]indol-9-ium;chloride",CC1=NCCC2=C1[NH2+]C3=C2C=CC(=C3)OC.[Cl-],,,,,,
2381,22382,"7-methoxy-1-methyl-9H-pyrido[3,4-b]indol-9-ium;chloride",CC1=NC=CC2=C1[NH2+]C3=C2C=CC(=C3)OC.[Cl-],,,,,,
2382,22383,Dipropyl trisulfide,CCCSSSCCC,,,,,,
2383,22384,Echinatine,CC(C)C(C(C)O)(C(=O)OCC1=CCN2C1C(CC2)O)O,,,,,,
2384,22385,2-Phenylhexane,CCCCC(C)C1=CC=CC=C1,,,,,,
2385,22386,2-Pentanol,CCCC(C)O,,,,,,
2386,22387,CID 22387,CCCCCCCCC=CCCCCCCCC(=O)O.CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O,,,,,,
2387,22388,"3-(((Diethylamino)carbonyl)oxy)-N,N,N-trimethylbenzenaminium",CCN(CC)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C.COS(=O)(=O)[O-],,,,,,
2388,22389,[3-(Diethylcarbamoyloxy)phenyl]-trimethylazanium,CCN(CC)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,,,,,,
2389,22390,Hexalgon hydrobromide,CCC(=O)C(CC[NH+]1CCCCC1)(C2=CC=CC=C2)C3=CC=CC=C3.[Br-],,,,,,
2390,22391,Norpipanone,CCC(=O)C(CCN1CCCCC1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
2391,22392,"[(2R,3R,5R,8R,10R,17S)-8-acetyloxy-11-ethyl-5,7,14-trihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azoniahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] benzoate;bromide",CC[NH+]1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5C[C@]6(C([C@@H]5[C@@]4(C(C6OC)O)OC(=O)C)OC(=O)C7=CC=CC=C7)O)C(CC2O)OC)OC)COC.[Br-],,,,,,
2392,22393,Mild aconitate,CCN1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5C[C@]6(C([C@@H]5[C@@]4(C(C6OC)O)OC(=O)C)OC(=O)C7=CC=CC=C7)O)C(CC2O)OC)OC)COC,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Compounds that either stimulate the opening or prevent closure of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Agonists.)']",,,
2393,22394,Trypaflavine hydrochloride,C[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)[NH3+].[Cl-].[Cl-],,,,,,
2394,22395,(2-Naphthyloxy)acetic acid ethyl ester,CCOC(=O)COC1=CC2=CC=CC=C2C=C1,,,,,,
2395,22396,Ethylphenyl malonic acid 2-(diethylamino)ethyl ethyl ester hydrobromide,CC[NH+](CC)CCOC(=O)C(CCC1=CC=CC=C1)C(=O)OCC.[Br-],,,,,,
2396,22397,1-O-[2-(diethylamino)ethyl] 3-O-ethyl 2-(2-phenylethyl)propanedioate,CCN(CC)CCOC(=O)C(CCC1=CC=CC=C1)C(=O)OCC,,,,,,
2397,22398,Ethomoxane hydrochloride,CCCC[NH2+]CC1COC2=C(O1)C(=CC=C2)OCC.[Cl-],,,,,,
2398,22399,C.I. Pigment red 2,C1=CC=C(C=C1)NC(=O)C2=CC3=CC=CC=C3C(=C2O)N=NC4=C(C=CC(=C4)Cl)Cl,,,,,,
2399,22400,"4-(2-Bromo-4,5-dimethoxyphenyl)-1,1,7,7-tetraethyldiethylenetriamine",CCN(CC)CCN(CCN(CC)CC)C1=CC(=C(C=C1Br)OC)OC,,,,,,
2400,22401,Methiotriazamine,CC1(N=C(N=C(N1C2=CC=C(C=C2)SC)N)N)C,,,,,,
2401,22402,CID 22402,CO[C@@H]1C[C@@]23C(=CCN2CCC4=C3C=C(OC4)[O-])C=C1.[Na+],,,,,,
2402,22403,"(1S,16R)-16-methoxy-5-oxa-10-azatetracyclo[8.7.0.01,13.02,7]heptadeca-2(7),3,12,14-tetraen-4-ol",CO[C@@H]1C[C@@]23C(=CCN2CCC4=C3C=C(OC4)O)C=C1,,,,,,
2403,22404,beta-Erythroidine methiodide,C[N+]12CCC3=C([C@@]14C[C@H](C=CC4=CC2)OC)CC(=O)OC3.[I-],,,,,,
2404,22405,"(1S,16R)-16-methoxy-10-methyl-5-oxa-10-azoniatetracyclo[8.7.0.01,13.02,7]heptadeca-2(7),12,14-trien-4-one",C[N+]12CCC3=C([C@@]14C[C@H](C=CC4=CC2)OC)CC(=O)OC3,,,,,,
2405,22406,"11-Aza-7-azoniatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one;chloride",C1C2CNCC1C3=CC=CC(=O)[NH+]3C2.[Cl-],,,,,,
2406,22407,(-)-Cytisine,C1C2CNCC1C3=CC=CC(=O)N3C2,,,,,,
2407,22408,CID 22408,C1=CC=C2C(=C1)C=CC=C2CN=C([NH3+])N.[Cl-],,,,,,
2408,22409,(1-Naphthylmethyl)guanidine,C1=CC=C2C(=C1)C=CC=C2CN=C(N)N,,,,,,
2409,22410,"Formamide, 2-piperidino-1-piperidinocarbonyl-",C1CCN(CC1)C(=O)C(=O)NN2CCCCC2,,,,,,
2410,22411,Acetylthiocholine chloride,CC(=O)SCC[N+](C)(C)C.[Cl-],,,,,,
2411,22412,"3-Oxaspiro(5,5)undecan-2-one",C1CCC2(CC1)CCOC(=O)C2,,,,,,
2412,22413,7H-benzo[c]fluoren-7-one,C1=CC=C2C(=C1)C=CC3=C2C4=CC=CC=C4C3=O,,,,,,
2413,22414,3-Methyl-4-phenylbut-2-enoic acid,CC(=CC(=O)O)CC1=CC=CC=C1,,,,,,
2414,22415,"alpha,alpha'-Diethyl-alpha,alpha'-epoxybibenzyl-4,4'-diol",CCC1(C(O1)(CC)C2=CC=C(C=C2)O)C3=CC=C(C=C3)O,,,,,,
2415,22416,"1-Naphthalenamine, 4-[(4-aminophenyl)azo]-",C1=CC=C2C(=C1)C(=CC=C2N=NC3=CC=C(C=C3)N)N,,,,,,
2416,22417,"Propanenitrile, 3-((2-hydroxyethyl)(3-methyl-4-((4-nitrophenyl)azo)phenyl)amino)-",CC1=C(C=CC(=C1)N(CCC#N)CCO)N=NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
2417,22418,CID 22418,C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)[O-])C(=O)[O-])O.[Na+].[Na+],,,,,,
2418,22419,Olsalazine,C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O,['For the treatment of Inflammatory Bowel Disease and Ulcerative Colitis.'],"['Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine reduces the bowel inflammation, diarrhea (stool frequency), rectal bleeding, and abdominal pain. Olsalazine is thought to work like balsalazide, delivering mesalazine or 5-aminosalicylic acid past the small intestine to the large intestine to act on the site of disease.']","['Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)', 'Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)']","['After oral administration, olsalazine, has limited systemic bioavailability.  98-99% of the dose is converted to mesalamine (5-ASA) in the colon, which is absorbed slowly resulting in very high local concentrations in the colon.', 'Approximately 0.1% of an oral dose of olsalazine is metabolized in the liver to olsalazine-O-sulfate (olsalazine-S).The remaining 5-ASA is partially acetylated and is excreted in the feces.']","['Most (98 to 99%) of an oral dose is rapidly converted into two molecules of 5-aminosalicylic acid (5-ASA) by colonic bacteria and the low prevailing redox potential found in this environment. The conversion of olsalazine to mesalamine in the colon is similar to that of sulfasalazine, which is converted into sulfapyridine and mesalamine. Approximately 0.1% of an oral dose of olsalazine is metabolized in the liver to olsalazine-O-sulfate (olsalazine-S)']","['Olsalazine has an elimination half-life of 0.9 hours, however, olsalazine-S has a half-life of 7 days.']"
2419,22420,Cyclophosphamide monohydrate,C1CNP(=O)(OC1)N(CCCl)CCCl.O,,,"['Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)', 'A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) (See all compounds classified as Antineoplastic Agents, Alkylating.)', 'Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION. (See all compounds classified as Myeloablative Agonists.)', 'Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)', 'Drugs that are used to treat RHEUMATOID ARTHRITIS. (See all compounds classified as Antirheumatic Agents.)']",,,
2420,22421,Hexamethylene diammoniumdichloride,C(CCC[NH3+])CC[NH3+].[Cl-].[Cl-],,,,,,
2421,22422,"[(2R,8R,10R,17S)-8-acetyloxy-11-ethyl-5,7,14-trihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azoniahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] benzoate;chloride",CC[NH+]1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5CC6(C(C5[C@@]4(C(C6OC)O)OC(=O)C)OC(=O)C7=CC=CC=C7)O)C(CC2O)OC)OC)COC.[Cl-],,,,,,
2422,22423,"[(2R,8R,10R,17S)-8-acetyloxy-11-ethyl-5,7,14-trihydroxy-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-4-yl] benzoate",CCN1CC2([C@H]3C(C4[C@@H]1C3([C@@H]5CC6(C(C5[C@@]4(C(C6OC)O)OC(=O)C)OC(=O)C7=CC=CC=C7)O)C(CC2O)OC)OC)COC,,,,,,
2423,22424,Pipazethate hydrochloride,C1CCN(CC1)CCOCCOC(=O)N2C3=CC=CC=C3SC4=C2N=CC=C4.Cl,,,"['Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally. (See all compounds classified as Antitussive Agents.)']",,,
2424,22425,Pipazethate,C1CCN(CC1)CCOCCOC(=O)N2C3=CC=CC=C3SC4=C2N=CC=C4,['For the treatment of cough.'],['Antitussive agents act centrally on the medullary cough center.'],"['Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally. (See all compounds classified as Antitussive Agents.)']",,,
2425,22426,CID 22426,C=CCC1(C(=O)NC(=NC1=O)[O-])C2=CC=CC=C2.[Na+],,,,,,
2426,22427,((o-Nitrophenyl)azo)malononitrile,C1=CC=C(C(=C1)N=NC(C#N)C#N)[N+](=O)[O-],,,,,,
2427,22428,((2-Nitro-p-tolyl)azo)malononitrile,CC1=CC(=C(C=C1)N=NC(C#N)C#N)[N+](=O)[O-],,,,,,
2428,22429,"1,1-Dichlorobuta-1,3-diene",C=CC=C(Cl)Cl,,,,,,
2429,22430,"(2,2-dimethylpropylideneamino) N-methylcarbamate",CC(C)(C)C=NOC(=O)NC,,,,,,
2430,22431,CID 22431,CC1=C(C=CC(=C1)Cl)OCCCC(=O)[O-].[Na+],,,,,,
2431,22432,"3,3-Bis-(4-aminophenyl)-propylamine",C1=CC(=CC=C1CCC(C2=CC=C(C=C2)N)N)N,,,,,,
2432,22433,4-Oxononanoic acid,CCCCCC(=O)CCC(=O)O,,,,,,
2433,22434,Methyl heneicosanoate,CCCCCCCCCCCCCCCCCCCCC(=O)OC,,,,,,
2434,22435,5-Nitronon-4-ene,CCCCC(=CCCC)[N+](=O)[O-],,,,,,
2435,22436,4-Nitronon-3-ene,CCCCCC(=CCC)[N+](=O)[O-],,,,,,
2436,22437,3-Nitro-3-nonene,CCCCCC=C(CC)[N+](=O)[O-],,,,,,
2437,22438,3-Nitronon-2-ene,CCCCCCC(=CC)[N+](=O)[O-],,,,,,
2438,22439,4-Nitro-oct-4-ene,CCCC=C(CCC)[N+](=O)[O-],,,,,,
2439,22440,4-Nitro-oct-3-ene,CCCCC(=CCC)[N+](=O)[O-],,,,,,
2440,22441,3-Nitrooct-3-ene,CCCCC=C(CC)[N+](=O)[O-],,,,,,
2441,22442,3-Nitrooct-2-ene,CCCCCC(=CC)[N+](=O)[O-],,,,,,
2442,22443,2-Nitro-oct-2-ene,CCCCCC=C(C)[N+](=O)[O-],,,,,,
2443,22444,4-Nitro-hept-3-ene,CCCC(=CCC)[N+](=O)[O-],,,,,,
2444,22445,3-Nitro-hept-2-ene,CCCCC(=CC)[N+](=O)[O-],,,,,,
2445,22446,2-Nitro-hept-2-ene,CCCCC=C(C)[N+](=O)[O-],,,,,,
2446,22447,3-Nitrohex-2-ene,CCCC(=CC)[N+](=O)[O-],,,,,,
2447,22448,2-Nitro-hex-2-ene,CCCC=C(C)[N+](=O)[O-],,,,,,
2448,22449,"13-Chloro-5-nitro-2-iodonia-9-oxatricyclo[8.4.0.03,8]tetradeca-1(10),4,7,11,13-pentaene;sulfite",C1C=C2C(C=C1[N+](=O)[O-])[I+]C3=C(O2)C=CC(=C3)Cl.[O-]S(=O)[O-],,,,,,
2449,22450,"13-Chloro-5-nitro-2-iodonia-9-oxatricyclo[8.4.0.03,8]tetradeca-1(10),4,7,11,13-pentaene",C1C=C2C(C=C1[N+](=O)[O-])[I+]C3=C(O2)C=CC(=C3)Cl,,,,,,
2450,22451,Phenethyltrimethylammonium bromide,C[N+](C)(C)CCC1=CC=CC=C1.[Br-],,,,,,
2451,22452,"S-Ethyl O-(2-(1-methylpropyl)-4,6-dinitrophenyl) carbonothioate",CCC(C)C1=C(C(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])OC(=O)SCC,,,,,,
2452,22453,3-(p-Chlorophenyl)-5-(2-(dimethylamino)ethyl)isoxazole hydrochloride,C[NH+](C)CCC1=CC(=NO1)C2=CC=C(C=C2)Cl.[Cl-],,,,,,
2453,22454,"2-[3-(4-chlorophenyl)-1,2-oxazol-5-yl]-N,N-dimethylethanamine",CN(C)CCC1=CC(=NO1)C2=CC=C(C=C2)Cl,,,,,,
2454,22455,Diacetyldigoxigenin,CC(=O)O[C@H]1CC[C@]2([C@@H](C1)CCC3C2C[C@H]([C@]4([C@@]3(CC[C@@H]4C5=CC(=O)OC5)O)C)OC(=O)C)C,,,,,,
2455,22456,Lead acetate trihydrate,CC(=O)[O-].CC(=O)[O-].O.O.O.[Pb+2],,,,,,
2456,22457,CID 22457,[Li+].C(C(=O)O)C(CC(=O)[O-])(C(=O)O)O,,,,,,
2457,22458,"1-Benzyl-1,2,4-triazole",C1=CC=C(C=C1)CN2C=NC=N2,,,,,,
2458,22459,"1-Methyl-1,2,4-triazole",CN1C=NC=N1,,,,,,
2459,22460,"1-Butyl-1H-1,2,4-triazole",CCCCN1C=NC=N1,,,,,,
2460,22461,CID 22461,CC1(CN=C(N1)S)C,,,,,,
2461,22462,"6H-Dibenzo(b,d)pyran-1-ol, 6a-beta,7,8,10-a-beta-tetrahydro-3-pentyl-6,6,9-trimethyl-, (+-)-Z-",CCCCCC1=CC(=C2[C@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O,,,,,,
2462,22463,6-Hydroxy-2-naphthyl disulfide,C1=CC2=C(C=CC(=C2)SSC3=CC4=C(C=C3)C=C(C=C4)O)C=C1O,,,,,,
2463,22464,4-Pentynoic acid,C#CCCC(=O)O,,,,,,
2464,22465,Piperidinium chloride,C1CC[NH2+]CC1.[Cl-],,,,,,
2465,22466,Hexyl chloroformate,CCCCCCOC(=O)Cl,,,,,,
2466,22467,"Carbamic acid, hydroxy-, isobutyl ester",CC(C)COC(=O)NO,,,,,,
2467,22468,2-Methyl-1-hexene,CCCCC(=C)C,,,,,,
2468,22469,Acetoxyacetylaminofluorene,CC(=O)N(C1=CC2=C(C=C1)C3=CC=CC=C3C2)OC(=O)C,,,"['Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. (See all compounds classified as Alkylating Agents.)']",,,
2469,22470,Tripotassium;3-(carboxylatomethyl)-3-hydroxypentanedioate,C(C(=O)[O-])C(CC(=O)[O-])(CC(=O)[O-])O.[K+].[K+].[K+],,,,,,
2470,22471,3-(Carboxymethyl)-3-hydroxypentanedioic acid,C(C(=O)O)C(CC(=O)O)(CC(=O)O)O,,,,,,
2471,22472,CID 22472,COC1=CC=CC=C1OS(=O)(=O)[O-].[K+],,,,,,
2472,22473,o-Methoxyphenyl sulfate,COC1=CC=CC=C1OS(=O)(=O)O,,,,,['O-Methoxyphenyl sulfate is a known human metabolite of Catechol.'],
2473,22474,"Ethanedioic acid, potassium salt (2:1)",C(=O)(C(=O)O)O.C(=O)(C(=O)[O-])O.[K+],,,,,,
2474,22475,Succinylcholine chloride,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-],,,['Drugs that interrupt transmission at the skeletal neuromuscular junction by causing sustained depolarization of the motor end plate. These agents are primarily used as adjuvants in surgical anesthesia to cause skeletal muscle relaxation. (See all compounds classified as Neuromuscular Depolarizing Agents.)'],,,
2475,22476,CID 22476,C1=CC=NC(=C1)[N-]S(=O)(=O)C2=CC=C(C=C2)N.O.[Na+],,,,,,
2476,22477,"m-DIOXANE, 5,5-BIS(CHLOROMETHYL)-2-PHENYL-",C1C(COC(O1)C2=CC=CC=C2)(CCl)CCl,,,,,,
2477,22478,Isobutylidenediurea,CC(C)C(NC(=O)N)NC(=O)N,,,,,,
2478,22479,CID 22479,CCCCC(=O)[O-].[Na+],,,,,,
2479,22480,"[(1S,2R,4S,5S)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] 3-hydroxy-2-phenylpropanoate;nitrate",C[N+]1([C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(CO)C4=CC=CC=C4)C.[N+](=O)([O-])[O-],,,,,,
2480,22481,"[(1S,2R,4S,5S)-9-methyl-9-oxido-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] 3-hydroxy-2-phenylpropanoate;hydrobromide",C[N+]1([C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(CO)C4=CC=CC=C4)[O-].Br,,,,,,
2481,22482,CID 22482,C[N+]1([C@H]2CC(C[C@H]1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4)[O-],,,,,,
2482,22483,Dalcaine,CC[NH+](CC)CC(=O)NC1=C(C=CC=C1C)C.O.[Cl-],,,"['A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)', 'Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate. (See all compounds classified as Anesthetics, Local.)']",,,
2483,22484,CID 22484,[Li+].C12=C(NC(=O)N1)NC(=NC2=O)[O-],,,,,,
2484,22485,4-Pentenyltrimethylammonium iodide,C[N+](C)(C)CCCC=C.[I-],,,,,,
2485,22486,Trimethyl(4-pentenyl)aminium,C[N+](C)(C)CCCC=C,,,,,,
2486,22487,(9-Ethyl-9H-carbazol-3-yl)ammonium chloride,CCN1C2=C(C=C(C=C2)[NH3+])C3=CC=CC=C31.[Cl-],,,,,,
2487,22488,11-Methylbenz[a]anthracene,CC1=C2C=C3C(=CC2=CC=C1)C=CC4=CC=CC=C43,,,,,,
2488,22489,"Benzothiazolium, 3-methyl-, salt with 4-methylbenzenesulfonic acid (1:1)",CC1=CC=C(C=C1)S(=O)(=O)[O-].C[N+]1=CSC2=CC=CC=C21,,,,,,
2489,22490,"3-Methyl-1,3-benzothiazol-3-ium",C[N+]1=CSC2=CC=CC=C21,,,,,,
2490,22491,CID 22491,C1=NC2=C(N1)C(=NC=N2)S.O,,,,,,
2491,22492,"6H-CYCLOHEPTA(b)QUINOLINE, 7,8,9,10-TETRAHYDRO-11-CHLORO-1,4-DIMETHYL-",CC1=C2C(=C(C=C1)C)N=C3CCCCCC3=C2Cl,,,,,,
2492,22493,"7-Chloro-1,2,3,4-tetrahydroacridin-9-amine",C1CCC2=NC3=C(C=C(C=C3)Cl)C(=C2C1)N,,,,,,
2493,22494,"2-Benzofurancarboxamide, 5-(piperidinomethyl)-",C1CCN(CC1)CC2=CC3=C(C=C2)OC(=C3)C(=O)N,,,,,,
2494,22495,"Indol-4(5H)-one, 6,7-dihydro-2,3-dimethyl-",CC1=C(NC2=C1C(=O)CCC2)C,,,,,,
2495,22496,(5-Ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol;phosphenous acid,COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O.OP=O,,,,,,
2496,22497,phosphenous acid,OP=O,,,,,,
2497,22498,"2-(1-Methylheptyl)-4,6-dinitrophenyl crotonate",CCCCCCC(C)C1=C(C(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])OC(=O)C=CC,,,,,,
2498,22499,"4-Dimethylamino-3,5-xylenol",CC1=CC(=CC(=C1N(C)C)C)O,,,,,,
2499,22500,"Hexane, 2,3-epoxy-, cis-",CCCC1C(O1)C,,,,,,
2500,22501,"1,2-Diphenyl-4-carbamoyl-3,5-pyrazolidinedione",C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)C(=O)N,,,,,,
2501,22502,Penicillin G procaine,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
2502,22503,"2,4,5-Trichloroanisole",COC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
2503,22504,Hexachlorocyclobutene,C1(=C(C(C1(Cl)Cl)(Cl)Cl)Cl)Cl,,,,,,
2504,22505,Tetramethyltetrazene,CN(C)N=NN(C)C,,,,,,
2505,22506,"1-Nitroso-2,2,6,6-tetramethylpiperidine",CC1(CCCC(N1N=O)(C)C)C,,,,,,
2506,22507,CID 22507,CC(=O)[O-].O.O.O.[Na+],,,,,,
2507,22508,CID 22508,C[As](=O)(C)[O-].[Na+],,,,,,
2508,22509,N-Methylcarbanilic acid 1-cyclopenten-1-yl ester,CN(C1=CC=CC=C1)C(=O)OC2=CCCC2,,,,,,
2509,22510,"2-(Tert-butyl)-2-methyl-1,3-dioxolane",CC1(OCCO1)C(C)(C)C,,,,,,
2510,22511,3-Methyloctan-2-one,CCCCCC(C)C(=O)C,,,,,,
2511,22512,4-Methyl-3-heptanone,CCCC(C)C(=O)CC,,,,,,
2512,22513,1-(3-Cyclohexyl-3-hydroxy-3-phenylpropyl)-1-methylpyrrolidin-1-ium hydrogen sulfate,C[N+]1(CCCC1)CCC(C2CCCCC2)(C3=CC=CC=C3)O.OS(=O)(=O)[O-],,,,,,
2513,22514,Tricyclamol cation,C[N+]1(CCCC1)CCC(C2CCCCC2)(C3=CC=CC=C3)O,,,,,,
2514,22515,sodium;gold(1+);2-sulfido-1H-benzimidazole-4-carboxylate,C1=CC(=C2C(=C1)NC(=N2)[S-])C(=O)[O-].[Na+].[Au+],,,,,,
2515,22516,CID 22516,C1=CC(=C2C(=C1)NC(=N2)S)C(=O)O,,,,,,
2516,22517,CID 22517,CC1=CC=C(C=C1)C(=CC[NH+]2CCCC2)C3=CC=CC=N3.[Cl-],,,,,,
2517,22518,3-Acetamidophenyltrimethylammonium iodide,CC(=O)NC1=CC(=CC=C1)[N+](C)(C)C.[I-],,,,,,
2518,22519,[3-(Acetylamino)phenyl]trimethylaminium,CC(=O)NC1=CC(=CC=C1)[N+](C)(C)C,,,,,,
2519,22520,6-Methylcaprolactam,CC1CCCC(=O)NC1,,,,,,
2520,22521,alpha-Methylstyrene dimer,CC(=C)C1=CC=CC=C1.CC(=C)C1=CC=CC=C1,,,,,,
2521,22522,Tris(2-chloropropyl) phosphate,CC(COP(=O)(OCC(C)Cl)OCC(C)Cl)Cl,,,,,,
2522,22523,5-Nitroindole,C1=CC2=C(C=CN2)C=C1[N+](=O)[O-],,,,,,
2523,22524,CID 22524,C1=CC(=NC2=CC=C(C=C2)N(O)O)C=CC1=N,,,,,,
2524,22525,CID 22525,CC1=CC(=C(N1C2=CC=CC=C2)C)C=CC3=[N+](C4=C(C=C3)C=C(C=C4)N(C)C)C.[Cl-],,,,,,
2525,22526,"2-[2-(2,5-dimethyl-1-phenylpyrrol-3-yl)ethenyl]-N,N,1-trimethylquinolin-1-ium-6-amine",CC1=CC(=C(N1C2=CC=CC=C2)C)C=CC3=[N+](C4=C(C=C3)C=C(C=C4)N(C)C)C,,,,,,
2526,22527,4-[(6-Chloro-2-methoxyacridin-9-yl)azaniumyl]pentyl-diethylazanium;dichloride,CC[NH+](CC)CCCC(C)[NH2+]C1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC.[Cl-].[Cl-],,,,,,
2527,22528,(2-(Dimethylamino)ethyl) (o-benzylphenoxy)ether hydrochloride,C[NH+](C)CCOC1=CC=CC=C1CC2=CC=CC=C2.[Cl-],,,,,,
2528,22529,Mebhydrolin napadisilate,CN1CCC2=C(C1)C3=CC=CC=C3N2CC4=CC=CC=C4.CN1CCC2=C(C1)C3=CC=CC=C3N2CC4=CC=CC=C4.C1=CC2=C(C=CC=C2S(=O)(=O)O)C(=C1)S(=O)(=O)O,,,,,,
2529,22530,Mebhydrolin,CN1CCC2=C(C1)C3=CC=CC=C3N2CC4=CC=CC=C4,,,,,,
2530,22531,CID 22531,C1=CC=C2C(=C1)C(=NS2(=O)=O)[O-].O.O.[Na+],,,,,,
2531,22532,"2-Azetidinone, 1-(20-alpha-(dimethylamino)-4-oxo-5-alpha-pregnan-3-beta-yl)-3-isopropyl-, (3R)-",CC(C)[C@@H]1CN(C1=O)[C@H]2CC[C@@]3([C@H]4CC[C@]5([C@H]([C@@H]4CC[C@H]3C2=O)CC[C@H]5C(C)N(C)C)C)C,,,,,,
2532,22533,"N,N-Diethyl-2-{[17-(methoxyimino)androst-5-en-3-yl]oxy}ethan-1-amine",CCN(CC)CCOC1CCC2(C3CCC4(C(C3CC=C2C1)CCC4=NOC)C)C,,,,,,
2533,22534,"[(7R,9S,14S,17S)-7,13-dimethyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate",C[C@@H]1CC2=CC(=O)CCC2[C@@H]3C1[C@@H]4CC[C@@H](C4(CC3)C)OC(=O)C,,,,,,
2534,22535,1-Isopropylnaphthalene,CC(C)C1=CC=CC2=CC=CC=C21,,,,,,
2535,22536,Dehydrochloramphenicol,C1=CC(=CC=C1C(=O)C(CO)NC(=O)C(Cl)Cl)[N+](=O)[O-],,,,,,
2536,22537,2-Methylhexylazanium;chloride,CCCCC(C)C[NH3+].[Cl-],,,,,,
2537,22538,2-Methylhexan-1-amine,CCCCC(C)CN,,,,,,
2538,22539,2-(2-Methylphenoxy)ethanol,CC1=CC=CC=C1OCCO,,,,,,
2539,22540,2-[Bis(2-aminoethyl)boranyl]ethanamine,B(CCN)(CCN)CCN,,,,,,
2540,22541,Di-tert-butyl ether,CC(C)(C)OC(C)(C)C,,,,,,
2541,22542,Tris(2-methoxyethyl) phosphate,COCCOP(=O)(OCCOC)OCCOC,,,,,,
2542,22543,Protopine hydrochloride,CN1CCC2=CC3=C(C=C2C(=O)CC4=C(C1)C5=C(C=C4)OCO5)OCO3.Cl,,,"['Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)', 'Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)']",,,
2543,22544,Chlordimeform,CC1=C(C=CC(=C1)Cl)N=CN(C)C,,,"['Chemical agents that uncouple oxidation from phosphorylation in the metabolic cycle so that ATP synthesis does not occur. Included here are those IONOPHORES that disrupt electron transfer by short-circuiting the proton gradient across mitochondrial membranes. (See all compounds classified as Uncoupling Agents.)', 'Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)', 'A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman&apos;s The Pharmacological Basis of Therapeutics, 8th ed, p414) (See all compounds classified as Monoamine Oxidase Inhibitors.)']","[""(14)C-N'-(4-CHLORO-O-TOLYL)-NN-DIMETHYLFORMAMIDINE WAS READILY ABSORBED."", 'AQ SOLN OF (14)C-CHLORDIMEFORM WERE ADMIN BY STOMACH TUBE TO SPRAGUE-DAWLEY RATS. ... HALF OF DOSE WAS EXCRETED IN URINE IN 24 HR; 87.1 & 95.4% IN 96 HR BY MALES & FEMALES, RESPECTIVELY. ... ABSORPTION & METABOLISM OF CHLORDIMEFORM BY RICE STEM BORER WAS SLOW.', 'The base, but not the hydrochloride, is readily absorbed by the skin.', 'Chlordimeform is readily absorbed through the skin of pesticide applicators. It also enters the body whenbreathed into the lungs. Chlordimeform can be found in the urine of workers who handle or are involved in applying pesticide products which contain the chemical, even when they are wearing special protective clothing and respirators.Because of the adverse health effects seen in heavily exposed workers and the cancerous tumors seen in mice, special precautions are necessary when handling products containing chlordimeform to reduce the risk of adverse health effects. Because chlordimeform is known to enter the body very easily, with serious injury potential, workers handling pesticide products containing chlordimeform in California are required to have medical supervision including a blood test at the beginning and end of each application season and monthly testing of urine for possible cellular change and pesticide residues during the time chlordimeform exposure takes place.']","[""RATE OF BIOTRANSFORMATION ... WAS SPECIES DEPENDENT, BUT ESSENTIALLY SAME ARRAY OF URINARY METABOLITES WAS EXCRETED BY RATS, DOGS, & GOATS. UNCONJUGATED METABOLITES INCL N'-(4-CHLORO-O-TOLYL)-N-METHYLFORMAMIDINE, 4'-CHLORO-O-FORMOTOLUIDIDE, 4-CHLORO-O-TOLUIDINE, N-FORMYL-5-CHLOROANTHRANILIC ACID, & 5-CHLOROANTHRANILIC ACID."", '/IN RATS, DOGS, & GOATS/ THE CONCN OF ... /METABOLITES N- FORMYL-5-CHLOROANTHRANILIC ACID & 5-CHLOROANTHRANILIC ACID/ IN URINE INCR WITH THE TIME AFTER DOSING, GOAT BEING MOST EFFICIENT PRODUCER ... .', 'ENZYME DECONJUGATION SHOWED THAT ALL OF THE FREE METABOLITES OF CHLORPHENAMIDINECORRESPONDED TO THE UNCONJUGATED GLYCONES OF THE WATER-SOL GLUCURONIDE &/OR ETHER SULFATE CONJUGATES. /THOSE/ ... WITH AMINO- OR CARBOXY-GROUPS...WERE CONJUGATED WITH GLUCURONIC ACID IN VIVO, & ... /SOME/ COULD ALSO FORM SULFAMATES. ALL 6 EXCRETORY PRODUCTS FOUND IN URINE WERE ALSO SECRETED IN CONJUGATED & UNCONJUGATED FORMS IN BILE OF TREATED DOGS, TOGETHER WITH SEVERAL UNIDENTIFIED COMPD, WHICH CO-CHROMATOGRAPHED WITH SOME UNIDENTIFIED URINARY METABOLITES.', 'RAT-LIVER FORMAMIDASE ... THE NATURAL SUBSTRATE OF WHICH IS N-FORMYLKYNURENINE, IS ACTIVE IN THE HYDROLYSIS OF METABOLIC INTERMEDIATES OF ... CHLOROPHENAMIDINE ... .', 'For more Metabolism/Metabolites (Complete) data for CHLORDIMEFORM (8 total), please visit the HSDB record page.']",
2544,22545,7-Methylpentadecane,CCCCCCCCC(C)CCCCCC,,,,,,
2545,22546,"1,4-Dicyclohexylbutane",C1CCC(CC1)CCCCC2CCCCC2,,,,,,
2546,22547,Propargyl p-toluenesulfonate,CC1=CC=C(C=C1)S(=O)(=O)OCC#C,,,,,,
2547,22548,"2-(2,4-Dimethoxyphenyl)-3-methylbutan-2-ol",CC(C)C(C)(C1=C(C=C(C=C1)OC)OC)O,,,,,,
2548,22549,Isometheptene hydrochloride,CC(CCC=C(C)C)NC.Cl,,,,,,
2549,22550,"2,2''-(1-Methyl-2,6-piperidinediyl)diacetophenone hydrochloride",C[NH+]1C(CCCC1CC(=O)C2=CC=CC=C2)CC(=O)C3=CC=CC=C3.[Cl-],,,,,,
2550,22551,"1-Methyl-2,6-diphenacylpiperidine",CN1C(CCCC1CC(=O)C2=CC=CC=C2)CC(=O)C3=CC=CC=C3,,,,,,
2551,22552,"2,3,4,5-Tetrahydro-1-benzoxepin",C1CCOC2=CC=CC=C2C1,,,,,,
2552,22553,alpha-(alpha-Aminopropyl)benzyl alcohol hydrochloride,CCC(C(C1=CC=CC=C1)O)[NH3+].[Cl-],,,,,,
2553,22554,Clamidoxic acid,C1=CC=C(C(=C1)NC(=O)C2=CC(=C(C=C2)Cl)Cl)OCC(=O)O,,,,,,
2554,22555,"2,2-Diethoxyacetophenone",CCOC(C(=O)C1=CC=CC=C1)OCC,,,,,,
2555,22556,2-Dodecanone,CCCCCCCCCCC(=O)C,,,,,,
2556,22557,"1-Benzyl-2,3-dicyclohexylguanidine hydrochloride",C1CCC(CC1)NC(=NC2CCCCC2)[NH2+]CC3=CC=CC=C3.[Cl-],,,,,,
2557,22558,"1-Benzyl-2,3-dicyclohexylguanidine",C1CCC(CC1)NC(=NCC2=CC=CC=C2)NC3CCCCC3,,,,,,
2558,22559,p-Nitrophenyl p-benzyloxycarbanilate,C1=CC=C(C=C1)COC2=CC=C(C=C2)NC(=O)OC3=CC=C(C=C3)[N+](=O)[O-],,,,,,
2559,22560,3-Nitro-hept-3-ene,CCCC=C(CC)[N+](=O)[O-],,,,,,
2560,22561,CID 22561,CN1CC[C@]23[C@@H]4C(=O)CCC2[C@@H]1CC5=C3C(=C(C=C5)OC)O4.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
2561,22562,"(4S,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one",CN1CC[C@]23[C@@H]4C(=O)CCC2[C@@H]1CC5=C3C(=C(C=C5)OC)O4,,,,,,
2562,22563,Deethylatrazine,CC(C)NC1=NC(=NC(=N1)N)Cl,,,,"['... The atrazine (ATZ) concentrations in urine samples of the workers collected from an atrazine plant were determined by /a gas chromatograph-electron capture detector/ method /for detecting ATZ and its metabolites (deethylatrazine (DEA), deisopropylatrazine (DIA), deethyldeisopropylatrazine (DEDIA)) in human urine/. The concentration ranges were 0.003 -0.301 mg/L for DEDIA, 0.005 -0.011 mg/L for DEA, 0.006 -0.276 mg/L for DIA, and 0.005 -0.012 mg/L for ATZ.', '... After atrazine ingestion, the urine and carcass of treated animals /contained/ atrazine and its metabolites, indicating that atrazine was absorbed through the GI tract. /Atrazine & metabolites/']","['Deethylatrazine (desethyl atrazine) is a metabolite of atrazine.', 'Three species of Pseudomonas capable of utilizing atrazine as a sole source of carbon were isolated by enrichment from soil with a long history of atrazine application. Atrazine was metabolized via N-dealkylation with preferential formation of deisopropylatrazine over deethylatrazine. Two of the species were able to carry out the following incubation in glucose-supplemented mineral salts medium.', 'Deethylatrazine is primarily a mammalian metabolite but can be produced in plants and bacteria. Dealkylation of the ethyl group from the 4 position of the triazine ring yields deethylatrazine.', 'Manganese enhanced atrazine transformation by the fungus Pleurotus pulmonarius when added to a liquid culture medium at concentration of up to 300 uM. Both N-dealkylated and propylhydroxylated metabolites accumulated in the culture medium, with the former accumulating to a greater extent than did the latter. Lipid peroxidation, oxygenase and peroxidase activities, and the cytochrome P-450 concentration increased. In addition, an increase in the spectral interactions between atrazine and components in the cell extract was observed. Antioxidants, mainly nordihydroguaiaretic acid, which inhibits lipoxygenase, peroxidase, and P-450 activities, and piperonyl butoxide, which inhibits P-450 activity, inhibited atrazine transformation by the mycelium. It is suggested that the stimulation of oxidative activity by manganese might be responsible for increasing the biotransformation of atrazine and for nonspecific transformations of other xenobiotic compounds.']",
2563,22564,Aminopentamide hydrochloride,CC(CC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N)N(C)C.Cl,,,,,,
2564,22565,Aminopentamide,CC(CC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N)N(C)C,,,,,,
2565,22566,1-Butylspiropentane,CCCCC1CC12CC2,,,,,,
2566,22567,Neodymium triacetate,CC(=O)[O-].CC(=O)[O-].CC(=O)[O-].[Nd+3],,,,,,
2567,22568,2-Phenoxyethyl acetate,CC(=O)OCCOC1=CC=CC=C1,,,,,,
2568,22569,"5,6,7,8-Tetrahydrodibenz[c,e]azocine",C1CNCC2=CC=CC=C2C3=CC=CC=C31,,,,,,
2569,22570,"Benzene, 1,2-dimethyl-4-(1-phenylethyl)-",CC1=C(C=C(C=C1)C(C)C2=CC=CC=C2)C,,,,,,
2570,22571,Octocrylene,CCCCC(CC)COC(=O)C(=C(C1=CC=CC=C1)C2=CC=CC=C2)C#N,"['In the US, Octocrylene has been evaluated by the FDA and is considered safe for use up to 10% in the formula. Similarly, the EU allows its use up to 10% in a formula while Health Canada allows a maximum use level of 12%.']",,,"['Ecamsule is used topically, it not absorbed or metabolized.', 'Ecamsule is used topically, it not absorbed.', 'Ecamsule is only used topically, it not absorbed.', 'Ecamsule is used topically, it not absorbed or metabolized.']","['Ecamsule is used topically, it not absorbed.']","['Ecamsule is only used topically, it does not have half life']"
2571,22572,"[(6R)-6-[(2S,8S,9R,10R,13R,14S,16R)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-2,7,8,10,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl] acetate",CC(=O)OC(C)(C)C=CC(=O)[C@@](C)(C1[C@@H](C[C@@]2([C@@]1(CC(=O)[C@@]3([C@H]2CC=C4[C@H]3C[C@@H](C(=O)C4(C)C)O)C)C)C)O)O,,,,,,
2572,22573,3-Amino-5-sulfosalicylic acid,C1=C(C=C(C(=C1C(=O)O)O)N)S(=O)(=O)O,,,,,,
2573,22574,5-Amino-3-sulfosalicylic acid,C1=C(C=C(C(=C1C(=O)O)O)S(=O)(=O)O)N,,,,,,
2574,22575,"methyl 2-[(2S,3S)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate",CC[C@@H]1CN2CCC3=C(C2C[C@@H]1C(=COC)C(=O)OC)NC4=C3C(=CC=C4)OC,,,,,,
2575,22576,Cyclobenzaprine hydrochloride,CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31.Cl,,,"['A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) (See all compounds classified as Muscle Relaxants, Central.)', 'A traditional grouping of drugs said to have a soothing or calming effect on mood, thought, or behavior. Included here are the ANTI-ANXIETY AGENTS (minor tranquilizers), ANTIMANIC AGENTS, and the ANTIPSYCHOTIC AGENTS (major tranquilizers). These drugs act by different mechanisms and are used for different therapeutic purposes. (See all compounds classified as Tranquilizing Agents.)', 'Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)']",,,
2576,22577,"2,4-Heptadione, 7-chloro-6-(chlorodifluoromethyl)-7,7-difluoro-6-hydroxy-",CC(=O)CC(=O)CC(C(F)(F)Cl)(C(F)(F)Cl)O,,,,,,
2577,22578,2-Acetoxy-2-butene,CC=C(C)OC(=O)C,,,,,,
2578,22579,"Uridine, 2'-P-toluenesulfonate",CC1=CC=C(C=C1)S(=O)(=O)O[C@@H]2[C@@H]([C@H](O[C@H]2N3C=CC(=O)NC3=O)CO)O,,,,,,
2579,22580,Adamantane;2-hydroxy-5-sulfobenzoic acid,C1C2CC3CC1CC(C2)C3.C1=CC(=C(C=C1S(=O)(=O)O)C(=O)O)O,,,,,,
2580,22581,"Heliotrine, N-oxide",CC(C)C(C(C)OC)(C(=O)OCC1=CC[N+]2([C@@H]1[C@H](CC2)O)[O-])O,,,,,,
2581,22582,Methyl 4-nitrobenzenesulfonate,COS(=O)(=O)C1=CC=C(C=C1)[N+](=O)[O-],,,,,,
2582,22583,Diphenylarsinous acid,C1=CC=C(C=C1)[As](C2=CC=CC=C2)O,,,,,,
2583,22584,2-Chloro-p-phenylenediamine sulfate,C1=CC(=C(C=C1N)Cl)N.OS(=O)(=O)O,,,,,,
2584,22585,CID 22585,C1=CC(=N)C(=N)C=C1N(O)O.Cl.Cl,,,,,,
2585,22586,4-Amino-4'-hydroxy-3-methyldiphenylamine,CC1=C(C=CC(=C1)NC2=CC=C(C=C2)O)N,,,,,,
2586,22587,(Dodecyloxy)trimethylsilane,CCCCCCCCCCCCO[Si](C)(C)C,,,,,,
2587,22588,(Hexadecyloxy)trimethylsilane,CCCCCCCCCCCCCCCCO[Si](C)(C)C,,,,,,
2588,22589,Tetradecyl propionate,CCCCCCCCCCCCCCOC(=O)CC,,,,,,
2589,22590,CID 22590,CC1=C2C(=CC(=C2C=C(C=C1)C(C)C)C)S(=O)(=O)[O-].[Na+],,,,,,
2590,22591,N-Methylpentanamide,CCCCC(=O)NC,,,,,,
2591,22592,"Tetrasodium;3-hydroxy-4-[[2-sulfonato-5-[(4-sulfonatophenyl)diazenyl]phenyl]diazenyl]naphthalene-2,7-disulfonate",C1=CC(=CC=C1N=NC2=CC(=C(C=C2)S(=O)(=O)[O-])N=NC3=C4C=CC(=CC4=CC(=C3O)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],,,,,,
2592,22593,"3-Hydroxy-4-[[2-sulfo-5-[(4-sulfophenyl)diazenyl]phenyl]diazenyl]naphthalene-2,7-disulfonic acid",C1=CC(=CC=C1N=NC2=CC(=C(C=C2)S(=O)(=O)O)N=NC3=C4C=CC(=CC4=CC(=C3O)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,,,,,,
2593,22594,"C.I. Direct Violet 9, disodium salt",CC1=CC(=C(C=C1N=NC2=CC=C(C=C2)S(=O)(=O)[O-])OC)N=NC3=C(C=C4C=C(C=CC4=C3O)NC5=CC=CC=C5)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
2594,22595,C.I. Direct violet 9,CC1=CC(=C(C=C1N=NC2=CC=C(C=C2)S(=O)(=O)O)OC)N=NC3=C(C=C4C=C(C=CC4=C3O)NC5=CC=CC=C5)S(=O)(=O)O,,,,,,
2595,22596,2-Aminoacetic acid;dihydroiodide,C(C(=O)O)N.I.I,,,,,,
2596,22597,Hexanal phenylhydrazone,CCCCCCON=NC1=CC=CC=C1,,,,,,
2597,22598,"2-((4-((2,6-Dichloro-4-nitrophenyl)azo)phenyl)methylamino)ethanol",CN(CCO)C1=CC=C(C=C1)N=NC2=C(C=C(C=C2Cl)[N+](=O)[O-])Cl,,,,,,
2598,22599,4-(Bromomethyl)benzoic acid,C1=CC(=CC=C1CBr)C(=O)O,,,,,,
2599,22600,"Isobutyric acid, 2-isopropylhydrazide",CC(C)C(=O)NNC(C)C,,,,,,
2600,22601,Micofur,C1=C(OC(=C1)[N+](=O)[O-])C=NO,,,,,,
2601,22602,2-Nitro-9-(dimethylaminopropylamino)acridine,CN(C)CCCNC1=C2C=C(C=CC2=NC3=CC=CC=C31)[N+](=O)[O-],,,,,,
2602,22603,"Acridine, 9-((3-(dimethylamino)propyl)amino)-2-nitro-, dihydrochloride",C[NH+](C)CCC[NH2+]C1=C2C=C(C=CC2=NC3=CC=CC=C31)[N+](=O)[O-].[Cl-].[Cl-],,,,,,
2603,22604,3-Nitro-9-(dimethylaminopropylamino)acridine,CN(C)CCCNC1=C2C=CC(=CC2=NC3=CC=CC=C31)[N+](=O)[O-],,,,,,
2604,22605,CID 22605,CC1=NC(=NC(=N1)S)S,,,,,,
2605,22606,"ACETIC ACID, ((2-(alpha,alpha,alpha-TRIFLUORO-m-TOLUAMIDO)-p-TOLYL)OXY)-",CC1=CC(=C(C=C1)OCC(=O)O)NC(=O)C2=CC(=CC=C2)C(F)(F)F,,,,,,
2606,22607,"Acetic acid, (2-(3,4-dichlorobenzamido)-5-methoxyphenoxy)-",COC1=CC(=C(C=C1)NC(=O)C2=CC(=C(C=C2)Cl)Cl)OCC(=O)O,,,,,,
2607,22608,(2-Benzamido-4-chlorophenoxy)acetic acid,C1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)Cl)OCC(=O)O,,,,,,
2608,22609,"ACETIC ACID, (2-(p-CHLOROBENZAMIDO)-4-CHLOROPHENOXY)-",C1=CC(=CC=C1C(=O)NC2=C(C=CC(=C2)Cl)OCC(=O)O)Cl,,,,,,
2609,22610,"ACETIC ACID, ((2-(p-CHLOROBENZAMIDO)-p-TOLYL)OXY)-",CC1=CC(=C(C=C1)OCC(=O)O)NC(=O)C2=CC=C(C=C2)Cl,,,,,,
2610,22611,"1,2-Dichloro-3-nitronaphthalene",C1=CC=C2C(=C1)C=C(C(=C2Cl)Cl)[N+](=O)[O-],,,,,,
2611,22612,"Ethylenediamine, 2-(chlorobenzyl)-",C1=CC=C(C(=C1)CNCCN)Cl,,,,,,
2612,22613,"4-Chloro-4'-nitro-1,1'-biphenyl",C1=CC(=CC=C1C2=CC=C(C=C2)Cl)[N+](=O)[O-],,,,,,
2613,22614,Methyl-4-phenylmandelic acid,CC(C1=CC=CC=C1)(C(=O)OC2=CC=CC=C2)O,,,,,,
2614,22615,"2,2-Dimethyloxetane",CC1(CCO1)C,,,,,,
2615,22616,"3-Hydroxy-8,14-epoxycard-20(22)-enolide",C[C@]12CC[C@@H](C[C@H]1CCC34C2CC[C@]5([C@]3(O4)CC[C@@H]5C6=CC(=O)OC6)C)O,,,,,,
2616,22617,Bipindosid [German],CC1[C@@H](C(C([C@H](O1)O[C@H]2CC[C@@]3(C4[C@@H](C[C@@]5([C@H](CC[C@@]5(C4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)O)C)O)O)O,,,,,,
2617,22618,"2,6-Dimethylocta-2,6-dienedioic acid",CC(=CC(=O)O)CCC=C(C)C(=O)O,,,,,,
2618,22619,"Ethylenediamine, N,N-diethyl-N'-isopropyl-N'-phenyl-",CCN(CC)CCN(C1=CC=CC=C1)C(C)C,,,,,,
2619,22620,(3-Carboxypropyl)trimethylammonium chloride,C[N+](C)(C)CCCC(=O)O.[Cl-],,,,,,
2620,22621,"Ammonium, (3-(dimethylcarbamoyloxy)phenyl)diethylmethyl-, iodide",CC[N+](C)(CC)C1=CC(=CC=C1)OC(=O)N(C)C.[I-],,,,,,
2621,22622,[3-(Dimethylcarbamoyloxy)phenyl]-diethyl-methylazanium,CC[N+](C)(CC)C1=CC(=CC=C1)OC(=O)N(C)C,,,,,,
2622,22623,p-[[p-(Phenylazo)phenyl]azo]phenol,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N=NC3=CC=C(C=C3)O,,,,,,
2623,22624,Acolongifloroside potassium,CC1[C@@H](C(C([C@H](O1)O[C@H]2C[C@H]([C@@]3(C4[C@@H](C[C@@]5([C@H](CC[C@@]5(C4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)O)CO)O)O)O)O,,,"['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)']",,,
2624,22625,Disperse Orange 13,C1=CC=C(C=C1)N=NC2=CC=C(C3=CC=CC=C32)N=NC4=CC=C(C=C4)O,,,,,,
2625,22626,"Benzenamine, 4,4'-azobis[N,N-dimethyl-",CN(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N(C)C,,,,,,
2626,22627,CID 22627,C1=CC=C2C(=C1)C(=O)C3=C(C=C(C(=C3C2=O)N)S(=O)(=O)[O-])Br.[Na+],,,,,,
2627,22628,Bromaminic acid,C1=CC=C2C(=C1)C(=O)C3=C(C=C(C(=C3C2=O)N)S(=O)(=O)O)Br,,,,,,
2628,22629,Hexyl salicylate,CCCCCCOC(=O)C1=CC=CC=C1O,,,,,,
2629,22630,1-(P-Chlorobenzoyl)-5-methoxy-2-methylindole,CC1=CC2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC,,,,,,
2630,22631,Pentachlorocyclopropane,C1(C(C1(Cl)Cl)(Cl)Cl)Cl,,,,,,
2631,22632,Meturin,CNC(=O)N(C1=CC=CC=C1)O,,,,,,
2632,22633,"INDOLE-3-ACETAMIDE, 1-(p-CHLOROBENZOYL)-5-METHOXY-2-METHYL-",CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)N,,,,,,
2633,22634,"2-Amino-2,4,6-cycloheptatrien-1-one",C1=CC=C(C(=O)C=C1)N,,,,,,
2634,22635,CID 22635,CC1=C(C(=N)C(=O)C=C1)N(O)O,,,,,,
2635,22636,CID 22636,CC1=CC(=N)C(=O)C=C1N(O)O,,,,,,
2636,22637,5-(Diethylamino)-4-methyl-2-nitrosophenol,CCN(CC)C1=CC(=C(C=C1C)N=O)O,,,,,,
2637,22638,"Phenol, 5-(dimethylamino)-4-methyl-2-nitroso-",CC1=CC(=C(C=C1N(C)C)O)N=O,,,,,,
2638,22639,4-Methyl-3-(methylamino)phenol,CC1=C(C=C(C=C1)O)NC,,,,,,
2639,22640,"5-(4-Aminobenzamido)-2,3-cresotic acid",CC1=CC(=CC(=C1O)C(=O)O)NC(=O)C2=CC=C(C=C2)N,,,,,,
2640,22641,"7,8-Dimethyl-10-(2'-acetoxyethyl)isoalloxazine",CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)CCOC(=O)C,,,,,,
2641,22642,4-(p-Arsenosophenyl)butyric acid,C1=CC(=CC=C1CCCC(=O)O)[As]=O,,,,,,
2642,22643,"1,2,3,4-Tetrahydro-6,7-dimethoxy-3-methylisoquinoline hydrochloride",CC1CC2=CC(=C(C=C2C[NH2+]1)OC)OC.[Cl-],,,,,,
2643,22644,"6,7-Dimethoxy-3-methyl-1,2,3,4-tetrahydroisoquinoline",CC1CC2=CC(=C(C=C2CN1)OC)OC,,,,,,
2644,22645,"6,7-Dimethoxy-1,2-dimethyl-1,2,3,4-tetrahydroisoquinolin-2-ium;chloride",CC1C2=CC(=C(C=C2CC[NH+]1C)OC)OC.[Cl-],,,,,,
2645,22646,Carnegine,CC1C2=CC(=C(C=C2CCN1C)OC)OC,,,,,,
2646,22647,"9,9-Dimethyl-9,10-dihydroacridine",CC1(C2=CC=CC=C2NC3=CC=CC=C31)C,,,,,,
2647,22648,"N,N'-Bis(2-methoxyphenyl)guanidine",COC1=CC=CC=C1NC(=NC2=CC=CC=C2OC)N,,,,,,
2648,22649,"Urea, N-nitroso-N-phenyl-",C1=CC=C(C=C1)N(C(=O)N)N=O,,,,,,
2649,22650,4-Dimethylamino-4'-carboxylazobenzene,CN(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)C(=O)O,,,,,,
2650,22651,"3,4-Dihydro-6,7-dimethoxy-1-methylisoquinoline hydrochloride",CC1=[NH+]CCC2=CC(=C(C=C12)OC)OC.[Cl-],,,,,,
2651,22652,"6,7-Dimethoxy-1-methyl-3,4-dihydroisoquinoline",CC1=NCCC2=CC(=C(C=C12)OC)OC,,,,,,
2652,22653,"1,3-Dioxolo(4,5-g)isoquinoline, 7,8-dihydro-5-(3,4,5-trimethoxyphenyl)-, hydrochloride",COC1=CC(=CC(=C1OC)OC)C2=[NH+]CCC3=CC4=C(C=C32)OCO4.[Cl-],,,,,,
2653,22654,"5-(3,4,5-Trimethoxyphenyl)-7,8-dihydro-[1,3]dioxolo[4,5-g]isoquinoline",COC1=CC(=CC(=C1OC)OC)C2=NCCC3=CC4=C(C=C32)OCO4,,,,,,
2654,22655,"4a,5,8,8a-Tetrahydro-1,4-naphthoquinone",C1C=CCC2C1C(=O)C=CC2=O,,,,,,
2655,22656,"Dibenzylamine, N-(2-hydroxyethyl)-, hydrochloride",C1=CC=C(C=C1)C[NH+](CCO)CC2=CC=CC=C2.[Cl-],,,,,,
2656,22657,"N,N-Dibenzylethanolamine",C1=CC=C(C=C1)CN(CCO)CC2=CC=CC=C2,,,,,,
2657,22658,"4'-Nitro-[1,1'-biphenyl]-2-amine",C1=CC=C(C(=C1)C2=CC=C(C=C2)[N+](=O)[O-])N,,,,,,
2658,22659,Lapyrium chloride,CCCCCCCCCCCC(=O)OCCNC(=O)C[N+]1=CC=CC=C1.[Cl-],,,,,,
2659,22660,Lapyrium,CCCCCCCCCCCC(=O)OCCNC(=O)C[N+]1=CC=CC=C1,"['Used as a surfactant, antistatic agent, and biocide in cosmetic products.']","['Lapyrium is a quaternary ammonium cation (QAC). QACs exert broad spectrum antimicrobial activity, acting as bactericidal agents.']",,,,
2660,22661,"6-Ethoxy-7-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride",CCOC1=C(C=C2C[NH2+]CCC2=C1)OC.[Cl-],,,,,,
2661,22662,"6-Ethoxy-7-methoxy-1,2,3,4-tetrahydroisoquinoline",CCOC1=C(C=C2CNCCC2=C1)OC,,,,,,
2662,22663,"Benzeneethanamine, N-ethyl-4-methoxy-alpha-(4-methoxyphenyl)-, hydrochloride",CC[NH2+]C(CC1=CC=C(C=C1)OC)C2=CC=C(C=C2)OC.[Cl-],,,,,,
2663,22664,"N-ethyl-1,2-bis(4-methoxyphenyl)ethanamine",CCNC(CC1=CC=C(C=C1)OC)C2=CC=C(C=C2)OC,,,,,,
2664,22665,Diethylammonium bromide,CC[NH2+]CC.[Br-],,,,,,
2665,22666,"1,2,3,4-Tetrahydro-6,7-dimethoxy-2,3-dimethylisoquinoline hydrochloride",CC1CC2=CC(=C(C=C2C[NH+]1C)OC)OC.[Cl-],,,,,,
2666,22667,"1,2,3,4-Tetrahydro-6,7-dimethoxy-2,3-dimethylisoquinoline",CC1CC2=CC(=C(C=C2CN1C)OC)OC,,,,,,
2667,22668,"1,2,3,4-Tetrahydro-6,7-dimethoxy-2,2-dimethylisoquinolinium chloride",C[N+]1(CCC2=CC(=C(C=C2C1)OC)OC)C.[Cl-],,,,,,
2668,22669,"1,2,3,4-Tetrahydro-6,7-dimethoxy-2,2-dimethylisoquinolinium",C[N+]1(CCC2=CC(=C(C=C2C1)OC)OC)C,,,,,,
2669,22670,"1,2,3,4-Tetrahydro-6,7-dimethoxy-2,2,3-trimethylisoquinolinium chloride",CC1CC2=CC(=C(C=C2C[N+]1(C)C)OC)OC.[Cl-],,,,,,
2670,22671,"6,7-dimethoxy-2,2,3-trimethyl-3,4-dihydro-1H-isoquinolin-2-ium",CC1CC2=CC(=C(C=C2C[N+]1(C)C)OC)OC,,,,,,
2671,22672,"1,2,3,4-Tetrahydro-2-amyl-6,7-dimethoxyisoquinoline hydrochloride",CCCCC[NH+]1CCC2=CC(=C(C=C2C1)OC)OC.[Cl-],,,,,,
2672,22673,"6,7-dimethoxy-2-pentyl-3,4-dihydro-1H-isoquinoline",CCCCCN1CCC2=CC(=C(C=C2C1)OC)OC,,,,,,
2673,22674,2-Diethylamino-2-phenylacetophenone hydrochloride,CC[NH+](CC)C(C1=CC=CC=C1)C(=O)C2=CC=CC=C2.[Cl-],,,,,,
2674,22675,"2-(Diethylamino)-1,2-diphenylethanone",CCN(CC)C(C1=CC=CC=C1)C(=O)C2=CC=CC=C2,,,,,,
2675,22676,Methyl 3-((dimethylamino)methyl)-4-hydroxybenzoate,CN(C)CC1=C(C=CC(=C1)C(=O)OC)O,,,,,,
2676,22677,Butyl 3-((dimethylamino)methyl)-4-hydroxybenzoate,CCCCOC(=O)C1=CC(=C(C=C1)O)CN(C)C,,,,,,
2677,22678,2-Cyclohexylethyl chloroacetate,C1CCC(CC1)CCOC(=O)CCl,,,,,,
2678,22679,"1,2-Ethanediamine, N,N'-bis(1-phenylethyl)-",CC(C1=CC=CC=C1)NCCNC(C)C2=CC=CC=C2,,,,,,
2679,22680,5-Nitro-2-furanacrylic acid;Nitrofurylacrylamide;Trans-5-nitro-2-furanacrylic acid,C1=C(OC(=C1)[N+](=O)[O-])C=CC(=O)O,,,,,,
2680,22681,1-Methyl-1-[(5-nitrofuran-2-yl)methylideneamino]urea,CN(C(=O)N)N=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
2681,22682,"Acetonitrile, 2-cyclohexylamino-2-dimethyl-",CC(C)(C#N)NC1CCCCC1,,,,,,
2682,22683,Phenyl alpha-piperidinobenzyl ketone hydrochloride,C1CC[NH+](CC1)C(C2=CC=CC=C2)C(=O)C3=CC=CC=C3.[Cl-],,,,,,
2683,22684,alpha-Piperidino-alpha-phenylacetophenone,C1CCN(CC1)C(C2=CC=CC=C2)C(=O)C3=CC=CC=C3,,,,,,
2684,22685,"NICOTINIC ACID, 2-((p-TOLYL)SULFONYL)HYDRAZIDE",CC1=CC=C(C=C1)S(=O)(=O)NNC(=O)C2=CN=CC=C2,,,,,,
2685,22686,N-Propylformamide,CCCNC=O,,,,,,
2686,22687,"N,N-Dipropylformamide",CCCN(CCC)C=O,,,,,,
2687,22688,"Hexanoic acid, 2-bromoethyl ester",CCCCCC(=O)OCCBr,,,,,,
2688,22689,Acetic acid;(4-aminophenyl)mercury,CC(=O)O.C1=CC(=CC=C1N)[Hg],,,,,,
2689,22690,(4-Aminophenyl)mercury,C1=CC(=CC=C1N)[Hg],,,,,,
2690,22691,2-Chloro-5-nitroaniline,C1=CC(=C(C=C1[N+](=O)[O-])N)Cl,,,,,,
2691,22692,"Propanoic acid, 2-hydroxy-, dodecyl ester",CCCCCCCCCCCCOC(=O)C(C)O,,,,,,
2692,22693,"1,5-Dioxaspiro(5.5)undecane, 3-ethyl-3-nitro-",CCC1(COC2(CCCCC2)OC1)[N+](=O)[O-],,,,,,
2693,22694,"Acetamide, N-(2-diethylaminoethyl)-2-chloro-2-(tetrachloro-2,4-cyclopentadien-1-ylidene)-",CCN(CC)CCNC(=O)C(=C1C(=C(C(=C1Cl)Cl)Cl)Cl)Cl,,,,,,
2694,22695,"1,1,2,2-Tetrabutoxyethane",CCCCOC(C(OCCCC)OCCCC)OCCCC,,,,,,
2695,22696,"1,3,5-Trichloro-2,4-dinitrobenzene",C1=C(C(=C(C(=C1Cl)[N+](=O)[O-])Cl)[N+](=O)[O-])Cl,,,,,,
2696,22697,4'-Chloropropiophenone,CCC(=O)C1=CC=C(C=C1)Cl,,,,,,
2697,22698,3-Ethyl-1-pentyn-3-ol,CCC(CC)(C#C)O,,,,,,
2698,22699,"Ketone, 4-decyloxy-2-hydroxyphenyl 4-decyloxyphenyl",CCCCCCCCCCOC1=CC=C(C=C1)C(=O)C2=C(C=C(C=C2)OCCCCCCCCCC)O,,,,,,
2699,22700,"2-{2-[4-(Dimethylamino)phenyl]ethenyl}-1-methylnaphtho[1,2-d][1,3]thiazol-1-ium iodide",C[N+]1=C(SC2=C1C3=CC=CC=C3C=C2)C=CC4=CC=C(C=C4)N(C)C.[I-],,,,,,
2700,22701,"N,N-dimethyl-4-[2-(1-methylbenzo[e][1,3]benzothiazol-1-ium-2-yl)ethenyl]aniline",C[N+]1=C(SC2=C1C3=CC=CC=C3C=C2)C=CC4=CC=C(C=C4)N(C)C,,,,,,
2701,22702,N-Phenethyl-beta-phenylisopropylamine hydrochloride,CC(CC1=CC=CC=C1)[NH2+]CCC2=CC=CC=C2.[Cl-],,,,,,
2702,22703,"Benzeneethanamine, alpha-methyl-N-(2-phenylethyl)-",CC(CC1=CC=CC=C1)NCCC2=CC=CC=C2,,,,,,
2703,22704,2-Amino-6-nitrobenzothiazole,C1=CC2=C(C=C1[N+](=O)[O-])SC(=N2)N,,,,,,
2704,22705,"2,3-Dibromo-3-phenylpropionic acid",C1=CC=C(C=C1)C(C(C(=O)O)Br)Br,,,,,,
2705,22706,6-Azoniaspiro(5.5)undecane bromide,C1CC[N+]2(CC1)CCCCC2.[Br-],,,,,,
2706,22707,6-Azoniaspiro[5.5]undecane,C1CC[N+]2(CC1)CCCCC2,,,,,,
2707,22708,"Acridine, 6-chloro-9-((4-(diethylamino)butyl)amino)-2-methoxy-, dihydrochloride",CC[NH+](CC)CCCC[NH2+]C1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC.[Cl-].[Cl-],,,,,,
2708,22709,"N-(6-chloro-2-methoxyacridin-9-yl)-N',N'-diethylbutane-1,4-diamine",CCN(CC)CCCCNC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC,,,,,,
2709,22710,"3,4-Dichlorobenzaldehyde",C1=CC(=C(C=C1C=O)Cl)Cl,,,,,,
2710,22711,N-[1-(4-chlorophenyl)octadecylidene]hydroxylamine,CCCCCCCCCCCCCCCCCC(=NO)C1=CC=C(C=C1)Cl,,,,,,
2711,22712,N-(2-Chloroethyl)benzylamine hydrochloride,C1=CC=C(C=C1)C[NH2+]CCCl.[Cl-],,,,,,
2712,22713,N-Benzyl-N-(2-chloroethyl)amine,C1=CC=C(C=C1)CNCCCl,,,,,,
2713,22714,"1,2-Propanediol, 3-(o-tolyloxy)-, ethylcarbamate",CCNC(=O)OCC(COC1=CC=CC=C1C)O,,,,,,
2714,22715,"Ethanol, 1-((1-ethynylcyclohexyl)oxy)-2,2,2-trichloro-",C#CC1(CCCCC1)OC(C(Cl)(Cl)Cl)O,,,,,,
2715,22716,"1,1'-Methylidynebisurea",C(=NC(=O)N)NC(=O)N,,,,,,
2716,22717,"Phenylcarbamic acid 1,1-dimethyl-2-propynyl ester",CC(C)(C#C)OC(=O)NC1=CC=CC=C1,,,,,,
2717,22718,"2-Hexyl-2,4-dimethyl-1,3-dioxane",CCCCCCC1(OCCC(O1)C)C,,,,,,
2718,22719,"AMMONIUM, DODECYLTRIMETHYL-, p-CHLOROPHENYLSULFONATE",CCCCCCCCCCCC[N+](C)(C)C.C1=CC(=CC=C1S(=O)(=O)[O-])Cl,,,,,,
2719,22720,3-Ethoxypropylamine,CCOCCCN,,,,,,
2720,22721,"s-Triazine, 2-(allyloxy)-4,6-diamino-",C=CCOC1=NC(=NC(=N1)N)N,,,,,,
2721,22722,N-3-Fluorenylacetamide,CC(=O)NC1=CC2=C(CC3=CC=CC=C32)C=C1,,,,,,
2722,22723,Diphenyliodonium p-toluenesulfonate,CC1=CC=C(C=C1)S(=O)(=O)[O-].C1=CC=C(C=C1)[I+]C2=CC=CC=C2,,,,,,
2723,22724,"IODONIUM, DI-p-TOLYL-, BROMIDE",CC1=CC=C(C=C1)[I+]C2=CC=C(C=C2)C.[Br-],,,,,,
2724,22725,Toliodium,CC1=CC=C(C=C1)[I+]C2=CC=C(C=C2)C,,,,,,
2725,22726,"HYDRAZINE, (o-NITROPHENYL)-, HYDROCHLORIDE",C1=CC=C(C(=C1)N[NH3+])[N+](=O)[O-].[Cl-],,,,,,
2726,22727,1-Bromo-4-methylcyclohexane,CC1CCC(CC1)Br,,,,,,
2727,22728,CID 22728,C1=CC=C(C(=C1)O)O.O.[SbH3],,,,,,
2728,22729,"s-Triazine, 2,4-diamino-6-propoxy-",CCCOC1=NC(=NC(=N1)N)N,,,,,,
2729,22730,"3,5,7-Triaza-1-azoniaadamantane, 1-(2-thienyl)-, chloride",C1N2CN3CN1C[N+](C2)(C3)CC4=CC=CS4.[Cl-],,,,,,
2730,22731,"1-(Thiophen-2-ylmethyl)-3,5,7-triaza-1-azoniatricyclo[3.3.1.13,7]decane",C1N2CN3CN1C[N+](C2)(C3)CC4=CC=CS4,,,,,,
2731,22732,2-Chloroethyl-N-nitrosourethane,CCOC(=O)N(CCCl)N=O,,,,,,
2732,22733,3-Hydroxy-3-(2-pyridylmethyl)-2-indolinone,C1=CC=C2C(=C1)C(C(=O)N2)(CC3=CC=CC=N3)O,,,,,,
2733,22734,4-Ethylhexanoic acid,CCC(CC)CCC(=O)O,,,,,,
2734,22735,"8-[2-[(2-Chlorophenyl)methylidene]hydrazinyl]-1,3,7-trimethylpurine-2,6-dione",CN1C2=C(N=C1NN=CC3=CC=CC=C3Cl)N(C(=O)N(C2=O)C)C,,,,,,
2735,22736,Disperse Yellow 7,CC1=C(C=CC(=C1)N=NC2=CC=C(C=C2)N=NC3=CC=CC=C3)O,,,,,,
2736,22737,"2,4-Dimethyl-2-propyl-1,3-dioxolane",CCCC1(OCC(O1)C)C,,,,,,
2737,22738,"[(5R,17S)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] propanoate",CCC(=O)O[C@H]1CCC2C1(CCC3C2CC[C@@H]4C3(CCCC4)C)C,,,,,,
2738,22739,"2-(4-Chlorophenyl)-2-methyl-1,3-dithiolane",CC1(SCCS1)C2=CC=C(C=C2)Cl,,,,,,
2739,22740,"Acetic acid, thiodi-, diallyl ester",C=CCOC(=O)CSCC(=O)OCC=C,,,,,,
2740,22741,4-Phenoxybutyric acid,C1=CC=C(C=C1)OCCCC(=O)O,,,,,,
2741,22742,"2-(Diethylamino)-2'-methylacetanilide, hydrochloride",CC[NH+](CC)CC(=O)NC1=CC=CC=C1C.[Cl-],,,,,,
2742,22743,"2,3,3-Triphenylacrylonitrile",C1=CC=C(C=C1)C(=C(C2=CC=CC=C2)C3=CC=CC=C3)C#N,,,,,,
2743,22744,"2-Imidazoline, 2-(3-trimethylaminopropylthio)-, dihydrobromide",C[N+](C)(C)CCCSC1=NCC[NH2+]1.[Br-].[Br-],,,,,,
2744,22745,"[3-[(4,5-Dihydro-1H-imidazol-2-yl)thio]propyl]trimethylaminium",C[N+](C)(C)CCCSC1=NCCN1,,,,,,
2745,22746,CID 22746,CCC(=O)OC1CCC2C1(CCC3C2[C@@H](CC4=CC(=O)CCC34C)C)C,,,,,,
2746,22747,"1,4-Dibromo-2,3-butanedione",C(C(=O)C(=O)CBr)Br,,,,,,
2747,22748,"[(2R,3R)-3-(2-iodoacetyl)oxybutan-2-yl] 2-iodoacetate",C[C@H]([C@@H](C)OC(=O)CI)OC(=O)CI,,,,,,
2748,22749,"2,4-Dimethyl-1-pentanol",CC(C)CC(C)CO,,,,,,
2749,22750,1-Acenaphthenol,C1C(C2=CC=CC3=C2C1=CC=C3)O,,,,,,
2750,22751,"3-Indoleacetic acid, 4,7-dimethyl-",CC1=C2C(=CNC2=C(C=C1)C)CC(=O)O,,,,,,
2751,22752,Lobendazole,CCOC(=O)NC1=NC2=CC=CC=C2N1,,,,,,
2752,22753,"ARSINE, DICHLORO(m-NITROPHENYL)-",C1=CC(=CC(=C1)[As](Cl)Cl)[N+](=O)[O-],,,,,,
2753,22754,Methyl 2-chloro-5-nitrobenzoate,COC(=O)C1=C(C=CC(=C1)[N+](=O)[O-])Cl,,,,,,
2754,22755,2-(2-(Diethylammonio)ethyl)-2-methylisoindolinium diiodide,CC[N+](C)(CC)CC[N+]1(CC2=CC=CC=C2C1)C.[I-].[I-],,,,,,
2755,22756,"Diethyl-methyl-[2-(2-methyl-1,3-dihydroisoindol-2-ium-2-yl)ethyl]azanium",CC[N+](C)(CC)CC[N+]1(CC2=CC=CC=C2C1)C,,,,,,
2756,22757,"2-Methyl-2-(3-(4-methyl-4-morpholinio)propyl)-3a,4,7,7a-tetrahydroisoindolinium diiodide",C[N+]1(CCOCC1)CCC[N+]2(CC3CC=CCC3C2)C.[I-].[I-],,,,,,
2757,22758,"4-Methyl-4-[3-(2-methyl-1,3,3a,4,7,7a-hexahydroisoindol-2-ium-2-yl)propyl]morpholin-4-ium",C[N+]1(CCOCC1)CCC[N+]2(CC3CC=CCC3C2)C,,,,,,
2758,22759,"Isoindolinium, hexahydro-2-methyl-2-(3-(4-methyl-4-morpholinio)propyl)-, diiodide",C[N+]1(CCOCC1)CCC[N+]2(CC3CCCCC3=C2)C.[I-].[I-],,,,,,
2759,22760,"4-Methyl-4-[3-(2-methyl-1,4,5,6,7,7a-hexahydroisoindol-2-ium-2-yl)propyl]morpholin-4-ium",C[N+]1(CCOCC1)CCC[N+]2(CC3CCCCC3=C2)C,,,,,,
2760,22761,Methyltris(2-chloroethyl)ammonium chloride,C[N+](CCCl)(CCCl)CCCl.[Cl-],,,,,,
2761,22762,Tris(2-chloroethyl)-methylazanium,C[N+](CCCl)(CCCl)CCCl,,,,,,
2762,22763,2-{[(4-Methylphenyl)sulfonyl]amino}benzoic acid,CC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)O,,,,,,
2763,22764,"3,4'-Dinitrobiphenyl",C1=CC(=CC(=C1)[N+](=O)[O-])C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
2764,22765,"2,2',5,5'-Tetramethylazobenzene",CC1=CC(=C(C=C1)C)N=NC2=C(C=CC(=C2)C)C,,,,,,
2765,22766,3-Hexylpyridine,CCCCCCC1=CN=CC=C1,,,,,,
2766,22767,2-(Phenethylamino)-2-phenyl-acetophenone hydrochloride,C1=CC=C(C=C1)CC[NH2+]C(C2=CC=CC=C2)C(=O)C3=CC=CC=C3.[Cl-],,,,,,
2767,22768,"1,2-Diphenyl-2-(2-phenylethylamino)ethanone",C1=CC=C(C=C1)CCNC(C2=CC=CC=C2)C(=O)C3=CC=CC=C3,,,,,,
2768,22769,"ethyl 5-acetyl-2,4-dimethyl-1H-pyrrole-3-carboxylate",CCOC(=O)C1=C(NC(=C1C)C(=O)C)C,,,,,,
2769,22770,"3,4-Dimethoxyaniline",COC1=C(C=C(C=C1)N)OC,,,,,"['4-aminoveratrole has known human metabolites that include N-(3,4-Dimethoxyphenyl)acetamide.']",
2770,22771,"2,2-Diphenyl-1,3-dithiolane",C1CSC(S1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
2771,22772,Methylene dithiocyanate,C(SC#N)SC#N,,,,"['... Chemical disposition studies of (14)C labeled methylene bis(thiocyanate) were conducted in male F344/N rats. In these studies more than 90% of the admin radioactivity was eliminated in 48 hr. ... As the dose was incr from 0.2 to 1 to 10 mg/kg, greater percentages of the admin radioactivity remained in the tissues. Blood cyanide concn were incr shortly after the admin of 10 mg/kg (14)C methylene bis(thiocyanate) but were similar to control values 2 hr after dosing.']",,
2772,22773,"p-ARSANILIC ACID, 2-HYDROXY-",C1=CC(=C(C=C1N)O)[As](=O)(O)O,,,,,,
2773,22774,"3,4-Dihydro-6,7-dihydroxy-2-amylisoquinolinium chloride",CCCCC[N+]1=CC2=CC(=C(C=C2CC1)O)O.[Cl-],,,,,,
2774,22775,"2-Pentyl-3,4-dihydroisoquinolin-2-ium-6,7-diol",CCCCC[N+]1=CC2=CC(=C(C=C2CC1)O)O,,,,,,
2775,22776,(2-Methoxyphenyl)phenyldiazene,COC1=CC=CC=C1N=NC2=CC=CC=C2,,,,,,
2776,22777,"3,3'-Dimethoxyazobenzene",COC1=CC=CC(=C1)N=NC2=CC(=CC=C2)OC,,,,,,
2777,22778,"(2,6-Dimethylphenyl)-(2-methylphenyl)diazene",CC1=C(C(=CC=C1)C)N=NC2=CC=CC=C2C,,,,,,
2778,22779,"N,N-dimethyl-1,2-diphenylethanamine",CN(C)C(CC1=CC=CC=C1)C2=CC=CC=C2,,,,,,
2779,22780,"Caffeine, 8-(2-hydroxyethylamino)-",CN1C2=C(N=C1NCCO)N(C(=O)N(C2=O)C)C,,,,,,
2780,22781,"3H-Indolium, 2-[3-(1,3-dihydro-1,3,3-trimethyl-2H-indol-2-ylidene)-1-propenyl]-1,3,3-trimethyl-, chloride",CC1(C2=CC=CC=C2[N+](=C1C=CC=C3C(C4=CC=CC=C4N3C)(C)C)C)C.[Cl-],,,,,,
2781,22782,"1,3,3-Trimethyl-2-[3-(1,3,3-trimethylindol-1-ium-2-yl)prop-2-enylidene]indole",CC1(C2=CC=CC=C2[N+](=C1C=CC=C3C(C4=CC=CC=C4N3C)(C)C)C)C,,,,,,
2782,22783,2-(2-Hydroxyphenoxy)acetic acid,C1=CC=C(C(=C1)O)OCC(=O)O,,,,,,
2783,22784,4-Nitrobenzenesulfonamide,C1=CC(=CC=C1[N+](=O)[O-])S(=O)(=O)N,,,,,,
2784,22785,"5-Cyclohexyl-5-methylimidazolidine-2,4-dione",CC1(C(=O)NC(=O)N1)C2CCCCC2,,,,,,
2785,22786,"N-(3,5-Dichlorophenyl)formamide",C1=C(C=C(C=C1Cl)Cl)NC=O,,,,,,
2786,22787,Thiohippuric acid,C1=CC=C(C=C1)C(=O)NCC(=O)S,,,,,,
2787,22788,2-Methyl-2-phenyl-m-dithiane,CC1(SCCCS1)C2=CC=CC=C2,,,,,,
2788,22789,1-(4-Bromophenyl)-3-(4-chlorophenyl)prop-2-en-1-one,C1=CC(=CC=C1C=CC(=O)C2=CC=C(C=C2)Br)Cl,,,,,,
2789,22790,"Diphenethylamine, hydrochloride",C1=CC=C(C=C1)CC[NH2+]CCC2=CC=CC=C2.[Cl-],,,,,,
2790,22791,Diphenethylamine,C1=CC=C(C=C1)CCNCCC2=CC=CC=C2,,,,,,
2791,22792,"Benzenepropanoic acid, alpha-cyclohexyl-4-hydroxy-3,5-diiodo-",C1CCC(CC1)C(CC2=CC(=C(C(=C2)I)O)I)C(=O)O,,,,,,
2792,22793,2-Hydroxy-3-nitropyridine,C1=CNC(=O)C(=C1)[N+](=O)[O-],,,,,,
2793,22794,"ARSINE, (m-NITROPHENYL)OXO-",C1=CC(=CC(=C1)[As]=O)[N+](=O)[O-],,,,,,
2794,22795,4-(Ethylsulfonyl)aniline,CCS(=O)(=O)C1=CC=C(C=C1)N,,,,,,
2795,22796,Aminomesitylene hydrochloride,CC1=CC(=C(C(=C1)C)[NH3+])C.[Cl-],,,,,,
2796,22797,4-(2-Phenylethenyl)cinnoline,C1=CC=C(C=C1)C=CC2=CN=NC3=CC=CC=C32,,,,,,
2797,22798,"Isoindolinium, 2-(beta-(diethylmethylammonio)ethyl)-2-methyl-4,5,6,7-tetrachloro-, diiodide",CC[N+](C)(CC)CC[N+]1(CC2=C(C1)C(=C(C(=C2Cl)Cl)Cl)Cl)C.[I-].[I-],,,,,,
2798,22799,"Diethyl-methyl-[2-(4,5,6,7-tetrachloro-2-methyl-1,3-dihydroisoindol-2-ium-2-yl)ethyl]azanium",CC[N+](C)(CC)CC[N+]1(CC2=C(C1)C(=C(C(=C2Cl)Cl)Cl)Cl)C,,,,,,
2799,22800,Bis(4-chlorobutyl) ether,C(CCCl)COCCCCCl,,,,,,
2800,22801,"Malonic acid, 2-methoxyethyl-, diethyl ester",CCOC(=O)C(CCOC)C(=O)OCC,,,,,,
2801,22802,2-(1-Pyrrolidinyl)bicyclo(3.3.1)nonan-9-one,C1CCN(C1)C2CCC3CCCC2C3=O,,,,,,
2802,22803,Dioctylnitrosamine,CCCCCCCCN(CCCCCCCC)N=O,,,,,,
2803,22804,"Acetic acid;1,3-dimethylimidazo[4,5-b]pyrazin-4-ide-2,5-dione;mercury(1+)",CC(=O)O.CN1C2=C(N=CC(=O)[N-]2)N(C1=O)C.[Hg+],,,,,,
2804,22805,"1,3-dimethyl-4H-imidazo[4,5-b]pyrazine-2,5-dione",CN1C2=C(N=CC(=O)N2)N(C1=O)C,,,,,,
2805,22806,"Anthraquinone, 1-mercapto-",C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=CC=C3)S,,,,,,
2806,22807,"3-Thiophenamine, tetrahydro-, 1,1-dioxide",C1CS(=O)(=O)CC1N,,,,,,
2807,22808,(Methylthiomethyl)trimethylammonium chloride,C[N+](C)(C)CSC.[Cl-],,,,,,
2808,22809,Trimethyl(methylsulfanylmethyl)azanium,C[N+](C)(C)CSC,,,,,,
2809,22810,alpha-Methyl-4-biphenylacetic acid,CC(C1=CC=C(C=C1)C2=CC=CC=C2)C(=O)O,,,,,,
2810,22811,"2-Methyl-1,2,3,4-diepoxybutane",CC1(CO1)C2CO2,,,,,,
2811,22812,"2,4-Dichlorophenyl acetate",CC(=O)OC1=C(C=C(C=C1)Cl)Cl,,,,,,
2812,22813,CID 22813,CCCCCCCCCCCCCCCCCCN=C(C(=NCCCCCCCCCCCCCCCCCC)S)S,,,,,,
2813,22814,"1-Cyano-N,N'-diphenylformamidine",C1=CC=C(C=C1)NC(=NC2=CC=CC=C2)C#N,,,,,,
2814,22815,(Methoxymethyl)trimethylammonium chloride,C[N+](C)(C)COC.[Cl-],,,,,,
2815,22816,Trimethylmethoxymethylammonium,C[N+](C)(C)COC,,,,,,
2816,22817,1-Aminofluorene,C1C2=CC=CC=C2C3=C1C(=CC=C3)N,,,,,,
2817,22818,9H-Fluoren-3-amine,C1C2=C(C=C(C=C2)N)C3=CC=CC=C31,,,,,,
2818,22819,1-Indanol,C1CC2=CC=CC=C2C1O,,,,,,
2819,22820,CID 22820,C1=C(C(=CC(=N)C1=O)Cl)N(O)O,,,,,,
2820,22821,CID 22821,C1=C(C=C(C(=O)C1=N)N(O)O)Cl,,,,,,
2821,22822,CID 22822,C1=C(C=C(C(=O)C1=N)Cl)N(O)O,,,,,,
2822,22823,"2-Amino-3,4,6-trichlorophenol",C1=C(C(=C(C(=C1Cl)Cl)N)O)Cl,,,,,,
2823,22824,CID 22824,C1=CC(=C(C=C1N(O)O)[N+](=O)[O-])N=C2C=C(C=CC2=O)Cl,,,,,,
2824,22825,5-(Diethylamino)-2-nitrosophenol,CCN(CC)C1=CC(=C(C=C1)N=O)O,,,,,,
2825,22826,CID 22826,C1=CC(=NC2=C(C=C(C=C2)N(O)O)[N+](=O)[O-])C(=O)C=C1,,,,,,
2826,22827,C.I. Direct Red 39,CCOC1=CC=C(C=C1)N=NC2=C(C=C(C=C2)C3=CC(=C(C=C3)N=NC4=C(C=CC5=CC(=CC(=C54)S(=O)(=O)[O-])S(=O)(=O)[O-])O)C)C.[Na+].[Na+],,,,,,
2827,22828,Direct Fast Scarlet 3B,CCOC1=CC=C(C=C1)N=NC2=C(C=C(C=C2)C3=CC(=C(C=C3)N=NC4=C(C=CC5=CC(=CC(=C54)S(=O)(=O)O)S(=O)(=O)O)O)C)C,,,,,,
2828,22829,C.I. Pigment Yellow 74,CC(=O)C(C(=O)NC1=CC=CC=C1OC)N=NC2=C(C=C(C=C2)[N+](=O)[O-])OC,,,,,,
2829,22830,Citrus red 2,COC1=CC(=C(C=C1)OC)N=NC2=C(C=CC3=CC=CC=C32)O,,,,"['After single oral doses of 2-20 mg in corn oil solution to rats, five to seven percent of the administered color was recovered in the feces in 48 hr. When the dose was reduced to 0.5 mg no color was found. When administered as a 0.5 percent dry mixture, 26.3 percent was found in the feces. Rabbits and dogs showed similar results.', 'After a single dose small amounts of the color were found in the body fat. Repeated administration resulted in gradual reduction of the concentration of the color in the fat and finally it disappeared altogether after seven to 10 days.']","['When citrus red number 2 was administered to rats with cannulated bile ducts, 6 red-colored, water-soluble metabolites were detected in bile, and traces of 1-amino-2-naphthol glucuronide and 1-amino-2-naphthol sulfate were present in urine.', '1-Amino-2-naphthyl glucuronide is a metabolite of citrus red number 2 in humans.', 'The urine of normal rats dosed with the color contained 6 metabolites: 1 of the two red-colored metabolites was the O-glucuronide of citrus red number 2 (2,5-dimethoxyphenylazo-2-naphthyl glucuronide); two of the products were unidentified; two others were 1-amino-2-naphthol glucoronide  and 1-amino-2-napthol sulfate. The urine of dogs given color contained 12 metabolites, one of which, 1-amino-2-naphthol sulfate, was present in high concentrations; however, 1-amino-2-napthyl glucoronide was not detected.', 'In vitro incubation of emulsions of the color with the intestinal contents of the rat, rabbit and dog resulted in destruction of the color by the bacterial flora.', 'Small amounts of 1-amino-2-naphthyl sulphate were identified in the urine of rats. This demonstrates that the color is reduced at the azo linkage in the animal body followed by conjugation to give the o-glucuronide and ethereal sulphate derivatives of 1-amino-2-naphthol.']",
2830,22831,Acid Red 111,CC1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)N=NC3=CC(=C(C=C3)C4=C(C=C(C=C4)N=NC5=C(C=C6C=C(C=CC6=C5O)S(=O)(=O)[O-])S(=O)(=O)[O-])C)C.[Na+].[Na+],,,,,,
2831,22832,Acid Red 111 free acid,CC1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)N=NC3=CC(=C(C=C3)C4=C(C=C(C=C4)N=NC5=C(C=C6C=C(C=CC6=C5O)S(=O)(=O)O)S(=O)(=O)O)C)C,,,,,,
2832,22833,"4-Chloro-2,5-dimethoxyaniline",COC1=CC(=C(C=C1N)OC)Cl,,,,,,
2833,22834,"1,3-Benzenediamine, 4,4'-[(4-methoxy-1,3-phenylene)bis(azo)]bis-",COC1=C(C=C(C=C1)N=NC2=C(C=C(C=C2)N)N)N=NC3=C(C=C(C=C3)N)N,,,,,,
2834,22835,"2-[[4-[4-[2-(1-anilino-1,3-dioxobutan-2-ylidene)hydrazinyl]-3-chlorophenyl]-2-chlorophenyl]hydrazinylidene]-3-oxo-N-phenylbutanamide",CC(=O)C(=NNC1=C(C=C(C=C1)C2=CC(=C(C=C2)NN=C(C(=O)C)C(=O)NC3=CC=CC=C3)Cl)Cl)C(=O)NC4=CC=CC=C4,,,,,,
2835,22836,C.I.Basic Violet 16,CCN(CC)C1=CC=C(C=C1)C=CC2=[N+](C3=CC=CC=C3C2(C)C)C.[Cl-],,,,,,
2836,22837,"2-[2-[4-(Diethylamino)phenyl]ethenyl]-1,3,3-trimethyl-3H-indolium",CCN(CC)C1=CC=C(C=C1)C=CC2=[N+](C3=CC=CC=C3C2(C)C)C,,,,,,
2837,22838,CID 22838,CC1=C(C=C(C=C1)N=NC2C(=NN(C2=O)C3=CC=C(C=C3)S(=O)(=O)[O-])C)S(=O)(=O)NC4=CC=CC=C4.[Na+],,,,,,
2838,22839,"p-(4,5-Dihydro-3-methyl-4-((4-methyl-3-((phenylamino)sulphonyl)phenyl)azo)-5-oxo-1H-pyrazol-1-yl)benzenesulphonic acid",CC1=C(C=C(C=C1)N=NC2C(=NN(C2=O)C3=CC=C(C=C3)S(=O)(=O)O)C)S(=O)(=O)NC4=CC=CC=C4,,,,,,
2839,22840,CID 22840,CC1=NN(C(=O)C1N=NC2=CC=CC=C2)C3=C(C=CC(=C3)S(=O)(=O)[O-])Cl.[Na+],,,,,,
2840,22841,"4-Chloro-3-[(4,5-dihydro-3-methyl-5-oxo-4-phenylazo-1H-pyrazol)-1-yl]benzenesulfonic acid",CC1=NN(C(=O)C1N=NC2=CC=CC=C2)C3=C(C=CC(=C3)S(=O)(=O)O)Cl,,,,,,
2841,22842,"C.I. Acid Yellow 17, disodium salt",CC1=NN(C(=O)C1N=NC2=CC=C(C=C2)S(=O)(=O)[O-])C3=CC(=C(C=C3Cl)S(=O)(=O)[O-])Cl.[Na+].[Na+],,,,,,
2842,22843,Yellow 2G,CC1=NN(C(=O)C1N=NC2=CC=C(C=C2)S(=O)(=O)O)C3=CC(=C(C=C3Cl)S(=O)(=O)O)Cl,,,,,,
2843,22844,CID 22844,CC1=CC=C(C=C1)S(=O)(=O)N=C(NC2=CC=CC=C2)S,,,,,,
2844,22845,Ethyl 3-cyano-3-phenylpyruvate,CCOC(=O)C(=O)C(C#N)C1=CC=CC=C1,,,,,,
2845,22846,"Dicalcium;3-[(2,4-dihydroxy-3,3-dimethylbutanoyl)amino]propanoate;dichloride",CC(C)(CO)C(C(=O)NCCC(=O)[O-])O.[Cl-].[Cl-].[Ca+2].[Ca+2],,,,,,
2846,22847,Cevine hydrochloride dihydrate,C[C@H]1CC[C@H]2[C@@]([C@]3([C@H](C[C@]4(C5CCC6[C@]7([C@]5(C[C@]4(C3C[NH+]2C1)O)O[C@@]6([C@@H](CC7)O)O)C)O)O)O)(C)O.[Cl-],,,,,,
2847,22848,CID 22848,C[C@H]1CC[C@H]2[C@@]([C@]3(C(C[C@]4(C5CCC6[C@]7([C@]5(C[C@]4(C3CN2C1)O)O[C@@]6(C(CC7)O)O)C)O)O)O)(C)O,,,,,,
2848,22849,"1-Amino-9,10-dioxo-9,10-dihydroanthracene-2-carbaldehyde",C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3)C=O)N,,,,,,
2849,22850,"4-((4-Aminophenyl)azo)1,3-benzenediamine",C1=CC(=CC=C1N)N=NC2=C(C=C(C=C2)N)N,,,,,,
2850,22851,Dinoseb-ammonium,CCC(C)C1=C(C(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])[O-].[NH4+],,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)', 'Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)', 'Chemicals used to destroy pests of any sort. The concept includes fungicides (FUNGICIDES, INDUSTRIAL); INSECTICIDES; RODENTICIDES; etc. (See all compounds classified as Pesticides.)']",,,
2851,22852,N-epsilon-Carbobenzyloxy-L-lysine benzyl ester hydrochloride,C1=CC=C(C=C1)CC(=O)ONCCCC[C@@H](C(=O)OCC2=CC=CC=C2)[NH3+].[Cl-],,,,,,
2852,22853,benzyl (2S)-2-amino-6-[(2-phenylacetyl)oxyamino]hexanoate,C1=CC=C(C=C1)CC(=O)ONCCCC[C@@H](C(=O)OCC2=CC=CC=C2)N,,,,,,
2853,22854,S-2-Aminoethyl-homocysteine monohydrochloride,C(CSCC[NH3+])[C@H](C(=O)O)N.[Cl-],,,,,,
2854,22855,(2R)-2-amino-4-(2-aminoethylsulfanyl)butanoic acid,C(CSCCN)[C@H](C(=O)O)N,,,,,,
2855,22856,"2,5-Diaminotoluene sulfate",CC1=C(C=CC(=C1)N)N.OS(=O)(=O)O,,,,"['2,5-Diaminotoluene sulfate is absorbed through the skin of dogs and excreted in the urine. About 40 mg of the compound were absorbed from 50 mL of a lauryl sulfate-based gel containing 1.4 g 2,5-diaminotoluene within 3 hr. When 6% hydrogen peroxide was added to the gel immediately before use, the amount of 2,5-diaminotoluene sulfate absorbed was less than 3 mg', ""Ten milligrams of 2,5-diaminotoluene sulfate (equivalent to 5.54 mg 2,5- diamino-toluene) injected subcutaneously into six adult volunteers were excreted in the urine as the N,N'-diacetyl derivative, which accounted for approximately half of the injected dose, over 48 hr. During the process of hair dyeing with a dye formulation in which a total of 2.5 g 2,5-diaminotoluene sulfate were applied in conjunction with 6% hydrogen peroxide added just before application, it was estimated that 4.6 mg 2,5-diaminotoluene sulfate had been absorbed through the skin of five volunteers."", 'The absorption and elimination of toluene-2,5-diamine were studied in 5 male human subjects. A test formulation was prepared with [Me-(14)C]-toluene-2,5-diamine plus unlabeled toluene-2,5-diamine sulfate in a hair dye cream formulation containing 0.825% resorcinol. The final concentration of toluene-2,5-diamine sulfate was 1.65%. This formulation was then mixed with either 100 g of water (1:1) or 100 g of 6% hydrogen peroxide to produce formulation 1 and formulation 2, respectively. The subjects received 1 of the 2 formulations (45 g, containing a total of 371 mg of toluene-2,5-diamine) on a 250-sq cm area of the scalp. The formulation was thoroughly rinsed off after 30 minutes and the hair was shampooed. The mean total elimination rate of radioactivity of the applied dose in the urine and the feces was 4.81% +/-0.62% for formulation 1 and 1.31% +/- 0.14% in formulation 2. The amounts of toluene-2,5-diamine sulfate were 71 +/- 9.26 mgeq/ sq cm for formulation 1 and 20 +/- 2.02 mgeq/sq cm for formulation 2. The area under the curve (AUC) for whole blood recovery was 41.6 +/- 1.7 ngeq.hr/L and 9.2 +/- 3.1 ngeq.hr/L for formulations 1 and 2, respectively. The total recovery for formulation 1 was 91.2% +/- 1.73%, whereas the total recovery for formulation 2 was 47.64% +/- 3.43%. The authors concluded that the lower recovery for formulation 2 was due to higher retention of radiolabel in the hair as a result of the oxidative hair coloring process.', 'Percutaneous absorption of toluene-2,5-diamine sulfate in human skin samples was studied... Radiolabeled (97.2% pure) and non-radiolabeled (99.7% pure) toluene-2,5-diamine sulfate was added to a final concentration of 9% to 2 hair dye bases, one of which contained an equimolar amount of m-aminophenol as a coupler. The formulation containing the coupler was mixed with hydrogen peroxide (50:50) to yield a test substance with a final toluene-2,5-diamine sulfate concentration of 4.5%. The formulation base without the coupler was mixed with water or hydrogen peroxide, in both cases 50:50, to yield 2 other test substances with final concentrations of toluene-2,5-diamine sulfate of 4.5%. The formulations were then applied over an area of 2-sq cm to 350-mm-thick human skin (20 mg/sq cm) or samples of isolated epidermis mounted in perfusion cells. After an application period of 30 minutes, the test substance was rinsed off with water and a solution of sodium lauryl sulfate. Most of the test substance (93.5% of the applied dose) was recovered during rinsing at 30 minutes post application. Cumulative penetration (based on radioactivity in the receptor fluid) neared a plateau at approximately 5 hours. The total absorption in the formulation without coupler mixed with water was 4.17% +/- 2.54% (40.31 +/- 23.77 mgeq/sq cm). In the formulations mixed with peroxide, the total absorption was 3.41% +/- 1.32% (31.26 +/- 11.64 mgeq/sq cm) with the coupler and 3.44% +/- 2.84% (32.03 +/- 26.58 mgeq/sq cm) without the coupler.', 'The absorption, distribution, metabolism, and excretion of (14)C-toluene-2,5-diamine sulfate were investigated in rats in a series of studies...  Groups of female Wistar Kyoto rats (4 per group in the mass balance portion of the study and 6 per group in the toxicokinetics portion of the study) received the test substance at either 2.5 or 25.0 mg/kg of body weight in a single oral gavage dose or at 33.3 mg/kg of body weight as a dermal application. Vehicle for the oral groups was water, whereas in the dermal group it was water/acetone (1:1). In the urine of the oral dose groups after 96 hours, the mean cumulative recovery of the applied dose was 62.2% in the 2.5-mg/kg dose group and 72.9% in the 25-mg/kg dose group, whereas in the feces, the recovery was 31.4% and 22.0%, respectively. The mean mass balance for both oral doses was about 98%. In the dermal application groups, 10.9% and 2.7% of the applied dose were recovered in the urine and feces, respectively. The mean mass balance for the dermal dose was nearly 100%. ...In plasma kinetics results, the time to peak concentration (Tmax) was 0.5 hours and 0.25 hours for the low- and high-dose oral groups, respectively, indicating rapid absorption. The AUC values for the 2 oral dose groups were 17.59 and 174 mgeq.hr/L, respectively, and for the dermal dose group 4.39 mgeq.hr/L.']","['Incubation of the (14)C-toluene-2,5-diamine sulfate with the human hepatocytes yielded an acetylated metabolite but no sulfated, glucuronidated, or monohydroxylated metabolites.', 'Three major metabolites were observed in the urine /of female Wistar Kyoto rats/ after oral dosing /of (14)C-toluene-2,5-diamine sulfate/, with the main metabolite identified as N,N-diacetyl-toluene-2,5-diamine. No parent compound was identified in the urine. Radioactivity in the urine of the dermal dose group was too low for separation and detection of metabolites.']",
2856,22857,"Dimethylammonium 2,4,5-trichlorophenoxyacetate",C[NH2+]C.C1=C(C(=CC(=C1Cl)Cl)Cl)OCC(=O)[O-],,,,,,
2857,22858,"C.I. Acid Blue 158, disodium salt",C1=CC=C2C(=C1)C(=CC(=C2N=NC3=C(C4=C(C=CC=C4S(=O)(=O)[O-])C=C3)[O-])[O-])S(=O)(=O)[O-].[OH-].[Na+].[Na+].[Cr+3],,,,,,
2858,22859,"1',2-Dihydroxy-(1,2'-azobisnaphthalene)-4,8'-disulfonic acid",C1=CC=C2C(=C1)C(=CC(=C2N=NC3=C(C4=C(C=CC=C4S(=O)(=O)O)C=C3)O)O)S(=O)(=O)O,,,,,,
2859,22860,4-Benzyloxyaniline,C1=CC=C(C=C1)COC2=CC=C(C=C2)N,,,,,,
2860,22861,CID 22861,C1=CC(=NC2=C(C=C(C=C2)N(O)O)[N+](=O)[O-])C=CC1=N,,,,,,
2861,22862,CID 22862,C1=CC=C(C=C1)N=C2C=CC(=NC3=C(C=C(C=C3)N(O)O)[N+](=O)[O-])C=C2S(=O)(=O)[O-].[Na+],,,,,,
2862,22863,CID 22863,C1=CC=C(C=C1)N=C2C=CC(=NC3=C(C=C(C=C3)N(O)O)[N+](=O)[O-])C=C2S(=O)(=O)O,,,,,,
2863,22864,"Anthraquinone, 2-amino-1-mercapto-",C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3)N)S,,,,,,
2864,22865,N-(3-Amino-4-methylphenyl)acetamide,CC1=C(C=C(C=C1)NC(=O)C)N,,,,,,
2865,22866,Acid yellow 42,CC1=NN(C(=O)C1N=NC2=CC(=C(C=C2)C3=C(C=C(C=C3)N=NC4C(=NN(C4=O)C5=CC=CC=C5)C)S(=O)(=O)[O-])S(=O)(=O)[O-])C6=CC=CC=C6.[Na+].[Na+],,,,,,
2866,22867,"4,4'-Bis(4,5-dihydro-1-phenyl-3-methyl-5-oxo-1H-pyrazol-4-ylazo)biphenyl-2,2'-disulfonic acid",CC1=NN(C(=O)C1N=NC2=CC(=C(C=C2)C3=C(C=C(C=C3)N=NC4C(=NN(C4=O)C5=CC=CC=C5)C)S(=O)(=O)O)S(=O)(=O)O)C6=CC=CC=C6,,,,,,
2867,22868,"1-Naphthaleneacetic acid, alpha-(3-(dimethylamino)propyl)-alpha-ethyl-, hydrochloride",CCC(CCC[NH+](C)C)(C1=CC=CC2=CC=CC=C21)C(=O)O.[Cl-],,,,,,
2868,22869,5-(Dimethylamino)-2-ethyl-2-naphthalen-1-ylpentanoic acid,CCC(CCCN(C)C)(C1=CC=CC2=CC=CC=C21)C(=O)O,,,,,,
2869,22870,"alpha,alpha-Bis(2-piperidinoethyl)-1-naphthaleneacetic acid dihydrochloride",C1CC[NH+](CC1)CCC(CC[NH+]2CCCCC2)(C3=CC=CC4=CC=CC=C43)C(=O)O.[Cl-].[Cl-],,,,,,
2870,22871,2-Naphthalen-1-yl-4-piperidin-1-yl-2-(2-piperidin-1-ylethyl)butanoic acid,C1CCN(CC1)CCC(CCN2CCCCC2)(C3=CC=CC4=CC=CC=C43)C(=O)O,,,,,,
2871,22872,"(6aR)-10-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-6-ium-11-ol;chloride",C[NH+]1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)OC)O.[Cl-],,,,,,
2872,22873,Hexyl hexanoate,CCCCCCOC(=O)CCCCC,,,,,,
2873,22874,"Octylamine, methanearsonate (1:1)",CCCCCCCC[NH3+].C[As](=O)(O)[O-],,,,,,
2874,22875,"1,2,3-Trichloro-4,6-dinitrobenzene",C1=C(C(=C(C(=C1[N+](=O)[O-])Cl)Cl)Cl)[N+](=O)[O-],,,,,,
2875,22876,CID 22876,CC(=CC1=CC(=C(C=C1)O[C@H]2[C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O)C(=O)NC3C(C(C4C(C3O)OCO4)O)O,,,,,,
2876,22877,Ammonium saccharin,C1=CC=C2C(=C1)C(=O)NS2(=O)=O.N,,,,,,
2877,22878,CID 22878,C([C@@H](C1C(=O)C(=C(O1)[O-])O)O)O.[Na+],,,,,,
2878,22879,"1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide, calcium salt, hydrate (4:7)",C1=CC=C2C(=C1)C(=NS2(=O)=O)[O-].C1=CC=C2C(=C1)C(=NS2(=O)=O)[O-].O.[Ca+2],,,,,,
2879,22880,N-methyl-D-aspartic acid,CN[C@H](CC(=O)O)C(=O)O,,,['Drugs that bind to and activate excitatory amino acid receptors. (See all compounds classified as Excitatory Amino Acid Agonists.)'],,,
2880,22881,CID 22881,CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)[O-])Cl.[Na+],,,,,,
2881,22882,Bithionolate sodium,C1=C(C=C(C(=C1SC2=C(C(=CC(=C2)Cl)Cl)[O-])[O-])Cl)Cl.[Na+].[Na+],,,,,,
2882,22883,Cloxyfonac,C1=CC(=C(C=C1Cl)CO)OCC(=O)O,,,,,,
2883,22884,"1-Naphthaleneacetic acid, alpha-(2-(dimethylamino)ethyl)-alpha-ethyl-, hydrochloride",CCC(CC[NH+](C)C)(C1=CC=CC2=CC=CC=C21)C(=O)O.[Cl-],,,,,,
2884,22885,4-(Dimethylamino)-2-ethyl-2-naphthalen-1-ylbutanoic acid,CCC(CCN(C)C)(C1=CC=CC2=CC=CC=C21)C(=O)O,,,,,,
2885,22886,alpha-(2-(Diethylamino)ethyl)-1-naphthaleneacetic acid hydrochloride,CC[NH+](CC)CCC(C1=CC=CC2=CC=CC=C21)C(=O)O.[Cl-],,,,,,
2886,22887,4-(Diethylamino)-2-naphthalen-1-ylbutanoic acid,CCN(CC)CCC(C1=CC=CC2=CC=CC=C21)C(=O)O,,,,,,
2887,22888,alpha-(2-(Dimethylamino)ethyl)-1-naphthaleneacetic acid hydrochloride,C[NH+](C)CCC(C1=CC=CC2=CC=CC=C21)C(=O)O.[Cl-],,,,,,
2888,22889,4-(Dimethylamino)-2-naphthalen-1-ylbutanoic acid,CN(C)CCC(C1=CC=CC2=CC=CC=C21)C(=O)O,,,,,,
2889,22890,Allyxycarb,CC1=CC(=CC(=C1N(CC=C)CC=C)C)OC(=O)NC,,,,,,
2890,22891,CID 22891,CSC(=NCC1=CC=CC=C1)S,,,,,,
2891,22892,"2,6-Dinitro-4-methylaniline",CC1=CC(=C(C(=C1)[N+](=O)[O-])N)[N+](=O)[O-],,,,,,
2892,22893,"1-Naphthaleneacetic acid, alpha-(3-(diethylamino)propyl)-alpha-isopropyl-, hydrochloride",CC[NH+](CC)CCCC(C1=CC=CC2=CC=CC=C21)(C(C)C)C(=O)O.[Cl-],,,,,,
2893,22894,5-(Diethylamino)-2-naphthalen-1-yl-2-propan-2-ylpentanoic acid,CCN(CC)CCCC(C1=CC=CC2=CC=CC=C21)(C(C)C)C(=O)O,,,,,,
2894,22895,"1-Naphthaleneacetic acid, alpha,alpha-bis(2-(dimethylamino)ethyl)-, dihydrochloride",C[NH+](C)CCC(CC[NH+](C)C)(C1=CC=CC2=CC=CC=C21)C(=O)O.[Cl-].[Cl-],,,,,,
2895,22896,4-(Dimethylamino)-2-[2-(dimethylamino)ethyl]-2-naphthalen-1-ylbutanoic acid,CN(C)CCC(CCN(C)C)(C1=CC=CC2=CC=CC=C21)C(=O)O,,,,,,
2896,22897,"1-Naphthaleneacetic acid, alpha,alpha-bis(3-(diethylamino)propyl)-, dihydrochloride",CC[NH+](CC)CCCC(CCC[NH+](CC)CC)(C1=CC=CC2=CC=CC=C21)C(=O)O.[Cl-].[Cl-],,,,,,
2897,22898,5-(Diethylamino)-2-[3-(diethylamino)propyl]-2-naphthalen-1-ylpentanoic acid,CCN(CC)CCCC(CCCN(CC)CC)(C1=CC=CC2=CC=CC=C21)C(=O)O,,,,,,
2898,22899,"1-Naphthaleneacetic acid, alpha,alpha-bis(3-(dimethylamino)propyl)-, dihydrochloride",C[NH+](C)CCCC(CCC[NH+](C)C)(C1=CC=CC2=CC=CC=C21)C(=O)O.[Cl-].[Cl-],,,,,,
2899,22900,5-(Dimethylamino)-2-[3-(dimethylamino)propyl]-2-naphthalen-1-ylpentanoic acid,CN(C)CCCC(CCCN(C)C)(C1=CC=CC2=CC=CC=C21)C(=O)O,,,,,,
2900,22901,CID 22901,CC1=CC(=C(C(=C1)C)NC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)S(=O)(=O)[O-])C.[Na+],,,,,,
2901,22902,"1-Amino-9,10-dihydro-9,10-dioxo-4-(2,4,6-trimethylanilino)anthracene-2-sulphonic acid",CC1=CC(=C(C(=C1)C)NC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)S(=O)(=O)O)C,,,,,,
2902,22903,O-(4-(2-(4-Chlorophenyl)propan-2-yl)phenyl) N-methyl-N-(3-methylphenyl)carbamothioate,CC1=CC(=CC=C1)N(C)C(=S)OC2=CC=C(C=C2)C(C)(C)C3=CC=C(C=C3)Cl,,,,,,
2903,22904,2-Dodecendisaure,C(CCCCC(=O)O)CCCC=CC(=O)O,,,,,,
2904,22905,Disodium;3-[[4-[(4-anilino-3-sulfonatophenyl)diazenyl]naphthalen-1-yl]diazenyl]-4-hydroxynaphthalene-1-sulfonate,C1=CC=C(C=C1)NC2=C(C=C(C=C2)N=NC3=CC=C(C4=CC=CC=C43)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)[O-])O)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
2905,22906,3-[[4-[(4-Anilino-3-sulfophenyl)diazenyl]naphthalen-1-yl]diazenyl]-4-hydroxynaphthalene-1-sulfonic acid,C1=CC=C(C=C1)NC2=C(C=C(C=C2)N=NC3=CC=C(C4=CC=CC=C43)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)O)O)S(=O)(=O)O,,,,,,
2906,22907,Sodium 4-(4-(2-hydroxynaphthalenylazo)phenylazo)benzenesulphonate,C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC=C(C=C3)N=NC4=CC=C(C=C4)S(=O)(=O)O)O.[Na+],,,,,,
2907,22908,"Benzenesulfonic acid, 4-[[4-[(2-hydroxy-1-naphthalenyl)azo]phenyl]azo]-",C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC=C(C=C3)N=NC4=CC=C(C=C4)S(=O)(=O)O)O,,,,,,
2908,22909,Dibenzofuran-3-yl(phenyl)methanone,C1=CC=C(C=C1)C(=O)C2=CC3=C(C=C2)C4=CC=CC=C4O3,,,,,,
2909,22910,CID 22910,C1=CC2=C(C=C1NCS(=O)(=O)[O-])C=C(C(=NN=C3C=C(C=C(C3=O)S(=O)(=O)[O-])N([O-])[O-])C2=O)S(=O)(=O)[O-].C1=CC2=C(C=C1[N-]CS(=O)(=O)[O-])C(=O)C(=N[N-]C3=C(C(=CC(=C3)[N+](=O)O)S(=O)(=O)[O-])[O-])C(=C2)S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Cr],,,,,,
2910,22911,CID 22911,C1=CC2=C(C=C1NCS(=O)(=O)O)C=C(C(=NN=C3C=C(C=C(C3=O)S(=O)(=O)O)N([O-])[O-])C2=O)S(=O)(=O)O,,,,,,
2911,22912,CID 22912,C1=CC(=CC2=C(C(=C(C=C21)S(=O)(=O)O)N=NC3=C(C(=CC(=C3)[N+](=O)O)S(=O)(=O)O)O)O)NCS(=O)(=O)O,,,,,,
2912,22913,Bucolan Red GRE,CC1=NN(C(=C1N=NC2=C(C(=CC(=C2)Cl)S(=O)(=O)[O-])[O-])[O-])C3=CC(=CC=C3)S(=O)(=O)[O-].[OH-].[Na+].[Na+].[Cr],,,,,,
2913,22914,"Benzenesulfonic acid, 5-chloro-2-hydroxy-3-((3-methyl-5-oxo-1-(M-sulfophenyl)-2-pyrazolin-4-YL)azo)-",CC1=C(C(=O)N(N1)C2=CC(=CC=C2)S(=O)(=O)O)N=NC3=C(C(=CC(=C3)Cl)S(=O)(=O)O)O,,,,,,
2914,22915,CID 22915,C1=CC=C(C=C1)NC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)S(=O)(=O)[O-].[Na+],,,,,,
2915,22916,"2-Anthracenesulfonic acid, 1-amino-9,10-dihydro-9,10-dioxo-4-(phenylamino)-",C1=CC=C(C=C1)NC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)S(=O)(=O)O,,,,,,
2916,22917,Para Red,C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC=C(C=C3)[N+](=O)[O-])O,,,,,,
2917,22918,1-((2-Methoxy-3-methylphenyl)azo)-2-naphthol,CC1=CC(=C(C=C1)OC)N=NC2=C(C=CC3=CC=CC=C32)O,,,,,,
2918,22919,"2-Naphthalenecarboxamide, N-(4-chlorophenyl)-3-hydroxy-4-[(2-methyl-5-nitrophenyl)azo]-",CC1=C(C=C(C=C1)[N+](=O)[O-])N=NC2=C(C(=CC3=CC=CC=C32)C(=O)NC4=CC=C(C=C4)Cl)O,,,,,,
2919,22920,"2-Naphthalenecarboxamide, 4-[(2,5-dichlorophenyl)azo]-3-hydroxy-N-(2-methoxyphenyl)-",COC1=CC=CC=C1NC(=O)C2=CC3=CC=CC=C3C(=C2O)N=NC4=C(C=CC(=C4)Cl)Cl,,,,,,
2920,22921,Heptan-2-ylazanium;sulfate,CCCCCC(C)[NH3+].CCCCCC(C)[NH3+].[O-]S(=O)(=O)[O-],,,,,,
2921,22922,"4-Methyl-2-prop-1-enyl-1,3-dioxolane",CC=CC1OCC(O1)C,,,,,,
2922,22923,"1,5-Dioxaspiro(5.5)undecan-3-OL, 9-methyl-",CC1CCC2(CC1)OCC(CO2)O,,,,,,
2923,22924,1-Methyl-3-phenylindan,CC1CC(C2=CC=CC=C12)C3=CC=CC=C3,,,,,,
2924,22925,"1-Naphthalenesulfonic acid, 4-hydroxy-3-((4'-((1-hydroxy-5-sulfo-2-naphthalenyl)azo)-3,3'-dimethyl(1,1'-biphenyl)-4-yl)azo)-, disodium salt",CC1=CC(=CC=C1)C2=CC(=C(C=C2)N=NC3=CC(=C(C4=C3C(=CC=C4)S(=O)(=O)[O-])O)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)[O-])O)C.[Na+].[Na+],,,,,,
2925,22926,5-Hydroxy-6-[(1-hydroxy-4-sulfonaphthalen-2-yl)diazenyl]-8-[[2-methyl-4-(3-methylphenyl)phenyl]diazenyl]naphthalene-1-sulfonic acid,CC1=CC(=CC=C1)C2=CC(=C(C=C2)N=NC3=CC(=C(C4=C3C(=CC=C4)S(=O)(=O)O)O)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)O)O)C,,,,,,
2926,22927,Direct red 24,CC1=C(C=CC(=C1)S(=O)(=O)[O-])N=NC2=C(C=C3C=C(C=CC3=C2O)NC(=O)NC4=CC5=CC(=C(C(=C5C=C4)O)N=NC6=CC=CC=C6OC)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+],,,,,,
2927,22928,Direct Red 24 free acid,CC1=C(C=CC(=C1)S(=O)(=O)O)N=NC2=C(C=C3C=C(C=CC3=C2O)NC(=O)NC4=CC5=CC(=C(C(=C5C=C4)O)N=NC6=CC=CC=C6OC)S(=O)(=O)O)S(=O)(=O)O,,,,,,
2928,22929,Dinoseb-trolamine,CCC(C)C1=C(C(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])O.C(CO)N(CCO)CCO,,,,,,
2929,22930,"Ammonium, thiodiethylenebis(trimethyl-, diiodide",C[N+](C)(C)CCSCC[N+](C)(C)C.[I-].[I-],,,,,,
2930,22931,"Ethanaminium, 2,2'-thiobis[N,N,N-trimethyl-",C[N+](C)(C)CCSCC[N+](C)(C)C,,,,,,
2931,22932,Bis(2-ethylhexyl) terephthalate,CCCCC(CC)COC(=O)C1=CC=C(C=C1)C(=O)OCC(CC)CCCC,,,,"['Rats readily excreted (14)C EHT given in a single dose at 100 mg/kg. 57.9%, 28.6%, and 3.6% of the (14)C was recovered in the feces, urine an expired air, respectively, within 144 hr after admin. Only 2.1% remained in the carcass.', 'The hydrolysis of di(2-ethylhexyl) terephthalate and di(2-ethylhexyl) phthalate were studied using rat gut homogenate fractions in vitro. Both isomers were hydrolysed by the intestinal fraction; however di(2-ethylhexyl) phthalate was hydrolysed to 2-ethylhexanol and mono(2-ethylhexyl) phthalate in about equal proportions whereas di(2-ethylhexyl) terephthalate was hydrolysed to 2-ethylhexanol and terephthalic acid. The half-lives for disappearance of the diesters were determined to be 12.6 min for di(2-ethylhexyl) phthalate and 53.3 min for di(2-ethylhexyl) terephthalate. 2. The absorption and metabolism of di(2-ethylhexyl) terephthalate were studied by administering (hexyl-(14)C)di(2-ethylhexyl) terephthalate (in corn oil) by oral gavage at a dose level of 100 mg/kg to 10 adult male Sprague Dawley rats. Urine feces and expired air were collected for 144 hr and analysed for the presence of radioactivity and feces and urine were analysed for unlabelled metabolites. 3. Radioactivity was eliminated in feces (56.5 +/- 12.1% of dose) primarily as unchanged di(2-ethylhexyl) terephthalate, small amounts of mono(2-ethylhexyl) phthalate and polar metabolites; excreted in urine (31.9 +/- 10.9% of dose) principally as mono(2-ethylhexyl) phthalate and metabolic products of 2-ethylhexanol; and expired as (14)C02 (3.6 +/-0.9% of dose). Less than 2% of the administered radioactivity was found in the carcass. Small amounts of (14)C were found in the tissues with the highest amounts found in liver and fat. 4. Metabolites identified in urine included terephthalic acid (equivalent to 51% of dose), oxidized metabolites of 2-ethylhexanol and mono(2-ethylhexyl) phthalate, and glucuronic and sulfuric acid conjugates (equivalent to about 10% of dose). 5. These findings indicate that di(2-ethylhexyl) terephthalate was hydrolysed more extensively than di(2-ethylhexyl) phthalate and consequently the urinary metabolite profiles for these two isomeric plasticizers were very different. The hydrolysis and metabolism of di(2-ethylhexyl) terephthalate were found to be similar to those of di(2-ethylhexyl) adipate in that hydrolysis of both ester bonds occurs.']",,
2932,22933,Propylene glycol dinitrate,CC(CO[N+](=O)[O-])O[N+](=O)[O-],,,,"['The substance can be absorbed into the body by inhalation, through the skin or by ingestion.', 'Information supporting the dermal absorption of propylene glycol dinitrate was obtained from studies demonstrating systemic toxicity after dermal exposure in rabbits  For example, a transient decrease in hemoglobin was observed following dermal application of doses of propylene glycol dinitrate as low as 1,000 mg/kg/day, 2 hours/day, for 20 days to rabbits. Also, observation of elevated levels of the metabolite nitrate in the urine of rabbits receiving a dermal dose of 4,000 mg/kg/day supported the absorption of propylene glycol dinitrate after dermal exposure.', 'Exposure of monkeys to concentrations of 1.6 ppm and 4.2 ppm of propylene glycol dinitrate for 20 and 14 days, respectively, resulted in the detection of small amounts of propylene glycol dinitrate in plasma. During exposures to 1 .6 ppm, 35 ug/mL propylene glycol dinitrate was detected in plasma, and during exposures at 4.2 ppm, 170 ug/mL was detected in plasma.', 'In vitro studies using dog blood have shown that propylene glycol dinitrate preferentially associates with red blood cells in the blood.', 'For more Absorption, Distribution and Excretion (Complete) data for 1,2-PROPANEDIOL DINITRATE (6 total), please visit the HSDB record page.']","['The metabolism of /propylene glycol, 1,2-dinitrate/ (PGDN), as determined in vitro in blood and in vivo in rats, showed that 50% was broken down in 1 hr, and 50% of the remainder in the following hour. Small concentrations of inorganic nitrite were produced during incubation in blood, whereas inorganic nitrate accumulated. At the end of 3 hr, the first time it was measured, there were large amounts of propylene glycol 2-mononitrate (PGMN-2), together with small amounts of PGMN-1). The summed quantities of mononitrates, inorganic nitrate, and nitrite represented 95% of the initial amount added to blood. this metabolism occurred in the erythrocytes. In the intact rat, in contrast to in vitro in the blood, mononitrates undergo further degradation to nitrogen compounds other than the mononitrates and inorganic nitrate. Only 56% of the administered PGDN appeared in the urine as inorganic nitrate. THus, there is qualitatively little to distinguish the in vitro and in vivo metabolism of PGDN from that of /ethylene glycol dinitrate/ (EGDN). The only difference is that PGDN gives rise to two mononitrates and the 2-isomer is predominant, whereas EGDN gives rise only to /ethylene glycol mononitrate/. Quantitatively, there is less dinitrate and inorganic nitrite in the bloodstream after subcutaneous injection from PGDN than from a comparable injection of EGDN. Excretion was complete in 24 hr following a 65 mg/kg PGDN subcutaneous injection in rats.', 'Metabolic studies show that inorganic nitrate /is/ the major metabolite of propylene glycol dinitrate (PGDN) in rats administered 65 mg/kg subcutaneously; PGDN and nitrite were almost undetectable. Excretion was complete in 24 hours.', '... An effort was made to understand the oxidative process /which produces methemoglobin in vivo/ better and explain the role of hemoglobin in detoxifying nitrate esters. The reaction was nonenzymatic and first-order for dinitrate and O2Hb. The rate of oxidation proceeds linearly with dinitrate concentration and does not approach a limit as would be the case if it were enzymatically driven. The rate of oxidation is related complexly to the oxygen concentration. No oxidation occurs at zero oxygen concentration and none at very high concentrations. The stoichiometry was thought to be 1.5 hemes oxidized per ester bond broken in hemolysates and 1.9 to 2.3 per mole reacted ester in whole cells. From these studies, it was reasoned that hemoglobin would fulfill an important role in detoxifying the effects caused by the dinitrates. Hemoglobin in vivo, with the methemoglobin reductase system, acts catalytically to metabolize dinitrates to nitrite and nitrate, and the mononitrates are further degraded by the denitrifying tissue enzymes.', 'Subcutaneous injection of 65 mg/kg propylene glycol dinitrate in rats caused a rapid increase in blood levels of propylene glycol dinitrate.  Appearance of metabolites of propylene glycol dinitrate in the blood was maximal 2-4 hours postinjection and had declined to essentially zero by 8-12 hours postinjection. The predominant metabolite observed in the blood was nitrate, with propylene glycol 2-mononitrate observed at approximately one-half the concentration of inorganic nitrate. The levels of propylene glycol 1-mononitrate and inorganic nitrite were less than half that of propylene glycol 2-mononitrate.', 'For more Metabolism/Metabolites (Complete) data for 1,2-PROPANEDIOL DINITRATE (6 total), please visit the HSDB record page.']","['The metabolism of /propylene glycol, 1,2-dinitrate/, as determined in vitro in blood and in vivo in rats, showed that 50% was broken down in 1 hr, and 50% of the remainder in the following hour.', 'For /intravenous/ doses of 0.3, 3, and 30 mg/kg /in rats/, the elimination half-time of propylene glycol dinitrate was 8.8, 13.1, and 17.4 hours, respectively. Elimination of the parent compound from blood was monoexponential.']"
2933,22934,"5A-Estran-3-on-17B-ol, 17A-methyl",C[C@@]1(CCC2C1(CCC3C2CC[C@@H]4C3CCC(=O)C4)C)O,,,,,,
2934,22935,"Sodium;4-(4-acetamidoanilino)-1-amino-9,10-dioxoanthracene-2-sulfonic acid",CC(=O)NC1=CC=C(C=C1)NC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)S(=O)(=O)O.[Na+],,,,,,
2935,22936,"2-Anthracenesulfonic acid, 4-[[4-(acetylamino)phenyl]amino]-1-amino-9,10-dihydro-9,10-dioxo-",CC(=O)NC1=CC=C(C=C1)NC2=CC(=C(C3=C2C(=O)C4=CC=CC=C4C3=O)N)S(=O)(=O)O,,,,,,
2936,22937,"ANTHRAQUINONE, 1,2-DIHYDROXY-5,8-BIS(p-HYDROXYANILINO)-",C1=CC(=CC=C1NC2=C3C(=C(C=C2)NC4=CC=C(C=C4)O)C(=O)C5=C(C3=O)C=CC(=C5O)O)O,,,,,,
2937,22938,4-Cyclohexylmorpholine,C1CCC(CC1)N2CCOCC2,,,,,,
2938,22939,"N-Benzyl-N,N,N-trimethylammonium hexafluorophosphate",C[N+](C)(C)CC1=CC=CC=C1.F[P-](F)(F)(F)(F)F,,,,,,
2939,22940,CID 22940,C1=CC(=CC=C1NN=C2C(=CC3=C(C2=N)C(=O)C(=NNC4=CC=C(C=C4)N=NC5=C(C=C(C=C5)N)N)C(=C3)S(=O)(=O)[O-])S(=O)(=O)[O-])N=NC6=C(C=C(C=C6)N)N.[Na+].[Na+],,,,,,
2940,22941,CID 22941,C1=CC(=CC=C1NN=C2C(=CC3=C(C2=N)C(=O)C(=NNC4=CC=C(C=C4)N=NC5=C(C=C(C=C5)N)N)C(=C3)S(=O)(=O)O)S(=O)(=O)O)N=NC6=C(C=C(C=C6)N)N,,,,,,
2941,22942,C.I. Direct violet 32,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=CC=CC=C4C(=C3)S(=O)(=O)[O-])O)OC)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)[O-])N.[Na+].[Na+],,,,,,
2942,22943,"4-Amino-3-((4'-((1-hydroxy-4-sulfo-2-naphthalenyl)diazenyl)-3,3'-dimethoxy[biphenyl]-4-yl)diazenyl)-1-naphthalenesulfonic acid",COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=CC=CC=C4C(=C3)S(=O)(=O)O)O)OC)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)O)N,,,,,,
2943,22944,"1-(3,4-Dimethoxybenzyl)-1,2,3,4-tetrahydro-6,7-dimethoxyisoquinolinium chloride",COC1=C(C=C(C=C1)CC2C3=CC(=C(C=C3CC[NH2+]2)OC)OC)OC.[Cl-],,,,,,
2944,22945,CID 22945,C1=CC=C(C=C1)C(=O)CCC2=C(OC3=CC=CC=C3C2=O)O,,,,,,
2945,22946,"4,5,6,7-Tetrahydro-1-benzothiophene",C1CCC2=C(C1)C=CS2,,,,,,
2946,22947,"1,3-Bis(hydroxymethyl)-5,5-dimethylimidazolidine-2,4-dione",CC1(C(=O)N(C(=O)N1CO)CO)C,,,,"[""A 0.1 mL aqueous solution containing 0.1 mCi of 1,3-dihydroxymethyl-5,5'-dimethylhydantoin-5-(14)-C was applied to the middorsal area of young adult male Sprague-Dawley rats. After 72 hours, more than 90% of the applied dose was recovered; more than 98% of the recovered activity was confined to the dose site. At the time of killing, less than 1% of the radioactivity was distributed in all body tissues. The higher counts of radioactivity were reported for the gastrointestinal tract, liver, and bone marrow. For most tissue samples, there was no evidence of accumulation of DMDM Hydantoin or its metabolites. DMDM Hydantoin and its metabolites are excreted primarily via the urine. The amount of (14)C activity in the urine decreased approximately 6 times over a 72-hour period; radioactivity in the feces remained approximately constant and significantly below that of the urine.""]",,
2947,22948,Phloxin,C1=CC(=C2C(=C1Cl)C(=O)OC23C4=CC(=C(C(=C4OC5=C(C(=C(C=C35)Br)[O-])Br)Br)[O-])Br)Cl.[K+].[K+],,,,,,
2948,22949,"2',4',5',7'-Tetrabromo-4,7-dichloro-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one",C1=CC(=C2C(=C1Cl)C(=O)OC23C4=CC(=C(C(=C4OC5=C(C(=C(C=C35)Br)O)Br)Br)O)Br)Cl,,,,,,
2949,22950,Xylamidine tosylate,CC1=CC=C(C=C1)S(=O)(=O)[O-].CC1=CC(=CC=C1)CC(=N)[NH2+]CC(C)OC2=CC=CC(=C2)OC,,,"['Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)']",,,
2950,22951,Xylamidine,CC1=CC(=CC=C1)CC(=NCC(C)OC2=CC=CC(=C2)OC)N,,,"['Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)']",,,
2951,22952,"1,5-Dimethoxyanthraquinone",COC1=CC=CC2=C1C(=O)C3=C(C2=O)C(=CC=C3)OC,,,,,,
2952,22953,"C.I. Direct blue 151, disodium salt",COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3O)N)S(=O)(=O)[O-])OC)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)[O-])O.[Na+].[Na+],,,,,,
2953,22954,"3-((4''-((6-Amino-1-hydroxy-3-sulfonaphthalen-2-yl)diazenyl)-3,3''-dimethoxybiphenyl-4-yl)diazenyl)-4-hydroxynaphthalene-1-sulfonic acid",COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3O)N)S(=O)(=O)O)OC)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)O)O,,,,,,
2954,22955,Scoulerine,COC1=C(C2=C(CC3C4=CC(=C(C=C4CCN3C2)OC)O)C=C1)O,,,,,,
2955,22956,"Carbamic acid, methyl-, 4-((dimethylamino)methyl)-3,5-dimethylphenyl ester",CC1=CC(=CC(=C1CN(C)C)C)OC(=O)NC,,,,,,
2956,22957,3-Morpholinomethyl-4-hydroxybiphenyl,C1COCCN1CC2=C(C=CC(=C2)C3=CC=CC=C3)O,,,,,,
2957,22958,Ethyl dimethyl oleyl ammonium bromide,CCCCCCCCC=CCCCCCCCC[N+](C)(C)CC.[Br-],,,,,,
2958,22959,"N-Ethyl-N,N-dimethyl-9-octadecen-1-aminium",CCCCCCCCC=CCCCCCCCC[N+](C)(C)CC,,,,,,
2959,22960,C.I. Acid Red 114,CC1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)N=NC3=C(C=C(C=C3)C4=CC(=C(C=C4)N=NC5=C(C=CC6=CC(=CC(=C65)S(=O)(=O)[O-])S(=O)(=O)[O-])O)C)C.[Na+].[Na+],,,,"[""CI Acid Red 114 (100 mg/kg) containing less than 1% 3,3'-dimethylbenzidine as an impurity was administered once in the diet to two female mongrel dogs weighing 15 kg, and 48-hr urine was analyzed for 3,3' -dimethylbenzidine, the potential metabolic product. Excretion was found to be 0.04% of the dose of dye administered, which is in excess of what would be expected from the level of impurity; para-aminophenyl-paratoluenesulfonate was also identified as a urinary metabolite. The same dose of CI Acid Red 114 was also administered once to four male Sprague- Dawley rats by intragastric intubation; after 72 hr, only 0.01 % of the dose could be identified as 3,3'-dimethylbenzidine.""]",,
2960,22961,"8-((3,3'-Dimethyl-4'-((4-(((p-tolyl)sulphonyl)oxy)phenyl)azo)(1,1'-biphenyl)-4-yl)azo)-7-hydroxynaphthalene-1,3-disulphonic acid",CC1=CC=C(C=C1)S(=O)(=O)OC2=CC=C(C=C2)N=NC3=C(C=C(C=C3)C4=CC(=C(C=C4)N=NC5=C(C=CC6=CC(=CC(=C65)S(=O)(=O)O)S(=O)(=O)O)O)C)C,,,,,,
2961,22962,DL-Hexahydro-gamma-benzamido-delta-oxo-1H-azepine-1-valeric acid,C1CCCN(CC1)C(=O)C(CCC(=O)O)NC(=O)C2=CC=CC=C2,,,,,,
2962,22963,"Benzonitrile, 4,4'-sulfonyldi-",C1=CC(=CC=C1C#N)S(=O)(=O)C2=CC=C(C=C2)C#N,,,,,,
2963,22964,"2H-1-Benzopyran-3,6-dicarboxylic acid, 2-oxo-, dimethyl ester",COC(=O)C1=CC2=C(C=C1)OC(=O)C(=C2)C(=O)OC,,,,,,
2964,22965,"2H-1-Benzopyran-3,6-dicarboxylic acid, 2-oxo-, diethyl ester",CCOC(=O)C1=CC2=C(C=C1)OC(=O)C(=C2)C(=O)OCC,,,,,,
2965,22966,"2H-1-Benzopyran-3,6-dicarboxylic acid, 2-oxo-",C1=CC2=C(C=C1C(=O)O)C=C(C(=O)O2)C(=O)O,,,,,,
2966,22967,3-Carbomethoxy-6-carboxycoumarin,COC(=O)C1=CC2=C(C=CC(=C2)C(=O)O)OC1=O,,,,,,
2967,22968,3-Carbethoxy-6-carboxycoumarin,CCOC(=O)C1=CC2=C(C=CC(=C2)C(=O)O)OC1=O,,,,,,
2968,22969,"2H-1-Benzopyran-6-carboxylic acid, 3-acetyl-2-oxo-",CC(=O)C1=CC2=C(C=CC(=C2)C(=O)O)OC1=O,,,,,,
2969,22970,"2H-1-Benzopyran-6-carboxylic acid, 3-acetyl-2-oxo-, methyl ester",CC(=O)C1=CC2=C(C=CC(=C2)C(=O)OC)OC1=O,,,,,,
2970,22971,"2H-1-Benzopyran-6-carboxylic acid, 3-acetyl-2-oxo-, ethyl ester",CCOC(=O)C1=CC2=C(C=C1)OC(=O)C(=C2)C(=O)C,,,,,,
2971,22972,"2H-1-Benzopyran-6-carboxylic acid, 3-acetyl-2-oxo-, isopropyl ester",CC(C)OC(=O)C1=CC2=C(C=C1)OC(=O)C(=C2)C(=O)C,,,,,,
2972,22973,"2H-1-Benzopyran-6-carboxylic acid, 3-glyoxyloyl-2-oxo-",C1=CC2=C(C=C1C(=O)O)C=C(C(=O)O2)C(=O)C=O,,,,,,
2973,22974,"2H-1-Benzopyran-6-carboxylic acid, 3-glyoxyloyl-2-oxo-, methyl ester",COC(=O)C1=CC2=C(C=C1)OC(=O)C(=C2)C(=O)C=O,,,,,,
2974,22975,3-Carbomethoxy-6-carbethoxycoumarin,CCOC(=O)C1=CC2=C(C=C1)OC(=O)C(=C2)C(=O)OC,,,,,,
2975,22976,3-Carbethoxy-6-carbomethoxycoumarin,CCOC(=O)C1=CC2=C(C=CC(=C2)C(=O)OC)OC1=O,,,,,,
2976,22977,"Disodium 3,3'-((3,3'-dichloro(1,1'-biphenyl)-4,4'-diyl)bis(azo))bis(4-aminonaphthalene-1-sulphonate)",C1=CC=C2C(=C1)C(=CC(=C2N)N=NC3=C(C=C(C=C3)C4=CC(=C(C=C4)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)[O-])N)Cl)Cl)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
2977,22978,C.I. Direct Red 61,C1=CC=C2C(=C1)C(=CC(=C2N)N=NC3=C(C=C(C=C3)C4=CC(=C(C=C4)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)O)N)Cl)Cl)S(=O)(=O)O,,,,,,
2978,22979,C.I. Pigment Red 23,COC1=C(C=C(C=C1)[N+](=O)[O-])N=NC2=C(C(=CC3=CC=CC=C32)C(=O)NC4=CC(=CC=C4)[N+](=O)[O-])O,,,,,,
2979,22980,C.I. Direct black 22,C1=CC(=CC=C1NC2=C(C=C(C=C2)N=NC3=C(C=C4C=CC(=CC4=C3O)N=NC5=C(C=C(C=C5)N)N)S(=O)(=O)[O-])S(=O)(=O)[O-])N=NC6=C(C=C7C=CC(=CC7=C6O)N=NC8=C(C=C(C=C8)N)N)S(=O)(=O)[O-].[Na+].[Na+].[Na+],,,,,,
2980,22981,"6-((2,4-Diaminophenyl)azo)-3-((4-((4-((7-((2,4-diaminophenyl)azo)-1-hydroxy-3-sulpho-2-naphthyl)azo)phenyl)amino)-3-sulphophenyl)azo)-4-hydroxynaphthalene-2-sulphonic acid",C1=CC(=CC=C1NC2=C(C=C(C=C2)N=NC3=C(C=C4C=CC(=CC4=C3O)N=NC5=C(C=C(C=C5)N)N)S(=O)(=O)O)S(=O)(=O)O)N=NC6=C(C=C7C=CC(=CC7=C6O)N=NC8=C(C=C(C=C8)N)N)S(=O)(=O)O,,,,,,
2981,22982,Phenbutrazate hydrochloride,CCC(C1=CC=CC=C1)C(=O)OCC[NH+]2CCOC(C2C)C3=CC=CC=C3.[Cl-],,,,,,
2982,22983,"3-(6-Methyl-6-phenyl-1,3-oxazinan-3-yl)-1-phenylpropan-1-one",CC1(CCN(CO1)CCC(=O)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
2983,22984,"6-Anthracenesulfonic acid, 9,10-dihydro-9,10-dioxo-1-nitro-",C1=CC2=C(C(=C1)[N+](=O)[O-])C(=O)C3=C(C2=O)C=C(C=C3)S(=O)(=O)O,,,,,,
2984,22985,Ammonium nitrate,[NH4+].[N+](=O)([O-])[O-],,,"['Substances that are energetically unstable and can produce a sudden expansion of the material, called an explosion, which is accompanied by heat, pressure and noise. Other things which have been described as explosive that are not included here are explosive action of laser heating, human performance, sudden epidemiological outbreaks, or fast cell growth. (See all compounds classified as Explosive Agents.)', 'Substances or mixtures that are added to the soil to supply nutrients or to make available nutrients already present in the soil, in order to increase plant growth and productivity. (See all compounds classified as Fertilizers.)']","['12 Healthy volunteers ingested orally 7-10.5 g ammonium nitrate in a single dose & 12 others received 9.5 g of sodium nitrate iv in approx 60 min. Samples of blood, saliva & urine were collected just before a 24 hr period. Saliva and urine were analyzed for volatile N-nitrosamines, nitrate & nitrite. Blood was analyzed for nitrate. Neither in urine nor in saliva were N-nitrosamines other than N-nitrosodiethylamine detected. Of the 188 urine samples, 13% contained greater than 0.1 ug N-nitrosodiethylamine/kg the highest level being 0.5 ug/kg. In 92% of the 179 saliva samples, less than 0.5 ug N-nitrosodiethylamine/l was found. Peak values for nitrate plus nitrite in saliva, which were reached 2-6 hr after intake, varied strongly between individuals, ranging from 4-43 mmol/L. Nitrite was detected in 26% of the urine samples. An average of 75% of administered nitrate was excreted in urine in 24 hr. Nitrate contents in blood, urine & saliva after 24 hr were still higher than before the nitrate intake.']",,
2985,22986,CID 22986,C1=CC(=CC=C1C(=O)N[C@H](CCC(=O)[O-])C(=O)[O-])NCC2=CN=C3C(=N2)C(=O)N=C(N3)N.[Na+].[Na+],,,,,,
2986,22987,CID 22987,C1=CC(=CC=C1C(=O)N[C@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=O)N=C(N3)N,,,,,,
2987,22988,Manganese gluconate,C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.[Mn+2],['Manganese gluconate is currently only available in combination products. It is indicated for the prophylactic or nutritional supplementation of [DB06757].'],['Manganese gluconate is a salt which dissociates in body fluids to form manganese and gluconic acid. Its pharmacological effects are due to the normal role of [DB06757] in the body.'],,,,
2988,22989,CID 22989,C1=CC(=CN=C1)C(=O)N.C(C(C1C(=O)C(=C(O1)O)O)O)O,,,,,,
2989,22990,p-tert-Amylphenyl acetate,CCC(C)(C)C1=CC=C(C=C1)OC(=O)C,,,,,,
2990,22991,"1-Naphthaleneacetic acid, alpha-(2-(diethylamino)ethyl)-alpha-isopropyl-, hydrochloride",CC[NH+](CC)CCC(C1=CC=CC2=CC=CC=C21)(C(C)C)C(=O)O.[Cl-],,,,,,
2991,22992,2-[2-(Diethylamino)ethyl]-3-methyl-2-naphthalen-1-ylbutanoic acid,CCN(CC)CCC(C1=CC=CC2=CC=CC=C21)(C(C)C)C(=O)O,,,,,,
2992,22993,"3H-Indol-3-one, 5-bromo-2-(1,3-dihydro-3-oxo-2H-indol-2-ylidene)-1,2-dihydro-",C1=CC=C2C(=C1)C(=O)C(=N2)C3=C(C4=C(N3)C=CC(=C4)Br)O,,,,,,
2993,22994,"Caffeine, 8-((2-aminoethyl)thio)-",CN1C2=C(N=C1SCCN)N(C(=O)N(C2=O)C)C,,,,,,
2994,22995,"Caffeine, 8-((2-aminoethyl)thio)-, hydrochloride",C[NH+]1C2=C(N=C1SCCN)N(C(=O)N(C2=O)C)C.[Cl-],,,,,,
2995,22996,"N-butan-2-yl-3-formamido-N-methyl-1,2,4-triazole-1-carboxamide",CCC(C)N(C)C(=O)N1C=NC(=N1)NC=O,,,,,,
2996,22997,"2,4-Bis(ethylamino)-6-(4-nitrophenoxy)-1,3,5-triazine",CCNC1=NC(=NC(=N1)OC2=CC=C(C=C2)[N+](=O)[O-])NCC,,,,,,
2997,22998,"2,4-Bis(ethylamino)-6-phenoxy-1,3,5-triazine",CCNC1=NC(=NC(=N1)OC2=CC=CC=C2)NCC,,,,,,
2998,22999,"2,4-Bis(ethylamino)-6-(p-tolylthio)-1,3,5-triazine",CCNC1=NC(=NC(=N1)SC2=CC=C(C=C2)C)NCC,,,,,,
2999,23000,"4-N-ethyl-6-phenoxy-2-N-propan-2-yl-1,3,5-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)OC2=CC=CC=C2)NC(C)C,,,,,,
3000,23001,"2-(2-Chlorophenoxy)-4,6-bis(ethylamino)-1,3,5-triazine",CCNC1=NC(=NC(=N1)OC2=CC=CC=C2Cl)NCC,,,,,,
3001,23002,"2,4-Bis(ethylamino)-6-phenylthio-1,3,5-triazine",CCNC1=NC(=NC(=N1)SC2=CC=CC=C2)NCC,,,,,,
3002,23003,CID 23003,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)[O-])Cl)Cl.[Na+],,,,,,
3003,23004,"Benzoin, deoxy-alpha-(bis(2-hydroxyethyl))amino-",C1=CC=C(C=C1)C(C(=O)C2=CC=C(C=C2)Cl)[NH+](CCO)CCO.[Cl-],,,,,,
3004,23005,2-[Bis(2-hydroxyethyl)amino]-1-(4-chlorophenyl)-2-phenylethanone,C1=CC=C(C=C1)C(C(=O)C2=CC=C(C=C2)Cl)N(CCO)CCO,,,,,,
3005,23006,"6-Pteridinecarboxamide, 4-amino-N-(2-methoxyethyl)-7-((2-methoxyethyl)amino)-2-phenyl-",COCCNC1=NC2=NC(=NC(=C2N=C1C(=O)NCCOC)N)C3=CC=CC=C3,,,,,,
3006,23007,"GLYCINE, N,N'-(6-CHLORO-s-TRIAZINE-2,4-DIYL)DI-",C(C(=O)O)NC1=NC(=NC(=N1)Cl)NCC(=O)O,,,,,,
3007,23008,CID 23008,CN1C(=C2C(=NC(=N2)SCCCC(=O)C3=CC=C(C=C3)F)N(C1=O)C)S,,,,,,
3008,23009,Nimorazole,C1COCCN1CCN2C=NC=C2[N+](=O)[O-],,,['Agents used to treat trichomonas infections. (See all compounds classified as Antitrichomonal Agents.)'],,,
3009,23010,Oxiraneacetonitrile,C1C(O1)CC#N,,,,,,
3010,23011,"9H-Carbazole, 1-methyl-",CC1=C2C(=CC=C1)C3=CC=CC=C3N2,,,,,,
3011,23012,Bis(2-carboxyphenyl)diselenide,C1=CC=C(C(=C1)C(=O)O)[Se][Se]C2=CC=CC=C2C(=O)O,,,,,,
3012,23013,(4-Bromo-1-naphthylazo)malononitrile,C1=CC=C2C(=C1)C(=CC=C2Br)N=NC(C#N)C#N,,,,,,
3013,23014,(2-Butoxyphenyl)methanol,CCCCOC1=CC=CC=C1CO,,,,,,
3014,23015,Ledakrin,C[NH+](C)CCC[NH2+]C1=C2C(=NC3=CC=CC=C31)C=CC=C2[N+](=O)[O-].[Cl-].[Cl-],,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Compounds that inhibit cell production of DNA or RNA. (See all compounds classified as Nucleic Acid Synthesis Inhibitors.)']",,,
3015,23016,"2,3,6-Trichloropyridine",C1=CC(=NC(=C1Cl)Cl)Cl,,,,,,
3016,23017,"3,5,6-Trichloro-2-pyridinol",C1=C(C(=O)NC(=C1Cl)Cl)Cl,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']",,"['3,5,6-Trichloro-2-pyridinol is a known human metabolite of Chlorpyrifos and Chlorpyrifos-oxon.']",
3017,23018,"2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-1-(2-ethoxyethyl)-5-phenyl-",CCOCCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,,,,,,
3018,23019,Pentyl 4-hydroxybenzoate,CCCCCOC(=O)C1=CC=C(C=C1)O,,,,,,
3019,23020,"5-[(4,6-Dichloro-1,3,5-triazin-2-yl)amino]-4-hydroxy-3-(phenylazo)naphthalene-2,7-disulphonic acid",C1=CC=C(C=C1)N=NC2=C(C3=C(C=C(C=C3C=C2S(=O)(=O)O)S(=O)(=O)O)NC4=NC(=NC(=N4)Cl)Cl)O,,,,,,
3020,23021,CID 23021,C1=CC=C(C=C1)N=C([NH3+])N.[Cl-],,,,,,
3021,23022,"1-Naphthaleneacetic acid, alpha-isopropyl-alpha-(3-piperidinopropyl)-, hydrochloride",CC(C)C(CCC[NH+]1CCCCC1)(C2=CC=CC3=CC=CC=C32)C(=O)O.[Cl-],,,,,,
3022,23023,2-Naphthalen-1-yl-5-piperidin-1-yl-2-propan-2-ylpentanoic acid,CC(C)C(CCCN1CCCCC1)(C2=CC=CC3=CC=CC=C32)C(=O)O,,,,,,
3023,23024,"1-Naphthaleneacetic acid, alpha-isopropyl-alpha-(3-morpholinopropyl)-, hydrochloride",CC(C)C(CCC[NH+]1CCOCC1)(C2=CC=CC3=CC=CC=C32)C(=O)O.[Cl-],,,,,,
3024,23025,5-Morpholin-4-yl-2-naphthalen-1-yl-2-propan-2-ylpentanoic acid,CC(C)C(CCCN1CCOCC1)(C2=CC=CC3=CC=CC=C32)C(=O)O,,,,,,
3025,23026,"Benzamide, 5-acetamido-2-allyloxy-N-isopropyl-",CC(C)NC(=O)C1=C(C=CC(=C1)NC(=O)C)OCC=C,,,,,,
3026,23027,"Benzamide, 5-acetamido-N-allyl-2-allyloxy-",CC(=O)NC1=CC(=C(C=C1)OCC=C)C(=O)NCC=C,,,,,,
3027,23028,"Carbamic acid, phenyl-, (1-methyl-2-nitropropyl) ester",CC(C(C)OC(=O)NC1=CC=CC=C1)[N+](=O)[O-],,,,,,
3028,23029,1-(2-Bromoethyl)-4-chlorobenzene,C1=CC(=CC=C1CCBr)Cl,,,,,,
3029,23030,[4-[4-(4-Acetyloxyphenyl)hex-3-en-3-yl]phenyl] acetate,CCC(=C(CC)C1=CC=C(C=C1)OC(=O)C)C2=CC=C(C=C2)OC(=O)C,,,,,,
3030,23031,Thallium carbonate,C(=O)([O-])[O-].[Tl+].[Tl+],,,,"['RETENTION OF THALLIUM IN ORGAN TISSUES IS PROLONGED; 45% OF AN INGESTED DOSE OF DITHALLIUM CARBONATE (TL2CO3) WAS STILL PRESENT IN THE HUMAN BODY AFTER 25 DAYS, & THALLIUM COULD BE DETECTED IN CEREBROSPINAL FLUID. SIMILAR THALLIUM RETENTION WAS RECORDED IN DOGS & GEESE.', 'In acute thallium poisoning, human brain areas densely populated with neurons were found to accumulate thallium more than other areas, and the gray matter contained higher thallium levels than nonneural tissues. /Soluble thallium cmpd/']",,['BODY BURDEN AS % OF ADMIN DOSE WAS DETERMINED IN RATS FOLLOWING ADMIN OF (204)THALLIUM ... OVER A PERIOD OF 21 DAYS. BODY CLEARANCE /OCCURRED/ ... EXPONENTIALLY WITH HALFTIME 3.3 DAYS ... AT THE END OF 21 DAYS ... 1% OF ADMIN DOSE REMAINED. ... WITH BIOLOGICAL HALF-TIME OF 3.3 DAYS ... DAILY DOSING /GIVES/ AN EQUILIBRIUM ... @ 20 DAYS. /SOLUBLE THALLIUM SALTS/']
3031,23032,"1,4-Diacetamidoanthraquinone",CC(=O)NC1=C2C(=C(C=C1)NC(=O)C)C(=O)C3=CC=CC=C3C2=O,,,,,,
3032,23033,alpha-(4-Dimethylaminobutyl)-1-naphthylacetonitrile,CN(C)CCCCC(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
3033,23034,Pigment red 112,CC1=CC=CC=C1NC(=O)C2=CC3=CC=CC=C3C(=C2O)N=NC4=CC(=C(C=C4Cl)Cl)Cl,,,,,,
3034,23035,Leucoindigo,C1=CC=C2C(=C1)C(=C(N2)C3=C(C4=CC=CC=C4N3)O)O,,,,,,
3035,23036,3-Amino-6-dimethylamino-9-dimethylaminophenylacridine hydrochloride,C[NH+](C)C1=CC=C(C=C1)C2=C3C=CC(=CC3=NC4=C2C=CC(=C4)N)N(C)C.[Cl-],,,,,,
3036,23037,"9-[4-(dimethylamino)phenyl]-6-N,6-N-dimethylacridine-3,6-diamine",CN(C)C1=CC=C(C=C1)C2=C3C=CC(=CC3=NC4=C2C=CC(=C4)N)N(C)C,,,,,,
3037,23038,"2,4,6-Tris(trichloromethyl)-1,3,5-triazine",C1(=NC(=NC(=N1)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl,,,,,,
3038,23039,"methyl (16S)-16-methyl-17-oxa-3,13-diazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-1,3,5,7,9,11,18-heptaene-19-carboxylate",C[C@H]1C2CN3C=CC4=C5C=CC=CC5=NC4=C3CC2C(=CO1)C(=O)OC,,,,,,
3039,23040,"4-Hydroxy-N,N,N-trimethylbenzenaminium iodide",C[N+](C)(C)C1=CC=C(C=C1)O.[I-],,,,,,
3040,23041,NoName_919,C[N+](C)(C)C1=CC=C(C=C1)O,,,,,,
3041,23042,o-(Methylseleno)benzoic acid,C[Se]C1=CC=CC=C1C(=O)O,,,,,,
3042,23043,"p-CYMENE-2-CARBOXYLIC ACID, 3-HYDROXY-, METHYL ESTER",CC1=C(C(=C(C=C1)C(C)C)O)C(=O)OC,,,,,,
3043,23044,"ACETIC ACID, ((2-(3,4-DICHLOROBENZAMIDO)-p-TOLYL)OXY)-",CC1=CC(=C(C=C1)OCC(=O)O)NC(=O)C2=CC(=C(C=C2)Cl)Cl,,,,,,
3044,23045,"DIBENZO(b,f)(1,4)THIAZEPINE, 2-CHLORO-11-((2-DIMETHYLAMINOETHYL)METHYLAMINO)-",CN(C)CCNCC1=NC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,,,,,,
3045,23046,Fenthion oxon,CC1=C(C=CC(=C1)OP(=O)(OC)OC)SC,,,,,['Fenthion oxon is a known human metabolite of Fenthion.'],
3046,23047,Fenthion oxon sulfoxide,CC1=C(C=CC(=C1)OP(=O)(OC)OC)S(=O)C,,,,,,
3047,23048,N-Ethyl-norgranatanol-3-alpha-benzhydrylaether [German],CCN1C2CCCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
3048,23049,1-Methoxy-4-methylbicyclo(2.2.2)octane,CC12CCC(CC1)(CC2)OC,,,,,,
3049,23050,N-n-Butyl-N-nitrosourethane,CCCCN(C(=O)OCC)N=O,,,,,,
3050,23051,"6-(4-chlorophenyl)sulfanyl-2-N,4-N-diethyl-1,3,5-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)SC2=CC=C(C=C2)Cl)NCC,,,,,,
3051,23052,"1,4-Oxamercurane",C1C[Hg]CCO1,,,,,,
3052,23053,2-Chloro-6-methylbenzonitrile,CC1=C(C(=CC=C1)Cl)C#N,,,,,,
3053,23054,"AZULENO(5,6,7-cd)PHENALENE",C1=CC2=C3C(=C1)C=CC4=CC5=CC=CC5=CC(=C43)C=C2,,,,,,
3054,23055,"1-Aziridineacetamide, N,N'-(heptamethylene)bis-",C1CN1CC(=O)NCCCCCCCNC(=O)CN2CC2,,,,,,
3055,23056,3-Quinuclidinyl benzilate,C1CN2CCC1C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,,,"['Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)']","['QNB usually is disseminated as an aerosol, and the primary route of absorption is through the respiratory system. Absorption also can occur through the skin or gastrointestinal tract.', 'Bioavailability via ingestion and by inhalation of one-micron particles approximates 80%, and 40 to 50%, respectively, of a parenterally delivered dose of BZ. Percutaneous absorption of BZ dissolved in propylene glycol yields, after a latent period of up to 24 hours, serum levels approximately 5 to 10% of those achieved with intravenous or intramuscular administration. ... Following absorption, BZ is systemically distributed to most organs and tissues of the body. Its ability to reach synapses and neuromuscular and neuroglandular junctions throughout the body is responsible for its peripheral nervous system (PNS) effects, whereas its ability to cross the blood-brain barrier confers upon it the ability to cause CNS effects. Atropine and hyoscyamine both cross the placenta and can be found in small quantities in breast milk; whether this is also true for BZ is unclear.', 'Most of the QNB that enters the body is excreted by the kidneys, making urine the choice for detection.']","['Information on the metabolism of BZ in humans is limited, but Benzylic Acid (BA) and 3-Quinuclidinol are the probable main metabolites ... .  It has been estimated that 3% of the BZ is excreted as the parent compound.']",
3056,23057,2-Methoxytetrahydropyran,COC1CCCCO1,,,,,,
3057,23058,"Ammonium, (2-(5-methoxyindol-3-YL)ethyl)trimethyl-, iodide",C[N+](C)(C)CCC1=C(NC2=CC=CC=C21)OC.[I-],,,,,,
3058,23059,2-(2-methoxy-1H-indol-3-yl)ethyl-trimethylazanium,C[N+](C)(C)CCC1=C(NC2=CC=CC=C21)OC,,,,,,
3059,23060,Ferric methanearsonate,C[As](=O)([O-])[O-].C[As](=O)([O-])[O-].C[As](=O)([O-])[O-].[Fe].[Fe+3].[Fe+3],,,,,,
3060,23061,"2-(4-Chlorophenoxy)-4,6-bis(ethylamino)-1,3,5-triazine",CCNC1=NC(=NC(=N1)OC2=CC=C(C=C2)Cl)NCC,,,,,,
3061,23062,"1,4-Bis(chloromethyl)naphthalene",C1=CC=C2C(=CC=C(C2=C1)CCl)CCl,,,,,,
3062,23063,"Benzimidazole, 4-bromo-2-(trifluoromethyl)-",C1=CC2=C(C(=C1)Br)N=C(N2)C(F)(F)F,,,,,,
3063,23064,2-Cyclohexylamino-1-phenylethanol,C1CCC(CC1)NCC(C2=CC=CC=C2)O,,,,,,
3064,23065,"3,4-Dichlorophenyl isothiocyanate",C1=CC(=C(C=C1N=C=S)Cl)Cl,,,,,,
3065,23066,"N,N'-bis[[(1R,4aS)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methyl]ethane-1,2-diamine;3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC(C)C1=CC2=C(C=C1)[C@]3(CCC[C@@](C3CC2)(C)CNCCNC[C@@]4(CCC[C@]5(C4CCC6=C5C=CC(=C6)C(C)C)C)C)C.CC1(C(N2C(S1)C(C2=O)NC(=O)COC3=CC=CC=C3)C(=O)O)C,,,,,,
3066,23067,CID 23067,CCC1(C(=O)NC(=NC1=O)[O-])C(C)C=C(C)C.[Na+],,,,,,
3067,23068,"Formaldehyde, seleno-",C=[Se],,,,,,
3068,23069,3-Hydroxypyridine 1-oxide,C1=CC(=C[N+](=C1)[O-])O,,,,,,
3069,23070,2-Bromo-3-hydroxypyridine,C1=CC(=C(N=C1)Br)O,,,,,,
3070,23071,5-21-01-00301 (Beilstein Handbook Reference),CC1=CC=CC=C1C(C2=CC=CC=C2)OC3CC4CCCC(C3)N4C,,,,,,
3071,23072,"N,7-Dimethyl-norgranatanol-3-alpha-benzhydrylaether [German]",CC1CC2CC(CC(C1)N2C)OC(C3=CC=CC=C3)C4=CC=CC=C4,,,,,,
3072,23073,N-Methyl-norgranatanol-3-alpha-(4-methylbenzhydryl)aether [German],CC1=CC=C(C=C1)C(C2=CC=CC=C2)OC3CC4CCCC(C3)N4C,,,,,,
3073,23074,"N-Ethyl-norgranatanol-3,alpha-(2-methyl-benzhydryl)aether [German]",CCN1C2CCCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4C,,,,,,
3074,23075,N-Propyl-norgranatanol-3-alpha-(2-methylbenzhydryl)aether [German],CCCN1C2CCCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4C,,,,,,
3075,23076,N-Allyl-norgranatanol-3-alpha-(2-methylbenzhydryl)aether [German],CC1=CC=CC=C1C(C2=CC=CC=C2)OC3CC4CCCC(C3)N4CC=C,,,,,,
3076,23077,N-Phenethyl-norgranatanol-3-alpha-(2-methylbenzhydryl)aether [German],CC1=CC=CC=C1C(C2=CC=CC=C2)OC3CC4CCCC(C3)N4CCC5=CC=CC=C5,,,,,,
3077,23078,N-Methyl-norgranatanol-3-alpha-(2-tert-butylbenzhydryl)aether [German],CC(C)(C)C1=CC=CC=C1C(C2=CC=CC=C2)OC3CC4CCCC(C3)N4C,,,,,,
3078,23079,Norgranatanol-3-alpha-(2-methylbenzhydryl)aether [German],CC1=CC=CC=C1C(C2=CC=CC=C2)OC3CC4CCCC(C3)N4,,,,,,
3079,23080,9-(2-Hydroxypropyl)-9-azabicyclo(3.3.1)nonane benzilate,CC(CN1C2CCCC1CCC2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,,,,,,
3080,23081,9-(2-Hydroxyethyl)-9-azabicyclo(3.3.1)nonane alpha-hydroxy-alpha-phenylcyclohexaneacetate,C1CCC(CC1)C(C2=CC=CC=C2)(C(=O)OCCN3C4CCCC3CCC4)O,,,,,,
3081,23082,9-(2-Hydroxyethyl)-9-azabicyclo(3.3.1)nonane o-methylbenzilate,CC1=CC=CC=C1C(C2=CC=CC=C2)(C(=O)OCCN3C4CCCC3CCC4)O,,,,,,
3082,23083,9-(2-Hydroxyethyl)-9-azabicyclo(3.3.1)nonane p-chlorobenzilate,C1CC2CCCC(C1)N2CCOC(=O)C(C3=CC=CC=C3)(C4=CC=C(C=C4)Cl)O,,,,,,
3083,23084,9-Phenethyl-9-azabicyclo(3.3.1)nonan-3-beta-ol benzilate,C1CC2CC(CC(C1)N2CCC3=CC=CC=C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O,,,,,,
3084,23085,CID 23085,C=CCC1(C(=NC(=NC1=O)S)[O-])C2=CCCCC2.[Na+],,,,,,
3085,23086,N-Methyl-norgranatanol-3-alpha-(4-chlorobenzhydryl)aether [German],CN1C2CCCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=C(C=C4)Cl,,,,,,
3086,23087,Enbucrilate,CCCCOC(=O)C(=C)C#N,,,,,,
3087,23088,"alpha,beta-Dichlorostyrene",C1=CC=C(C=C1)C(=CCl)Cl,,,,,,
3088,23089,2-(Butylthio)ethyl vinyl ether,CCCCSCCOC=C,,,,,,
3089,23090,"Benzimidazole, 6-bromo-4-nitro-2-(trifluoromethyl)-",C1=C(C=C(C2=C1NC(=N2)C(F)(F)F)[N+](=O)[O-])Br,,,,,,
3090,23091,"Benzimidazole, 4-bromo-6-nitro-2-(trifluoromethyl)-",C1=C(C=C(C2=C1NC(=N2)C(F)(F)F)Br)[N+](=O)[O-],,,,,,
3091,23092,"Benzimidazole, 4,6-dinitro-2-(trifluoromethyl)-",C1=C(C=C(C2=C1NC(=N2)C(F)(F)F)[N+](=O)[O-])[N+](=O)[O-],,,,,,
3092,23093,CID 23093,C1=C2C(=CC(=C1Cl)[N+](=O)[O-])N=C(N2)C(F)(F)F,,,,,,
3093,23094,"Benzimidazole, 5,6-dichloro-4-nitro-2-(trifluoromethyl)-",C1=C2C(=C(C(=C1Cl)Cl)[N+](=O)[O-])N=C(N2)C(F)(F)F,,,,,,
3094,23095,"Benzimidazole, 4,5-dichloro-6-nitro-2-(trifluoromethyl)-",C1=C2C(=C(C(=C1[N+](=O)[O-])Cl)Cl)N=C(N2)C(F)(F)F,,,,,,
3095,23096,"Benzimidazole, 4,6-dichloro-5-nitro-2-(trifluoromethyl)-",C1=C2C(=C(C(=C1Cl)[N+](=O)[O-])Cl)N=C(N2)C(F)(F)F,,,,,,
3096,23097,"Benzimidazole, 4,6-dibromo-2-(trifluoromethyl)-",C1=C(C=C(C2=C1NC(=N2)C(F)(F)F)Br)Br,,,,,,
3097,23098,2-Nitrosonaphthalene,C1=CC=C2C=C(C=CC2=C1)N=O,,,,,,
3098,23099,CID 23099,CN=C(NN)S,,,,,,
3099,23100,"N,N'-Tetramethylenebis(1-aziridinecarboxamide)",C1CN1C(=O)NCCCCNC(=O)N2CC2,,,,,,
3100,23101,2-[(2-Hydroxynaphthalen-1-yl)diazenyl]benzenesulfinic acid,C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC=CC=C3S(=O)O)O,,,,,,
3101,23102,"3-Ethyl-1-(4-fluorophenyl)-6-phenyl-4,5-dihydropyrazolo[3,4-c]pyridin-7-one",CCC1=NN(C2=C1CCN(C2=O)C3=CC=CC=C3)C4=CC=C(C=C4)F,,,,,,
3102,23103,4'-Allyloxyacetanilide,CC(=O)NC1=CC=C(C=C1)OCC=C,,,,,,
3103,23104,Methyl 2-methylbut-2-enoate,CC=C(C)C(=O)OC,,,,,,
3104,23105,Diisoamyl adipate,CC(C)CCOC(=O)CCCCC(=O)OCCC(C)C,,,,,,
3105,23106,CID 23106,CN(C)C1C2CC3CC4=C(C(=CC=C4)O)C(=C3C(=O)C2(C(=O)C(=C(N)O)C1=O)O)O,,,,,,
3106,23107,"7,10-Dichloro-2-methoxybenzo[b]-1,5-naphthyridine",COC1=NC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)Cl,,,,,,
3107,23108,"2,5-Dichloro-4-nitroaniline",C1=C(C(=CC(=C1Cl)[N+](=O)[O-])Cl)N,,,,,,
3108,23109,2-Bromo-4-methylphenol,CC1=CC(=C(C=C1)O)Br,,,,,,
3109,23110,"1,2-Bis(methylthio)ethane",CSCCSC,,,,,,
3110,23111,"4,5-Dihydropyrene",C1CC2=CC=CC3=C2C4=C(C=CC=C41)C=C3,,,,,,
3111,23112,N-Cyanoacetylurethane,CCOC(=O)NC(=O)CC#N,,,,,,
3112,23113,"Salicylic acid, nicotinate",C1=CC=C(C(=C1)C(=O)O)OC(=O)C2=CN=CC=C2,,,,,,
3113,23114,3-tert-Butyl-5-ethyltoluene,CCC1=CC(=CC(=C1)C)C(C)(C)C,,,,,,
3114,23115,9-Chloro-9H-fluorene,C1=CC=C2C(=C1)C(C3=CC=CC=C32)Cl,,,,,,
3115,23116,"ANILINE, N-(p-CHLOROPHENYLTHIOMETHYL)-p-NITRO-",C1=CC(=CC=C1NCSC2=CC=C(C=C2)Cl)[N+](=O)[O-],,,,,,
3116,23117,"Ether, 2-cyclohexyl-4,6-dinitrophenyl 2,4-dinitrophenyl",C1CCC(CC1)C2=C(C(=CC(=C2)[N+](=O)[O-])[N+](=O)[O-])OC3=C(C=C(C=C3)[N+](=O)[O-])[N+](=O)[O-],,,,,,
3117,23118,CID 23118,C1=CC(=CC=C1N=NC=O)N(O)O,,,,,,
3118,23119,2-Hydroxy-7-nitrofluorene,C1C2=C(C=CC(=C2)[N+](=O)[O-])C3=C1C=C(C=C3)O,,,,,,
3119,23120,"Acetic acid, oxydi-, dibutyl ester",CCCCOC(=O)COCC(=O)OCCCC,,,,,,
3120,23121,"Oxamic acid, N-amidino-N-methyl-",CN(C(=O)C(=O)N)C(=O)N,,,,,,
3121,23122,CID 23122,C1=CC=C(C=C1)N=C(N=C(N)S)S,,,,,,
3122,23123,"ISOTHIOCYANIC ACID, (p-CETOXYPHENYL) ESTER",CCCCCCCCCCCCCCCCOC1=CC=C(C=C1)N=C=S,,,,,,
3123,23124,CID 23124,CC1=CC(=C(C(=C1N)N=NC2=C(C=C(C=C2)C3=CC(=C(C=C3)N=NC4=CC(=C(C=C4)O)C(=O)[O-])C)C)N)S(=O)(=O)[O-].[Na+].[Na+],,,,,,
3124,23125,"5-((4'-((2,6-Diamino-3-methyl-5-sulfophenyl)diazenyl)-3,3'-dimethyl[biphenyl]-4-yl)diazenyl)-2-hydroxybenzoic acid",CC1=CC(=C(C(=C1N)N=NC2=C(C=C(C=C2)C3=CC(=C(C=C3)N=NC4=CC(=C(C=C4)O)C(=O)O)C)C)N)S(=O)(=O)O,,,,,,
3125,23126,2-Amino-7-bromofluorene,C1C2=C(C=CC(=C2)N)C3=C1C=C(C=C3)Br,,,,,,
3126,23127,2-Bromo-7-nitrofluorene,C1C2=C(C=CC(=C2)[N+](=O)[O-])C3=C1C=C(C=C3)Br,,,,,,
3127,23128,"2,4,5-Trichlorotoluene",CC1=CC(=C(C=C1Cl)Cl)Cl,,,,,,
3128,23129,2-Biphenylarsonic acid,C1=CC=C(C=C1)C2=CC=CC=C2[As](=O)(O)O,,,,,,
3129,23130,beta-Dihydroequilenin,CC12CCC3=C(C1CCC2O)C=CC4=C3C=CC(=C4)O,,,,,,
3130,23131,2-Benzyl-1-(2-(dimethylamino)-1-methylethyl)benzimidazole hydrochloride,CC(C[NH+](C)C)N1C2=CC=CC=C2N=C1CC3=CC=CC=C3.[Cl-],,,,,,
3131,23132,"2-(2-benzylbenzimidazol-1-yl)-N,N-dimethylpropan-1-amine",CC(CN(C)C)N1C2=CC=CC=C2N=C1CC3=CC=CC=C3,,,,,,
3132,23133,"Sodium hydroxy(4-hydroxy-3-nitro-5-((1,2,3,4-tetrahydro-2,4-dioxoquinolin-3-yl)azo)benzenesulphonato(3-))chromate(1-)",C1=CC=C2C(=C1)C(=O)C(C(=O)N2)N=NC3=C(C(=CC(=C3)S(=O)(=O)[O-])[N+](=O)[O-])O.O.[Na+].[Cr],,,,,,
3133,23134,"3-[2-(2,4-Dioxo-1,2,3,4-tetrahydroquinolin-3-yl)hydrazinylidene]-5-nitro-4-oxocyclohexa-1,5-diene-1-sulfonic acid",C1=CC=C2C(=C1)C(=O)C(C(=O)N2)N=NC3=C(C(=CC(=C3)S(=O)(=O)O)[N+](=O)[O-])O,,,,,,
3134,23135,Candicine,C[N+](C)(C)CCC1=CC=C(C=C1)O,,,,,,
3135,23136,"Benzoic acid, bromoacetylmethyl ester",C1=CC=C(C=C1)C(=O)OCC(=O)CBr,,,,,,
3136,23137,2-Oxopropyl benzoate,CC(=O)COC(=O)C1=CC=CC=C1,,,,,,
3137,23138,2-Chloro-4-(phenylazo)phenol,C1=CC=C(C=C1)N=NC2=CC(=C(C=C2)O)Cl,,,,,,
3138,23139,"Propanenitrile, 3-[[4-[(2-chloro-4-nitrophenyl)azo]phenyl](2-hydroxyethyl)amino]-",C1=CC(=CC=C1N=NC2=C(C=C(C=C2)[N+](=O)[O-])Cl)N(CCC#N)CCO,,,,,,
3139,23140,Dioxylium phosphate,CCOC1=C(C=C(C=C1)CC2=[NH+]C(=CC3=CC(=C(C=C32)OC)OC)C)OC.OP(=O)(O)[O-],,,,,,
3140,23141,Spiroxasone,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCCO5)C,,,,,,
3141,23142,"17-Ethynyl-2,18-dimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,9-trien-17-ol",CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NN5,,,,,,
3142,23143,(2-Methylphenyl)phenyldiazene,CC1=CC=CC=C1N=NC2=CC=CC=C2,,,,,,
3143,23144,"[2-[(17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] butanoate",CCCC(=O)OCC(=O)[C@]1(CCC2C1(CC(C3C2CCC4=CC(=O)CCC34C)O)C)O,,,,,,
3144,23145,"1-Naphthaleneacetic acid, alpha-sec-butyl-alpha-(2-(dimethylamino)ethyl)-, hydrochloride",CCC(C)C(CC[NH+](C)C)(C1=CC=CC2=CC=CC=C21)C(=O)O.[Cl-],,,,,,
3145,23146,2-[2-(Dimethylamino)ethyl]-3-methyl-2-naphthalen-1-ylpentanoic acid,CCC(C)C(CCN(C)C)(C1=CC=CC2=CC=CC=C21)C(=O)O,,,,,,
3146,23147,"1-Naphthaleneacetic acid, alpha-(2-(dimethylamino)ethyl)-alpha-methyl-, hydrochloride",CC(CC[NH+](C)C)(C1=CC=CC2=CC=CC=C21)C(=O)O.[Cl-],,,,,,
3147,23148,4-(Dimethylamino)-2-methyl-2-naphthalen-1-ylbutanoic acid,CC(CCN(C)C)(C1=CC=CC2=CC=CC=C21)C(=O)O,,,,,,
3148,23149,Magnoflorine chloride,C[N+]1(CCC2=CC(=C(C3=C2[C@@H]1CC4=C3C(=C(C=C4)OC)O)O)OC)C.[Cl-],,,,,,
3149,23150,"4,5,7-Trimethylindan",CC1=CC(=C2CCCC2=C1C)C,,,,,,
3150,23151,"4,7-Dimethylindan",CC1=C2CCCC2=C(C=C1)C,,,,,,
3151,23152,alpha-Isopropyl-alpha-(4-dimethylaminobutyl)-1-naphthylacetic acid hydrochloride,CC(C)C(CCCC[NH+](C)C)(C1=CC=CC2=CC=CC=C21)C(=O)O.[Cl-],,,,,,
3152,23153,6-(Dimethylamino)-2-naphthalen-1-yl-2-propan-2-ylhexanoic acid,CC(C)C(CCCCN(C)C)(C1=CC=CC2=CC=CC=C21)C(=O)O,,,,,,
3153,23154,"2,4-Dichloro-6-isopropoxy-1,3,5-triazine",CC(C)OC1=NC(=NC(=N1)Cl)Cl,,,,,,
3154,23155,"Alanine, 3-phenyl-N-tryptophyl-, L-",C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)C(CC2=CNC3=CC=CC=C32)N,,,,,,
3155,23156,"Malononitrile, ((3,4-dihydro-2(1H)-isoquinolyl)methylene)-",C1CN(CC2=CC=CC=C21)C=C(C#N)C#N,,,,,,
3156,23157,4-Nitro-9-(dimethylaminopropylamino)acridine,CN(C)CCCNC1=C2C=CC=C(C2=NC3=CC=CC=C31)[N+](=O)[O-],,,,,,
3157,23158,CID 23158,C1=CC(=CC=C1N)[As](=O)(O)[O-].[Na+],,,,,,
3158,23159,7-(Dimethylamino)-4-ethyl-4-(1-naphthyl)-3-heptanone,CCC(=O)C(CC)(CCCN(C)C)C1=CC=CC2=CC=CC=C21,,,,,,
3159,23160,"1-Pyrrolidinevaleronitrile, alpha-isopropyl-alpha-1-naphthyl-",CC(C)C(CCCN1CCCC1)(C#N)C2=CC=CC3=CC=CC=C32,,,,,,
3160,23161,alpha-Isopropyl-alpha-(3-pyrrolidinopropyl)-1-naphthaleneacetamide,CC(C)C(CCCN1CCCC1)(C2=CC=CC3=CC=CC=C32)C(=O)N,,,,,,
3161,23162,alpha-(3-(Dimethylamino)propyl)-alpha-isopropyl-1-naphthaleneacetic acid methyl ester,CC(C)C(CCCN(C)C)(C1=CC=CC2=CC=CC=C21)C(=O)OC,,,,,,
3162,23163,alpha-(3-(Dimethylamino)propyl)-alpha-isopropyl-1-naphthaleneacetic acid ethyl ester,CCOC(=O)C(CCCN(C)C)(C1=CC=CC2=CC=CC=C21)C(C)C,,,,,,
3163,23164,alpha-(3-(Diethylamino)propyl)-alpha-isopropyl-1-naphthaleneacetonitrile,CCN(CC)CCCC(C#N)(C1=CC=CC2=CC=CC=C21)C(C)C,,,,,,
3164,23165,Ethoheptazine citrate,CCOC(=O)C1(CCCN(CC1)C)C2=CC=CC=C2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,,,,,,
3165,23166,Heptyl 2-cyanoacrylate,CCCCCCCOC(=O)C(=C)C#N,,,,,,
3166,23167,Ocrilate,CCCCCCCCOC(=O)C(=C)C#N,,,"['Substances used to cause adherence of tissue to tissue or tissue to non-tissue surfaces, as for prostheses. (See all compounds classified as Tissue Adhesives.)']",,,
3167,23168,(3-Hydroxypropyl)trimethylammonium chloride,C[N+](C)(C)CCCO.[Cl-],,,,,,
3168,23169,Homocholine,C[N+](C)(C)CCCO,,,,,,
3169,23170,11-Cyclopentylheneicosane,CCCCCCCCCCC(CCCCCCCCCC)C1CCCC1,,,,,,
3170,23171,"Cyclopentane, heneicosyl-",CCCCCCCCCCCCCCCCCCCCCC1CCCC1,,,,,,
3171,23172,"2,2'-Bis(1,3-dioxolane)",C1COC(O1)C2OCCO2,,,,,,
3172,23173,"1,6-Dioxacycloheptadecan-7-one",C1CCCCCOCCCCOC(=O)CCCC1,,,,,,
3173,23174,Dicyclobutylidene,C1CC(=C2CCC2)C1,,,,,,
3174,23175,"4-Methoxyphenyl-1,3-dithiolane",COC1=CC=C(C=C1)C2SCCS2,,,,,,
3175,23176,CID 23176,CC(C)[NH+](C)C(=NC(=NC1=CC=C(C=C1)Cl)N)N.CC(=O)[O-],,,,,,
3176,23177,2-[N'-(4-chlorophenyl)carbamimidoyl]-1-methyl-1-propan-2-ylguanidine,CC(C)N(C)C(=NC(=NC1=CC=C(C=C1)Cl)N)N,,,,,,
3177,23178,Hept-2-en-6-one,CC=CCCC(=O)C,,,,,,
3178,23179,"Malononitrile, (2,3,6-trichlorobenzylidene)-",C1=CC(=C(C(=C1Cl)C=C(C#N)C#N)Cl)Cl,,,,,,
3179,23180,"N,N-Dimethyl beta-methoxy beta-phenylethylamine",CN(C)CC(C1=CC=CC=C1)OC,,,,,,
3180,23181,"Carbamic acid, diethyl-, 3-oxetanylidenedimethylene ester",CCN(CC)C(=O)OCC1(COC1)COC(=O)N(CC)CC,,,,,,
3181,23182,"2,4,6-Tris(4-methylphenyl)-1,3,5-triazine",CC1=CC=C(C=C1)C2=NC(=NC(=N2)C3=CC=C(C=C3)C)C4=CC=C(C=C4)C,,,,,,
3182,23183,"1-Naphthaleneacetic acid, alpha-(3-(dimethylamino)propyl)-alpha-isopropyl-, hydrochloride",CC(C)C(CCC[NH+](C)C)(C1=CC=CC2=CC=CC=C21)C(=O)O.[Cl-],,,,,,
3183,23184,5-(Dimethylamino)-2-naphthalen-1-yl-2-propan-2-ylpentanoic acid,CC(C)C(CCCN(C)C)(C1=CC=CC2=CC=CC=C21)C(=O)O,,,,,,
3184,23185,"1-Naphthaleneacetic acid, alpha-isopropyl-alpha-(3-pyrrolidinopropyl)-, hydrochloride",CC(C)C(CCC[NH+]1CCCC1)(C2=CC=CC3=CC=CC=C32)C(=O)O.[Cl-],,,,,,
3185,23186,2-Naphthalen-1-yl-2-propan-2-yl-5-pyrrolidin-1-ylpentanoic acid,CC(C)C(CCCN1CCCC1)(C2=CC=CC3=CC=CC=C32)C(=O)O,,,,,,
3186,23187,5-Ethyl-5-phenyl-1-(piperidinomethyl)barbituric acid ethanolate,CCC1(C(=O)NC(=O)N(C1=O)CN2CCCCC2)C3=CC=CC=C3.CCO,,,,,,
3187,23188,"5-ethyl-5-phenyl-1-(piperidin-1-ylmethyl)pyrimidine-2,4,6(1H,3H,5H)-trione",CCC1(C(=O)NC(=O)N(C1=O)CN2CCCCC2)C3=CC=CC=C3,,,,,,
3188,23189,1-(5-Methyl-3-pyrazolylcarbonyl)-2-isopropylhydrazine,CC1=CC(N=N1)C(=O)NNC(C)C,,,,,,
3189,23190,3-Deazaadenosine,C1=CN=C(C2=C1N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N,,,,,,
3190,23191,"6-chloro-N,N'-bis(4-methoxyphenyl)-1,3,5-triazine-2,4-diamine",COC1=CC=C(C=C1)NC2=NC(=NC(=N2)Cl)NC3=CC=C(C=C3)OC,,,,,,
3191,23192,Ara-C triacetate,CC(=O)OC[C@@H]1[C@H]([C@@H]([C@@H](O1)N2C=CC(=NC2=O)N)OC(=O)C)OC(=O)C,,,,,,
3192,23193,Tetraacetylarabinosylcytosine,CC(=O)NC1=NC(=O)N(C=C1)[C@H]2[C@H]([C@@H]([C@H](O2)COC(=O)C)OC(=O)C)OC(=O)C,,,,,,
3193,23194,Undecylbenzene,CCCCCCCCCCCC1=CC=CC=C1,,,,,,
3194,23195,"5,5-Diethyl-2-methyltetrahydro-3-furanol",CCC1(CC(C(O1)C)O)CC,,,,,,
3195,23196,"2,5-Dimethyl-5-propyltetrahydro-3-furanol",CCCC1(CC(C(O1)C)O)C,,,,,,
3196,23197,5-Ethyl-2-methyl-5-propyltetrahydro-3-furanol,CCCC1(CC(C(O1)C)O)CC,,,,,,
3197,23198,Norchlorambucil,C1=CC(=CC=C1CCC(=O)O)N(CCCl)CCCl,,,,,,
3198,23199,CID 23199,COC1=C(C=CC(=C1)C(=O)[O-])O,,,,,,
3199,23200,CID 23200,CCOC1=C2C3=C(C[C@H]4[C@H]5[C@]3(CCN4C)[C@@H](O2)[C@H](C=C5)O)C=C1.O.O.Cl,,,,,,
3200,23201,3-Tropanyl 2-(p-chlorophenyl)acrylate hydrochloride,CN1C2CCC1CC(C2)OC(=O)C(=C)C3=CC=C(C=C3)Cl.Cl,,,,,,
3201,23202,(8-Methyl-8-azabicyclo[3.2.1]octan-3-yl) 2-(4-chlorophenyl)prop-2-enoate,CN1C2CCC1CC(C2)OC(=O)C(=C)C3=CC=C(C=C3)Cl,,,,,,
3202,23203,"Nona-2,4-dienal",CCCCC=CC=CC=O,,,,,,
3203,23204,"1,4,8-Cycloundecatriene, 2,6,6,9-tetramethyl-, (1E,4E,8E)-",CC1=CCC(C=CCC(=CCC1)C)(C)C,,,,,,
3204,23205,Helenalin,C[C@@H]1C[C@@H]2[C@H]([C@@H]([C@]3([C@H]1C=CC3=O)C)O)C(=C)C(=O)O2,,,"['Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)', 'Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)', 'Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)', 'Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)']",,,
3205,23206,N-(Carbamoylmethyl)-o-anisamide,CNC(=O)NC(=O)C1=CC=CC=C1OC,,,,,,
3206,23207,"o-ANISAMIDE, alpha-(DIMETHYLCARBAMOYL)-N-((DIMETHYLCARBAMOYL)METHYL)-",CN(C)C(=O)CNC(=O)C1=CC=CC=C1OCC(=O)N(C)C,,,,,,
3207,23208,"BENZOIC ACID, 3,4,5-TRIMETHOXY-, ESTER with N,N-DIMETHYLGLYCOLAMIDE",CN(C)C(=O)COC(=O)C1=CC(=C(C(=C1)OC)OC)OC,,,,,,
3208,23209,"o-ANISAMIDE, alpha-(DIMETHYLCARBAMOYL)-",CN(C)C(=O)COC1=CC=CC=C1C(=O)N,,,,,,
3209,23210,"ACETIC ACID, (o-(DIMETHYLCARBAMOYL)PHENOXY)-",CN(C)C(=O)C1=CC=CC=C1OCC(=O)O,,,,,,
3210,23211,"N,N-dimethyl-3-(5-nitrofuran-2-yl)prop-2-enamide",CN(C)C(=O)C=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
3211,23212,CID 23212,CCNC(=O)C=CC1=CC=C(O1)[N+](=O)[O-],,,,,,
3212,23213,1-Benzoylmethyl-4-piperonylpiperazine dihydrochloride,C1CN(CCN1CC2=CC3=C(C=C2)OCO3)CC(=O)C4=CC=CC=C4.Cl.Cl,,,,,,
3213,23214,"2-[4-(1,3-Benzodioxol-5-ylmethyl)piperazin-1-yl]-1-phenylethanone",C1CN(CCN1CC2=CC3=C(C=C2)OCO3)CC(=O)C4=CC=CC=C4,,,,,,
3214,23215,4-Piperonyl-1-piperonyloylmethylpiperazine dihydrochloride,C1CN(CCN1CC2=CC3=C(C=C2)OCO3)CC(=O)C4=CC5=C(C=C4)OCO5.Cl.Cl,,,,,,
3215,23216,"1-(1,3-Benzodioxol-5-yl)-2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]ethanone",C1CN(CCN1CC2=CC3=C(C=C2)OCO3)CC(=O)C4=CC5=C(C=C4)OCO5,,,,,,
3216,23217,1-Heptadecene,CCCCCCCCCCCCCCCC=C,,,,,,
3217,23218,CID 23218,CCCCCCCC=CCCCCCCCCC(=O)[O-].CN1C=NC2=C1C(=O)N=C(N2C)[O-].[Mg+2],,,,,,
3218,23219,"Biuret, 1-phenethyl-",C1=CC=C(C=C1)CCNC(=O)NC(=O)N,,,,,,
3219,23220,"Biuret, 1-methyl-1-phenethyl-",CN(CCC1=CC=CC=C1)C(=O)NC(=O)N,,,,,,
3220,23221,"Biuret, 1-(3-phenylpropyl)-",C1=CC=C(C=C1)CCCNC(=O)NC(=O)N,,,,,,
3221,23222,"Biuret, 1-(4-phenylbutyl)-",C1=CC=C(C=C1)CCCCNC(=O)NC(=O)N,,,,,,
3222,23223,"BIURET, 1-(p-METHOXYPHENETHYL)-",COC1=CC=C(C=C1)CCNC(=O)NC(=O)N,,,,,,
3223,23224,CID 23224,CCOP(=O)O,,,,,,
3224,23225,alpha-(3-(Dimethylamino)propyl)-alpha-isopropyl-1-naphthaleneacetic acid phenyl ester,CC(C)C(CCCN(C)C)(C1=CC=CC2=CC=CC=C21)C(=O)OC3=CC=CC=C3,,,,,,
3225,23226,alpha-(3-(Diethylamino)propyl)-1-naphthaleneacetonitrile,CCN(CC)CCCC(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
3226,23227,alpha-(3-(Diethylamino)propyl)-alpha-isopropyl-1-naphthaleneacetic acid ethyl ester,CCN(CC)CCCC(C1=CC=CC2=CC=CC=C21)(C(C)C)C(=O)OCC,,,,,,
3227,23228,Ethyl dimethylaminomethylcarbamate,CCOC(=O)NCN(C)C,,,,,,
3228,23229,"1,3-Diacetylbenzene",CC(=O)C1=CC(=CC=C1)C(=O)C,,,,,,
3229,23230,Diformyldapsone,C1=CC(=CC=C1NC=O)S(=O)(=O)C2=CC=C(C=C2)NC=O,,,,,,
3230,23231,CID 23231,C[C@]12C[C@H](C3C([C@]1(CC[C@@H]2C4=CC(=O)OC4)O)CC[C@]5([C@@]3(CC[C@@H](C5)O)CO)O)O,,,,,,
3231,23232,"3,5,11,14-Tetrahydroxy-18-oxocard-20(22)-enolide",C[C@]12CC[C@@H](C[C@]1(CC[C@@H]3C2C(C[C@]4([C@@]3(CCC4C5=CC(=O)OC5)O)C=O)O)O)O,,,,,,
3232,23233,"N-(3,4,5,14-tetramethoxy-13-oxo-17-oxatetracyclo[12.2.1.01,11.02,7]heptadeca-3,5,7,11,15-pentaen-10-ylidene)acetamide",CC(=O)N=C1CC=C2C=C(C(=C(C2C34C1=CC(=O)C(O3)(C=C4)OC)OC)OC)OC,,,,,,
3233,23234,Hex-3-enal,CCC=CCC=O,,,,,,
3234,23235,Hexyl benzoate,CCCCCCOC(=O)C1=CC=CC=C1,,,,,,
3235,23236,"Cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6a,9a-tetrahydro-9a-hydroxy-4-methoxy-",COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4C(=C1)OC5C4(C=CO5)O,,,,,,
3236,23237,CID 23237,C1COC(=O)N1N=CC2=C[N+](=O)C3=CC=CC=C3N2[O-],,,,,,
3237,23238,Sec-butyl methyl ether,CCC(C)OC,,,,,,
3238,23239,"Benzoxazole, 2-ethyl-",CCC1=NC2=CC=CC=C2O1,,,,,,
3239,23240,"Benzoxazole, 2-hexyl-",CCCCCCC1=NC2=CC=CC=C2O1,,,,,,
3240,23241,"Benzoxazole, 2-heptyl-",CCCCCCCC1=NC2=CC=CC=C2O1,,,,,,
3241,23242,Ethyl 2-cyano-2-[2-(4-methylphenyl)hydrazinylidene]acetate,CCOC(=O)C(=NNC1=CC=C(C=C1)C)C#N,,,,,,
3242,23243,Bipiperidyl mustard,C1CN(CCC1C2CCN(CC2)CCCl)CCCl,,,,,,
3243,23244,CID 23244,CC=C(C)C(=O)O[C@H]1[C@@H]([C@@]2([C@@H](C[C@@]3(C(=CCC4[C@]3(CCC5[C@@]4(CCC([C@]5(C)CO)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C)C)C2CC1(C)C)C)O)CO)OC(=O)C.CC=C(C)C(=O)O[C@H]1[C@@H]([C@@]2([C@@H](C[C@@]3(C(=CCC4[C@]3(CCC5[C@@]4(CCC([C@]5(C)CO)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C)C)C2CC1(C)C)C)O)CO)OC(=O)C,,,,,,
3244,23245,CID 23245,CC=C(C)C(=O)O[C@H]1[C@@H]([C@@]2([C@@H](C[C@@]3(C(=CCC4[C@]3(CCC5[C@@]4(CCC([C@]5(C)CO)OC6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C)C)C2CC1(C)C)C)O)CO)OC(=O)C,,,,,,
3245,23246,1-Benzocyclobutenyl n-butyl ketone,CCCCC(=O)C1CC2=CC=CC=C12,,,,,,
3246,23247,"Bicyclo(4.2.0)octa-1,3,5-triene, 7-benzoyl-",C1C(C2=CC=CC=C21)C(=O)C3=CC=CC=C3,,,,,,
3247,23248,"Bicyclo(4.2.0)octa-1,3,5-trien-7-yl benzyl ketone",C1C(C2=CC=CC=C21)C(=O)CC3=CC=CC=C3,,,,,,
3248,23249,N-methyl-N-nitro-nitroguanidine,CN(C(=N[N+](=O)[O-])N)[N+](=O)[O-],,,,,,
3249,23250,"Cyclohexane, hexadecyl-",CCCCCCCCCCCCCCCCC1CCCCC1,,,,,,
3250,23251,"N-[1-(7-bicyclo[4.2.0]octa-1,3,5-trienyl)-2-phenylethylidene]hydroxylamine",C1C(C2=CC=CC=C21)C(=NO)CC3=CC=CC=C3,,,,,,
3251,23252,"1-(7-bicyclo[4.2.0]octa-1,3,5-trienyl)-N-methoxyethanimine",CC(=NOC)C1CC2=CC=CC=C12,,,,,,
3252,23253,"1-[1-(7-Bicyclo[4.2.0]octa-1,3,5-trienyl)ethylideneamino]oxypropan-2-ol",CC(CON=C(C)C1CC2=CC=CC=C12)O,,,,,,
3253,23254,"Ethanone,1-bicyclo4.2.0octa-1,3,5-trien-7-yl-,O-acetyloxime",CC(=NOC(=O)C)C1CC2=CC=CC=C12,,,,,,
3254,23255,"1-(7-bicyclo[4.2.0]octa-1,3,5-trienyl)-N-prop-2-enoxyethanimine",CC(=NOCC=C)C1CC2=CC=CC=C12,,,,,,
3255,23256,5-Chloro-3-methyl-4-nitro-1H-pyrazole,CC1=C(C(=NN1)Cl)[N+](=O)[O-],,,,,,
3256,23257,Olaflur,CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCO.F.F,,,,,,
3257,23258,"N-Stearyl-N-(2-hydroxyethyl)-N',N'-bis(2-hydroxyethyl)trimethylenediamine",CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCO,,,,,,
3258,23259,Perchloroisobutane,C(C(Cl)(Cl)Cl)(C(Cl)(Cl)Cl)(C(Cl)(Cl)Cl)Cl,,,,,,
3259,23260,Aceclidine salicylate,CC(=O)OC1CN2CCC1CC2.C1=CC=C(C(=C1)C(=O)O)O,,,,,,
3260,23261,CID 23261,C[NH+](C)CCOC1CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl.C(=CC(=O)[O-])C(=O)O,,,,,,
3261,23262,"2-[(3-chloro-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)oxy]-N,N-dimethylethanamine",CN(C)CCOC1CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,,,,,,
3262,23263,"3,6-Diphenyl-1,2,4,5-tetrazine",C1=CC=C(C=C1)C2=NN=C(N=N2)C3=CC=CC=C3,,,,,,
3263,23264,CID 23264,CC1=[N+](C2=CC=CC=C2N(C1=CN=NC(=O)N)O)[O-],,,,,,
3264,23265,2-Chlorobenzanilide,C1=CC=C(C=C1)NC(=O)C2=CC=CC=C2Cl,,,,,,
3265,23266,Sodium silicate,[O-][Si](=O)[O-].[Na+].[Na+],,,,"['Radiolabeled (31)Si-sodium metasilicate, partially neutralized, was given orally to male guinea pigs... Most of the silica was rapidly absorbed and excreted in the urine but a significant amount was retained in the tissues. These findings are consistent with the recognition that silicon is an essential trace element for bone formation in animals.', 'Partly absorbed and excreted in the urine; thus excretion during chronic exposures may contribute to the production of urinary calculi.']",,['SODIUM SILICATE HALF-LIFE 24 HR. FIRST ORDER EXCRETION KINETICS WERE FOLLOWED IN DETERMINING URINARY SILICON EXRETION BY RATS.']
3266,23267,Hydroxystreptomycin,CN[C@H]1[C@@H]([C@H]([C@@H](O[C@H]1O[C@H]2[C@@H](O[C@H]([C@@]2(C=O)O)CO)O[C@@H]3[C@H]([C@@H]([C@H]([C@@H]([C@H]3O)O)N=C(N)N)O)N=C(N)N)CO)O)O,,,,,,
3267,23268,6-Dodecanol,CCCCCCC(CCCCC)O,,,,,,
3268,23269,3-Phenyloxolan-2-one,C1COC(=O)C1C2=CC=CC=C2,,,,,,
3269,23270,Kyselina o-tosyl-h,CC1=CC=C(C=C1)S(=O)(=O)OC2=CC(=CC3=CC(=CC(=C32)N)S(=O)(=O)O)S(=O)(=O)O,,,,,,
3270,23271,"9,10-Anthracenedione, 1,5-dichloro-4,8-dihydroxy-",C1=CC(=C2C(=C1O)C(=O)C3=C(C=CC(=C3C2=O)O)Cl)Cl,,,,,,
3271,23272,2-Methyl-2-nitrosopropane,CC(C)(C)N=O,,,,,,
3272,23273,"Indole, 5-dimethylamino-3-(2-(dimethylamino)ethyl)-",CN(C)CCC1=CNC2=C1C=C(C=C2)N(C)C,,,,,,
3273,23274,"Indole, 5-(dimethylamino)-",CN(C)C1=CC2=C(C=C1)NC=C2,,,,,,
3274,23275,"3-Indoleacetonitrile, 5-dimethylamino-",CN(C)C1=CC2=C(C=C1)NC=C2CC#N,,,,,,
3275,23276,"Indole, 5-(dimethylamino)-3-((dimethylamino)methyl)-",CN(C)CC1=CNC2=C1C=C(C=C2)N(C)C,,,,,,
3276,23277,"Indole-3-carboxaldehyde, 5-dimethylamino-",CN(C)C1=CC2=C(C=C1)NC=C2C=O,,,,,,
3277,23278,"Ketone, 5-dimethylamino-3-indolyl phenyl",CN(C)C1=CC2=C(C=C1)NC=C2C(=O)C3=CC=CC=C3,,,,,,
3278,23279,"Indole, 3-benzyl-5-(dimethylamino)-",CN(C)C1=CC2=C(C=C1)NC=C2CC3=CC=CC=C3,,,,,,
3279,23280,Dodicin,CCCCCCCCCCCCNCCNCCNCC(=O)O,,,,,,
3280,23281,(5-Indolyl)trimethylammonium chloride,C[N+](C)(C)C1=CC2=C(C=C1)NC=C2.[Cl-],,,,,,
3281,23282,1H-indol-5-yl(trimethyl)azanium,C[N+](C)(C)C1=CC2=C(C=C1)NC=C2,,,,,,
3282,23283,CID 23283,C1(=N)N=C(SS1)S,,,,,,
3283,23284,"2,2,4-Trimethyl-1,3-pentanediol diisobutyrate",CC(C)C(C(C)(C)COC(=O)C(C)C)OC(=O)C(C)C,,,,"['Three rats received single oral doses of radiolabeled TXIB (236, 250, or 283 mg/kg bw) and urine, feces and (14)CO2 were collected daily.  The percentages of the total oral doses of 236, 250, and 283 mg/kg bw accounted for were 98.9 percent (after 10 days), 99.2 percent (after 10 days), and 95.3 percent (after seven days), respectively.  Two-thirds of the total dose was excreted in 48hours, 90 percent in five days, and nearly 100 percent in 10 days.  The major route (50-67% of the total dose) of elimination was urine.  Fecal excretion accounted for 14-31 percent of the dose with the majority excreted within the first 48 hours; elimination was essentially complete in seven days.  Radiolabeled CO2 was not detected. In rats administered 475 mg/kg unlabeled TXIB, fecal acetone extracts taken after 24 hours indicated 8-36 percent of the dose remained as TXIB, 18-27 percent was the monoester, and there were trace amounts of TMPD.  In urine, concentrations were not quantified, but TXIB, TMPD, the monoester of TMPD, and conjugates of TMPD and 2,2,4-trimethyl-3-hydroxyvaleric acid were detected.Oral doses of TMPD (196 and 208 mg/kg bw) were also eliminated rapidly and almost entirely in the urine of rats.', 'Male Holtzman albino rats receiving single oral doses of radiolabeled TXIB (236-895 mg/kg bw) were sacrificed one-by-one 8, 15, and 22 days later. Liver, kidney, perirenal and omental fat, brain, lung, and carcass tissue were analyzed for radioactivity after sacrifice.  After eight days of exposure, the carcass and organs combined accounted for 2.9 percent of the original dose, and at days 15 and 22, essentially no radioactivity remained (<1%).', 'The majority of an oral dose was absorbed quickly in Holtzman albino rats. An acetone extract of the feces 24 hours after a single oral dose of 475 mg/kg bw TXIB indicated that one-half to two-thirds of TXIB indeed had been absorbed by the animal.  The percent of total oral doses of 236, 250, and 283 mg/kg bw (14)C-TXIB accounted for in urine and feces of rats was 98.9, 99.2, and 95.3 percent, respectively, after 7-10 days.']","['After an oral dose of radiolabeled TXIB, the first metabolic step was hydrolysis to the monoisobutyrate of the parent glycol 2,2,4-trimethyl-1,2-pentanediol (TMPD), presumably in the gastrointestinal tract since a large proportion of the total dose detected in feces was this compound...  A second hydrolysis takes place, transforming some of the dose into TMPD.  Major urinary metabolites of TXIB detected three days after an oral dose of 255 mg/kg bw were free 2,2,4-trimethyl-3-hydroxyvaleric acid (11.6% of dose), as well as its glucuronide (3.1%) and its sulfate form (4.3%), and also TMPD in its glucuronide (6.5%), sulfate (1.8%), and free form (0.5%). Forty-eight hours following an oral dose of TMPD (196 or 208 mg/kg bw), the major urinary metabolite in rats was the O-glucuronide of TMPD (72-73% of the dose); other compounds found in the urine were the sulfate (6.4-6.5%) and free (1-1.7%) forms of TMPD, and free 2,2,4-trimethyl-3-hydroxyvaleric acid (3%) and its glucuronide (4.3-4.4%).']",
3284,23285,"3-Chloro-N,N-dimethylaniline",CN(C)C1=CC(=CC=C1)Cl,,,,,,
3285,23286,2-Aminocyclohexanol,C1CCC(C(C1)N)O,,,,,,
3286,23287,"Cyclopropanemethanol, alpha,alpha-diphenyl-2-(4-pyridyl)-, hydrochloride",C1C(C1C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C4=CC=NC=C4,,,,,,
3287,23288,"Indole, 5-(dimethylamino)-3-(piperidinomethyl)-",CN(C)C1=CC2=C(C=C1)NC=C2CN3CCCCC3,,,,,,
3288,23289,"Indole, 3-bromoacetyl-5-(dimethylamino)-",CN(C)C1=CC2=C(C=C1)NC=C2C(=O)CBr,,,,,,
3289,23290,4-Pentylbenzaldehyde,CCCCCC1=CC=C(C=C1)C=O,,,,,,
3290,23291,Dithiodiglycolic acid dihydrazide,C(C(=O)NN)SSCC(=O)NN,,,,,,
3291,23292,"3-[(6-Deoxy-3-O-methylhexopyranosyl)oxy]-14,19-dihydroxycard-20(22)-enolide",CC1[C@H](C(C([C@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)CO)O)OC)O,,,,,,
3292,23293,3-Hydroxypiperidine,C1CC(CNC1)O,,,,,,
3293,23294,Di-sec-butyl ether,CCC(C)OC(C)CC,,,,,,
3294,23295,"1,3,5-Triazin-2-amine, 4-ethoxy-N,6-diethyl-",CCC1=NC(=NC(=N1)OCC)NCC,,,,,,
3295,23296,"2,6,10-Trimethylundecane",CC(C)CCCC(C)CCCC(C)C,,,,,,
3296,23297,2-Chloro-3-nitrosobutane dimer,CC(C(C)Cl)N=O.CC(C(C)Cl)N=O,,,,,,
3297,23298,2-Chloro-3-nitrosobutane,CC(C(C)Cl)N=O,,,,,,
3298,23299,"BENZIMIDAZOLE, 5(or 6)-CHLORO-2-(HEPTAFLUOROPROPYL)-",C1=CC2=C(C=C1Cl)NC(=N2)C(C(C(F)(F)F)(F)F)(F)F,,,,,,
3299,23300,CID 23300,CC1[C@H](C(C([C@H](O1)O[C@H]2CC[C@@]3(C4[C@@H](C[C@@]5([C@H](CC[C@@]5(C4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)O)C)O)O)O.O,,,,,,
3300,23301,CID 23301,CC1[C@H](C(C([C@H](O1)O[C@H]2CC[C@@]3(C4[C@@H](C[C@@]5([C@H](CC[C@@]5(C4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)O)C)O)O)O,,,,,,
3301,23302,"(3S,5R,10R,13R,14S,17R)-14-hydroxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-3-[(2S,5S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-10-carbaldehyde",CC1[C@H](C(C([C@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)C=O)O)O)O,,,,,,
3302,23303,"(4S)-7-hydroxy-3',6,7-trimethylspiro[2,9-dioxa-14-azatricyclo[9.5.1.014,17]heptadec-11-ene-4,2'-oxirane]-3,8-dione",CC1C[C@]2(C(O2)C)C(=O)OC3CCN4C3C(=CC4)COC(=O)C1(C)O,,,,"[""Excretion of pyrrolizidine alkaloids (pa's) in diet of rabbits was not affected by the addition of copper and zinc to the diet. Isolated pa's from Senecio jacobaea were found to be readily transferred across the mucosa of isolated everted sacs of jejunum and ileum in vitro against a concentration gradient. These results suggest that the effects of dietary Senecio jacobaea on alterations in mineral metabolism are not due to changes in GI mineral absorption. In addition, it appears that the resistance of rabbits to dietary Senecio jacobaea intoxication is not caused by low GI absorption of pyrrolizidine alkaloids, but rather by efficient urinary elimination.""]","['In general, the hepatotoxic pyrrolidine alkaloids are metabolized in rat liver to give hydrolysis products, n-oxides and dehydropyrrolizidine (pyrrolic) deriv. The latter group appears on current evidence to mediate most of toxic reactions of alkaloids. These pyrrolic deriv are produced by mixed-function oxidases of liver cells. Initial product formed from alkaloids that are esters of...retronecine (eg, jacobine...) is very probably the dehydroalkaloid. Dehydroalkaloids are highly reactive alkylating agents which react immediately with cell constituents to give soluble or bound secondary metabolites or which hydrolyze to dehydroaminoalcohol. /pyrrolizidine alkaloids/', 'The effect of prolonged phenobarbital (pb) administration on the toxicity of Senecio jacobaea (sj) was studied in sheep. Results suggested that mixed-function oxidase induction by pb does not increase the susceptibility of sheep to sj intoxication. Sheep possess a high activity of hepatic microsomal epoxide hydrolase which could account for their resistance to sj intoxication.', 'Comparison is made of the alkylating activities of a series of semi-synthetic pyrrole esters and pyrrole derivatives of pyrrolizidine alkaloids under pseudo-first-order reaction conditions. Data for alkylation by jacobine pyrrole (a reactive metabolite of jacobine) fit a simple first-order rate expression for product formation. The large increase in reaction rate for jacobine pyrrole is suggestive of an electronic field effect due to the epoxide ring in proximity to the C-7 ester moiety.']",
3303,23304,CID 23304,CC=C1C[N+]2(CC[C@@]34[C@@]2(CCC1C3(CO)C(=O)OC)NC5=CC=CC=C45)C,,,,,,
3304,23305,2-Methylindoline,CC1CC2=CC=CC=C2N1,,,,,,
3305,23306,Coralyne chloride,CC1=C2C=C(C(=CC2=CC3=[N+]1C=CC4=CC(=C(C=C43)OC)OC)OC)OC.[Cl-],,,,,,
3306,23307,"2,3,10,11-Tetramethoxy-8-methylisoquinolino[2,1-b]isoquinolin-7-ium",CC1=C2C=C(C(=CC2=CC3=[N+]1C=CC4=CC(=C(C=C43)OC)OC)OC)OC,,,,,,
3307,23308,CID 23308,C=CCSC(=NCCC1=CC=CC=C1)S,,,,,,
3308,23309,2-tert-Butyl-6-methylbromoacetanilide,CC1=C(C(=CC=C1)C(C)(C)C)NC(=O)CBr,,,,,,
3309,23310,"3,14-Dihydroxy-7,8-epoxycard-20(22)-enolide",C[C@]12CCC3[C@]4(CC[C@@H](C[C@H]4C[C@H]5C3([C@]1(CC[C@@H]2C6=CC(=O)OC6)O)O5)O)C,,,,,,
3310,23311,"10a,12a-dimethyl-4,4a,4b,10b,11,12-hexahydro-3H-naphtho[2,1-f]chromene-2,8-dione",CC12CCC3C(C1CCC(=O)O2)C=CC4=CC(=O)C=CC34C,,,,,,
3311,23312,"(3S,5S,10S,11R,13R,14S,17R)-5,11,14-trihydroxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-3-[(2S,5S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-10-carbaldehyde",CC1[C@H](C(C([C@H](O1)O[C@H]2CC[C@@]3(C4[C@@H](C[C@@]5([C@H](CC[C@@]5(C4CC[C@@]3(C2)O)O)C6=CC(=O)OC6)C)O)C=O)O)O)O,,,,,,
3312,23313,"trans-1,2-Dimethylcyclohexane",C[C@@H]1CCCC[C@H]1C,,,,,,
3313,23314,"Ammonium, trimethyl(5-(trimethylammonio)-3-indolylmethyl)-, diiodide",C[N+](C)(C)CC1=CNC2=C1C=C(C=C2)[N+](C)(C)C.[I-].[I-],,,,,,
3314,23315,trimethyl-[[5-(trimethylazaniumyl)-1H-indol-3-yl]methyl]azanium,C[N+](C)(C)CC1=CNC2=C1C=C(C=C2)[N+](C)(C)C,,,,,,
3315,23316,"Indole, 5-(dimethylamino)-3-(trifluoroacetyl)-",CN(C)C1=CC2=C(C=C1)NC=C2C(=O)C(F)(F)F,,,,,,
3316,23317,"Indole, 3-((diethylamino)acetyl)-5-(dimethylamino)-",CCN(CC)CC(=O)C1=CNC2=C1C=C(C=C2)N(C)C,,,,,,
3317,23318,"2,3,6a,8,9,9a-Hexahydro-9a-hydroxy-4-methoxycyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione",COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4C(=C1)OC5C4(CCO5)O,,,,,,
3318,23319,"4,4'-(Hexamethylenedioxy)dianiline dihydrochloride",C1=CC(=CC=C1[NH3+])OCCCCCCOC2=CC=C(C=C2)[NH3+].[Cl-].[Cl-],,,,,,
3319,23320,"4,4'-(1,6-Hexanediyl)dioxydianiline",C1=CC(=CC=C1N)OCCCCCCOC2=CC=C(C=C2)N,,,,,,
3320,23321,4-Hydroxypyridine 1-oxide,C1=CN(C=CC1=O)O,,,,,,
3321,23322,CID 23322,CCCCC1C(=O)N=C(N(C1=O)C2CCCCC2)[O-].[Na+],,,,,,
3322,23323,Sarhamnolosid [German],CC1[C@H](C(C([C@H](O1)O[C@H]2CC[C@@]3(C4C(CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(CC4O)C)C6=CC(=O)OC6)O)CO)O)O)O,,,,,,
3323,23324,1-Methoxy-2-acetamidofluorene,CC(=O)NC1=C(C2=C(C=C1)C3=CC=CC=C3C2)OC,,,,,,
3324,23325,"1-Methoxyfluoren-2-amine, hydrochloride",COC1=C(C=CC2=C1CC3=CC=CC=C32)[NH3+].[Cl-],,,,,,
3325,23326,"Fluoren-2-amine, 1-methoxy-",COC1=C(C=CC2=C1CC3=CC=CC=C32)N,,,,,,
3326,23327,D-glutamic acid,C(CC(=O)O)[C@H](C(=O)O)N,,,,,,
3327,23328,Triethyl(2-(2-pyridyl)ethyl)ammonium iodide,CC[N+](CC)(CC)CCC1=CC=CC=N1.[I-],,,,,,
3328,23329,Triethyl(2-pyridin-2-ylethyl)azanium,CC[N+](CC)(CC)CCC1=CC=CC=N1,,,,,,
3329,23330,"N,N,N-Trimethyl-2-pyridineethanaminium iodide",C[N+](C)(C)CCC1=CC=CC=N1.[I-],,,,,,
3330,23331,Trimethyl(2-pyridin-2-ylethyl)azanium,C[N+](C)(C)CCC1=CC=CC=N1,,,,,,
3331,23332,Balduilin,C[C@H]1C[C@@H]2[C@H]([C@H]([C@]3([C@H]1C=CC3=O)C)OC(=O)C)C(=C)C(=O)O2,,,,,,
3332,23333,Benzimidazole mustard,CC1=CC2=C(C=C1C)N=C(N2)C[NH+](CCCl)CCCl.[Cl-],,,,,,
3333,23334,"2-chloro-N-(2-chloroethyl)-N-[(5,6-dimethyl-1H-benzimidazol-2-yl)methyl]ethanamine",CC1=CC2=C(C=C1C)N=C(N2)CN(CCCl)CCCl,,,,,,
3334,23335,(-)-Caaverine,COC1=C(C2=C3[C@@H](CC4=CC=CC=C42)NCCC3=C1)O,,,,,,
3335,23336,Diethynyl hexanedioate,C#COC(=O)CCCCC(=O)OC#C,,,,,,
3336,23337,CID 23337,CC(=O)O[C@@]12[C@@H]3[C@@H](C[C@@](C3OC(=O)C4=CC=CC=C4)(C(C1O)OC)O)C56[C@@H]7C(C2[C@H]5N(CC7(CCC6OC)COC)C)OC,,,,,,
3337,23338,CID 23338,C1C(CC(C(C1O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].C1C(CC(C(C1O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[SbH3],,,,,,
3338,23339,"4,5-Dihydroxycyclohexane-1,3-disulfonic acid",C1C(CC(C(C1O)O)S(=O)(=O)O)S(=O)(=O)O,,,,,,
3339,23340,"Methyl 1-hydroxy-7-(hydroxymethyl)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylate",COC(=O)C1=COC(C2C1CC=C2CO)O,,,,,,
3340,23341,"2,4'-Dichlorodiphenyl ether",C1=CC=C(C(=C1)OC2=CC=C(C=C2)Cl)Cl,,,,,,
3341,23342,Creatinolfosfate,CN(CCOP(=O)(O)O)C(=N)N,,,,,,
3342,23343,"Ketone, 1-(2-(diethylamino)ethyl)pyrrol-2-YL 3-pyridyl, citrate",CC[NH+](CC)CCN1C=CC=C1C(=O)C2=CN=CC=C2.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O,,,,,,
3343,23344,[1-[2-(Diethylamino)ethyl]pyrrol-2-yl]-pyridin-3-ylmethanone,CCN(CC)CCN1C=CC=C1C(=O)C2=CN=CC=C2,,,,,,
3344,23345,1-Benzylisoquinoline,C1=CC=C(C=C1)CC2=NC=CC3=CC=CC=C32,,,,,,
3345,23346,"N,N'-Benzylidenebisacetamide",CC(=O)NC(C1=CC=CC=C1)NC(=O)C,,,,,,
3346,23347,2-Thienyl disulfide,C1=CSC(=C1)SSC2=CC=CS2,,,,,,
3347,23348,"INDOLE, 2-(p-(2-(DIETHYLAMINO)ETHOXY)PHENYL)-3-PHENYL-",CCN(CC)CCOC1=CC=C(C=C1)C2=C(C3=CC=CC=C3N2)C4=CC=CC=C4,,,,,,
3348,23349,Dipropargyl ether,C#CCOCC#C,,,,,,
3349,23350,Dipropargylamine,C#CCNCC#C,,,,,,
3350,23351,Tripropargylamine,C#CCN(CC#C)CC#C,,,,,,
3351,23352,"3,3-Dimethyloxetane",CC1(COC1)C,,,,,,
3352,23353,Alphate,CC(=CC(=O)NC)OP(=O)(OC)OC,,,,,,
3353,23354,Antimony triacetate,CC(=O)[O-].CC(=O)[O-].CC(=O)[O-].[Sb+3],,,,,,
3354,23355,"3,4-Dihydroxy-alpha-((isobutylamino)methyl)benzyl alcohol",CC(C)CNCC(C1=CC(=C(C=C1)O)O)O,,,,,,
3355,23356,1-Azidohexane,CCCCCCN=[N+]=[N-],,,,,,
3356,23357,3-Ethynyl-1-hepten-3-ol,CCCCC(C=C)(C#C)O,,,,,,
3357,23358,"3,4-Diethyl-3,4-hexanediol",CCC(CC)(C(CC)(CC)O)O,,,,,,
3358,23359,4-Bromo-3-methylaniline,CC1=C(C=CC(=C1)N)Br,,,,,,
3359,23360,Clorprenaline hydrochloride,CC(C)NCC(C1=CC=CC=C1Cl)O.Cl,,,"['Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)']",,,
3360,23361,3-Tert-butyl-6-methylsalicylic acid,CC1=C(C(=C(C=C1)C(C)(C)C)O)C(=O)O,,,,,,
3361,23362,2-Benzylaminopyridine,C1=CC=C(C=C1)CNC2=CC=CC=N2,,,,,,
3362,23363,"Quinoxaline, 1-oxide",C1=CC=C2C(=C1)N=CC=[N+]2[O-],,,,,,
3363,23364,4-Aminobutyrate ethyl hydrochloride,CCOC(=O)CCC[NH3+].[Cl-],,,,,,
3364,23365,Ethyl 4-aminobutanoate,CCOC(=O)CCCN,,,,,,
3365,23366,"1,4-NAPHTHOQUINONE, 2,2'-(SULFONYLBIS(p-PHENYLENEIMINO))BIS(3-CHLORO-",C1=CC=C2C(=C1)C(=O)C(=C(C2=O)Cl)NC3=CC=C(C=C3)S(=O)(=O)C4=CC=C(C=C4)NC5=C(C(=O)C6=CC=CC=C6C5=O)Cl,,,,,,
3366,23367,Benzyl hexanoate,CCCCCC(=O)OCC1=CC=CC=C1,,,,,,
3367,23368,Diisopropyl adipate,CC(C)OC(=O)CCCCC(=O)OC(C)C,,,,,,
3368,23369,"Fluorene, 2-chloro-7-nitro-",C1C2=C(C=CC(=C2)[N+](=O)[O-])C3=C1C=C(C=C3)Cl,,,,,,
3369,23370,CID 23370,CN=C(N=C(N)S)S,,,,,,
3370,23371,"Acetic acid, 2-(2-mercaptoethyl)amino-, hydrochloride",C(CS)[NH2+]CC(=O)O.[Cl-],,,,,,
3371,23372,"Glycine, N-(2-mercaptoethyl)-",C(CS)NCC(=O)O,,,,,,
3372,23373,3-(p-(Bis(2-chloroethyl)amino)benzylsulfonyl)-L-alanine,C1=CC(=CC=C1CS(=O)(=O)CC(C(=O)O)N)N(CCCl)CCCl,,,,,,
3373,23374,2-Bromoallylamine,C=C(CN)Br,,,,,,
3374,23375,"4,4-Dimethylpent-2-enoic acid",CC(C)(C)C=CC(=O)O,,,,,,
3375,23376,Cyclohexyl acetoacetate,CC(=O)CC(=O)OC1CCCCC1,,,,,,
3376,23377,Dihexylnitrosamine,CCCCCCN(CCCCCC)N=O,,,,,,
3377,23378,1-Aminocycloheptanecarboxylic acid,C1CCCC(CC1)(C(=O)O)N,,,,,,
3378,23379,"N,N'-Tetramethylenebis(N-(2-chloroethyl)benzylamine) dihydrochloride",C1=CC=C(C=C1)C[NH+](CCCC[NH+](CCCl)CC2=CC=CC=C2)CCCl.[Cl-].[Cl-],,,,,,
3379,23380,"N,N'-dibenzyl-N,N'-bis(2-chloroethyl)butane-1,4-diamine",C1=CC=C(C=C1)CN(CCCCN(CCCl)CC2=CC=CC=C2)CCCl,,,,,,
3380,23381,3-Bromobenzonitrile,C1=CC(=CC(=C1)Br)C#N,,,,,,
3381,23382,1-Naphthohydroxamic acid,C1=CC=C2C(=C1)C=CC=C2C(=O)NO,,,,,,
3382,23383,(6-chloro-1H-benzo[d]imidazol-2-yl)methanol,C1=CC2=C(C=C1Cl)NC(=N2)CO,,,,,,
3383,23384,"6-Bromonaphthalene-1,2-dione",C1=CC2=C(C=CC(=O)C2=O)C=C1Br,,,,,,
3384,23385,6-Nitrogramine,CN(C)CC1=CNC2=C1C=CC(=C2)[N+](=O)[O-],,,,,,
3385,23386,"11H-Indeno[1,2-b]quinoxalin-11-one",C1=CC=C2C(=C1)C3=NC4=CC=CC=C4N=C3C2=O,,,,,,
3386,23387,"o-CRESOL, 4-CHLORO-alpha-(3,4-XYLYL)-",CC1=C(C=C(C=C1)CC2=C(C=CC(=C2)Cl)O)C,,,,,,
3387,23388,N-(furan-2-ylmethylideneamino)pyridine-4-carboxamide,C1=COC(=C1)C=NNC(=O)C2=CC=NC=C2,,,,,,
3388,23389,2-Formylaminofluorene,C1C2=CC=CC=C2C3=C1C=C(C=C3)NC=O,,,,,,
3389,23390,[2-[2-[(2-Hydroxy-3-methoxyphenyl)methylidene]hydrazinyl]-2-oxoethyl]-trimethylazanium;chloride,C[N+](C)(C)CC(=O)NN=CC1=C(C(=CC=C1)OC)O.[Cl-],,,,,,
3390,23391,[2-[2-[(2-Hydroxy-3-methoxyphenyl)methylidene]hydrazinyl]-2-oxoethyl]-trimethylazanium,C[N+](C)(C)CC(=O)NN=CC1=C(C(=CC=C1)OC)O,,,,,,
3391,23392,2-(Chloromethyl)pyridine hydrochloride,C1=CC=NC(=C1)CCl.Cl,,,,"['PYRIDINE & ITS ALKYL DERIVATIVES ARE ABSORBED FROM GI TRACT, INTRAPERITONEAL CAVITY & LUNGS. PERITONEAL ABSORPTION IS APPARENTLY ONLY SLIGHTLY MORE RAPID & COMPLETE THAN GI ABSORPTION ... IN GENERAL THE BASES ARE RAPIDLY ABSORBED THROUGH INTACT SKIN. /ALKYL DERIVATIVES OF PYRIDINE/']",,
3392,23393,2-(Chloromethyl)pyridine,C1=CC=NC(=C1)CCl,,,,,,
3393,23394,3-(Chloromethyl)pyridine hydrochloride,C1=CC(=CN=C1)CCl.Cl,,,,,,
3394,23395,3-Butoxypropionitrile,CCCCOCCC#N,,,,,,
3395,23396,7-Nitroindole,C1=CC2=C(C(=C1)[N+](=O)[O-])NC=C2,,,,,,
3396,23397,N-(2-Hydroxyethyl)-3-phenyl-2-propenamide,C1=CC=C(C=C1)C=CC(=O)NCCO,,,,,,
3397,23398,"Colchicine, 10-demethoxy-10-(diethylamino)-",CCN(CC)C1=CC=C2C(=CC1=O)[C@H](CCC3=CC(=C(C(=C32)OC)OC)OC)NC(=O)C,,,,,,
3398,23399,4-Chlorobutyl acetate,CC(=O)OCCCCCl,,,,,,
3399,23400,"2-FURANPROPANOL, alpha-METHYL-",CC(CCC1=CC=CO1)O,,,,,,
3400,23401,CID 23401,C1=NC(=C(N1)Br)[N+](=O)[O-],,,,,,
3401,23402,4-Chloro-3-pentadecylphenol,CCCCCCCCCCCCCCCC1=C(C=CC(=C1)O)Cl,,,,,,
3402,23403,Tiadenol,C(CCCCCSCCO)CCCCSCCO,,,['Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. (See all compounds classified as Hypolipidemic Agents.)'],,,
3403,23404,3-Thiopheneacetic acid,C1=CSC=C1CC(=O)O,,,,,,
3404,23405,CID 23405,COC(=NC(=O)C1=CC(=C(C=C1)Cl)Cl)S,,,,,,
3405,23406,(1-Methyl-1H-indol-3-YL)methanol,CN1C=C(C2=CC=CC=C21)CO,,,,,,
3406,23407,"3,4-Dimethylbenzyl alcohol",CC1=C(C=C(C=C1)CO)C,,,,,,
3407,23408,CID 23408,CCCCC1=C(NC(=CC1=O)C)O,,,,,,
3408,23409,"Malononitrile, salicylidene-",C1=CC=C(C(=C1)C=C(C#N)C#N)O,,,,,,
3409,23410,"2-Hydroxy-2,5-dimethylhexanedial",CC(CCC(C)(C=O)O)C=O,,,,,,
3410,23411,Methylenebis(N-carbamylmaleimide),C1=CC(=O)N(C1=O)C(=O)NCNC(=O)N2C(=O)C=CC2=O,,,,,,
3411,23412,"AMMONIUM, (2-(p-TOLYLOXY)ETHYL)TRIMETHYL-, BROMIDE",CC1=CC=C(C=C1)OCC[N+](C)(C)C.[Br-],,,,,,
3412,23413,Trimethyl-[2-(4-methylphenoxy)ethyl]azanium,CC1=CC=C(C=C1)OCC[N+](C)(C)C,,,,,,
3413,23414,CID 23414,C1=CN(C=CC1=C(N=N)O)O,,,,,,
3414,23415,2-Methyldecane,CCCCCCCCC(C)C,,,,,,
3415,23416,"Carbamic acid, dipropyl-, ethyl ester",CCCN(CCC)C(=O)OCC,,,,,,
3416,23417,16-Dehydrostrophanthidin,C[C@]12CCC3C([C@]1(CC=C2C4=CC(=O)OC4)O)CC[C@]5([C@@]3(CC[C@@H](C5)O)C=O)O,,,,,,
3417,23418,Ormetoprim,CC1=CC(=C(C=C1CC2=CN=C(N=C2N)N)OC)OC,,,,,,
3418,23419,"Ether, bis(1-chloroethyl)",CC(OC(C)Cl)Cl,,,,,,
3419,23420,CID 23420,C1=CC=C(C=C1)NC(=NC2=CC=C(C=C2)O)S,,,,,,
3420,23421,Dioxacarb,CNC(=O)OC1=CC=CC=C1C2OCCO2,,,,,,
3421,23422,Curare,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC.O.O.O.O.O.Cl.[Cl-],,,"['Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. (See all compounds classified as Neuromuscular Nondepolarizing Agents.)', 'Drugs that bind to nicotinic cholinergic receptors (RECEPTORS, NICOTINIC) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses. (See all compounds classified as Nicotinic Antagonists.)']",,,
3422,23423,"2-[(3R,4S,5S,8S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoic acid",C[C@H]1[C@@H]2CC[C@]3(C([C@]2(CC[C@H]1O)C)[C@@H](C[C@@H]4[C@@]3(C[C@@H](C4=C(CCC=C(C)C)C(=O)O)OC(=O)C)C)O)C,,,,,,
3423,23424,"Ethanol, 2,2'-((p-nitrosophenyl)imino)di-, dimethanesulfonate",CS(=O)(=O)OCCN(CCOS(=O)(=O)C)C1=CC=C(C=C1)N=O,,,,,,
3424,23425,"Benzoxazole, 2-pentyl-",CCCCCC1=NC2=CC=CC=C2O1,,,,,,
3425,23426,"Phosphonothioic acid, methyl-, O,O-diethyl ester",CCOP(=S)(C)OCC,,,,,,
3426,23427,Benzeneseleninic acid,C1=CC=C(C=C1)[Se](=O)O,,,,,,
3427,23428,N-phenyloctanamide,CCCCCCCC(=O)NC1=CC=CC=C1,,,,,,
3428,23429,"[(7S,11S,12R,13S,14R,15R,16R,17S,18S)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate",C[C@H]1C=CC=C(C(=O)NC2=CC(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,,,,,,
3429,23430,2-Benzoyl-1-(3-(dimethylamino)propyl)pyrrole citrate,CC(CN1C=CC=C1C(=O)C2=CC=CC=C2)[NH+](C)C.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O,,,,,,
3430,23431,[1-[2-(Dimethylamino)propyl]pyrrol-2-yl]-phenylmethanone,CC(CN1C=CC=C1C(=O)C2=CC=CC=C2)N(C)C,,,,,,
3431,23432,2-Methylcyclohexylamine,CC1CCCCC1N,,,,,,
3432,23433,Methyl 8-nonynoate,COC(=O)CCCCCCC#C,,,,,,
3433,23434,"(16R,17S)-3-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-16,17-diol",CC12CCC3C(C1C[C@H]([C@H]2O)O)CCC4=C3C=CC(=C4)OC,,,,,,
3434,23435,2-(Dimethylamino)-2-methylpropan-1-ol,CC(C)(CO)N(C)C,,,,,,
3435,23436,4-Chlorodiphenyl ether,C1=CC=C(C=C1)OC2=CC=C(C=C2)Cl,,,,,,
3436,23437,"Ethanaminium, 2-hydroxy-N,N-bis(2-hydroxyethyl)-N-methyl-, chloride",C[N+](CCO)(CCO)CCO.[Cl-],,,,,,
3437,23438,"Ethanaminium, 2-hydroxy-N,N-bis(2-hydroxyethyl)-N-methyl-",C[N+](CCO)(CCO)CCO,,,,,,
3438,23439,Butadiazamide,CCCCC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)Cl,,,,,,
3439,23440,CID 23440,CC=C/C=N/NC(=O)C1=CC=NC=C1,,,,,,
3440,23441,"9,11-Dichloro-17,21-dihydroxypregna-1,4-diene-3,20-dione",CC12CC([C@]3(C(C1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=CC43C)Cl)Cl,,,,,,
3441,23442,"6-methoxy-3,3,12-trimethyl-7H-pyrano[2,3-c]acridin-7-ol",CC1(C=CC2=C3C(=C(C=C2O1)OC)C(C4=CC=CC=C4N3C)O)C,,,,,,
3442,23443,CID 23443,C1CCC(CC1)(CC(=O)[O-])CO.[Na+],,,,,,
3443,23444,Hexacyclonic acid,C1CCC(CC1)(CC(=O)O)CO,,,,,,
3444,23445,"Disodium;3-(4-hydroxy-3,5-diiodophenyl)-2-phenylpropanoate",C1=CC=C(C=C1)C(CC2=CC(=C(C(=C2)I)O)I)C(=O)[O-].[Na+].[Na+],,,,,,
3445,23446,"Indole, 5-(dimethylamino)-3-morpholinomethyl-",CN(C)C1=CC2=C(C=C1)NC=C2CN3CCOCC3,,,,,,
3446,23447,4-Hydroxy-4-methyldecanoic acid,CCCCCCC(C)(CCC(=O)O)O,,,,,,
3447,23448,"2,4,4'-Trichlorobiphenyl",C1=CC(=CC=C1C2=C(C=C(C=C2)Cl)Cl)Cl,,,,,,
3448,23449,"2-Amino-2-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]acetic acid",C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C(C(=O)O)N,,,,,,
3449,23450,5-Aminotropolone,C1=CC(=O)C(=CC=C1N)O,,,,,,
3450,23451,2-Methyl-4'-nitroazobenzene,CC1=CC=CC=C1N=NC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
3451,23452,"Acridine, 1,2,3,4-tetrahydro-9-(4-methyl-1-piperazinyl)-",CN1CCN(CC1)C2=C3CCCCC3=NC4=CC=CC=C42,,,,,,
3452,23453,"Acridine, 1,2,3,4-tetrahydro-9-(4-phenyl-1-piperazinyl)-",C1CCC2=NC3=CC=CC=C3C(=C2C1)N4CCN(CC4)C5=CC=CC=C5,,,,,,
3453,23454,"Bis(1,2,2-trimethylpropyl) methylphosphonate",CC(C(C)(C)C)OP(=O)(C)OC(C)C(C)(C)C,,,,,,
3454,23455,3-Phenyl-5-(1-hydroxy-3-dimethylaminopropyl)isoxazole hydrochloride,C[NH+](C)CCC(C1=CC(=NO1)C2=CC=CC=C2)O.[Cl-],,,,,,
3455,23456,"3-(Dimethylamino)-1-(3-phenyl-1,2-oxazol-5-yl)propan-1-ol",CN(C)CCC(C1=CC(=NO1)C2=CC=CC=C2)O,,,,,,
3456,23457,trans-o-Chlorobenzyl(4-(o-chlorobenzylaminomethyl)cyclohexylmethyl)dimethylammonium iodide,C[N+](C)(CC1CCC(CC1)CNCC2=CC=CC=C2Cl)CC3=CC=CC=C3Cl.[I-],,,,,,
3457,23458,(o-Chlorobenzyl)[[4beta-[(o-chlorobenzyl)aminomethyl]cyclohexan-1alpha-yl]methyl]dimethylaminium,C[N+](C)(CC1CCC(CC1)CNCC2=CC=CC=C2Cl)CC3=CC=CC=C3Cl,,,,,,
3458,23459,2-Methylundecane,CCCCCCCCCC(C)C,,,,,,
3459,23460,"Ethanamine, 2-isocyanato-N-(2-isocyanatoethyl)-N-nitro-",C(CN(CCN=C=O)[N+](=O)[O-])N=C=O,,,,,,
3460,23461,CID 23461,CCCCCCCCCCCCCCCCCC(=O)[O-].[Al+3],,,,,,
3461,23462,L-Cysteine hydrochloride monohydrate,C([C@@H](C(=O)O)N)S.O.Cl,,,,,,
3462,23463,4-Chloro-alpha-cyclopropyl-alpha-methylbenzyl alcohol,CC(C1CC1)(C2=CC=C(C=C2)Cl)O,,,,,,
3463,23464,2-(5-Bromo-2-methoxybenzoyl)-1-(2-(dimethylamino)propyl)pyrrole citrate,CC(CN1C=CC=C1C(=O)C2=C(C=CC=C2Br)OC)[NH+](C)C.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O,,,,,,
3464,23465,(2-Bromo-6-methoxyphenyl)-[1-[2-(dimethylamino)propyl]pyrrol-2-yl]methanone,CC(CN1C=CC=C1C(=O)C2=C(C=CC=C2Br)OC)N(C)C,,,,,,
3465,23466,Mebenil,CC1=CC=CC=C1C(=O)NC2=CC=CC=C2,,,,,,
3466,23467,Didodecyl hydrogen phosphate,CCCCCCCCCCCCOP(=O)(O)OCCCCCCCCCCCC,,,,,,
3467,23468,sec-Butylcyclohexane,CCC(C)C1CCCCC1,,,,,,
3468,23469,2-[1-(Diaminomethylidenehydrazinylidene)propan-2-ylideneamino]guanidine;dihydrochloride,CC(=NN=C(N)N)C=NN=C(N)N.Cl.Cl,,,,,,
3469,23470,CID 23470,CC1CC(CC(O1)OC2CC(OC(C2O)C)OC3C(CC4=C(C3=O)C(=C5C(=C4)C=C(C(=C5O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)OC)O)OC(=O)C)O)C(C(=O)C(C(C)O)O)OC)OC8CC(C(C(O8)C)OC(=O)C)(C)O,,,,,,
3470,23471,Nitrosomethyl-N-butylamine,CCCCN(C)N=O,,,,,,
3471,23472,Magnesium nicotinate,C1=CC(=CN=C1)C(=O)[O-].C1=CC(=CN=C1)C(=O)[O-].[Mg+2],,,,,,
3472,23473,"CARBAMIC ACID, METHYL-, o-(1,3-DITHIOLAN-2-YL)PHENYL ESTER",CNC(=O)OC1=CC=CC=C1C2SCCS2,,,,,,
3473,23474,N-(3-Chloro-4-methoxyphenyl)acetamide,CC(=O)NC1=CC(=C(C=C1)OC)Cl,,,,,,
3474,23475,1-Bromo-2-isopropylbenzene,CC(C)C1=CC=CC=C1Br,,,,,,
3475,23476,Carpipramine dihydrochloride,C1CCN(CC1)C2(CCN(CC2)CCCN3C4=CC=CC=C4CCC5=CC=CC=C53)C(=O)N.O.Cl.Cl,,,"['Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)']",,,
3476,23477,CID 23477,CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].O.[Na+],,,,,,
3477,23478,1-Chloro-1-ethoxyethane,CCOC(C)Cl,,,,,,
3478,23479,Terodiline hydrochloride,CC(CC(C1=CC=CC=C1)C2=CC=CC=C2)NC(C)(C)C.Cl,,,"['Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)']",,,
3479,23480,Terodiline,CC(CC(C1=CC=CC=C1)C2=CC=CC=C2)NC(C)(C)C,,,"['A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)', 'Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)']",,,
3480,23481,Trimoxamine,CNC(CC=C)CC1=CC(=C(C(=C1)OC)OC)OC,,,,,,
3481,23482,Ampyzine sulfate,CN(C)C1=NC=CN=C1.OS(=O)(=O)O,,,,,,
3482,23483,Ampyzine,CN(C)C1=NC=CN=C1,,,,,,
3483,23484,Triampyzine,CC1=C(N=C(C(=N1)C)N(C)C)C,,,,,,
3484,23485,"(3S,5S,10S,13R,14S,17R)-3-[(2R,5S)-6-[[(3R,6S)-4,6-dihydroxy-2-methyloxan-3-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5,14-dihydroxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-10-carbaldehyde",CC1[C@@H](C(C[C@H](O1)O)O)OCC2[C@H](C(C([C@@H](O2)O[C@H]3CC[C@@]4(C5CC[C@@]6([C@H](CC[C@@]6(C5CC[C@@]4(C3)O)O)C7=CC(=O)OC7)C)C=O)O)O)O,,,,,,
3485,23486,1-(2-(Dimethylamino)propyl)-2-(phenylacetyl)pyrrole citrate,CC(CN1C=CC=C1C(=O)CC2=CC=CC=C2)[NH+](C)C.C(C(=O)O)C(CC(=O)O)(C(=O)[O-])O,,,,,,
3486,23487,1-[1-[2-(Dimethylamino)propyl]pyrrol-2-yl]-2-phenylethanone,CC(CN1C=CC=C1C(=O)CC2=CC=CC=C2)N(C)C,,,,,,
3487,23488,4-Aminofluorene,C1C2=C(C3=CC=CC=C31)C(=CC=C2)N,,,,,,
3488,23489,Methaphenilene hydrochloride,C[NH+](C)CCN(CC1=CC=CS1)C2=CC=CC=C2.[Cl-],,,,,,
3489,23490,CID 23490,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)[N-]C=N2.[Na+],,,,,,
3490,23491,CID 23491,CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=O)C4=C3O)OCCO)C5=CC(=C(C=C5)OCCO)OCCO)O)O)O)O)O)O,,,,,,
3491,23492,2-(1-methyl-1H-indol-3-yl)ethanamine,CN1C=C(C2=CC=CC=C21)CCN,,,,,,
3492,23493,Nitrosocarbaryl,CN(C(=O)OC1=CC=CC2=CC=CC=C21)N=O,,,,,,
3493,23494,Tetratetracontane,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,,,,,,
3494,23495,"(9R,17S)-9-chloro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one",C[C@@]1(CCC2C1(CC([C@]3(C2CCC4=CC(=O)CCC43C)Cl)O)C)O,,,,,,
3495,23496,Dimethyl diselenide,C[Se][Se]C,,,,,,
3496,23497,Melevodopa,COC(=O)[C@H](CC1=CC(=C(C=C1)O)O)N,,,['Agents used in the treatment of Parkinson&apos;s disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)'],,,
3497,23498,"Acridine-9-carboxamide, 1,2,3,4-tetrahydro-N,N-diethyl-",CCN(CC)C(=O)C1=C2CCCCC2=NC3=CC=CC=C31,,,,,,
3498,23499,"Ketone, piperidino(1,2,3,4-tetrahydro-9-acridinyl)",C1CCN(CC1)C(=O)C2=C3CCCCC3=NC4=CC=CC=C42,,,,,,
3499,23500,"6H-CYCLOHEPTA(b)QUINOLINE-11-CARBOXAMIDE, 7,8,9,10-TETRAHYDRO-N,N-DIETHYL-",CCN(CC)C(=O)C1=C2CCCCCC2=NC3=CC=CC=C31,,,,,,
3500,23501,"6H-Cyclohepta(b)quinoline, 7,8,9,10-tetrahydro-11-(morpholinocarbonyl)-",C1CCC2=C(C3=CC=CC=C3N=C2CC1)C(=O)N4CCOCC4,,,,,,
3501,23502,"5,5-Dimethylhex-1-ene",CC(C)(C)CCC=C,,,,,,
3502,23503,4-Isopropylbiphenyl,CC(C)C1=CC=C(C=C1)C2=CC=CC=C2,,,,,,
3503,23504,"1,4-Butanediol, dicarbamate",C(CCOC(=O)N)COC(=O)N,,,,,,
3504,23505,N-Nitrodiethylamine,CCN(CC)[N+](=O)[O-],,,,,,
3505,23506,N-Nitropiperidine,C1CCN(CC1)[N+](=O)[O-],,,,,,
3506,23507,Fondaren,CC1C(OC(O1)C2=CC=CC=C2OC(=O)NC)C,,,,,,
3507,23508,Metoquizine,CC1=CC(=NN1C(=O)N[C@@H]2C[C@H]3[C@@H](CC4=CN(C5=CC=CC3=C45)C)N(C2)C)C,,,,,,
3508,23509,Amiquinsin hydrochloride,COC1=CC2=C(C=CN=C2C=C1OC)N.O.Cl,,,,,,
3509,23510,Amiquinsin,COC1=CC2=C(C=CN=C2C=C1OC)N,,,,,,
3510,23511,Toquizine,CCN1C=C2CC3C(CC(CN3C)NC(=O)N4C(=CC(=N4)C)C)C5=C2C1=CC=C5,,,,,,
3511,23512,Flumetramide,C1C(OCC(=O)N1)C2=CC=C(C=C2)C(F)(F)F,,,,,,
3512,23513,CID 23513,CN1CC[C@]23[C@@H]4[C@@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3C(=NOCC(=O)O)CC4,,,,,,
3513,23514,"Dibutylamine, hexafluoroarsenate(1-)",CCCC[NH2+]CCCC.F[As-](F)(F)(F)(F)F,,,,,,
3514,23515,Hexafluoroarsenic(1-),F[As-](F)(F)(F)(F)F,,,,,,
3515,23516,"Ammonium, pentamethylenebis(triethyl-, dibromide",CC[N+](CC)(CC)CCCCC[N+](CC)(CC)CC.[Br-].[Br-],,,,,,
3516,23517,"1,5-Bis(triethylaminio)pentane",CC[N+](CC)(CC)CCCCC[N+](CC)(CC)CC,,,,,,
3517,23518,Methyl pentadecanoate,CCCCCCCCCCCCCCC(=O)OC,,,,,,
3518,23519,"Acridine, 9-amino-4,5-dimethyl-",CC1=C2C(=CC=C1)C(=C3C=CC=C(C3=N2)C)N,,,,,,
3519,23520,9-Amino-2-hydroxyacridine,C1=CC=C2C(=C1)C(=C3C=C(C=CC3=N2)O)N,,,,,,
3520,23521,"Acridine, 9-heptylamino-",CCCCCCCNC1=C2C=CC=CC2=NC3=CC=CC=C31,,,,,,
3521,23522,CID 23522,C1=CC=C2C(=C1)C=C3C=CC(=O)C=C3N2,,,,,,
3522,23523,Dicyclohexyl sulphide,C1CCC(CC1)SC2CCCCC2,,,,,,
3523,23524,Heptacosanoic acid,CCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)O,,,,,,
3524,23525,"Ammonium, (3-(methylcarbamoyloxy)-p-tolyl)trimethyl-, iodide",CC1=C(C=C(C=C1)[N+](C)(C)C)OC(=O)NC.[I-],,,,,,
3525,23526,"3-[[(Methylamino)carbonyl]oxy]-N,N,N,4-tetramethylbenzenaminium",CC1=C(C=C(C=C1)[N+](C)(C)C)OC(=O)NC,,,,,,
3526,23527,4-(Aminomethyl)piperidine,C1CNCCC1CN,,,,,,
3527,23528,"2,3-Dimethyl-2-hexene",CCCC(=C(C)C)C,,,,,,
3528,23529,Trimethyl-3-aminophenylarsonium chloride,C[As+](C)(C)C1=CC=CC(=C1)N.[Cl-],,,,,,
3529,23530,(3-Aminophenyl)-trimethylarsanium,C[As+](C)(C)C1=CC=CC(=C1)N,,,,,,
3530,23531,"2,3-Dimethyloctane",CCCCCC(C)C(C)C,,,,,,
3531,23532,"Phenol, 4-chloro-5-methyl-2-nitro-",CC1=CC(=C(C=C1Cl)[N+](=O)[O-])O,,,,,,
3532,23533,"Indeno[1,2,3-de]isoquinoline",C1=CC=C2C(=C1)C3=CC=CC4=CN=CC2=C43,,,,,,
3533,23534,"Benzene, 1-(3,3-diethoxy-2-methylpropyl)-4-(1-methylethyl)-",CCOC(C(C)CC1=CC=C(C=C1)C(C)C)OCC,,,,,,
3534,23535,Linalyl anthranilate,CC(=CCCC(C)(C=C)OC(=O)C1=CC=CC=C1N)C,,,,,,
3535,23536,4-Chloro-3-methylaniline,CC1=C(C=CC(=C1)N)Cl,,,,,,
3536,23537,N-(3-Chloro-4-methylphenyl)acetamide,CC1=C(C=C(C=C1)NC(=O)C)Cl,,,,,,
3537,23538,"Formamide, N-((1-benzyl-4-phenyl-4-piperidyl)methyl)-",C1CN(CCC1(CNC=O)C2=CC=CC=C2)CC3=CC=CC=C3,,,,,,
3538,23539,2-(Methylthio)benzimidazole,CSC1=NC2=CC=CC=C2N1,,,,,,
3539,23540,"Thiocyanic acid, 4-(dimethylamino)phenyl ester",CN(C)C1=CC=C(C=C1)SC#N,,,,,,
3540,23541,"N',N'''-Bis(p-(methylamidino)phenyl)terephthalamidine",CN=C(C1=CC=C(C=C1)N=C(C2=CC=C(C=C2)C(=NC3=CC=C(C=C3)C(=NC)N)N)N)N,,,,,,
3541,23542,2-Bromobenzoyl chloride,C1=CC=C(C(=C1)C(=O)Cl)Br,,,,,,
3542,23543,"5,8-Dimethoxy-2-methylchromone",CC1=CC(=O)C2=C(C=CC(=C2O1)OC)OC,,,,,,
3543,23544,"3,3,5-Trimethylheptane",CCC(C)CC(C)(C)CC,,,,,,
3544,23545,"Ketone, morpholino(1,2,3,4-tetrahydro-9-acridinyl)",C1CCC2=NC3=CC=CC=C3C(=C2C1)C(=O)N4CCOCC4,,,,,,
3545,23546,"4,4'-Oxybisbenzoyl chloride",C1=CC(=CC=C1C(=O)Cl)OC2=CC=C(C=C2)C(=O)Cl,,,,,,
3546,23547,Pyroxychlor,COC1=NC(=CC(=C1)C(Cl)(Cl)Cl)Cl,,,,,,
3547,23548,Ethyl (3-hydroxyphenyl)carbamate,CCOC(=O)NC1=CC(=CC=C1)O,,,,,,
3548,23549,"1,1-Dimethyl-3-(p-tolyl)urea",CC1=CC=C(C=C1)NC(=O)N(C)C,,,,,,
3549,23550,"N'-(4-Methoxyphenyl)-N,N-dimethylurea",CN(C)C(=O)NC1=CC=C(C=C1)OC,,,,,,
3550,23551,Paridocaine,CCCCNC1=CC=C(C=C1)C(=O)OC2CCN(CC2)C,,,,,,
3551,23552,"11-phenoxy-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinoline",C1CCC2=C(C3=CC=CC=C3N=C2CC1)OC4=CC=CC=C4,,,,,,
3552,23553,"N,N'-Bis(o-chlorobenzyl)-1,6-dimethyl-1,6-hexanediamine dihydrochloride",CC(CCCCC(C)[NH2+]CC1=CC=CC=C1Cl)[NH2+]CC2=CC=CC=C2Cl.[Cl-].[Cl-],,,,,,
3553,23554,N-(2-Chlorobenzyl)-7-[(2-chlorobenzyl)amino]-2-octanamine,CC(CCCCC(C)NCC1=CC=CC=C1Cl)NCC2=CC=CC=C2Cl,,,,,,
3554,23555,Bromonitrostyrene,C1=CC=C(C=C1)C=C([N+](=O)[O-])Br,,,,,,
3555,23556,Benzofuran-3(2H)-one,C1C(=O)C2=CC=CC=C2O1,,,,,,
3556,23557,"N-benzyl-1-phenylmethanamine;3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C.C1=CC=C(C=C1)CNCC2=CC=CC=C2,,,,,,
3557,23558,Didecyldimethylammonium chloride,CCCCCCCCCC[N+](C)(C)CCCCCCCCCC.[Cl-],,,,"['DDAC (40% aqueous in both radiolabled (14C) and nonradiolabled form), used in a definitive pharmacokinetic study to determine absorption, distribution and excretion and was administered orally (single dose), by gavage, to Charles River CD Rats (Crl CD(SD)Br--5/sex/group) in 3 dose regimens: 1) A single low dose (5 mg/kg), 2) a repeated low dose in diet containing 34 ppm ""cold"" in the feed daily for 14 days, followed by a 5 mg/kg dose of (14C)]-DDCA (9.01 mCi/mmole, and 99% radiochemical purity) or 3) a single high dose of 50 mg/kg. Excretion of radioactivity was shown to occur primarily in the feces (89-99%), some in urine (<2.5%), and an insignificant amount was expired. Highly ionic DDAC is not readily absorbed from the GI tract...']","['DDAC (40% aqueous in both radiolabled (14C) and nonradiolabled form), used in a definitive pharmacokinetic study to determine absorption, distribution and excretion and was administered orally (single dose), by gavage, to Charles River CD (Crl CD(SD)Br--5/sex/group) ... . In the addendum the metabolic profile was determined in a 2 step experiment. First, another group of rats (10 male Charles River CD (Crl CD(SD)Br) were treated with (14C)-DDAC at 50 mg/kg in order to obtain enough (14C) residues to use as standards. The (14C) metabolites were characterized by TLC, HPLC and MS. The second part of the experiment involved using the ""standard"" metabolic profiles to analyze the metabolites from feces samples obtained in the initial study. It was shown that metabolism tends to be sex specific. Females metabolize the parent compound more so than males. Metabolism, which may be microbial in nature, involved the oxidation of the 2 decyl side chains to form hydroxy and hydroxyketo derivatives. Modification of methyl substituents was not evident.']",
3558,23559,Danifos,CCOP(=O)(OCC)SCSC1=CC=C(C=C1)Cl,,,,,,
3559,23560,Oxydipentonium chloride,C[N+](C)(C)CCCCCOCCCCC[N+](C)(C)C.[Cl-].[Cl-],,,,,,
3560,23561,Oxydipentonium,C[N+](C)(C)CCCCCOCCCCC[N+](C)(C)C,,,,,,
3561,23562,1-Isocyano-4-methylbenzene,CC1=CC=C(C=C1)[N+]#[C-],,,,,,
3562,23563,N-Ethyldicyclohexylamine,CCN(C1CCCCC1)C2CCCCC2,,,,,,
3563,23564,Tersavin,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,,,,,,
3564,23565,Ampicillin trihydrate,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C.O.O.O,,,['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)'],,,
3565,23566,L-(+)-Ampicillin,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)O)C,,,,,,
3566,23567,CID 23567,CCOC1=C(C2=CC=CC=C2C=C1)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)[O-].[Na+],,,,,,
3567,23568,"4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-ethoxy-1-naphthamido)-3,3-dimethyl-7-oxo-",CCOC1=C(C2=CC=CC=C2C=C1)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,,,,,,
3568,23569,CID 23569,CC1(C(N2C(S1)C(C2=O)NC(=O)CSCC=C)C(=O)[O-])C.[Na+],,,,,,
3569,23570,"2-(Diethylamino)ethyl 4-amino-2-chlorobenzoate;3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid",CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)Cl.CC1(C(N2C(S1)C(C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,,,,,,
3570,23571,"4-Methoxy-5-methyl-4-cyclopenten-1,3-dione",CC1=C(C(=O)CC1=O)OC,,,,,,
3571,23572,"Benzoic acid, 3-butyramido-2,4,6-triiodo-",CCCC(=O)NC1=C(C=C(C(=C1I)C(=O)O)I)I,,,,,,
3572,23573,Talopram,CC1(C2=CC=CC=C2C(O1)(CCCNC)C3=CC=CC=C3)C,,,,,,
3573,23574,"Methane, dinitrofluoro-",C([N+](=O)[O-])([N+](=O)[O-])F,,,,,,
3574,23575,CID 23575,CN1CC[C@]23[C@@H]4[C@H](CC[C@]2([C@@H]1CC5=C3C(=C(C=C5)OC)O4)O)O,,,,,,
3575,23576,Trimethaphan,C1CC2C3C(C[S+]2C1)N(C(=O)N3CC4=CC=CC=C4)CC5=CC=CC=C5,['For the controlled reduction of blood pressure during surgery and in the treatment of hypertensive emergencies.'],"['Trimethaphan is indicated for production of controlled hypotension during surgery to reduce bleeding into the surgical field and also for rapid reduction of blood pressure in the treatment of hypertensive emergencies, especially in patients with acute dissecting aneurysm, and in the emergency treatment of pulmonary edema in patients with pulmonary hypertension associated with systemic hypertension.']","['Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (See all compounds classified as Adjuvants, Anesthesia.)', 'Agents having as their major action the interruption of neural transmission at nicotinic receptors on postganglionic autonomic neurons. Because their actions are so broad, including blocking of sympathetic and parasympathetic systems, their therapeutic use has been largely supplanted by more specific drugs. They may still be used in the control of blood pressure in patients with acute dissecting aortic aneurysm and for the induction of hypotension in surgery. (See all compounds classified as Ganglionic Blockers.)', 'Drugs that bind to nicotinic cholinergic receptors (RECEPTORS, NICOTINIC) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses. (See all compounds classified as Nicotinic Antagonists.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)']","['Trimethaphan crosses the placenta. The drug may be metabolized by pseudocholinesterase and is filtered and actively secreted by the kidneys.', 'Animal studies indicate that trimethaphan camsylate is erratically and incompletely absorbed after oral administration.']",,
3576,23577,tert-BUTYL ISOCYANIDE,CC(C)(C)[N+]#[C-],,,,,,
3577,23578,2-Benzyl-5-nitro-1H-benzimidazole,C1=CC=C(C=C1)CC2=NC3=C(N2)C=C(C=C3)[N+](=O)[O-],,,,,,
3578,23579,2'-Pentyloxyacetophenone,CCCCCOC1=CC=CC=C1C(=O)C,,,,,,
3579,23580,"Benzoic acid, 4-(allyloxy)-3,5-diisopropyl-",CC(C)C1=CC(=CC(=C1OCC=C)C(C)C)C(=O)O,,,,,,
3580,23581,"Benzoic acid, 4-(allyloxy)-3,5-dimethyl-",CC1=CC(=CC(=C1OCC=C)C)C(=O)O,,,,,,
3581,23582,"Benzoic acid, 3,5-dipropyl-4-((2-methylallyl)oxy)-",CCCC1=CC(=CC(=C1OCC(=C)C)CCC)C(=O)O,,,,,,
3582,23583,"3,5-Diethyl-4-hydroxybenzoic acid",CCC1=CC(=CC(=C1O)CC)C(=O)O,,,,,,
3583,23584,"Benzoic acid, 4-(allyloxy)-3,5-diethyl-",CCC1=CC(=CC(=C1OCC=C)CC)C(=O)O,,,,,,
3584,23585,"Benzoic acid, 2-(allyloxy)-3,5-dipropyl-, methyl ester",CCCC1=CC(=C(C(=C1)C(=O)OC)OCC=C)CCC,,,,,,
3585,23586,"Benzoic acid, 2-(allyloxy)-3,5-dipropyl-",CCCC1=CC(=C(C(=C1)C(=O)O)OCC=C)CCC,,,,,,
3586,23587,"4-Allyloxy-3,5-dipropylbenzylamine citrate",CCCC1=CC(=CC(=C1OCC=C)CCC)C[NH3+].C(C(=O)[O-])C(CO)(C(=O)O)C(=O)O,,,,,,
3587,23588,"(4-Prop-2-enoxy-3,5-dipropylphenyl)methanamine",CCCC1=CC(=CC(=C1OCC=C)CCC)CN,,,,,,
3588,23589,"4-Allyloxy-N-methyl-3,5-dipropylbenzylamine hydrochloride",CCCC1=CC(=CC(=C1OCC=C)CCC)C[NH2+]C.[Cl-],,,,,,
3589,23590,"N-methyl-1-(4-prop-2-enoxy-3,5-dipropylphenyl)methanamine",CCCC1=CC(=CC(=C1OCC=C)CCC)CNC,,,,,,
3590,23591,"4-Allyloxy-N,N-diethyl-3,5-dipropylbenzylamine hydrochloride",CCCC1=CC(=CC(=C1OCC=C)CCC)C[NH+](CC)CC.[Cl-],,,,,,
3591,23592,"N-ethyl-N-[(4-prop-2-enoxy-3,5-dipropylphenyl)methyl]ethanamine",CCCC1=CC(=CC(=C1OCC=C)CCC)CN(CC)CC,,,,,,
3592,23593,"Benzylamine, 4-(allyloxy)-N,N,3,5-tetraethyl-, hydrochloride",CCC1=CC(=CC(=C1OCC=C)CC)C[NH+](CC)CC.[Cl-],,,,,,
3593,23594,"N-(4-(Allyloxy)-3,5-diethylbenzyl)-N-ethylethanamine",CCC1=CC(=CC(=C1OCC=C)CC)CN(CC)CC,,,,,,
3594,23595,"2-Allyloxy-3,5-dipropylbenzylamine hydrochloride",CCCC1=CC(=C(C(=C1)C[NH3+])OCC=C)CCC.[Cl-],,,,,,
3595,23596,"(2-Prop-2-enoxy-3,5-dipropylphenyl)methanamine",CCCC1=CC(=C(C(=C1)CN)OCC=C)CCC,,,,,,
3596,23597,"Isoxazole, 5-methyl-3-(5-nitro-2-furyl)-",CC1=CC(=NO1)C2=CC=C(O2)[N+](=O)[O-],,,,,,
3597,23598,Heptatriacontane,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,,,,,,
3598,23599,Octatriacontane,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,,,,,,
3599,23600,Diglycidyl isophthalate,C1C(O1)COC(=O)C2=CC(=CC=C2)C(=O)OCC3CO3,,,,,,
3600,23601,Dichlorozinc;[7-(dimethylamino)-2-methylphenoxazin-3-ylidene]-diethylazanium;chloride,CC[N+](=C1C=C2C(=NC3=C(O2)C=C(C=C3)N(C)C)C=C1C)CC.[Cl-].Cl[Zn]Cl,,,,,,
3601,23602,3-(Diethylamino)-7-(dimethylamino)-2-methylphenoxazin-5-ium,CC[N+](=C1C=C2C(=NC3=C(O2)C=C(C=C3)N(C)C)C=C1C)CC,,,,,,
3602,23603,Cyheptamide,C1CC2=CC=CC=C2C(C3=CC=CC=C31)C(=O)N,,,,,,
3603,23604,"Dibenzo(1,2,5)thiadiazepine, 6,11-dihydro-11-(3-(dimethylamino)propyl)-6-methyl-, 5,5-dioxide",CN1C2=CC=CC=C2N(C3=CC=CC=C3S1(=O)=O)CCCN(C)C,,,,,,
3604,23605,"1-(4-Chlorophenyl)-3,3-dimethyltriazene",CN(C)N=NC1=CC=C(C=C1)Cl,,,,,,
3605,23606,"1-(4-Carboxyphenyl)-3,3-dimethyltriazene",CN(C)N=NC1=CC=C(C=C1)C(=O)O,,,['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)'],,,
3606,23607,CID 23607,C1CCC(=NCC1)S,,,,,,
3607,23608,Triethylene glycol monophenyl ether,C1=CC=C(C=C1)OCCOCCOCCO,,,,,,
3608,23609,"Nonasodium;[2,3,4-tris[[hydroxy(oxido)phosphoryl]oxy]-5,6-diphosphonatooxycyclohexyl] phosphate",C1(C(C(C(C(C1OP(=O)(O)[O-])OP(=O)([O-])[O-])OP(=O)([O-])[O-])OP(=O)([O-])[O-])OP(=O)(O)[O-])OP(=O)(O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],,,,,,
3609,23610,Chloromethyl 4-chlorophenyl sulfide,C1=CC(=CC=C1SCCl)Cl,,,,,,
3610,23611,Phenylethylmalonamide,CCC(C1=CC=CC=C1)(C(=O)N)C(=O)N,,,,,,
3611,23612,Methyldiiodoarsine,C[As](I)I,,,,,,
3612,23613,"D-Glucitol, hexaacetate",CC(=O)OCC(C(C(C(COC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C,,,,,,
3613,23614,"Hexamethylenebis(dimethyldodecylammonium), dichloride",CCCCCCCCCCCC[N+](C)(C)CCCCCC[N+](C)(C)CCCCCCCCCCCC.[Cl-].[Cl-],,,,,,
3614,23615,"1,6-Hexanediaminium, N,N'-didodecyl-N,N,N',N'-tetramethyl-",CCCCCCCCCCCC[N+](C)(C)CCCCCC[N+](C)(C)CCCCCCCCCCCC,,,,,,
3615,23616,"3,7,11-Trimethyldodeca-1,6,10-trien-1-ol",CC(CCC=C(C)CCC=C(C)C)C=CO,,,,,,
3616,23617,Dermoglaucin,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C(=C(C=C3C2=O)OC)O)O,,,,,,
3617,23618,1-Nitroethylbenzene,CC(C1=CC=CC=C1)[N+](=O)[O-],,,,,,
3618,23619,3-(4-Bromophenyl)azetidine,C1C(CN1)C2=CC=C(C=C2)Br,,,,,,
3619,23620,3-(4-Chlorophenyl)azetidine,C1C(CN1)C2=CC=C(C=C2)Cl,,,,,,
3620,23621,4-(Azetidin-3-yl)benzonitrile,C1C(CN1)C2=CC=C(C=C2)C#N,,,,,,
3621,23622,4-(Azetidin-3-yl)aniline,C1C(CN1)C2=CC=C(C=C2)N,,,,,,
3622,23623,3-(4-Nitrophenyl)azetidine,C1C(CN1)C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
3623,23624,"AZETIDINE, 3-p-TOLYL-",CC1=CC=C(C=C1)C2CNC2,,,,,,
3624,23625,"Azetidine, 1-methyl-3-phenyl-",CN1CC(C1)C2=CC=CC=C2,,,,,,
3625,23626,"1-Azetidineethanol, 3-phenyl-",C1C(CN1CCO)C2=CC=CC=C2,,,,,,
3626,23627,1-(2-Chloroethyl)-3-phenylazetidine,C1C(CN1CCCl)C2=CC=CC=C2,,,,,,
3627,23628,"Azetidine, 1-isopropyl-3-phenyl-",CC(C)N1CC(C1)C2=CC=CC=C2,,,,,,
3628,23629,"Azetidine, 1-butyl-3-phenyl-",CCCCN1CC(C1)C2=CC=CC=C2,,,,,,
3629,23630,"Azetidine, 1-isobutyl-3-phenyl-",CC(C)CN1CC(C1)C2=CC=CC=C2,,,,,,
3630,23631,1-Benzyl-3-phenylazetidine,C1C(CN1CC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3631,23632,"Azetidine, 1-allyl-3-phenyl-",C=CCN1CC(C1)C2=CC=CC=C2,,,,,,
3632,23633,CID 23633,C1C(CN1CC=CC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3633,23634,3-Ethyl-3-phenylazetidine,CCC1(CNC1)C2=CC=CC=C2,,,,,,
3634,23635,"Azetidine, 3-phenyl-3-propyl-",CCCC1(CNC1)C2=CC=CC=C2,,,,,,
3635,23636,"Azetidine, 3-isopropyl-3-phenyl-",CC(C)C1(CNC1)C2=CC=CC=C2,,,,,,
3636,23637,"Azetidine, 3-butyl-3-phenyl-",CCCCC1(CNC1)C2=CC=CC=C2,,,,,,
3637,23638,"3,3-Diphenylazetidine",C1C(CN1)(C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3638,23639,3-Cyclohexyl-3-phenylazetidine,C1CCC(CC1)C2(CNC2)C3=CC=CC=C3,,,,,,
3639,23640,3-Benzyl-3-phenylazetidine,C1C(CN1)(CC2=CC=CC=C2)C3=CC=CC=C3,,,,,,
3640,23641,"Azetidine, 1-ethyl-3-methyl-3-phenyl-",CCN1CC(C1)(C)C2=CC=CC=C2,,,,,,
3641,23642,2-Methoxybenzenethiol,COC1=CC=CC=C1S,,,,,,
3642,23643,Thihexinol methylbromide,C[N+](C)(C)C1CCC(CC1)C(C2=CC=CS2)(C3=CC=CS3)O.[Br-],,,,,,
3643,23644,Methyl thihexinolium,C[N+](C)(C)C1CCC(CC1)C(C2=CC=CS2)(C3=CC=CS3)O,,,,,,
3644,23645,CID 23645,CCSC(=NC1=CC(=C(C=C1)Br)Cl)S,,,,,,
3645,23646,CID 23646,C1=CC(=CC=C1CSC(=NC2=CC=C(C=C2)Cl)S)[N+](=O)[O-],,,,,,
3646,23647,Flutiazin,C1=CC(=C2C(=C1)SC3=C(N2)C=C(C=C3)C(F)(F)F)C(=O)O,,,,,,
3647,23648,Aflatoxin B2 alpha,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4C5CCOC5OC4=C1,,,,,,
3648,23649,CID 23649,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C(N)O)C(=O)[C@]3(C(=O)C2=C(C4=C(C=CC(=C41)Cl)O)O)O)N(C)C)O,,,,,,
3649,23650,Echitovenidine,CC([C@@]12CCCN3[C@@H]1[C@@]4(CC3)C5=CC=CC=C5NC4=C(C2)C(=O)OC)OC(=O)C=C(C)C,,,,,,
3650,23651,CID 23651,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)[O-])I)N(C)C(=O)C)I.[Na+],,,,,,
3651,23652,"2,2,3,3,5,6,6-Heptamethylheptane",CC(CC(C)(C)C(C)(C)C)C(C)(C)C,,,,,,
3652,23653,"1,6-Dibenzoyl-D-mannitol",C1=CC=C(C=C1)C(=O)OCC(C(C(C(COC(=O)C2=CC=CC=C2)O)O)O)O,,,,,,
3653,23654,"1-Phenyl-3,3-dimethyltriazene",CN(C)N=NC1=CC=CC=C1,,,,,,
3654,23655,"4-Allyloxy-N,N-dimethyl-3,5-dipropylbenzylamine hydrochloride",CCCC1=CC(=CC(=C1OCC=C)CCC)C[NH+](C)C.[Cl-],,,,,,
3655,23656,"N,N-dimethyl-1-(4-prop-2-enoxy-3,5-dipropylphenyl)methanamine",CCCC1=CC(=CC(=C1OCC=C)CCC)CN(C)C,,,,,,
3656,23657,"4-Allyloxy-3,5-diisopropylbenzylamine hydrochloride",CC(C)C1=CC(=CC(=C1OCC=C)C(C)C)C[NH3+].[Cl-],,,,,,
3657,23658,"[3,5-Di(propan-2-yl)-4-prop-2-enoxyphenyl]methanamine",CC(C)C1=CC(=CC(=C1OCC=C)C(C)C)CN,,,,,,
3658,23659,Metoclopramide hydrochloride,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl.Cl,,,"['Compounds and drugs that bind to and inhibit or block the activation of DOPAMINE D2 RECEPTORS. (See all compounds classified as Dopamine D2 Receptor Antagonists.)', 'Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)']",,,
3659,23660,3-Methyl-4-phenyl-3-butenamide,CC(=CC1=CC=CC=C1)CC(=O)N,,,,,,
3660,23661,2-Oxaspiro[4.5]decan-3-one,C1CCC2(CC1)CC(=O)OC2,,,,,,
3661,23662,3-(1-Methyl-2-pyrrolidinyl)indole,CN1CCCC1C2=CNC3=CC=CC=C32,,,,,,
3662,23663,CID 23663,CC1=C(C(=NO1)C2=CC=CC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)[O-].[Na+],,,,,,
3663,23664,Isopaque cerebral,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)N(C)C(=O)C)I.CNCC(C(C(C(CO)O)O)O)O,,,,,,
3664,23665,"Butyrophenone, 5'-amino-6'-(2-(diisopropylamino)ethoxy)-, dihydrochloride",CCCC(=O)C1=C(C(=CC=C1)[NH3+])OCC[NH+](C(C)C)C(C)C.[Cl-].[Cl-],,,,,,
3665,23666,1-[3-Amino-2-[2-[di(propan-2-yl)amino]ethoxy]phenyl]butan-1-one,CCCC(=O)C1=C(C(=CC=C1)N)OCCN(C(C)C)C(C)C,,,,,,
3666,23667,"Benzyl alcohol, 6-(2-(diisopropylamino)ethoxy)-alpha-propyl-, hydrochloride",CCCC(C1=CC=CC=C1OCC[NH+](C(C)C)C(C)C)O.[Cl-],,,,,,
3667,23668,Ketocainol,CCCC(C1=CC=CC=C1OCCN(C(C)C)C(C)C)O,,,,,,
3668,23669,Zolertine,C1CN(CCN1CCC2=NNN=N2)C3=CC=CC=C3,,,,,,
3669,23670,Dihydroaflatoxin G1,COC1=C2C3=C(C(=O)OCC3)C(=O)OC2=C4C5CCOC5OC4=C1,,,,,,
3670,23671,Methyl 2-benzamidopropanoate,CC(C(=O)OC)NC(=O)C1=CC=CC=C1,,,,,,
3671,23672,"2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid",CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,,,,,,
3672,23673,CID 23673,CCOC1=C2C(=C(C=C1)S(=O)(=O)[O-])C=CC=N2.[Na+],,,,,,
3673,23674,Actinoquinol,CCOC1=C2C(=C(C=C1)S(=O)(=O)O)C=CC=N2,,,,,,
3674,23675,CID 23675,CC1(C(N2C(S1)C(C2=O)NC(=O)C3=C(C=CC=C3OC)OC)C(=O)[O-])C.[Na+],,,,,,
3675,23676,CID 23676,CCCC(=O)NC1=C(C=C(C(=C1I)CC(CC)C(=O)[O-])I)I.[Na+],,,,,,
3676,23677,2-Methylnitrosopiperidine,CC1CCCCN1N=O,,,,,,
3677,23678,"N,N'-Ethylenebis(iodoacetamide)",C(CNC(=O)CI)NC(=O)CI,,,,,,
3678,23679,"N,N-Bis(2-(iodoacetoxy)ethyl)-N-methylamine hydriodide",C[NH+](CCOC(=O)CI)CCOC(=O)CI.[I-],,,,,,
3679,23680,2-[2-(2-Iodoacetyl)oxyethyl-methylamino]ethyl 2-iodoacetate,CN(CCOC(=O)CI)CCOC(=O)CI,,,,,,
3680,23681,Glycerol-tris(iodoacetate),C(C(COC(=O)CI)OC(=O)CI)OC(=O)CI,,,,,,
3681,23682,"BENZOIC ACID, o-CHLORO-, NICKEL(II) SALT",C1=CC=C(C(=C1)C(=O)[O-])Cl.C1=CC=C(C(=C1)C(=O)[O-])Cl.[Ni+2],,,,,,
3682,23683,"1,4-Diethoxybut-2-ene",CCOCC=CCOCC,,,,,,
3683,23684,2-((m-Chlorobenzyl)thio)-2-imidazoline monohydrobromide,C1CN=C([NH2+]1)SCC2=CC(=CC=C2)Cl.[Br-],,,,,,
3684,23685,2-[(m-Chlorobenzyl)thio]-2-imidazoline,C1CN=C(N1)SCC2=CC(=CC=C2)Cl,,,,,,
3685,23686,2-Methylquinoxaline,CC1=NC2=CC=CC=C2N=C1,,,,,,
3686,23687,Dichloromannitol,C(C(C(C(C(CCl)O)O)O)O)Cl,,,,,,
3687,23688,2-Butoxyethyl acrylate,CCCCOCCOC(=O)C=C,,,,,,
3688,23689,"4-Chloro-6-methoxy-1,3,5-triazin-2-amine",COC1=NC(=NC(=N1)N)Cl,,,,,,
3689,23690,"28,38-Di(ethylidene)-14,30-dimethyl-8,24-diaza-14,30-diazoniadodecacyclo[25.5.2.211,14.11,26.110,17.02,7.09,25.013,17.018,23.030,33.08,35.024,36]octatriaconta-2,4,6,18,20,22-hexaene-35,36-diol",CC=C1C[N+]2(CCC34C2CC1C5C3(N(C6C5N7C8=CC=CC=C8C91C7(C6C2CC9[N+](CC1)(CC2=CC)C)O)C1=CC=CC=C41)O)C,,,,,,
3690,23691,"N,3,7,11-tetramethyldodeca-2,6,10-trien-1-amine",CC(=CCCC(=CCCC(=CCNC)C)C)C,,,,,,
3691,23692,"11H-Indeno(2,1-A)pyren-11-one",C1=CC=C2C(=C1)C3=C(C2=O)C4=C5C(=C3)C=CC6=C5C(=CC=C6)C=C4,,,,,,
3692,23693,"ETHYLAMINE, 2-((5H-DIBENZO(a,d)CYCLOHEPTEN-5-YL)SULFONYL)-N,N-DIMETHYL-",CN(C)CCS(=O)(=O)C1C2=CC=CC=C2C=CC3=CC=CC=C13,,,,,,
3693,23694,"Hydrazine, (2-(diphenylmethylsulfonyl)ethyl)-",C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)(=O)CCNN,,,,,,
3694,23695,"Ethylamine, N,N-dimethyl-2-(2-(diphenylmethylsulfonyl)ethoxy)-",CN(C)CCOCCS(=O)(=O)C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
3695,23696,"Ethylamine, 2-((10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-yl)sulfonyl)-N,N-dimethyl-",CN(C)CCS(=O)(=O)C1C2=CC=CC=C2CCC3=CC=CC=C13,,,,,,
3696,23697,"ethyl 3-methyl-4-oxo-4,5,6,7-tetrahydro-1H-indole-2-carboxylate",CCOC(=O)C1=C(C2=C(N1)CCCC2=O)C,,,,,,
3697,23698,"1,2,3-Trimethyl-4-oxo-4,5,6,7-tetrahydroindole",CC1=C(N(C2=C1C(=O)CCC2)C)C,,,,,,
3698,23699,"2,2'-Bipyridine, 1,1'-dioxide",C1=CC(=C2C=CC=C[N+]2=O)N(C=C1)[O-],,,,,,
3699,23700,Uridine-diphosphate-n-acetylgalactosamine,CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@@H]1OP(=O)(O)OP(=O)(O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=CC(=O)NC3=O)O)O)CO)O)O,,,,,,
3700,23701,"3,7,11-Trimethyldodecan-3-ol",CCC(C)(CCCC(C)CCCC(C)C)O,,,,,,
3701,23702,Isoetharine mesylate,CCC(C(C1=CC(=C(C=C1)O)O)O)NC(C)C.CS(=O)(=O)O,,,"['Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS. (See all compounds classified as Adrenergic beta-2 Receptor Agonists.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)']",,,
3702,23703,"17-Oxoestra-1(10),2,4-trien-3-yl hydrogen sulfate--piperazine (1/1)",CC12CC[C@H]3C([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O.C1CNCCN1,,,,,,
3703,23704,CID 23704,CC12CC[C@H]3C(C1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O,,,,,,
3704,23705,Benzyldodecyldimethylammonium bromide,CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1.[Br-],,,"['Substances used on inanimate objects that destroy harmful microorganisms or inhibit their activity. Disinfectants are classed as complete, destroying SPORES as well as vegetative forms of microorganisms, or incomplete, destroying only vegetative forms of the organisms. They are distinguished from ANTISEPTICS, which are local anti-infective agents used on humans and other animals. (From Hawley&apos;s Condensed Chemical Dictionary, 11th ed) (See all compounds classified as Disinfectants.)', 'Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)']",,,
3705,23706,[4-Hydroxy-2-(1-octadecanoyloxy-4-oxohenicosan-2-yl)oxolan-3-yl] nonadecanoate,CCCCCCCCCCCCCCCCCCC(=O)OC1C(COC1C(CC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC)O,,,,,,
3706,23707,"methyl (1R,9R,10S,11R,12R,19R)-11-[2-(dimethylamino)acetyl]oxy-12-ethyl-4-[(13S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate;sulfuric acid",CC[C@@]1(CC2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)CN(C)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O,,,,,,
3707,23708,"methyl (1R,9R,10S,11R,12R,19R)-11-[2-(dimethylamino)acetyl]oxy-12-ethyl-4-[(13S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate",CC[C@@]1(CC2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)CN(C)C)CC)OC)C(=O)OC)O,,,,,,
3708,23709,"ZINC O,O-dihexyl dithiophosphate",CCCCCCOP(=S)(OCCCCCC)[S-].CCCCCCOP(=S)(OCCCCCC)[S-].[Zn+2],,,,,,
3709,23710,"2-Butenedioic acid (2Z)-, bis(2-methylpropyl) ester",CC(C)COC(=O)C=CC(=O)OCC(C)C,,,,,,
3710,23711,"2-Butenedioic acid (2Z)-, bis(1-methylethyl) ester",CC(C)OC(=O)C=CC(=O)OC(C)C,,,,,,
3711,23712,Sebuthylazine,CCC(C)NC1=NC(=NC(=N1)NCC)Cl,,,,,,
3712,23713,"Uracil, 5-bromo-3-tert-butyl-6-methyl-",CC1=C(C(=O)N(C(=O)N1)C(C)(C)C)Br,,,,,,
3713,23714,"Methyl 3-amino-2,5-dichlorobenzoate",COC(=O)C1=C(C(=CC(=C1)Cl)N)Cl,,,,,,
3714,23715,Monalide,CCCC(C)(C)C(=O)NC1=CC=C(C=C1)Cl,,,,,,
3715,23716,1-Methoxydecane,CCCCCCCCCCOC,,,,,,
3716,23717,Propaphos,CCCOP(=O)(OCCC)OC1=CC=C(C=C1)SC,,,,"['...Elimination of the phosphorus-containing residue may be via the urine or feces. Some bound residues remain in exposed animals. Binding seems to be to proteins, principally, and the turnover appears to be related to the half-life of these proteins. There are limited data showing that incorporation of residues into DNA occurs only in trace amounts and not by direct alkylation, such as might be believed to be associated with genetic damage. /Organophosphorus Pesticides/', 'Most organophosphorus pesticides are not ionized and are very lipophilic. Thus, inhaled or swallowed material will be easily taken up. /Organophosphorus Pesticides/', 'In rats, the /gastrointestinal/ uptake of most of the organophosphorus pesticides reviewed seems to be rapid and efficient under test conditions usually involving a dose well below the LD50. /Organophosphorus Pesticides/']","['It is well-known that active metabolites of most organophosphorus insecticides react covalently to some extent with tissue esterases other than AChE. Since few of these esterases appear vital to health, the binding reaction may be considered a detoxification process. Although the catalytic activity of these esterases is high, the actual quantity of such sites is comparatively small. ... Binding was principally in liver and muscle. The quantity bound would not be expected to be much greater whatever the LD50 of an administered organophosphorus insecticide. Thus, it is a significant proportion of the total dose only for a very toxic compound such as paraoxon but not for compounds with much higher LD50s. However, the number of binding sites may, in some cases, be very significant compared with the quantity of circulating anticholinesterase oxon that has avoided other metabolic disposal processes. Molecules of oxon bound to these non-vital sites are prevented from attacking the vital sites such as AChE or NTE. Binding sites can therefore be considered an important second line of defense against intoxication. /Organophosphorus pesticides/', 'Metabolism occurs principally by oxidation, hydrolysis by esterases, and by transfer of portions of the molecule to glutathione.  Oxidation of organophosphorus insecticides may result in more or less toxic products.  The glutathione transferase reactions produce products, that are, in most cases, of low toxicity. Hydrolytic and transferase reactions affect both thioates and their oxons. /Organophosphorus Pesticides/']",
3717,23718,"3,4,4-Trimethyl-3-pentanol",CCC(C)(C(C)(C)C)O,,,,,,
3718,23719,3-Methoxypyridine,COC1=CN=CC=C1,,,,,,
3719,23720,"2-Anilino-4-chloro-6-(4-chlorophenyl)-1,3,5-triazine",C1=CC=C(C=C1)NC2=NC(=NC(=N2)C3=CC=C(C=C3)Cl)Cl,,,,,,
3720,23721,"(3-Carbamoyl-3,3-diphenylpropyl)diethylmethylammonium iodide",CC[N+](C)(CC)CCC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N.[I-],,,,,,
3721,23722,"N,N-Diethyl-N-methyl-3-carbamoyl-3,3-diphenyl-1-propanaminium",CC[N+](C)(CC)CCC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N,,,,,,
3722,23723,Cardilate,C(C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-],,,['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],,,
3723,23724,N-(4-Ethoxyphenyl)-N-methylacetamide,CCOC1=CC=C(C=C1)N(C)C(=O)C,,,,,,
3724,23725,Psoromic acid,CC1=CC(=C(C2=C1C(=O)OC3=C(O2)C(=CC(=C3C)OC)C(=O)O)C=O)O,,,,,,
3725,23726,But-2-enoic acid butyl ester,CCCCOC(=O)C=CC,,,,,,
3726,23727,Imidoline hydrochloride,CN(C)CCN1CCN(C1=O)C2=CC(=CC=C2)Cl.Cl,,,,,,
3727,23728,Imidoline,CN(C)CCN1CCN(C1=O)C2=CC(=CC=C2)Cl,,,,,,
3728,23729,"Carbamic acid, dimethyl-, 3-nitrophenyl ester",CN(C)C(=O)OC1=CC=CC(=C1)[N+](=O)[O-],,,,,,
3729,23730,Dimethylcarbamic acid o-tolyl ester,CC1=CC=CC=C1OC(=O)N(C)C,,,,,,
3730,23731,"Phosphonic acid, ethyl-, monoethyl ester",CCOP(=O)(CC)O,,,,,,
3731,23732,"Heptane-2,4-dione",CCCC(=O)CC(=O)C,,,,,,
3732,23733,CID 23733,CCCCCCCCCCOC(=S)[S-].[K+],,,,,,
3733,23734,Decyl xanthate,CCCCCCCCCCOC(=S)S,,,,,,
3734,23735,"2,4,6-Triamino-5-(4-carbethoxyphenylazo)-6-N-(3-anilino)propylpyrimidine",CCOC(=O)C1=CC=C(C=C1)N=NC2=C(N=C(N=C2NCCCNC3=CC=CC=C3)N)N,,,,,,
3735,23736,Dimethylpropiothetin,C[S+](C)CCC(=O)[O-],,,['Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)'],,,
3736,23737,3-(Dimethyl-Lambda~4~-Sulfanyl)propanoic Acid,C[S+](C)CCC(=O)O,,,,,,
3737,23738,"1-Bicyclo[4.2.0]octa-1,3,5-trien-7-ylethanone O-butyloxime",CCCCON=C(C)C1CC2=CC=CC=C12,,,,,,
3738,23739,3-Methyl-4-phenylbutanoic acid,CC(CC1=CC=CC=C1)CC(=O)O,,,,,,
3739,23740,Potassium pyrophosphate,[O-]P(=O)([O-])OP(=O)([O-])[O-].[K+].[K+].[K+].[K+],,,,,,
3740,23741,"1,2-Epoxyhexadecane",CCCCCCCCCCCCCCC1CO1,,,,,"['1-HEXADECENE IS METABOLIZED TO 1,2-DIHYDROXYHEXADECANE VIA 1,2-EPOXYHEXADECANE BY HEPATIC MICROSOMES.']",
3741,23742,Dimethylmalononitrile,CC(C)(C#N)C#N,,,,,,
3742,23743,"2-Furanol, tetrahydro-2-methyl-",CC1(CCCO1)O,,,,,,
3743,23744,Tripropyl(tripropylsilylsulfanyl)silane,CCC[Si](CCC)(CCC)S[Si](CCC)(CCC)CCC,,,,,,
3744,23745,"N,N-Bis(2-(2,3-epoxypropoxy)ethyl)aniline",C1C(O1)COCCN(CCOCC2CO2)C3=CC=CC=C3,,,,,,
3745,23746,Inositol hexanitrate,C1(C(C(C(C(C1O[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-],,,['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],,,
3746,23747,"(2S,4R,6R,8S,11S,12R)-12-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,9,13-trimethyl-6-phenyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one",C[C@]1(O[C@@H]2C[C@H]3C4CCC5=CC(=O)C=CC5([C@]4([C@H](CC3([C@@]2(O1)C(=O)CO)C)O)F)C)C6=CC=CC=C6,,,,,,
3747,23748,CID 23748,CCCCCCCCC=CCCCCCCCC[NH3+].[F-],,,,,,
3748,23749,p-AZOBENZENEARSONATE,C1=CC(=CC=C1N=NC2=CC=C(C=C2)[As](=O)(O)O)[As](=O)(O)O,,,,,,
3749,23750,"Diazene, bis(2-chlorophenyl)-",C1=CC=C(C(=C1)N=NC2=CC=CC=C2Cl)Cl,,,,,,
3750,23751,Benzoyl diethyl phosphate,CCOP(=O)(OCC)OC(=O)C1=CC=CC=C1,,,,,,
3751,23752,"N,N,N',N'-Tetramethylsuccinamide",CN(C)C(=O)CCC(=O)N(C)C,,,,,,
3752,23753,"Dihydrazine, oxalate",C(=O)(C(=O)O)O.NN.NN,,,,,,
3753,23754,CID 23754,C1=CC(=C(C=C1C=CC2=C(C=C(C=C2)N)S(=O)(=O)[O-])S(=O)(=O)[O-])N.[Na+].[Na+],,,,,,
3754,23755,2-Amino-5-[2-(4-amino-2-sulfophenyl)ethenyl]benzenesulfonic acid,C1=CC(=C(C=C1C=CC2=C(C=C(C=C2)N)S(=O)(=O)O)S(=O)(=O)O)N,,,,,,
3755,23756,CID 23756,CC(=O)NC1CCC2=CC(=C(C(=C2C3=CCC(C(=O)C=C13)OC)OC)OC)O,,,,,,
3756,23757,2-Demethylcolchicine,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)O)OC,,,,,,
3757,23758,"Colchicine, N-methyl-",CC(=O)N(C)[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,,,,,,
3758,23759,"Methylademecolcine, N-",CN(C)[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,,,,,,
3759,23760,CID 23760,COC1=CC=C(C=C1)C=CC(=O)[O-].[Na+],,,,,,
3760,23761,CID 23761,C(#N)C(=C(S)[S-])C(=N)[O-].[Na+].[Na+],,,,,,
3761,23762,"2-Propenamide, 2-cyano-3,3-dimercapto-",C(#N)C(=C(S)S)C(=O)N,,,,,,
3762,23763,Triisobutyltin chloride,CC(C)C[Sn](CC(C)C)(CC(C)C)Cl,,,,,,
3763,23764,"Stannane, iodotripropyl-",CCC[Sn](CCC)(CCC)I,,,,,,
3764,23765,Iodotributylstannane,CCCC[Sn](CCCC)(CCCC)I,,,,,,
3765,23766,"Carbamic acid, (alpha-methylbenzylamino)-, methyl ester",CC(C1=CC=CC=C1)NNC(=O)OC,,,,,,
3766,23767,Eicosyltrimethylammonium bromide,CCCCCCCCCCCCCCCCCCCC[N+](C)(C)C.[Br-],,,,,,
3767,23768,Icosyltrimethylaminium,CCCCCCCCCCCCCCCCCCCC[N+](C)(C)C,,,,,,
3768,23769,"3,4,5,6-Tetramethylphenanthrene",CC1=C(C2=C(C=C1)C=CC3=C2C(=C(C=C3)C)C)C,,,,,,
3769,23770,"6-Benzyl-1,2,3,4,5,6-hexahydro-azepino(4,5-b)indole hydrochloride",C1CNCCC2=C1C3=CC=CC=C3[NH+]2CC4=CC=CC=C4.[Cl-],,,,,,
3770,23771,"6-Benzyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole",C1CNCCC2=C1C3=CC=CC=C3N2CC4=CC=CC=C4,,,,,,
3771,23772,"Ethylenediamine, N,N'-diethyl-N,N'-dinitroso-",CCN(CCN(CC)N=O)N=O,,,,,,
3772,23773,"N,N-Dimethyl-4-(2-methyl-4-pyridylazo)aniline N-oxide",CC1=NC=CC(=C1)N=NC2=CC=C(C=C2)[N+](C)(C)[O-],,,,,,
3773,23774,2-(2-(Dimethylamino)propoxy)benzophenone hydrochloride,CC(COC1=CC=CC=C1C(=O)C2=CC=CC=C2)[NH+](C)C.[Cl-],,,,,,
3774,23775,[2-[2-(Dimethylamino)propoxy]phenyl]-phenylmethanone,CC(COC1=CC=CC=C1C(=O)C2=CC=CC=C2)N(C)C,,,,,,
3775,23776,2-(2-(Diethylamino)propoxy)benzophenone hydrochloride hydrate,CC[NH+](CC)C(C)COC1=CC=CC=C1C(=O)C2=CC=CC=C2.[Cl-],,,,,,
3776,23777,[2-[2-(Diethylamino)propoxy]phenyl]-phenylmethanone,CCN(CC)C(C)COC1=CC=CC=C1C(=O)C2=CC=CC=C2,,,,,,
3777,23778,(1-((2-Benzoylphenoxy)methyl)ethyl)diethylmethylammonium iodide,CC[N+](C)(CC)C(C)COC1=CC=CC=C1C(=O)C2=CC=CC=C2.[I-],,,,,,
3778,23779,1-(2-Benzoylphenoxy)propan-2-yl-diethyl-methylazanium,CC[N+](C)(CC)C(C)COC1=CC=CC=C1C(=O)C2=CC=CC=C2,,,,,,
3779,23780,(1-((2-Benzylphenoxy)methyl)ethyl)diethylmethylammonium iodide,CC[N+](C)(CC)C(C)COC1=CC=CC=C1CC2=CC=CC=C2.[I-],,,,,,
3780,23781,"N,N-Diethyl N-[1-methyl-2-(2-benzylphenoxy)ethyl]methanaminium",CC[N+](C)(CC)C(C)COC1=CC=CC=C1CC2=CC=CC=C2,,,,,,
3781,23782,(1-((2-Benzylphenoxy)methyl)ethyl)tert-butyldimethylammonium iodide,CC(COC1=CC=CC=C1CC2=CC=CC=C2)[N+](C)(C)C(C)(C)C.[I-],,,,,,
3782,23783,1-(2-Benzylphenoxy)propan-2-yl-tert-butyl-dimethylazanium,CC(COC1=CC=CC=C1CC2=CC=CC=C2)[N+](C)(C)C(C)(C)C,,,,,,
3783,23784,N-((1-(2-Benzylphenoxy)methyl)ethyl)diethylamine hydrochloride,CC[NH+](CC)C(C)COC1=CC=CC=C1CC2=CC=CC=C2.[Cl-],,,,,,
3784,23785,"1-(2-benzylphenoxy)-N,N-diethylpropan-2-amine",CCN(CC)C(C)COC1=CC=CC=C1CC2=CC=CC=C2,,,,,,
3785,23786,(1-((2-Benzylphenoxy)methyl)ethyl)trimethylammonium toluenesulfonate,CC1=CC=C(C=C1)S(=O)(=O)[O-].CC(COC1=CC=CC=C1CC2=CC=CC=C2)[N+](C)(C)C,,,,,,
3786,23787,Trimethyl[1-methyl-2-(2-benzylphenoxy)ethyl]aminium,CC(COC1=CC=CC=C1CC2=CC=CC=C2)[N+](C)(C)C,,,,,,
3787,23788,2-(N-Ethyl-N-((5-methylbenzo(b)thien-3-yl)methyl)amino)ethanol hydrochloride,CC[NH+](CCO)CC1=CSC2=C1C=C(C=C2)C.[Cl-],,,,,,
3788,23789,3-[[N-Ethyl-N-(2-hydroxyethyl)amino]methyl]-5-methylbenzo[b]thiophene,CCN(CCO)CC1=CSC2=C1C=C(C=C2)C,,,,,,
3789,23790,"BENZO(b)THIOPHENE-3-METHYLAMINE, N-(2-CHLOROETHYL)-N-ETHYL-, HYDROCHLORIDE",CC[NH+](CCCl)CC1=CSC2=CC=CC=C21.[Cl-],,,,,,
3790,23791,N-(1-benzothien-3-ylmethyl)-2-chloro-N-ethylethanamine,CCN(CCCl)CC1=CSC2=CC=CC=C21,,,,,,
3791,23792,"Benzo(b)thiophene-3-methylamine, 5-bromo-N-(2-chloroethyl)-N-ethyl-, hydrochloride",CC[NH+](CCCl)CC1=CSC2=C1C=C(C=C2)Br.[Cl-],,,,,,
3792,23793,Mitotenamine,CCN(CCCl)CC1=CSC2=C1C=C(C=C2)Br,,,,,,
3793,23794,Benzo(b)thien-3-yl piperidinomethyl ketone hydrochloride,C1CC[NH+](CC1)CC(=O)C2=CSC3=CC=CC=C32.[Cl-],,,,,,
3794,23795,1-(1-Benzothiophen-3-yl)-2-piperidin-1-ylethanone,C1CCN(CC1)CC(=O)C2=CSC3=CC=CC=C32,,,,,,
3795,23796,Benzo(b)thien-3-yl pyrrolidinomethyl ketone hydrochloride,C1CC[NH+](C1)CC(=O)C2=CSC3=CC=CC=C32.[Cl-],,,,,,
3796,23797,1-(1-Benzothiophen-3-yl)-2-pyrrolidin-1-ylethanone,C1CCN(C1)CC(=O)C2=CSC3=CC=CC=C32,,,,,,
3797,23798,Benzo(b)thien-3-yl morpholinomethyl ketone hydrochloride,C1COCC[NH+]1CC(=O)C2=CSC3=CC=CC=C32.[Cl-],,,,,,
3798,23799,1-(1-Benzothiophen-3-yl)-2-morpholin-4-ylethanone,C1COCCN1CC(=O)C2=CSC3=CC=CC=C32,,,,,,
3799,23800,alpha-(Pyrrolidinomethyl)benzo(b)thiophene-3-methanol hydrochloride,C1CC[NH+](C1)CC(C2=CSC3=CC=CC=C32)O.[Cl-],,,,,,
3800,23801,1-(1-Benzothiophen-3-yl)-2-pyrrolidin-1-ylethanol,C1CCN(C1)CC(C2=CSC3=CC=CC=C32)O,,,,,,
3801,23802,alpha-(Dibenzylaminomethyl)benzo(b)thiophene-3-methanol hydrochloride,C1=CC=C(C=C1)C[NH+](CC2=CC=CC=C2)CC(C3=CSC4=CC=CC=C43)O.[Cl-],,,,,,
3802,23803,1-(1-Benzothiophen-3-yl)-2-(dibenzylamino)ethanol,C1=CC=C(C=C1)CN(CC2=CC=CC=C2)CC(C3=CSC4=CC=CC=C43)O,,,,,,
3803,23804,"beta-Chloro-N,N-dimethylbenzo(b)thiophene-3-ethylamine hydrochloride",C[NH+](C)CC(C1=CSC2=CC=CC=C21)Cl.[Cl-],,,,,,
3804,23805,"2-(1-benzothiophen-3-yl)-2-chloro-N,N-dimethylethanamine",CN(C)CC(C1=CSC2=CC=CC=C21)Cl,,,,,,
3805,23806,"2,6-Lutidine, 4-((4-(dimethylamino)phenyl)azo)-, 1-oxide",CC1=CC(=CC(=[N+]1[O-])C)N=NC2=CC=C(C=C2)N(C)C,,,,,,
3806,23807,"N-[4-[2-(5-nitrofuran-2-yl)ethenyl]-1,3-thiazol-2-yl]acetamide",CC(=O)NC1=NC(=CS1)C=CC2=CC=C(O2)[N+](=O)[O-],,,,,,
3807,23808,"DIBENZO(b,def)CHRYSENE, 7,14-DIHYDRO-",C1C2=C3C(=CC=C4C3=C(C=C2)C5=CC=CC=C5C4)C6=CC=CC=C61,,,,,,
3808,23809,"3,4-Dihydro-2-(piperidinomethyl)-1(2H)-naphthalenone hydrochloride",C1CC[NH+](CC1)CC2CCC3=CC=CC=C3C2=O.[Cl-],,,,,,
3809,23810,"3,4-Dihydro-2-(morpholinomethyl)-1(2H)-naphthalenone hydrochloride",C1CC2=CC=CC=C2C(=O)C1C[NH+]3CCOCC3.[Cl-],,,,,,
3810,23811,"1(2H)-Naphthalenone, 3,4-dihydro-2-(4-morpholinylmethyl)-",C1CC2=CC=CC=C2C(=O)C1CN3CCOCC3,,,,,,
3811,23812,2-Dimethylaminomethyltetralone,CN(C)CC1CCC2=CC=CC=C2C1=O,,,,,,
3812,23813,"3,4-Dihydro-6,7-dihydroxy-2,3-dimethylisoquinolinium chloride",CC1CC2=CC(=C(C=C2C=[N+]1C)O)O.[Cl-],,,,,,
3813,23814,"2,3-Dimethyl-3,4-dihydroisoquinolin-2-ium-6,7-diol",CC1CC2=CC(=C(C=C2C=[N+]1C)O)O,,,,,,
3814,23815,1-[(4-Isothiocyanatophenyl)sulfonyl]piperidine,C1CCN(CC1)S(=O)(=O)C2=CC=C(C=C2)N=C=S,,,,,,
3815,23816,"Isoquinoline, N-methyl-6-ethoxy-7-methoxy-1,2,3,4-tetrahydro-, hydrochloride",CCOC1=C(C=C2C[NH+](CCC2=C1)C)OC.[Cl-],,,,,,
3816,23817,"6-ethoxy-7-methoxy-2-methyl-3,4-dihydro-1H-isoquinoline",CCOC1=C(C=C2CN(CCC2=C1)C)OC,,,,,,
3817,23818,CID 23818,C(CCCN=C([NH3+])N)CCN=C([NH3+])N.[Cl-].[Cl-],,,,,,
3818,23819,"1,6-Diguanidinohexane",C(CCCN=C(N)N)CCN=C(N)N,,,,,,
3819,23820,"(17R)-17-hydroxy-13-methyl-17-prop-2-enyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one",CC12CCC3C(C1CC[C@]2(CC=C)O)CCC4=CC(=O)CCC34,,,,,,
3820,23821,"Barbituric acid, 1,3-dimethyl-5-isopropyl-",CC(C)C1C(=O)N(C(=O)N(C1=O)C)C,,,,,,
3821,23822,CID 23822,C1OC2=C(O1)C=C(C=C2)C(=O)C=CC3=C(C=C(C=C3)F)Cl,,,,,,
3822,23823,"2,3,4-Trichlorotoluene",CC1=C(C(=C(C=C1)Cl)Cl)Cl,,,,,,
3823,23824,"(17S)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one",CC#C[C@@]1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C)O,,,,,,
3824,23825,CID 23825,C[C@H](C=C)C1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C)O,,,,,,
3825,23826,"1,1-Dichloro-2-ethoxycyclopropane",CCOC1CC1(Cl)Cl,,,,,,
3826,23827,Methyl 4-ethylbenzoate,CCC1=CC=C(C=C1)C(=O)OC,,,,,,
3827,23828,"1,2,4-Dithiazol-1-ium, 3,5-diamino-, bromide",C1(=NC(=[NH2+])SS1)N.[Br-],,,,,,
3828,23829,"1,2,4-Dithiazolidine-3,5-diimine",C1(=NC(=N)SS1)N,,,,,,
3829,23830,2-[4-(2-Hydroxyethyl)piperazin-4-ium-1-yl]ethanesulfonate,C1CN(CC[NH+]1CCO)CCS(=O)(=O)[O-],,,,,,
3830,23831,4-(2-Hydroxyethyl)-1-piperazine ethanesulfonic acid,C1CN(CCN1CCO)CCS(=O)(=O)O,,,['A chemical system that functions to control the levels of specific ions in solution. When the level of hydrogen ion in solution is controlled the system is called a pH buffer. (See all compounds classified as Buffers.)'],,,
3831,23832,2-Octenoic acid ethyl ester,CCCCCC=CC(=O)OCC,,,,,,
3832,23833,Methyl dec-4-enoate,CCCCCC=CCCC(=O)OC,,,,,,
3833,23834,Ethyl dec-4-enoate,CCCCCC=CCCC(=O)OCC,,,,,,
3834,23835,(1-Benzyl-3-methyl-5-pyrazolyloxyethyl)trimethylammonium iodide,CC1=NN(C(=C1)OCC[N+](C)(C)C)CC2=CC=CC=C2.[I-],,,,,,
3835,23836,[2-[(1-Benzyl-3-methyl-1H-pyrazol-5-yl)oxy]ethyl]trimethylaminium,CC1=NN(C(=C1)OCC[N+](C)(C)C)CC2=CC=CC=C2,,,,,,
3836,23837,"Propionic acid, 3,3'-diselenodi-",C(C[Se][Se]CCC(=O)O)C(=O)O,,,,,,
3837,23838,"1,8-Dimethylphenanthrene",CC1=C2C=CC3=C(C=CC=C3C2=CC=C1)C,,,,,,
3838,23839,1-Methyldibenzothiophene,CC1=C2C3=CC=CC=C3SC2=CC=C1,,,,,,
3839,23840,2-Nitrophenyl N-methylcarbamate,CNC(=O)OC1=CC=CC=C1[N+](=O)[O-],,,,,,
3840,23841,Silvex ethanolamine salt,CC(C(=O)[O-])OC1=CC(=C(C=C1Cl)Cl)Cl.C(CO)[NH3+],,,,,,
3841,23842,CID 23842,CC(C)NC1=NC(=O)N=C(N1)NC(C)C,,,,,,
3842,23843,Deterenol,CC(C)NCC(C1=CC=C(C=C1)O)O,,,['Drugs that selectively bind to and activate alpha adrenergic receptors. (See all compounds classified as Adrenergic alpha-Agonists.)'],,,
3843,23844,4-[2-(Tert-butylamino)-1-hydroxyethyl]phenol,CC(C)(C)NCC(C1=CC=C(C=C1)O)O,,,,,,
3844,23845,"3,4-Dihydroxy-alpha-((propylamino)methyl)benzyl alcohol",CCCNCC(C1=CC(=C(C=C1)O)O)O,,,,,,
3845,23846,N-Hydroxyoctanamide,CCCCCCCC(=O)NO,,,,,,
3846,23847,2-Methyl-3-hexanone,CCCC(=O)C(C)C,,,,,,
3847,23848,CID 23848,C(CN(CC(=O)O)CC(=O)[O-])N(CC(=O)O)CC(=O)O.[Na+],,,,,,
3848,23849,CID 23849,C([C@@H](C(=O)[O-])N)SS(=O)(=O)O.[Na+],,,,,,
3849,23850,2-Amino-3-(hydroxysulfonylthio)propionic acid,C(C(C(=O)O)N)SS(=O)(=O)O,,,,,,
3850,23851,4-[1-Hydroxy-2-(hydroxymethoxy)-2-(2-methoxyphenyl)ethyl]-2-methoxyphenol,COC1=CC=CC=C1C(C(C2=CC(=C(C=C2)O)OC)O)OCO,,,,,,
3851,23852,1-Nonyn-3-OL,CCCCCCC(C#C)O,,,,,,
3852,23853,2-Propynyltrimethylammonium iodide,C[N+](C)(C)CC#C.[I-],,,,,,
3853,23854,Propargyltrimethylaminium,C[N+](C)(C)CC#C,,,,,,
3854,23855,"Ammonium, (4-(2-oxo-1-pyrrolidinyl)butyl)trimethyl-, iodide",C[N+](C)(C)CCCCN1CCCC1=O.[I-],,,,,,
3855,23856,Trimethyl-[4-(2-oxopyrrolidin-1-yl)butyl]azanium,C[N+](C)(C)CCCCN1CCCC1=O,,,,,,
3856,23857,"Ammonium, (5-(2-oxo-1-pyrrolidinyl)pentyl)trimethyl-, iodide",C[N+](C)(C)CCCCCN1CCCC1=O.[I-],,,,,,
3857,23858,Trimethyl-[5-(2-oxopyrrolidin-1-yl)pentyl]azanium,C[N+](C)(C)CCCCCN1CCCC1=O,,,,,,
3858,23859,"3,4'-Dimethylbiphenyl",CC1=CC=C(C=C1)C2=CC=CC(=C2)C,,,,,,
3859,23860,"Carbazole, 9-(2-(dimethylamino)ethyl)-",CN(C)CCN1C2=CC=CC=C2C3=CC=CC=C31,,,,,,
3860,23861,"Ethanol, 2-(N-(2-(3-indolyl)ethyl)-N-isopropylamino)-",CC(C)N(CCC1=CNC2=CC=CC=C21)CCO,,,,,,
3861,23862,"Benzo(b)thiophene-3-methylamine, 5-chloro-N-(2-chloroethyl)-N-ethyl-, hydrochloride",CC[NH+](CCCl)CC1=CSC2=C1C=C(C=C2)Cl.[Cl-],,,,,,
3862,23863,2-chloro-N-[(5-chloro-1-benzothiophen-3-yl)methyl]-N-ethylethanamine,CCN(CCCl)CC1=CSC2=C1C=C(C=C2)Cl,,,,,,
3863,23864,alpha-(Piperidinomethyl)benzo(b)thiophene-3-methanol hydrochloride,C1CC[NH+](CC1)CC(C2=CSC3=CC=CC=C32)O.[Cl-],,,,,,
3864,23865,1-(1-Benzothiophen-3-yl)-2-piperidin-1-ylethanol,C1CCN(CC1)CC(C2=CSC3=CC=CC=C32)O,,,,,,
3865,23866,"3,4-Dimethyl-1-pentene",CC(C)C(C)C=C,,,,,,
3866,23867,Benzo(b)thien-3-yl dimethylaminomethyl ketone hydrochloride,C[NH+](C)CC(=O)C1=CSC2=CC=CC=C21.[Cl-],,,,,,
3867,23868,1-(1-Benzothiophen-3-yl)-2-(dimethylamino)ethanone,CN(C)CC(=O)C1=CSC2=CC=CC=C21,,,,,,
3868,23869,alpha-(Morpholinomethyl)benzo(b)thiophene-3-methanol hydrochloride,C1COCC[NH+]1CC(C2=CSC3=CC=CC=C32)O.[Cl-],,,,,,
3869,23870,1-(1-Benzothiophen-3-yl)-2-morpholin-4-ylethanol,C1COCCN1CC(C2=CSC3=CC=CC=C32)O,,,,,,
3870,23871,"Benzene, 1,1'-(2,2-dichloroethylidene)bis(4-ethoxy-",CCOC1=CC=C(C=C1)C(C2=CC=C(C=C2)OCC)C(Cl)Cl,,,,,,
3871,23872,"1,2-Epoxyoctadecane",CCCCCCCCCCCCCCCCC1CO1,,,,,,
3872,23873,"5-Ethyl-1,3-dimethylbarbituric acid",CCC1C(=O)N(C(=O)N(C1=O)C)C,,,,,,
3873,23874,"Barbituric acid, 5-butyl-1,3-dimethyl-",CCCCC1C(=O)N(C(=O)N(C1=O)C)C,,,,,,
3874,23875,"BARBITURIC ACID, 5-sec-BUTYL-1,3-DIMETHYL-",CCC(C)C1C(=O)N(C(=O)N(C1=O)C)C,,,,,,
3875,23876,"Barbituric acid, 5-cyclohexyl-1,3-dimethyl-",CN1C(=O)C(C(=O)N(C1=O)C)C2CCCCC2,,,,,,
3876,23877,CID 23877,C1=CC(=CC=C1C(=O)C=CC2=C(C=C(C=C2)F)Cl)F,,,,,,
3877,23878,Indriline,CN(C)CCC1(C=CC2=CC=CC=C21)C3=CC=CC=C3,,,,,,
3878,23879,3-(3-Chlorophenyl)propiolic acid,C1=CC(=CC(=C1)Cl)C#CC(=O)O,,,,,,
3879,23880,"2,4,5,7-Tetramethylphenanthrene",CC1=CC(=C2C(=C1)C=CC3=CC(=CC(=C32)C)C)C,,,,,,
3880,23881,CID 23881,CCCCCCCCCOC(=O)C[S-].CCCCCCCCCOC(=O)C[S-].CCCC[Sn]CCCC,,,,,,
3881,23882,Nonyl mercaptoacetate,CCCCCCCCCOC(=O)CS,,,,,,
3882,23883,"Oxanilic acid, 3'-chloro-, isopropyl ester",CC(C)OC(=O)C(=O)NC1=CC(=CC=C1)Cl,,,,,,
3883,23884,"1,3-DIOXANE, 2-(p-CHLOROPHENYL)-5-METHYL-5-NITRO-",CC1(COC(OC1)C2=CC=C(C=C2)Cl)[N+](=O)[O-],,,,,,
3884,23885,N-Ethyl-N-(2-methoxyethyl)acetamide,CCN(CCOC)C(=O)C,,,,,,
3885,23886,"2,4-Dichlorophenoxyacetylvaline",CC(C)C(C(=O)O)NC(=O)COC1=C(C=C(C=C1)Cl)Cl,,,,,,
3886,23887,"Butanedioic acid, 2,2'-oxybis-",C(C(C(=O)O)OC(CC(=O)O)C(=O)O)C(=O)O,,,,,,
3887,23888,"1,10-Decanediamine, dihydrochloride",C(CCCCC[NH3+])CCCC[NH3+].[Cl-].[Cl-],,,,,,
3888,23889,"Ethanol, 2-(heptyloxy)-",CCCCCCCOCCO,,,,,,
3889,23890,Gloriosine,COC1=CC=C2C(=CC1=O)[C@H](CCC3=CC(=C(C(=C32)OC)OC)OC)NC=O,,,,,,
3890,23891,"3-Ethyl-1H-1,2,4-triazole",CCC1=NC=NN1,,,,,,
3891,23892,"3,3'-Diaminobenzidine tetrahydrochloride",C1=CC(=C(C=C1C2=CC(=C(C=C2)N)N)N)N.Cl.Cl.Cl.Cl,,,,,,
3892,23893,Methotrexate (disodium),CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)[O-])C(=O)[O-].[Na+].[Na+],,,,,,
3893,23894,Etidronate disodium,CC(O)(P(=O)(O)[O-])P(=O)(O)[O-].[Na+].[Na+],,,['Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)'],,,
3894,23895,Imiclopazine dihydrochloride,CN1CCN(C1=O)CCN2CCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)Cl.Cl.Cl,,,,,,
3895,23896,Imiclopazine,CN1CCN(C1=O)CCN2CCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)Cl,,,,,,
3896,23897,Molindone,CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C,['Molindone is used for the management of the manifestations of psychotic disorders.'],"['Molindone is a dihydroindolone compound which is not structurally related to the phenothiazines, the butyrophenones, or the thioxanthenes. Molindone has a pharmacological profile in laboratory animals which predominantly resembles that of major tranquilizers causing reduction of spontaneous locomotion and aggressiveness, suppression of a conditioned response and antagonism of the bizarre stereotyped behavior and hyperactivity induced by amphetamines. In addition, molindone antagonizes the depression caused by the tranquilizing agent tetrabenazine.']","['Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)']","['Rapidly absorbed from the gastrointestinal tract following oral administration.', 'Human metabolic studies show molindone to be rapidly absorbed and metabolized when given orally. There are 36 recognized metabolites with less than 2-3% unmetabolized molindone being excreted in urine and feces.', 'REACHES PEAK BLOOD LEVELS WITHIN 1 HR AFTER ORAL ADMIN.']","['Most likely hepatic. 36 metabolites have been recognized, some of which may be active.']",
3897,23898,N-Methyl-N-nitrosoacetamide,CC(=O)N(C)N=O,,,,,,
3898,23899,"disodium;(2S,6aR,6aS,8aR,10S)-10-(3-carboxylatopropanoyloxy)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylate",C[C@@]1(CCC2(CC[C@@]3(C(=CC(=O)[C@H]4C3(CC[C@@H]5C4(CC[C@@H](C5(C)C)OC(=O)CCC(=O)[O-])C)C)C2C1)C)C)C(=O)[O-].[Na+].[Na+],,,,,,
3899,23900,"(2S,6aR,6aS,8aR,10S)-10-(3-carboxypropanoyloxy)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid",C[C@@]1(CCC2(CC[C@@]3(C(=CC(=O)[C@H]4C3(CC[C@@H]5C4(CC[C@@H](C5(C)C)OC(=O)CCC(=O)O)C)C)C2C1)C)C)C(=O)O,,,,,,
3900,23901,"4,4,4a,4b,5,5-Hexachlorodecahydro-1H-cyclopenta[cd]cyclopropa[a]pentalene-2-carbaldehyde",C1C(C2CC(C3(C2C1C4C3(C4(Cl)Cl)Cl)Cl)(Cl)Cl)C=O,,,,,,
3901,23902,"1,1-Dibutylhydrazine",CCCCN(CCCC)N,,,,,,
3902,23903,"Propionaldehyde, ethylhydrazone",CCC=NNCC,,,,,,
3903,23904,Tris(3-chloro-2-hydroxypropyl)isocyanurate,C(C(CCl)O)N1C(=O)N(C(=O)N(C1=O)CC(CCl)O)CC(CCl)O,,,,,,
3904,23905,"Malononitrile, (3-pyridylmethylene)-",C1=CC(=CN=C1)C=C(C#N)C#N,,,,,,
3905,23906,2-Ethylhexyl 2-ethylhexanoate,CCCCC(CC)COC(=O)C(CC)CCCC,,,,,,
3906,23907,"Aziridine, 1,1'-hexamethylenedicarbonyldi-",C1CN1C(=O)CCCCCCC(=O)N2CC2,,,,,,
3907,23908,"s-Triazine, 2-amino-4-anilino-6-methyl-",CC1=NC(=NC(=N1)NC2=CC=CC=C2)N,,,,,,
3908,23909,4-(Dimethylamino)-2'-phenethylbutyrophenone hydrochloride,C[NH+](C)CCCC(=O)C1=CC=CC=C1CCC2=CC=CC=C2.[Cl-],,,,,,
3909,23910,4-(Dimethylamino)-1-[2-(2-phenylethyl)phenyl]butan-1-one,CN(C)CCCC(=O)C1=CC=CC=C1CCC2=CC=CC=C2,,,,,,
3910,23911,6-Aminobenzo(a)pyrene,C1=CC=C2C(=C1)C3=C4C(=C2N)C=CC5=CC=CC(=C54)C=C3,,,,,,
3911,23912,Dysprosium,[Dy],,,,,,
3912,23913,Einsteinium,[Es],,,,,,
3913,23914,Etaqualone,CCC1=CC=CC=C1N2C(=NC3=CC=CC=C3C2=O)C,,,,,,
3914,23915,Schisandrin,CC1CC2=CC(=C(C(=C2C3=C(C(=C(C=C3CC1(C)O)OC)OC)OC)OC)OC)OC,,,,,,
3915,23916,5-Decene,CCCCC=CCCCC,,,,,,
3916,23917,"Ammonium, trimethyl(3-(2-oxo-1-pyrrolidinyl)propyl)-, iodide",C[N+](C)(C)CCCN1CCCC1=O.[I-],,,,,,
3917,23918,Trimethyl-[3-(2-oxopyrrolidin-1-yl)propyl]azanium,C[N+](C)(C)CCCN1CCCC1=O,,,,,,
3918,23919,"Glycine, N-(2-(diethylamino)ethyl)-2-phenyl-, isopentyl ester, hydrochloride",CCN(CC)CC[NH2+]C(C1=CC=CC=C1)C(=O)OCCC(C)C.[Cl-],,,,,,
3919,23920,"17-Sulfanylestra-1(10),2,4-trien-3-ol",CC12CCC3C(C1CCC2S)CCC4=C3C=CC(=C4)O,,,,,,
3920,23921,Cetylpyridinium acetate,CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1.CC(=O)[O-],,,,,,
3921,23922,Hexamethylenebis((carboxymethyl)dimethylammonium) dichloride diheptyl ester,CCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCC.[Cl-].[Cl-],,,,,,
3922,23923,(2-Heptoxy-2-oxoethyl)-[6-[(2-heptoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium,CCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCC,,,,,,
3923,23924,Iridium,[Ir],,,,,,
3924,23925,Iron,[Fe],['Used in preventing and treating iron-deficiency anemia.'],"['The major activity of supplemental iron is in the prevention and treatment of iron deficiency anemia. Iron has putative immune-enhancing, anticarcinogenic and cognition-enhancing activities.']",,"['The efficiency of absorption depends on the salt form, the amount administered, the dosing regimen and the size of iron stores. Subjects with normal iron stores absorb 10% to 35% of an iron dose. Those who are iron deficient may absorb up to 95% of an iron dose.', 'The disposition of iron is regulated by a complex mechanism to maintain homeostasis, mainly involving intake, stores, and loss. Generally, about 2-15% is absorbed from the gastrointestinal tract, whereas elimination of absorbed iron,is only about 0.01%/day (percent body burden or amount absorbed). Iron absorption is influenced by quantity and bioavailability of dietary iron, amount of storage iron, and rate of erythrocyte production. The best known enhancer is vitamin C (ascorbic acid). Dietary inhibitors of nonheme iron absorption include calcium phosphate, bran, phytic acid, and polyphenols present in some plants. During periods of increased iron need (childhood, pregnancy, or blood loss), absorption of iron is greatly increased. Absorption occurs in two steps: (1) absorption of ferrous ions from the intestinal lumen into the mucosal cells and (2) transfer from the mucosal cell to plasma, where it is bound to transferrin for transfer to storage sites. Transferrin is a beta1-globulin with a molecular weight of 75,000 and is produced in the liver. As ferrous ion is released into plasma, it becomes oxidized by oxygen in the presence of ferroxidase I, which is identical to ceruloplasmin. There are 3-5 g of iron in the body. About 2/3 is bound to hemoglobin, 10% in myoglobin and iron-containing enzymes, and the remainder is bound to the iron storage proteins ferritin and hemosiderin. Exposure to iron induces synthesis of apoferritin, which then binds ferrous ions. The ferrous ion becomes oxidized probably by histidine and cysteine residues and carbonyl groups. Iron may be released from ferritin by reducing agents. Ascorbic acid, cysteine, and reduced glutathione release iron slowly. Normally, excess ingested iron is excreted, and some is contained within shed intestinal cells and in bile and urine and in even smaller amounts in sweat, nails, and hair. Total iron excretion is usually on the order of 0.5 mg/day. /ferrous ions/', 'The body store of iron is divided between essential iron-containing compounds and  excess iron, which is held in storage. ... Hemoglobin dominates the essential fraction. ... The two predominant sites of iron storage are the reticuloendothelial system and the hepatocytes, although some storage also occurs in muscle ... . Internal exchange of iron is accomplished by the plasma protein transferrin. ... About 80% of the iron in plasma goes to the erythroid marrow to be packaged into new erythrocytes; these normally circulate for about 120 days before being catabolized by the reticuloendothelium. At that time a portion of the iron is immediately returned to the plasma bound to transferrin, while another portion is incorporated into the ferritin stores of the reticuloendothelial cell and is returned to the circulation more gradually. /Iron & iron salts/', 'The most remarkable feature of iron metabolism in man is the degree to which the body store is conserved. Only 10% of the total is lost per year from normal men, that is, about 1 mg per day ... . Two thirds of this iron is excreted from the GI tract as extravasated red cells, iron in bile, and iron in exfoliated mucosal cells. The other third is accounted for by small amounts of iron in desquamated skin and in the urine. ... The biochemical nature of the absorptive process is understood only in general terms ... . After acidification and partial digestion of food in the stomach, its content of iron is presented to the intestinal mucosa as either inorganic or heme iron. These fractions are taken up by the absorptive cells of the duodenum and upper small intestine, and the iron is either transported directly into the plasma or is stored as mucosal ferritin. ... Normal absorption is about 1 mg per day in the adult male and 1.4 mg per day in the adult female. /Iron & iron salts/', 'Substantial amounts of many metals are excreted in the sweat, including ... iron. ... The potential exists, depending on sweat rates and acclimatization, for substantial losses of these metals in sweat. /Iron salts/', 'For more Absorption, Distribution and Excretion (Complete) data for IRON COMPOUNDS (23 total), please visit the HSDB record page.', '/The researchers/ goal is to develop, characterize and optimize functionalized super paramagnetic iron oxide nanoparticles (SPION) demonstrating the capacity to be internalized by human cancer cells. SPION (mean diameter 9 nm) were coated with various ratios to iron oxide of either polyvinyl alcohol (PVA), carboxylate-functionalized PVA, thiol-functionalized PVA and amino-functionalized PVA (amino-PVA). The interaction with cells and cytotoxicity of the SPION preparations were determined using human melanoma cells. From the four functionalized SPION preparations, only the amino-PVA SPION demonstrated the capacity to interact with, and were not cytotoxic to, human melanoma cells. This interaction with melanoma cells was dependent on the amino-PVA to iron oxide ratio, was an active and saturable mechanism displayed by all cells in a culture. These functionalized SPION were characterized by transmission electron microscopy and electrophoretic mobility. The physical comportment of SPION changed at specific PVAs to iron oxide ratios, and this ratio corresponded to the ratio of optimal interaction with cells. In conclusion, the successful development of functionalized SPION displaying potential cellular uptake by human cancer cells depends both on the presence of amino groups on the coating shell of the nanoparticles and of its ratio to the amount of iron oxide. /Superparamagnetic iron oxide nanoparticles/', 'Poly-L-lysine-modified iron oxide nanoparticle (IONP-PLL), which is formed by modifying poly-L-lysine to the surface of iron oxide nanoparticles, can deliver exogenous genes to cells in vitro and in vivo. However, there is relatively little information available about how is IONP-PLL uptaken by cells. In this study, /the researchers/ are focusing on the transferrin receptor (TFR) mediated and TFR-independent cellular internalization of IONP-PLL. The cells were incubated with 1 uM of IONP-PLL with or without transferrin bound. Transferrin-TFR pathway blockers, such as NH4 Cl, CH3 NH2 , or trypsin, were added to the media and their effects were observed. Atomic absorption spectrophotometer was used to quantify the cellular concentration of iron. The cellular concentrations of iron were evaluated at 37 Â°C or 4 Â°C. (1) Transferrin-IONP-PLL uptake into cells was reliant on time and temperature. (2) The addition of blockers, either NH4 CL, CH3 NH2 , or trypsin, decreased the cellular transferrin-dependent IONP-PLL uptake, but not completely blocked the entry of IONP-PLL. (3) When the cells were culture at pH 6.5, under conditions which the binding of iron and transferrin were inhibited, IONP-PLL still had the capacity to enter into cells with time and temperature-dependent manner. These results suggest that the cellular internalization of IONP-PLL, much like iron ion, were mediated by TFR-dependent endocytosis and TFR-free uptake. /Poly-L-lysine-modified iron oxide nanoparticles/', 'Nanoparticles (NPs) are being used or explored for the development of biomedical applications in diagnosis and therapy, including imaging and drug delivery. Therefore, reliable tools are needed to study the behavior of NPs in biological environment, in particular the transport of NPs across biological barriers, including the blood-brain tumor barrier (BBTB), a challenging question. Previous studies have addressed the translocation of NPs of various compositions across cell layers, mostly using only one type of cells. Using a co-culture model of the human BBTB, consisting in human cerebral endothelial cells preloaded with ultrasmall superparamagnetic iron oxide nanoparticles (USPIO NPs) and unloaded human glioblastoma cells grown on each side of newly developed ultrathin permeable silicon nitride supports as a model of the human BBTB, /the researchers/ demonstrate ... the transfer of USPIO NPs from human brain-derived endothelial cells to glioblastoma cells. The reduced thickness of the permeable mechanical support compares better than commercially available polymeric supports to the thickness of the basement membrane of the cerebral vascular system. These results ... support the possibility that USPIO NPs could be directly transferred from endothelial cells to glioblastoma cells across a BBTB. Thus, the use of such ultrathin porous supports provides a new in vitro approach to study the delivery of nanotherapeutics to brain cancers. /The/ results also suggest a novel possibility for nanoparticles to deliver therapeutics to the brain using endothelial to neural cells transfer. /Superparamagnetic iron oxide nanoparticles/', 'Superparamagnetic iron-oxide particles (SPIO) are used in different ways as contrast agents for magnetic resonance imaging (MRI): Particles with high nonspecific uptake are required for unspecific labeling of phagocytic cells whereas those that target specific molecules need to have very low unspecific cellular uptake. /The researchers/ compared iron-oxide particles with different core materials (magnetite, maghemite), different coatings (none, dextran, carboxydextran, polystyrene) and different hydrodynamic diameters (20-850 nm) for internalization kinetics, release of internalized particles, toxicity, localization of particles and ability to generate contrast in MRI. Particle uptake was investigated with U118 glioma cells and human umbilical vein endothelial cells (HUVEC), which exhibit different phagocytic properties. In both cell types, the contrast agents Resovist, B102, non-coated Fe(3)O(4) particles and microspheres were better internalized than dextran-coated Nanomag particles. SPIO uptake into the cells increased with particle/iron concentrations. Maximum intracellular accumulation of iron particles was observed between 24 hr to 36 hr of exposure. Most particles were retained in the cells for at least two weeks, were deeply internalized, and only few remained adsorbed at the cell surface. Internalized particles clustered in the cytosol of the cells. Furthermore, all particles showed a low toxicity. By MRI, monolayers consisting of 5000 Resovist-labeled cells could easily be visualized. Thus, for unspecific cell labeling, Resovist and microspheres show the highest potential, whereas Nanomag particles are promising contrast agents for target-specific labeling. /Superparamagnetic iron oxide nanoparticles/']","['Iron metabolism occurs in a virtually closed system. Most of the iron liberated by destruction of hemoglobin is conserved and reused by the body. ... /Iron preparations, oral/', 'In cells Fe 2+ ... converted to Fe 3+ in ferritin. No Fe absorption as ferritin occurs until cell is physiologically ""depleted."" Fe, however, is withdrawn from ferritin as Fe 2+ as need arises. Fe released directly into blood stream ... quickly oxidized by dissolved O2 to Fe 3+ which complexes with specific Fe-transport B1-globulin ... . /Iron ions/']",
3925,23926,Lanthanum,[La],,,,,,
3926,23927,lambda2-Plumbane,[PbH2],,,,,,
3927,23928,CID 23928,[LiH],,,,,,
3928,23929,Lutetium,[Lu],,,,,,
3929,23930,Manganese (II) ion,[Mn],,,"['A group of chemical elements that are needed in minute quantities for the proper growth, development, and physiology of an organism. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) (See all compounds classified as Trace Elements.)']","['... This study investigated the tissue distribution of manganese in iron-sufficient and iron-deficient rats after welding-fume exposure. The feeding of an iron-deficient diet for 4 wk produced a depletion of body iron, such as decreased iron levels in the serum and tissues, and upregulated the divalent metal transporter 1 expression in the rat duodenum. The iron-sufficient and iron-deficient rats were then exposed to welding fumes generated from manual metal arc stainless steel at a concentration of 63.5 +/- 2.3 mg/cu m for 2 hr per day over a 30-day period. Animals were sacrificed on days 1, 15, and 30. The level of body iron in the iron-deficient rats was restored to the control level after the welding-fume exposure. However, the tissue distributions of manganese after the welding-fume exposure showed similar patterns in both the iron-sufficient and iron-deficient groups. The concentration of manganese increased in the lungs and liver on days 15 and 30, and increased in the olfactory bulb on day 30. Slight and heterogeneous increases of manganese were observed in different brain regions. Consequently, these findings suggest that the presence of Fe in the inhaled welding fumes may not have a significant effect on the uptake of Mn into the brain. Thus, the condition of iron deficiency did not seem to have any apparent effect on the transport of Mn into the brain after the inhalation of welding fumes.', '... To investigate the movement of manganese after welding-fume exposure, six cynomolgus monkeys were acclimated and assigned to three dose groups: unexposed, low dose (31 mg/cu m total suspended particulate [TSP], 0.9 mg/cu m of Mn), and high dose (62 mg/cu m TSP, 1.95 mg/cu m of Mn) of total suspended particulate. The primates were exposed to manual metal arc stainless steel (MMA-SS) welding fumes for 2 hr per day in an inhalation chamber system equipped with an automatic fume generator. Magnetic resonance imaging (MRI) studies were conducted before the initiation of exposure and thereafter every month. The tissue Mn concentrations were then measured after a plateau was reached regarding the shortening of the MRI T1 relaxation time. A dose-dependent increase in the Mn concentration was found in the lungs, while noticeable increases in the Mn concentrations were found in certain tissues, such as the liver, kidneys, and testes. Slight increases in the Mn concentrations were found in the caudate, putamen, frontal lobe, and substantia nigra, while a dose-dependent noticeable increase was only found in the globus pallidus. Therefore, the present results indicated that a shortening of the MRI T1 relaxation time corresponded well with the Mn concentration in the globus pallidus after prolonged welding-fume exposure.']",,"['Whole body: 2-5 weeks depending on body stores; [TDR, p. 803]']"
3930,23931,Mercury,[Hg],,,,"['Several studies have correlated the number of dental amalgam fillings or amalgam surfaces with the mercury content in brain and kidney tissue from human autopsy. Subjects with no dental amalgam had a mean mercury level of 6.7 ng/g (2.4-12.2) in the occipital cortex; whereas, subjects with amalgams had a mean level of 12.3 ng/g (4.8-28.7) ... Amalgam-free subjects had a mean mercury level in kidneys of 49 ng/g (21-105), whereas subjects with amalgam fillings had a corresponding level of 433 ng/g (48-810). /Mercury alloy/']","['... ONE OF THE ... PATHWAYS, IF NOT THE ONLY PATHWAY, BY WHICH ELEMENTAL MERCURY (HG(0+)) IS ABSORBED ... /& CONVERTED IN VIVO/ IS BY ITS OXIDATION /IN ERYTHROCYTES/ TO HG(2+). ... STUDIES WITH ACATALASEMIC RED BLOOD CELLS (RBCS) /SHOW/ THAT CATALASE-HYDROGEN PEROXIDE SYSTEM PLAYS A DETERMINANT ROLE IN MERCURY UPTAKE THROUGH THIS CATALYTIC OXIDATION SYSTEM; HUMAN ACATALASEMIC RBCS HAD ONLY 1/100 TO 6/100 THE UPTAKE OF MERCURY VAPOR FOUND IN NORMAL RBCS WITH HYDROGEN PEROXIDE.', 'The oxidation of metallic mercury vapor to divalent ionic mercury ... takes place very soon after absorption, but some elemental mercury remains dissolved in the blood long enough (a few min) for it to be carried to the blood-brain barrier and the placenta ... Recent in vitro studies on the oxidation of mercury by the blood ... indicate that because of the short transit time from the lung to the brain almost all the mercury vapor (97%) arrives at the brain unoxidized. Its lipid solubility and high diffusibility allow rapid transit across these barriers. Oxidation of the mercury vapor in brain and fetal tissues converts it to the ionic form, which is much less likely to cross the blood-brain and placental barriers.']","['Metallic and inorganic in whole body: 1-2 months; blood: 2 days to 1 month; methylmercury in blood: 1 month; methylmercury in whole body: 44-79 days; [TDR, p. 813]', 'The biological half-life of mercury in fish is approx 2 to 3 yr.', 'The whole body half-time of mercury in man is approximately 50 to 70 days. A rapid component in blood has a half-time of about three days, and a slower component has a half-time of about 30 days. A rapid component in the brain has a half-time of about 21 days. There is evidence of a much slower component in brain with a half-time on the order of several years.', 'For pike, mercury (Hg) concn in muscle after 70-90 days were 1000-1500 times that in water. ... The half-life for elimination of Hg from contaminated pike placed in clean water was 65-70 days.']"
3931,23932,Molybdenum,[Mo],,,"['A group of chemical elements that are needed in minute quantities for the proper growth, development, and physiology of an organism. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) (See all compounds classified as Trace Elements.)']","['The chronic inhalation of molybdenum dusts (57 mg molybdenum/cu m during 120 days, 4 hr/day) in rats showed a high accumulation of molybdenum in lung, spleen, and heart and a decrease of DNA and RNA levels in liver, kidneys, and spleen. /Molybdenum dusts/']",,"['Plasma clearance in humans: 4-70 minutes (fast component) and 3-30 hours (slow component); [Nordberg, p. 734]']"
3932,23933,Neptunium,[Np],,,,,,['Biological half-life: 20 years (liver) and 50 years (bone); [ANL Radiological Fact Sheets]']
3933,23934,Neodymium,[Nd],,,,,,
3934,23935,Neon,[Ne],['Indicated for use as a diagnostic tracer gas in pulmonary function tests.'],"['A study demonstrated that neon beam radiotherapy improved the 5-year actuarial disease-specific survival rate and local control in patients with paranasal sinus tumours, macroscopic salivary gland tumours, bile duct carcinomas, macroscopic soft tissue and bone sarcomas, and advanced prostate carcinomas.']",,"['No pharmacokinetic data available.', 'No pharmacokinetic data available.', 'No pharmacokinetic data available.', 'No pharmacokinetic data available.']",['No pharmacokinetic data available.'],['No pharmacokinetic data available.']
3935,23936,Niobium,[Nb],,,,,,
3936,23937,Osmium,[Os],,,,,,
3937,23938,Palladium,[Pd],,,,"['Six months after a single intratracheal application of 50 mg palladium dust (mass median aerodynamic diameter [MMAD] 3.92 um) to Sprague-Dawley rats, palladium particles were found to be localized intracellularly in alveolar macrophages.', 'The absorption of palladium from the GI tract is insignificant. A single intragastrical dose of 103Pd isotope given to male Charles River CD-1 rats was rapidly excreted from their organism with feces. ...After a single acute exposure, most of the absorbed dose is excreted within 48 hr to 5 days, although in the organs where Pd is accumulated, it may remain for 30 days after termination of the exposure.', '...Colloidal palladium of known particle size (maximum diameter mostly 10-20 nm) was able to pass into the blood from the cerebrospinal subarachnoid space after its subarachnoid injection into cats.', 'No or little information is available on the mode of action of metallic palladium in its solid (alloys) or dispersed (dust particles) form in biological systems. It is assumed that, at least for processes in the oral cavity, ions can be formed from metallic palladium in dental restorations, leading to solution in the saliva and finally to distribution in the body. Fine particles of palladium may also be taken up by epithelial cells or lymphocytes and macrophages, etc., and be transported within the lymphatic system.']",,
3938,23939,Platinum,[Pt],,,,"['Platinum is rapidly distributed to most tissues of the body, with a large proportion of the dose being excreted within a few hours. This initial high plasma concentration falls quickly, and the great majority of the remaining Pt is protein bound. Platinum is mainly excreted in the urine ... .', 'Data on the gastrointestinal absorption of platinum and its cationic salts are rare. Studies on the tissue distribution of a single oral dose of cationic platinum in rats revealed practically no tissue retention or absorption and almost total excretion in the feces. Intravenous administration to rats of minute doses of nontoxic Na2PtCl4 labeled with platinum indicated higher platinum retention in the liver, kidneys, spleen, and muscle than in the bones; about 35% of the dose was excreted within 24 hr in urine and feces. The low fecal excretion suggests an enterohepatic excretion pathway. The appearance of platinum in the fetus of pregnant rats indicates that platinum can cross the placental barrier. /Platinum and its salts/']",,
3939,23940,Plutonium,[Pu],,,,"['Inhalation: Measurements in human autopsy material of plutonium-239 resulting from the atmospheric testing of nuclear weapons show that a relatively high proportion of plutonium-239 is retained in lung tissue and tracheobronchial lymph nodes, consistent with low solubility. /Plutonium-239/', 'Inhalation: Intermediate solubility has been reported for plutonium nitrate inhaled by rats and dogs and plutonium tributyl-phosphate inhaled by rats and baboons. The oxides of plutonium are the most thoroughly studied of the actinide aerosols. Generally, two phases of absorption from the respiratory tract to blood can be distinguished. A small fraction, typically less than 1%, is absorbed within about one day, and the remainder is cleared with half-times of the order of years. The solubility has been shown to be highly dependent on how the aerosol is formed. /Plutonium nitrate and plutonium tributyl-phosphate/', 'Ingestion: The absorption of plutonium in newborn hamsters and guinea-pigs has been shown to be greatest on the first day of life, with values of about 0.02-0.03, and to decrease progressively during the period of suckling to reach adult values by about the time of weaning at 21 to 22 days. /Plutonium, NOS/', 'Ingestion: The fractional absorption values after uptake of plutonium administered to animals as the nitrate, chloride or bicarbonate are in the range of 1X10-5  to 1X10-4. Fasting has been shown to increase absorption by up to an order of magnitude. ... In general, the ingested mass and valence appear to have little effect on absorption; however, when large masses of pentavalent plutonium are ingested, absorption may be increased by an order of magnitude, as demonstrated ... in baboons. The fractional absorption of plutonium administered to animals as organic complexes or incorporated into food is generally greater than that of inorganic forms. /Plutonium salts/', 'For more Absorption, Distribution and Excretion (Complete) data for PLUTONIUM, RADIOACTIVE (37 total), please visit the HSDB record page.']",,"['Absorption of elements in the human lung after inhalation: Plutonium, soluble compounds, medium, 10 min (10%), 140 days (90%); oxide, 90%); slow, 10 min (0.1%), 7,000 days (99.9%). /From table/', 'Biodistribution of elements in human adults: Plutonium, Principal deposition sites, liver, skeleton (30% entering blood); Retention half-time > or = to 20 years /From table/', 'When inhaled, plutonium is retained in the lung with an effective half-life that varies from hundreds of days for plutonium oxides to tens days for more soluble forms. A significant portion of the plutonium oxide that leaves the lung is translocated to the tracheobronchial lymph nodes. Plutonium apparently solubilized within the lung is translocated to the liver and skeleton where it is very tenaciously retained. /Plutonium oxide/', 'An example of an inhaled material with long pulmonary retention is the highly insoluble actinide oxide, 239-PuO2; studies in dogs indicate an exponential clearance of 98% of the inhaled material, with a half-time of approximately three years. In contrast, after inhalation of the more soluble compound 239-Pu(NO3)4, about 40% of the initial lung burden was lost within three months and about 80% within one year. /Plutonium compounds/']"
3940,23941,Polane,[PoH2],,,,,,
3941,23942,Praseodymium,[Pr],,,,,,
3942,23943,Mendelevium,[Md],,,,,,
3943,23944,Promethium,[Pm],,,,,,
3944,23945,Protactinium,[Pa],,,,,,['Biological half life: 50 years (skeleton); 10 days (liver); 10 days to 60 days (kidneys); [ANL Radiological Fact Sheets]']
3945,23946,CID 23946,[RaH2],,,,,,
3946,23947,Rhenium,[Re],,,,,,
3947,23948,Rhodium,[Rh],,,,,,
3948,23949,CID 23949,[RbH],,,,,,
3949,23950,Ruthenium,[Ru],,,,,,
3950,23951,Samarium,[Sm],,,,,,
3951,23952,Scandium,[Sc],,,,,,
3952,23953,Silane,[SiH4],,,,['The substance can be absorbed into the body by inhalation.'],,
3953,23954,Silver,[Ag],['Indicated for the treatment of acne for topical use or the management of dental caries for dental use.'],"['Silver exhibits a broad-spectrum antimicrobial activity. Silver ions were shown to mediate an effective antibacterial action against _Streptococcus mutans_, one of major bacteria present in the human oral cavity and one of etiological microorganism of dental caries. A study reported a dose-dependent antimicrobial activity of silver nanoparticles against MRSA and non-MRSA bacteria. Silver nanoparticles were also shown to mediate antibacterial activity against Gram-positive _S. aureus_ and Gram-negative _E. coli_ by inhibiting the growth.    In experimental dinitrochlorobenzene-induced inflammatory models in porcine or murine skin, topical application of silver nitrate and nanocrystalline silver were shown to exert anti-inflammatory effects associated with lymphocyte apoptosis, decreased expression of pro-inflammatory cytokines, and reduced gelatinase activity. In a rat model of ulcerative colitis, orally or intracolonically administered nanocrystalline silver were shown to suppress matrix metalloproteinase (MMP-9), tumour necrosis factor (TNF), and interleukin-Î² (IL-Î²) and IL-12.']",,"['Although metallic silver is inert in the presence of human tissues, silver and its compounds may dissociate upon contact with skin surface, body fluids, and secretions, allowing the silver ions to be absorbed into the blood circulation. Soluble silver salts are absorbed from the respiratory and gastrointestinal tracts. However, up to 90-99% of orally ingested silver is not absorbed and percutaneous absorption of silver ions through intact or damaged skin is also reported to be low. Absorbed silver ions are deposited into elastic and connective tissues throughout the body. Biologically active silver ions mainly binds to intracellular proteins as inert complexes, and readily binds and precipitates with inorganic cations like chloride and phosphate, which explains low absorption.', 'Silver mainly undergoes biliary elimination to be excreted as feces. Findings from a rat study demonstrates that biliary excretion accounted for between 24% and 45% of total silver administered, and animal studies indicate that fecal elimination may account for up to 99% of the ingested silver.', 'Following exposure to large amounts, excess silver is reported to accumulate in skin, liver, kidneys, spleen, corneas, gingival, mucous membranes and nails. In a study of rats with ligated bile ducts, deposition of silver was 48% in the liver and  2.5% in the gastrointestinal tract. Clinical and experimental studies suggest that silver is bound as inert precipitates in lysosomal vacuoles of the blood brain barrier and blood-CSF barrier without being absorbed into neurological tissue.', 'Excretion of silver from the body is mainly gastrointestinal. Urinary excretion (around 10 ug/day) and fecal elimination (30-80 ug/day) has been reported from two healthy subjects. ... These values might reflect a certain overestimation of true silver concn. ... Using neutron activation analysis ... 1 ug/day /was found/ in urine of normal persons.', 'The deposition fraction of 0.5 um spherical silver particles in the lung of dogs has been found to be about 17%. ... The intestinal absorption of silver by mice, rats, monkeys, and dogs has been recorded at about 10% or less following ingestion of radioactive silver.', 'Absorption upon exposure or the extent of exposure, itself, may vary considerably among normals as reflected in tissue levels. For example, the silver content of the hair of school children from 21 school districts in Selesia, Poland, ranged from 0.23 to 1.96 mg/kg (average 0.69 mg/kg; analyses by neutron activation).', 'Distribution of silver in the rat at day 6 following intramuscular injections of 1.0 mg dose of silver; 53.5 percent of the dose was absorbed (0.59 percent absorbed by the heart and lung; 2.69 percent absorbed by spleen; 3.03 percent absorbed by blood; 33.73 percent absorbed by liver; 0.63 percent absorbed by kidney; 8.21 percent absorbed by GI tract; 2.39 percent absorbed by muscle; 2.20 percent absorbed by bone; 7.39 percent absorbed by skin; 1.82 percent excreted by urine; 37.33 percent absorbed by feces) and 46.5 percent of absorbed by the heart and lung; 0.01 percent absorbed by spleen; 0.50 percent absorbed by blood; 0.36 percent absorbed by liver; 0.07 percent absorbed by kidney; 1.12 percent absorbed by GI tract; 0.27 percent absorbed by muscle; 0.18 percent absorbed by bone; 0.24 percent absorbed by skin; 0.64 percent excreted by urine; 96.56 percent excreted in feces) and 7.9 percent was unabsorbed.', 'For more Absorption, Distribution and Excretion (Complete) data for SILVER, ELEMENTAL (22 total), please visit the HSDB record page.', 'Silver, once deposited in the body, is poorly excreted in the urine in amounts detectable by spectrochemical methods. /Silver metal and soluble silver compounds/', 'IF DUST OF METAL OR ITS SALTS IS ABSORBED, IT IS PRECIPITATED IN TISSUES IN METALLIC STATE & CANNOT BE ELIMINATED FROM BODY IN THIS STATE. /SILVER & CMPD/', 'Extensive toxicokinetics of binary combinations of metals including silver are described in rats following their administration at small (0.004-0.01 LD50) and large doses (0.04-0.1 LD50). Absorption of these metals after their combined administration shows a definite pattern. Thus, in a majority of cases silver inhibited absorption. ... /Ag cation/', 'Gel filtration chromatographs of cytosols from the clam Macoma balthica analyzed from both field and lab treated specimens showed that uptake of silver in the metallothionein-like protein pool follows exposure both in nature and in the lab. ... A marked increase in silver, in a very low mol wt pool occurred when concn were highest in the metallothionein-like protein pool. ... /Silver cation/', 'For more Absorption, Distribution and Excretion (Complete) data for SILVER COMPOUNDS (26 total), please visit the HSDB record page.', '...This study tested the oral toxicity of silver nanoparticles (60 nm) over a period of 28 days in Sprague-Dawley rats following Organization for Economic Cooperation and Development (OECD) test guideline 407 with Good Laboratory Practice (GLP) application. Eight-week-old rats, weighing about 283 g for the males and 192 g for the females, were divided into four 4 groups (10 rats in each group): vehicle control, low-dose group (30 mg/kg), middle-dose group (300 mg/kg), and high-dose group (1000 mg/kg). After 28 days of exposure ... the tissue distribution of silver nanopaticles did show a dose-dependent accumulation of silver content in all the tissues examined. In particular, a gender-related difference in the accumulation of silver was noted in the kidneys, with a twofold increase in the female kidneys when compared with the male kidneys.', 'The objective of the present study was to quantify the local biodistribution of two types of silver (Ag) nanoparticles, Ag-citrate and Ag-silica, in the isolated perfused porcine skin flap (IPPSF). IPPSFs were perfused for 4 hr with 0.84 ug mL (-1) Ag-citrate or 0.48 ug mL (-1) Ag-silica followed by a 4-hr perfusion with media only during a washout phase. Arterial and venous concentrations of Ag were measured in the media by inductively coupled plasma optical emission spectrometry (ICP-OES). Venous concentrations of Ag for both types of nanoparticles were best fit with a two compartment model. The normalized volumes of distribution estimated from the noncompartmental analysis of the venous concentrations indicated distribution of Ag greater than the vascular space; however, because total Ag was measured, the extravascular distribution could be attributed to diffusion of Ag ions. The estimated clearance for both types of Ag nanoparticles was 1 mL min(-1) , which was equal to the flap perfusion rate, indicating no detectable elimination of Ag from the system. Four hours after infusion of the Ag nanoparticles, the recovery of Ag in the venous effluent was 90 +/- 5.0% and 87 +/- 22% of the infused Ag for Ag-citrate and Ag-silica, respectively.', 'Silver nanoparticles (AgNPs) were synthesized with a size distribution of 14 +/- 4 nm in diameter (90% of the nanoparticle volume) and stabilized in aqueous suspension by the polymer polyvinylpyrrolidone (PVP). The AgNPs remained stable throughout the duration of the 28-day oral toxicity study in rats. The organ distribution pattern of silver following administration of AgNPs and AgAc /silver acetate/ was similar. However the absolute silver concentrations in tissues were lower following oral exposure to AgNPs. This was in agreement with an indication of a higher fecal excretion following administration of AgNPs. Besides the intestinal system, the largest silver concentrations were detected in the liver and kidneys. Silver was also found in the lungs and brain. Autometallographic (AMG) staining revealed a similar cellular localization of silver in ileum, liver, and kidney tissue in rats exposed to AgNPs or AgAc. Using transmission electron microscopy (TEM), nanosized granules were detected in the ileum of animals exposed to AgNPs or AgAc and were mainly located in the basal lamina of the ileal epithelium and in lysosomes of macrophages within the lamina propria. Using energy dispersive x-ray spectroscopy it was shown that the granules in lysosomes consisted of silver, selenium, and sulfur for both AgNP and AgAc exposed rats. The diameter of the deposited granules was in the same size range as that of the administered AgNPs. No silver granules were detected by TEM in the liver. The results of the present study demonstrate that the organ distribution of silver was similar when AgNPs or AgAc were administered orally to rats...', 'This study aims at evaluating in vitro skin penetration of silver nanoparticles. Experiments were performed using the Franz diffusion cell method with intact and damaged human skin. Physiological solution was used as receiving phase and 70 ug/sq cm of silver nanoparticles coated with polyvinylpirrolidone dispersed in synthetic sweat were applied as donor phase to the outer surface of the skin for 24hr. The receptor fluid measurements were performed by electro thermal atomic absorption spectroscopy (ETAAS). Human skin penetration was also determined by using transmission electron microscope (TEM) to verify the location of silver nanoparticles in exposed membranes. Median silver concentrations of 0.46 ng sq cm (range <LOD-2.23) and 2.32 ng sq cm (range 0.43-11.6) were found in the receiving solutions of cells where the nanoparticles solution was applied on intact skin (eight cells) and on damaged skin (eight cells), respectively. Twenty-four hours silver flux permeation in damaged skin was 0.62+/-0.2 ng sq cm with a lag time <1hr. /The/ experimental data showed that silver nanoparticles absorption through intact and damaged skin was very low but detectable, and that in case of damaged skin it was possible an increasing permeation of silver applied as nanoparticles ... /Investigators/ demonstrated ... that silver applied as nanoparticles coated with polyvinylpirrolidone is able to permeate the damaged skin in an in vitro diffusion cell system.']","['No pharmacokinetic data on metabolic pathways.', 'Colloidal silver compounds have been widely used to treat upper respiratory infections, but the amount of silver absorbed and permanently retained by the respiratory tract has not been determined. The total safe period for nasal instillation of colloidal silver is believed to be 3 to 6 months. Colloidal silver compounds in the nose interfere with normal ciliary activity. /Colloidal silver compounds/', 'The deposition of silver in tissues is the result of the precipitation of insoluble silver salts, such as silver chloride and silver phosphate. These insoluble silver salts appear to be transformed into soluble silver sulfide albuminates, to bind to or form complexes with amino groups or carboxyl groups in RNA, DNA, and proteins, or to be reduced to metallic silver by ascorbic acid or catecholamines ... . The blue or gray discoloration of skin exposed to UV light in humans with argyria may be caused by the photoreduction of silver chloride to metallic silver. The metallic silver is then oxidized by tissue and bound as black silver sulfide ... . /Silver cmpd/', 'Colloidal silver compounds have been widely used to treat upper respiratory infections, but the amount of silver absorbed and permanently retained by the respiratory tract has not been determined. The total safe period for nasal instillation of colloidal silver is believed to be 3 to 6 months. Colloidal silver compounds in the nose interfere with normal ciliary activity.']","['The biological half-life for silver is a few days for animals and up to 50 days for human liver. In humans, the biological half-life of silver in lungs has been estimated to range from 1 to 52 days.', 'No reports found; [TDR, p. 1083]', 'The biological half-life for silver is a few days for animals and up to 50 days for human liver.', 'After rabbits had inhaled 4 um monodispersed silver coated Teflon particles, /it was/ found that an avg of 30% of the particles deposited were cleared from the lung in one day and another 30% during the rest of the first week of the exposure. After exposure by inhalation, dogs cleared 59% of an admin dose of radioactive silver from the lungs in 1.7 days. The liver had a somewhat slower clearance of 9 days. An apparent biological half-time of about 1 day was found by whole-body scintillation counting in mice, rats, monkeys, and dogs after oral ingestion. ... Somewhat longer half-times were observed for these species after iv injection of silver, with monkeys and dogs having half-times of 1.8 and 2.4 days, respectively.', 'High local concn of silver from a prosthetic cement were associated with a slowly resolving focal neuropathy. The terminal elimination half-life in this 78 year old patient was long (approx 6 months).', 'In rats, silver is eliminated from the lung in two or three phases. The fastest phase (0.3 to 1.7 days) removes most of the inhaled dose by mucociliary clearance. A second phase and third phase remove absorbed silver, mostly via the liver, with half-lives of about 8 to 15 and 40 to 50 days, respectively.', 'For more Biological Half-Life (Complete) data for SILVER, ELEMENTAL (6 total), please visit the HSDB record page.']"
3954,23955,CID 23955,[SrH2],,,,,,
3955,23956,Tantalum,[Ta],,,,"['There are no reports of accumulation of Ta in tissues or existence of any homeostatic excretory mechanism for Ta.', '... The clearance times of tantalum metal powder following its introduction into the respiratory tract /was examined/. The tantalum was inhaled or insufflated in female beagle dogs as a partly neutron-activated 182Ta powder with a specific activity of about 2 microcuries/g for inhalation studies; for insufflation, it was blended with tantalum powder with a specific activity of about 5 microcuries/g. Airborne concns approximated 1 g/cu m at an aerodynamic mass of 4 um. Exposures were usually <1 hr, and were nasal only. 182Ta retention measurements indicated a rapid, early tracheobronchial passage, later followed by a prolonged alveolar clearance phase. After inhalation there was, on avg, 7 times more tantalum in te alveolar phase, compared to the amount insufflated. This ""alveolarization"" leads to prolonged retention with a mena biologic removal half-life >2 yr. The dominant clearance minsoluble mucociliary transport, was slower than that of most other insolubel dusts and appeared independent of the presence of tantalum in the respiratory tract. Pulmonary clearance of tantalum dust following insufflation in dogs was dependent on particle size; a 1 um powder was removed form the alveolar regions with a clearance half-life of 2.1 yr and 5 or 10 um powders were removed with a half-time of 333 days. Rapid postinsufflation uptake by the pulmonary lymph nodes was observed with up to 12% of the initial alveolar burden present in the lymph nodes at 240 days and 6% present at 816 days.']",,"['This ""alveolarization"" leads to prolonged retention with a mena biologic removal half-life >2 yr. The dominant clearance minsoluble mucociliary transport, was slower than that of most other insolubel dusts and appeared independent of the presence of tantalum in the respiratory tract. Pulmonary clearance of tantalum dust following insufflation in dogs was dependent on particle size; a 1 um powder was removed form the alveolar regions with a clearance half-life of 2.1 yr and 5 or 10 um powders were removed with a half-time of 333 days.']"
3956,23957,Technetium,[Tc],,,,,,
3957,23958,Terbium,[Tb],,,,,,
3958,23959,Thalliumhydrid,[TlH],,,,,,
3959,23960,Thorium,[Th],,,,"['After inhalation exposure, the primary route of excretion is in the feces following ciliary clearance from the lungs to the gastrointestinal tract. /Thorium/']",,
3960,23961,Thulium,[Tm],,,,,,
3961,23962,Dihydridotin,[SnH2],,,,,,
3962,23963,Titanium,[Ti],,,,"['APPROX 3% OF ORAL DOSE OF TITANIUM IS ABSORBED. MAJORITY OF THAT ABSORBED IS EXCRETED IN URINE. NORMAL URINE CONCN HAS BEEN ESTIMATED @ 10 UG/L.', '... CONCN OF 430, 1300 & 91 PPM IN ASHED LUNG TISSUE HAVE BEEN REPORTED ... NEWBORNS HAVE LITTLE TITANIUM. LUNG BURDENS TEND TO INCREASE WITH AGE.', '... /INVESTIGATORS/ FOUND AMT /OF TITANIUM/ RANGING FROM 1.5-11 UG/100 G FRESH TISSUE ... IN ANIMALS & ... MAN. ... IN MAN, HIGHEST CONCN WAS PRESENT IN SPLEEN & ADRENALS (11 & 10 UG/100 G), FOLLOWED BY STRIATED MUSCLE (8.1 UG), LIVER ... (3.0 UG) & KIDNEYS ... (1.5 UG).', 'TITANIUM HAS ... BEEN FOUND IN INFANT KIDNEY & LUNG ... INDICATING A TRANSPLACENTAL TRANSFER.', 'Most ingested titanium is eliminated unabsorbed. In man, titanium is probably excreted with the urine at a rate of about 10 ug/l. However, high urinary losses of 0.41 and 0.46 mg/day (30-day mean), respectively, were reported in two adults ... . The mechanism of excretion and the possible amount of titanium excreted by the intestinal route are unknown.']",,
3963,23964,Tungsten,[W],,,,"['RATS...FED...100 DAYS ON DIETS IN WHICH TUNGSTEN...AS FINELY GROUND METAL, /OR/ TUNGSTEN OXIDE... PRINCIPLE SITES OF DEPOSITION WERE BONE & SPLEEN WITH TRACE QUANTITIES (LESS THAN 1.0 MG %...) IN KIDNEY & LIVER & IN SOME ANIMALS IN BLOOD, LUNG, MUSCLE & TESTES.', 'IN RAT FOLLOWING INGESTION OF (185)W 40% OF DOSE...EXCRETED IN URINE AFTER 24 HR & ABOUT 58%...ELIMINATED IN FECES OR HAD REMAINED UNABSORBED IN GUT WITH ONLY 2% REMAINING IN TISSUES. ... FOLLOWING INHALATION OF A (181)W-LABELLED TUNGSTIC OXIDE AEROSOL BY BEAGLE DOGS, 60% OF INHALED ACTIVITY WAS DEPOSITED IN RESP TRACT.', 'IN MAN TRACE QUANTITIES OF TUNGSTEN...EXCRETED IN URINE & ELIMINATED IN FECES. IN LIMITED STUDY ON 4 NORMAL YOUNG ADULTS WITHOUT SPECIFIC EXPOSURE ELIMINATION BY THESE 2 ROUTES OVER 24-HR PERIODS BALANCED TUNGSTEN INTAKE...WITH ONLY SMALL POSITIVE & NEGATIVE VARIATIONS.', 'URINARY EXCRETION...RANGED FROM 2.0-13.0 UG/24 HR IN 4 SUBJECTS OVER 8 EST. FECAL ELIMINATION...1.6-5.7 UG TUNGSTEN/24 HR. ...HEALTHY YOUNG MALE & FEMALE ADULTS...', 'Following ingestion, tungsten is eliminated in urine & feces. Following parenteral injection, tungsten is eliminated principally in urine, with excretion complete at 12 hr after admin. After ingestion, tungsten accumulates in rat bones & spleen, with some deposition in the kidneys & liver; traces were detected in the lung, testes, & skeletal muscle.']",,['INHALED TUNGSTIC OXIDE IN DOGS REMOVED WITH BIOL T/2 OF LITTLE LESS THAN 9 HR FOR 94% OF ACTIVITY IN VISCERAL AREA WITH LONGEST T/2 OF 139 DAYS FOR 1.6% ACTIVITY.']
3964,23965,Actinium,[Ac],,,,,,
3965,23966,Americium,[Am],,,,"['A 38-y-old Caucasian male who suffered an acute accidental inhalation intake of 6.3 kBq of americium-241 was monitored over 2,135 days using periodic in vivo measurements of the activity in the lungs, liver, and skeleton. Lung clearance was described by a two-compartment exponential model with half-times of 110 days and 10,000 days. The observed uptake of americium-241 in the liver (72 Bq) and skeleton (170 Bq) was significantly greater than predicted by the ICRP models for liver (5 Bq) and skeleton (8 Bq). The half-time in the liver was approximately 850 d. Estimates of skeletal activity based on head, wrist, and knee counts generally agreed within 25% over the course of the monitoring period. The half-time in the skeleton was approximately 20,000 d. /Americium-241/', '... An adult worker inhaled aerosols of plutonium and americium dioxides (239-PuO2 and 241-AmO2). Thoracic counts of radioactivity that were determined by an external radiation detector starting 7 days after the exposure showed that 241-Am was removed from the chest area with biological half-times of 11 (80%) and 920 (20%)days. These estimates were assumed to reflect clearance from the lung to systemic compartments. However, fecal excretion was estimated to be approximately 50% of the estimated initial deposit of americium-241 in the lung, suggesting that extensive mechanical transport to the gastrointestinal tract, typical of inhaled large particles, may have occurred. External counting also detected Americium-241 in the skull on day 913 post accident, suggesting that americium-241 was transferred to the skeleton. /Plutonium and americium dioxides/', 'Available information from human exposures indicates that airborne americium-containing particles are deposited in the respiratory tract, cleared to some extent via mucociliary action, and swallowed or expelled. /Airborne americium/', '... An adult worker inhaled mixed oxides of curium and americium dioxides (244-CmO2 and 241-AmO2) (244-Cm:241-Am airborne ratio, 3:1), which resulted in the deposition of approximately 450 nCi (16.6 kBq) of radioactivity in the lungs, or approximately 112 nCi (4.1 kBq) of 241-Am. Chest counts of the subject indicated that total radioactivity was retained in the lungs with a half-time (i.e., decay-corrected) of 28 days; however, data on the elimination of each isotope from the lung were not reported. Most of the elimination from the chest area was accounted for by recovery of radioactivity in the feces, consistent with mechanical clearance of the deposited activity to the gastrointestinal tract. Evidence for systemic absorption in this case was the detection of 241-Am in urine; approximately 1.1 nCi (41 Bq, 1% of the deposited activity) of 241-Am was excreted in urine in 365 days, with a half-time of 35 days. /Mixed oxides of curium and americium/', 'For more Absorption, Distribution and Excretion (Complete) data for AMERICIUM, RADIOACTIVE (26 total), please visit the HSDB record page.']","['The metabolism of americium involves binding interactions with proteins and probably complex formation with various inorganic anions, such as carbonate and phosphate, and carboxylic acids, such as citrate and lactate. These types of interactions would be expected for all routes of exposure.']","['A case of pure americium inhalation showed that the effective half-life in bone is more likely to be about 20 yr. /Americium, NOS/', 'An adult male accidentally inhaled americium-241(believed to be in oxide form) which resulted in an intake of approximately 6.3 kBq (170 nCi) of activity. Results of radioactivity measurements in the chest area between days 48 and 2,135 following the accident indicated that americium-241 was cleared from the lungs with half-times of 110 and 10,000 days. /Americium-241 oxide/', 'Two adults accidentally inhaled 241-AmO2 which resulted in the deposition of approximately 15 nCi (555 Bq) of activitiy in the lungs. Chest activity measured over a period of 200 to 1,500 days after the accident indicated that the retention half-time for americium-241 in the lungs was between 900 and 1400 days. /Americium-241 oxide/', 'An adult worker inhaled mixed oxides of curium and americium dioxides (244-Cm:241-Am airborne ratio, 3:1) which resulted in the deposition of approximately 450 nCi (16.6 kBq) of radioactivity in the lungs. ... Chest counts of the subject indicted that total radioactivity was retained in the lungs with a decay-corrected half-time of 28 days. /Americium and curium dioxides/', 'For more Biological Half-Life (Complete) data for AMERICIUM, RADIOACTIVE (9 total), please visit the HSDB record page.']"
3966,23967,Diantimony,[Sb]#[Sb],,,,,,
3967,23968,Argon,[Ar],,,,,,
3968,23969,Arsine,[AsH3],,,,"['... Few studies of arsine absorption, distribution, or metabolism /were available/. One human study, however, provides some information. /Investigators/ studied a worker with acute arsine intoxication. The worker excreted dark red urine the morning following exposure and was hospitalized and hemodialyzed on the 3 successive days with gradual improvement. Daily blood samples and 24-hour urine samples were begun 20 hours after exposure and were collected during the subsequent 24 days. During this period, the amount of arsenic excreted was 41 mg. The species of arsenic excreted were monomethylarsonate (MMA) (about 16 mg), dimethylarsinate (DMA) (about 13 mg), and As(III) (8 mg). A much smaller amount of arsenobetaine was also detected, but in subsequent studies, this was thought to have been derived from diet.', 'Practically all arsenic compounds which are toxic may be absorbed from ... Alimentary tract. The vapors, particularly arsine & ethyl arsine diffuse through the pulmonary sac.', '/Among 9 men exposed several months to undetermined amounts of arsine in extraction of gold/ arsine content of urine ranged from 0.3-3.3 mg/L (0.37-4.3 mg of arsenic trioxide (As2O3)). Max arsenic excretions in urine of 7/9 men ranged from 1.0-3.3 mg of As/L, with an average of 2 mg/L. Three months later 1 man ... excreting slightly above 1 mg/L; one 0.4 mg/L ...', 'Since arsenic appears to be excreted rather freely in urine, ...levels found in urine of intoxicated workers could have resulted from inhalation of concentrations below 1 mg/cu m or 0.31 ppm.', 'About 60% of arsine gas is absorbed by mice exposed to 0.025-2.5 mg/L by inhalation. In rabbits, highest concentrations were found in liver, lung and kidneys.']","['... Following inhalation of arsine and conversion to As(III), arsenic metabolism included methylation, and urinary excretion followed a triphasic model with periods of 28 hours, 59 hours, and 9 days.']",
3969,23970,CID 23970,[BaH2],,,,,,
3970,23971,Berkelium,[Bk],,,,,,
3971,23972,CID 23972,[BeH2],,,,,,
3972,23973,Cadmium,[Cd],,,,"['The relationship between tissue levels of metallothionein and metal concentrations was assessed for zinc, copper, and cadmium in ten different organs from human autopsies and rats. Human autopsy specimens were obtained from ten males between the ages of 20 and 50 years within 2 days of sudden death. Tissues assayed included pancreas, liver, kidney, brain, small intestine, stomach, muscle, heart, lung, and spleen. Human metallothionein levels were higher than rat levels for all tissues assayed except brain and small intestine. The highest metallothionein levels were found in human liver and kidney cortex and rat kidney and brain. Zinc levels were highest for human liver, kidney, and muscle; and copper levels were highest for human liver, brain, and heart and rat liver, kidney, and heart. Elevated cadmium levels were found in human liver and kidney. All cadmium levels were below detectable limits in rats. Significant correlations were established between metallothionein levels and zinc and copper in human liver and between metallothionein and cadmium in human kidney cortex.']",,"['Blood: 1-3 months; whole body: 10-100 years; [TDR, p. 233] Whole body half-life exceeds 15 years; [Zenz, p. 482] The half-life of cadmium is long (10-30 years) due to accumulation of Cd in kidneys. [ACGIH]']"
3973,23974,Cerium,[Ce],,,,,,
3974,23975,CID 23975,[CsH],,,,,,
3975,23976,Chromium,[Cr],"['Indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN), to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.']","['Trivalent chromium is part of glucose tolerance factor, an essential activator of insulin-mediated reactions. Chromium helps to maintain normal glucose metabolism and peripheral nerve function. Chromium increases insulin binding to cells, increases insulin receptor density and activates insulin receptor kinase leading to enhanced insulin sensitivity. In chromium deficiency, intravenous administration of chromium resulted in normalization of the glucose tolerance curve from the diabetic-like curve typical of chromium deficiency.']","['A group of chemical elements that are needed in minute quantities for the proper growth, development, and physiology of an organism. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) (See all compounds classified as Trace Elements.)']","['Chromium compounds are both absorbed by the lung and the gastrointestinal tract. Oral absorption of chromium compounds in humans can range between 0.5% and 10%, with the hexavalent (VI) chromium more easily absorbed than the trivalent (III) form. Absorption of chromium from the intestinal tract is low, ranging from less than 0.4% to 2.5% of the amount consumed. Vitamin C and the vitamin B niacin is reported to enhance chromium absorption.  Most hexavalent Cr (VI) undergoes partial intragastric reduction to Cr (III) upon absorption, which is an action mainly mediated by sulfhydryl groups of amino acids. Cr (VI) readily penetrates cell membranes and chromium can be found in both erythrocytes and plasma after gastrointestinal absorption of Cr (IV). In comparison, the presence of chromium is limited to the plasma as Cr (III) displays poor cell membrane penetration. Once transported through the cell membrane, Cr (VI) is rapidly reduced to Cr (III), which subsequently binds to macromolecules or conjugate with proteins. Cr (III) may be bound to transferrin or other plasma proteins, or as complexes, such as glucose tolerance factor (GTF).', 'Absorbed chromium is excreted mainly in the urine, accounting for 80% of total excretion of chromium; small amounts are lost in hair, perspiration and bile. Chromium is excreted primarily in the urine by glomerular filtration or bound to a low molecular-weight organic transporter.', 'Absorbed chromium is distributed to all tissues of the body and its distribution in the body depends on the species, age, and chemical form. Circulating Cr (III) following oral or parenteral administration of different compounds can be taken up by tissues and accumulates in the liver, kidney, spleen, soft tissue, and bone.', 'Excretion of chromium is via the kidneys ranges from 3 to 50 Î¼g/day. The 24-hour urinary excretion rates for normal human subjects are reported to be 0.22 Î¼g/day.', 'The objective of the Part II analysis was to evaluate animal and in vitro toxicology studies of CoCr particles with respect to their physicochemistry and dose relevance to metal-on-metal (MoM) implant patients as derived from Part I. In the various toxicology studies, physicochemical characteristics were infrequently considered and administered doses were orders of magnitude higher than what occurs in patients. Co was consistently shown to rapidly release from CoCr particles for distribution and elimination from the body. CoCr micron sized particles appear more biopersistent in vivo resulting in inflammatory responses that are not seen with similar mass concentrations of nanoparticles. We conclude, that in an attempt to obtain data for a complete risk assessment, future studies need to focus on physicochemical characteristics of nano and micron sized particles and on doses and dose metrics relevant to those generated in patients or in properly conducted hip simulator studies. /CoCr particles/', 'The kinetics of metal ions release from orthodontic appliances in in vitro, in in vivo on pigs, and in vivo trials on patients (where hair samples were taken) was discussed. We have evaluated (by means of ICP-OES and ISO 17025) and compared the mass of Cr and Ni ions released. Not all the metal ions released from the appliance were transferred to hair tissue. The transfer factor was expressed as coefficient omega and evaluated as: omegaCr(patients) 33.0%, omegaCr(pigs) 17.2%, omegaNi(patients) 49.8%, omegaNi(pigs) 0.553%. The kinetics was described by a power function. Coefficient omega was used to combine the models: the in vitro and in vivo on animals on the one hand and the in vitro and in vivo on human on the other, which enabled the extrapolation of in vitro and translation of the results into in vivo conditions. The dose of metal ions released during orthodontic treatment was estimated.']","['The metabolism of Cr (VI) involves reduction by small molecules and enzyme systems to generate Cr (III) and reactive intermediates. During this process, free radicals can be generated, which is thought to induce damage of cellular components and cause toxicity of chromium. The metabolites bind to cellular constituents.']","['The elimination half-life of hexavalent chromium is 15 to 41 hours.', 'Blood: 24 days; body: initial elimination 1/2 life = 2-3 days; extended 1/2 life = 1 month; [TDR, p. 368] After chronic exposure, workers can have high levels of chromium in the urine for years. [ACGIH]']"
3976,23977,CID 23977,[Co]=[Co],,,,,,
3977,23978,Copper,[Cu],['For use in the supplementation of total parenteral nutrition and in contraception with intrauterine devices.'],['Copper is incorporated into many enzymes throughout the body as an essential part of their function. Copper ions are known to reduce fertility when released from copper-containing IUDs.'],"['A group of chemical elements that are needed in minute quantities for the proper growth, development, and physiology of an organism. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) (See all compounds classified as Trace Elements.)']","['Copper absorption varies inversely with intake. Absorption range is 12-65%.', 'Copper appears to be eliminated primarily through bile.', 'Small fragments of copper ... in the anterior vitreous just behind the lens in a number of cases have been observed for years, gradually dissolving & disseminating copper to lens, cornea & iris, where copper has a predilection for the basement membranes.', 'Copper dissolved from the wire used in certain intrauterine contraceptive devices has been shown to be absorbed systemically.', '... Intrauterine devices containing metallic copper ... raise the endometrial copper concentration 2 fold, & this copper excess might be transferred to the fetus.', 'Circadian rhythms in the urinary excretion of eleven heavy metals and organic substances were examined under free, water restrictive and water loading conditions for 6 days (2 days for each of the three conditions) in twenty metal workers exposed to lead, zinc, and copper. Circadian rhythms were found for all heavy metals and organic substances as well as for urinary flow rate, creatinine and total urinary solutes. The rhythm in the copper excretion depends on the creatinine rhythm, ie the rhythm of glomerular filtration.', 'For more Absorption, Distribution and Excretion (Complete) data for COPPER, ELEMENTAL (6 total), please visit the HSDB record page.']",,"['Whole body: 4 weeks; [TDR, p. 392]']"
3978,23979,Curium,[Cm],,,,,,['Biological half-life: 20 years (liver) and 50 years (bone); [ANL Radiological Fact Sheets]']
3979,23980,Erbium,[Er],,,,,,
3980,23981,Europium,[Eu],,,['Compound such as LUMINESCENT PROTEINS that cause or emit light (PHYSICAL LUMINESCENCE). (See all compounds classified as Luminescent Agents.)'],,,
3981,23982,Gadolinium,[Gd],,,,"['... Gadolinium-153 ((153)Gd)-labeled gadopentetate (Magnevist), gadoteridol (ProHance), gadoterate (Dotarem), and gadodiamide (Omniscan) were administered iv to mice (0.48 mmol/kg) and rats (0.1 mmol/kg). At various times up to 14 days posttreatment, the residual 153Gd was measured in selected tissues. The tissue distributions obtained were used to make intra- and interchelate distribution evaluations and comparisons regarding tissue clearance and any possible in vivo dissociation of the Gd chelates. .... Differences were found among the chelates studied relative to the amounts of residual 153Gd present in tissues known to sequester free Gd, particularly in liver and femur at 7 and 14 days after administration, in both mice and rats. The pattern of the 153Gd distribution suggested that the linear chelates, gadopentetate and gadodiamide, dissociated in vivo resulting in more 153Gd present in bone and liver at the longer residence times than in the subjects injected with the macrocyclic chelates, gadoteridol and gadoterate. The only excipient found to affect the distribution profile was calcium(DTPA-BMA); this excipient in formulated gadodiamide decreased the amounts of residual Gd measured in whole body, bone, and liver in mice compared with levels obtained when gadodiamide was injected alone. ...']",,
3982,23983,Gallane,[GaH3],,,,,,
3983,23984,Germane,[GeH4],,,,,,
3984,23985,Gold,[Au],,,,"['Adult human body contains less than 10 mg Au, about 50% of which is concentration in bones.', '... The relative tissue distributions of trace elements in nonoccupationally exposed individuals following death /was assessed/ and ...for gold, there was no consistent pattern among tissues or organs. Gold was observed with the greatest frequency in the adrenal and aorta and in the highest concn in the aorta.']",,
3985,23986,Hafnium,[Hf],,,,"['Hafnium can be absorbed into the body by inhalation of its aerosol.', 'The whole body retention of 181Hf was studied in marmosets (Callithrex jacchus) and found to be closely similar to that in rats and Chinese hamsters. Limited tissue distribution studies suggest a higher uptake in liver and much lower deposition in skin and muscle in the marmoset as compared to the rat or Chinese hamster. Studies in Chinese hamsters showed that treatment with the chelating agent diethylenetriaminepentaacetic acid resulted in only a small reduction in the whole body retention of 181Hf. The absorption of orally administered 181Hf, in various chemical forms, was found to be between 0.04 and 0.13% of the ingested dose and was unaffected by age between 5 and 21 months but was increased by fasting. The measured absorption of 181Hf in Chinese hamsters and in rats was similar to that of plutonium suggesting that radiohafnium could be used as a surrogate for plutonium for selected studies in human volunteers. /Radiohafnium/']",,
3986,23987,Helium,[He],"['For use in patients who are not getting enough oxygen into their blood due to blockages in the lungs from pathological conditions or injuries. Suggested potential benefit in upper airway obstruction, in severe asthma, and in exacerbations of COPD/COLD. Helium may be used in place of carbon monoxide during laparoscopic surgeries as it lowers the risk of developing respiratory acidosis in selected patients.']","['Helium provides lung ventilation and prevents narrowing or collapse in respiratory units. It increases the tendency to laminar flow and reduces the resistance in turbulent flow, leading to more efficient penetration of gases to the distal alveoli, higher minute volumes and improved ventilation.']",,"['Respiration', 'Helium ... is quite insolubility in body tissues.']",,['0.8 seconds']
3987,23988,Holmium,[Ho],,,,,,
3988,23989,Uranium,[U],,,,"['Absorption of uranium is low by all exposure routes (inhalation, oral, and dermal).', 'Uranium workers exposed to high levels of uranium dust had a very low lung burden of uranium, indicating that only a small fraction penetrates into the alveolar region and remains there without being cleared (or being very slowly cleared) via retrograde tracheobronchial mucus transport to the gastrointestinal tract, into lymph nodes, or dissolved into the circulating blood. /Uranium dusts/', 'The distribution of uranium metal implanted in muscle has been investigated in rats. In these experiments, pellets of depleted uranium were implanted into the gastrocnemius muscle and uranium levels were measured in kidney, muscle, liver, spleen, brain, serum and bone at 1 day and at 6, 12, 18 months after implantation. Within 1 day uranium was measurable in kidney and bone but not in the other tissues. At later time points, significant amounts of uranium were found in the other tissues, although levels were always highest in the kidney and bone./Depleted uranium/', 'Based on measurements in some uranium plants, estimates have been made that only 1-5% of uranium-containing dust will penetrate to the pulmonary region. The rest will be deposited in the upper respiratory tract & will eventually be swallowed. /Uranium-containing dust/', 'For more Absorption, Distribution and Excretion (Complete) data for URANIUM, ELEMENTAL (7 total), please visit the HSDB record page.']",,"['Kidney: 1-6 days; bone: 300 days; [TDR, p. 1204]', 'Biodistribution of elements in human adults: Uranium, Retention half-time > or + 20 years /From table/']"
3989,23990,Vanadium,[V],,,"['A group of chemical elements that are needed in minute quantities for the proper growth, development, and physiology of an organism. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) (See all compounds classified as Trace Elements.)']","['Absorption of vanadium from the gastrointestinal tract is poor, not exceeding 2% in humans. ... Absorbed vanadium is widely distributed in the body. In animals, the highest values are found in the bone, kidney, liver, and spleen. Bone maintains essentially unchanged levels for several weeks. Low concentrations have been detected in the brain, and in animal placenta and testes.', 'Urine is the predominant route of excretion of absorbed vanadium. Animal and human data indicate that excretion occurs in at least two phases.', 'Absorption: Primarily though inhalation; oral and dermal absorption is poor. Distribution: Although vanadium is found throughout tissues, the majority is found in fat. Elimination: Excreted through both urine and feces. /SRP:Disolution from prostheses is a route of exposure./', 'The bioaccessibility of vanadium metal has been investigated experimentally in vitro by simulating dissolution under physiological conditions considered to mimic the most relevant exposure routes (oral, dermal, and inhalation). Dissolved V concentrations were below 2% at the loading of 0.1 g/L vanadium, corresponding to a solubility of less than 2%. ...', 'For more Absorption, Distribution and Excretion (Complete) data for VANADIUM, ELEMENTAL (9 total), please visit the HSDB record page.']",,"['12 days for rats to eliminate from the kidneys after drinking water containing VOSO4; [Nordberg, p. 911]', 'A three-compartment model for elimination is described in humans, with half-times after intravenous injection of 1.2 hr, 26 hr, and 10-12 days.', 'Vanadium is excreted in urine with a biological half-life of about 20 to 40 hours ... .']"
3990,23991,Xenon,[Xe],,,"['Gases or volatile liquids that vary in the rate at which they induce anesthesia; potency; the degree of circulation, respiratory, or neuromuscular depression they produce; and analgesic effects. Inhalation anesthetics have advantages over intravenous agents in that the depth of anesthesia can be changed rapidly by altering the inhaled concentration. Because of their rapid elimination, any postoperative respiratory depression is of relatively short duration. (From AMA Drug Evaluations Annual, 1994, p173) (See all compounds classified as Anesthetics, Inhalation.)']",,,
3991,23992,Ytterbium,[Yb],,,,,,
3992,23993,Yttrium,[Y],,,,,,
3993,23994,Zinc,[Zn],"['Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections.']","['Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations.  Studies on oral zinc for specific conditions shows the following evidence in various conditions:  **Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently.  **Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements.   **Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition.']","['A group of chemical elements that are needed in minute quantities for the proper growth, development, and physiology of an organism. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) (See all compounds classified as Trace Elements.)']","['Zinc is absorbed in the small intestine by a carrier-mediated mechanism. Under regular physiologic conditions, transport processes of uptake do not saturate. The exact amount of zinc absorbed is difficult to determine because zinc is secreted into the gut. Zinc administered in aqueous solutions to fasting subjects is absorbed quite efficiently (at a rate of 60-70%), however, absorption from solid diets is less efficient and varies greatly, dependent on zinc content and diet composition.    Generally, 33% is considered to be the average zinc absorption in humans. More recent studies have determined different absorption rates for various populations based on their type of diet and phytate to zinc molar ratio. Zinc absorption is concentration dependent and increases  linearly with  dietary zinc up to a maximum rate.  Additionally zinc status may influence zinc absorption. Zinc-deprived humans absorb this element with increased efficiency, whereas humans on a high-zinc diet show a reduced efficiency of absorption.', 'The excretion of zinc through gastrointestinal tract accounts for approximately one-half of all zinc eliminated from the body.   Considerable amounts of zinc are secreted through both biliary and intestinal secretions, however most is reabsorbed. This is an important process in the regulation of zinc balance. Other routes of zinc excretion include both urine and surface losses (sloughed skin, hair, sweat).   Zinc has been shown to induce intestinal metallothionein, which combines zinc and copper in the intestine and prevents their serosal surface transfer. Intestinal cells are sloughed with approximately a 6-day turnover, and the metallothionein-bound copper and zinc are lost in the stool and are thus not absorbed.  Measurements in humans of endogenous intestinal zinc have primarily been made as fecal excretion; this suggests that the amounts excreted are responsive to zinc intake, absorbed zinc and physiologic need.  In one study, elimination kinetics in rats showed that a small amount of ZnO nanoparticles was excreted via the urine, however, most of the nanoparticles were excreted via the feces.', 'A pharmacokinetic study was done in rats to determine the distribution and other metabolic indexes of zinc in two particle sizes.  It was found that zinc particles were mainly distributed to organs including the liver, lung, and kidney within 72 hours without any significant difference being found according to particle size or rat gender.', 'In one study of healthy patients, the clearance of zinc was found to be 0.63 Â± 0.39 Î¼g/min.', 'In mice injected SC with finely dispersed zinc (Zn) powder (particle size 0.05-0.1 mu) increased amounts of Zn were found in the liver.']","['Zinc is released from food as free ions during its digestion. These freed ions may then combine with endogenously secreted ligands before their transport into the enterocytes in the duodenum and jejunum.. Selected transport proteins may facilitate the passage of zinc across the cell membrane into the hepatic circulation. With high intake, zinc may also be absorbed through a passive paracellular route.   The portal system carries absorbed zinc directly into the hepatic circulation, and then it is released into systemic circulation for delivery to various tissues. Although, serum zinc represents only 0.1% of the whole body zinc, the circulating zinc turns over rapidly to meet tissue needs.']",['The half-life of zinc in humans is approximately 280 days.']
3994,23995,Zirconium,[Zr],,,,,,
3995,23996,Astatane,[AtH],,,,,,
3996,23997,Californium,[Cf],,,,"['The metabolism of californium was studied in 11 beagles 0-160 days after intravenous injection of californium-249 or californium-252 as Cf (III) citrate. Total excreta collections were made for the first 21 days after injection, and the samples were analyzed for their californium content by gamma-ray counting of the 333 and 388 keV gamma-rays of californium-249 or the fission gamma-rays of californium-252. It was found that the excretion of californium during this period was mainly in the urine. ... A combination of total-body and partial-body counting was used to determine serially the total-body retention and partitioning of retained californium between liver and non-liver tissue. These measurements indicated that 1 week following injection, about 20% of the injected californium was deposited in the liver and that about 60% remained in non-liver tissue (mainly skeleton). The relative bone-to-bone distribution of californium-249 in the skeletons of 2 dogs sacrificed 7 and 21 days after injection was similar to that of americium-241 and plutonium-238Pu injected as citrates. /249,252Cf(III)citrate/', 'The microscopic distribution pattern of californium-249 and berkelinium-249 in the soft tissues of beagles, one to three weeks following a single intravenous injection of a citrate solution, was found to be very similar to that of plutonium-241 > americium. Relatively high concentrations occurred in the hepatic cells of the liver, the glomeruli of the kidney, the interfollicular region of the thyroid, the cartilaginous tissues of the lung, and the media of the smaller arterioles of most organs. Very intense, but sparsely scattered ""hot spots"" were also present in the renal papillae and in the submucosa of the bronchioles. Lesser sites of localization were the endocardium of the AV heart valves, the glassy membranes of the larger hairs of the coat, the zona pellucida of the Graafian follicles and the zona arcuata of the adrenal cortex. With the exception of the liver, where the radionuclide was principally within the hepatic cells, most of the deposition sites were extracellular, within or associated with connective tissue which gave a positive periodic acid-Schiff reaction. /Californium-249 and berkelinium-249 citrates/', 'Beagles were injected with californium-249 or californium-252 in citrate buffer. The concentration of nuclide in plasma and whole blood was measured from 5 min to 48 hr post injection. Small amounts of californium were found associated with the cellular elements. The concentration of californium in plasma decreased rapidly during the first few hours after injection. At 24 hr post injection less than 1 % of the injected dose was circulating. Californium-249 and -252 disappeared from the circulation at the same rate. Separation of plasma constituents by gel filtration demonstrated that californium in plasma was associated with compounds with a molecular weight of approximately 70,000. Additional information obtained by ion exchange chromatography indicated that this protein was transferrin. Data obtained in vivo from canines were extended by in vitro experiments with human blood. Gel chromatography of human plasma protein incubated in vitro with californium indicated that a californium protein complex was formed and appeared to be nearly identical to that seen in dogs. Re-chromatography of these fractions on DEAE-Sephadex showed that transferrin and californium did not coincide exactly. Thus californium-transferrin is either held more tenaciously by the ion exchange resin than iron-transferrin or apo-transferrin, or the shift was caused by the presence of another as yet un-identified minor protein component. The stability of the protein complex(s) formed is less than that of the plutonium-transferrin complex and this decreased stability is responsible for the high rate of its disappearance from the bloodstream. /Californium-249 and californium-252 citrates/', 'Young adult beagles are given single intravenous injections of monomeric californium-252, californium-249, americium-24, plutonium-239, thorium-228, radium-226, radium-228 or strontium-90 in citrate solution to achieve reproducible deposition patterns in tissue. Injected transuranium atoms become attached to transferrin and other substances in blood plasma. The skeleton and liver are the primary sites of deposition, although high local concentrations of californium, berkelium and americium also occur in the thyroid and kidney, and radium also concentrates in the eye. The initial skeletal deposition of monomeric transuranium elements is on bone surfaces. The mean local dose-rate to the soft-tissue layer 0-10 mi from the mineralized bone surfaces of the beagle is about 20 times higher when 239-Pu is on bone surfaces than for an equal amount of 239-Pu randomly distributed throughout the bone mineral. Thus, the rate of bone-surface remodeling has a very important influence on the skeletal toxicity of the transuranium elements. The initial liver deposition of monomeric transuranium elements is rather uniform and mainly in the hepatic cells. Subsequently, much of the radioactivity shifts into the liver reticulo-endothelial cells that line the sinusoids. At long times after injection, the distribution is very non-uniform, being highest in the portal region and lowest in the regenerative nodules...  /Californium-252, californium-249, americium-24, plutonium-239, thorium-228, radium-226, radium-228 or strontium-90 citrates/', 'Radioactive atoms of radionuclides of the actinide and lanthanide series and other easily hydrolyzable metallic radionuclides ... may tend to aggregate and concentrate within lysosomes. This creates a non-uniform distribution of the radioactivity at the intracellular level, which could in principle lead to more intense radiation-induced changes in the immediate vicinity of the decaying atom. /Lanthanides and actinides/']",,"['Biological half-life: 20 years (liver) and 50 years (bone); [ANL Radiological Fact Sheets]', 'Radionuclide: Californium-252, Physical Half Life: 2.6 years, Effective Half Life: 2.2 years. /From table; Californium-252/']"
3997,23998,Fermium,[Fm],,,,,,
3998,23999,CID 23999,[FrH],,,,,,
3999,24000,Indigane,[InH3],,,,,,
4000,24001,CID 24001,CC(=NN=C(N)S)C1=CC=C(C=C1)NC(=O)C,,,,,,
4001,24002,CID 24002,C1=CC2=C(C=C1N)SC(=N2)S,,,,,,
4002,24003,CID 24003,C[PbH](C)C,,,,,,
4003,24004,trans-2-Methylcyclohexanol,C[C@@H]1CCCC[C@H]1O,,,,,,
4004,24005,"Cyclohexanol, 3-methyl-, trans-",CC1CCC[C@H](C1)O,,,,,,
4005,24006,cis-2-Methylcyclohexanol,C[C@H]1CCCC[C@H]1O,,,,,,
4006,24007,Selenium dioxide,O=[Se]=O,,,,,"['... In vitro experiments suggested that trace amounts of hydrogen selenide, which is an intermediate of selenite metabolism, probably induced hemolysis. For evaluation of the therapeutic value of hemoperfusion in selenium poisoning, in vitro hemoperfusion experiments were performed, which revealed only a moderate effect on selenium blood levels.']",
4007,24008,Lead sulfate,[O-]S(=O)(=O)[O-].[Pb+2],,,,"['... The lead content on the skin surface of 10 lead-battery workers was measured by the method of skin stripping, and urinary lead content of rats was measured with epicutaneous application of four lead compounds: lead sulfate, lead oxide, lead powder, and lead stearate. There were significant amounts of lead on the 9th and 10th skin strippings of the dorsal hand and the back of lead workers. The amount of lead on the dorsal hand was significantly correlated with the amount in the blood (n = 10, r 2 = 0.66, p < 0.05, linear regression). In rats, after lead compounds were applied for 12 days, total lead amount in urine significantly increased to 146.0 +/- 6.4 ng (SD) for lead stearate, 123.1 +/- 7.2 ng for lead sulfate, 115.9 +/- 5.3 ng for lead oxide, 47.8 +/- 6.9 ng for lead powder, and 10.3 ng for the control, which indicated significant skin absorption. It was concluded that significant amounts of inorganic lead compounds can be absorbed through the skin, and skin protection in lead-working or any contaminated environment should be carefully considered.']",,
4008,24009,Lead phosphate,[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Pb+2].[Pb+2].[Pb+2],,,,,,
4009,24010,Antimony sulfate,[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[Sb+3].[Sb+3],,,,,,
4010,24011,Selenium sulfide,S=[Se],,,['Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)'],['The percutaneous absorption of selenium sulfide was ... studied in /a/ groups who applied the drug to the entire skin for five minutes for eighteen days. Fluorimetric analysis of urinary samples collected on the third and thirteenth days of treatment revealed no significant increase in the excretion of selenium as compared to pretreatment levels. Systemic toxicity was not observed in any of the patients treated. The results suggest that the selenium sulfide is absorbed poorly from the skin...'],,
4011,24012,Aluminum Chloride,[Al](Cl)(Cl)Cl,['- Indicated for the control of minor hemorrhage during dental restorative procedures. - Indicated to reduce underarm perspiration.'],['Aluminum chloride is a hemostatic and antiperspirant agent.'],['Agents that are put on the SKIN to reduce SWEATING or prevent excess sweating (HYPERHIDROSIS). (See all compounds classified as Antiperspirants.)'],"['It is reported that about 17-30 % of aluminum chloride formed from the reaction between orally ingested aluminum hydroxide and hydrochloric acid of the stomach is absorbed. In rabbits, administration of a single maximum safe oral dose aluminum chloride (333 mg Al/kg) resulted in aluminum absorption of 0.57 %. Aluminum chloride may be absorbed via dermal route, with the uptake increasing in the microgram range but with an upper limit.', 'Absorbed aluminum chloride is rapidly excreted by the kidneys in individuals with normal renal function. Aluminum chloride may be absorbed dermally.', 'Following oral administration of 8.1 mg/kg of aluminum chloride, the steadyâstate volume of distribution of aluminum was 38.4 Â± 6.4 mL/kg.', 'Following oral administration of 8.1 mg/kg of aluminum chloride, the clearance of aluminum was 8.87 Â± 1.76 mL/(h*kg).', 'Rainbow trout (9 to 220 g) were individually placed in 1 liter chambers having aerated, fresh flowing water for 1 hr (control conditions, aluminum concentration= 0.033 mg/L, pH 4.61). They were then exposed to an aerated artificial medium (flow rate= 297 + or - 11 mL/min, pH= 5.4) containing 0.954 + or - 0.133 mg/L aluminum (as aluminum chloride) for up to 1 hr. There was no significant difference (p= 0.05) between episodic aluminum levels and episodic blank (no fish) aluminum levels, indicating that the flow rate through the chambers was sufficient to maintain aluminum levels such that absorption of aluminum from the apparatus was negligible. Fish were removed for tissue sampling after 5, 10, 20, 30, and 60 min exposure. Skin and blood showed no significant increase in aluminum content (p=0.05). Gill tissue episodic aluminum values were significantly higher (p=0.05)) than control levels at 30 and 60 min, having increased from 8 ug/g to 50 ug/g wet weight in 1 hr. Mucous aluminum content was significantly higher (p=0.05) than control values after 5 min of exposure increased to 4.5 mg/L from 0.2 mg/L. Mucous cells on the secondary lamellae showed discharged mucous globules on the gill surface after 1 hr of episodic exposure, a feature not shown by unexposed gill lamellae.', 'Aluminum hydroxide or oxide is slowly solubilized in the stomach and reacts with hydrochloric acid to form aluminum chloride and water. In addition to forming aluminum chloride, dihydroxyaluminum sodium carbonate and aluminum carbonate form carbon dioxide, and aluminum phosphate forms phosphoric acid. About 17-30% of the aluminum chloride formed is absorbed and is rapidly excreted by the kidneys in patients with normal renal functions. In the small intestine, aluminum chloride is rapidly converted to insoluble poorly absorbed basic aluminum salts which probably /include/ a mixture of hydrated aluminum oxide, oxyaluminum hydroxide, various basic aluminum carbonates, and aluminum soaps. Aluminum-containing antacids (except aluminum phosphate) also combine with dietary phosphate in the intestine forming insoluble, nonabsorbable aluminum phosphate which is excreted in the feces. If phosphate intake is limited in patients with normal renal function, aluminum antacids (except aluminum phosphate) decrease phosphate absorption and hypophosphatemia and hypophosphaturia occur; calcium absorption is increased. In vitro studies indicate that aluminum hydroxide binds bile salts with an affinity & capacity similar to that of cholestyramine; aluminum phosphate binds bile salts, but to a much lesser degree than does aluminum hydroxide. /Aluminum antacids/', 'Evidence of transdermal uptake of aluminum was reported... when /aluminum chloride/ was chronically placed on the skin of mice. Uptake increased in the microgram range and appeared to have an upper limit, failing to increase at larger doses. ...A similar finding was reported when /aluminum chloride/ was placed in the nasal passages of experimental animals; apparently aluminum wa translocated to the olfactory region of the brain. However, the chemically irritant nature of this mode of administration and the potential damage to the mucosa so treated was not factored into the evaluation of the integrity of this barrier.', 'Following a single maximum safe oral dose of the water soluble compounds aluminum chloride (333 mg Al/kg), aluminum nitrate (934 mg Al/kg), aluminum citrate (1,081 mg Al/kg), and aluminum lactate (2,942 mg Al/kg) in rabbits, aluminum absorption was 0.57, 1.16, 2.18, and 0.63%, respectively.', 'For more Absorption, Distribution and Excretion (Complete) data for ALUMINUM CHLORIDE (12 total), please visit the HSDB record page.']","['In the small intestine, aluminum chloride is rapidly converted to insoluble poorly absorbed basic aluminum salts, consisting of a mixture of hydrated aluminum oxide, oxyaluminum hydroxide, various basic aluminum carbonates, and aluminum soaps.']","['Following oral administration of 8.1 mg/kg of aluminum chloride, the half-life of aluminum was 5.29 Â± 0.47 h.']"
4012,24013,CID 24013,C=CC(=O)[O-].[Na+],,,,,,
4013,24014,Cupric chloride,Cl[Cu]Cl,['For use as a supplement to intravenous solutions given for total parenteral nutrition (TPN).'],"['Copper is an essential nutrient which serves as a co factor for serum ceruloplasmin, an oxidase necessary for proper formation of the iron carrier protein, transferrin. Copper also helps maintain normal rates of red and white blood cell formation. Providing copper during Total Parenteral Nutrition  helps prevent development of the following deficiency symptoms: Leukopenia, neutropenia, anemia, depressed ceruloplasmin levels, impaired transferrin formation, secondary iron deficiency and osteoporosis.']",,"['Mean copper absorption of 57 percent (range 40 to 70 per cent) following oral administration of 0.4 - 4.5 mg copper (as copper acetate) to four volunteers. An early human study suggested a maximum blood copper concentration was reached some two hours after oral copper chloride administration (1.5 - 12 mg copper)', 'Renal', 'Copper is distributed to all tissues with the highest concentrations  in liver, heart, brain, kidneys and muscle. Intracellular copper is  predominantly metallothionein-bound.   Reported copper in the lungs, liver, kidney, blood, bile and stomach (33.7, 35.1, 41.4, 13.8, 2.8, and 2988 Âµg/g wet weight respectively)', 'ICR male mice aged 5 weeks were injected subcutaneously with cadmium chloride, lead acetate, silver nitrate, cupric chloride, a combination of cadmium and silver compounds, or a combination of copper and silver compounds. These injections were carried out 3 times. Twenty four hours after the last injection, they were sacrificed. Cadmium injection significantly stimulated serum ceruloplasmin activity and copper concentration, accompanied by an increase in hepatic copper. Lead injection also slightly increased the serum ceruloplasmin level. In contrast, silver injection markedly decreased both serum ceruloplasmin activity and copper concentration in the serum. Hepatic copper increased slightly after silver injection. The copper injection stimulated copper binding to metallothionein and bile excretion of copper, but not serum ceruloplasmin release. With a copper and silver combination, the effect of silver on serum ceruloplasmin was lost, with a concomitant disappearance of silver from the serum ceruloplasmin fraction in the serum. In the mouse, cadmium and silver, copper antagonistic metals, influence different sites of serum ceruloplasmin metabolism. Excess hepatic copper is partly eliminated by excretion of bile and is partly detoxified by metallothionein induction.']",,
4014,24015,CID 24015,[Cl-].[K+],,,,,,
4015,24016,CID 24016,[Li+].[Cl-],,,,,,
4016,24017,4'-Methoxyacrylophenone,COC1=CC=C(C=C1)C(=O)C=C,,,,,,
4017,24018,1-(2-Methoxyphenyl)-1-propanol,CCC(C1=CC=CC=C1OC)O,,,,,,
4018,24019,"Benzoic acid, 2-((diethoxyphosphinothioyl)oxy)-, ethyl ester",CCOC(=O)C1=CC=CC=C1OP(=S)(OCC)OCC,,,,,,
4019,24020,Ethyl 2-methylbutyrate,CCC(C)C(=O)OCC,,,,,,
4020,24021,"2-Phenyl-4-(2-piperidyl)-1,3-dioxolane hydrochloride",C1CC[NH2+]C(C1)C2COC(O2)C3=CC=CC=C3.[Cl-],,,,,,
4021,24022,"2-(2-Phenyl-1,3-dioxolan-4-yl)piperidine",C1CCNC(C1)C2COC(O2)C3=CC=CC=C3,,,,,,
4022,24023,"METHANE, BIS(p-CHLOROPHENYL)-DICHLORO-",C1=CC(=CC=C1C(C2=CC=C(C=C2)Cl)(Cl)Cl)Cl,,,,,,
4023,24024,"2-(p-Chlorophenyl)-2-phenyl-4-(2-piperidyl)-1,3-dioxolane hydrochloride",C1CC[NH2+]C(C1)C2COC(O2)(C3=CC=CC=C3)C4=CC=C(C=C4)Cl.[Cl-],,,,,,
4024,24025,"2-[2-(4-Chlorophenyl)-2-phenyl-1,3-dioxolan-4-yl]piperidine",C1CCNC(C1)C2COC(O2)(C3=CC=CC=C3)C4=CC=C(C=C4)Cl,,,,,,
4025,24026,"2,2-Bis(p-chlorophenyl)-4-(2-piperidyl)-1,3-dioxolane hydrochloride",C1CC[NH2+]C(C1)C2COC(O2)(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl.[Cl-],,,,,,
4026,24027,"2-[2,2-Bis(4-chlorophenyl)-1,3-dioxolan-4-yl]piperidine",C1CCNC(C1)C2COC(O2)(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl,,,,,,
4027,24028,"alpha-2,2-Bis(p-methoxyphenyl)-4-(2-piperidyl)-1,3-dioxolane hydrochloride",COC1=CC=C(C=C1)C2(OCC(O2)C3CCCC[NH2+]3)C4=CC=C(C=C4)OC.[Cl-],,,,,,
4028,24029,"2-[2,2-Bis(4-methoxyphenyl)-1,3-dioxolan-4-yl]piperidine",COC1=CC=C(C=C1)C2(OCC(O2)C3CCCCN3)C4=CC=C(C=C4)OC,,,,,,
4029,24030,"2-Benzyl-4-(2-piperidyl)-1,3-dioxolane hydrochloride",C1CC[NH2+]C(C1)C2COC(O2)CC3=CC=CC=C3.[Cl-],,,,,,
4030,24031,"2-(2-Benzyl-1,3-dioxolan-4-yl)piperidine",C1CCNC(C1)C2COC(O2)CC3=CC=CC=C3,,,,,,
4031,24032,"beta-2,2-Dicyclohexyl-4-(2-piperidyl)-1,3-dioxolane hydrochloride",C1CCC(CC1)C2(OCC(O2)C3CCCC[NH2+]3)C4CCCCC4.[Cl-],,,,,,
4032,24033,"2-(2,2-Dicyclohexyl-1,3-dioxolan-4-yl)piperidine",C1CCC(CC1)C2(OCC(O2)C3CCCCN3)C4CCCCC4,,,,,,
4033,24034,"1-Benzazocine, 1,2,3,4,5,6-hexahydro-1-(2'-methyl-3'-(N-methylamino)propyl)-, hydrochloride",CC(C[NH2+]C)CN1CCCCCC2=CC=CC=C21.[Cl-],,,,,,
4034,24035,"1,2,3,4,5,6-Hexahydro-1-[2-methyl-3-(methylamino)propyl]-1-benzazocine",CC(CNC)CN1CCCCCC2=CC=CC=C21,,,,,,
4035,24036,"6-Phenyl-1,3,5-triazine-2,4(1H,3H)-dione",C1=CC=C(C=C1)C2=NC(=O)NC(=O)N2,,,,,,
4036,24037,Zinc di(thiobenzoate),C1=CC=C(C=C1)C(=O)[S-].C1=CC=C(C=C1)C(=O)[S-].[Zn+2],,,,,,
4037,24038,"A-Norpregn-3(5)-ene-3,20-dione",CC(=O)C1CCC2C1(CCC3C2CCC4=CC(=O)CC34C)C,,,,,,
4038,24039,"3-Pyrazolin-5-one, 3-benzyl-1-(1-methyl-4-piperidyl)-4-phenyl-",CN1CCC(CC1)N2C(=O)C(=C(N2)CC3=CC=CC=C3)C4=CC=CC=C4,,,,,,
4039,24040,Agn-PC-0jkhes,C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.C1=CC(=N)C=CC1=C(C2=CC=C(C=C2)N)C3=CC=C(C=C3)N,,,,,,
4040,24041,CID 24041,C1=CC=C(C(=C1)C(=O)[O-])O.[BiH3],,,,,,
4041,24042,"2-bromo-5,7-dimethyl-6-oxo-7H-imidazo[4,5-c]pyridin-4-olate;(1-hydroxy-2-methylpropan-2-yl)azanium",CC1C2=NC(=NC2=C(N(C1=O)C)[O-])Br.CC(C)(CO)[NH3+],,,,,,
4042,24043,"2-Bromo-5,7-dimethyl-1,7-dihydroimidazo[4,5-c]pyridine-4,6-dione",CC1C2=C(C(=O)N(C1=O)C)N=C(N2)Br,,,,,,
4043,24044,Butyl coumarin-3-carboxylate,CCCCOC(=O)C1=CC2=CC=CC=C2OC1=O,,,,,,
4044,24045,"BENZAMIDE, p-CHLORO-N-ISOPROPYL-",CC(C)NC(=O)C1=CC=C(C=C1)Cl,,,,,,
4045,24046,"HEPTANEDINITRILE, 4-(2-CYANOETHYL)-4-p-TOLUOYL-",CC1=CC=C(C=C1)C(=O)C(CCC#N)(CCC#N)CCC#N,,,,,,
4046,24047,2-(4-Nitrophenyl)butyric acid,CCC(C1=CC=C(C=C1)[N+](=O)[O-])C(=O)O,,,,,,
4047,24048,"1,5-Dimethyl-4-nitroimidazole",CC1=C(N=CN1C)[N+](=O)[O-],,,,,,
4048,24049,"Acetamide, N-ethyl-N-(2-phenoxyethyl)-",CCN(CCOC1=CC=CC=C1)C(=O)C,,,,,,
4049,24050,4-Phenylazobenzene,C1=CC=C(C=C1)C2=CC=C(C=C2)N=NC3=CC=CC=C3,,,,,,
4050,24051,2-Methoxybenzhydrazide,COC1=CC=CC=C1C(=O)NN,,,,,,
4051,24052,"1,1-Diphenyl-3-dimethylaminoprop-1-ene hydrochloride",C[NH+](C)CC=C(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
4052,24053,"N,N-dimethyl-3,3-diphenyl-allylamine",CN(C)CC=C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
4053,24054,"4-Phenyl-1,2-dihydronaphthalene",C1CC2=CC=CC=C2C(=C1)C3=CC=CC=C3,,,,,,
4054,24055,2-Methyl-1-naphthol,CC1=C(C2=CC=CC=C2C=C1)O,,,,,,
4055,24056,3-Phenanthrenecarboxylic acid,C1=CC=C2C(=C1)C=CC3=C2C=C(C=C3)C(=O)O,,,,,,
4056,24057,2-Amino-4-hydroxybenzothiazole,C1=CC(=C2C(=C1)SC(=N2)N)O,,,,,,
4057,24058,N-Butyl-2-ethylhexanamide,CCCCC(CC)C(=O)NCCCC,,,,,,
4058,24059,"4-(Dimethylamino)-2,2-diphenylbutyronitrile hydrochloride",C[NH+](C)CCC(C#N)(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
4059,24060,"4-(Dimethylamino)-2,2-diphenylbutanenitrile",CN(C)CCC(C#N)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
4060,24061,"Butyric acid, 2,3,4,6-tetrachlorophenyl ester",CCCC(=O)OC1=C(C(=C(C=C1Cl)Cl)Cl)Cl,,,,,,
4061,24062,"Acetic acid, chloro-, 2-phenylethyl ester",C1=CC=C(C=C1)CCOC(=O)CCl,,,,,,
4062,24063,"as-TRIAZINE, 5,6-DIPHENYL-3-METHOXY-",COC1=NC(=C(N=N1)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
4063,24064,"(1,1'-Biphenyl)-4,4'-diethanaminium, N,N,N,N',N',N'-hexamethyl-beta,beta'-dioxo-, dibromide",C[N+](C)(C)C(=O)CC1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)[N+](C)(C)C.[Br-].[Br-],,,,,,
4064,24065,Trimethyl-[2-[4-[4-[2-oxo-2-(trimethylazaniumyl)ethyl]phenyl]phenyl]acetyl]azanium,C[N+](C)(C)C(=O)CC1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)[N+](C)(C)C,,,,,,
4065,24066,Zalcitabine,C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N,['For the treatment of Human immunovirus (HIV) infections in conjunction with other antivirals.'],"[""Zalcitabine is an analog of 2'-deoxycytidine that is pharmacologically related to but structurally different from other nucleotide reverse transcriptase inhibitors (NRTIs). Zalcitabine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA.""]","['Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. (See all compounds classified as Anti-HIV Agents.)', 'Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Antimetabolites.)', 'Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)']","['Bioavailability is over 80% following oral administration.', 'Renal excretion of unchanged drug appears to be the primary route of elimination, accounting for approximately 80% of an intravenous dose and 60% of an orally administered dose within 24 hours after dosing (n=19). Renal clearance exceeds glomerular filtration rate suggesting renal tubular secretion contributes to the elimination of zalcitabine by the kidneys.', '0.304 to 0.734 L/kg', '285 mL/min [HIV-infected patients receiving 1.5 mg IV infusion for 1 hour]', 'Zalcitabine is eliminated principally in urine. Approximately 60-70% of an oral dose or 75-80% of an IV dose of the drug is eliminated unchanged in urine within 24 hours; approximately 10% of an orally administered dose is eliminated in feces as unchanged drug and ddU.', 'Only limited information is available on the pharmacokinetics of zalcitabine in children; however, oral bioavailability of the drug appears to be lower in children than in adults. In a study in children 6 months to 13 years of age with symptomatic HIV infection, oral bioavailability of zalcitabine averaged 54% (range: 29-100%). Following oral administration of 0.03- or 0.04-mg/kg doses of zalcitabine every 6 hours in these children, peak plasma concentrations were 23.1-52.5 or 31.5-63 ng/mL, respectively. Following IV administration over 1 hour of 0.03- or 0.04-mg/kg doses of zalcitabine every 6 hours in these children, peak plasma concentrations were 39.9-44.1 or 79.8-165.9 ng/mL, respectively.', 'Pregnant rhesus monkeys (Macaca mulatta) that were near term (146 days) received radiolabelled zalcitabine as a bolus dose of 0.6 mg/kg body weight via the radial vein. During a 3 hour sampling of both the mother and the fetus, the fetal:maternal ratio of the integrated area under the curve of plasma concentration-time was 0.32 +/- 0.02, and the fetal tissues were found to contain zalcitabine (0.05-0.8 umol/l equivalents) and zalcitabine monophosphate (0.008-0.09 nmol/g).', 'About 10% of the drug appears in the feces and approximately 75% is excreted unchanged in the urine, suggesting that renal integrity is important for clearance.', 'For more Absorption, Distribution and Excretion (Complete) data for ZALCITABINE (9 total), please visit the HSDB record page.']","['Zalcitabine is not reported to undergo significant hepatic metabolism; it is mainly phosphorylated intracellularly to zalcitabine triphosphate, the active substrate for HIV-reverse transcriptase. The concentration of zalcitabine triphosphate remains low for quantitative detection and measurement in the plasma following administration of therapeutic doses.', 'The metabolic fate of zalcitabine has not been fully evaluated in humans. Dideoxyuridine (ddU) is the principal metabolite that has been identified for zalcitabine. In both urine and feces, ddU accounts for less than 15% of an oral dose of zalcitabine. Zalcitabine is not metabolized substantially in the liver and is relatively resistant to human cytidine deaminase, a catabolic enzyme that degrades many cytidine derivatives. Because zalcitabine is relatively resistant to degradation by cytidine deaminase, the drug is stable in plasma and resistant to first-pass metabolism in the liver.', ""Hepatic metabolites have not been observed. The antiviral action of zalcitabine, like that of zidovudine and didanosine, is dependent on phosphorylation and incorporation into DNA. The first step is the formation of zalcitabine monophosphate by the enzyme 2'-deoxycytidine kinase, which is followed by formation of the diphosphate and triphosphate metabolites through the action of the cytosine monophosphate kinase and nucleotide diphosphate kinase enzymes, respectively.""]","['2 hours', 'Mean elimination half-life was 1.4 hr (range, 1.0-3.5) /in 23 mildly symptomatic human immunodeficiency virus-infected children (mean age, 4.2 years)/.', '... The plasma half-time is reported to be 1-2.7 hours.']"
4066,24067,2-(Pyridin-3-yl)quinoline-4-carboxylic acid,C1=CC=C2C(=C1)C(=CC(=N2)C3=CN=CC=C3)C(=O)O,,,,,,
4067,24068,"Acetanilide, 4'-(1-allyl-1-carbamoyl-3-butenyl)-",CC(=O)NC1=CC=C(C=C1)C(CC=C)(CC=C)C(=O)N,,,,,,
4068,24069,"BENZOIC ACID, p-(1-ALLYL-1-CARBAMOYL-3-BUTENYL)-, METHYL ESTER",COC(=O)C1=CC=C(C=C1)C(CC=C)(CC=C)C(=O)N,,,,,,
4069,24070,"BENZOIC ACID, p-(1-ALLYL-1-CARBAMOYL-3-BUTENYL)-, 2-(DIETHYLAMINO)ETHYL ESTER",CCN(CC)CCOC(=O)C1=CC=C(C=C1)C(CC=C)(CC=C)C(=O)N,,,,,,
4070,24071,"BENZOIC ACID, p-(1-ALLYL-1-CARBAMOYL-3-BUTENYL)-, HYDRAZIDE",C=CCC(CC=C)(C1=CC=C(C=C1)C(=O)NN)C(=O)N,,,,,,
4071,24072,"DIETHYLENE GLYCOL, DIESTER with BUTYLPHTHALATE",CCCCOC(=O)C1=CC=CC=C1C(=O)OCCOCCOC(=O)C2=CC=CC=C2C(=O)OCCCC,,,,,,
4072,24073,Sodium adipate,C(CCC(=O)[O-])CC(=O)[O-].[Na+].[Na+],,,,,,
4073,24074,Magnesium adipate,C(CCC(=O)[O-])CC(=O)[O-].[Mg+2],,,,,,
4074,24075,"Bis(2,3-epoxy-2-methylpropyl) ether",CC1(CO1)COCC2(CO2)C,,,,,,
4075,24076,CID 24076,CC(=O)NS(=O)(=O)C1=CC=C(C=C1)NC(=O)C2=CC=CC=C2C(=O)[O-].[Na+],,,,,,
4076,24077,Agn-PC-0469JR,CC(C(C1=CC=CC=C1)O)NC.CC1(C(CCC1(C)C(=O)O)C(=O)O)C,,,,,,
4077,24078,"1,4-Di(1-aziridinyl)-2,3-butanediol",C1CN1CC(C(CN2CC2)O)O,,,,,,
4078,24079,"Diethyl benzene-1,2-dicarboxylate; ethyl 2-hydroxyacetate",CCOC(=O)CO.CCOC(=O)C1=CC=CC=C1C(=O)OCC,,,,,,
4079,24080,"9-Fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl 3,3-dimethylbutanoate",CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)COC(=O)CC(C)(C)C)O)C)O)F)C,,,,,,
4080,24081,CID 24081,CC(CCC(=O)NCCS(=O)(=O)[O-])C1CCC2C1([C@H](CC3C2[C@@H](CC4C3(CC[C@H](C4)O)C)O)O)C.[K+],,,,,,
4081,24082,Lauric diethanolamine,CCCCCCCCCCCC(=O)O.C(CO)NCCO,,,,,,
4082,24083,Magnesium Sulfate,[O-]S(=O)(=O)[O-].[Mg+2],"['Used for immediate control of life-threatening convulsions in the treatment of severe toxemias (pre-eclampsia and eclampsia) of pregnancy and in the treatment of acute nephritis in children. Also indicated for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia. Also used in uterine tetany as a myometriat relaxant.']","['Magnesium sulfate is a small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. Magnesium sulfate is gaining popularity as an initial treatment in the management of various dysrhythmias, particularly torsades de pointes, and dyrhythmias secondary to TCA overdose or digitalis toxicity.']","['Agents capable of inducing a total or partial loss of sensation, especially tactile sensation and pain. They may act to induce general ANESTHESIA, in which an unconscious state is achieved, or may act locally to induce numbness or lack of sensation at a targeted site. (See all compounds classified as Anesthetics.)', 'Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)', 'Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)', 'Drugs that prevent preterm labor and immature birth by suppressing uterine contractions (TOCOLYSIS). Agents used to delay premature uterine activity include magnesium sulfate, beta-mimetics, oxytocin antagonists, calcium channel inhibitors, and adrenergic beta-receptor agonists. The use of intravenous alcohol as a tocolytic is now obsolete. (See all compounds classified as Tocolytic Agents.)', 'A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)', 'Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)']","['Magnesium is excreted solely by the kidney at a rate proportional to the serum concentration and glomerular filtration.', 'Magnesium sulfate is excreted by the kidneys at a rate that varies from one patient to another but that is directly proportional to the serum concn and glomerular filtration.', 'PLASMA CONCN OF MAGNESIUM INCR IN FETUS & APPROACH MATERNAL BLOOD VALUES AFTER MAGNESIUM SULFATE ADMIN IN ECLAMPSIA & PREECLAMPSIA.']",['None'],['43.2 hours (for newborns)']
4083,24084,CID 24084,C1=NC2=C(N1)C(=NC=N2)[S-].[Na+],,,,,,
4084,24085,Mercuric chloride,Cl[Hg]Cl,,,"['Substances used on inanimate objects that destroy harmful microorganisms or inhibit their activity. Disinfectants are classed as complete, destroying SPORES as well as vegetative forms of microorganisms, or incomplete, destroying only vegetative forms of the organisms. They are distinguished from ANTISEPTICS, which are local anti-infective agents used on humans and other animals. (From Hawley&apos;s Condensed Chemical Dictionary, 11th ed) (See all compounds classified as Disinfectants.)', 'Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)']","[""A COMPARATIVE STUDY OF THE LOCALIZATION OF HG FROM HGCL2 ... FOLLOWING SC ADMIN IN RABBIT SHOWED HG TO ACCUMULATE IN ... COLLECTING TUBULES, THE DISTAL PORTIONS OF PROXIMAL CONVOLUTED TUBULES & THE WIDE PARTS OF HENLE'S LOOP. NO HG ... IN GLOMERULI ..."", 'KINETIC STUDIES OF MERCURIC CHLORIDE INDICATED THAT MERCURY WAS CONTAINED IN 3 COMPARTMENTS OF SHORT, MEDIUM & LONG RETENTION TIME WITHIN RAT. KIDNEYS WERE LARGEST COMPARTMENT FOR MERCURY & KIDNEY RETENTION PROBABLY ACCOUNTED FOR LONG-TERM COMPARTMENT.', 'WHEN GOAT WAS GIVEN (203)HGCL2, LESS THAN 30% OF DOSE WAS ABSORBED. EXCRETION OF (203)HG IN MILK ACCOUNTED FOR 0.22% OF DOSE.', 'DATA ... INDICATE THAT LESS THAN 10% OF INGESTED MERCURIC CHLORIDE IS ABSORBED. UPON HIGH INTAKE CORROSIVE ACTION ... MAY ALTER PERMEABILITY OF GASTROINTESTINAL TRACT ENHANCING ABSORPTION.', 'For more Absorption, Distribution and Excretion (Complete) data for MERCURIC CHLORIDE (9 total), please visit the HSDB record page.']","['STUDIES INDICATED THAT LIVERS OF YELLOWFIN TUNA AND ALBACORE HAVE HIGH ACTIVITY IN FORMATION OF METHYLMERCURY FROM HGCL2. THIS ACTIVITY ... NOT FOUND IN THE MEAT. WHEN LIVER-HGCL2 MIXTURES WERE EXPOSED TO VISIBLE LIGHT DURING INCUBATION, FORMATION OF METHYL MERCURY WAS REDUCED BY ABOUT 75%.']",
4085,24086,"(8R,9S,13S,14S,17R)-17-ethynyl-3-methoxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol;hydrogen carbonate",C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC.C(=O)(O)[O-],,,,,,
4086,24087,Selenium disulfide,S=[Se]=S,"['For treatment of tinea versicolor, tinea capitis, dandruff and seborrheic dermatitis of the scalp.']","['Selenium sulfide is an antifungal agent often used in shampoos for the treatment of dandruff and seborrheic dermatitis. Selenium sulfide is highly active in inhibiting the growth of <i>P. ovale</i>. It is also a proven cytostatic agent, slowing the growth of both hyperproliferative and normal cells in dandruff and seborrheic dermatitis. A 0.6% micronized form of selenium sulfide is also safe and effective for dandruff.']",['Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)'],"['There is no substantial absorption through intact skin. Absorption has been reported in patients with open lesions on the scalp or in patients using a 1% cream on the back - a patient with scalp lesions that used selenium shampoos had a level of selenium sulfide as high as 32 &mu;g/ml in her urine.', 'Selenium sulfide does not appear to be absorbed percutaneously through intact skin following topical application to the scalp of a 1% lotion during usual shampooing conditions. The drug can be absorbed percutaneously when applied to damaged skin, and systemic toxicity may occur.', 'The treatment of pityriasis versicolor by the topical application of selenium sulfide 1% was studied. ... The percutaneous absorption of selenium sulfide was studied in groups who applied the drug to the entire skin for five minutes for eighteen days. Fluorimetric analysis of urinary samples collected on the third and thirteenth days of treatment revealed no significant increase in the excretion of selenium as compared in any of the patients treated.', '... Selenium is absorbed through intact skin following overnight topical application of 2.5% selenium sulfide lotion. Selenium is then excreted, at least partially, in urine, for at least a week following treatment. Absorption and excretion of selenium vary on an individual basis. Selenium levels in urine following a single application of selenium sulfide lotion do not indicate that toxic amounts of selenium are being absorbed. Repeated treatments with selenium sulfide result in selenium concentrations in urine which are significantly higher than normal. ...']",,
4087,24088,2-(1-Hydroxy-1-phenylbutoxy)ethyl-di(propan-2-yl)azanium;chloride,CCCC(C1=CC=CC=C1)(O)OCC[NH+](C(C)C)C(C)C.[Cl-],,,,,,
4088,24089,1-{2-[Di(propan-2-yl)amino]ethoxy}-1-phenylbutan-1-ol,CCCC(C1=CC=CC=C1)(O)OCCN(C(C)C)C(C)C,,,,,,
4089,24090,"1,3,3-Trimethyl-2-[3,7,12,16-tetramethyl-18-(2,6,6-trimethylcyclohex-2-en-1-yl)octadeca-1,3,5,7,9,11,13,15,17-nonaenyl]cyclohexene",CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2C(=CCCC2(C)C)C)C)C,,,,,,
4090,24091,Stearamidoethyl diethylamine,CCCCCCCCCCCCCCCCCC(=O)NCCN(CC)CC,,,,,,
4091,24092,"1-Pentyn-3-ol, 1-chloro-3-ethyl-",CCC(CC)(C#CCl)O,,,,,,
4092,24093,2-Aminoacetic acid hydroiodide,C(C(=O)O)N.I,,,,,,
4093,24094,CID 24094,CN1CC[C@]23[C@@H]4C(=O)CCC2[C@@H]1CC5C3C(O4)C(CC5)OC.C1=CC(=CC=C1C(=O)O)C(=O)O,,,,,,
4094,24095,CID 24095,CN1CC[C@]23[C@@H]4C(=O)CCC2C1CC5C3C(O4)C(CC5)OC,,,,,,
4095,24096,Diisopropyl sebacate,CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C,,,,,,
4096,24097,CID 24097,CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)[O-].[K+],,,,,,
4097,24098,Diphenhydramine salicylate,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2.C1=CC=C(C(=C1)C(=O)O)O,,,,,,
4098,24099,Dodecylamine salicylate,CCCCCCCCCCCCN.C1=CC=C(C(=C1)C(=O)O)O,,,,,,
4099,24100,Fluminorex,C1C(OC(=N1)N)C2=CC=C(C=C2)C(F)(F)F,,,,,,
4100,24101,Gentisic acid ethanolamine,C1=CC(=C(C=C1O)C(=O)O)O.C(CO)N,,,,,,
4101,24102,CID 24102,C1=CC=C(C(=C1)C(=O)[O-])O.O.[AlH+2],,,,,,
4102,24103,2-Pyridin-2-yl-quinoline-4-carboxylic acid,C1=CC=C2C(=C1)C(=CC(=N2)C3=CC=CC=N3)C(=O)O,,,,,,
4103,24104,(alpha-Hydroxybenzyl)phosphinic acid sodium salt,C1=CC=C(C=C1)C(O)P(=O)[O-].[Na+],,,,,,
4104,24105,CID 24105,C1=CC=C(C=C1)C(O)P(=O)O,,,,,,
4105,24106,Isobornyl thiocyanate,CC1(C2CCC1(C(C2)SC#N)C)C,,,,,,
4106,24107,Clazolam,CN1C(=O)CN2CCC3=CC=CC=C3C2C4=C1C=CC(=C4)Cl,,,,,,
4107,24108,CID 24108,CCCCCCC(CC=CCCCCCCCC(=O)[O-])O.[K+],,,,,,
4108,24109,"N,6-dimethylhept-5-en-2-amine;2,3,4,5-tetrahydroxyhexanedioic acid",CC(CCC=C(C)C)NC.C(C(C(C(=O)O)O)O)(C(C(=O)O)O)O,,,,,,
4109,24110,"(4-Amino-4-oxo-3,3-diphenylbutyl)-methyl-di(propan-2-yl)azanium;hydroxide;iodide",CC(C)[N+](C)(CCC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N)C(C)C.[OH-].[I-],,,,,,
4110,24111,2-(Phenylmethylene)hexanal,CCCCC(=CC1=CC=CC=C1)C=O,,,,,,
4111,24112,"2,4-Hexadienoic acid, calcium salt, (2E,4E)-",CC=CC=CC(=O)[O-].CC=CC=CC(=O)[O-].[Ca+2],,,,,,
4112,24113,"1,1-Diethoxy-3,7-dimethyl-2,6-octadiene",CCOC(C=C(C)CCC=C(C)C)OCC,,,,,,
4113,24114,Butyl butyryllactate,CCCCOC(=O)C(C)OC(=O)CCC,,,,,,
4114,24115,Acetyl isobutyryl,CC(C)C(=O)C(=O)C,,,,,,
4115,24116,Allyl anthranilate,C=CCOC(=O)C1=CC=CC=C1N,,,,,,
4116,24117,Allyl phenoxyacetate,C=CCOC(=O)COC1=CC=CC=C1,,,,,,
4117,24118,1-Phenyloct-1-en-3-yl acetate,CCCCCC(C=CC1=CC=CC=C1)OC(=O)C,,,,,,
4118,24119,"Acetic acid, diphenylethoxy-",CCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)O,,,,,,
4119,24120,"Propanoic acid, 4-methylphenyl ester",CCC(=O)OC1=CC=C(C=C1)C,,,,,,
4120,24121,6-Nitrochrysene,C1=CC=C2C(=C1)C=CC3=C2C=C(C4=CC=CC=C34)[N+](=O)[O-],,,,"['In rats injected with [3,4,9,10-3H]6-nitrochrysene i.p., after 24 hr, only 1.3% of the dose was excreted in the urine and 23% in the feces.']","['... Both the in vitro metabolism of (3H)6-Nitrochrysene (NC) by 9000 g supernatants (S9) prepared from the livers of preweanling mice and the in vivo metabolism of (3H)NC in these animals. The in vitro covalent binding of primary metabolites of NC to DNA after further reductive and/or oxidative metabolism was then examined in an attempt to define the metabolic activation pathway responsible for the formation of carcinogen--DNA adducts in NC-treated preweanling mice. NC-1,2-dihydrodiol, NC-9,10-dihydrodiol, 6-aminochrysene (AC), and several unidentified compounds were found in ethyl acetate extracts of incubations containing (3H)NC and liver S9 from 1- or 8-day-old BLU:Ha mice. Comparison of the in vivo metabolism of NC in 1-day-old animals and 8-day-old animals which had been treated with NC on day 1 indicated that the formation of AC and the two NC dihydrodiols was greater in the younger animals. Further metabolism of NC-1,2-dihydrodiol by S9 from 8-day-old mice yielded AC-1,2-dihydrodiol as a major product. Incubation of AC-1,2-dihydrodiol, calf thymus DNA and liver microsomes from 3-methylcholanthrene-induced rats yielded a single major adduct that was chromatographically and chemically identical to the major adduct formed in (3H)NC- and (3H)-AC-treated preweanling mice. The results indicated that the major DNA adduct found in vivo is derived from the further metabolism of the proximate carcinogen AC-1,2-dihydrodiol.', '... The major metabolic activation pathway of 6-nitrochrysene in newborn mice is initially through the formation of the proximate tumorigen trans-1,2-dihydro-1,2-dihydroxy-6-aminochrysene with subsequent formation of 1,2-dihydroxy-3,4-epoxy-1,2,3,4-tetrahydro-6-aminochrysene ... The ability of human hepatic and pulmonary microsomes to metabolize 6-nitrochrysene was investigated. The major metabolites identified in 11 hepatic microsomes were trans-1,2-dihydro-1,2-dihydroxy-6-nitrochrysene, trans-9,10-dihydro-9,10-dihydroxy-6-nitrochrysene, trans-1,2-dihydro-1,2-dihydroxy-6-aminochrysene, 6-aminochrysene, and chrysene-5,6-quinone. Following the incubations of 6-nitrochrysene with 11 different human pulmonary microsomes, qualitatively similar metabolic patterns were obtained, although quantitative differences were evident. These results demonstrated that human liver and lung are capable of metabolizing 6-nitrochrysene to known potent carcinogenic metabolites via ring oxidation and nitroreduction. In an attempt to define the roles of individual human hepatic P450 involved in the metabolism of 6-nitrochrysene, the catalytic activities known to be associated with a specific P450 were analyzed and compared with the levels of each metabolite of 6-nitrochrysene formed with the same microsomes. Rates of phenacetin O-deethylation (P450 1A2) and nifedipine oxidation (P450 3A4) were well correlated with the rates of formation of trans-1,2-dihydro-1,2-dihydroxy-6-nitrochrysene and 6-aminochrysene, respectively. Inhibition studies with specific P450 inhibitors and antibodies further support the view that P450 1A2 and P450 3A4 are the major forms responsible for the formation of trans-1,2-dihydro-1,2-dihydroxy-6-nitrochrysene and 6-aminochrysene, respectively, in human liver. Further metabolism of trans-1,2-dihydro-1,2-dihydroxy-6-nitrochrysene appears to require P450 3A4. In the human lung, P450 1A1 appears to play a major role in the metabolism of 6-nitrochrysene to trans-1,2-dihydro-1,2-dihydroxy-6-nitrochrysene ...', '... Three female CD rats were injected ip with [3,4,9,10-3H]6-nitrochrysene (6-NC) [9 umol/rat (346 uCi/rat)], and urine and feces were collected daily for 3 days. In the first 24 hr, radioactivity corresponding to 1.3% of the dose was excreted in the urine, whereas 23.0% was recovered in the feces. After 3 days, the total excretions in urine and feces were 2.8% and 34.9% of the dose, respectively. Radioactivity measured in various organs 3 days after injection of [3,4,9,10-3H]6-NC amounted to 24.8% of the administered dose. Fecal metabolites were identified, based on comparison of their chromatographic characteristics with those of standards, as trans-1,2-dihydro-1,2-dihydroxy-6-NC, chrysene-5,6-quinone, and 6-aminochrysene (6-AC); the structure of the latter was further confirmed by mass spectrometry and UV spectral analysis. Metabolites identified in the urine were 6-AC, trans-1,2-dihydro-1,2-dihydroxy-6-NC, and trans-9,10-dihydro-9,10-dihydroxy-6-NC in free forms and also as glucuronide and/or sulfate conjugates. The (32)P-postlabeling assay was used to determine the metabolic pathways that were leading to DNA adduct formation in the target (colon) and nontarget (liver, lung, and mammary tissues) organs of female CD rats injected with 6-NC under conditions identical to those of the bioassay (total, 14.8 umol/rat; single ip injections on days 1, 8, 15, 22 and 29). Twenty-four hr after the last carcinogen administration, the levels of the adduct derived from trans-1,2-dihydro-1,2-dihydroxy-6-AC were higher than those derived from N-hydroxy-6-AC in all organs examined; however, the highest levels of DNA adducts were found in the lung and not in the target organ, the colon. Although the role of each adduct in colon carcinogenesis needs to be determined, the results favor the ring oxidation and nitroreduction combination pathway as the primary contributor to the activation of 6-NC as a colon carcinogen in the rat.', ""The environmental pollutant 6-nitrochrysene (6-NC) is a potent mammary carcinogen in the rat. To determine if the results obtained in 6-NC-treated rodents can be applicable to humans, ...  its metabolic activation in primary cultures of human breast cells prepared from tissues obtained from reduction mammoplasty from 3 women and in a cultured, immortalized human mammary epithelial cell line (MCF-10A), as well as estrogen-dependent (MCF-7) and estrogen-independent (MDA-MB-435s) human breast cancer cell lines /was examined/. Metabolites identified following 24 hr incubations of (3H)6-NC (2.5, 5.0 and 10 uM) with human breast cells were derived from ring-oxidation (trans-1,2-dihydroxy-1,2-dihydro-6-nitrochrysene [1,2-DHD-6-NC]) and nitro-reduction (6-aminochrysene [6-AC]); chrysene-5,6-quinone (C-5,6-Q) was also detected. Levels of metabolites (pmol/mg protein) varied greatly depending on the concentration of 6-NC and the individual breast tissue used; 1,2-DHD-6-NC, ranged from not detected to 15.6 +/- 1.0; 6-AC, from 11.5 +/- 4.0 to 155 +/- 10.2; C-5,6-Q, from 18.3 +/- 10.8 to 196.7 +/- 15.4. Qualitatively similar metabolic profiles were obtained upon incubation of [(3)H]6-NC with MCF-10A, MCF-7 and MDA-MB-435s. ... 1,2-dihydroxy-6-aminochrysene (1,2-DH-6-AC ranged from not detected to 50.4 +/- 9.8). Some of the metabolites identified in our study are known to be proximate carcinogenic forms of 6-NC in rodents. MCF-7 was the most efficient cell line in catalyzing 6-NC to genotoxic metabolites, and ...  the major DNA adduct is chromatographically identical to that found in the mammary gland of rats treated by gavage with 6-NC and that obtained from the incubation of [(3)H]1,2-DHD-6-NC with MCF7 cells or from nitro-reduction of 1,2-DHD-6-NC in the presence of 2'-deoxyguanosine 5'-monophosphate in vitro. This is the first report to demonstrate the ability of human breast cells, MCF-10A, and breast cancer cell lines to activate 6-NC to metabolites that can damage DNA."", 'For more Metabolism/Metabolites (Complete) data for 6-Nitrochrysene (8 total), please visit the HSDB record page.', '6-nitrochrysene has known human metabolites that include 1,2-DHD-6-NC and N-hydroxy-6-AC.']",
4121,24122,"BENZO(a)PYRENE, 9,10-DIHYDRO-7-METHYL-",CC1=CCCC2=C1C=C3C=CC4=C5C3=C2C=CC5=CC=C4,,,,,,
4122,24123,"1,2-Phenylenediacetic acid",C1=CC=C(C(=C1)CC(=O)O)CC(=O)O,,,,,,
4123,24124,"Dimethyl 4-cyclohexene-1,2-dicarboxylate",COC(=O)C1CC=CCC1C(=O)OC,,,,,,
4124,24125,"Acetoacetic acid, 2-(1-hydroxyamino-2,2,2-trichloroethyl)-, ethyl ester",CCOC(=O)C(C(C(Cl)(Cl)Cl)NO)C(=O)C,,,,,,
4125,24126,"2,4,6-Trinitrobenzoyl chloride",C1=C(C=C(C(=C1[N+](=O)[O-])C(=O)Cl)[N+](=O)[O-])[N+](=O)[O-],,,,,,
4126,24127,"ETHANOL, 2-(o-BIPHENYLYLOXY)-",C1=CC=C(C=C1)C2=CC=CC=C2OCCO,,,,,,
4127,24128,"6-Ethyl-1,3,5-triazine-2,4(1H,3H)-dione",CCC1=NC(=O)NC(=O)N1,,,,,,
4128,24129,N-Hexylacetamide,CCCCCCNC(=O)C,,,,,,
4129,24130,"Ether, cyclohexyl 2,4-dinitrophenyl",C1CCC(CC1)OC2=CC(=CC(=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
4130,24131,"BENZOIC ACID, o-(2,4-DINITROPHENOXY)-",C1=CC=C(C(=C1)C(=O)O)OC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
4131,24132,"Ether, 2,4-dinitrophenyl 4-methylcyclohexyl",CC1CCC(CC1)OC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-],,,,,,
4132,24133,"Heptanedioic acid, 4,4-dicyano-, diallyl ester",C=CCOC(=O)CCC(CCC(=O)OCC=C)(C#N)C#N,,,,,,
4133,24134,"(3,5-Dibromophenoxy)acetic acid",C1=C(C=C(C=C1Br)Br)OCC(=O)O,,,,,,
4134,24135,"2',6'-Dihydroxy-4'-methoxyacetophenone",CC(=O)C1=C(C=C(C=C1O)OC)O,,,,,,
4135,24136,"Phosphorothioic acid, O,O-bis(p-nitrophenyl) O-ethyl ester",CCOP(=S)(OC1=CC=C(C=C1)[N+](=O)[O-])OC2=CC=C(C=C2)[N+](=O)[O-],,,,,,
4136,24137,"2-Amyl-1,2,3,4-tetrahydroisoquinoline hydrochloride",CCCCC[NH+]1CCC2=CC=CC=C2C1.[Cl-],,,,,,
4137,24138,"1,2,3,4-Tetrahydro-2-pentylisoquinoline",CCCCCN1CCC2=CC=CC=C2C1,,,,,,
4138,24139,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O)O,,,,,,
4139,24140,"[3,4-Dihydroxy-2,5,6-tris(methylsulfonyloxy)hexyl] methanesulfonate",CS(=O)(=O)OCC(C(C(C(COS(=O)(=O)C)OS(=O)(=O)C)O)O)OS(=O)(=O)C,,,,,,
4140,24141,Nitrosoproline,C1CC(N(C1)N=O)C(=O)O,,,,,,
4141,24142,Butyltrichlorosilane,CCCC[Si](Cl)(Cl)Cl,,,,,['... Chlorosilanes will be rapidly hydrolyzed upon contact with tissue fluids to release hydrochloric acid. /Chlorosilanes/'],
4142,24143,"Benzene, 1-ethenyl-3-ethyl-",CCC1=CC(=CC=C1)C=C,,,,,,
4143,24144,Acrisorcin,CCCCCCC1=C(C=C(C=C1)O)O.C1=CC=C2C(=C1)C(=C3C=CC=CC3=N2)N,,,,,,
4144,24145,Alkofanone,C1=CC=C(C=C1)C(CC(=O)C2=CC=CC=C2)S(=O)(=O)C3=CC=C(C=C3)N,,,,,,
4145,24146,CID 24146,COC(=O)C1=CC=CC=C1C(=O)O.O.[AlH2]Cl,,,,,,
4146,24147,CID 24147,CC(=O)C(=O)OCCCCOC(=O)C=CC1=CC=CC=C1,,,,,,
4147,24148,"L-Glutamic acid, calcium salt",C(CC(=O)[O-])C(C(=O)[O-])N.[Ca+2],,,,,,
4148,24149,Carperidine,CCOC(=O)C1(CCN(CC1)CCC(=O)N)C2=CC=CC=C2,,,,,,
4149,24150,5-Vinyl-2-pyrrolidinone,C=CC1CCC(=O)N1,,,,,,
4150,24151,Ethylene glycol diallyl ether,C=CCOCCOCC=C,,,,,,
4151,24152,"2,2,4,4-Tetramethylcyclobutane-1,3-diamine",CC1(C(C(C1N)(C)C)N)C,,,,,,
4152,24153,"exo-1,7,7-Trimethylbicyclo[2.2.1]hept-2-yl methacrylate",CC(=C)C(=O)OC1CC2CCC1(C2(C)C)C,,,,,"['Small quantities of methacrylates may readily be metabolized by saponification into the alcohol and methacrylic acid. The latter may form an acetyl-coenzyme A derivative, which then enters the normal lipid metabolism. /Methacrylates/', 'Acrylates and methacrylates are detoxified predominantly via conjugation with glutathione via the Michael addition reaction or glutathione-S-transferase. They are also likely to be hydrolyzed via carboxylesterases. The lower molecular weight esters are rapidly metabolized and eliminated, therefore, will not likely cause cumulative toxicity. /Acrylates andMethacrylates/']",
4153,24154,D-Galactosamine,C([C@@H]1[C@@H]([C@@H]([C@H](C(O1)O)N)O)O)O,,,,,,
4154,24155,"2-(2-Piperidyl)-1,4-dioxaspiro(4.6)undecane hydrochloride",C1CCCC2(CC1)OCC(O2)C3CCCC[NH2+]3.[Cl-],,,,,,
4155,24156,"2-(1,4-Dioxaspiro[4.6]undecan-3-yl)piperidine",C1CCCC2(CC1)OCC(O2)C3CCCCN3,,,,,,
4156,24157,"beta-6-Chloro-2-(2-piperidyl)-1,4-dioxaspiro(4.5)decane hydrochloride",C1CCC2(C(C1)Cl)OCC(O2)C3CCCC[NH2+]3.[Cl-],,,,,,
4157,24158,"2-(6-Chloro-1,4-dioxaspiro[4.5]decan-3-yl)piperidine",C1CCC2(C(C1)Cl)OCC(O2)C3CCCCN3,,,,,,
4158,24159,"alpha-8-tert-Butyl-2-(2-piperidyl)-1,4-dioxaspiro(4.5)decane hydrochloride",CC(C)(C)C1CCC2(CC1)OCC(O2)C3CCCC[NH2+]3.[Cl-],,,,,,
4159,24160,"2-(8-Tert-butyl-1,4-dioxaspiro[4.5]decan-3-yl)piperidine",CC(C)(C)C1CCC2(CC1)OCC(O2)C3CCCCN3,,,,,,
4160,24161,"7,9-Dimethyl-2-(2-piperidyl)-1,4-dioxaspiro(4.5)decane hydrochloride",CC1CC(CC2(C1)OCC(O2)C3CCCC[NH2+]3)C.[Cl-],,,,,,
4161,24162,"2-(7,9-Dimethyl-1,4-dioxaspiro[4.5]decan-3-yl)piperidine",CC1CC(CC2(C1)OCC(O2)C3CCCCN3)C,,,,,,
4162,24163,"8-Methyl-2-(2-piperidyl)-1,4-dioxaspiro(4.5)decane hydrochloride",CC1CCC2(CC1)OCC(O2)C3CCCC[NH2+]3.[Cl-],,,,,,
4163,24164,"2-(8-Methyl-1,4-dioxaspiro[4.5]decan-3-yl)piperidine",CC1CCC2(CC1)OCC(O2)C3CCCCN3,,,,,,
4164,24165,"7-Methyl-2-(2-piperidyl)-1,4-dioxaspiro(4.5)decane hydrochloride",CC1CCCC2(C1)OCC(O2)C3CCCC[NH2+]3.[Cl-],,,,,,
4165,24166,"2-(7-Methyl-1,4-dioxaspiro[4.5]decan-3-yl)piperidine",CC1CCCC2(C1)OCC(O2)C3CCCCN3,,,,,,
4166,24167,"beta-6-Ethyl-2-(2-piperidyl)-1,4-dioxaspiro(4.5)decane hydrochloride",CCC1CCCCC12OCC(O2)C3CCCC[NH2+]3.[Cl-],,,,,,
4167,24168,"2-(6-Ethyl-1,4-dioxaspiro[4.5]decan-3-yl)piperidine",CCC1CCCCC12OCC(O2)C3CCCCN3,,,,,,
4168,24169,"6-Methyl-2-(2-piperidyl)-1,4-dioxaspiro(4.5)decane hydrochloride",CC1CCCCC12OCC(O2)C3CCCC[NH2+]3.[Cl-],,,,,,
4169,24170,"2-(6-Methyl-1,4-dioxaspiro[4.5]decan-3-yl)piperidine",CC1CCCCC12OCC(O2)C3CCCCN3,,,,,,
4170,24171,Mesuprine,CC(C(C1=CC(=C(C=C1)O)NS(=O)(=O)C)O)NCCC2=CC=C(C=C2)OC,,,,,,
4171,24172,4-Formylphenyltrimethylammonium iodide,C[N+](C)(C)C1=CC=C(C=C1)C=O.[I-],,,,,,
4172,24173,"4-Formyl-N,N,N-trimethylbenzenaminium iodide",C[N+](C)(C)C1=CC=C(C=C1)C=O,,,,,,
4173,24174,"Calcium;2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetate",CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)[O-])Cl)Cl.[Ca+2],,,,,,
4174,24175,Octadecyltrimethylammonium stearate,CCCCCCCCCCCCCCCCCC[N+](C)(C)C.CCCCCCCCCCCCCCCCCC(=O)[O-],,,,,,
4175,24176,"(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(2R,3S,4R)-5-[(1R,3S,5R,6S)-3,5-diamino-2-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol",C1[C@H]([C@@H]([C@H](C([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)N)OC3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N,,,"['Substances that are destructive to protozoans. (See all compounds classified as Antiprotozoal Agents.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)']",,,
4176,24177,"Ethanol, 2-(8-quinolylthio)-",C1=CC2=C(C(=C1)SCCO)N=CC=C2,,,,,,
4177,24178,Calcium;2-acetamido-3-sulfanylpropanoate,CC(=O)NC(CS)C(=O)[O-].[Ca+2],,,,,,
4178,24179,"Calcium;2,3,4,5-tetrahydroxypentanoate",C(C(C(C(C(=O)[O-])O)O)O)O.[Ca+2],,,,,,
4179,24180,Calcium guaiacol sulfonate,COC1=C(C=C(C=C1)S(=O)(=O)[O-])O.COC1=C(C=C(C=C1)S(=O)(=O)[O-])O.[Ca+2],,,,,,
4180,24181,3-Hydroxy-4-methoxybenzenesulfonic acid,COC1=C(C=C(C=C1)S(=O)(=O)O)O,,,,,,
4181,24182,Chloromercury,Cl[Hg],,,,,,
4182,24183,"3-Methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole",CN1CCC2=C(CC1)NC3=CC=CC=C23,,,,,,
4183,24184,"AZEPINO(4,5-b)INDOLE, 3-BENZYL-1,2,3,4,5,6-HEXAHYDRO-",C1CN(CCC2=C1C3=CC=CC=C3N2)CC4=CC=CC=C4,,,,,,
4184,24185,"5,5-Diethyl-1-(2-hydroxypropyl)barbituric acid",CCC1(C(=O)NC(=O)N(C1=O)CC(C)O)CC,,,,,,
4185,24186,"Barbituric acid, 1-allyl-5,5-diethyl-",CCC1(C(=O)NC(=O)N(C1=O)CC=C)CC,,,,,,
4186,24187,5-(2-Cyclohexyl-2-hydroxyethyl)-5-ethylbarbituric acid,CCC1(C(=O)NC(=O)NC1=O)CC(C2CCCCC2)O,,,,,,
4187,24188,5-Allyl-5-(2-bromopropyl)barbituric acid,CC(CC1(C(=O)NC(=O)NC1=O)CC=C)Br,,,,,,
4188,24189,5-Allyl-5-(2-methoxypropyl)barbituric acid,CC(CC1(C(=O)NC(=O)NC1=O)CC=C)OC,,,,,,
4189,24190,"5-(2,3-Dimethyl-2-hydroxybutyl)-5-ethylbarbituric acid",CCC1(C(=O)NC(=O)NC1=O)CC(C)(C(C)C)O,,,,,,
4190,24191,"2,6-Octadiene, 1,1-dimethoxy-3,7-dimethyl-",CC(=CCCC(=CC(OC)OC)C)C,,,,,,
4191,24192,"1H-AZEPINE-1-ETHANOL, HEXAHYDRO-beta-PHENYL-",C1CCCN(CC1)C(CO)C2=CC=CC=C2,,,,,,
4192,24193,Titanium tetrachloride,Cl[Ti](Cl)(Cl)Cl,,,,"['... Particles (presumably of titanium dioxide) were detected in the liver & spleen from rats exposed to 10 mg/cu m titanium tetrachloride aerosol 6 hr/day, 5 days/wk for 2 yr suggesting that absorption of titanium occurred. It is well known, however, that particles are swallowed after being expelled from the respiratory tract by mucocilliary clearance.', '... In a case report of chronic inhalation exposure to titanium dioxide, which is one of the titanium tetrachloride hydrolysis products, particles similar to titanium dioxide were found in lysosomes of phagocytes within the alveolar lumen. Spectrometric & spectrographic analysis showed accumulation of titanium dioxide in the lungs. Analysis of tissues from one worker who drowned 4 months after stopping work showed that titanium was also present in the lymph nodes adjacent to the lung. No titanium was found in the tissue specimens for brain, thyroid gland, myocardium, spleen, liver, kidneys, & nerve ganglia of the sympathetic trunk. These results suggest that titanium selectively accumulates in the lung & adjacent lymph nodes ... .']",,
4193,24194,Aminopterinum natricum,C1=CC(=CC=C1C(=O)NC(CCC(=O)[O-])C(=O)[O-])NCC2=CN=C3C(=N2)C(=NC(=N3)N)N.[Na+].[Na+],,,,,,
4194,24195,"2-(2-Piperidyl)-1,4-dioxaspiro(4.5)decane hydrochloride",C1CCC2(CC1)OCC(O2)C3CCCC[NH2+]3.[Cl-],,,,,,
4195,24196,"2-(1,4-Dioxaspiro[4.5]decan-3-yl)piperidine",C1CCC2(CC1)OCC(O2)C3CCCCN3,,,,,,
4196,24197,Diethyl malate,CCOC(=O)CC(C(=O)OCC)O,,,,,,
4197,24198,"2,4-Dichloromandelic acid",C1=CC(=C(C=C1Cl)Cl)C(C(=O)O)O,,,,,,
4198,24199,Hexocyclium,C[N+]1(CCN(CC1)CC(C2CCCCC2)(C3=CC=CC=C3)O)C,"['The World Health Organization classifies hexocyclium as a drug for functional gastrointestinal disorders. Like other anti-muscarinic agents, hexocyclium was likely used to treat peptic ulcers or diarrhea.']",['Hexocyclium reduces gastrointesitinal motility and gastric acid secretion.'],,,,
4199,24200,Azanium;4-amino-5-hydroxy-5-oxopentanoate,C(CC(=O)[O-])C(C(=O)O)N.[NH4+],,,,,,
4200,24201,CID 24201,C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)[O-])O)O)C(=O)O.[K+],,,,,,
4201,24202,Potassium;sodium;2-aminopentanedioate,C(CC(=O)[O-])C(C(=O)[O-])N.[Na+].[K+],,,,,,
4202,24203,Disodium hydrogen phosphate,OP(=O)([O-])[O-].[Na+].[Na+],['Used to treat constipation or to clean the bowel before a colonoscopy.'],['Sodium phosphate inceases fecal water content to increase mobility through the large intestine.'],,"['Tmax for phosphate absorption with orally administered liquid sodium phosphate is 1-3h.', '... Phosphates (dibasic and monobasic sodium phosphate) are slowly and incompletely absorbed. /Dibasic and Monobasic Sodium phosphate/', 'Net phosphorus absorption may occur in the small intestine in some species but is primarily a function of the colon in horses. /Phosphorus/', 'Elimination: Renal (90%) and fecal (10%). /Phosphates/', 'Ingested phosphates are absorbed from the gastrointestinal tract. However, the presence of large amounts of calcium or aluminum may lead to formation of insoluble phosphate and reduce the net absorption. Vitamin D stimulates phosphate absorption. /Phosphates/', 'For more Absorption, Distribution and Excretion (Complete) data for DISODIUM HYDROGEN PHOSPHATE (9 total), please visit the HSDB record page.']",,
4203,24204,CID 24204,OP(=O)(O)[O-].[Na+],,,,,,
4204,24205,"2-(3-Hydroxy-3,7,11,15-tetramethylhexadecyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione",CC1=C(C(=O)C(=C(C1=O)C)CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)O)C,,,"['Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)', 'Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)', 'Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)']",,,
4205,24206,"2,4-Dimethyl-6-propyl-1,3,5-triazine",CCCC1=NC(=NC(=N1)C)C,,,,,,
4206,24207,S-Hexadecyl hexadecanethiosulfonate,CCCCCCCCCCCCCCCCSS(=O)(=O)CCCCCCCCCCCCCCCC,,,,,,
4207,24208,S-Methyl octanethiosulfonate,CCCCCCCCS(=O)(=O)SC,,,,,,
4208,24209,S-Hexadecyl octanethiosulfonate,CCCCCCCCCCCCCCCCSS(=O)(=O)CCCCCCCC,,,,,,
4209,24210,N-Cyclohexyl-N-methylcyclohexanamine,CN(C1CCCCC1)C2CCCCC2,,,,,,
4210,24211,(+)-Usnic acid,CC1=C(C(=C2C(=C1O)C3(C(=CC(=C(C3=O)C(=O)C)O)O2)C)C(=O)C)O,,,,,,
4211,24212,"alpha-(1-((3-Methoxypropyl)amino)ethyl)-1,4-benzodioxan-2-methanol",CC(C(C1COC2=CC=CC=C2O1)O)NCCCOC,,,,,,
4212,24213,"Aniline, 4,4'-(2-cyanoethylidene)DI-",C1=CC(=CC=C1C(CC#N)C2=CC=C(C=C2)N)N,,,,,,
4213,24214,"(3R,5S,6S,7R,8S,9R,12R,13R,14S,15R)-6-[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-8-(5-hydroxy-4-methoxy-6-methyloxan-2-yl)oxy-5,7,9,12,13,15-hexamethyl-1,11-dioxaspiro[2.13]hexadecane-10,16-dione",C[C@H]1C[C@@]2(CO2)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]([C@H]([C@@H]([C@H]1OC3C(C(CC(O3)C)N(C)C)O)C)OC4CC(C(C(O4)C)O)OC)C)C)C)O)C,,,,,,
4214,24215,CID 24215,C1=CC=C(C=C1)CC2=CC=CC=C2[O-].[Na+],,,,,,
4215,24216,2-Benzylphenol,C1=CC=C(C=C1)CC2=CC=CC=C2O,,,,,,
4216,24217,CID 24217,C1=CC=C(C=C1)CC2=CC=C(C=C2)[O-].[Na+],,,,,,
4217,24218,2-Ethylstyrene,CCC1=CC=CC=C1C=C,,,,,,
4218,24219,"3-Methylpentane-1,3,5-triol",CC(CCO)(CCO)O,,,,,,
4219,24220,"2-Butanol, 1-(2-methoxyethyl)amino-3-phenoxy-",CC(C(CNCCOC)O)OC1=CC=CC=C1,,,,,,
4220,24221,"2-Butanol, 1-(3-methoxypropyl)amino-3-phenoxy-",CC(C(CNCCCOC)O)OC1=CC=CC=C1,,,,,,
4221,24222,"2-Butanol, 1-(3-methoxypropyl)amino-3-methyl-3-phenoxy-",CC(C)(C(CNCCCOC)O)OC1=CC=CC=C1,,,,,,
4222,24223,"2-Butanol, 1-(4-methoxybutyl)amino-3-methyl-3-phenoxy-",CC(C)(C(CNCCCCOC)O)OC1=CC=CC=C1,,,,,,
4223,24224,alpha-(Dimethylaminomethyl)benzo(b)thiophene-3-methanol picrate,C[NH+](C)CC(C1=CSC2=CC=CC=C21)O.C1=C(C=C(C(=C1[N+](=O)[O-])[O-])[N+](=O)[O-])[N+](=O)[O-],,,,,,
4224,24225,1-(1-Benzothiophen-3-yl)-2-(dimethylamino)ethanol,CN(C)CC(C1=CSC2=CC=CC=C21)O,,,,,,
4225,24226,N-[2-hydroxy-5-[1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenyl]methanesulfonamide,CC(COC1=CC=CC=C1)NC(C)C(C2=CC(=C(C=C2)O)NS(=O)(=O)C)O,,,,,,
4226,24227,Dichloroacetylene,C(#CCl)Cl,,,,"['The metabolism of inhaled 14(C)dichloroacetylene has been studied in male Wistar rats exposed to 20 or 40 ppm (78 or 156 mg/cu m) atmospheres for 1 hr. During the next 96 hr, elimination of retained (approximately 17%) 20 and 40 ppm doses, respectively, was: urine, 68% and 60%; feces, 28% and 27%. About 3.5% remained in the carcasses.', 'Using a nose-only dynamic system, ...rats /were given 14C-dichloroacetylene/ for 1 hr at concentrations of 20 or 40 ppm. Retention rates of 17.6 and 15.6% of the radioactivity were reported for 20 and 40 ppm, respectively. Elimination of radioactivity was almost quantitative in 96 hr. Elimination of radioactivity in urine was 67.8% at 20 ppm and 60% at 40 ppm. Elimination in feces was 27.5% at 20 ppm and 27% at 40 ppm. Only 3.4 to 3.5% remained in the carcass.']","['Glutathione conjugation has been shown in rats following inhalation of dichloroacetylene. ...S-(1,2-dichlorovinyl)glutathione (DCVG) /was identified/ as a product of the glutathione (GSH)-dependent metabolism of /dichloroacetylene/ (DCA) in vitro and ...N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine (N-Ac-DCVC) /was identified/ as a urinary metabolite of DCA in rats. The product, DCVG, was definitively identified by H-NMR spectrometry (400 MHz), mass spectrometry and UV spectroscopy. N-Ac-DCVC was identified as a urinary metabolite from rats by GC/MS after esterification. Urine (collected for 24 hr) from male rats exposed to 36 n 5 ppm DCA (100 mmol of DCA introduced into the exposure system) for 1 hr contained 10.7 mmol of N-Ac-DCVC as determined by HPLC analysis. Formation of DCVG, renal processing to S-(1,2-dichlorovinyl)-L-cysteine, and cleavage of this cysteine S-conjugate by cysteine S-conjugate beta-lyase in the kidney and the formation of reactive and mutagenic intermediates may account for DCA nephrotoxicity and nephrocarcinogenicity. N-Ac-CDVC is the end product of DCVG processing by the enzymes of mercapturic acid formation.', 'Metabolites in the urine were identified as N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine, dichloroethanol, dichloroacetic acid, oxalic acid, and chloracetic acid /after inhalation exposure of rats/. Only the cysteine conjugate was found in feces. It was formed in the kidneys because only S-(1,2-dichlorovinyl) glutathione was found in the bile. Biliary cannulation did not influence renal excretion of the cysteine conjugate. /From this study, it was concluded that/ ...two metabolic pathways are operative in dichloroacetylene metabolism in vivo. Cytochrome P450-dependent oxidation represents a minor pathway accounting for the formation of 1,1-dichloro compounds after chlorine migration. The major pathway is the biosynthesis of toxic glutathione conjugates. Organ-specific toxicity and carcinogenicity of dichloroethyne (acetylene dichloride) is due most likely to the topographical distribution of gamma-glutamyl transpeptidase which is concentrated mainly in the kidney of rats.', 'The metabolism of inhaled 14(C)dichloroacetylene has been studied in male Wistar rats exposed to 20 or 40 ppm (78 or 156 mg/cu m) atmospheres for 1 hr. During the next 96 hr, elimination of retained (approximately 17%) 20 and 40 ppm doses, respectively, was: urine, 68% and 60%; feces, 28% and 27%. About 3.5% remained in the carcasses. Metabolites of dichloroacetylene that were identified were: N-acetyl-S-(1,2-dichlorovinyl)- L-cysteine (62%), dichloroethanol (12%), dichloroacetic acid (9%), oxalic acid (8%) and chloroacetic acid (5%) in urine; and N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine in faeces. In bile, only S-(1,2-dichlorovinyl)glutathione was identified. Biliary cannulation did not influence the renal excretion of N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine, a result that was interpreted to indicate that glutathione conjugation also occurs in the kidney. The identified metabolites are consistent with the existence of two metabolic pathways: the major pathway involves glutathione conjugation, while a minor pathway is cytochrome P450-dependent oxidation that accounts for the formation of 1,1- dichloro-compounds after chlorine migration.', 'In vitro studies have demonstrated that glutathione conjugation of dichloroacetylene is predominantly enzymatic and the rate of reaction resulting in the formation of S-(1,2- dichlorovinyl)glutathione is similar for microsomes from rat kidney and liver. However, under different reaction conditions (20-500-fold higher protein concentrations), the rate was highest for microsomes from liver, followed by lung, brain and kidney. The further handling of this metabolite in kidney is not clearly defined, but it is known that gamma-glutamyltranspeptidase and dipeptidases (e.g., in biliary epithelium) can transform S-(1,2-dichlorovinyl)glutathione to S-(1,2-dichlorovinyl)- L-cysteine, which can then be acetylated in tissues or by intestinal bacteria . An alternative to acetylation is beta-lyase-mediated metabolism to form chlorothioketene as an intermediate, which can react with tissue nucleophiles or with water, when it forms chloroacetic acid. Cysteine conjugate beta-lyase activity has also been shown in rat cerebellar tissue.', 'The glutathione (GSH) dependent metabolism of dichloroacetylene (DCA) was investigated in rat liver and kidney subcellular fractions. The study also included the metabolism of DCA in rats to identify and quantify any metabolites formed by GSH conjugation. S-(1,2-dichlorovinyl)glutathione (DCVG) was identified as a product of the in-vitro metabolism and N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine (N-Ac-DCVC) was identified as a urinary metabolite of DCA in rats. ...N-Ac-DCVC was identified as a urinary metabolite from rats by gas chromatography/mass spectrometry after esterification. Male rats exposed to 36 ppm DCA for 1 hr produced urine which contained 10.7 micromoles of N-Ca-DCVC as determined by high pressure liquid chromatographic analysis. .../It was suggested/ that the formation of DCVG, renal processing to cysteine S-conjugate beta-lyase in the kidney with formation of reactive and mutagenic intermediates may account for DCA nephrotoxicity and nephrocarcinogenicity.']",
4227,24228,"1H-Indene-1,3(2H)-dione, 2-(3-hydroxy-2-quinolinyl)-",C1=CC=C2C(=C1)C=C(C(=N2)C3C(=O)C4=CC=CC=C4C3=O)O,,,,,,
4228,24229,CID 24229,C(CN(CC(=O)O)CC(=O)O)N(CCN(CC(=O)O)CC(=O)[O-])CC(=O)O.[Na+],,,,,,
4229,24230,"Sodium 1,2-diaminocyclohexane tetraacetate",C1CCC(C(C1)N(CC(=O)O)CC(=O)[O-])N(CC(=O)O)CC(=O)[O-].[Na+].[Na+],,,,,,
4230,24231,Nickel 2-ethylhexanoate,CCCCC(CC)C(=O)O.[Ni],,,,,,
4231,24232,2-tert-Butoxyethanol,CC(C)(C)OCCO,,,,,,
4232,24233,"2,3-Dichlorobutane",CC(C(C)Cl)Cl,,,,,,
4233,24234,Diethylaminopropyl p-fluorobenzoate hydrochloride,CC[NH+](CC)CCCOC(=O)C1=CC=C(C=C1)F.[Cl-],,,,,,
4234,24235,3-(Diethylamino)propyl 4-fluorobenzoate,CCN(CC)CCCOC(=O)C1=CC=C(C=C1)F,,,,,,
4235,24236,"2-Butanol, 2-((2-methoxyethyl)amino)-3-methyl-3-phenoxy-",CC(C)(C(C)(NCCOC)O)OC1=CC=CC=C1,,,,,,
4236,24237,Zirconium acetate,CC(=O)[O-].CC(=O)[O-].CC(=O)[O-].CC(=O)[O-].[Zr+4],,,,,,
4237,24238,"(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol",C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H](C6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@H](O2)[C@@H]([C@H]8O)O)CO)CO)CO)CO)CO)CO)O)O)O,,,"['Substances used in the processing or storage of foods or animal feed including ANTIOXIDANTS; FOOD PRESERVATIVES; FOOD COLORING AGENTS; FLAVORING AGENTS; ANTI-INFECTIVE AGENTS; EXCIPIENTS and other similarly used substances. Many of the same substances are used as PHARMACEUTIC AIDS. (See all compounds classified as Food Additives.)', 'Compounds that bind to and reduce the biological availability of a chemical or pharmaceutical agent. (See all compounds classified as Sequestering Agents.)']",,,
4238,24239,6-Nitroindazole,C1=CC2=C(C=C1[N+](=O)[O-])NN=C2,,,,,,
4239,24240,2-tert-Butyl-4-isopropylphenol,CC(C)C1=CC(=C(C=C1)O)C(C)(C)C,,,,,,
4240,24241,"5H-NAPHTHO(2,3-a)CARBAZOLE-5,13(12H)-DIONE",C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C4=C(C=C3)C5=CC=CC=C5N4,,,,,,
4241,24242,Triethylamine salicylate,CCN(CC)CC.C1=CC=C(C(=C1)C(=O)O)O,,,,,,
4242,24243,Trisodium phosphate,[O-]P(=O)([O-])[O-].[Na+].[Na+].[Na+],,,,"['Sodium orthophosphate is poorly absorbed & relatively nontoxic /SRP: systemically/', '/Ortho/ phosphate is absorbed from, and to a limited extent secreted into, the gastrointestinal tract. Transport of phosphate from the gut lumen is an active, energy-dependent process that is modified by several factors. ... Vitamin D stimulates phosphate absorption, an effect reported to precede its action on calcium ion transport. In adults, about two thirds of the ingested phosphate is absorbed, and that which is absorbed is almost entirely excreted into the urine. In growing children, phosphate balance is positive. Concentrations of phosphate in plasma are higher in children than in adults. This ""hyperphosphatemia"" decreases the affinity of hemoglobin for oxygen and is hypothesized to explain the physiological ""anemia"" of childhood. /Phosphates/']",,
4243,24244,Metocurine iodide,C[N+]1(CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)OC)O3)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)C.[I-].[I-],['For use as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy.'],"['Metocurine iodide is a benzylisoquinolinium competitive nondepolarizing neuromuscular blocking agent. Metocurine iodide has a moderate risk of inducing histamine release and has some ganglion blocking activity. Metocurine iodide can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of metocurine iodide. Repeated administration of maintenance doses of metocurine iodide has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.']","['Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. (See all compounds classified as Neuromuscular Nondepolarizing Agents.)']",,,['3 to 4 hours']
4244,24245,"N,N'-Dimethyl-N,N'-dinitrosooxamide",CN(C(=O)C(=O)N(C)N=O)N=O,,,,,,
4245,24246,CID 24246,[O-]Cl(=O)(=O)=O.[Na+],,,,,,
4246,24247,Perchloric acid,OCl(=O)(=O)=O,,,,,,
4247,24248,p-Phenylazophenyl isothiocyanate,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N=C=S,,,,,,
4248,24249,"1,8-Octanediamine, dihydrochloride",C(CCCC[NH3+])CCC[NH3+].[Cl-].[Cl-],,,,,,
4249,24250,"1,8-Diaminooctane",C(CCCCN)CCCN,,,,,,
4250,24251,Diethylaminoethyl p-fluorobenzoate hydrochloride,CC[NH+](CC)CCOC(=O)C1=CC=C(C=C1)F.[Cl-],,,,,,
4251,24252,2-(Diethylamino)ethyl 4-fluorobenzoate,CCN(CC)CCOC(=O)C1=CC=C(C=C1)F,,,,,,
4252,24253,"2-Butanol, 1-(4-methoxybutyl)amino-3-phenoxy-",CC(C(CNCCCCOC)O)OC1=CC=CC=C1,,,,,,
4253,24254,"1,1'-(3-Methyl-1-propene-1,3-diyl)bis-benzene",CC(C=CC1=CC=CC=C1)C2=CC=CC=C2,,,,,,
4254,24255,"1,3,5-Triazine-2,4,6-tricarbonitrile",C(#N)C1=NC(=NC(=N1)C#N)C#N,,,,,,
4255,24256,"Hexylamine, 1-methyl-N-2-propynyl-",CCCCCC(C)NCC#C,,,,,,
4256,24257,"Hexylamine, N-2-propynyl-N,1,5-trimethyl-",CC(C)CCCC(C)N(C)CC#C,,,,,,
4257,24258,Perchloryl fluoride,O=Cl(=O)(=O)F,,,,['CAN BE ABSORBED THROUGH SKIN.'],,
4258,24259,"1,2-Dinitrosobenzene",C1=CC=C(C(=C1)N=O)N=O,,,,,,
4259,24260,2-(4-Aminophenyl)-1H-benzimidazol-5-amine,C1=CC(=CC=C1C2=NC3=C(N2)C=C(C=C3)N)N,,,,,,
4260,24261,Silicon Dioxide,O=[Si]=O,,,,"['...Rats /were exposed/ by inhalation to... silica (particle size 0.5 to 5 m) in the form of Belgian glass sand for periods ranging from 0.5 to 40 hr. The initial deposition of silica was highest in the tracheobronchial ciliated air passages; it also was seen throughout the acini, where the extent of deposition decreased as the respiratory airways proceeded distally. The distribution of particles was not uniform between the different acini, and, 2 to 3 months following cessation of exposure, aggregates were formed, primarily in the proximal alveolar ducts but also in the distal portion of the acini.', 'Inhalation studies with rats... indicate that the long-term clearance of quartz after inhalation is slow and biphasic, whereas amorphous silica dusts are cleared more rapidly. The absolute amount of silica dust eliminated increased with lung burden, but the efficiency of the elimination was either constant or decreased with time. ...The half-life lung clearance of rats exposed via inhalation to an amorphous silica suspension (Ludox ) at concentrations up to 150 mg/cu m was about 50 days.', 'A study /in (1983)/, showed that the total silica content in the lungs of guinea pigs exposed by inhalation for up to 2 years to a cristobalite sample or to amorphous silica (at dust concentrations of 150 mg/cu m or 100 mg/cu m , respectively) increased linearly over 21 months, without evidence that lung retention rates changed with time. ...The maximum lung content of cristobalite was only 68 mg/lung, whereas that of amorphous silica was 120 mg/lung. The total amount of accumulated silica varied inversely with the degree of pulmonary damage. /It was/ suggested that silica dust producing cell damage may be more efficiently cleared from the lung than are the less toxic amorphous forms. However, this difference also could be due to different rates of deposition for the two dust forms. The cristobalite sample, which was 45% cristobalite and 55% diatomaceous earth, was significantly coarser (and less likely to deposit in the lungs) than the amorphous silica, which contained 100% diatomaceous earth. Also, tissue changes induced by cristobalite could have altered particle deposition.', 'In a long-term inhalation study with guinea pigs, ...the amount of silica retained as a result of 8-hr/day exposures to amorphous silica (Hi-Sil 233) /was compared/ with that retained during inhalation of quartz dust for a comparable 12-month period. Guinea pigs that inhaled quartz dust at a concentration of 106 mg/cu m retained between 500 and 600 mg of silica, whereas <10 mg of dust was retained in those that inhaled 126 mg/cu m of amorphous silica. After 12 months of exposure, the relative silica content (silica mass/lung mass) decreased in guinea pigs exposed to quartz dust, but continued to increase slowly in the animals exposed to the amorphous silica. This difference was explained by an increasing nonsiliceous materials content (e.g., collagen, minerals) in the lungs of the quartz-exposed animals associated with the progressive deposition of fibrous tissue in the lungs. Six months after cessation of exposure, the silica content of the lungs of Hi-Sil 233-exposed animals was similar to that of untreated controls. This lack of accumulation may be due, in large part, to the higher solubility of amorphous silica compared to quartz... . By comparison, the elimination of silica from the quartz-exposed guinea pigs was negligible, and the silicotic lesions continued to progress during this elimination phase.', 'For more Absorption, Distribution and Excretion (Complete) data for AMORPHOUS SILICA (6 total), please visit the HSDB record page.', 'Rats were exposed for 6 hr/day, on 5 days/week, for up to 13 weeks to 3 mg/cu m crystalline... Lung burdens were 819... ug for crystalline...', 'Deposition of particles in the respiratory bronchioles and proximal alveoli results in slow clearance, interaction with macrophages and a greater likelihood of lung injury. This contrasts with deposition on the conducting airways where the majority of the particles are cleared by the mucociliary escalator. Therefore, quartz particles with an aerodynamic diameter below 10 um are likely to be the most harmful to humans.', 'There are few data on human lung quartz-dust burdens that allow conclusions to be drawn about deposition or clearance. However, quartz is found in the bronchoalveolar macrophages and sputum of silicotic patients. Also, at autopsy, there is wide variation in the masses and proportions of quartz retained in the lung. For example... 25-264 mg /were reported/ per single lung at autopsy in hard-rock miners with 14-36 years of exposure; these miners had variable amounts of pathological response but there was not a good correlation between lung crystalline quartz content and pathological score. The well-documented effect of smoking on clearance is a further confounding factor in drawing conclusions about clearance kinetics in humans.', ""The physico-chemical changes in quartz that result from residence in the lung could be an important factor in determining the continuing toxicity of quartz to the lung following deposition. As a response to the rejection of the 'mechanical model' of silicosis, which had propounded that any particle with 'sharp or jagged edges' might injure tissue, a solubility theory of silicosis was proposed. The solubility theory was based on the release from silica of silicic acid, which was considered to be a 'protoplasmic poison.'  In fact very little dissolution occurs; for example, 9 mg SiO2 (0.45%) was released from 2 g crystalline silica placed in ascitic fluid for two weeks. Current theories no longer consider that the dissolution of quartz contributes substantially to its clearance or to changes in its biological activity. Indeed there is evidence of enrichment of crystalline silica in lungs of individuals exposed to hard rock compared to the dust in the air they breathed, suggesting that crystalline silica is less-efficiently cleared, either by dissolution or mechanical clearance, than the non-silica mineral components of the dust... biopersistence was assessed in occupationally exposed subjects by counting silica particles in bronchoalveolar lavage (BAL) fluid after varying periods of time since their last occupational exposure. Crystalline silica was found to be among the most biopersistent of non-fibrous mineral particles."", 'For more Absorption, Distribution and Excretion (Complete) data for CRYSTALLINE SILICA (17 total), please visit the HSDB record page.']",,
4261,24262,Sodium;arsoric acid,O[As](=O)(O)O.[Na+],,,,,,
4262,24263,CID 24263,[O-]S(=O)=O.[Na+],,,,,,
4263,24264,CID 24264,OS(=O)=O,,,,,,
4264,24265,CID 24265,COC(=O)C1=CC=CC=C1[O-].[Na+],,,,,,
4265,24266,Sodium monofluorophosphate,[O-]P(=O)([O-])F.[Na+].[Na+],['Sodium monofluorophosphate is indicated for the treatment of cavities'],,"['Substances that inhibit or arrest DENTAL CARIES formation. (Boucher&apos;s Clinical Dental Terminology, 4th ed) (See all compounds classified as Cariostatic Agents.)']",,,
4266,24267,Fluorophosphoric acid,OP(=O)(O)F,,,,"['THE AMOUNT OF TOTAL FLUORIDE RETAINED AFTER BRUSHING WITH A DENTIFRICE WAS AN AVG 19.3% OF THAT APPLIED, WHILE THAT AFTER TOPICAL APPLICATION OF 2% NAF SOLN FOR 4 MIN WAS 13.6%. AFTER RINSING WITH 10 ML OF 500 PPM NAF SOLN FOR 30 SEC 11.6%, & AFTER CRUNCHING TABLET CONTAINING 1 MG F, 8.9% WAS RETAINED. AFTER MOUTH RINSING OR TOPICAL APPLICATION, RESIDUAL FLUORIDE WAS FOUND IN SALIVA FOR 24-48 HR. SALIVARY FLUORIDE WAS FOUND FOR ONLY 90-120 MIN AFTER APPLICATION OF MONOFLUOROPHOSPHATE CONTAINING DENTIFRICE OR FLUORIDE TABLETS.']",,
4267,24268,Sodium Nitrate,[N+](=O)([O-])[O-].[Na+],,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']","['In humans, ingested nitrate is rapidly absorbed from the proximal small bowel and distributed throughout the body. Nitrate then enters the large bowel from the blood, where it is rapidly converted to highly reactive nitrite, in part by fecal microorganisms. The formed nitrite is reabsorbed into the blood, where it reacts with the ferrous (Fe2+) iron of deoxyhemoglobin, forming methemoglobin with iron in the ferric (Fe3+) valence state. Ferric iron is unable to transport oxygen. Nitrates are rapidly converted in the liver to denitrated metabolites and inorganic nitrites, which are then excreted in urine. Approximately 60% to 70% of an ingested nitrate dose is excreted in urine within the first 24 hours. About 25% is excreted in saliva through an active blood nitrate transport system and potentially is reabsorbed. Half-lives of parent nitrate compounds are usually <1 hour; half-lives of metabolites range from 1 to 8 hours. /Nitrates/', '... Nitrate is concentrated in saliva, where a part of it is reduced to nitrite by bacterial nitrate reductases. /The authors/ tested if ingestion of inorganic nitrate would affect the salivary and systemic levels of nitrite and S-nitrosothiols, both considered to be circulating storage pools for NO. Levels of nitrate, nitrite, and S-nitrosothiols were measured in plasma, saliva, and urine before and after ingestion of sodium nitrate (10 mg/kg). Nitrate levels increased greatly in saliva, plasma, and urine after the nitrate load. Salivary S-nitrosothiols also increased, but plasma levels remained unchanged. A 4-fold increase in plasma nitrite was observed after nitrate ingestion. If, however, the test persons avoided swallowing after the nitrate load, the increase in plasma nitrite was prevented, thereby illustrating its salivary origin. We show that nitrate is a substrate for systemic generation of nitrite. There are several pathways to further reduce this nitrite to NO. These results challenge the dogma that nitrate is biologically inert and instead suggest that a complete reverse pathway for generation of NO from nitrate exists.', 'Nitrite was quickly eliminated from blood plasma of sheep (T1/2 = 0.49 hr). Three hours after its administration, nitrite ion disappeared from blood plasma. Simultaneously the appearance of nitrate was observed. After sodium nitrite or nitrate intravenous administration, the kinetic parameters for nitrate were similar (Kel = 0.150/ h and 0.154/ hr, respectively). Urine excretion of nitrite amounted to only 0.29%+/- 0.22 of the administered dose. Urine excretion of nitrate was 13.80%+/-5.78 of the administered dose of nitrite and was slightly lower than that observed after the administration of nitrate (16.12%+/- 6.95). The quick elimination of nitrite appears to be mainly from its conversion into nitrate, because the nitrate elimination in urine. as well as the values of its kinetic parameters, were similar after the administration of nitrite or nitrate. Elimination of nitrate from blood plasma of sheep over 80% was different than its excretion in urine in the unchanged.', '... Sodium ... nitrate /is/ for the most part rapidly absorbed & excreted unchanged ... /following oral ingestion/.', 'For more Absorption, Distribution and Excretion (Complete) data for SODIUM NITRATE (10 total), please visit the HSDB record page.']","['Transformation of nitrate to nitrite usually occurs within alimentary tract. Nitrite is intermediary product in redn of nitrate to ammonia within rumen of sheep & cow: it appears that above certain concn of nitrate, rate of redn of nitrite to ammonia becomes limiting & ... nitrite accumulates. Danger of nitrate poisoning is considered slight if nitrate is reduced in rumen or if complete redn to ammonia occurs rapidly ... /Inorganic nitrate salts/', '... Bacterial redn of nitrate to nitrite in human stomach was reported ... & n-nitrosodiphenylamine was identified in stomach contents of 31 human subjects who had received sodium nitrate & diphenylamine intragastrically.', 'Where bacteria are present and the environment can be anaerobic, nitrate can be reduced to nitrite. The main site for this reaction is mouth and stomach, but nitrite formation in the lower intestine and in the bladder (urinary infection) may also be of some toxicological importance.  Nitrite may be further reduced to nitrogen by bacteria under some conditions. In blood, nitrite transforms hemoglobin to methemoglobin and is simultaneously oxidized to nitrate. Normally methemoglobin gradually reverts to hemoglobin through enzymatic reactions. Nitrite has vasodilating properties, probably through transformation into nitric oxide (NO) or a NO-containing molecule acting as a signal factor for smooth muscle relaxation. Nitrite easily transforms into a nitrosating agent in an acidic environment and can react with a variety of compounds, eg ascorbic acid, amines, amides.  Nitrosation can also be mediated by bacteria, eg in the stomach. Some reaction products are carcinogenic (eg most nitrosoamines and amides). /Nitrate and nitrite/', 'Nitrate salts as such are no more toxic than other neutral salts, but if not promptly absorbed, they may be reduced to nitrites by bacteria in the bowel ... /Nitrate salts/', 'For more Metabolism/Metabolites (Complete) data for SODIUM NITRATE (8 total), please visit the HSDB record page.']",
4268,24269,CID 24269,N(=O)[O-].[Na+],,,,,,
4269,24270,CID 24270,B(=O)O[O-].[Na+],,,,,,
4270,24271,Perborate (BO(O2)1-),B(=O)O[O-],,,,,,
4271,24272,N'-(7-amino-1H-indol-3-yl)-N-hydroxyethanimidamide,CC(=NC1=CNC2=C1C=CC=C2N)NO,,,,,,
4272,24273,Vanadium tetrachloride,Cl[V](Cl)(Cl)Cl,,,,"['The distribution of vanadium among the tissues of the body studied using intravenously injected V(3+), intratracheally injected vanadium chloride or vanadium oxytrichloride, and oral doses of vanadyl sulfate or orthovanadate. The relative levels of V in organs and tissues differed according to the route of administration; however, differences in the distribution of different compounds administered by the same route were small, indicating that the vanadium may be converted to a common oxidation state in vivo. ... Rats injected with V(5+) later contained V(4+) in their tissues. In general, kidney, liver, and bone accumulated the highest levels of vanadium. The tissues that retained vanadium the longest were bone, kidney, testicle, and lung. Reported preliminary results for vanadium levels in fluids and hard tissues from humans. Vanadium appears to concentrate in bone and hair.']","['Within tissues in organisms, V3+ and V4+ predominate because of largely reducing conditions; in plasma, however, which is high in oxygen, V5+ is formed.']",
4273,24274,"Indoline, 1-nitroso-",C1CN(C2=CC=CC=C21)N=O,,,,,,
4274,24275,"3-(2-Dimethylaminoethyloxy)-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one",CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)OCCN(C)C)C,,,,,,
4275,24276,Amiphenazole hydrochloride,C1=CC=C(C=C1)C2=C(N=C(S2)N)N.Cl,,,,,,
4276,24277,ZINC pelargonate,CCCCCCCCC(=O)[O-].CCCCCCCCC(=O)[O-].[Zn+2],,,,,,
4277,24278,"1,2,3,4,5,6-Hexamethylbicyclo[2.2.0]hexa-2,5-diene",CC1=C(C2(C1(C(=C2C)C)C)C)C,,,,,,
4278,24279,"(3S,5S,7R,17S)-7,10,13-trimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol",C[C@@H]1C[C@H]2C[C@H](CCC2(C3C1C4CC[C@@H](C4(CC3)C)O)C)O,,,,,,
4279,24280,"(7R)-17-hydroxy-7,10,13-trimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one",C[C@@H]1CC2=CC(=O)CCC2(C3C1C4CCC(C4(CC3)C)O)C,,,,,,
4280,24281,"(2S)-2-amino-5-[[(2S)-1-[[(1S)-1-carboxy-4-(3H-diazirin-3-yl)-4-oxobutyl]amino]-5-(3H-diazirin-3-yl)-1,5-dioxopentan-2-yl]amino]-5-oxopentanoic acid",C(CC(=O)N[C@@H](CCC(=O)C1N=N1)C(=O)N[C@@H](CCC(=O)C2N=N2)C(=O)O)[C@@H](C(=O)O)N,,,,,,
4281,24282,"Magnesium;5-ethyl-2,6-dioxo-5-phenylpyrimidin-4-olate",CCC1(C(=O)NC(=O)N=C1[O-])C2=CC=CC=C2.[Mg+2],,,,,,
4282,24283,Phenobarbital calcium,CCC1(C(=O)NC(=O)N=C1[O-])C2=CC=CC=C2.CCC1(C(=O)NC(=O)N=C1[O-])C2=CC=CC=C2.[Ca+2],,,,,,
4283,24284,Cyclohexylsulfamic acid;3-[1-hydroxy-2-(methylamino)ethyl]phenol,CNCC(C1=CC(=CC=C1)O)O.C1CCC(CC1)NS(=O)(=O)O,,,,,,
4284,24285,Agn-PC-0jkhjx,CNCC(C1=CC(=CC=C1)O)O.C1=CC(=CC=C1N)S(=O)(=O)NC2=NC=CS2,,,,,,
4285,24286,1-Benzoylaziridine,C1CN1C(=O)C2=CC=CC=C2,,,,,,
4286,24287,Tin tetrachloride,Cl[Sn](Cl)(Cl)Cl,,,,,,
4287,24288,Cobalt chloride (CoCl2),Cl[Co]Cl,,,['Agents that reduce the frequency or rate of spontaneous or induced mutations independently of the mechanism involved. (See all compounds classified as Antimutagenic Agents.)'],"['... gastrointestinal absorption of cobalt chloride given to rats is estimated to be about 30%.', 'When radioactive (60)cobalt as cobaltous chloride was given orally to humans, the avg absorption was calculated at 5-44%, with these figures being based on the amt of unabsorbed cobalt remaining in the feces. Based on 24 hr urinary excretion figures of perorally given (60)cobalt absorption has been estimated to be on avg 18%, individual values ranging from 9% to 42%. Absorption and/or excretion is influenced by the amt of cobalt given and by nutritional factors.', 'Twelve to 36 hr after the admin of a small dose of radioactive cobalt chloride to pregnant mice ... the highest activity of radioactive cobalt /was found/ in liver, kidney, fetus, and placenta.', '... One week after /rats/ ... had received ten daily sc injections of cobalt chloride (40 mg/kg) and ... the highest amt of cobalt /was found/ in the liver, which on avg contained 11% of the admin dose.', 'For more Absorption, Distribution and Excretion (Complete) data for Cobaltous chloride (22 total), please visit the HSDB record page.']",,"['Following a single oral dose /of cobalt chloride/, the blood cobalt concentration-time curve /in male fischer 344 rats/ was triphasic, peaked at 3.2 hr, and had an absorptive half-life of 0.9 hr, an elimination phase half-life of 3.9 hr, and a terminal elimination half-life of 22.9 hr. ... Following intravenous administration, 10.1% of the dose was excreted in the feces, indicating that cobalt can be secreted in the bile. Following a single intravenous injection, the concentration-time curve displayed three segments. The first segment, which occurred during the first 4 hr, had a rapid half-life of 1.3 hr. The second phase, from 4 to 12 hr, demonstrated a slower clearance rate with a half-life of 4.3 hr. The final and slowest phase, from 12 to 36 hr, had a half-life of 19 hr.', 'The retention of (60)CoCl2 (cobaltous chloride) given iv has been studied by total body counting for periods of up to 1000 days. Following a rapid initial clearance within days of about 90% of a given dose, 10% was eliminated with a biological half-time of about 2 yr. /(60)Cobaltous chloride/']"
4288,24289,Ammonium trichloroacetate,C(=O)(C(Cl)(Cl)Cl)[O-].[NH4+],,,,,,
4289,24290,Palladium(II) chloride,Cl[Pd]Cl,,,,"['Palladium chloride is not readily absorbed from sc injection ... .', ""The absorption of palladium from the GI tract is insignificant. A single intragastrical dose of 103Pd isotope given to male Charles River CD-1 rats was rapidly excreted from their organism with feces. The total retention was lower than 0.5%. After 24 hr, insignificant quantities of palladium chloride were found only in liver and kidneys; after 104 days no palladium chloride was found in any analyzed tissue or organ. A considerably higher absorption and retention were observed after iv administration of palladium chloride. The highest concentration of 103PdCl2 isotope was found in kidneys, spleen, liver, adrenals, lungs, and bones. ...In male Charles River CD-1 rats receiving 25 ug PdCl2 in 0.2 mL saline, the retention in the animals' organs after 3 days was 0.4% of the initial charge and the absorption was <0.5% of the initial dose. ...After intratracheal administration, the highest concentrations of 103Pd were observed in lungs, followed by kidneys, spleen, bones, and liver."", 'The presence of 103Pd isotope was also examined in the internal organs of female rats receiving PdCl2 iv on 16th day of gestation. The concentration of 103Pd was assessed in various organs of the dams and in fetuses 24 hr after the administration. The low concentration of 103Pd isotope in fetal bodies indicates that Pd does not easily penetrate the placenta.', 'Dietary administration to rats of high levels of the slightly water-soluble palladium salts /including/ palladium(II) chloride... (about 3000 mg palladium/kg feed for 4 weeks; corresponding to about 700 mg/kg bw/day) resulted in palladium tissue concentrations (in mg/kg wet weight) as follows: kidney (35, respectively) >liver (2) >spleen (0.7) >testis (0.24) >blood (<0.04) >brain (<0.01). ...The total consumption during the 4-wk diet period amounted to about 2000 mg palladium/rat (i.e., 2020 mg palladium/rat from palladium(II) chloride; mean body weights of the rats when started on the diets: 100-110 g).', 'For more Absorption, Distribution and Excretion (Complete) data for PALLADIUM(2+) CHLORIDE (7 total), please visit the HSDB record page.']",,['...In adult rats (Charles River CD-1 strain) ...after iv exposure... a biological half-life of 12 days /was estimated/.']
4290,24291,CID 24291,[Na+].[Cl-],,,,,,
4291,24292,CID 24292,[Na+].[Br-],,,,,,
4292,24293,Cesium chloride,[Cl-].[Cs+],,,,"['Real and simulated particulate fallout solutions of 134CsCl were fed to 102 healthy volunteers.  An average of 3% of the radioactivity of week-old fallout was absorbed: the range was 0-9%.', 'Data were obtained for the distribution-excretion pattern of 137Cs in guinea pigs over a period of 100 days after administration by three different routes. Three groups of twenty guinea pigs were used. Solutions of cesium chloride containing 137Cs as a tracer were administered to the animals by inhalation, by ingestion and by i.p. injection. Urine and feces were collected daily until sacrifice, and the time-tissue distribution patterns were determined after death. All measurements were made by gamma counting with a NaI (Tl) detector. Since cesium chloride is extremely soluble, it was absorbed rapidly from the lungs, the digestive tract and the abdominal cavity. After the first day, the skeletal muscle had the largest concentration of 137Cs. Its retention in muscle may be approximated by a single exponential function with an average biological half-life of 10 days. Concentration in other tissues did not differ significantly from that in the muscle. The 137Cs concentration in total excretion followed an exponential pattern with a rapidly and a slowly decreasing component. The average urine-to-feces ratio was 2.8. More than 95 per cent was excreted within 32 days; at this time, approximately 65 per cent of the remaining radioactivity was located in the skeletal muscle.', 'Absorption of CsCl, SrCl2, BaCl2 and CeCl3 deposited on nasal membranes directly into the general circulation was studied in Syrian hamsters and compared with gastrointestinal tract absorption. More than 50 % of the cesium, strontium and barium was absorbed directly from the nasal membranes but <4 % of the cerium. For all isotopes, nasal absorption was approximately = or >gastrointestinal absorption during the first 4 hr after administration. This study emphasized the importance of direct nasal absorption of deposited materials in inhalation toxicity evaluations especially with readily soluble aerosols having mass median aerodynamic diameters >5 m when nasopharyngeal deposition predominates.']",,
4293,24294,Antimony pentachloride,Cl[Sb](Cl)(Cl)(Cl)Cl,,,,"['Following intraperitoneal injection in the rat, 88% of pentavalent antimony is excreted in the urine and 1% in the feces. ...A limited subchronic study gave weak indications of partly reversible damage to the lungs, heart, liver, kidneys and thyroid gland as well as accumulation of antimony in the spleen, heart, lymph nodes and thyroid gland, following inhalation exposure of rats to 0.037 mg antimony-V-chloride/L air, 2 hours/day for 4 months.', 'Distribution in rats after chronic poisoning by inhalation of antimony pentachloride showed high antimony concn in blood. Levels in liver, kidneys, spleen and pancreas were similar.']",,
4294,24295,Phosphorus pentafluoride,FP(F)(F)(F)F,,,,,,
4295,24296,Chlorcyclizine pamoate,CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O,,,,,,
4296,24297,CID 24297,CC#CC(C)C1(C(=O)NC(=NC1=O)S)CC=C,,,,,,
4297,24298,"10-[2-(1-Methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine;naphthalene-1,5-disulfonic acid",CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)C.C1=CC2=C(C=CC=C2S(=O)(=O)O)C(=C1)S(=O)(=O)O,,,,,,
4298,24299,CID 24299,CC(=NN=C(N)S)C1=CC=C(C=C1)Cl,,,,,,
4299,24300,"Octanesulfonic acid, thio-, S-octyl ester",CCCCCCCCSS(=O)(=O)CCCCCCCC,,,,,,
4300,24301,"1,1'-(1,3-Phenylenedicarbonyl)bis[2-methylaziridine]",CC1CN1C(=O)C2=CC(=CC=C2)C(=O)N3CC3C,,,,,,
4301,24302,"3-Methyl-2H-1,4-benzoxazin-2-one",CC1=NC2=CC=CC=C2OC1=O,,,,,,
4302,24303,"2-(Diethylamino)-5-phenyl-1,3,4-oxadiazole hydrochloride",CC[NH+](CC)C1=NN=C(O1)C2=CC=CC=C2.[Cl-],,,,,,
4303,24304,"N,N-Diethyl-5-phenyl-1,3,4-oxadiazole-2-amine",CCN(CC)C1=NN=C(O1)C2=CC=CC=C2,,,,,,
4304,24305,"(2-pentan-3-yl-2H-1,3,4-oxadiazol-5-ylidene)azanium chloride",CCC(CC)C1N=NC(=[NH2+])O1.[Cl-],,,,,,
4305,24306,"2-pentan-3-yl-2H-1,3,4-oxadiazol-5-imine",CCC(CC)C1N=NC(=N)O1,,,,,,
4306,24307,"2-(Chloroacetamido)-5-phenyl-1,3,4-oxadiazole",C1=CC=C(C=C1)C2=NN=C(O2)CNC(=O)Cl,,,,,,
4307,24308,"Acrylonitrile, 2-(chloromethyl)-",C=C(CCl)C#N,,,,,,
4308,24309,2-Ethylhexyl thioglycolate,CCCCC(CC)COC(=O)CS,,,,,,
4309,24310,beta-D-Fructopyranose,C1[C@H]([C@H]([C@@H]([C@](O1)(CO)O)O)O)O,,,,"['TWICE THE CONCN OF FRUCTOSE CAN BE INFUSED AT THE SAME RATE AS DEXTROSE WITH BETTER RETENTION AND LESS DISTURBANCE OF FLUID BALANCE.', '...ADVANTAGES OF FRUCTOSE IS ITS RAPID REMOVAL FROM EXTRACELLULAR SPACE, & THEREFORE, URINARY EXCRETION IS MINIMIZED.']","['IN ABSENCE OF GLUCOSE, FRUCTOSE IS PHOSPHORYLATED PERIPHERALLY BY HEXOKINASE TO FRUCTOSE-6-PHOSPHATE, &, ON ACCOUNT OF HIGH KM VALUE FOR FRUCTOSE & LOW KM VALUE FOR GLUCOSE, LATTER IS PREFERENTIALLY PHOSPHORYLATED BY THIS ENZYME IN PERIPHERAL TISSUES.', 'ORAL FRUCTOSE IS OFTEN CONVERTED TO GLUCOSE IN INTESTINAL MUCOSA OF A NUMBER OF SPECIES, SUCH AS GUINEA PIG, HAMSTER, & DOG. NEWBORN PIGS & YOUNG CALVES UP TO 1 MO OF AGE CANNOT UTILIZE IT. SPECIES...WITH LOW GLUCOSE-6-PHOSPHATE DEHYDROGENASE & RELATED ENZYME DEFICIENCIES MAY HAVE DIFFICULTY IN METABOLIZING IT.', 'FRUCTOSE IS MORE RAPIDLY METABOLIZED & MORE QUICKLY CONVERTED TO GLYCOGEN THAN IS DEXTROSE, & PRESENCE OF INSULIN IS NOT NECESSARY FOR THIS REACTION TO TAKE PLACE. WHEN...INJECTED LOWER LEVELS OF BLOOD SUGAR & LESS SPILLAGE RESULT THAN WHEN SIMILAR AMT OF DEXTROSE ARE GIVEN @ SAME RATE.']",
4310,24311,7-Ethylquinoline,CCC1=CC2=C(C=CC=N2)C=C1,,,,,,
4311,24312,5-Methylquinoline,CC1=C2C=CC=NC2=CC=C1,,,,,,
4312,24313,"Alanine, N-benzyloxycarbonyl-3-phenyl-, cyanomethyl ester, L-",C1=CC=C(C=C1)C[C@@H](C(=O)OCC#N)NC(=O)OCC2=CC=CC=C2,,,,,,
4313,24314,tert-Butyl glycidyl ether,CC(C)(C)OCC1CO1,,,,,,
4314,24315,"N,1-Dimethyl-N-2-propynylhexylamine",CCCCCC(C)N(C)CC#C,,,,,,
4315,24316,CID 24316,C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C=NC4=C3NC(=NC4=O)N)O)OP(=O)(O1)O,,,,,,
4316,24317,"Cyclohexane, 1,2,3-trimethyl-, cis-1,2,trans-1,3-",C[C@@H]1CCC[C@H](C1C)C,,,,,,
4317,24318,Hexacontane,CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC,,,,,,
4318,24319,2-Nitrobenzenesulfenyl chloride,C1=CC=C(C(=C1)[N+](=O)[O-])SCl,,,,,,
4319,24320,Tribenzylammonium chloride,C1=CC=C(C=C1)C[NH+](CC2=CC=CC=C2)CC3=CC=CC=C3.[Cl-],,,,,,
4320,24321,Tribenzylamine,C1=CC=C(C=C1)CN(CC2=CC=CC=C2)CC3=CC=CC=C3,,,,,,
4321,24322,Trichloromelamine,C1(=NC(=NC(=N1)NCl)NCl)NCl,,,,,,
4322,24323,2-(2-Aminoethylmercapto)benzimidazoline bromide hydrobromide,C1=CC=C2C(=C1)NC(=[NH+]2)SCC[NH3+].[Br-].[Br-],,,,,,
4323,24324,2-(1H-benzimidazol-2-ylsulfanyl)ethanamine,C1=CC=C2C(=C1)NC(=N2)SCCN,,,,,,
4324,24325,"L-Arginine, L-aspartate",C(C[C@H](C(=O)O)N)CN=C(N)N.C(C(C(=O)O)N)C(=O)O,,,,,,
4325,24326,"4',5-Dichlorosalicylanilide",C1=CC(=CC=C1NC(=O)C2=C(C=CC(=C2)Cl)O)Cl,,,,,,
4326,24327,5-Diazouracil monohydrate,C1=C(C(=O)NC(=N1)[O-])[N+]#N.O,,,,,,
4327,24328,"2,4-dioxo-1H-pyrimidine-5-diazonium",C1=C(C(=O)NC(=O)N1)[N+]#N,,,,,,
4328,24329,"[(17R)-17-hydroxy-13-methyl-17-(2-methylprop-2-enyl)-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-yl] acetate",CC(=C)C[C@@]1(CCC2C1(CCC3C2CCC4=C3C=CC(=C4)OC(=O)C)C)O,,,,,,
4329,24330,CID 24330,[K+].[I-],,,,,,
4330,24331,Propyl nicotinate,CCCOC(=O)C1=CN=CC=C1,,,,,,
4331,24332,"[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate;2-(diethylamino)ethyl 4-aminobenzoate",CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N,,,,,,
4332,24333,CID 24333,CC1=CC2=C(C=C1C)N(C3=NC(=NC(=O)C3=N2)[O-])C[C@H]([C@H]([C@H](CO)O)O)O.[Na+],,,,,,
4333,24334,CID 24334,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C(NCN4CCCC4)O)C(=O)[C@]3(C(=O)C2=C(C5=C1C=CC=C5O)O)O)N(C)C)O.[N+](=O)(O)[O-],,,,,,
4334,24335,CID 24335,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C(NCN4CCCC4)O)C(=O)[C@]3(C(=O)C2=C(C5=C1C=CC=C5O)O)O)N(C)C)O,,,,,,
4335,24336,CID 24336,CN1C2=C(C(=O)N(C1=O)C)NC=N2.COC(CNC(=O)C1=CC=CC=C1OCC(=O)[O-])C[Hg].O.[Na+],,,,,,
4336,24337,"7-Benzhydryloxy-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonane",CN1C2CC(CC1C3C2O3)OC(C4=CC=CC=C4)C5=CC=CC=C5,,,,,,
4337,24338,CID 24338,C1=CC(=CC=C1NC(=O)N)[As](=O)(O)[O-].[Na+],,,,,,
4338,24339,CID 24339,[F-].[Na+],,,,,,
4339,24340,CID 24340,[O-]Cl.[Na+],,,,,,
4340,24341,Hypochlorous acid,OCl,,,['Electron-accepting molecules in chemical reactions in which electrons are transferred from one molecule to another (OXIDATION-REDUCTION). (See all compounds classified as Oxidants.)'],,,
4341,24342,CID 24342,[O-]P=O.[Na+],,,,,,
4342,24343,CID 24343,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)[O-].[Na+],,,,,,
4343,24344,CID 24344,[O-]I(=O)=O.[Na+],,,,,,
4344,24345,Iodic acid,OI(=O)=O,,,,,,
4345,24346,Sodium disulphite,[O-]S(=O)OS(=O)[O-].[Na+].[Na+],,,,,,
4346,24347,Sulfur hydroxide oxide (S2(OH)2O3),OS(=O)OS(=O)O,,,,,,
4347,24348,3-Iodo-L-tyrosine calcium,C1=CC(=C(C=C1C(C(=O)[O-])N)I)O.[Ca+2],,,,,,
4348,24349,2-Amino-2-(4-hydroxy-3-iodophenyl)acetic acid,C1=CC(=C(C=C1C(C(=O)O)N)I)O,,,,,,
4349,24350,Iodocopper,[Cu]I,,,,,,
4350,24351,Propionylpromazine hydrochloride,CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN(C)C.Cl,,,,,,
4351,24352,Propionylpromazine,CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN(C)C,,,,,,
4352,24353,CID 24353,[Na+].[I-],,,,,,
4353,24354,Tetrahydro-2-furancarboxaldehyde,C1CC(OC1)C=O,,,,,,
4354,24355,CID 24355,CC1CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC3C(O3)C=CC(=O)O1)O)O)O)C(=O)O)O[C@H]4C(C([C@@H](C(O4)C)O)N)O,,,,,,
4355,24356,"5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine",CC1=CC(=NC2=NC=NN12)C,,,,,,
4356,24357,"2,4,5-Trichloroimidazole",C1(=C(N=C(N1)Cl)Cl)Cl,,,,,,
4357,24358,"Maleimide, N-vinyl-",C=CN1C(=O)C=CC1=O,,,,,,
4358,24359,"Maleimide, N-chloromethyl-",C1=CC(=O)N(C1=O)CCl,,,,,,
4359,24360,Camptothecin,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O,['Investigated for the treatment of cancer.'],['Camptothecin demonstrated strong anticancer activity in preliminary clinical trials but also low solubility and adverse drug reaction. Camptothecin is believed to be a potent topoisomerase inhibitor that interferes with the essential function of topoisomerase in DNA replication.'],"['Compounds that inhibit the activity of DNA TOPOISOMERASE I. (See all compounds classified as Topoisomerase I Inhibitors.)', 'Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)']",,,
4360,24361,Pyrrocaine,CC1=C(C(=CC=C1)C)NC(=O)CN2CCCC2,,,,,,
4361,24362,"2,3-Dimethoxy-5-methyl-6-(3,7,11,15-tetramethylhexadec-2-enyl)cyclohexa-2,5-diene-1,4-dione",CC1=C(C(=O)C(=C(C1=O)OC)OC)CC=C(C)CCCC(C)CCCC(C)CCCC(C)C,,,,,,
4362,24363,"Citric acid, calcium salt",C(C(=O)[O-])C(CC(=O)[O-])(C(=O)O)O.[Ca+2],,,,,,
4363,24364,4-Bromo-2-nitrophenol,C1=CC(=C(C=C1Br)[N+](=O)[O-])O,,,,,,
4364,24365,d-Tetramethrin,CC(=C[C@@H]1[C@H](C1(C)C)C(=O)OCN2C(=O)C3=C(C2=O)CCCC3)C,,,,,,
4365,24366,"ETHER, BUTYL p-NITROSOPHENYL",CCCCOC1=CC=C(C=C1)N=O,,,,,,
4366,24367,"Acetic acid, phenyl-, 2,2-bis(2-chloroallyl)hydrazide",C=C(CN(CC(=C)Cl)NC(=O)CC1=CC=CC=C1)Cl,,,,,,
4367,24368,4-Chloro-2-(2-chloroprop-2-enyl)pent-4-enehydrazide,C=C(CC(CC(=C)Cl)C(=O)NN)Cl,,,,,,
4368,24369,"Acetic acid, phenyl-, (2-chloro-1-(chloromethyl)ethylidene)hydrazide",C1=CC=C(C=C1)CC(=O)NN=C(CCl)CCl,,,,,,
4369,24370,2-Benzoylpyrrole,C1=CC=C(C=C1)C(=O)C2=CC=CN2,,,,,,
4370,24371,Fenestrel,CCC1C(C(CC=C1C2=CC=CC=C2)C(=O)O)C,,,,,,
4371,24372,"1,2-Diethylhydrazine dihydrochloride",CCNNCC.Cl.Cl,,,,,,
4372,24373,Zirconium oxychloride,O=[Zr].Cl.Cl,,,,,,
4373,24374,Oxozirconium,O=[Zr],,,,,,
4374,24375,Zinc bromide (ZnBr2),[Zn](Br)Br,,,,,,
4375,24376,"2-Butenoic acid, 3-((dimethoxyphosphinyl)oxy)-, 1-phenylethyl ester (9CI)",CC(C1=CC=CC=C1)OC(=O)C=C(C)OP(=O)(OC)OC,,,,,,
4376,24377,Metalol,CC(C(C1=CC=C(C=C1)NS(=O)(=O)C)O)NC,,,,,,
4377,24378,Magnesium;but-2-enedioate,C(=CC(=O)[O-])C(=O)[O-].[Mg+2],,,,,,
4378,24379,Dipotassium;but-2-enedioate,C(=CC(=O)[O-])C(=O)[O-].[K+].[K+],,,,,,
4379,24380,Ferric Chloride,Cl[Fe](Cl)Cl,,,['Agents capable of exerting a harmful effect on the body. (See all compounds classified as Noxae.)'],"['An ovine model of maternal iron poisoning in pregnancy was used to examine the placental transport of deferoxamine and ferrioxasmine and to follow maternal and fetal serum iron concentrations when maternal serum iron levels exceeded total iron-binding capacity. Ewes in the third stage of gestation underwent hysterectomy and delivery of the fetal head through an abdominal incision while under ketamine and halothane anesthesia. The fetal external jugular vein was catheterized for sampling of venous blood while the fetus remained in utero. Administration of deferoxamine mesylate or ferrioxamine mesylate IV to ewes was not accompanied by measurable deferoxamine or ferrioxamine in fetal blood. In a final experiment, four gravid ewes in a control group received 2 mg/kg maternal body wt iron IV over 60 minutes. An experimental group comprision another four ewes received similar doses of iron but then received 50 mg/kg deferoxamine mesylate IV over 15 minutes. Control and deferoxamine ewes reached similar peak maternal serum iron concentration (2,479 + or - 266 and 2,121 + or - 343 ug/dL, respectively). The markedly elevated maternal serum iron concentrations were not accompanied by meaningful elevations in fetal serum iron level over baseline values. Maternal deferoxamine infusion resulted in a more rapid fall in maternal serum iron concentrations but had no effect on fetal serum iron levels. The ovine fetus appears to be protected from elevated maternal serum iron concentrations in the last trimester of prenancy. It could not be demonstrated that meaningful quantities of deferoxamine or ferrioxamine cross the placenta in the last trimester.']",,
4380,24381,"4-Chloro-1,3,5-triazin-2-amine",C1=NC(=NC(=N1)Cl)N,,,,,,
4381,24382,"Acetophenone, 4'-(2-(diethylamino)ethoxy)-6'-hydroxy-, hydrochloride",CC[NH+](CC)CCOC1=CC(=C(C=C1)C(=O)C)O.[Cl-],,,,,,
4382,24383,1-[4-[2-(Diethylamino)ethoxy]-2-hydroxyphenyl]ethanone,CCN(CC)CCOC1=CC(=C(C=C1)C(=O)C)O,,,,,,
4383,24384,Calcium;but-2-enedioate,C(=CC(=O)[O-])C(=O)[O-].[Ca+2],,,,,,
4384,24385,Nickel chloride,Cl[Ni]Cl,,,,"['THE KIDNEYS SHOWED LARGEST AMT OF NICKEL/G IN MALE RATS 6 HR AFTER INTRATRACHEAL INJECTION OF 1 MG NICKEL AS NICKEL CHLORIDE, FOLLOWED BY LUNG, ADRENAL, LIVER, PANCREAS, SPLEEN, HEART, & TESTIS IN ORDER.', 'TETA, 0.75 MMOL/KG IM ADMIN TO FISCHER RATS IMMEDIATELY PRIOR TO (63)NICKEL CHLORIDE, 0.068 OR 0.10 MMOL/KG IP OR IM. RENAL CLEARANCE WAS EST TO BE GREATER THAN 20 TIMES NONCHELATED-(63)NICKEL.', 'AFTER SINGLE IP INJECTION OF NICKEL CHLORIDE (17 OR 816 UG NICKEL/ANIMAL, RESP) INTO RATS OR RABBITS, (63)NICKEL ION RAPIDLY CLEARED PLASMA OR SERUM FIRST 2 DAYS & SLOWER NEXT 5 DAYS.', 'SOL NICKEL CHLORIDE ... RAPIDLY CLEARED AFTER INTRATRACHEAL INJECTION /IN RATS/. BY 72 HR, 90% OF INJECTED NICKEL ... EXCRETED, MAINLY (75%) IN THE URINE. ... 6 HR AFTER /ONE/ INTRATRACHEAL INJECTION OF 1 MG NICKEL CHLORIDE, KIDNEYS SHOWED GREATEST AMT OF NI/G. /THEN/ ... LUNG, KIDNEYS ... PANCREAS, SPLEEN, HEART, TESTES.', 'For more Absorption, Distribution and Excretion (Complete) data for NICKEL CHLORIDE (14 total), please visit the HSDB record page.']","['The effects of nickel on hepatic glutathione and the enzymes glutathione reductase, glutathione-peroxidase, glutathione-S-transferase, and gamma-glutamyl-transpeptidase were investigated in female albino rats. Three groups of rats were sacrificed 16, 24, or 72 hr after a subcutaneous injection of nickel as nickel chloride at a level of 200 micromol/kg. Four groups of rats were sacrificed 16 hr after a single subcutaneous injection of either 50, 100, 200, or 400 micromol/kg nickel chloride. The single dose of 200 micromol/kg nickel chloride increased glutathione levels and glutathione reductase and glutathione-S-transferase activity at 16 and 24 hr post treatment. Glutathione peroxidase and gamma-glutamyl-transpeptidase activity were reduced at 16 and 24 hr. The effect on enzyme activity was dose dependent at all levels of nickel chloride. Glutathione levels were decreased at 50 micromol/kg relative to the control values but increased with increasing nickel levels.', 'Induction of heme oxygenase in liver, kidney, and other organs of rodents is a nonspecific, toxic response to parenteral administration of numerous metal compounds. Cobalt and cadmium ions are especially potent inducers of heme oxygenase in rat liver; tin ion, nickel ion, and arsenic ion, are potent inducter of enzyme in rat adrenal. Rat spleen testis, and brain are relatively refractory to metal induction of heme oxygenase activity; in testicular microsomes from cadmium ion-treated rats, heme oxygenase activity is markedly inhibited. Metal induction of heme oxygenase requires de novo synthesis of mRNA and protein, based on 1) experiments with metabolic inhibitrors (actinomycin d, puromyci, and cycloheximide) and 2) translation assays of heme oxygenase mRNa. Heme oxygenase induction by metals is generally suppressed by treatments with SH compounds (for example, cysteine and glutathione) and enhanced by agents that deplete tissue SH levels (for example, diethyl maleate). Administration of DDC exerts a pronounced synergistic effect on Ni2+ induction of heme oxygenase activity in rat tissues, attributable in part to enhanced cellular uptake of nickel. Induction of heme oxygenase activity in rat tissues, attributable in part to enhanced cellular uptake of nickel. Induction of heme oxygenase is not sustained during repeated daily treatments of rats with nickel chloride.']",['The biological half-life /in fetal tissues of mice/ was calculated to be 8.9 hr in the rapid phase and 33 hr in the slow phase.']
4385,24386,Thionyl chloride,O=S(Cl)Cl,,,,"['Thionyl chloride is rapidly hydrolyzed to sulfur dioxide and hydrogen chloride and the metabolism and disposition follow those two compounds. Following inhalation, sulfur dioxide is distributed throughout the body after dissolving into surface fluid. Some remains in the respiratory system for a week or more following exposure. Urinary excretion clears it from the body. Hydrogen chloride dissolves in the nasal passages. Hydrogen chloride is not metabolized; however, hydrogen and chloride ions resulting from adsorption in the respiratory tract may be distributed throughout the body.']","['Thionyl chloride is rapidly hydrolyzed to sulfur dioxide and hydrogen chloride and the metabolism and disposition follow those two compounds. Following inhalation, sulfur dioxide is distributed throughout the body after dissolving into surface fluid. Some remains in the respiratory system for a week or more following exposure. Urinary excretion clears it from the body. Hydrogen chloride dissolves in the nasal passages. Hydrogen chloride is not metabolized; however, hydrogen and chloride ions resulting from adsorption in the respiratory tract may be distributed throughout the body.', 'In view of its reactivity with water, moisture, etc., rapid hydrolysis upon contact with mucous membranes (eyes, respiratory tract) releaseing sulfur dioxide and hydrogen chloride can be expected.']",
4386,24387,Phosphorus trichloride,P(Cl)(Cl)Cl,,,,"['The substance can be absorbed into the body by inhalation or by ingestion.', 'Phosphorus trichloride /reacts/ with the water component of the tissues /it/ first contact. The resulting hydrogen chloride and phosphorus oxyacid ions, if absorbed, join the body pools of these ions. Phosphate, chloride, and hydrogen ions are easily excreted by the kidneys by normal physiological mechanisms.']","['Phosphorus trichloride /reacts/ with the water component of the tissues /it/ first contact. The resulting hydrogen chloride and phosphorus oxyacid ions, if absorbed, join the body pools of these ions. Phosphate, chloride, and hydrogen ions are easily excreted by the kidneys by normal physiological mechanisms.']",
4387,24388,CID 24388,C1=CC(=CC(=C1)O)C(=O)[O-].[Na+],,,,,,
4388,24389,"Acetic acid, ((2,4-dichlorophenyl)thio)-",C1=CC(=C(C=C1Cl)Cl)SCC(=O)O,,,,,,
4389,24390,"INDOLE, 5-FLUORO-3-PHENYL-2-(p-(2-(1-PYRROLIDINYL)ETHOXY)PHENYL)-",C1CCN(C1)CCOC2=CC=C(C=C2)C3=C(C4=C(N3)C=CC(=C4)F)C5=CC=CC=C5,,,,,,
4390,24391,"INDOLE, 3-PHENYL-2-(p-(2-(1-PYRROLIDINYL)ETHOXY)PHENYL)-",C1CCN(C1)CCOC2=CC=C(C=C2)C3=C(C4=CC=CC=C4N3)C5=CC=CC=C5,,,,,,
4391,24392,4'-(2-(Diethylamino)ethoxy)-2-(p-methoxyanilino)-2-phenylacetophenone,CCN(CC)CCOC1=CC=C(C=C1)C(=O)C(C2=CC=CC=C2)NC3=CC=C(C=C3)OC,,,,,,
4392,24393,Ferrous Sulfate,[O-]S(=O)(=O)[O-].[Fe+2],['Ferrous sulfate is used for the prevention and treatment of iron deficiency anemia in adults and children.'],"['Ferrous sulfate replenishes iron, an essential component in hemoglobin, myoglobin, and various enzymes. It replaces the iron that is usually found in hemoglobin and myoglobin. Iron participates in oxygen transport and storage, electron transport and energy metabolism, antioxidant and beneficial pro-oxidant functions, oxygen sensing, tissue proliferation and growth, as well as DNA replication and repair.']",,"['Approximately 5 â 10% of dietary iron is absorbed, and this absorption rate increases to up to 30% in iron deficiency states. Oral iron supplements are absorbed up to 60% via active and passive transport processes. Gastrointestinal absorption of iron occurs via strict regulation by the enterocyte and duodenal cytochrome and ferric reductase enzymes. The hormone hepcidin heavily regulates iron absorption and distribution throughout the body.  The median time to maximum serum concentration (Tmax) is generally 4 hours after administration. Between 2-8 hours post administration, average serum iron concentrations fluctuate by 20%, according to one study. Bioavailability of iron depends on whether it is administered in a film coated tablet or enteric coated tablet. One pharmacokinetic study in healthy volunteers revealed a 30% bioavailability for enteric coated tablets. The AUC of enteric coated tablets varied between a lower limit of -46.93 to 5.25 Âµmolxh/l. Cmax is higher for film coated tablets, ranging from 3.4 to 22.1 Âµmol/h/l.  It is advisable to take ferrous sulfate with ascorbic acid, as this practice may increase absorption.  Avoid antacids, tea, coffee,tea, dairy products, eggs, and whole-grain bread for at least an hour after taking ferrous sulfate. Calcium can decrease iron absorption by 33% if taken concomitantly.', 'Oral iron is recycled, with some loss in the urine, sweat, and desquamation. Some iron can be lost during menstrual bleeding   This loss is balanced by changes in intestinal absorption. The enzyme hepcidin promotes the excretion of iron via the sloughing of enterocytes with ferritin stores into the feces.', 'About 60% of iron is distributed the erythrocytes.  The remainder of the iron is found in muscle tissues (as a part of myoglobin), and in a variety of different enzymes, as well as in storage form. Most stored iron is in the form of ferritin, which can be found in the liver, bone marrow, spleen and, and muscle. Iron crosses the placenta and is also found in breast milk.', '... The bioavailability studies were carried out using four groups of 30 female mice each. In two groups, we studied the absorption of ferrous ascorbate and ferrous sulfate, both in water as reference standards, which show absorptions of 13.1+/-4.9% and 13.2+/-4.3%, respectively. With the third group, we studied the absorption of ferrous sulfate in milk; its value, 7.9+/-3.2%, is significantly lower than that of the remaining groups, with a p < 0.01. The studies with SFE-171 in milk, were performed on the fourth group, with a result of 11.6+/-4.5%, demonstrating that its absorption does not differ significantly from that of the reference standards. The absorption mechanism was determined by means of in vivo self-displacement studies of the ferrous ion and the SFE-171, taking ferrous sulfate as the reference compound. For this study, 210 female mice were used, and no significant difference between the absorption mechanism of both products could be observed.', 'We investigated the iron bioavailability of microencapsulated ferrous sulfate (SFE-171) in a diet based on powdered milk by using the prophylactic method in rats.The SFE-171 was added into fluid milk and industrially processed into powdered milk, which was then mixed in our laboratory with a normalized diet (17.2 +/- 2.1 mg Fe/kg). A reference standard diet using ferrous sulfate as iron-fortifying source (19.8 p+/- 2.9 mg Fe/kg) and a control diet without added iron (4.6 +/- 0.8 mg Fe/kg) were prepared in the laboratory in a similar way. These diets were administered to different groups of weaning rats for 28 d as the only solid nourishment. The iron bioavailability of the different sources was calculated as the relation between the mass of iron incorporated into hemoglobin during the treatment and the total iron intake per animal. The iron bioavailability values of SFE-171 and ferrous sulfate in the fortified diets were 41.6 +/- 6.6% and 42.6 +/- 4.2%, respectively; these results were significantly higher (P < 0.01) than the iron bioavailability of the control diet (28.8 +/- 8.1%).', 'A prospective analytical study was conducted to determine the relationship between nonprotein-bound iron and serum iron concentrations following gastric instillation of ferrous sulfate. Four female pigs (2022 kg) with indwelling central venous lines and gastrostomy tubes were studied. A 5% solution of ferrous sulfate (20 mg elemental iron/kg bwt) was administered through the gastrostomy tube over 1 to 2 min. Six hourly blood samples were collected, and serum samples were subjected to ultrafiltration with the filtrate representing nonprotein-bound iron. Iron concentrations were determined by atomic absorption spectrophotometry. Baseline (mean | SD) iron concentrations were 73 | 25 mug/dL as the serum total and 21 | 4 mug/dL as nonprotein-bound iron. The serum iron and nonprotein-bound iron concentrations achieved a peak of 191 | 66 and 23 | 10, respectively, at 2 h and declined to near baseline values at 6 h. The mean ratio of filtrate to serum iron concentration was 0.', 'Gastrointestinal absorption of iron is adequate and essentially equal from...ferrous...sulfate, fumarate, gluconate, succinate, glutamate, and lactate.']","['The metabolism of iron is complex. Normally, iron exists in the ferrous (Fe2+) or ferric (Fe3+) state, but since Fe2+ is oxidized to Fe3+, which hydrolyzes to insoluble iron(III)hydroxides in neutral aqueous solutions, iron binds to plasma proteins and is either transported or stored throughout the body.  There are three proteins that serve to regulate the storage and transport of ingested iron. The first protein , transferrin, transports iron in both the plasma and extracellular fluid. Ceruloplasmin in the plasma and hephaestin on the enterocyte participate in the oxidation and binding of iron to transferrin. The main role of transferrin is the chelation of iron to prevent the production of reactive oxygen species, while facilitating its transport into cells.   The transferrin receptor, located on many cells that require iron, binds the transferrin complex and internalizes this complex. Ferritin is a protein that stores iron, making it readily available for body requirements.']","['The half-life of orally administered iron is not readily available in the literature, with total effects lasting 2-4 months (congruent with the red blood cell life span) with an onset of action of 4 days and peak activity at 7-10 days.']"
4393,24394,Tantalum pentachloride,Cl[Ta](Cl)(Cl)(Cl)Cl,,,,,,
4394,24395,"Copper(2+) dioctadeca-9,12-dienoate",CCCCCC=CCC=CCCCCCCCC(=O)[O-].CCCCCC=CCC=CCCCCCCCC(=O)[O-].[Cu+2],,,,,,
4395,24396,CID 24396,C1C(=NC2=C(C=C(C=C2)Cl)C(=[N+]1[O-])C3=CC=CC=C3)[NH3+].[Cl-],,,,,,
4396,24397,"3H-1,4-Benzodiazepin-2-amine, 7-chloro-5-phenyl-, 4-oxide",C1C(=N)N=C2C=CC(=CC2=C(N1O)C3=CC=CC=C3)Cl,,,,,,
4397,24398,Trimethylbutylammonium iodide,CCCC[N+](C)(C)C.[I-],,,,,,
4398,24399,"N,N,N-trimethylbutan-1-aminium",CCCC[N+](C)(C)C,,,,,,
4399,24400,CID 24400,[O-][Mn](=O)(=O)=O.[K+],,,,,,
4400,24401,Permanganate,[O-][Mn](=O)(=O)=O,,,['Electron-accepting molecules in chemical reactions in which electrons are transferred from one molecule to another (OXIDATION-REDUCTION). (See all compounds classified as Oxidants.)'],,,
4401,24402,Ammonium dihydrogen phosphate,[NH4+].OP(=O)(O)[O-],,,"['Substances or mixtures that are added to the soil to supply nutrients or to make available nutrients already present in the soil, in order to increase plant growth and productivity. (See all compounds classified as Fertilizers.)', 'Substances used in the processing or storage of foods or animal feed including ANTIOXIDANTS; FOOD PRESERVATIVES; FOOD COLORING AGENTS; FLAVORING AGENTS; ANTI-INFECTIVE AGENTS; EXCIPIENTS and other similarly used substances. Many of the same substances are used as PHARMACEUTIC AIDS. (See all compounds classified as Food Additives.)']","['/Ortho/ phosphate is absorbed from, and to a limited extent secreted into, the gastrointestinal tract. Transport of phosphate from the gut lumen is an active, energy-dependent process that is modified by several factors. ... Vitamin D stimulates phosphate absorption, an effect reported to precede its action on calcium ion transport. In adults, about two thirds of the ingested phosphate is absorbed, and that which is absorbed is almost entirely excreted into the urine. In growing children, phosphate balance is positive. Concentrations of phosphate in plasma are higher in children than in adults. This ""hyperphosphatemia"" decreases the affinity of hemoglobin for oxygen and is hypothesized to explain the physiological ""anemia"" of childhood. /Phosphates/']",['A defect in phosphate metabolism occurs in a variety of diseases. ... Rickets ... Osteomalacia ... Primary or Secondary Hyperparathyroidism ... Chronic Renal Failure. /Phosphates/'],
4402,24403,Tetrasodium pyrophosphate,[O-]P(=O)([O-])OP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+],,,,,['Pyrophosphate is hydrolyzed to the orthophosphate in the gut.'],
4403,24404,Phosphine,P,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['Studies with (32)P-phosphine showed that residues did remain in grain after proper ventilation ... Residues were ... incorporated into the tissues of mice that ate fumigated flour. The excreta were highly radioactive at first, but activity disappeared about 3 weeks after feeding was stopped.']","['... Absorbed phosphine is rapidly metabolized into phosphite and hypophosphite. ...', 'Metal phosphides are hydrolysed to phosphine and the corresponding metal cation. In rats, phosphine that is not excreted in the expired air is oxidized and appears in the urine, chiefly as hypophosphite and phosphite.']",
4404,24405,Riboprine,CC(=CCNC1=C2C(=NC=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)C,,,"['Any of the hormones produced naturally in plants and active in controlling growth and other functions. There are three primary classes: auxins, cytokinins, and gibberellins. (See all compounds classified as Plant Growth Regulators.)']",,,
4405,24406,CID 24406,CC1=C(SC(=N1)S)C(=O)C,,,,,,
4406,24407,Diisoamyl sulfoxide,CC(C)CCS(=O)CCC(C)C,,,,,,
4407,24408,Bromine,BrBr,,,,"['Bromine vapors enter body by respiratory system, skin and digestive system. It has cumulative properties, being deposited in tissues as bromides.']","['In water, and living organisms, bromine forms bromide.']","['Biological half-lives of bromine in 15 different organs and tissues of the rat, in addition to the whole-body half-life, were determined by measuring the radioactive concentration of 82Br-bromide in samples of tissues collected at the time intervals of 12-396 hr from animals that continuously (up to 17 d) received 82Br-labeled bromide in their drinking water. The half-life values, calculated from the experimental data by the method of gradual estimates of the parameters in question with the SPSS statistical program, ranged from 94.3 + or - 14.6 hr in the thyroid gland to 235.0 + or - 88.9 hr in liver. In most of the studied tissues, the biological half-lives of bromine were shorter than in the whole body, in which it equaled 197.8 + or - 22.2 hr. Significant correlation between the values of the steady-state concentration of bromide and of the biological half-life was found for most tissues (except for liver). ...', 'The biological half-life for bromide through ingestion is 12 to 30 days.', 'Bromide has a half-life of about 12 days in the human body.', '10.5 days and in an average clearance of 0.68 mL/min.']"
4408,24409,Aluminum bromide,[Al](Br)(Br)Br,,,,,,
4409,24410,Vanadium oxytrichloride,O=[V].Cl.Cl.Cl,,,,"['... /A study was/ performed in rats ... to determine the ... distribution /of vanadium/ in organs and subcellular particles ... /but it has/ the shortcomings resulting from observations made after a single administration ... . The chief ... information ... relates to distribution of (48)vanadium as the pentavalent vanadium oxytrichloride in subcellular fractions of the liver; although supernatant contained 57% of the isotope 10 min after administration with the remainder equally divided among the microsomal, mitochondrial, and nuclear fractions, at 8 days (48)vanadium had migrated mainly into the nuclear fractions and mitochondria about equally to the total extent of 80%, with the isotope now being equally distributed between microsomes and supernatant of 10% each.', '(48)Vanadium oxytrichloride was administered intratracheally to juvenile male Wistar rats. All major tissues were analyzed for (48)vanadium content. Over half was removed from lung within 15 min of exposure, vanadium isotope translocated to all organs except brain. The peak uptake for most organs occurred between 4 and 24 hr after injection with kidney maintaining largest fraction. Bones accumulated large fractions, testes small fraction. Excretion occurred by urine and fecal routes. Three percent of the burden remained after 63 days.', 'Male Wistar rats were given vanadyl trichloride (48VOCl3) ip in doses of V ranging from 0.1 to 8 mg/kg and their tissues were collected 1 and 5 d after the injection. V was distributed in the order bone greater then kidney greater then liver greater than spleen greater than intestines greater than stomach greater than muscle greater than testis greater than lung greater than brain. Residues of V in tissues declined rapidly between 24 hr and 5 d after administration. The tissue:blood ratios of V were greater than unity for bone, kidney, liver, and spleen and near unity for all other organs except the brain. Brain levels of V were found to be considerably lower than blood in all cases. V residues were linearly related to dose in most organs when the dose was below 2 mg/kg. At 8 mg/kg, however, liver and kidney showed consistently higher amounts than would be expected from the linear relationship at the low doses. Subcellular distribution of V in liver and kidney indicated that it was associated with nuclei, mitochondria, microsomes, and primarily with high-molecular-weight proteins in the soluble fraction of liver. The results suggest that the distribution pattern of V is dependent on exposure level.', 'The distribution of vanadium among the tissues of the body studied using intravenously injected V(3+), intratracheally injected vanadium chloride or vanadium oxytrichloride, and oral doses of vanadyl sulfate or orthovanadate. The relative levels of V in organs and tissues differed according to the route of administration; however, differences in the distribution of different compounds administered by the same route were small, indicating that the vanadium may be converted to a common oxidation state in vivo. ... Rats injected with V(5+) later contained V(4+) in their tissues. In general, kidney, liver, and bone accumulated the highest levels of vanadium. The tissues that retained vanadium the longest were bone, kidney, testicle, and lung. Reported preliminary results for vanadium levels in fluids and hard tissues from humans. Vanadium appears to concentrate in bone and hair.']","['Within tissues in organisms, V3+ and V4+ predominate because of largely reducing conditions; in plasma, however, which is high in oxygen, V5+ is formed.']",
4410,24411,Vanadium(II) oxide,O=[V],,,,,,
4411,24412,Potassium persulfate,[O-]S(=O)(=O)OOS(=O)(=O)[O-].[K+].[K+],,,,,,
4412,24413,Peroxydisulfuric acid,OS(=O)(=O)OOS(=O)(=O)O,,,,,,
4413,24414,Barium Sulfate,[O-]S(=O)(=O)[O-].[Ba+2],['Barium sulfate is a radiographic contrast agent indicated for use in computed tomography (CT) of the abdomen to delineate the gastrointestinal (GI) tract in adult and pediatric patients.'],"['Barium sulfate increases the absorption of x-rays as they are passed throughout the body, delineating body structures, in which barium sulfate is localized. This allows for the clear visualization of normal organs/defect in normal anatomy.']",['Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)'],"['Barium sulfate is not absorbed following oral or rectal administration with a normal gastrointestinal tract. In patients with a normal GI tract, barium sulfate is normally excreted within 24 hr after oral ingestion. Post rectal administration of barium sulfate suspensions, the drug is generally excreted when the enema is released. Some barium may remain in the colon for several weeks, however, and eventually clears, especially in patients with impaired intestinal peristalsis. It is difficult to quantify the uptake of ingested barium because of a number of factors affect its absorption. The presence of sulfate in food can cause the precipitation of barium sulfate.  The following is the approximate time to peak opacification of organs by barium sulfate in a healthy GI tract:  Esophagus, stomach, and duodenum uptake of barium sulfate occurs almost immediately after oral administration.  Small intestine uptake is dependent on gastric emptying rate and viscosity of the preparation; it may be delayed 15-90 minutes post ingestion.  Small intestine (enteroclysis studies) uptake is immediate, following direct instillation.  Colon and distal small intestine uptake are dependent on patient positioning. Hydrostatic pressure also determines the rate and degree of opacification.', 'Barium sulfate is excreted unchanged in the feces.', 'The rate of excretion of barium sulfate is dependent on the route of administration and the status of peristaltic activity and motility of the gastrointestinal tract.', '/In female beagle dog,/ (131)barium sulfate was found to be cleared from lung, with a biological half-time of 8-9 days ... . This indicated some solubility ... In body fluids, possibly in colloidal form. ... Barium sulfate ... Clearance rate /depends/ on specific surface area of inhaled particles and was lower for heat treated than for untreated particles.', 'In an extensive study, temperature and pulse rate measurements were taken as an indication of an acute inflammatory response for 291 humans administered a single unstated dose of a 50% w/v barium sulfate suspension for bronchographic purposes. The method of administration was unstated, but the suspension was presumed to have been instilled into the trachea and then blown into the lungs. In 154 patients, there was radiological evidence of the presence of barium sulfate in the bronchial tree at the time of the last available X-ray (various time points ranging from < 1 week to > 1 year after administration); in 135 patients, on the other hand, there was no radiological evidence of residual barium sulfate in the lungs 1 year after bronchography. Forty-one of these patients exhibited complete elimination of the barium sulfate from the lungs within 1 week; it was stated that in some of these patients, this clearance occurred within 24 hr.', 'After inhalation exposure of rats to a BaSO4 aerosol at 40 mg/cu m, 5 hr daily for 2 months, lymphatic transport was slight. The skeletal concentration of Ba was 0.8-1.5 mg/g dry substance (10-100 times the pulmonary concentration). Skeletal uptake decreased somewhat with advancing age.', 'Of BaSO4 injected intratracheally, about 5% of the initial dose was recovered in the urine during the first 10 days after administration.', 'For more Absorption, Distribution and Excretion (Complete) data for Barium sulfate (11 total), please visit the HSDB record page.']","['Barium sulfate is poorly water soluble and shows negligible levels of absorption from the gastrointestinal tract following both oral or rectal administration.  In healthy subjects, orally administered barium sulfate is generally excreted within 24 hours. Rectally administered barium sulfate is eliminated with clearance of the enema.', 'The in vivo solubility in rats of barium chloride, barium carbonate, barium sulfate, and barium fused in clay /was studied/. The chloride and the carbonate disappeared rapidly from the injection site. The sulfate dissolved more slowly; a half-life of 26 days was calculated. The fused clay was largely retained, the half-life being calculated as 1390 days.']","['... In rats barium sulfate disappeared from the injection site with a half-life of 26 days ...', 'In Syrian hamsters, barium sulfate was found to be cleared from the lungs with a biological half-life of 8-9 days ...', '(131)BaSO4 was found to be cleared from the lungs, with a biological half-life time of 8-9 days, through absorption into the general circulation with subsequent urinary clearance.', 'Measurements of the clearance of tracer levels of (131)barium sulfate (estimated maximum initial burden of 90 ug or 0.09 mg/kg from a 30 to 90 minute exposure) from the respiratory tract of female beagle dogs (10 + or - 1 kg) were performed. The biological half-life was eight days.', '/Barium/ sulfate ... /has a calculated/ half-life of 26 days /in rats/.']"
4414,24415,Monoethylglycinexylidide,CCNCC(=O)NC1=C(C=CC=C1C)C,,,,,['Monoethylglycinexylidide has known human metabolites that include 3-Hydroxymonoethyl glycinexylidide and Glycinexylidide.'],
4415,24416,(3-Amino-3-carboxypropyl)dimethylselenonium,C[Se+](C)CCC(C(=O)O)N,,,,,,
4416,24417,S-Methyl-L-cysteine,CSC[C@@H](C(=O)O)N,,,,,,
4417,24418,Piprocurarium iodide,CC[N+](C)(CC)CCOCCOC(=O)C(C1=CC=CC=C1)[N+]2(CCCCC2)C.[I-].[I-],,,,,,
4418,24419,Piprocurarium,CC[N+](C)(CC)CCOCCOC(=O)C(C1=CC=CC=C1)[N+]2(CCCCC2)C,,,,,,
4419,24420,"Estra-1(10),2,4-triene-3,17-diyl diheptanoate",CCCCCCC(=O)OC1CCC2C1(CCC3C2CCC4=C3C=CC(=C4)OC(=O)CCCCCC)C,,,,,,
4420,24421,Hexane-1-selenol,CCCCCC[SeH],,,,,,
4421,24422,Cadmium(2+);1-oxidopyridin-1-ium-2-thiolate,C1=CC=[N+](C(=C1)[S-])[O-].C1=CC=[N+](C(=C1)[S-])[O-].[Cd+2],,,,,,
4422,24423,Methylphenylisopropylamine,CC(C)N(C)C1=CC=CC=C1,,,,,,
4423,24424,Zinc Sulfate,[O-]S(=O)(=O)[O-].[Zn+2],"['This medication is a mineral used to treat or prevent low levels of zinc alone and together with oral rehydration therapy (ORT). It is also used as a topical astringent. Zinc Sulfate Injection, USP is indicated for use as a supplement to intravenous solutions given for TPN.']","['Zinc has been identified as a cofactor for over 70 different enzymes, including alkaline phosphatase, lactic dehydrogenase and both RNA and DNA polymerase. Zinc facilitates wound healing, helps maintain normal growth rates, normal skin hydration and the senses of taste and smell.']","['Agents, usually topical, that cause the contraction of tissues for the control of bleeding or secretions. (See all compounds classified as Astringents.)']","['Approximately 20 to 30% of dietary zinc is absorbed, primarily from the duodenum and ileum. The amount absorbed is dependent on the bioavailability from food. Zinc is the most bioavailable from red meat and oysters. Phytates may impair absorption by chelation and formation of insoluble complexes at an alkaline pH. After absorption, zinc is bound in the intestine to the protein metallothionein. Endogenous zinc can be reabsorbed in the ileum and colon, creating an enteropancreatic circulation of zinc.', 'Primarily fecal (approximately 90%); to a lesser extent in the urine and in perspiration.', 'After absorption zinc is bound to protein metallothionein in the intestines. Zinc is widely distributed throughout the body. It is primarily stored in RBCs, WBCs, muscles, bones, Skin, Kidneys, Liver, Pancreas, retina, and prostate.', 'The pharmacokinetics of zinc sulfate were compared with those of a new zinc pantothenate, in rabbits. Each salt was administered to rabbits at a dosage of 3.3 uCi of zinc-65/kg of body weight. The measured pharmacokinetics of the two compounds responded to a two compartment open model. The urinary elimination of the two salts was similar, as was their localization in the skin and fur, but Zn pantothenate was retained by the liver to a lesser extent than was zinc sulfate (ZnSO4).', 'Absorption: 20% to 30%. Protein binding: 99%. Elimination: Through small bowel excretion.', 'In women in different trimesters of pregnancy, the oral administration of 200 mg zinc sulfate per day resulted in an increase of serum zinc levels from 109.7 to 205.4 mg/dL. In the control group, serum zinc levels declined from 113.0 mg/dL in the first trimester to 83.8 in the third trimester.', '...An absorption half-life of 0.4 hr /was reported/ when 45 mg Zn2+ as zinc sulfate was administered once in gelatine capsules to 10 healthy young men. Serum concentrations were measured frequently during a total investigation time of 8 hours. A mean maximum concentration of 8.2 umol Zn2+/L serum was found after 2.3 hours (tmax). There is evidence of an enteral recirculation, the first rebound effect appeared after 1.4 hours during the absorption phase before tmax was reached, and exhibited mean reabsorption rates of 70% of the dose given. The subsequent ones (max. of 5) appeared at regular intervals of 1.2 hours with a decrease of the quantity reabsorbed.', 'For more Absorption, Distribution and Excretion (Complete) data for ZINC SULFATE (14 total), please visit the HSDB record page.']",,"['3 hours', 'Half-life: 3 hours']"
4424,24425,Chromic acid,O[Cr](=O)(=O)O,,,,"['Inhalation of highly water-soluble hexavalent chromium salts, such as chromic acid, ... may result in systemic absorption.', 'Absorption of inhaled chromium cmpds takes place in the lung via transfer across cell membranes and in the GI tract from particles cleared from the lungs. Absorption after oral exposure in humans varies from essentially none for the highly insoluble chromium(III) cmpd chromic oxide, to 0.5-2.0% for chromium(III) cmpds in the diet, to approx 2-10% for chromium(VI) as potassium chromate. Dermal absorption depends on the physical and chemical properties of the cmpd, the vehicle, and the integrity of the skin. Concentrated soln of chromium(VI) cmpds such as potassium chromate can cause chemical burns and facilitate absorption. /Chromium cmpds/']",,
4425,24426,3-Ethoxy-3-methyl-1-butyne,CCOC(C)(C)C#C,,,,,,
4426,24427,1-Chloroprop-1-yne,CC#CCl,,,,,,
4427,24428,"Hydantoin, 3-(bis(2-chloroethyl)aminomethyl)-",C1C(=O)N(C(=O)N1)CN(CCCl)CCCl,,,,,,
4428,24429,"2-Benzoxazolinone, 3-(bis(2-chloroethyl)aminomethyl)-",C1=CC=C2C(=C1)N(C(=O)O2)CN(CCCl)CCCl,,,,,,
4429,24430,"2-(2-Furyl)-4,6-diphenyl-1,3,5-triazine",C1=CC=C(C=C1)C2=NC(=NC(=N2)C3=CC=CO3)C4=CC=CC=C4,,,,,,
4430,24431,"2-(3-Nitrophenyl)-4,6-diphenyl-1,3,5-triazine",C1=CC=C(C=C1)C2=NC(=NC(=N2)C3=CC(=CC=C3)[N+](=O)[O-])C4=CC=CC=C4,,,,,,
4431,24432,"2,4,6-Tris(4-methoxyphenyl)-1,3,5-triazine",COC1=CC=C(C=C1)C2=NC(=NC(=N2)C3=CC=C(C=C3)OC)C4=CC=C(C=C4)OC,,,,,,
4432,24433,Butyl anthranilate,CCCCOC(=O)C1=CC=CC=C1N,,,,,,
4433,24434,Potassium Nitrate,[N+](=O)([O-])[O-].[K+],"['For the relief of tooth sensitivity, and is also used as a pesticide, insecticide, as a food additive, and a rodenticide.']","['The potassium cation is an essential electrolyte that is important for the maintenance of intracellular osmotic pressure and for the maintenance of cell membrane potential, in particular, the potential of electrically excitable tissues. It is a regular component of the diet and is particularly abundant in fruit and vegetables. The recommended daily intake varies from 350-1275 mg in children to 1875 and 5625 mg in adults. In the United Kingdom, the recommended intake is 3.5 g/day for healthy adults. Potassium ions are believed to disturb the synapse between nerve cells, thus decreasing nerve excitation and the associated pain.  Potassium nitrates are ignitable fumigants also utilized as rodenticides and insecticides. They are added to other pesticide active ingredients (sulfur and carbon) and placed into fumigant gas cartridges, designed to be ignited and placed in pest-infested areas. The activated cartridge bombs release toxic gases which are lethal to select rodents, skunks, coyotes, and wasps.  Potassium ions have demonstrated in animal studies to act directly on the nerves and to reduce sensory activity. Tooth hypersensitivity can be relieved by inactivating the intra-dental nerve and inhibiting neural transmission, using suitable medications.  It has been found that potassium-to-sodium intake ratios are strongly related to cardiovascular disease risk than either nutrient alone. The data describing this relationship warrants further research for various target tissue endpoints.']","['Substances that are energetically unstable and can produce a sudden expansion of the material, called an explosion, which is accompanied by heat, pressure and noise. Other things which have been described as explosive that are not included here are explosive action of laser heating, human performance, sudden epidemiological outbreaks, or fast cell growth. (See all compounds classified as Explosive Agents.)']","['It is established that nitrate is quickly and almost entirely absorbed from the proximal and small intestine subsequent to ingestion in most animals, with little if any absorption from the stomach and lower intestine.  The vast majority of intestinal K+ absorption occurs in the small intestine; the contribution of the normal colon to net K+ absorption and secretion is trivial.', 'Nitrates are excreted in the urine primarily as inorganic nitrates.', 'Nitrates are absorbed into the general blood circulation and are transported across the body. Radioactive tracer experiments have demonstrated that nitrates are distributed evenly among body organs, and their rate of distribution depends on blood flow.', 'It is generally assumed that absorption takes place in upper portion of small intestine & ... excretion is primarily, if not exclusively, through kidney. ... preliminary observations ... have shown that not all animals reduce nitrate to nitrite in saliva. It is of considerable significance that major differences occur among mammalian species in the ability to concn nitrate from plasma into saliva. Large interspecies differences have also been shown to occur in elimination kinetics of nitrate. /Nitrate/', 'Nitrate and nitrite given orally are absorbed and transferred to the blood in the upper part of the gastrointestinal tract. Abundant pectin in the food may delay absorption which may then occur lower down in the intestine, with possible increased risk for microbial transformation of nitrate into nitrite. /Nitrate and nitrite/', 'Regardless of route of exposure, nitrate and nitrite are rapidly transferred into the blood. Nitrite is gradually oxidized to nitrate which is readily distributed into most body fluids (urine, saliva, gastric juice, sweat, ileostomy fluid). Distribution of nitrate into plasma, erythrocytes, saliva and urine following an oral dose of sodium nitrate has been demonstrated ... Nitrate does not accumulate in the body. /Nitrate and nitrite/', 'Approximately 60% of oral nitrate is excreted in urine ... bacterial or endogenous metabolism probably accounts for the remainder. A minor part is excreted in sweat. /Nitrate/', '... Potassium nitrate ... /is/ rapidly absorbed and excreted unchanged ... Under some circumstances, however, appreciable amt of nitrate are converted to nitrite.']","['Nitrates are reduced to nitrites by the bacteria in saliva and the gastrointestinal system. The in vivo reduction of nitrates to nitrites depends on conditions that are subject to much variations such the volume and species of microflora present in the saliva/gastrointestinal tract, and stomach pH. Gastric pH is higher in infants younger than 6 months of age and during certain gastrointestinal tract infections, thereby favoring the reduction of nitrates.   Nitrate is metabolized to a small extent. The biotransformation of potassium nitrate consists of nitrate reduction, nitrite formation, nitrite reoxidation to nitrate, and formation of methemoglobin or NO, in a dynamic equilibrium,,.', 'Nitrate salts/ including potassium nitrate/ ... if not promptly absorbed, they may be reduced to nitrites by bacteria in bowel. I', '... nitrate metabolism in man cannot be readily predicted from animal data. Several studies have suggested that large differences in nitrate metab may occur between individuals. These differences can span about three orders of magnitude when all available data, incl diet & physiological status, are taken into consideration. /nitrate/', 'Where bacteria are present and the environment can be anerobic, nitrate can be reduced to nitrite. The main site for this reaction is mouth and stomach, but nitrite formation in the lower intestine and in the bladder (urinary infection) may also be of some toxicological importance.  Nitrite may be further reduced to nitrogen by bacteria under some conditions. In blood, nitrite transforms hemoglobin to methemoglobin and is simultaneously oxidized to nitrate. Normally methemoglobin gradually reverts to hemoglobin through enzymatic reactions. Nitrite has vasodilating properties, probably through transformation into nitric oxide (NO) or a NO-containing molecule acting as a signal factor for smooth muscle relaxation. Nitrite easily transforms into a nitrosating agent in an acidic environment and can react with a variety of compounds, eg ascorbic acid, amines, amides. Nitrosation can also be mediated by bacteria, eg in the stomach. Some reaction products are carcinogenic (eg most nitrosoamines and amides). /Nitrate and nitrite/', 'BACKGROUND/AIMS: It has been suggested that dietary nitrate, after concentration in the saliva and reduction to nitrite by tongue surface bacteria, is chemically reduced to nitric oxide (NO) in the acidic conditions of the stomach. This study aimed to quantify this in humans. METHODS: Ten healthy fasting volunteers were studied twice, after oral administration of 2 mmol of potassium nitrate or potassium chloride. Plasma, salivary and gastric nitrate, salivary and gastric nitrite, and gastric headspace NO concentrations were measured over six hours. RESULTS: On the control day the parameters measured varied little from basal values. Gastric nitrate concentration was 105.3+/-13 umol/L (mean (SEM), plasma nitrate concentration was 17.9+/-2.4 umol/L, salivary nitrate concentration 92.6+/-31.6 umol/L, and nitrite concentration 53.9+/-22.8 umol/L. Gastric nitrite concentrations were minimal (< 1 mumol/l). Gastric headspace gas NO concentration was 16.4+/-5.8 parts per million (ppm). After nitrate ingestion, gastric nitrate peaked at 20 minutes at 3,430+/-832 umol/L, plasma nitrate at 134+/-7.2 umol/L, salivary nitrate at 1516.7+/-280.5 umol/L, and salivary nitrite at 761.5+/-187.7 umol/L after 20-40 minutes. Gastric nitrite concentrations tended to be low, variable, and any rise was non-sustained. Gastric NO concentrations rose considerably from 14.8+/-3.1 ppm to 89.4+/-28.6 ppm (p < 0.0001) after 60 minutes. All parameters remained increased significantly for the duration of the study. CONCLUSIONS: A very large and sustained increase in chemically derived gastric NO concentrations after an oral nitrate load was shown, which may be important both in host defense against swallowed pathogens and in gastric physiology.', 'For more Metabolism/Metabolites (Complete) data for POTASSIUM NITRATE (6 total), please visit the HSDB record page.']",
4434,24435,CID 24435,CC=CC=CC(=O)[O-].[Na+],,,,,,
4435,24436,Sodium Sulfate,[O-]S(=O)(=O)[O-].[Na+].[Na+],['indicated for bowel cleansing prior to colonoscopy or barium enema X-ray examination.'],"['Induces catharsis by the osmotic effects of the unabsorbed sulfate salts and polyethylene glycol (PEG) in the GI tract. Specifically, sulfate salts provide sulfate anions, which are poorly absorbed, and PEG, which is primarily unabsorbed, causes water to be retained in the GI tract resulting in watery diarrhea.']",['Agents that are used to stimulate evacuation of the bowels. (See all compounds classified as Cathartics.)'],"['Absorption of sodium sulfate after ingestion in rats was investigated. 35)S-Radioactivity excreted in urine during 24 hr indicated almost complete absorption from GI tract.  Determination in serum 2 hr after admin revealed 3-fold increase in sulfate concentration rapid and  almost complete absorption of inorganic  sulfate occurs after oral admin in rats.', 'Rectal effluent if unabsorbed sulfates ;  urine (predominant route for absorbed sulfates  )', ""The importance of tissue sulfate concentrations in regulating 3'-phosphoadenosine 5'-phosphosulfate (PAPS) synthesis is not known. Therefore, this study was conducted to determine the influence of increased availability of inorganic sulfate on steady-state PAPS concentrations in various tissues. To increase tissue sulfate concentrations, 2-16 mmol/kg of sodium sulfate and sulfur-containing amino acids (cysteine or methionine) were infused intravenously for 2 hr into pentobarbital-anesthetized rats. Serial blood samples were taken during the infusion and analyzed for sulfate concentrations. After 2 hr of infusion, liver, kidney, and brain were removed for quantification of tissue PAPS and sulfate concentrations. Infusion of sodium sulfate, cysteine, and methionine increased serum and tissue sulfate concentrations in a dose- and time-dependent manner. Serum sulfate concentrations increased from 0.8 to 14 mM during the infusion of sodium sulfate, whereas infusions of cysteine and methionine increased serum sulfate concentrations to 4.8 and 2.0 mM, respectively. Tissue sulfate concentrations also increased during sulfate infusion. Liver sulfate concentration increased from 0.8 to 4.8 mM, kidney concentration increased from 0.6 to 31 mM, and brain concentration increased from 0.1 to 0.6 mM. Similar to the serum sulfate concentrations, sulfate infusion was the most effective in increasing tissue sulfate concentrations, cysteine was intermediate, and methionine the least effective. Although sulfate concentrations in liver, kidney, and brain increased 6-, 50-, and 6-fold by infusing sulfate, respectively; tissue PAPS levels were not altered markedly. Hepatic PAPS concentrations increased significantly (30-35%) only when infused with the higher doses (8 or 16 mmol/kg/2 hr) of sodium sulfate."", 'The absorption of inorganic sulfate after ingestion was investigated in rats. After oral administration of Na235SO4, 35S radioactivity was measurable in plasma already after 15 min and its plasma concentration reached a peak after about 1.5-2 hr. The 35S-radioactivity excreted in urine during 24 hr after ingestion of Na235SO4 together with varying amounts of unlabelled Na2SO4 (0.25-5.0 mmol Na2SO4 per rat) indicated an almost complete absorption of inorganic sulfate from the gastrointestinal tract. Determination of the inorganic sulfate concentration in rat serum 2 hr after oral administration of 5.0 mmol Na2SO4 revealed a three-fold increase in serum sulfate concentration. The data suggest a rapid and almost complete absorption of inorganic sulfate after oral administration in the rat. Its importance in relation to the sulfate availability for sulfate conjugation of drugs is discussed.', 'Sodium sulfate can be used to enhance the conjugation of phenolic drugs with sulfate and to treat hypercalcemia. It is thought that sulfate in is absorbed slowly and incompletely from the digestive tract. The purposes of this investigation were to determine the absorption of large amount of sodium sulfate(18.1 g as the decahydrate, equivalent to 8.0 g of the anhydrous salt) and to compare the bioavailability when this amount is administered orally to normal subjects as a single dose and as four equally divided hourly doses. The 72-hr urinary recovery of free sulfate following single and divided doses was 53.4 +/- 15.8 and 61.8 +/- 7.8%, respectively (mean +/- SD, n=5, p > 0.2). The single dose produced severe diarrhea while the divided doses caused only mild or no diarrhea. Thus, a large amount of sodium sulfate, when administered orally in divided doses over 3 hr, is well tolerated and is absorbed to a significant extent. Orally administered sodium sulfate may be useful for the early treatment of acetaminophen overdose.', 'The renal excretion of potassium by unanesthetized sheep was studied in clearance studies in which water and sodium excretion were elevated by intravenous infusion of isotonic sodium chloride, hypertonic sodium phosphate, or hypertonic sodium sulfate. Aldosterone was infused at 10 ug/hr in some experiments with sodium sulfate. Sodium excretion increased in all experiments, rising at times to equal 25% of the filtered load. Urine flow increased in most experiments. Glomerular filtration rate increased only with infusion of isotonic saline. No consistent change in potassium excretion occurred under any of these loading conditions. This finding contrasts with the increase in potassium excretion commonly seen in man, dogs, and rats intravenously loaded with sodium salts.']",,['Serum sulfate: 8.5 hours']
4436,24437,Sodium sulfite,[O-]S(=O)[O-].[Na+].[Na+],,,,['Skin penetration would be low due to the highly charged nature of these particles and any sulfite that did penetrate would be converted to sulfate by the enzyme sulfate oxidase.'],"['Sulfites that enter mammals via ingestion, inhalation, or injection are metabolized by sulfite oxidase to sulfate.']",
4437,24438,Cyclamate magnesium dihydrate,C1CCC(CC1)NS(=O)(=O)O.[Mg+2],,,,,,
4438,24439,Magnesium phosphate,[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Mg+2].[Mg+2].[Mg+2],,,,,"['...A new component of calculi, trimagnesium orthophosphate /is described/. In a microscopical study of thin sections from 3,500 urinary calculi we detected this compound in 14 stones, all of which contained struvite. New data suggest that trimagnesium orthophosphate is a transformation product of struvite. This well-crystallized substance was always detected a few days after the surgical extraction of struvite kidney stones, in contrast to the newberyite that appears on the surface of very old removed stones or after long exposure of stones to the atmosphere.']",
4439,24440,O-Methylhomoserine calcium salt (2:1),COCCC(C(=O)[O-])N.[Ca+2],,,,,,
4440,24441,Calcium hydrogen phosphate,OP(=O)([O-])[O-].[Ca+2],,,,['... ITS ELEMENTS ARE SLOWLY ABSORBED FROM SMALL INTESTINE.'],,
4441,24442,3-Octenylsuccinic anhydride,CCCCCCC=CC1CC(=O)OC1=O,,,,,,
4442,24443,Pantothenamide,CC(C)(CO)C(C(=O)NCCC(=O)N)O,,,,,,
4443,24444,CID 24444,[O-]Br(=O)=O.[K+],,,,,,
4444,24445,Bromic acid,OBr(=O)=O,,,,,,
4445,24446,CID 24446,[K+].[Br-],,,,,,
4446,24447,CID 24447,C1CCC(CC1)NS(=O)(=O)[O-].[K+],,,,,,
4447,24448,CID 24448,[O-]I(=O)=O.[K+],,,,,,
4448,24449,CID 24449,N(=O)[O-].[K+],,,,,,
4449,24450,Dipotassium hydrogen phosphate,OP(=O)([O-])[O-].[K+].[K+],"['Dipotassium phosphate is used in imitation dairy creamers, dry powder beverages, mineral supplements, and starter cultures as an additive. It is used in non-dairy creamers to prevent coagulation. Dipotassium phosphate is also used to make buffer solutions and it is used in the production of trypticase soy agar which is used to make agar plates for culturing bacteria.']","['Phosphate is a major intracellular anion which participates in providing energy for metabolism of substances and contributes to important metabolic and enzymatic reactions in almost all organs and tissues. Phosphate exerts a modifying influence on calcium concentrations, a buffering effect on acid-base equilibrium, and has a major role in the renal excretion of hydrogen ions.']","['Substances that inhibit or arrest DENTAL CARIES formation. (Boucher&apos;s Clinical Dental Terminology, 4th ed) (See all compounds classified as Cariostatic Agents.)', 'A chemical system that functions to control the levels of specific ions in solution. When the level of hydrogen ion in solution is controlled the system is called a pH buffer. (See all compounds classified as Buffers.)']","['Potassium salts are well absorbed from gastro intestinal tract.  Net phosphorus absorption may occur in the small intestine in some species but is primarily a function of the colon in horses.', 'Potassium is excreted primarily by kidney.', 'Distribution is largely intracellular, but it is the intravascular concentration that is primarily  responsible for toxicity.', 'Phosphates are rapidly cleared by dialysis.', 'POTASSIUM SALTS ARE WELL ABSORBED FROM THE GASTROINTESTINAL TRACT. ... POTASSIUM IS EXCRETED PRIMARILY BY THE KIDNEY. /POTASSIUM SALTS/', 'Net phosphorus absorption may occur in the small intestine in some species but is primarily a function of the colon in horses. /SRP: Phosphates/', '/Ortho/ phosphate is absorbed from, and to a limited extent secreted into, the gastrointestinal tract. Transport of phosphate from the gut lumen is an active, energy-dependent process that is modified by several factors. ... Vitamin D stimulates phosphate absorption, an effect reported to precede its action on calcium ion transport. In adults, about two thirds of the ingested phosphate is absorbed, and that which is absorbed is almost entirely excreted into the urine. In growing children, phosphate balance is positive. Concentrations of phosphate in plasma are higher in children than in adults. This ""hyperphosphatemia"" decreases the affinity of hemoglobin for oxygen and is hypothesized to explain the physiological ""anemia"" of childhood. /Phosphates/']",['Phosphate is a major intracellular anion which participates in providing energy for metabolism of substances and contributes to important metabolic and enzymatic reactions in almost all organs and tissues.'],"['In healthy children with phosphate overdose, half-life  was 4.8 to 10.6 hours, and was prolonged to 17 hours in  a child with renal insufficiency.']"
4450,24451,Disodium diphosphate,OP(=O)([O-])OP(=O)(O)[O-].[Na+].[Na+],,,,,,
4451,24452,CID 24452,[O-]Cl=O.[Na+],,,,,,
4452,24453,Chlorous acid,OCl=O,,,,,,
4453,24454,Calcium biphosphate,OP(=O)(O)[O-].OP(=O)(O)[O-].[Ca+2],,,,"['/Ortho/ phosphate is absorbed from, and to a limited extent secreted into, the gastrointestinal tract. The transport of phosphate from the lumen of the gut is an active, energy-dependent process, and there are factors that appear to modify the degree of its intestinal absorption. ... Vitamin D stimulates phosphate absorption, and this effect has been reported to precede the action of the vitamin on transport of calcium ion. In general, in adults, about two thirds of the ingested phosphate is absorbed from the bowel, and that which is absorbed from the gut is almost entirely excreted into the urine. In growing children, there is a positive balance of phosphate. Concentrations of phosphate in plasma are higher in children than in adults. This ""hyperphosphatemia"" decreases the affinity of hemoglobin for oxygen and is hypothesized to explain the physiological ""anemia"" of childhood. /Phosphates/']",['A defect in phosphate metabolism occurs in a variety of diseases. ... Osteoporosis ... Rickets ... Osteomalacia ... Osteitis Fibrosa Cystica ... Secondary Hyperparathyroidism ... Hypoparathyroidism ... . /Phosphates/'],
4454,24455,Sodium tripolyphosphate,[O-]P(=O)([O-])OP(=O)([O-])OP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+].[Na+],,,,"['If ingested in large amounts nausea, vomiting and diarrhea are probable. Thought to be hydrolyzed to (ortho)phosphates before absorption. If appreciable amounts of the intact polymer are absorbed from the alimentary tract, hypocalcemic tetany may be a danger due to the binding (chelation) of ionized calcium. Hypocalcemic tetany apparently occurred in one ingestion episode. /Tripolyphosphate/']","['THOUGHT TO BE HYDROLYZED TO (ORTHO)PHOSPHATES BEFORE ABSORPTION. /TRIPOLYPHOSPHATE/', 'In the body, phosphorus is converted to phosphates. /Phosphorus/']",
4455,24456,Calcium Phosphate,[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2],"['For use as an over the counter calcium and phosphate supplement, antacid, or a source of calcium and phosphate in toothpaste.']","['Calcium phosphate reacts with acid in the stomach to raise the pH. In toothpaste it provides a source of calcium and phosphate ions to support remineralization of the teeth. As a supplement it provides a source of calcium and phospate, both of which are important ions in bone homeostasis.']",,"['/Ortho/ phosphate is absorbed from, and to a limited extent secreted into, the gastrointestinal tract. Transport of phosphate from the gut lumen is an active, energy-dependent process that is modified by several factors. ... Vitamin D stimulates phosphate absorption, an effect reported to precede its action on calcium ion transport. In adults, about two thirds of the ingested phosphate is absorbed, and that which is absorbed is almost entirely excreted into the urine. In growing children, phosphate balance is positive. Concentrations of phosphate in plasma are higher in children than in adults. This ""hyperphosphatemia"" decreases the affinity of hemoglobin for oxygen and is hypothesized to explain the physiological ""anemia"" of childhood. /Phosphates/']",['A defect in phosphate metabolism occurs in a variety of diseases. ... Rickets ... Osteomalacia ... Primary or Secondary Hyperparathyroidism ... Chronic Renal Failure. /Phosphates/'],
4456,24457,Cerium fluoride,[F-].[F-].[F-].[Ce+3],,,,,,
4457,24458,Iron(II) chloride,Cl[Fe]Cl,,,,"['ORAL ABSORPTION OF IRON IS VERY COMPLICATED & INTESTINAL MUCOSA IS PRINCIPAL SITE FOR LIMITING ABSORPTION ... IN THIS HOMEOSTATIC MECHANISM DIVALENT FORM IS ABSORBED INTO GI MUCOSA & CONVERTED TO TRIVALENT FORM & ATTACHED TO FERRITIN. ... /WHICH/ PASSES INTO BLOODSTREAM & IS THEN CONVERTED TO TRANSFERRIN WHERE THE IRON REMAINS IN THE TRIVALENT FORM OR IS TRANSPORTED TO THE LIVER OR SPLEEN FOR STORAGE AS FERRITIN OR HEMOSIDERIN. IRON HAS BEEN SHOWN TO CROSS PLACENTA & CONCENTRATE IN FETUS. ... WITH INCREASES IN IRON BEYOND PHYSIOLOGIC LIMITS, MOST IS EXCRETED IN FECES, BUT SMALL AMT MAY ACCUM. SOME IRON MAY BE EXCRETED VIA THE BILE. IN CASES OF OVERLOAD, IRON IS EXCRETED IN THE URINE, & THE PRESENCE OF HIGH URINARY IRON CONCN IS INDICATIVE OF EXCESSIVE IRON. /IRON SALTS/', 'The body store of iron is divided between iron-containing cmpd that are essential and those in which excess iron is held in storage. ... Hemoglobin dominates the essential fraction. ... The two predominant sites of iron storage are the reticuloendothelial system and the hepatocytes, although some storage also occurs in muscle ... . Internal exchange of iron is accomplished by the plasma protein transferrin. ... About 80% of the iron in plasma goes to the erythroid marrow to be packaged into new erythrocytes; these normally circulate for about 120 days before being catabolized by the reticuloendothelium. At that time a portion of the iron is immediately returned to the plasma bound to transferrin, while another portion is incorporated into the ferritin stores of the reticuloendothelial cell and is returned to the circulation more gradually. /Iron & iron salts/', 'The most remarkable feature of iron metabolism in man is the degree to which the body store is conserved. Only 10% of the total is lost per year from normal men, that is, about 1 mg per day ... . Two thirds of this iron is excreted from the GI tract as extravasated red cells, iron in bile, and iron in exfoliated mucosal cells. The other third is accounted for by small amounts of iron in desquamated skin and in the urine. ... The biochemical nature of the absorptive process is understood only in general terms ... . After acidification and partial digestion of food in the stomach, its content of iron is presented to the intestinal mucosa as either inorganic or heme iron. These fractions are taken up by the absorptive cells of the duodenum and upper small intestine, and the iron is either transported directly into the plasma or is stored as mucosal ferritin. ... Normal absorption is about 1 mg per day in the adult male and 1.4 mg per day in the adult female. /Iron & iron salts/', 'Substantial amounts of many metals are excreted in the sweat, including ... iron. ... The potential exists, depending on sweat rates and acclimatization, for substantial losses of these metals in sweat. /Iron salts/']","['IN CELL FE++ ... CONVERTED TO FE+++ IN FERRITIN. NO IRON ABSORPTION AS FERRITIN OCCURS UNTIL CELL IS PHYSIOLOGICALLY ""DEPLETED."" FE, HOWEVER, IS WITHDRAWN FROM FERRITIN AS FE++ AS NEED ARISES. FE RELEASED DIRECTLY INTO BLOOD STREAM ... QUICKLY OXIDIZED BY DISSOLVED O2 TO FE+++ WHICH COMPLEXES WITH SPECIFIC FE-TRANSPORT B1-GLOBULIN ... . /IRON IONS/']",
4458,24459,Lead chloride,Cl[Pb]Cl,,,,"['... There was a wide variation in absorption between individuals in most studies; absorption was up to 96% in subjects who ingested lead with alcohol while fasting ... but was generally less than 10% in subjects who received lead with food.', '... The temporal distribution of lead ((203)Pb), injected iv at no-carrier-added (NCA) (0.6-0.7 umol/kg) and at carrier-added (7.0-62.3 umol/kg) levels was determined in mice. Concn of (203)Pb were measured in major organs and in different regions of the brain. Ex-vivo autoradiographic visualization was used to confirm and extend the brain distribution findings. The highest concn of NCA (203)Pb were observed initially in the kidneys (52% of the injected dose (ID)/g at 1 hr) and liver (10.5% ID/g at 30 min). Uptake into bone occurred gradually, reaching 25% ID/g at 24 hr. In accord with previous reports, excretion of the tracer was very slow. Approximately 80% of total ID remained in the body after 24 hr and 68% at 48 hr. Interestingly, in the mouse brain, the highest levels of (203)Pb were noted in the area of the hypothalamus. At all times between 30 min and 16 hr postinjection, and at all Pb dose levels injected, the accumulation of (203)Pb in the hypothalamic region exceeded that in all other brain regions examined. Autoradiography performed at the 16 hr time point confirmed the high uptake and strong retention of (203)Pb by the hypothalamus ...', 'The solubility of lead from various lead salts and vitrified slagged aggregate in aqueous solutions. The solubility and absorption of lead as lead acetate, lead chloride, lead superoxide, as well as vitrified slagged aggregate were studied. Solubility profiles at pH 1, 3, 5 and 7 differed for each compound. Maximal solubility of the lead salts ranged from 2.89 pH 3, with lead chloride, having intermediate values. In each case, the solubility of lead increased as pH decreased from pH 7 to pH 3. However, as pH was lowered further, solubility of lead decreased. Lead from vitrified slagged aggregate was found to be soluble at a maximal level of 2.3 ppm at pH 3. Mice were administered 10 mg of ground vitrified slagged aggregate by gavage and monitored for blood lead levels at 1, 4, 8, 12 and 24 hr. Peak blood lead levels of 13.8 ppb were found at 8 hr dropping to 3.4 ppb at 24 hr after administration. In other experiments, mice were given drinking water containing from approximately 100-1000 ppm of either lead chloride, lead acetate, or lead superoxide ad libitum for 30 consecutive days. The resulting blood lead levels at the end of this period appear to be a function of the concentration of the lead in the drinking water, as well as of the specific salt, with lead superoxide providing the lowest level of lead. These data further indicate that the lead in vitrified slagged aggregate, which reportedly exists as an oxide, is poorly absorbed from the gastrointestinal tract following gavage.', 'In 1-week-old suckling rats, an absorption rate of about 52% was reported after a single oral dose of lead chloride, compared to 0.4% in 6-week-old animals.']",,
4459,24460,Lead chromate,[O-][Cr](=O)(=O)[O-].[Pb+2],,,['Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)'],"['(51)Cr-labelled sodium, zinc and lead chromates were studied. Sodium chromate and the less soluble zinc chromate were absorbed by the blood, resulting in increased urinary excretion of chromium. ... The less water-soluble the chromate, the higher was its elimination via the feces. Absorbed chromium was retained in the spleen and bone marrow in all three cases, and also in the liver and kidneys in the case of sodium chromate. Chromium levels in blood and urine are not indicative of inhalation exposure to insoluble chromates.', 'Transmission electron microscopy (TEM) equipped with energy-dispersive x-ray analysis (EDX), electron spectroscopy for chemical analysis (ESCA), secondary ion mass spectrometry (SIMS), and laser microprobe for mass analysis (LAMMA) were used to follow the fate of chromium compounds deposited in the sheep tracheal lobe. Four chromium compounds were used: two chromium(VI) compounds (lead chromate and chromium trioxide) and two chromium(III) compounds (chronic oxide and chromium sulfate). Chromium trioxide is very soluble and the other three are slightly soluble. The compositions, concentrations, and sizes of particles were determined in the bronchoalveolar lavages (BAL) at d 2, 3, 5, and 30 after instillation and on the lung samples collected at d 31. The concentrations of particles in the BAL samples separated the chromium compounds in two groups where Cr2O3 and PbCrO4 (as Pb) were higher than Cr2(SO4)3, PbCrO4 (as Cr), and CrO3. The half-life for alveolar clearance of Cr2O3 and Cr2(SO4)3 has been calculated respectively at 11 and 80 d. Prismatic PbCrO4 particles break up in the lung and sustain a high concentration of isometric particles of lead chromate and another lead-containing compound in the BAL. The CrO3 instilled particles react with endogenous compounds or are transformed to insoluble hydroxyl complexes instead of diffusing very rapidly through the alveolar-capillary barrier. The alveolar clearance as measured in the BAL is not different from the control.']","['Hexavalent chromium compounds are known carcinogens for the respiratory tract in humans. The mechanism of cell transformation by hexavalent chromium compounds is not fully understood although a role for intracellular reduction is sought. The aim of this study was to determine the distribution of Cr valence states in human cells after in vitro exposure to soluble or particulate chromium compounds. A synchrotron X-ray-based microprobe was used to investigate the cellular reduction of Cr(VI) and to image chromium oxidation states in cells. It was shown that soluble Cr(VI) compounds are fully reduced to Cr(III) in cells. Cr(III) is homogeneously distributed within the cell volume and therefore present within the nucleus. In the case of low solubility particulate chromate compounds, Cr(VI) can coexist in the cell environment, as particles in the perinuclear region, together with intracellular and intranuclear Cr(III). Chemical distribution maps also suggest that intracellular Cr(III) originates from extracellular dissolution and reduction of lead chromate rather than from intracellular engulfed particles. The possible stronger carcinogenicity of low solubility chromate vs soluble chromate compounds may derive from the combinative genotoxic effects of intranuclear Cr(III) and the persistent exposure to a strong oxidant, Cr(VI). /Soluble and particulate chromates/', 'Exposure to certain particulate hexavalent chromium [Cr(VI)] compounds, such as lead chromate (PbCrO4), has been associated with lung cancer and respiratory tract toxicity. Previous studies indicate that the solubility of Cr(VI)-compounds is an important factor in Cr(VI)-induced carcinogenesis. The present study investigates reactive oxygen species (ROS) generation by PbCrO4 particles and cellular responses using RAW 264.7 cells. A mixture containing PbCrO4 and RAW 264.7 cells generated hydroxyl radical ((.)OH), using cellularly generated H2O2 as a precursor, as measured by electron spin resonance (ESR) spin trapping in combination with H2O2 and (.)OH scavengers, catalase and sodium formate. The effect of ascorbic acid on (.)OH radicals was also measured using ESR. Confocal microscopy showed that particles could become either bound to the cell surface or engulfed over a 120 min time period. H2O2 generation and O2 consumption were also increased after treatment of the cells with PbCrO4. Both NF-kappaB and AP-1 were activated after exposure to PbCrO4 particles as measured by the NF-kappaB or AP-1 luciferase reporter plasmid assay. Our investigation thus demonstrated that the RAW 264.7 cells phagocytized the PbCrO4 particles leading to accumulation of the particles within vacuoles in the cytoplasm. These particles could induce chronic production of ROS and activation of NF-kappaB and AP-1. Such induction of transcription pathways may be involved in the inflammatory and carcinogenic responses induced by Cr(VI)-containing particles. /Lead chromate oxide/', 'Free radical reactions are believed to play an important role in the mechanism of Cr(VI)-induced carcinogenesis. Most studies concerning the role of free radical reactions have been limited to soluble Cr(VI). Various studies have shown that solubility is an important factor contributing to the carcinogenic potential of Cr(VI) compounds. Here, we report that reduction of insoluble PbCrO4 by glutathione reductase in the presence of NADPH as a cofactor generated hydroxyl radicals (.OH) and caused DNA damage. The .OH radicals were detected by electron spin resonance (ESR) using 5,5-dimethyl-N-oxide as a spin trap. Addition of catalase, a specific H2O2 scavenger, inhibited the .OH radical generation, indicating the involvement of H2O2 in the mechanism of Cr(VI)-induced .OH generation. Catalase reduced .OH radicals measured by electron spin resonance and reduced DNA strand breaks, indicating .OH radicals are involved in the damage measured. The H2O2 formation was measured by change in fluorescence of scopoletin in the presence of horseradish peroxidase. Molecular oxygen was used in the system as measured by oxygen consumption assay. Chelation of PbCrO4 impaired the generation of .OH radical. The results obtained from this study show that reduction of insoluble PbCrO4 by glutathione reductase/NADPH generates .OH radicals. The mechanism of .OH generation involves reduction of molecular oxygen to H2O2, which generates .OH radicals through a Fenton-like reaction. The .OH radicals generated by PbCrO4 caused DNA strand breakage.']",['... The half-life for alveolar clearance of Cr2O3 and Cr2(SO4)3 has been calculated respectively at 11 and 80 d. ...']
4460,24461,Chromate,[O-][Cr](=O)(=O)[O-],,,,,,
4461,24462,Cupric Sulfate,[O-]S(=O)(=O)[O-].[Cu+2],"['Elemental use in copper deficiency  Copper and copper containing compounds are broadly used in medical practice. Metallic copper is used already for many years in dental fillings and in copper intrauterine devices (IUD) for reversible contraception. Ointments containing copper, which release copper ions that are absorbed by the skin in the management of cramps, disturbances of renal function, peripheral, venous hypostatic circulatory disturbances, rheumatic disease and swelling associated with trauma. There are also cosmetic facial creams containing copper as their main active ingredient.']","['Copper is an essential mineral that plays a key role in many physiological processes, including angiogenesis, skin generation and expression and stabilization of skin proteins.  Copper is found naturally in many food sources including meats, vegetables, and grains. Copper has potent biocidal properties and is used to eliminate bacteria, viruses and parasites,.  Copper is one of the nine essential minerals for humans, as it plays an imperative role in various physiological pathways in basically all human tissue, as well as in the health of the dermis and epidermis.   In addition to the above, copper is essential in wound healing, as it promotes angiogenesis and skin extracellular matrix formation and stabilization.']","['Agents that cause vomiting. They may act directly on the gastrointestinal tract, bringing about emesis through local irritant effects, or indirectly, through their effects on the chemoreceptor trigger zone in the postremal area near the medulla. (See all compounds classified as Emetics.)', 'Agents counteracting or neutralizing the action of POISONS. (See all compounds classified as Antidotes.)']","['Primarily absorbed in the small intestine.  Based on studies with radioactive isotopes of copper, most copper is absorbed from the stomach and duodenum of the gastrointestinal tract.   Maximum blood copper levels are observed within 1 to 3 hours following oral administration, and about 50 percent of ingested copper was absorbed. Copper absorption is proposed to occur by two mechanisms, one energy- dependent and the other enzymatic. Factors that can interfere with copper absorption include competition for binding sites with zinc, interactions with molybdenum and sulfates, chelation with phytates, and inhibition by ascorbic acid (vitamin C).  Copper absorbed from the gastrointestinal tract is transported rapidly to blood serum and deposited in the liver bound to metallothionein.  From 20 to 60% of the dietary copper is absorbed.', 'This drug is 80% eliminated via the liver in bile. Minimal excretion by the kidney. Metabolism studies show that persons with daily intakes of 2-5 mg of copper per day absorbed 0.6 to 1.6 mg (32%), excreted 0.5 to 1.3 mg in the bile, passed 0.1 to 0.3 mg directly into the bowel, and excreted 0.01 to 0.06 mg in the urine. As the data indicate, urinary excretion plays a negligible role in copper clearance, and the main route of excretion is in the bile. Other nonsignificant excretory routes include saliva, sweat, menstrual flow, and excretion into the intestine from the blood.', 'The body of a 70 kg healthy individual contains approximately 110 mg of copper, 50% of which is found in the bones and muscles, 15% in the skin, 15% in the bone marrow, 10% in the hepatic system, and 8% in the brain.  The distribution of copper is affected by sex, age, and the amount of copper in the diet. Brain and liver have the highest tissue levels (about one-third of the total body burden), with lesser concentrations found in the heart, spleen, kidneys, and blood. The iris and choroid of the eye have very high copper levels.  Erythrocyte copper levels are generally stable, however, plasma levels fluctuate widely in association with the synthesis and release of ceruloplasmin. Plasma copper levels during gestation may be 2-3 times levels measured before pregnancy, due to the increased synthesis of ceruloplasmin.', 'Effect of hydrogen ion (H+) concentration, water hardness, suspended solids, fish age, size, and species, acclimatization to copper, and levels of copper in food on poisoning of fish by copper sulfate used as a herbicide in freshwater ponds is discussed. Copper levels in muscle, kidney, and organs of rainbow trout were approximately 0.8-1.1, 2.0-2.3, and 115-150 mg/kg fresh weight, respectively, after 12 months intermittent exposure to various copper sulfate containing formulations 0.6, 2.0, and 100 mg/kg, respectively, in controls ... .', 'Male rats were orally administered for 2, 5, and 11 days with 0.5 mmol/kg of copper cmpd. ... In the case of cupric carbonate, copper was much more distributed in the tissues, especially in the liver, than for copper sulfate. The copper level increased progresively in mitochondria lysosomal fractions of the liver in proportion to the period of administration. In the 105,000 g supernatant fraction, copper was distributed in the metallothionein fraction rather than in the superoxide dismutase fraction. The administration of copper cmpd resulted in an increase in the zinc level in the liver, kidney and spleen, preferentially in the metallothionein fraction of the liver, but it seemed to have little effect on iron metabolism.']","['Maximum blood copper levels were observed within 1 to 3 hours following oral administration, and about 50 percent of ingested copper was absorbed. Copper absorption is believed to occur by two mechanisms, one energy- dependent and the other enzymatic. Factors that can interfere with copper absorption include competition for binding sites with zinc, interactions with molybdenum and sulfates, chelation with phytates, and inhibition by ascorbic acid.  Copper absorbed from the intestine is transported quickly into blood serum and deposited in the liver bound to metallothionein. It is released and incorporated into ceruloplasmin, a copper-specific transport protein. The remaining copper in the serum binds to albumin or amino acids or is contained in the erythrocytes. About 80 percent of the absorbed copper is bound to liver metallothionein; the remainder is included into cytochrome c oxidase or sequestered by lysosomes.']",['The biological half-life of copper from the diet is 13-33 days with biliary excretion being the primary route of elimination.']
4462,24463,Copper sulfate pentahydrate,O.O.O.O.O.[O-]S(=O)(=O)[O-].[Cu+2],,,"['Agents counteracting or neutralizing the action of POISONS. (See all compounds classified as Antidotes.)', 'Agents that cause vomiting. They may act directly on the gastrointestinal tract, bringing about emesis through local irritant effects, or indirectly, through their effects on the chemoreceptor trigger zone in the postremal area near the medulla. (See all compounds classified as Emetics.)']","['AFTER ADMIN COPPER(II) SULFATE, PENTAHYDRATE FOR 7 DAYS IP, COPPER ACCUMULATED IN MITOCHONDRIAL & LYSOSOMAL FRACTIONS OF RAT LIVER, MAINLY IN LYSOSOMES.']",,
4463,24464,Lead tungstate,[O-][W](=O)(=O)[O-].[Pb+2],,,,,,
4464,24465,Tungstate,[O-][W](=O)(=O)[O-],,,,,,
4465,24466,Metoprine,CC1=C(C(=NC(=N1)N)N)C2=CC(=C(C=C2)Cl)Cl,,,"['Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)', 'Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Folic Acid Antagonists.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
4466,24467,1-(4-Acetyl-1-naphthoxy)-2-propanol,CC(COC1=CC=C(C2=CC=CC=C21)C(=O)C)O,,,,,,
4467,24468,"2-Butanol, 1-(4-acetyl-1-naphthyloxy)-",CCC(COC1=CC=C(C2=CC=CC=C21)C(=O)C)O,,,,,,
4468,24469,1-(4-Acetyl-1-naphthyloxy)-3-isopropoxy-2-propanol,CC(C)OCC(COC1=CC=C(C2=CC=CC=C21)C(=O)C)O,,,,,,
4469,24470,Silver Nitrate,[N+](=O)([O-])[O-].[Ag+],,,"['Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)']","['SILVER, AS AG NITRATE, IS ABSORBED FROM THE RESP & GI TRACTS ... ABSORPTION OF SILVER NITRATE THROUGH THE INTACT SKIN IS OF NO PHYSIOLOGICAL SIGNIFICANCE, HOWEVER, SOME ABSORPTION THROUGH MUCOUS MEMBRANES OF THE NOSE & THROAT PROBABLY OCCURS. ABSORBED SILVER IS TENACIOUSLY RETAINED ... IN ELASTIC TISSUES THROUGHOUT THE BODY.', '... Silver in brain and spinal cord sections from rats treated with ... silver nitrate was visualized by physical appearance. The silver penetrated the blood brain barrier and accumulated in the neurons and glia. The distribution of silver in the central nervous system was heterogeneous. Even with low doses and short survival periods, silver accumulated in large motorneurons in the brain stem and spinal cord and in the neurons in the cerebellar nuclei. Silver was only found in the diecenphalic and telecenphalic structures after extensive exposure. Silver distribution following oral ... AgNO3 treatment ... resulted in a relatively high content of silver in the glia. ... Electron microscopic studies /revealed/ ... silver ... intracellularly in the lysosomes and extracellularly in basement membranes and elastic fibers of the vessels.', 'All forms of silver are cumulative once they enter body tissues, and very little is excreted.', ""In argyric rats given 0.5 percent silver nitrate in their drinking water for nine months, silver was especially found in lysosomes of the liver's Kupffer cells, at the basal membrane of the capillaries, and the connective tissue cells of the pancreas."", 'For more Absorption, Distribution and Excretion (Complete) data for SILVER NITRATE (17 total), please visit the HSDB record page.']","['/The investigators/ reported that rats injected iv with radioactive silver nitrate excreted silver in the bile mainly bound to a low molecular-wt complex which appeared to be glutathione.', 'A marked variation in biliary excretion was observed in different species administered silver as silver nitrate in a single iv injection at 0.1 mg/kg of silver over a 2 hour period ... . Thirty minutes after treatment, male Sprague Dawley rats excreted silver into the bile at a rate of 0.25 ug/min/kg, New Zealand White male rabbits excreted 0.05 ug/min/kg, and mongrel male dogs excreted 0.005 ug/min/kg. The concentration of silver in the plasma was markedly lower in the dog than in the rat or rabbit, indicating a larger volume of distribution in the dog. This variation appears to be attributable to differences in the transfer of silver from liver to bile. The species with the lowest biliary excretion rate (dog) had the highest liver concentration of silver (rat 1.24, rabbit = 2.13 and dog = 2.9 ug silver/g liver). In all species, the concentration of silver in the bile was greater than that in plasma with no observable dose gradient, thereby indicating an active transport process and a saturable mechanism.']","['Silver injected into rats as radioactive silver nitrate had a half-time of 2.2 days. ... For rats given a single ip injection of radioactive silver nitrate, a 50% reduction in radioactivity of whole blood, plasma, kidney, & liver after approx 40 hr. A 50% reduction in the radioactivity content of spleen occurred after about 70 hr while that of brain took about 84 hr. The biological half-time of silver in the lungs of a human exposed to silver has been estimated to be 1 day, while that in the liver was 52 days.', 'The biphasic elimination half-times after silver nitrate ingestion by monkeys were 0.3 & 3 days.', 'Whole-body retention studies in mice and monkeys following oral dosing with radiolabeled silver nitrate indicate that silver excretion in these species follows a biexponential profile with biological half-lives of 0.1 and 1.6 days in mice and 0.3 and 3 days in monkeys. In similarly exposed rats and dogs, silver excretion followed a triexponential profile with biological half-lives of 0.1, 0.7, and 5.9 days in rats and 0.1, 7.6, and 33.8 days in dogs .. .']"
4470,24471,"Guanidine, (2-(N-methylanilino)ethyl)-",CN(CCN=C(N)N)C1=CC=CC=C1,,,,,,
4471,24472,2-Chlorooxirane,C1C(O1)Cl,,,,,['2-Chlorooxirane is a known human metabolite of VINYL CHLORIDE.'],
4472,24473,Dihydrocarvone,CC1CCC(CC1=O)C(=C)C,,,,,,
4473,24474,4-(N-Methyl-3-indolylethyl)pyridinium hydrochloride,CN1C=C(C2=CC=CC=C21)CCC3=CC=[NH+]C=C3.[Cl-],,,,,,
4474,24475,1-Methyl-3-[2-(4-pyridyl)ethyl]-1H-indole,CN1C=C(C2=CC=CC=C21)CCC3=CC=NC=C3,,,,,,
4475,24476,"1'-Acetonaphthone, 4'-(2-hydroxyethoxy)-",CC(=O)C1=CC=C(C2=CC=CC=C21)OCCO,,,,,,
4476,24477,Sodium Thiosulfate,[O-]S(=O)(=S)[O-].[Na+].[Na+],['Prevention of platinum-induced ototoxic hearing loss'],,"['Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)', 'Agents counteracting or neutralizing the action of POISONS. (See all compounds classified as Antidotes.)', 'Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)', 'Drugs used in the treatment of tuberculosis. They are divided into two main classes: &quot;first-line&quot; agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and &quot;second-line&quot; drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. (See all compounds classified as Antitubercular Agents.)']",['POORLY ABSORBED FROM BOWEL. ... THIOSULFATE ION DISTRIBUTES ITSELF IN EXTRACELLULAR FLUID.'],,
4477,24478,Thiosulfuric acid,OS(=O)(=S)O,['Indicated for sequential intravenous use with sodium nitrite for the treatment of acute cyanide poisoning that is judged to be life-threatening.'],"['In dogs, pretreatment with sodium thiosulfate to achieve a steady state level of 2 Âµmol/mL increased the rate of conversion of cyanide to thiocyanate over 30-fold.']",,"['Thiosulfate taken orally is not systemically absorbed. Most of the thiosulfate is oxidized to sulfate or is incorporated into endogenous sulphur compounds; a small proportion is excreted through the kidneys.  After an intravenous injection of 1 g sodium thiosulfate in patients, the reported serum thiosulfate half-life was approximately 20 minutes. However, after an intravenous injection of a substantially higher dose of sodium thiosulfate (150 mg/kg, that is, 9 g for 60 kg body weight) in normal healthy men, the reported elimination half-life was 182 minutes.', 'Elimination is primarily renal, approximately 20-50% of exogenously administered thiosulfate is eliminated unchanged via the kidneys Antidote (to cyanide poisoning): Primarily as thiocyanate. Antineoplastic adjunct: As a nontoxic sodium thiosulfate/cisplatin complex.', '150 mL/kg.', '1.86 Â± 0.45 ml/min per kg.']",['Data not found.'],['Thiosulfate: 15 to 20 minutes.']
4478,24479,Stannous chloride,Cl[Sn]Cl,,,,"['The concn of tin in the diaphysis was higher than in the epiphysis both in controls and rats given oral doses of stannous chloride for 28 days.', 'The effect of dietary tin on zinc, copper, & iron utilization by rats was studied. Male weanling Sprague-Dawley rats were fed a diet containing 206 ug tin (as stannous chloride)/g feed for 21 days. The rats fed the test diet lost more zinc in feces and retained much lower levels of zinc in tibias and kidneys than rats fed the control diet 1 ug tin/g. Rats fed the tin supplemented diet retained higher levels of tin in kidneys and tibias and lower levels of copper in kidneys than controls.', 'Volunteers in a balance experiment given diets containing 0.11 or 49.67 mg tin (as stannous chloride) daily for 20 days appeared to absorb 50 and 3% of the tin, respectively, as estimated from dietary and fecal tin recovery.', '... Rats and rabbits absorbed <2% of orally administered tin from stannous chloride.']",,
4479,24480,Manganese dichloride,Cl[Mn]Cl,,,,,,
4480,24481,CID 24481,OS(=O)[O-].[K+],,,,,,
4481,24482,Ammonium sulfamate,[NH4+].NS(=O)(=O)[O-],,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)', 'Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']",,,
4482,24483,1-[(1E)-1-Ethyl-2-(4-methoxyphenyl)-1-butenyl]-4-methoxybenzene,CCC(=C(CC)C1=CC=C(C=C1)OC)C2=CC=C(C=C2)OC,,,,,,
4483,24484,"Guanidine, 4,4'-methylenediphenyldi-",C1=CC(=CC=C1CC2=CC=C(C=C2)N=C(N)N)N=C(N)N,,,,,,
4484,24485,Mercuric iodide,I[Hg]I,,,,,,
4485,24486,"Calcium chloride, hexahydrate",O.O.O.O.O.O.[Cl-].[Cl-].[Ca+2],,,,,,
4486,24487,CID 24487,[O-]Cl(=O)=O.[Na+],,,,,,
4487,24488,Sodium chromate,[O-][Cr](=O)(=O)[O-].[Na+].[Na+],,,,"['When injected intravenously into rats, sodium chromate(VI) accumulates in the kidneys and later in the spleen.', '(51)Chromium labelled sodium, zinc and lead chromates were studied. Sodium chromate and the less soluble zinc chromate were absorbed into the blood, resulting in increased urinary excretion of chromium. ... The less water soluble the chromate, the higher was its elimination via the feces. Absorbed chromium was retained in the spleen and bone marrow in all three cases, and also in the liver and kidneys in the case of sodium chromate. Chromium levels in blood and urine are not indicative of inhalation exposure to insoluble chromates.', 'Percutaneous absorption of labelled sodium chromate occurred in guinea pigs: a maximum of 4% of the dose applied on the skin disappeared within 5 hours, and labelled chromium was detected in a number of organs.', 'Following intratracheal administration of sodium chromate solution to rabbits, about 45% (as Cr) remained in the lungs 4 hours after instillation; 15% was excreted in urine. The highest concentration of chromium (IV) was reached in red cells after about 3 hours, and the corresponding plasma concentration at that time was about one-third of that in red cells.', 'For more Absorption, Distribution and Excretion (Complete) data for SODIUM CHROMATE (8 total), please visit the HSDB record page.']","['Hexavalent chromium, as sodium chromate in an aq soln, was reduced rapidly to trivalent chromium in the presence of glutathione (0.3-3.0 mM). Such glutathione-dependent redn of hexavalent chromium can take place in the cytosolic space of hexavalent chromium exposed cells, since glutathione is found in reactive concn in this compartment.', ""The capacity of glutathione (GSH) to reduce Cr(VI) to Cr(III) in vitro was investigated. The reaction was determined spectrophotometrically by following the absorption of Cr(VI) at 370 nm. At stoichiometric conditions (molar ratio Cr(VI)/GSH of 1:3) the reduction was strongly dependent on the solution's pH. It was much slower at pH 7.4 than at pH values below 5. An excess of GSH (100- or 1000-fold) accelerated the reaction. In any case, 3 GSH molecules were required to reduce 1 molecule of chromate. Incubation of human red blood cells (RBC) with an excess of Na2CrO4 (10 mM) decreased the GSH content of the cells to 10% of the original amount. This depletion of GSH was similar to that obtained when RBC were incubated with 62 mM diethylmaleate (DEM), a well known GSH depleting agent. Sephadex G-100 chromatography of lysates from human RBC incubated with radioactive chromate (51)Cr(VI] showed a strong affinity of (51)Cr for hemoglobin: 97% of the applied dose was bound to hemoglobin whilst only minor amounts of (51)Cr were found in the low-molecular fractions. However, incubations of prepared lysates (as opposed to intact cells) with 10 mM Na2 (51)CrO4 markedly raised the chromium content of low-molecular fractions (probably GSH-Cr-complexes), probably indicative of a role of GSH in the intra-cellular reduction of Cr(VI) to Cr(III), the latter being regarded as the ultimately toxic species of this metal."", 'Comparative metabolic fate of labelled chromium chloride and sodium chromate and interaction of these compounds in the rat liver and blood were investigated after their oral and intravenous administration. Gastrointestinal absorption of both compounds was below 1% of the oral dose, but trivalent chromium showed higher radioactivity than the hexavalent form in rats (biological half-life: CrCl3 91.79 days, Na2CrO4 22.24 days). The higher residual activity of the trivalent chromium was also observed after intravenous administration. Both forms of chromium were excreted more in the urine via the kidney than in the intestinal tract after intravenous administration. When (51)CrCl3 and Na2(51)CrO4 were injected into rats, in the time-distribution patterns of( 51)Cr in the organs, a significant difference was shown between oxidation states of the two compounds, especially in subcellular fractions of the liver and blood constituents. This significant difference mainly observed in the rat blood came from the fact that trivalent chromium possessed a high binding activity for transferrin in plasma, while hexavalent chromium was permeable into red cells and bound with hemoglobin.']","['/Rats were treated/ with (51)Cr labeled sodium chromate or chromium chloride by gavage or intravenous injection and found that, regardless of the route, (51)Cr from chromium(VI) was excreted more rapidly through the urine and feces than was (51)Cr from chromium(III). Following oral administration, the biologic half-life was 22.24 days for sodium chromate and 91.79 days for chromium chloride.', 'Gastrointestinal absorption of both compounds was below 1% of the oral dose, but trivalent chromium showed higher radioactivity than the hexavalent form in rats (biological half-life: CrCl3 91.79 days, Na2CrO4 22.24 days).', '... Gastrointestinal absorption of /chromium chloride and sodium chromate/ was below 1% of the oral dose, but trivalent chromium showed higher radioactivity than the hexavalent form in rats (biological half-life: CrCl3 91.79 days, Na2CrO4 22.24 days). ...']"
4488,24489,Sodium dithionite,[O-]S(=O)S(=O)[O-].[Na+].[Na+],,,,,"['Sodium dithionite is not stable under physiological conditions, with the rate of decomposition increasing with increasing acidity. Upon contact with moisture, it is oxidized to hydrogen sulfite, sulfite and hydrogen sulfate, and under strongly acidic conditions it may liberate sulfur dioxide. Under anaerobic conditions (such as in the lower gastrointestinal tract), hydrogen sulfite and thiosulfate may be formed. Hydrogen sulfite can be absorbed after ingestion. It is efficiently metabolized, and the major part rapidly excreted as sulfate into the urine.', 'As sodium dithionite is chemically unstable in the presence of water and oxygen, in particular under acidic conditions, rapid conversion of sodium dithionite into various related sulfite species is expected to occur under physiological conditions. Therefore, it is justified to take account of toxicological data of sodium sulfite, sodium hydrogen sulfite, and disodium disulfite (= sodium metabisulfite) in the human health assessment of dithionite ... In this context, sodium sulfite and sodium hydrogen sulfite are considered to be the predominant chemicals that are systemically available to the body.']",
4489,24490,Dithionous acid,OS(=O)S(=O)O,,,,,,
4490,24491,CID 24491,B(=O)[O-].[Na+],,,,,,
4491,24492,Boric acid (HBO2),B(=O)O,,,,,,
4492,24493,"Trioctadecyl 2-hydroxypropane-1,2,3-tricarboxylate",CCCCCCCCCCCCCCCCCCOC(=O)CC(CC(=O)OCCCCCCCCCCCCCCCCCC)(C(=O)OCCCCCCCCCCCCCCCCCC)O,,,,,"['BECAUSE NO HYPOCALCEMIA HAS BEEN NOTED IN ANY EXPERIMENT, IT IS ASSUMED THAT STEARYL CITRATE IS RAPIDLY METABOLIZED OR EXCRETED AND HYDROLYZED AT A SLOW RATE. /STEARYL CITRATE/']",
4493,24494,Thioridazine 5-Sulfoxide,CN1CCCCC1CCN2C3=CC=CC=C3S(=O)C4=C2C=C(C=C4)SC,,,,,['Thioridazine 5-sulfoxide is a known human metabolite of Thioridazine.'],
4494,24495,Calcium phytate,C1(C(C(C(C(C1OP(=O)([O-])[O-])OP(=O)([O-])[O-])OP(=O)([O-])[O-])OP(=O)([O-])[O-])OP(=O)([O-])[O-])OP(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2],,,,,,
4495,24496,Selenohomocystine,C(C[Se][Se]CCC(C(=O)O)N)C(C(=O)O)N,,,,,,
4496,24497,Calcium sulfate,[O-]S(=O)(=O)[O-].[Ca+2],,,"['Materials used in the production of dental bases, restorations, impressions, prostheses, etc. (See all compounds classified as Dental Materials.)']",,,
4497,24498,(1) Penethamate hydriodide,CCN(CC)CCOC(=O)C1C(SC2N1C(=O)C2NC(=O)CC3=CC=CC=C3)(C)C,,,,,,
4498,24499,Sulfamoyl chloride,NS(=O)(=O)Cl,,,,,,
4499,24500,Disodium arsenate,O[As](=O)([O-])[O-].[Na+].[Na+],,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']",,,
4500,24501,Calcium arsenate,[O-][As](=O)([O-])[O-].[O-][As](=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2],,,,"['FOLLOWING DIETARY ADMIN OF 215 MG/KG OF DIET AS CALCIUM ARSENATE ... FOR UP TO 52 DAYS IN RATS, HIGHEST ARSENIC LEVELS (146-537 UG/G DRY TISSUE) ... IN KIDNEYS & LIVER & RELATIVELY LOWER LEVELS IN HAIR, BRAIN, BONE, MUSCLE, & SKIN. LIVER & KIDNEY LEVELS WERE GREATER AFTER ADMIN OF CALCIUM ARSENATE THAN OF ARSENIC TRIOXIDE.', 'Hamsters were given weekly intratracheal instillations of ... calcium arsenate dust suspensions. Animals were killed at weekly intervals and the concn of arsenic was determined in lung, liver, and hair by atomic absorption spectrophotometry following wet digestion and arsine generation. Animals treated with calcium arsenate had concn of As in the lung about 100 times higher than that of animals given arsenic trisulfide and 1000 times higher than that of animals receiving arsenic trioxide. ... The substantial differentration in lung retention between these inorganic As cmpd is of importance for the design and interpretation of animal carcinogenicity tests involving the respiratory tract and could also have significance in human exposure situations.', 'Animal data have shown substantial differences in lung retention after intratracheal instillations of arsenic trisulfide, calcium arsenate and arsenic trioxide. Retention of ... arsenic trisulfide was 10 times higher compared to arsenic trioxide.']",,
4501,24502,Potassium Dichromate,[O-][Cr](=O)(=O)O[Cr](=O)(=O)[O-].[K+].[K+],,,"['Strong alkaline chemicals that destroy soft body tissues resulting in a deep, penetrating type of burn, in contrast to corrosives, that result in a more superficial type of damage via chemical means or inflammation. Caustics are usually hydroxides of light metals. SODIUM HYDROXIDE and potassium hydroxide are the most widely used caustic agents in industry. Medically, they have been used externally to remove diseased or dead tissues and destroy warts and small tumors. The accidental ingestion of products (household and industrial) containing caustic ingredients results in thousands of injuries per year. (See all compounds classified as Caustics.)', 'Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)']","['The acute and subacute toxicities of several Cr(III) and Cr(VI) compounds (chromium(3+) chloride, chromium(3+) nitrate, chromium(3+) sulfate, chromium trioxide, potassium dichromate) were determined in NZC and (CxO) mice injected ip. The distal median lethal doses (> 10 days after treatment) averaged (17.9 + or - 1.8) X 10(-6) g chromium/g body wt regardless of the oxidation state of the Cr compound injected (chromium(3+) sulfate may be an exception), but acute toxicity (3 days) was much greater with Cr(VI) compounds. Acid digests of entire male mice that were administered ip 1/6 of the distal LD50, either once or repeatedly at weekly intervals, were analyzed to determine the whole body persistence and clearance kinetics of Cr. Mice dosed once with Cr(III) retained 6.5 times more chromium at 21 days than mice treated with Cr(VI). When Cr(III) was given at weekly intervals mice accumulated 6 times more Cr by 8 wk than Cr(VI)-treated mice, though only the latter showed symptoms of chromic toxicity. Whole body Cr concentrations continued to rise with further Cr(III) treatments, but slowly declined with Cr(VI). Analyses of fecal and urinary excretion confirmed that most of the urinary Cr excretion from Cr(VI)-treated animals was much faster in both urine and feces than from mice given Cr(III). The differential storage and clearance kinetics of Cr(III) and Cr(VI) compounds may be significant in experimental Cr carcinogenesis studies and in the toxicology of Cr in workers exposed industrially to potentially carcinogenic chromium-containing dusts or aerosols.', 'The interaction of potassium dichromate (Cr(VI)) with bovine serum albumin (BSA) was investigated by fluorescence, synchronous fluorescence, resonance light scattering (RLS), ultraviolet-visible absorption, and circular dichroism (CD) spectroscopies under simulated physiological conditions. The experimental results showed that Cr(VI) could quench the intrinsic fluorescence of BSA following a static quenching process, which indicates the formation of a Cr(VI)-BSA complex. The binding constant (KA) and binding site (n) were measured at different temperatures. The spectroscopic results also revealed that the binding of Cr(VI) to BSA can lead to the loosening of the protein conformation and can change the microenvironment and skeleton of BSA.']",,
4502,24503,Dichromate,[O-][Cr](=O)(=O)O[Cr](=O)(=O)[O-],,,,,,
4503,24504,Calcium hypochlorite,[O-]Cl.[O-]Cl.[Ca+2],,,,"['Only ca. 50% is excreted mainly with the urine followed by excretion with feces. /Sodium hypochlorite/', 'Most of the data for toxicity of this substance by the oral route came from studies performed with sodium hypochlorite or chlorine gas. In biological systems, characterized by pH values in the range of 6-8, the most abundant active chemical species is HClO, in equilibrium with ClO-. Such available chlorine is readily absorbed via the oral route and distributed into plasma, bone marrow, testis, skin, kidney and lung. /sodium hypochlorite/']","['It is well known from studies on HClO in inflammation processes that HClO is not enzymatically metabolised and its (bio)transformation readily occurs through direct reactions with organic compounds or with other chemicals present in the cellular environment, including hydrogen peroxide. The toxicokinetic study showed that chloride ion accounted for >80% (36)Cl radioactivity present in rat plasma. /Hypochlorite/']",
4504,24505,CID 24505,[O-]Cl(=O)(=O)=O.[K+],,,,,,
4505,24506,Nutrol,OP(=O)(O)[O-].[K+],,,,,,
4506,24507,Potassium Sulfate,[O-]S(=O)(=O)[O-].[K+].[K+],['Potassium is used to regulate hypokalemia as a primary condition or secondary to other medical conditions.'],,,['Mostly urine but also skin and feces.'],,
4507,24508,"2-Propenoic acid, 3-phenyl-, propyl ester",CCCOC(=O)C=CC1=CC=CC=C1,,,,,,
4508,24509,"1,2-Dimethoxypropane",CC(COC)OC,,,,,,
4509,24510,Cyclohexyl anthranilate,C1CCC(CC1)OC(=O)C2=CC=CC=C2N,,,,,,
4510,24511,"1,2,3-Propanetricarboxylic acid, 2-hydroxy-, magnesium salt",C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Mg+2],,,,,,
4511,24512,"1,3,5-Triethylhexahydro-s-triazine",CCN1CN(CN(C1)CC)CC,,,,,,
4512,24513,"1,1-Dimethoxydecane",CCCCCCCCCC(OC)OC,,,,,,
4513,24514,4-Hydroxy-undecanoic acid,CCCCCCCC(CCC(=O)O)O,,,,,,
4514,24515,Isobutyl anthranilate,CC(C)COC(=O)C1=CC=CC=C1N,,,,,,
4515,24516,Isobutyl heptanoate,CCCCCCC(=O)OCC(C)C,,,,,,
4516,24517,Zinc dithionite,[O-]S(=O)S(=O)[O-].[Zn+2],,,,,,
4517,24518,ZINC nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Zn+2],,,,"['Upon intravenous injection zinc is distributed to erythrocytes, plasma, and leukocytes; about 80% of the zinc present in the blood is found in the erythrocytes, 12-20% in the plasma, and about 3% in the leukocytes. ... There is a dynamic exchange of zinc between plasma and erythrocytes. Inhalation of dusts of zinc salts results in a transient accumulation in the lung before its absorption into the blood. There is little absorption of zinc or its salts through the skin. ... About 80% of parenterally administered zinc is excreted in the feces, suggesting an enterohepatic circulation for zinc. In humans, about 10% of the absorbed zinc is excreted in the urine, and in tropical climates about 2-3 mg zinc/day may be lost in sweat. /Soluble zinc compounds/']",,
4518,24519,Zinc Phosphate,[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Zn+2].[Zn+2].[Zn+2],,,,,,
4519,24520,5-Hydroxydodecanoic acid,CCCCCCCC(CCCC(=O)O)O,,,,,,
4520,24521,Cinnamic Acid Isopropyl Ester,CC(C)OC(=O)C=CC1=CC=CC=C1,,,,,,
4521,24522,Ethyl 3-hydroxybenzoate,CCOC(=O)C1=CC(=CC=C1)O,,,,,,
4522,24523,Deuterium,[2H][2H],,,,,,
4523,24524,Fluorine,FF,,,,"['Fluorides are absorbed from gi tract, lung, and skin. GI tract is major site of absorption. The relatively sol compound, such as sodium fluoride, are almost completely absorbed. ... Fluoride has been detected in all organs and tissues, and it is concentrated in bone, thyroid, aorta, and perhaps kidney. Fluoride is primarily deposited in bone and teeth, and the degree of skeletal storage is related to intake and age. ... Major route of ... excretion is via the kidneys; ... /also excreted in small amount/ in sweat, milk, and intestinal secretions. ... About 90% of fluoride ion filtered by glomerulus is reabsorbed by renal tubules. /fluoride/', 'Solutions of fluoride salts are rapidly and almost completely absorbed from the gastrointestinal tract, probably by simple diffusion. ... Less than 10% of the ingested fluoride is excreted in the feces, but the proportion varies with circumstances. ... The simultaneous presence of strongly fluoride-binding ions, especially calcium ions, will reduce the absorption of fluoride. ... In patients ingesting aluminum-containing antacids, fluoride absorption decr to about 40%, and the retention decr to nil. /Fluorides/', 'In the industrial environment, the respiratory tract is the major route of absorption of both gaseous and particulate fluoride. Hydrogen fluoride being highly soluble in water is rapidly taken up in the upper respiratory tract. ... Depending on their aerodynamic characteristics, fluoride-containing particles will be deposited in the nasopharynx, the tracheo-bronchial tree and the alveoli. ... Dermal absorption of fluoride has only been reported in the case of burns resulting from exposure to hydrofluoric acid ... . /Fluorides/', 'About 75% of the blood fluoride is present in the plasma; the rest is mainly in or on the red blood cells ... Fluoride in human serum exists in both ionic and nonionic forms. ... For the general population under steady-state conditions of exposure, the concn of fluoride ions in plasma is directly related to the fluoride content of the drinking water. /Fluorides/', 'For more Absorption, Distribution and Excretion (Complete) data for FLUORINE (7 total), please visit the HSDB record page.']",,"['... Bone retains about 60% of iv-injected fluoride and that the half-time for this uptake is only about 13 min; both blood and extracellular fluid levels therefore decr rapidly. After ingestion of sodium fluoride, plasma fluoride levels show a much slower change with a half-life of about 3 hr ... . /Fluorides/']"
4524,24525,CID 24525,CC1C(C2C(C3C(C(C4C(C5C6C(C(C7C(C(C8C(C9C(C(C%10C(C(C%11C(C%12C(C%13C(C%14C(C(C1C)C2C1C3C4C2C5C3C4C6C7C8C5C9C%10C%11C(C54)C%12C3C%13C2C%141)C)C)C)C)C)C)C)C)C)C)C)C)C)C)C)C)C)C,,,,,,
4525,24526,Chlorine,ClCl,,,"['Chemicals that are used to cause the disturbance, disease, or death of humans during WARFARE. (See all compounds classified as Chemical Warfare Agents.)']","['Chlorine is eliminated primarily in urine and feces, mainly (81% of ingested label) as the chloride ion.', 'Chlorine gas is found to accumulate in the leaves of plants; entering via the stomata.', 'Chlorine, as chlorine gas, chlorite ion, and hypochlorite, is a strong oxidant that readily reacts with organic molecules to produce a variety of chlorinated compounds. This reactivity in biological systems makes it difficult to study the pharmacokinetics of chlorine and to separate the effects of chlorine from those of the chlorine compounds and metabolites.']","['Chlorine persists as an element only at a very low pH (less than 2), and at the higher pH found in living tissue it is rapidly converted into hypochlorous acid. In this form, it apparently can penetrate the cell and form N-chloro-derivatives that can damage cellular integrity.', 'Chlorine is a strong oxidizing agent that forms both hypochlorous and hydrochloric acid on contact with moist mucous membranes. The former cmpd decomposes into hypochloric acid and oxygen free radicals (.O2-). Damage results from the disruption of cellular proteins. These agents combine with sulfhydryl groups and disulfur bonds and form stable hydrates of organic chlorine.']","['No reports found; [TDR, p. 308]']"
4526,24527,Iron(3+);nitric acid;nonahydrate,[N+](=O)(O)[O-].[N+](=O)(O)[O-].[N+](=O)(O)[O-].O.O.O.O.O.O.O.O.O.[Fe+3],,,,,,
4527,24528,Manganese(II) fluoride,F[Mn]F,,,,,,
4528,24529,Nitrous acid,N(=O)O,['For sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning that is judged to be life-threatening.'],['Sodium nitrite reverses cyanide toxicity and produces blood vessel dilation.'],,"['Reactive nitrogen species derived from nitric oxide are potent oxidants formed during inflammation that can oxidize membrane and lipoprotein lipids in vivo. ... Several of these species react with unsaturated fatty acid to yield nitrated oxidation products. ... Reaction of HPODE, but not linoleate, with nitrous acid (HONO) or isobutyl nitrite (BuiONO) yielded a product at m/z 340, or 341 upon reacting with [15N]HONO. MS/MS analysis gave an NO2- fragment, and 15N NMR indicated that the product contained a nitro (RNO2) functional group, suggesting that the product was nitroepoxylinoleic acid [L(O)NO2]. This species could form via homolytic dissociation of LOONO to LO* and *NO2 and rearrangement of LO* to an epoxyallylic radical L(O)* followed by recombination of L(O)* with *NO2. Since unsaturated lipids of membranes and lipoproteins are critical targets of reactive oxygen and nitrogen species, these pathways lend insight into mechanisms for the formation of novel nitrogen-containing lipid products in vivo and provide synthetic strategies for further structural and functional studies.']","['Reduced by deoxyhemoglobin to form nitric oxide. Nitrite is also reduced to nitric oxide and further reduced to ammonia by gut bacteria. Nitrite can be oxidized to nitrate by oxyhemoglobin.', 'The reactions of nitrogen dioxide with cyclohexene have been studied as a model for the reactions that occur between nitrogen dioxide in smoggy air and unsaturated fatty acids in pulmonary lipids. As predicted from earlier studies at high nitrogen dioxide concentrations, this gas reacts with cyclohexene predominantly by addition to the double bond at nitrogen dioxide concentrations of 1 percent (10,000 parts per million) to 40 percent in nitrogen; in the presence of air or oxygen, this reaction initiates the autoxidation of the alkene. However, at concentrations below 100 parts per million in nitrogen, nitrogen dioxide reacts with cyclohexene almost exclusively by abstraction of allylic hydrogen; this unexpected reaction also initiates the autoxidation of the alkene in the presence of oxygen or air, but it leads to the production of nitrous acid rather than of a product containing a nitro group attached to a carbon atom. The nitrous acid can react with amines to produce nitrosamines. Moreover, the nitrite ion produced by the hydrogen abstraction mechanism would be expected to diffuse throughout the body, unlike nitrated lipids that would be confined to the pulmonary cavity. These findings have been confirmed with methyl oleate, linoleate, and linolenate; some of the kinetic features of the nitrogen dioxide-initiated autoxidation of these unsaturated fatty acids have been studied. .']",['Half life of 0.4-0.78h.']
4529,24530,Hydrazoic acid,N=[N+]=[N-],,,,,,
4530,24531,CID 24531,[O-]P=O.[K+],,,,,,
4531,24532,Lithium amide,[Li+].[NH2-],,,,"['All sol lithium cmpd are readily absorbed from GI tract as well as from sc, im, and ip depots, appearing in tissue fluids and organs within a few min of admin. /Sol lithium cmpd/', 'Li+ is absorbed readily and almost completely from the GI tract. Complete absorption occurs in about 8 hr, with peak concn in plasma occurring 2 to 4 hr after an oral dose. Slow-release preparations of lithium carbonate provide a slower rate of absorption and thereby minimize early peaks in plasma concn of the ion. However, absorption can be variable, and the incidence of lower intestinal tract symptoms may be incr. Li+ initially is distributed in the extracellular fluid and then gradually accumulates in various tissues. The concentration gradient across plasma membranes is much smaller than those for Na+ and K+. The final volume of distribution (0.7 to 0.9 L/kg) approaches that of total body water and is much lower than that of most other psychotropic agents, which are lipophilic and protein-bound. Passage through the blood-brain barrier is slow, and when a steady state is achieved, the concn of Li+ in the cerebrospinal fluid is about 40% to 50% of the concn in plasma. The ion does not bind appreciably to plasma proteins. /Li+/', 'LI+ OBEYS TWO-COMPARTMENT MODEL KINETICS AFTER ORAL DOSES TO HUMAN SUBJECTS. ITS DISTRIBUTION & ELIMINATION KINETICS ARE INDEPENDENT OF THE ACCOMPANYING ANION & THE TERMINAL ELIMINATION T/2 IS ABOUT 22 HR. /Li+/', 'Approximately 95% of a single dose of Li+ is eliminated in the urine. From one- to two-thirds of an acute dose is excreted during a 6- to 12-hr initial phase of excretion, followed by slow excretion over the next 10 to 14 days. The elimination half-life averages 20 to 24 hr. With repeated admin, Li+ excretion incr during the first 5 to 6 days until a steady state is reached between ingestion and excretion. When therapy with Li+ is stopped, there is a rapid phase of renal excretion followed by a slow 10- to 14-day phase. Since 80% of the filtered Li+ is reabsorbed by the proximal renal tubules, clearance of Li+ by the kidney is about 20% of that for creatinine, ranging between 15 and 30 mL/min. This is somewhat lower in elderly patients (10 to 15 mL/min). /Li+/', 'For more Absorption, Distribution and Excretion (Complete) data for LITHIUM AMIDE (11 total), please visit the HSDB record page.']",,"['The plasma half-life (in healthy volunteers) shows a considerable variability: from 5 to 40 hr, with most values between 15 and 30 hr, it depends on the duration of treatment as well as on kidney function and age. /Li+/', '...AFTER ORAL DOSES TO HUMAN SUBJECTS...THE TERMINAL ELIMINATION T/2 IS ABOUT 22 HR. /LITHIUM/', '... The clinical features and pharmacokinetics of 22 lithium overdoses are described. Effectiveness of different treatment regimens regarding elimination of lithium is discussed. Origin of overdose was due to deliberate poisoning or precipitated by concomitant diseases, coadministration of drugs, or combination of both. Treatment included supportive care, diuretics (15/22), hemodialysis (HD; 9/22), and mechanical ventilation (3/22). Severity of lithium intoxication was classified in 50% as I degrees, in 41% as II degrees, and in 9% as III degrees according to Hansen and Amdisen. Renal impairment on admission was diagnosed in 82% of the patients. Half-life of lithium in serum was 3.5 +/- 0.8 hr during the first HD, and 29 +/- 14 and 29 +/- 6 hr during therapy with diuretics or supportive treatment, respectively. Lithium clearance during HD was 160 +/- 15 mL/min, and renal clearance during HD or treatment with diuretics was approximately 20 and 15 +/- 9 mL/min, respectively. Renal lithium clearance was not influenced by HD therapy. There was no difference regarding half-life and clearance between the group that had an unspecific treatment or the group treated with diuretics. ... /Lithium NOS/', 'The usual elimination half-life is 12 to 27 hr, but it may rise to nearly 60 hr if renal excretion is compromised. /Li+/']"
4532,24533,Sodium amide,[NH2-].[Na+],,,,,,
4533,24534,Nitramide,N[N+](=O)[O-],,,,,,
4534,24535,Disodium dihydrogen hypophosphate,OP(=O)([O-])P(=O)(O)[O-].[Na+].[Na+],,,,,,
4535,24536,Hypophosphoric acid,OP(=O)(O)P(=O)(O)O,,,,,,
4536,24537,CID 24537,N.N.OS(=O)(=O)S,,,,,,
4537,24538,"Ammonium sulfate, ACS reagent",N.N.OS(=O)(=O)O,,,,,,
4538,24539,Diammonium zinc disulfate hexahydrate,[NH4+].[NH4+].O.O.O.O.O.O.[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[Zn+2],,,,,,
4539,24540,Diammonium hydrogen phosphate,[NH4+].[NH4+].OP(=O)([O-])[O-],,,"['Substances used in the processing or storage of foods or animal feed including ANTIOXIDANTS; FOOD PRESERVATIVES; FOOD COLORING AGENTS; FLAVORING AGENTS; ANTI-INFECTIVE AGENTS; EXCIPIENTS and other similarly used substances. Many of the same substances are used as PHARMACEUTIC AIDS. (See all compounds classified as Food Additives.)', 'Substances or mixtures that are added to the soil to supply nutrients or to make available nutrients already present in the soil, in order to increase plant growth and productivity. (See all compounds classified as Fertilizers.)']","['Ingested diphosphate is readily converted to monophosphate; no diphosphate was found in feces or urine of rats treated with diets containing up to 5% tetrasodium diphosphate. In these experiments diphosphate was almost completely absorbed by the gut and excreted as monophosphate in the urine. /Diphosphate/', '/Ortho/ phosphate is absorbed from, and to a limited extent secreted into, the gastrointestinal tract. Transport of phosphate from the gut lumen is an active, energy-dependent process that is modified by several factors. ... Vitamin D stimulates phosphate absorption, an effect reported to precede its action on calcium ion transport. In adults, about two thirds of the ingested phosphate is absorbed, and that which is absorbed is almost entirely excreted into the urine. In growing children, phosphate balance is positive. Concentrations of phosphate in plasma are higher in children than in adults. This ""hyperphosphatemia"" decreases the affinity of hemoglobin for oxygen and is hypothesized to explain the physiological ""anemia"" of childhood. /Phosphates/']","['In the animal body, diphosphate is formed from adenosyl triphosphate (ATP) in many enzymatic reactions. It is either utilized by entering phosphorolytic reactions, or it is hydrolysed by an inorganic diposphatase to monophosphate. /Diphosphate/', 'A defect in phosphate metabolism occurs in a variety of diseases. ... Rickets ... Osteomalacia ... Primary or Secondary Hyperparathyroidism ... Chronic Renal Failure. /Phosphates/']",
4540,24541,Mercury iodide (HgI),I[Hg],,,,,,
4541,24542,Potassium mercuric iodide,[K+].[K+].I[Hg-2](I)(I)I,,,,,,
4542,24543,Tetraiodomercurate(2-),I[Hg-2](I)(I)I,,,,,,
4543,24544,Mercuric sulfate,[O-]S(=O)(=O)[O-].[Hg+2],,,,['CHEM ANALYSES SHOWING ACCUMULATION OF MERCURY IN LENS /OF EYE/ IN MERCURIALENTIS HAVE BEEN REPORTED.'],,
4544,24545,Mercurous sulfate,[O-]S(=O)(=O)[O-].[Hg+].[Hg+],,,,,,
4545,24546,Afluon,[F-].[F-].[Mg+2],,,"['A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment. (See all compounds classified as Histamine H1 Antagonists, Non-Sedating.)', 'Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)', 'Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES. (See all compounds classified as Lipoxygenase Inhibitors.)']",,,
4546,24547,Oxygen difluoride,O(F)F,,,,"['FLUORIDES ARE ABSORBED FROM GI TRACT, LUNG, & SKIN. GI TRACT IS MAJOR SITE OF ABSORPTION. THE RELATIVELY SOL CMPD, SUCH AS SODIUM FLUORIDE, ARE ALMOST COMPLETELY ABSORBED. ... FLUORIDE HAS BEEN DETECTED IN ALL ORGANS & TISSUES, AND IT IS CONCENTRATED IN BONE, THYROID, AORTA, & PERHAPS KIDNEY. FLUORIDE IS PRIMARILY DEPOSITED IN BONE & TEETH, & THE DEGREE OF SKELETAL STORAGE IS RELATED TO INTAKE AND AGE. ... MAJOR ROUTE OF ... EXCRETION IS VIA THE KIDNEYS; ... /ALSO EXCRETED IN SMALL AMT/ IN SWEAT, MILK, AND INTESTINAL SECRETIONS. ... ABOUT 90% OF FLUORIDE ION FILTERED BY GLOMERULUS IS REABSORBED BY RENAL TUBULES. /FLUORIDE/', 'Solutions of fluoride salts are rapidly and almost completely absorbed from the gastrointestinal tract, probably by simple diffusion ... Less than 10% of the ingested fluoride is excreted in the feces, but the proportion varies with circumstances ... The simultaneous presence of strongly fluoride-binding ions, especially calcium ions, will reduce the absorption of fluoride ... In patients ingesting aluminum-containing antacids, fluoride absorption decr to about 40%, and the retention decr to nil. /Fluorides/', 'In the industrial environment, the respiratory tract is the major route of absorption of both gaseous and particulate fluoride. Hydrogen fluoride being highly soluble in water is rapidly taken up in the upper respiratory tract ... Depending on their aerodynamic characteristics, fluoride-containing particles will be deposited in the nasopharynx, the tracheo-bronchial tree and the alveoli ... Dermal absorption of fluoride has only been reported in the case of burns resulting from exposure to hydrofluoric acid ... . /Fluorides/', 'About 75% of the blood fluoride is present in the plasma; the rest is mainly in or on the red blood cells ... Fluoride in human serum exists in both ionic and nonionic forms. ... For the general population under steady-state conditions of exposure, the concn of fluoride ions in plasma is directly related to the fluoride content of the drinking water. /Fluorides/', 'For more Absorption, Distribution and Excretion (Complete) data for FLUORINE MONOXIDE (6 total), please visit the HSDB record page.']",,"['... Bone retains about 60% of iv-injected fluoride and that the half-time for this uptake is only about 13 min; both blood and extracellular fluid levels therefore decr rapidly. After ingestion of sodium fluoride, plasma fluoride levels show a much slower change with a half-life of about 3 hr ... . /Fluorides/']"
4547,24548,Thionyl fluoride,O=S(F)F,,,,,,
4548,24549,Lead fluoride,F[Pb]F,,,,,,
4549,24550,Stannous fluoride,F[Sn]F,"['Indicated for use to relieve dental hypersensitivity, increase enamel production, prevent gingivitis and cavities, and control periodontal infections.']",['Stannous fluoride mediates both bactericidal and bacteriostatic properties and provides an anti-erosive action on tooth enamel.'],"['Substances that inhibit or arrest DENTAL CARIES formation. (Boucher&apos;s Clinical Dental Terminology, 4th ed) (See all compounds classified as Cariostatic Agents.)']","['Tin is retained in the demineralized organic matrix to some extent, diffuses through the phosphorylated non-collagenous proteins in the dentine called phosphophoryn and accumulates in the underlying mineralized tissue.', 'Materials introduced into the oral cavity can be eliminated by salivary washout and swallowing, absorption through oral surfaces, or degradation.', 'Stannous fluoride is cleared from saliva rapidly but very well retained in gingival plaque for a prolonged period of time.', 'Stimulated and nonstimulated salivary elimination microrate constants in this case would be â¼1 and 0.5 min^â1, respectively.', 'Fluoride ion is rapidly & extensively absorbed from the gut. In rats, absorption of sodium fluoride ... & stannous fluoride is similar.', 'Fluoride is transported in the blood in the free rather than the protein-bound form; it is distributed rapidly throughout all soft tissues but is not accumulated. /Fluoride ion/', 'THE PLACENTA OF RATS WAS PERMEABLE TO FLUORIDE @ 25 PPM IN DRINKING WATER JUST BEFORE OR DURING GESTATION. LESS THAN 1% ADMIN TO PREGNANT RATS WAS TRANSFERRED IN PROGENY, INDICATING STRONG DISCRIMINATION AGAINST TRANSPLACENTAL TRANSFER. NO DIFFERENCE IN THE TRANSFERRED AMT WAS OBSERVED WHEN FLUORIDE WAS GIVEN AS SODIUM FLUORIDE OR TIN FLUORIDE.', 'THE FATE OF (113)TIN HAS BEEN EVALUATED IN THE RAT FOLLOWING THE ADMINISTRATION OF (113)TIN(II) AND (113)TIN(IV). CHANGING THE ANION COMPLEMENT FROM FLUORIDE TO CITRATE DID NOT AFFECT THE BIOLOGICAL FATE OF EITHER VALENCE FORM OF TIN. FROM A SINGLE PER ORAL DOSE OF 20 MG OF TIN(II) OR TIN(IV)/KG, 2.85 AND 0.64%, RESPECTIVELY, WERE ABSORBED. WITHIN 48 HR, ABOUT 50% OF THE ABSORBED TIN WAS EXCRETED. THE TISSUE DISTRIBUTION OF THE TIN REPORTED AS A PERCENT OF THE DOSED TIN(II) AND TIN(IV), RESPECTIVELY, WAS SKELETON 1.02 AND 0.24, LIVER 0.08 AND 0.02, AND KIDNEYS 0.09 AND 0.02. FROM A SINGLE IV DOSE OF 2 MG OF TIN(II) OR TIN(IV)/KG, ABOUT 30% WAS EXCRETED IN THE URINE; 11% OF THE TIN(II) WAS ELIMINATED IN THE BILE, BUT NONE OF THE TIN(IV). THE AVERAGE PERCENT OF TIN ABSORBED DURING A 28-DAY PER ORAL DOSING STUDY WAS LESS THAN FROM A SINGLE PER ORAL DOSE. IN A COMPARISON OF THE TIN IN TISSUES FROM A SINGLE AND FROM A 28-DAY PER ORAL DOSING, ONLY BONE HAD AN INCREASED ACCUMULATION APPROXIMATELY PROPORTIONAL TO THE INCREASED AMOUNT OF SYSTEMIC EXPOSURE.', 'For more Absorption, Distribution and Excretion (Complete) data for STANNOUS FLUORIDE (7 total), please visit the HSDB record page.']",,"['The half-life for the decay of the salivary elimination rate constant was 13 min.', 'THE FATE OF (113)TIN HAS BEEN EVALUATED IN THE RAT FOLLOWING THE ADMINISTRATION OF (113)TIN(II) AND (113)TIN(IV). ... THE BIOLOGICAL HALF-LIFE OF THE TIN IN BONES WAS CALCULATED TO BE 20 TO 40 DAYS.']"
4550,24551,Zinc fluorure,F[Zn]F,,,,,,
4551,24552,Ferric fluoride,F[Fe](F)F,,,,,,
4552,24553,Nitrogen trifluoride,N(F)(F)F,,,,,,
4553,24554,Antimony trifluoride,F[Sb](F)F,,,,,,
4554,24555,Sulfur tetrafluoride,FS(F)(F)F,,,,"['A study /was conducted/ to determine the absorption of inhaled hydrofluoric acid. Two human subjects were exposed for an 8 hour period in an industrial environment to fluorides consisting primarily of hydrogen fluoride and silicon tetrafluoride at an average airborne concentration of 3.8 mg F/cu m. Urine specimens were collected at 2 hour intervals during exposure and or approximately 2 days afterwards. There was a rapid rise in urinary fluoride excretion during exposure, and a peak output was reached in 2-4 hours after cessation of exposure. Within 24 hours, the urinary fluoride levels returned practically to base levels, although a slight elevation persisted into the following day. The total amounts of fluoride excreted daily by the two subjects were as follows: day of exposure, 9.64 and 8.56 mg fluoride; first day after exposure, 1.67 and 2.49; second day, 0.99 and 1.31; and third day, 0.89 and 1.34. The baseline daily urinary fluoride excretions before exposure were 0.9 and 1.2 mg fluoride, respectively. /Hydrofluoric acid/']","['In view of the violent reaction of the compound with water to hydrogen fluoride and thionyl fluoride, exposure to the compound itself will have a local character only. Thionyl fluoride hydrolyzes more slowly than its parent.']",
4555,24556,Silicon tetrafluoride,F[Si](F)(F)F,,,,,,
4556,24557,Antimony pentafluoride,F[Sb](F)(F)(F)F,,,,"['Distribution in rats after chronic poisoning by inhalation of antimony pentafluoride showed high antimony concentration in blood. Levels in liver, kidneys, spleen and pancreas were similar. The antimony was retained for a long time and could be detected in organs under examination one month after experiment discontinued.']",,
4557,24558,Selenium hexafluoride,F[Se](F)(F)(F)(F)F,,,,,"['Selenium hexafluoride may trigger electrolyte imbalance similar to that elicited by hydrogen fluoride, since selenium hexafluoride readily decomposes to selenium and hydrogen fluoride upon contact with moisture.']",
4558,24559,Tellurium hexafluoride,F[Te](F)(F)(F)(F)F,,,,"['... Two postgraduate chemists ... accidentally inhaled tellurium hexafluoride gas when 50 g leaked from a cylinder in their laboratory. ... They were hospitalized for 2 and 3 days, respectively. Apart from the pungent odor of their breaths, their only symptoms were tiredness and a tendency to fall asleep in the late afternoon. One of them showed a unique bluish black pigmentation below the skin surface on the webs of his fingers and to a lesser degree in streaks on his face and neck. These intradermal deposits of tellurium took several weeks to fade. Photographs of this case show very clearly a rare form of true skin absorption, in this instance probably of the volatile tellurium esters.']",,
4559,24560,Uranium hexafluoride,F[U](F)(F)(F)(F)F,,,,"['Daily urinary excretion of uranium by workers chronically inhaling dust from uranium and other uranium compounds was 10-40 mg/worker, with occasional peaks of 100-200 mg. Most of the time, the radioactivity at work places fluctuated from 60 picoCi/cu m (max permissible concn) & 190 picoCi/cu m. correlation between the air radioactivity and urinary uranium excretion was frequently disturbed by workers leaving the work place or wearing protective masks. Urinary elimination of uranium hexafluoride in workers lasted 48 hr.', 'Uranium hexafluoride is highly transportable in the body. /From table/', 'Inhalation Classification - Uranium hexafluoride - Class ""D"" most transportable (pulmonary removal half-time of days) /Table/', 'Urinalysis results obtained following 4 incidents in which 13 workers were exposed to airborne triuranium octaoxide, uranium hexafluoride, & uranium ore concn showed urinary uranium concentrations of less than or equal to 2.85 mg uranium/L. /Uranium compounds/', 'For more Absorption, Distribution and Excretion (Complete) data for URANIUM HEXAFLUORIDE (9 total), please visit the HSDB record page.']",,"['...After inhaling uranium hexafluoride particles, humans during the first day excrete in urine approximately 73% of the solubilized uranium from the lung, with a biological half-life of approximately 4 hours, and another 10% with a half-life of 1.3 days. In a second stage of slower excretion, abiological half-life of approximately 6 days is estimated by the second day or later.', 'The biologic half times of soluble uranium compounds (e.g., uranium hexafluoride, uranyl fluoride, uranium tetrachloride, uranyl nitrate hexahydrate) are estimated in days or weeks. /Soluble uranium compounds/']"
4560,24561,Silver chloride,Cl[Ag],,,,,,
4561,24562,Silver perchlorate,[O-]Cl(=O)(=O)=O.[Ag+],,,,,,
4562,24563,Silver Iodide,[Ag]I,,,,"['ORAL DOSES OF SILVER AS SILVER IODIDE HAD NO EFFECT ON THE MICROORGANISMS OF THE RABBIT CECUM OR GOAT RUMEN. RABBITS ELIMINATED 99% OF ORAL DOSE WITHIN 3 DAYS AND 100% IN 6.3 DAYS. 8-26% ENTERED CECUM, WHERE IT DID NOT ACCUM & WAS NOT ABSORBED. DIGESTION WAS NOT INHIBITED IN RABBITS AND GOATS FOLLOWING THE INGESTION OF DIETS CONTAINING 4.2 AND 1 PPM SILVER AS SILVER IODIDE, OR 10 AND 100 PPM SILVER AS SILVER NITRATE. THUS, AG PROBABLY WILL NOT ADVERSELY AFFECT THE DIGESTIVE MICROFLORA OF LIVESTOCK OR WILDLIFE.', 'SILVER IODIDE WAS ADMINISTERED ORALLY TO 15 YEARLING EWES (5/GROUP) AT DOSE LEVELS OF 0.1, 1.0, OR 10 MG/KG PER DAY FOR 86 DAYS WITHOUT CLINICAL SIGNS OF TOXICOSIS. ERYTHROCYTE AND LEUKOCYTE COUNTS, PACKED CELL VOLUMES, HB CONCENTRATIONS, AND CIRCULATING THRYOID HORMONE LEVELS (TRIIODOTHYRONINE AND THYROXINE) WERE NOT ALTERED SIGNIFICANTLY IN AGI-DOSED EWES. SILVER AT DOSE LEVELS OF 1 OR 10 MG AGI/KG BODY WT FOR 86 DAYS WAS ABSORBED FROM THE GASTROINTESTINAL TRACT AND DEPOSITED IN SOFT AND HARD TISSUES OF THE BODY. MAXIMUM SILVER RESIDUE FOUND WAS 17 PPM IN THE LIVER OF A EWE RECEIVING 10 MG/KG PER DAY.']","['Silver iodide was evaluated for mutagenicity in the Ames/microsome test (strains TA 1535, TA 102, TA 97, and TA 98) and for the ability to induce Sister Chromatid Exchanges (SCE) in human cultured lymphocytes and in P388 lymphocytic leukemia cells cultured in the mouse peritoneal cavity. From the cytogenetic in vitro studies, it was observed that silver iodide, either in acetone solutions or as a suspension with polyacryilamide, scarcely causes a doubling effect on SCEs at nearly toxic concentrations (1 ug/ml). Such a doubling effect by silver iodide on SCEs in P388 leukemia cells in vivo was not achieved even after using 100 ug/g mouse body weight. In the Ames/microsome test actually a doubling effect on revertants was only isolately achieved with 30 ug/ml in TA 102 (S9-) and at 150 ug/ml in TA 97 (S9+) doses, which appear to be nearly toxic for bacteria.']",
4563,24564,Aluminum chloride hexahydrate,O.O.O.O.O.O.[Al](Cl)(Cl)Cl,,,['Agents that are put on the SKIN to reduce SWEATING or prevent excess sweating (HYPERHIDROSIS). (See all compounds classified as Antiperspirants.)'],,,
4564,24565,Ammonium hexafluoroaluminate,[NH4+].[NH4+].[NH4+].F[Al-3](F)(F)(F)(F)F,,,,,,
4565,24566,"Sulfuric acid,aluminum ammonium salt(2:1:1)",N.OS(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[Al+3],,,,,,
4566,24567,Aluminum nitrate nonahydrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].O.O.O.O.O.O.O.O.O.[Al+3],,,,,,
4567,24568,Sodium aluminum sulfate dodecahydrate,O.O.O.O.O.O.O.O.O.O.O.O.[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[Na+].[Al+3],,,,"['It was calculated that a dialysate aluminum concn of 0.2-1.0 mg/l (a concn readily found in many water supplies) would result in the direct transfer of aluminum into the blood of 3-16 mg for each dialysis treatment or 42-211 mg/mo. /Aluminum/', 'A given oral dose of aluminum results in significantly higher serum and tissue levels of the metal in nephrectomized rats than in intact controls in spite of the fact that only minimal amounts of aluminum are normally excreted in the urine. /Aluminum/', 'It was found that 70-90% of total aluminum bound to plasma proteins (60-70% to a high molecular weight protein and 10-20% to albumin while only 10-30% was unbound). This high affinity of aluminum for plasma proteins strongly suggests high levels of binding of aluminum to a variety of tissue proteins. /Aluminum/', 'It was shown that the uptake of aluminum into the blood during renal dialysis was due to the extensive binding of aluminum to plasma proteins leaving very little aluminum in the non-bound state in plasma. Thus, the plasma proteins served as a trap for accumulating the metal. It was shown that the component of plasma protein that binds aluminum is saturable. Consistent with this ... is the fact that, during dialysis with aluminum-containing dialysate, plasma aluminum levels reach a plateau. /Aluminum/', 'For more Absorption, Distribution and Excretion (Complete) data for SODIUM ALUM (17 total), please visit the HSDB record page.']",,"['The mean plasma half-life of aluminum after iv admin in dogs is approx 4.5 hr. /Aluminum/', 'The shorter half-life for the urinary elimination of aluminum was about 8 hr. /Aluminum/']"
4568,24569,Arsenic tribromide,[As](Br)(Br)Br,,,,,,
4569,24570,Arsenic trichloride,Cl[As](Cl)Cl,,,,,,
4570,24571,Arsenic trifluoride,F[As](F)F,,,,,,
4571,24572,Lead arsenate,O[As](=O)([O-])[O-].[Pb+2],,,,"['... Lead arsenate /was/ ... cleared slowly, indicating that the rate of absorption may be lower /since/ the inhaled arsenic is in a highly insoluble form.', 'After exposure to ... arsenate, most arsenic is cleared from the blood. ... In humans as well as in most animal species, exposure to ... arsenate leads to an initial accumulation in the liver, kidneys, and lungs. /Arsenate/', 'The rate of absorption of arsenic in highly insoluble forms (e.g., arsenic sulfide, lead arsenate) is much lower than that of more soluble forms via both oral and inhalation routes.', '/In rabbits/, as in humans, when highly insoluble arsenic compounds are administered (arsenic trisulfide, lead arsenate), gastrointestinal absorption is reduced 20-30%.', 'For more Absorption, Distribution and Excretion (Complete) data for LEAD ARSENATE (9 total), please visit the HSDB record page.']",,
4572,24573,CID 24573,O[As](=O)(O)[O-].[K+],,,,,,
4573,24574,Ammonium arsenate,[NH4+].[NH4+].O[As](=O)([O-])[O-],,,,,,
4574,24575,Arsenic triiodide,[As](I)(I)I,,,,,,
4575,24576,CID 24576,[O-][As]=O.[Na+],,,,,,
4576,24577,Arsenenous acid,O[As]=O,,,,,,
4577,24578,Geranyltiglate,CC=C(C)C(=O)OCC=C(C)CCC=C(C)C,,,,,,
4578,24579,Sodium trimetaphosphate,[O-]P1(=O)OP(=O)(OP(=O)(O1)[O-])[O-].[Na+].[Na+].[Na+],,,"['Substances that inhibit or arrest DENTAL CARIES formation. (Boucher&apos;s Clinical Dental Terminology, 4th ed) (See all compounds classified as Cariostatic Agents.)']","['... LITTLE, IF ANY, CYCLIC METAPHOSPHATE IS ABSORBED THRU INTESTINAL WALL WHEN ADMIN ORALLY. THE METAPHOSPHATES MUST FIRST BE HYDROLYZED TO TRIPOLYPHOSPHATE & NEXT TO ORTHOPHOSPHATE, WHICH THEN CAN BE ABSORBED.']",,
4579,24580,Manganese sulphate,[O-]S(=O)(=O)[O-].[Mn+2],,,,"['WHEN LARGE DOSES OF MANGANESE SULFATE ARE INJECTED IV EXCRETION IS ALMOST EXCLUSIVELY IN FECES ... .', '/Manganese sulfate/ is poorly absorbed through lung and gut.']",,
4580,24581,CID 24581,[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3],,,,,,
4581,24582,"2,2'-Methylenebis(4-methyl-6-nonylphenol)",CCCCCCCCCC1=C(C(=CC(=C1)C)CC2=CC(=CC(=C2O)CCCCCCCCC)C)O,,,,,,
4582,24583,2-Methyloctanal,CCCCCCC(C)C=O,,,,,,
4583,24584,Magnesium chloride (MgCl2),[Mg+2].[Cl-].[Cl-],,,,,,
4584,24585,Isopulegol,CC1CCC(C(C1)O)C(=C)C,,,,,,
4585,24586,Nickel sulfate,[O-]S(=O)(=O)[O-].[Ni+2],,,['Drugs that act locally on cutaneous or mucosal surfaces to produce inflammation; those that cause redness due to hyperemia are rubefacients; those that raise blisters are vesicants and those that penetrate sebaceous glands and cause abscesses are pustulants; tear gases and mustard gases are also irritants. (See all compounds classified as Irritants.)'],"['Nickel concentration in serum and whole blood and excretion in urine was assayed at different time intervals before and after ingestion of nickel sulfate in 8 healthy volunteers for 3 days. The peak level of nickel in blood was reached 2.5 hours after nickel ingestion, and maximal urinary excretion of nickel occured during the first 8 hours after ingestion.', 'Absorption of nickel sulfate from the skin has been found to occur in guinea pigs, rabbits, and rats.', 'The relationship between dose level of nickel sulfate and lung clearance, tissue distribution, and excretion of the metal was examined. F344N rats were given intratracheal injections of 17, 190, or 1800 nm (63)nickel labelled nickel sulfate. Tissues containing the highest concentrations of (63)nickel after 4, 24, and 96 hr were the lung, trachea, larynx, kidney, urinary bladder, adrenals, blood, large intestine, and thyroid. (63)Nickel was rapidly cleared from the lungs to the blood. Eight to 49% of the nickel sulfate remained in the lungs at 4 hr post treatment depending upon the original dose. Urine was the major form of (63)nickel excretion and accounted for 50% of the doe at the 17 and 190 nm levels and 80% at the 1800 nm level. The half time for urinary clearance was 4.6 hours at the highest dose and 23 hours at the lowest dose. Over 50% of the (63)nickel remaining 96 hours post treatment was in the lungs, and the half time for lung (63)nickel clearance ranged from 36 hr at the lowest dose to 21 hr at the highest dose. Urinary and pulmonary clearance of (63)nickel were both dose dependent.', 'In human volunteers who ingested nickel sulfate in the drinking water or food, at doses of between 12 and 50 ug/kg body weight (one treatment), the amt of nickel absorbed avg 27 plus or minus 17% of the dose ingested in water compared with 0.7 plus or minus 0.4% of the same dose ingested in food ... .', 'For more Absorption, Distribution and Excretion (Complete) data for NICKEL SULFATE (6 total), please visit the HSDB record page.']",,"['The half-time for diminution of plasma nickel concn in human volunteers after oral intake of nickel sulfate is approx 11 hr.', 'Gave 1, 11.2, or 105.7 ug nickel sulfate/animal, by intratracheal instillation, to Fischer 344 rats ... The half-time for urinary excretion of nickel incr from 4.6 hr at the highest dose to 23 hr at the lowest dose ... The half-time for lung clearance of nickel sulfate ranged from 21 hr (highest dose) to 36 hr (lowest dose).']"
4586,24587,Barium permanganate,[O-][Mn](=O)(=O)=O.[O-][Mn](=O)(=O)=O.[Ba+2],,,,,,
4587,24588,Beryllium chloride,[Be+2].[Cl-].[Cl-],,,,"['Beryllium chloride admin iv to ICR mice before fertilization & on days 7 & 14 of pregnancy: beryllium penetrates placenta with difficulty, but part of dose admin circulated in blood long enough for beryllium to penetrate the fetuses.', 'Wistar rats were given iv beryllium chloride: unproportionally higher blood levels after a higher dose persisted for a longer time. Decr in blood after a higher dose was accompanied by incr liver & spleen content & incr urinary excretion, the principal route after iv admin.', 'Male guinea pigs inhaled beryllium chloride aerosol for 55 min. Was deposited in soft tissue, mostly in lung & GI tract, with trace amounts in liver, kidney, & trachea. Half of the animals had a right lung concn twice that of the left lung.', 'Beryllium chloride was injected into rats intraperitoneum every other day ... /1.2 mg/kg body weight/ for 1, 2 and 3 months respectively. ... Spleen and liver were ranked top in accumulation of injected beryllium followed by kidney, heart, and lung in a decreasing order. ...', 'For more Absorption, Distribution and Excretion (Complete) data for BERYLLIUM CHLORIDE (11 total), please visit the HSDB record page.']",,"['The biological half-life /of beryllium/ without a carrier was 24 hours; with /1 mg of beryllium chloride/ carrier, it was 20 days /after intratracheal introduction into rats/.', 'After an ip or iv dose of carrier-free (7)Be as chloride, the disappearance of beryllium was best characterized by three consecutive half-times of 0.2-0.5, 6.3-21.7 and 50.9-52.4 days in mice, rats, dogs and Macaca speciosa monkeys.']"
4588,24589,Beryllium fluoride,[Be+2].[F-].[F-],,,,"['... Skeletal deposition of beryllium from the fluoride ... inhaled for 40 to 100 days by dogs, showed 17% ... retained in lung; 27% ... in liver; & 199% ... in the pulmonary lymph nodes.', ""Accumulation, distribution, and excretion of inhaled aerosol beryllium fluoride soln was related to the animal's age; 15 min after the exposure, 26.3-33.5% of the inhaled metal was found in the body of adult rats and 2-4 week old rats, and 12.5% in the body of 1 wk old rats. The organ and tissue content varied in animals of different age. Be clearance from the nasal passages, oral cavity, and trachea was slower and Be retention period in the stomach and small and large intestine was longer in 1 wk old rats than in adult rats."", 'The effects of type of cmpd administered, isotope carrier, and animal development were studied on beryllium absorption from the gastrointestinal (GI) tract of rats. Isotope (7)Be labeled salts, with and without isotope carrier (9)Be (0.25-6 mg/kg), were administered via the stomach. Beryllium accumulation in the liver was 4-12 fold and in the kidney 16-37 fold less than that in the skeleton. The accumulation of beryllium depended on the type of cmpd In 1, 2, and 4 wk old and adult rats, the major amt of beryllium was observed in the skeleton, liver, and kidney. Beryllium chloride administration (with and without the carrier) showed 8 fold higher organ accumulation than that in 1 mo old and adult rats, and beryllium fluoride accumulation was 1.5 fold higher in 1, 2, and 4 wk old rats than that in the adult animals. The isotope carrier had no effect on the level of accumulation in rats of different age groups. Beryllium oxide absorption was higher than that of the hydroxide and beryllium fluoride was absorbed approx 15-20 fold higher than the chloride, sulfate, and nitrate and 210-260 fold higher than the hydroxide. Easily sol cmpd of beryllium are less absorbed presumably due to their hydrolysis in the alk medium of the GI tract. Beryllium fluoride absorption was higher in young animals than that in the adult rats.']",,
4589,24590,CID 24590,O=[BiH].Cl,,,,,,
4590,24591,Bismuth trichloride,Cl[Bi](Cl)Cl,,,,,,
4591,24592,Cesium bromide,[Br-].[Cs+],,,,,,
4592,24593,Copper(I) bromide,[Cu]Br,,,,,,
4593,24594,Bromine trifluoride,FBr(F)F,,,,,,
4594,24595,Ammonium chromate,[NH4+].[NH4+].[O-][Cr](=O)(=O)[O-],,,,,,
4595,24596,Chromic potassium sulfate dodecahydrate,O.O.O.O.O.O.O.O.O.O.O.O.[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[K+].[Cr+3],,,,,,
4596,24597,Potassium chromate,[O-][Cr](=O)(=O)[O-].[K+].[K+],,,,"['Chromium compounds are known to be associated with cytotoxicity and carcinogenicity when applied via a skin route. The aim of this study was to evaluate the skin permeability and toxicological profiles of four chromium species. Chromium permeation across the skin, as determined by an in vitro Franz cell, decreased in the order of sodium chromate>potassium chromate>potassium dichromate>chromium nitrate. The uptake of chromium species within the skin generally showed a contrary trend to the results of permeation, although differences among the various compounds were not large. Levels of in vivo skin deposition of the four compounds showed no statistically significant differences. Potassium chromate produced the greatest disruption of the skin structure as determined by HE staining, followed in order by sodium chromate, potassium dichromate, and chromium nitrate. This indicates that hexavalent chromium elicited greater toxicity to the skin compared to trivalent chromium. A similar result was observed for the viability of skin fibroblasts. To improve our understanding of the molecular mechanisms leading to functional changes in proteins, proteomic tools, including 2-DE and MS techniques combined with sequence database correlations, were applied to identify target proteins altered by pathologic states. Eight protein spots, corresponding to cutaneous enzymes involved in energy metabolism and chaperon proteins, which were identified and discussed in this study, were associated with skin cytotoxicity, immunity, and carcinogenesis. In addition, functional proteomics of skin tissues may provide a promising tool for developing therapeutic strategies and can serve as the basis for further research.', 'After exposure of growing chicks to different concentrations of dietary chromium (Cr) as potassium chromate (K2CrO4) for a period of 3 wk, the Cr uptake by different internal organs was determined. More Cr was accumulated in the kidney, liver, pancreas and spleen than in the blood, muscle, heart and lung. A very small amount was found in the brains of the birds given different concentrations of Cr.']",,
4597,24598,Chromic nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Cr+3],"['Indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN), to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.']","['Trivalent chromium is part of glucose tolerance factor, an essential activator of insulin-mediated reactions. Chromium helps to maintain normal glucose metabolism and peripheral nerve function. Chromium increases insulin binding to cells, increases insulin receptor density and activates insulin receptor kinase leading to enhanced insulin sensitivity. In chromium deficiency, intravenous administration of chromium resulted in normalization of the glucose tolerance curve from the diabetic-like curve typical of chromium deficiency.']",,"['Chromium compounds are both absorbed by the lung and the gastrointestinal tract. Oral absorption of chromium compounds in humans can range between 0.5% and 10%, with the hexavalent (VI) chromium more easily absorbed than the trivalent (III) form. Absorption of chromium from the intestinal tract is low, ranging from less than 0.4% to 2.5% of the amount consumed. Vitamin C and the vitamin B niacin is reported to enhance chromium absorption.  Most hexavalent Cr (VI) undergoes partial intragastric reduction to Cr (III) upon absorption, which is an action mainly mediated by sulfhydryl groups of amino acids. Cr (VI) readily penetrates cell membranes and chromium can be found in both erythrocytes and plasma after gastrointestinal absorption of Cr (IV). In comparison, the presence of chromium is limited to the plasma as Cr (III) displays poor cell membrane penetration. Once transported through the cell membrane, Cr (VI) is rapidly reduced to Cr (III), which subsequently binds to macromolecules or conjugate with proteins. Cr (III) may be bound to transferrin or other plasma proteins, or as complexes, such as glucose tolerance factor (GTF).', 'Absorbed chromium is excreted mainly in the urine, accounting for 80% of total excretion of chromium; small amounts are lost in hair, perspiration and bile. Chromium is excreted primarily in the urine by glomerular filtration or bound to a low molecular-weight organic transporter.', 'Absorbed chromium is distributed to all tissues of the body and its distribution in the body depends on the species, age, and chemical form. Circulating Cr (III) following oral or parenteral administration of different compounds can be taken up by tissues and accumulates in the liver, kidney, spleen, soft tissue, and bone.', 'Excretion of chromium is via the kidneys ranges from 3 to 50 Î¼g/day. The 24-hour urinary excretion rates for normal human subjects are reported to be 0.22 Î¼g/day.']","['The metabolism of Cr (VI) involves reduction by small molecules and enzyme systems to generate Cr (III) and reactive intermediates. During this process, free radicals can be generated, which is thought to induce damage of cellular components and cause toxicity of chromium. The metabolites bind to cellular constituents.']",['The elimination half-life of hexavalent chromium is 15 to 41 hours.']
4598,24599,Strontium chromate,[O-][Cr](=O)(=O)[O-].[Sr+2],,,,,,"['A survey of occupational exposure to hexavalent chromium in chromate pigment production was undertaken in factories producing lead chromate (PbCrO4) and strontium chromate (SrCrO4). ...Exceptionally high levels of chromium in blood (387-4160 nmol/L) and urine (41-1250 nmol /per/ nmol creatinine) as well as skin and nasal lesions, were discovered amongst the workforce at the strontium chromate plant. These contrasted with occupationally unexposed levels of less than 20 nmol/L and less than 1 nmol /per/ nmol creatinine, respectively, and led to the continuation of the biological monitoring program. ...A steady elimination of chromium from whole blood with a half-life of approximately 24 days was found. This elimination rate was confirmed over a 14 day period when the workforce were completely removed from exposure.']"
4599,24600,Ammonium dichromate,[NH4+].[NH4+].[O-][Cr](=O)(=O)O[Cr](=O)(=O)[O-],,,,,,['Half-life in total human body: 616 days.']
4600,24601,Cesium iodide,[I-].[Cs+],,,,,,
4601,24602,Deuterium oxide,[2H]O[2H],,,"['Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military. (See all compounds classified as Radiation-Protective Agents.)', 'Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)']",,,
4602,24603,Fluorosulfonic acid,OS(=O)(=O)F,,,,,,
4603,24604,CID 24604,[F-].[K+],,,,,,
4604,24605,CID 24605,[Li+].[F-],,,,,,
4605,24606,Bromine pentafluoride,FBr(F)(F)(F)F,,,,"['/Investigators/ measured fluoride in rat tissues following exposure to BrF5 at 500 ppm for 30 min or ClF3 at 400 ppm for 15 min... The data show increased fluoride content in the blood and lungs immediately after exposure, which declined over time. Mean fluoride in bone increased from 300 ug/g immediately after exposure to BrF5 to 353 ug/g 20 hr later. After exposure to ClF3, mean fluoride in bone increased from 118 to 172 ug/g over a 24-hr period. Although a small number of animals (four to six) are represented by the mean values and fluoride concentrations in untreated rats varied widely, the data suggest that, at higher concentrations of halogen fluorides, fluoride may be absorbed into the bloodstream and distributed to bone and other tissues.']",['...the halogen fluorides are expected to hydrolyze rapidly in the moist respiratory tract. /Halogen fluorides/'],
4606,24607,CID 24607,[O-]Br(=O)=O.[Na+],,,,,,
4607,24608,Calcium bromide (CaBr2),[Ca+2].[Br-].[Br-],,,,,,
4608,24609,Cadmium dibromide,Br[Cd]Br,,,,,,
4609,24610,Cobalt(II) bromide,[Co](Br)Br,,,,,,
4610,24611,Copper(II) bromide,[Cu](Br)Br,,,,,,
4611,24612,Mercuric bromide,Br[Hg]Br,,,,"['The transport and binding of inorganic mercury compounds in rat intestinal tissues were studied in vitro. Everted intestinal sacs and intestinal brush border membrane vesicles from male Wistar rats were incubated for 30 and 10 minutes, respectively, with 1X 10(-4) molar mercuric acetate, mercuric chloride, mercuric thiocyanate, mercuric bromide, or mercuric cyanide at pHs of 5.5, 6.4, or 7.4. The tissues were analyzed for mercury. The amount of each compound transported through the sac and brush border membrane vesicle walls and the amount bound to the tissues were calculated. The data were compared with the stability constants of the compounds. In the intestinal sacs increases in pH tended to increase the transport of each compound through the wall and tended to decrease the amount bound. Mercuric acetate was transported through the intestinal wall to the greatest extent, followed by mercuric chloride, mercuric thiocyanate, mercuric bromide, and mercuric cyanide, in that order. The degree of transport of the compounds correlated inversely with the logarithm of their stability constants. In brush border membrane vesicles, uptake of the compounds also correlated inversely with the logarithm of their stability constants. Increases in pH significantly increased uptake of all compounds except mercuric cyanide. Mercuric acetate, mercuric chloride, mercuric thiocyanate, mercuric bromide, and mercuric-cyanide were incubated with rat brush border membrane vesicles at pH 5.5, 6.4, or 7.4 in hypertonic medium to assess the effects of osmolarity on uptake. Uptake of mercuric acetate and mercuric chloride at each pH decreased linearly with increasing osmolarity. Uptake of mercuric thiocyanate and mercuric bromide at each pH tended to decrease with increasing osmolarity. Uptake of mercuric cyanide was not affected by changes in osmolarity.']",,
4612,24613,Phosphorus oxybromide,O=P(Br)(Br)Br,,,,,,
4613,24614,Phosphorus tribromide,P(Br)(Br)Br,,,,,"['Compounds containing direct phosphorus to halogen bonds hydrolyze readily, forming injurious phosphorus-containing acids and halogen halides. For example, phosphorus tribromide will hydrolyze to give H2PO3 and HBr.']",
4614,24615,Antimony tribromide,Br[Sb](Br)Br,,,,,,
4615,24616,"Stannane, tetrabromo-",Br[Sn](Br)(Br)Br,,,,,,
4616,24617,Fluorite,[F-].[F-].[Ca+2],,,,,,
4617,24618,Calciumphosphinat,[O-]P=O.[O-]P=O.[Ca+2],,,,,,
4618,24619,Calcium iodate,[O-]I(=O)=O.[O-]I(=O)=O.[Ca+2],,,,,,
4619,24620,Calcium molybdate,[O-][Mo](=O)(=O)[O-].[Ca+2],,,,,,
4620,24621,Molybdate,[O-][Mo](=O)(=O)[O-],,,,,,
4621,24622,Trichloropropane,CCC(Cl)(Cl)Cl,,,,,,
4622,24623,"2,2,3-Trichloropropionaldehyde",C(C(C=O)(Cl)Cl)Cl,,,,,,
4623,24624,"1,1,3-Triethoxypropane",CCOCCC(OCC)OCC,,,,,,
4624,24625,2-Methylpentyl acetate,CCCC(C)COC(=O)C,,,,,,
4625,24626,"1,1-Dicyanoethyl acetate",CC(=O)OC(C)(C#N)C#N,,,,,,
4626,24627,2-(2-Cyanoethoxy)ethyl acrylate,C=CC(=O)OCCOCCC#N,,,,,,
4627,24628,Bis[2-(2-ethylbutoxy)ethyl] adipate,CCC(CC)COCCOC(=O)CCCCC(=O)OCCOCC(CC)CC,,,,,,
4628,24629,Propan-2-yl 7-aminoheptanoate,CC(C)OC(=O)CCCCCCN,,,,,,
4629,24630,Antimony triiodide,[Sb](I)(I)I,,,,,,
4630,24631,Stannic iodide,[Sn](I)(I)(I)I,,,,,,
4631,24632,Calcium pyrophosphate,[O-]P(=O)([O-])OP(=O)([O-])[O-].[Ca+2].[Ca+2],,,,,,
4632,24633,Cadmium muriaticum,[Cl-].[Cl-].[Cd+2],,,,,,
4633,24634,Cadmium fluoride,F[Cd]F,,,,,,
4634,24635,Cadmium iodide,[Cd+2].[I-].[I-],,,,,,
4635,24636,Cerium(III) chloride,[Cl-].[Cl-].[Cl-].[Ce+3],,,,,,
4636,24637,Chlorine trifluoride,FCl(F)F,,,,,,
4637,24638,Chlorosulfonic acid,OS(=O)(=O)Cl,,,,,,
4638,24639,Ammonium perchlorate,[NH4+].[O-]Cl(=O)(=O)=O,,,,,,
4639,24640,Iodine monochloride,ClI,,,,['IODINE MONOCHLORIDE HAS ABILITY TO PENETRATE BACTERIAL CELL & ACCUM IN CELL WALL & PROTOPLASTS.'],,
4640,24641,Strontium chlorate,[O-]Cl(=O)=O.[O-]Cl(=O)=O.[Sr+2],,,,,,
4641,24642,Thallium chloride,Cl[Tl],"['For use as a diagnostic radiopharmaceutical. It is indicated to help diagnose heart disease (eg, coronary artery disease, heart attack). It is also used for the diagnosis of parathyroid problems.']",['Data not found.'],,"['After IV administration, thallous chloride clears rapidly from the blood, with maximum concentration in the myocardium after about 10 min. Only 5-8% of injected activity remained in the blood, following 5 minutes of intravenous administration.', 'Thallous Chloride Tl 201 is excreted slowly and to an equal extent in both feces and urine.', '3â10 L/kg', 'Approximately 4-8% of the injected dose was excreted in the urine in the first 24 hours. The whole body disappearance half-time was 9.8 Â± 2.5 days. Kidney concentration was found to be about 3 percent of the injected activity and the testicular content was 0.15 percent. Net thyroid activity was determined to be only 0.2 percent of the injected dose, and the activity disappeared in 24 hours. From anterior and posterior whole-body scans, it was determined that about 45 percent of the injected dose was in the large intestines and contiguous structures (liver, kidneys, abdominal musculature).', 'In acute thallium poisoning, human brain areas densely populated with neurons were found to accumulate thallium more than other areas, and the gray matter contained higher thallium levels than nonneural tissues. /Soluble thallium cmpd/']",['Data not found'],"['91% of the blood radioactivity has a t1/2 of 5 min. 9% has t1/2 of 40 hours.', 'BODY BURDEN AS % OF ADMIN DOSE WAS DETERMINED IN RATS FOLLOWING ADMIN OF (204)THALLIUM ... OVER A PERIOD OF 21 DAYS. BODY CLEARANCE /OCCURRED/ ... EXPONENTIALLY WITH HALFTIME 3.3 DAYS ... AT THE END OF 21 DAYS ... 1% OF ADMIN DOSE REMAINED. ... WITH BIOLOGICAL HALF-TIME OF 3.3 DAYS ... DAILY DOSING /GIVES/ AN EQUILIBRIUM ... @ 20 DAYS. /SOLUBLE THALLIUM SALTS/']"
4642,24643,Cobalt chloride hexahydrate,O.O.O.O.O.O.[Cl-].[Cl-].[Co+2],,,,,,
4643,24644,Magnesium chloride (MgCl2) hydrate (1:6),O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-],,,,,,
4644,24645,Nickel dichloride hexahydrate,O.O.O.O.O.O.[Cl-].[Cl-].[Ni+2],,,,,,
4645,24646,Chlorine monoxide,O(Cl)Cl,,,,,,
4646,24647,Selenium oxychloride,O=[Se](Cl)Cl,,,,['Selenium oxychloride ... was readily absorbed through the skin.'],,
4647,24648,Sulfuryl chloride,O=S(=O)(Cl)Cl,,,,,,
4648,24649,Pyrosulfuryl chloride,O=S(=O)(OS(=O)(=O)Cl)Cl,,,,,,
4649,24650,"2-Amino-4',4''-bis(5-methyl-2-imidazolin-2-yl)terephthalanilide",CC1CN=C(N1)C2=CC=C(C=C2)NC(=O)C3=CC(=C(C=C3)C(=O)NC4=CC=C(C=C4)C5=NCC(N5)C)N,,,,,,
4650,24651,"ETHYLAMINE, 2-((4-(BUTYLTHIO)-3-METHYL-alpha-PHENYLBENZYL)OXY)-N,N-DIMETHYL-",CCCCSC1=C(C=C(C=C1)C(C2=CC=CC=C2)OCCN(C)C)C,,,,,,
4651,24652,"ETHYLAMINE, 2-((p-(BUTYLTHIO)-alpha-(p-TOLYL)BENZYL)THIO)-N,N-DIMETHYL-",CCCCSC1=CC=C(C=C1)C(C2=CC=C(C=C2)C)SCCN(C)C,,,,,,
4652,24653,"1,1-Dichloro-1-fluoropropane",CCC(F)(Cl)Cl,,,,,,
4653,24654,Hydrazine hydrate,NN.O,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,,
4654,24655,Ammonium bisulfate,[NH4+].OS(=O)(=O)[O-],,,,,,
4655,24656,Phosphinic acid ammonium salt (1:1),[NH4+].[O-]P=O,,,,,,
4656,24657,CID 24657,CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(C(=O)[O-])N.[Na+],,,,,,
4657,24658,"Methane, bromo-mixt. with 1-bromopropane and trichloronitromethane (1:1:1)",CCCBr.CBr.C([N+](=O)[O-])(Cl)(Cl)Cl,,,,,,
4658,24659,CID 24659,CC(=O)O.CC(=O)O.O.[AlH3],,,,,,
4659,24660,Ammonium bicarbonate-ammonium carbamate,C(=O)(N)[O-].C(=O)(O)[O-].[NH4+].[NH4+],,,,,,
4660,24661,CID 24661,CN1C=NC2=C1C(=O)N(C(=O)N2C)C.C1=CC=C(C=C1)C(=O)[O-].[Na+],,,,,,
4661,24662,Sodium dimethyldithiocarbamate mixt. with sodium 2-mercaptobenzothiazole,CN(C)C(=S)[S-].C1=CC=C2C(=C1)N=C(S2)[S-].[Na+].[Na+],,,,,,
4662,24663,"3-[(3S,5R,8R,9S,10S,13R,14S,16S,17R)-14,16-dihydroxy-3-[(3R,4R,5R,6R)-3-hydroxy-4-methoxy-6-methyl-5-[(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",C[C@@H]1[C@H]([C@@H]([C@H](C(O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3CC[C@]5([C@@]4(C[C@@H]([C@@H]5C6=CC(=O)OC6)O)O)C)C)O)OC)OC7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O,,,,,,
4663,24664,CID 24664,CN1C=NC2=C1C(=O)N(C(=O)N2C)C.C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],,,,,,
4664,24665,CID 24665,CC(=O)[O-].CN1C2=C(C(=O)N(C1=O)C)NC=N2.[Na+],,,,,,
4665,24666,Thomapyrin,CCOC1=CC=C(C=C1)NC(=O)C.CC(=O)OC1=CC=CC=C1C(=O)O.CN1C=NC2=C1C(=O)N(C(=O)N2C)C,,,,,,
4666,24667,Butylhydroxyanisole,CC(C)(C)C1=C(C=CC(=C1)O)OC.CC(C)(C)C1=C(C=CC(=C1)OC)O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)', 'Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)']",,,
4667,24668,C.I. Direct Black 80,C1=CC(=CC=C1N=NC2=C3C=C(C=CC3=C(C=C2)N)S(=O)(=O)[O-])N=NC4=C(C=C5C=CC(=CC5=C4O)N=NC6=C(C=C7C=CC(=CC7=C6O)N)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+],,,,,,
4668,24669,6-Amino-3-{[7-({4-[(4-amino-7-sulfonaphthalen-1-yl)diazenyl]phenyl}diazenyl)-8-hydroxy-6-sulfonaphthalen-2-yl]diazenyl}-4-hydroxynaphthalene-2-sulfonic acid,C1=CC(=CC=C1N=NC2=C3C=C(C=CC3=C(C=C2)N)S(=O)(=O)O)N=NC4=C(C=C5C=CC(=CC5=C4O)N=NC6=C(C=C7C=CC(=CC7=C6O)N)S(=O)(=O)O)S(=O)(=O)O,,,,,,
4669,24670,Diphyl,C1=CC=C(C=C1)C2=CC=CC=C2.C1=CC=C(C=C1)OC2=CC=CC=C2,,,,,,
4670,24671,Acid yellow 3,C1=CC=C2C(=C1)C(=O)C(C2=O)C3=NC4=C(C=C(C=C4C=C3)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,"['The uptake, fate and excretion of quinoline yellow, a coloring in sweets and soft drinks, in the rat were studied. In the isolated perfused liver, 70% of the dose was excreted into the bile within 3 hr. Similar results were obtained after i.v. injection into anesthetized animals. When given by gavage, only approximately 1% was excreted in bile and urine within 4-5 hr. Quinoline yellow administered orally to rats was quantitatively excreted, the excretion being mainly fecal. ... Very little quinoline yellow is absorbed from the gastrointestinal tract of the rat. No evidence of metabolism was obtained.', 'Quinoline Yellow is absorbed from the gastro-intestinal tract to only a small extent in rats and dogs, and most of an orally administered dose is excreted unchanged.']",,
4671,24672,"2-(1,3-Dioxo-2,3-dihydro-1h-inden-2-yl)quinoline-6,8-disulfonic acid",C1=CC=C2C(=C1)C(=O)C(C2=O)C3=NC4=C(C=C(C=C4C=C3)S(=O)(=O)O)S(=O)(=O)O,,,,"['The uptake, fate and excretion of quinoline yellow, a coloring in sweets and soft drinks, in the rat were studied. In the isolated perfused liver, 70% of the dose was excreted into the bile within 3 hr. Similar results were obtained after i.v. injection into anesthetized animals. When given by gavage, only approximately 1% was excreted in bile and urine within 4-5 hr. Quinoline yellow administered orally to rats was quantitatively excreted, the excretion being mainly fecal. ... Very little quinoline yellow is absorbed from the gastrointestinal tract of the rat. No evidence of metabolism was obtained.', 'Quinoline Yellow is absorbed from the gastro-intestinal tract to only a small extent in rats and dogs, and most of an orally administered dose is excreted unchanged.']",,
4672,24673,CID 24673,CC1=C(C=C(C=C1)N=NC2=C(C=C(C(=C2)C)[NH3+])N)N=NC3=C(C=C(C(=C3)C)[NH3+])N.[Cl-].[Cl-],,,,,,
4673,24674,"1,3-Benzenediamine, 4,4'-[(4-methyl-1,3-phenylene)bis(azo)]bis[6-methyl-",CC1=C(C=C(C=C1)N=NC2=C(C=C(C(=C2)C)N)N)N=NC3=C(C=C(C(=C3)C)N)N,,,,,,
4674,24675,Amatol,CC1=C(C=C(C=C1[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-].[NH4+].[N+](=O)([O-])[O-],,,,,,
4675,24676,CID 24676,CCCCCCCC=CCCCCCCCC(=O)OCC([C@@H]1[C@H]([C@@H](CO1)O)O)O,,,,,,
4676,24677,"Acetic acid, (2,4-dichlorophenoxy)-, isooctyl ester, mixt. with S-ethyl dipropylcarbamothioate",CCCN(CCC)C(=O)SCC.CC(C)CCCCCOC(=O)COC1=C(C=C(C=C1)Cl)Cl,,,,,,
4677,24678,"2,4-D Isooctyl ester",CC(C)CCCCCOC(=O)COC1=C(C=C(C=C1)Cl)Cl,,,,"['... ISOOCTYL ESTER OF 2,4-D DISAPPEARED FROM BODIES OF INJECTED MICE MORE RAPIDLY THAN 2,4-D ACID.', 'Leaves absorb nonpolar (ester) forms most readily. ... The esters of 2,4-D tend to resist washing from plants and are rapidly converted to the acid by the plants. ... Following foliar absorption, 2,4-D translocates within the phloem, probably moving with food material. Following root absorption, it may move upward in the transpiration stream. Translocation is influenced by the growth status of the plant. Accumulation of the herbicide occurs principally at the meristematic regions of shoots and roots. /2,4-D or its esters/', 'Plasma 2,4-D concn did not exceed 0.2 mg/l in workers exposed to 2,4-D ester at an atmospheric concn of 0.1 to 0.2 mg/l; no accumulation was noted during the work week. ... Workers ... developed 2,4-D urine concentrations of 3 to 14 mg/l after a day of exposure. /2,4-Dichlorophenoxyacetic acid or its esters/', 'AFTER SC INJECTION OF 2,4-D & ITS BUTYL & ISOOCTYL ESTERS INTO MICE @ 100 MG/KG, ESTERS WERE ELIM RAPIDLY, & ONLY 5-10% OF THE 2,4-D REMAINED AFTER 1 DAY. ... 2,4-D WAS ELIM IN MILK OF COWS MAINTAINED IN PASTURES TREATED WITH 2,4-D OR ITS BUTYL OR ISOOCTYL ESTER.', 'For more Absorption, Distribution and Excretion (Complete) data for 2,4-D ISOOCTYL ESTERS (7 total), please visit the HSDB record page.']","['Plants hydrolyze 2,4-D esters to 2,4-D, which is the active herbicide. ... Further metabolism ... occurs through three mechanisms, namely, side chain degradation, hydroxylation of the aromatic ring, and conjugation with plant constituents. /2,4-D esters/', 'HERBICIDAL ACTIVITY OF ESTERS, NITRILES, AMINES (&, OF COURSE, SALTS) APPEARS SIMILAR IF NOT IDENTICAL TO PARENT ACID. THIS IS APPARENTLY DUE TO PRESENCE OF HYDROLYTIC ENZYMES IN PLANTS & IN SOIL MICROORGANISMS THAT CONVERT THESE DERIVATIVES TO PARENT ACID. /SRP: 2,4-D OR ITS ESTERS/', '2,4-D ESTERS ARE HYDROLYZED IN ANIMALS. THE PHENOXY ACIDS ARE EXCRETED PREDOMINANTLY AS SUCH IN THE URINE OF RATS AFTER THEIR ORAL ADMIN, ALTHOUGH MINOR PORTION IS CONJUGATED WITH AMINO ACIDS GLYCINE & TAURINE & WITH GLUCURONIC ACID. /2,4-D AND ESTERS/', 'Metabolites of 2,4-D other than conjugates have not been detected in human urine.']","['THESE HERBICIDES DO NOT ACCUM IN ANIMALS. THEY ARE NOT EXTENSIVELY METAB BUT ARE ACTIVELY EXCRETED INTO THE URINE ... THEIR PLASMA HALF-LIFE IN MAN IS ABOUT 1 DAY. /CHLOROPHENOXY COMPOUNDS/', 'The hydrolysis half-life of the n-butyl ester of 2,4-D was determined to be 100 hours in neutral water and much less in aqueous soil suspensions. Smith (1976) reported that the n-butyl ester of 2,4-D undergoes almost complete hydrolysis to 2,4-D in less than 24 hours in moist soil. Similar results were reported for the hydrolysis of the n-butyl and isooctyl esters of 2,4,5-T to 2,4,5-T. Esters of 2,4-D were completely hydrolyzed to 2,4-D within 9 days in lake water. Therefore, rates of biological hydrolysis appear to be greater than rates of chemical hydrolysis.']"
4678,24679,Donovan's solution,[As](I)(I)I.I[Hg],,,,,,
4679,24680,CID 24680,CC1=CCCC(C1C=CC(=O)C)(C)C,,,,,,
4680,24681,Oleum,OS(=O)(=O)O.O=S(=O)=O,,,,,,
4681,24682,Sulfur trioxide,O=S(=O)=O,,,,,"[""Sulfite oxidation and sulfur trioxide radical formation were studied in polymorphonuclear leukocytes (PMNs) isolated from healthy young, old and centenarian donors and from patients with Down's syndrome. The sulfur radical formation ... was correlated with the activity of sulfite oxidase and with the rate of sulfite oxidation to sulfate by PMNs. Sulfite metabolism was studied both in resting, and phorbol myristate acetate (PMA) stimulated freshly isolated cells. The rate of sulfur trioxide radical formation was demonstrated by use of the spin trapping agent 5,5-dimethyl-1-pyroline-1-oxide (DMPO) with subsequent formation of an adduct. The intensity of adduct formation was most intense in cells with low sulfite oxidase activity, while a mixture of the adduct and of DMPO hydroxyl radical was mainly observed in cells with high sulfite oxidase activity. Furthermore, experiments carried out on purified sulfite oxidase showed that in the presence of sulfite the enzyme could also give rise to a DMPO-OH adduct. Sulfite oxidase activity in cells isolated from healthy young and old donors was positive correlated with both rates of sulfur trioxide radical formation and sulfite oxidation to sulfate, respectively. However, sulfite oxidase activity in cells isolated from centenarians and patients with Down's syndrome seems to lose partly its rate of oxidising sulfite to sulfate. The intensity of the sulfur centered radical adduct increased in the two latter groups of population and the radical observed was predominantly sulfur trioxide radical.""]",
4682,24683,"2,4-D mixt. with 2,4,5-T",C1=CC(=C(C=C1Cl)Cl)OCC(=O)O.C1=C(C(=CC(=C1Cl)Cl)Cl)OCC(=O)O,,,"['Herbicides that remove leaves from trees and growing plants. They may be either organic or inorganic. Several of the more persistent types have been used in military operations and many are toxic. (From Hawley&apos;s Condensed Chemical Dictionary, 11th ed) (See all compounds classified as Defoliants, Chemical.)']",,,
4683,24684,Murbetol,CC(C)OC(=O)NC1=CC=CC=C1.C1CC2C(C(C1O2)C(=O)O)C(=O)O,,,,,,
4684,24685,Propham,CC(C)OC(=O)NC1=CC=CC=C1,,,,"['Main route of excretion of propham by goat was via urine. Small amount appeared in milk and feces.', 'After oral or ip administration of propham to rats, 80% of (14)C-isopropyl label appeared in urine within 4 days. Smaller amount appeared in feces and respired air.', '...Herbicide-related material was distributed throughout the body /of treated rats/, with highest concentration in the kidneys. ...Approximately 30% of iv dose of propham was excreted in 6 hr bile.', 'Propham is absorbed through coleoptiles of emerging grass seedlings and to lesser degree through roots of plants. ...Absorbed slowly through leaves... propham or its metabolites are readily transported acropetally following root absorption.', 'The tissue distribution and excretion of 14C-labelled propham (purity >99%, specific activity of chain-labelled molecule 4.9 mCi/mmol and of ring-labelled molecule 4.1 mCi/mmol) were investigated in adult female Wistar rats (mean body-weight 270 g). A single oral dose (2 animals per dose) of 0, 0.67, 19, 38, or 75 mg/kg bw 14C-labelled propham (5 uCi in 1.0 mL of 20% aqueous ethanol solution) was administered by intubation. Rats were housed individually in glass metabolism cages; expired air was continuously monitored for radioactivity for 72 hr. The feces and urine samples were collected at 24, 48, and 72 hr and analyzed for 14C by liquid scintillation counting. The urine was analyzed by paper chromatography and thin-layer chromatography. In a similar experiment, single rats were killed at various times (1-24 hr) after administration of a single dose of 0.81 mg/kg bw 14C-labelled propham/kg bw (5 uCi in 1.0 mL of a 20% aqueous ethanol solution). Tissue samples (kidneys, liver, blood, lungs, heart, spleen, intestine, brain, muscle, and fat) were freeze-dried, and analyzed for 14C... . The average 3-day excretion of radioactivity in urine, feces, and CO2 was 80, 5, and 5%, respectively after chain-labelling of propham, and 85, 5, and 0%, respectively after ring-labelling of propham. There was no significant difference in the rate of excretion or the route of elimination among rats receiving different dosages. The radioactivity was distributed in all examined tissues with the highest concentrations in the kidneys.']","['Isopropyl N-phenylcarbamate yields aniline in arthrobacter and in achromobacter... . /from table/', 'Soybean plants were root-treated with propham-(14)C. Analyses of metabolites indicated...glycosides of 2-hydroxypropham and...one...was probably beta-o-glucoside...', 'After dosing goat and chicken with labeled propham, analyses...showed presence of para-sulfate derivatives in goat milk and goat carcasses. Glucuronide was also found in chicken carcass... .', 'After administration of phenyl-(14)C-labeled propham to goat /and rats/... metabolites identified were: 1. glucuronic acid conjugate of 4-hydroxypropham, 2. sulfate ester of 4-hydroxypropham, 3. glucuronic acid conjugate of 4-hydroxyacetanilide, 4. sulfate ester of 2-hydroxyaniline, 5. conjugate of 2-hydroxyisopropyl 4-hydroxycarbanilate, 6. sulfate ester of 2-hydroxypropham, 7. sulfate ester of 4-hydroxyacetanilide /rats only/... Partial identification of other metabolites from goat indicated presence of: 1. 4-hydroxypropham conjugate, 2. 2-hydroxypropham conjugate, 3. para-aminophenol conjugate, 4. 3,4-dihydroxypropham conjugate.', 'For more Metabolism/Metabolites (Complete) data for ISOPROPYL PHENYLCARBAMATE (8 total), please visit the HSDB record page.']","['In rats, average biological half-life for IPC in internal organs was 5.0 hr, in brain, muscle and fat tissue, 13.3 hr.', 'The average biological half-life /in adult female Wistar rats/ of propham in most organs was short, ranging between 3 and 8 hr. However, in brain, fat, and muscle, the half-life was about twice the value for other organs.']"
4685,24686,Alipur,CC(C#C)OC(=O)NC1=CC(=CC=C1)Cl.CN(C)C(=O)NC1CCCCCCC1,,,,,,
4686,24687,"Nitrous acid, 2-methylbutyl ester, mixt. with 3-methylbutylnitrite",CCC(C)CON=O.CC(C)CCON=O,,,,,,
4687,24688,2-Methylbutyl nitrite,CCC(C)CON=O,,,,,,
4688,24689,CID 24689,CN1C2=C(C(=O)N(C1=O)C)NC=N2.COC(CC1=CC=CC2=C1OC(=O)C(=C2)C(=O)[O-])C[Hg].O.[Na+],,,,,,
4689,24690,Halquinols,C1=CC2=C(C(=C(C=C2)Cl)O)N=C1.C1=CC2=C(C=CC(=C2N=C1)O)Cl.C1=CC2=C(C(=C(C=C2Cl)Cl)O)N=C1,,,,,,
4690,24691,7-Chloroquinolin-8-ol,C1=CC2=C(C(=C(C=C2)Cl)O)N=C1,,,,,,
4691,24692,Methyl demeton,CCSCCOP(=S)(OC)OC.CCSCCSP(=O)(OC)OC,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']",,,
4692,24693,Methylphenol,CC1=CC=C(C=C1)O.CC1=CC(=CC=C1)O.CC1=CC=CC=C1O,,,,,,
4693,24694,Dilan,CCC(C(C1=CC=C(C=C1)Cl)C2=CC=C(C=C2)Cl)[N+](=O)[O-].CC(C(C1=CC=C(C=C1)Cl)C2=CC=C(C=C2)Cl)[N+](=O)[O-],,,,,,
4694,24695,Sodium;ethanol;ethylmercury(1+);2-sulfidobenzoate,CCO.CC[Hg+].C1=CC=C(C(=C1)C(=O)[O-])[S-].[Na+],,,,,,
4695,24696,CID 24696,CC1(CCC(CC1)C(C)(C)O)O.CN1CCC23C4[C@@H]1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,,,,,,
4696,24697,CID 24697,CN1CCC23C4[C@@H]1CC5=C2C(=C(C=C5)OC)OC3C(C=C4)O,,,,,,
4697,24698,"2,3-Dihydroxypropyl hexadecanoate;2,3-dihydroxypropyl octadecanoate",CCCCCCCCCCCCCCCCCC(=O)OCC(CO)O.CCCCCCCCCCCCCCCC(=O)OCC(CO)O,,,,,,
4698,24699,Glyceryl monostearate,CCCCCCCCCCCCCCCCCC(=O)OCC(CO)O,,,,,,
4699,24700,"Sodium;3,7-dimethylpurine-2,6-dione",CN1C=NC2=C1C(=O)NC(=O)N2C.[Na+],,,,,,
4700,24701,CID 24701,CN1C2C(=NC=N2)C(=O)N(C1=O)C.C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],,,,,,
4701,24702,"1,3-dimethyl-7H-purine-2,6-dione;6-(methylamino)hexane-1,2,3,4,5-pentol",CNCC(C(C(C(CO)O)O)O)O.CN1C2=C(C(=O)N(C1=O)C)NC=N2,,,,,,
4702,24703,"Acridine-3,6-diamine;9-methylacridin-10-ium-3,6-diamine;chloride",CC1=C2C=CC(=CC2=[NH+]C3=C1C=CC(=C3)N)N.C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N.[Cl-],,,,,,
4703,24704,"Acridine, 3,6-diamino-9-methyl-",CC1=C2C=CC(=CC2=NC3=C1C=CC(=C3)N)N,,,,,,
4704,24705,Octamethyltrisiloxane,C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C,,,,,,
4705,24706,Ovral,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34.C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,,,,,,
4706,24707,"(13S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",C[C@]12CCC3C(C1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,,,,,,
4707,24708,"2-{[(Bicyclo[2.2.1]hept-2-en-2-yl)(hydroxy)phenylacetyl]oxy}-N,N,N-trimethylethan-1-aminium bromide",C[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC3CCC2C3)O.[Br-],,,,,,
4708,24709,2-[2-(2-Bicyclo[2.2.1]hept-2-enyl)-2-hydroxy-2-phenylacetyl]oxyethyl-trimethylazanium,C[N+](C)(C)CCOC(=O)C(C1=CC=CC=C1)(C2=CC3CCC2C3)O,,,,,,
4709,24710,CID 24710,CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)[O-].C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=CC=C3O.[Na+],,,,,,
4710,24711,"Lignosulfonic acid, calcium salt",COC1=CC=CC(=C1O)CC(CS(=O)(=O)[O-])OC2=C(C=C(C=C2)CCCS(=O)(=O)[O-])OC.[Ca+2],,,,,,
4711,24712,Lignosulfonic acid,COC1=CC=CC(=C1O)CC(CS(=O)(=O)O)OC2=C(C=C(C=C2)CCCS(=O)(=O)O)OC,,,,,,
4712,24713,"Amyltricresols, secondary",CCCC(C)C1=CC(=CC(=C1)C)O,,,,,,
4713,24714,"N-[2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl)propyl]-4-pentylpyrrolidine-2-carboxamide;hydrochloride",CCCCCC1CC(NC1)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl.Cl,,,,,,
4714,24715,"N-[2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl)propyl]-4-pentylpyrrolidine-2-carboxamide",CCCCCC1CC(NC1)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl,,,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)']",,,
4715,24716,"Acetic acid, (4-chloro-2-methylphenoxy)-, butyl ester, mixt. with pentyl (2,4,5-trichlorophenoxy)acetate",CCCCCOC(=O)COC1=CC(=C(C=C1Cl)Cl)Cl.CCCCOC(=O)COC1=C(C=C(C=C1)Cl)C,,,,,,
4716,24717,CID 24717,CC=CC(=O)OC1=C(C=C(C=C1[N+](=O)[O-])C(C)(C)CCC(C)C)[N+](=O)[O-].C(CN=C(S)[S-])N=C(S)[S-].C(CN=C(S)[S-])N=C(S)[S-].[Mn+2].[Zn+2],,,,,,
4717,24718,"[4-(2,5-Dimethylhexan-2-yl)-2,6-dinitrophenyl] but-2-enoate",CC=CC(=O)OC1=C(C=C(C=C1[N+](=O)[O-])C(C)(C)CCC(C)C)[N+](=O)[O-],,,,,,
4718,24719,"4-[(5-Methyl-1,2-oxazol-3-yl)methylsulfonyl]aniline;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine",CC1=CC(=NO1)CS(=O)(=O)C2=CC=C(C=C2)N.COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N,,,,,,
4719,24720,"4-[(5-Methyl-1,2-oxazol-3-yl)methylsulfonyl]aniline",CC1=CC(=NO1)CS(=O)(=O)C2=CC=C(C=C2)N,,,,,,
4720,24721,Bufencarb,CCCC(C)C1=CC(=CC=C1)OC(=O)NC.CCC(CC)C1=CC(=CC=C1)OC(=O)NC,,,,,,
4721,24722,Demeton,CCOP(=O)(OCC)SCCSCC.CCOP(=S)(OCC)OCCSCC,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['UP TO 14 DAYS AFTER TOPICAL APPLICATION OF DEMETON-S TO COTTON, THIS ISOMER ACCUMULATED RAPIDLY IN LEAVES. SUBSEQUENTLY, THE SULFOXIDE ANALOG APPEARED IN GREATER QUANTITY. SOME SULFONE WAS ALSO OBSERVED. /DEMETON-S/', 'WITH MICE, ADMIN DOSE WAS RAPIDLY ABSORBED, METABOLIZED & ELIMINATED. ONLY 6% OR LESS WAS FOUND IN STOMACH AFTER 1-2 HR; AFTER 4 HR IT HAD ALMOST ENTIRELY DISAPPEARED FROM THESE TISSUES. SMALL AMT PASSED THROUGH INTESTINES BUT MOST WAS ELIMINATED IN URINE RATHER THAN FECES.', '... Absorption may occur from inhalation of the vapor, by skin absorption, or by ingestion of the liquid.', '/DEMETON IS/ A SYSTEMIC INSECTICIDE, IE, TRANSLOCATED IN SAP TO ALL PARTS OF PLANTS.', 'For more Absorption, Distribution and Excretion (Complete) data for SYSTOX (6 total), please visit the HSDB record page.']","['... RATES OF METABOLISM & DEGRADATION /WERE DIFFERENT IN MICE, COCKROACHES & PLANTS/ ... RATES WERE GREATER IN THE MAMMAL THAN IN THE INSECT & GREATER IN THE INSECT THAN IN PLANTS. ROUTES OF METABOLISM & METABOLITES, HOWEVER, WERE THE SAME IN EACH CASE. THE PRINCIPAL METABOLIC ... /PATHWAY/ FOR BOTH ISOMERS WAS OXIDN OF THE 2-ETHYLTHIO ETHER TO SULFOXIDE & SULFONE. IN CASE OF DEMETON O, A SECONDARY ... /PATHWAY/ INVOLVED OXIDN OF P=S TO P=O WITH SUBSEQUENT OXIDN TO SULFOXIDE & SULFONE. ... FOLLOWING APPLICATION TO PLANTS, DEMETON-S RAPIDLY GAVE RISE TO AT LEAST 3 METABOLITES, 2 OF WHICH PERSISTED FOR AS LONG AS 15 WK. USING CHROMATOGRAPHIC TECHNIQUES, 2 OF THE COMPOUNDS WERE IDENTIFIED AS THE CORRESPONDING SULFOXIDE & SULFONE.', '... /IT WAS/ SHOWN THAT THE ISOMERS /OF DEMETON/ ARE CONVERTED TO OXIDN PRODUCTS THAT ARE MORE POTENT INHIBITORS OF ACETYLCHOLINESTERASE THAN PARENT CMPD.', 'Studies in mice are consistent with the notion that oxidation of the mercapto sulfur of the ethylmercaptoethyl portion of demeton and the P-O isomer to the corresponding sulfoxide and finally to the sulfone is an important metabolic pathway for demeton.']",
4722,24723,Demeton-S,CCOP(=O)(OCC)SCCSCC,,,,"['DEMETON-S RAPIDLY PENETRATES INTO PLANTS.', 'UP TO 14 DAYS AFTER THE TOPICAL APPLICATION OF DEMETON S TO COTTON, THIS ISOMER ACCUMULATED RAPIDLY IN THE LEAVES.', 'THE PRINCIPAL ROUTE OF ELIMINATION IN THE MOUSE WAS THROUGH THE URINE, 50 TO 70% OF AN ORALLY ADMIN DOSE BEING ELIMINATED IN 24 HR, 90% OF WHICH WAS IN THE FORM OF HYDROLYZED NONTOXIC PRODUCTS.']","['THE THIOETHER SULFUR OF BOTH.../DEMETON-O AND DEMETON-S/ IS OXIDIZED, METABOLICALLY, TO THE SULFOXIDE AND SULFONE.', 'FOLLOWING APPLICATION TO PLANTS, DEMETON-S RAPIDLY GAVE RISE TO THREE METABOLITES, TWO OF WHICH PERSISTED FOR AS LONG AS 15 WK.']",
4723,24724,"Mercury chloride (Hg2Cl2), mixt. with mercury chloride (HgCl2)",Cl[Hg].Cl[Hg].Cl[Hg]Cl,,,,,,
4724,24725,CID 24725,C(C=CCl)Cl.C(C=CCl)Cl,,,,,,
4725,24726,"(E)-1,3-Dichloropropene",C(/C=C/Cl)Cl,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['Following oral admin of 8.3-13.5 mg/kg body weight cis- or trans-2-(14)carbon-1,3-dichloropropene to rats, 80% of the radioactivity of the cis-isomer and 57% of the radioactivity of the trans-isomer was excreted in the urine within 24 hr. Little further urinary excretion occurred over the next 72 hr. After 96 hr, 2-5% of the cis-isomer and 23-24% of the trans-isomer were expired as (14)carbon carbondioxide; exhalation of other radioactive compounds was minor. Little fecal excretion was observed. Recovery of both isomers was about 90%.', '... Rats were fed (14)carbon-labeled ... isomers of 1,3-dichloropropene and showed differences in their metabolism. With all compounds, 80-90% was eliminated in the first 24 hr. Major route of excretion was in the urine, where ... 56.5% of trans was found. The amount of (14)carbon dioxide excreted was 23.6%, with correspondingly less ... in the urine.', 'Tomato plants absorbed labeled cis- and trans-1,3-dichloropropene through their roots with max 1,3-dichloropropene absorbed and translocated after 2-4 hr and no 1,3-dichloropropene detected by 48 hr. 1,3-Dichloropropene was metabolized to trans-3-chloroallyl alcohol, part of which was converted to trans-3-chloroacrylic acid and 3-chloropropanol. At 12 and 24 hr after treatment both cis-1,3-dichloropropene and trans-1,3-dichloropropene disrupted the organellar structure of the chloroplasts and the rough endoplasmic reticulum of some plants. However, despite the disruption of normal cellular structure, cis-1,3-dichloropropene and trans-1,3-dichloropropene do not present residue problems and cause concern about their residue fate.', 'Following the oral administration to rats of (14)C labeled 1,2-dichloropropane, cis-1,3-dichloropropene, or trans-1,3-dichloropropene, 80-90% of the radioactivity was eliminated in the feces, urine and expired air within the first 24 hr. The urine was the major route of excretion in all three cases.', 'For more Absorption, Distribution and Excretion (Complete) data for TRANS-1,3-DICHLOROPROPENE (7 total), please visit the HSDB record page.']","['Groups of 3-9 male Fischer 344 rats (200-260g) were admin 50 mg cis-1,3-dichloropropene (94.1% cis- & 2.5% trans-) or 50 mg trans-1,3-dichloropropene (97.3% trans- & 0.8 cis-)/kg bw, by gavage. The rats were sacrificed at various intervals after dosing, to determine the tissue non-protein sulfhydryls (NPS) in the liver, kidneys, forestomach, glandular, stomach, & bladder. Blood samples were also taken to determine the presence of unchanged 1,3-dichloropropene. Cis-1,3-dichloropropene was only detected in the blood (6.58 ug/liter) 15 min after dosing, the blood levels of trans-1,3-dichloropropene were 11.72 & 8.38 ug/liter, respectively, 15 & 45 min after dosing. A statistically significant decr in the non-protein sulfhydryl contents of the liver, kidneys, forestomach, & glandular stomach was found. This depletion reached a max, approx 2 hr after dosing. No depletion was noted in the bladder. It is not possible to distinguish the effects of cis- & trans-1,3-dichloropropene on NPS, as the results for the individual isomers were not reported. The results indicated that orally admin 1,3-dichloropropene produces a rapid & significant depletion of tissue non-protein sulfhydryls in the rat.', 'The metabolism of cysteine S-conjugates of both cis and trans-1,3-dichloropropene in the presence of rat kidney microsomes and purified flavin containing monooxygenase from hog liver was investigated in vitro. Putative S-oxide metabolites of cysteine S-conjugates were chemically synthesized, and diastereomers were separated and identified by spectroscopic means. The metabolic products of cysteine S-conjugates were identified by comparing the chemical properties of the metabolites with authentic synthetic cysteine S-conjugate S-oxides. S-conjugate S-oxygenase activity was not observed with rat kidney microsomes but was present when cysteine S-conjugates were incubated with the highly purified flavin containing monooxygenase from hog liver. The kinetic parameters indicated that considerable S-oxygenase stereoselectivity and structural selectivity was observed: cis cysteine S-conjugates were preferred substrates and N-acetylation of cysteine S-conjugates decreased substrate activity. S-Oxygenation was considerably diastereoselective and diastereoselectivity was much greater for cysteine S-conjugates with higher Vmax values. Cysteine S-conjugate S-oxides were not indefinitely stable, and under certain conditions, the S-oxides under- went a (2,3)-sigmatropic rearrangement to acrolein. Formation of acrolein or other electrophilic products from S-(chloropropenyl)cysteine conjugate S-oxides may contribute to the renal effects observed for S-(chloropropenyl)cysteine conjugates. Thus, cytotoxicity studies with isolated rat proximal tubular cells or LLC-PK1 cells treated with cysteine S-conjugates showed a time and dose dependent decrease in cell viability. Reduction of renal cytotoxicity of cysteine S-conjugates in the presence of methimazole, an alternate substrate competitive inhibitor of the flavin-containing monooxygenase, suggested that this enzyme may contribute to the renal effects of 1,3-dichloropropene.', 'The biotransformation to sulfur containing products of the Z-isomers & E-isomers of 1,3-dichloropropene administered ip in combination to male Wistar-rats was investigated. The presence of mercapturic acids in the urine of the animals was determined using GC with nitrogen & sulfur selective detection (GC-NDP & GC-FDP, respectively) & GC/MS with negative chemical ionization & single ion detection. Quantification of mercapturic acids in the urine of animals treated with the dichloropropene isomers in doses of 5 ug each, was achieved with the use of GC-NDP & GC-FPD, while GC/negative chemical ionization/MS detected only the mercapturic acids generated by doses = 25 ug or higher, due to the interference of endogenous products. Both products tested are metabolized via glutathione conjugation, with the generation of 2 major mercapturic acid conjugates, & that all three analytical procedures tested are useful for the determination of human exposure to low levels of 1,3-dichloropropene.']",
4726,24727,Topogard,CCNC1=NC(=NC(=N1)SC)NC(C)(C)C.CCNC1=NC(=NC(=N1)Cl)NC(C)(C)C,,,,,,
4727,24728,Agn-PC-0jkhsw,C[As]=S.C1=CC=C(C=C1)C(=O)NNC2=CC=C(C=C2)N=O,,,,,,
4728,24729,"2,4-D mixture with Picloram",CC(CN(CC(C)O)CC(C)O)O.C1=CC(=C(C=C1Cl)Cl)OCC(=O)O.C1=C(C(=C(C(=C1Cl)Cl)N)Cl)C(=O)O,,,,,,
4729,24730,Triisopropanolamine,CC(CN(CC(C)O)CC(C)O)O,,,,,,
4730,24731,"3-Amino-2,4,5-trichlorobenzoic acid",C1=C(C(=C(C(=C1Cl)Cl)N)Cl)C(=O)O,,,,,,
4731,24732,Alfathesin,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@H](C4)O)C)C.CC(=O)OCC(=O)[C@H]1CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@H](C4)O)C)C,,,,,,
4732,24733,Alfadolone acetate,CC(=O)OCC(=O)[C@H]1CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@H](C4)O)C)C,,,"['Agents capable of inducing a total or partial loss of sensation, especially tactile sensation and pain. They may act to induce general ANESTHESIA, in which an unconscious state is achieved, or may act locally to induce numbness or lack of sensation at a targeted site. (See all compounds classified as Anesthetics.)', 'Endogenous compounds or drugs that affect neuronal excitability through modulation of specific ionotropic receptors (e.g., GABA-A RECEPTORS). Endogenous neurosteroids are steroid hormones de novo synthesized by neurons and glial cells from steroid metabolite precursors (e.g., PREGNENOLONE). (See all compounds classified as Neurosteroids.)']",,,
4733,24734,CID 24734,CC(=O)[C@H]1CCC2[C@@]1(CC(=O)[C@H]3[C@H]2CC[C@@H]4[C@@]3(CCC(C4)O)C)C,,,,,,
4734,24735,"Dicamba with 2,4-D",COC1=C(C=CC(=C1C(=O)O)Cl)Cl.C1=CC(=C(C=C1Cl)Cl)OCC(=O)O,,,,,,
4735,24736,"[3-(3-carboxypropanoylcarbamoylamino)-2-methoxypropyl]mercury;1,3-dimethyl-7H-purine-2,6-dione;hydrate",CN1C2=C(C(=O)N(C1=O)C)NC=N2.COC(CNC(=O)NC(=O)CCC(=O)O)C[Hg].O,,,,,,
4736,24737,Prefox,CCN(CC)C(=O)SCC.CC(C)NC1=NC(=NC(=N1)NC2CC2)Cl,,,,,,
4737,24738,Cyprazine,CC(C)NC1=NC(=NC(=N1)NC2CC2)Cl,,,,"['BOTH FOLIAR & ROOT ABSORPTION OCCUR /IN PLANTS/. ... CHEMICAL MOVES ACROPETALLY BUT NOT BASIPETALLY.', 'RATS ADMIN SINGLE ORAL DOSES OF (14)CARBON-LABELED CYPRAZINE EXCRETED 97.6% WITHIN 72 HR (72.7% IN URINE & 24.9% IN FECES). LESS THAN 1% OF RADIOACTIVITY WAS DETECTED IN EXPIRED AIR AS (14)CARBON DIOXIDE. RATS CONTAINED 7.5% OF RADIOACTIVITY @ SACRIFICE, 72 HR AFTER DOSING.']","['CYPRAZINE WAS RAPIDLY METABOLIZED TO WATER SOL CMPD IN LEAVES OF TOLERANT CORN, SORGHUM, & SUGAR CANE & MORE SLOWLY IN SUSCEPTIBLE BARLEY, BY DISPLACEMENT OF 2-CHLORO GROUP BY GLUTATHIONE OR GAMMA-GLUTAMYLCYSTEINE. THE RESULTING SULFIDE CONJUGATES WERE AMONG THE MOST ABUNDANT WATER SOL METABOLITES PRESENT 6 HR AFTER TREATMENT.', 'CHLOROTRIAZINES REACTED /WITH A PLANT ENZYME RESPONSIBLE FOR THEIR CONJUGATION/ IN THE DECREASING ORDER OF GS-13529, ATRAZINE, CYPROZINE, PROPAZINE, & SIMAZINE WITH NO CORRELATION TO THEIR WATER SOLUBILITY OR PARTITION COEFFICIENTS. APPARENTLY, INTACT ALKYLAMINO SUBSTITUENTS @ BOTH C4 & C6 POSITIONS ARE PREFERRED STRUCTURES FOR CONJUGATION SINCE MOST OF THE ENZYME ACTIVITY WAS LOST WHEN ONE OF THE SIDE CHAIN ALKYL GROUPS WAS REMOVED.', 'IN CORN, RAPID CONJUGATION OF FOLIARLY APPLIED CYPROZINE ... WAS OBSERVED, BUT DECR DRASTICALLY IN COURSE OF 3 WK. AT THAT TIME THE INCR HYDROXY DERIVATIVES REACHED CONCN OF THE CONJUGATES.', 'IN RATS ADMIN SINGLE ORAL DOSES OF (14)CARBON LABELED CYPRAZINE, FOUR URINARY METABOLITES WERE IDENTIFIED: 2-HYDROXY-4,6-DIAMINO-S-TRIAZINE; 2-CHLORO-4,6-DIAMINO-S-TRIAZINE; 2-HYDROXY-4-AMINO-6-ISOPROPYLAMINO-S-TRIAZINE; & 2-CHLORO-4-AMINO-6-ISOPROPYLAMINO-S-TRIAZINE.', 'For more Metabolism/Metabolites (Complete) data for CYPRAZINE (6 total), please visit the HSDB record page.']",
4738,24739,Gesapax multi,CCNC1=NC(=NC(=N1)SC)NC(C)C.C1=CC(=C(C=C1Cl)Cl)OCC(=O)O,,,,,,
4739,24740,Agelon,CCNC1=NC(=NC(=N1)Cl)NC(C)C.CC(C)NC1=NC(=NC(=N1)SC)NC(C)C,,,,,,
4740,24741,"2-chloro-N-(2,6-diethylphenyl)-N-(methoxymethyl)acetamide;S-ethyl N,N-dipropylcarbamothioate",CCCN(CCC)C(=O)SCC.CCC1=C(C(=CC=C1)CC)N(COC)C(=O)CCl,,,,,,
4741,24742,Betamix,CCOC(=O)NC1=CC(=CC=C1)OC(=O)NC2=CC=CC=C2.CC1=CC(=CC=C1)NC(=O)OC2=CC=CC(=C2)NC(=O)OC,,,,,,
4742,24743,Desmedipham,CCOC(=O)NC1=CC(=CC=C1)OC(=O)NC2=CC=CC=C2,,,,,,
4743,24744,Phenmedipham,CC1=CC(=CC=C1)NC(=O)OC2=CC=CC(=C2)NC(=O)OC,,,"['Pesticides used to destroy unwanted vegetation, especially various types of weeds, grasses (POACEAE), and woody plants. Some plants develop HERBICIDE RESISTANCE. (See all compounds classified as Herbicides.)']","['In rats, dogs & humans ... phenmedipham ... /is/ readily absorbed ... .', 'RECOVERY OF /ORALLY/ ADMIN DOSE /TO RATS/ IN URINE & FECES, AT 72 HR AFTER TREATMENT, WAS ... 99% ... URINE ... PRIMARY ROUTE OF ELIMINATION, WITH 80% ... EXCRETED VIA URINE IN INITIAL 24 HR ... TRACE AMT OF RADIOLABEL ... IN KIDNEY ... 0.039 PPM ... ALL OTHER TISSUES FELL BELOW THIS LEVEL.', 'It is absorbed through leaves & has little action by way of soil & roots.']","['WHEN ADMIN TO WHITE RATS, PHENMEDIPHAM ... RAPIDLY METABOLIZED ... HYDROLYSIS YIELDED METHYL N-(3-HYDROXYPHENOL) CARBAMATE (MHPC) ... HYDROXYPHENYLCARBAMATES FORMED ... DEGRADED TO M-AMINOPHENOL WHICH WAS ACETYLATED TO ... 3-HYDROXYACETANILIDE. THESE METABOLITES WERE THEN CONJUGATED AS GLUCURONIDES & SULFATES.', 'BETANAL ... WAS RAPIDLY METABOLIZED BY RATS TO CORRESPONDING PHENOL ... (60-70%)(WHICH WAS PARTLY CONJUGATED) & M-HYDROXYANILINE, WHICH WAS EXCRETED AS M-HYDROXYACETANILIDE ... (2%).']",
4744,24745,Agn-PC-0jkht9,CN(C(=O)NC1=CC(=C(C=C1)Cl)Cl)OC.C1=CC(=CC=C1[N+](=O)[O-])OC2=C(C=C(C=C2)Cl)Cl,,,,,,
4745,24746,Tromcardin,C(C(C(=O)[O-])N)C(=O)O.C(C(C(=O)[O-])N)C(=O)O.C(C(C(=O)[O-])N)C(=O)[O-].[Mg+2].[K+].[K+],,,['Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)'],,,
4746,24747,Quazolast,COC(=O)C1=NC2=CC(=C3C=CC=NC3=C2O1)Cl,,,,,,
4747,24748,Croscarmellose,CC(=O)O.C(C(C(C(C(C=O)O)O)O)O)O,"['Indicated for the symptomatic relief of burning, irritation and discomfort of the eyes due to dryness or exposure to wind or sun.']","['In a randomized clinical study of patients with mild or moderate forms of eye dryness, ophthalmic treatment with sodium carboxymethylcellulose resulted in a diminished frequency of symptoms compared to the placebo group. Carboxymethylcellulose interacts with human corneal epithelial cells to facilitate corneal epithelial wound healing and attenuate eye irritation in a dose-dependent manner. It exhibits protective actions on the ocular surface in various applications; it mediates cytoprotective effects on the ocular surface when applied prior to contact lenses and reduces the incidence of epithelial defects during LASIK.']","['Agents that produce a soft formed stool, and relax and loosen the bowels, typically used over a protracted period, to relieve CONSTIPATION. (See all compounds classified as Laxatives.)']","['No pharmacokinetic data available.', 'No pharmacokinetic data available.', 'No pharmacokinetic data available.', 'No pharmacokinetic data available.']",['No pharmacokinetic data available.'],['No pharmacokinetic data available.']
4748,24749,"Mannose, D-",C(C(C(C(C(C=O)O)O)O)O)O,,,"['Substances that sweeten food, beverages, medications, etc., such as sugar, saccharine or other low-calorie synthetic products. (From Random House Unabridged Dictionary, 2d ed) (See all compounds classified as Sweetening Agents.)']","['Members of the IL-6 family, IL-6 and ciliary neurotrophic factor (CNTF), have been shown to increase glucose uptake and fatty acid oxidation in skeletal muscle. However, the metabolic effects of another family member, leukemia inhibitory factor (LIF), are not well characterized. Effects of LIF on skeletal muscle glucose uptake and palmitate oxidation and signaling were investigated in ex vivo incubated mouse soleus and EDL muscles from muscle-specific AMPKalpha2 kinase-dead, muscle-specific SOCS3 knockout, and lean and high-fat-fed mice. Inhibitors were used to investigate involvement of specific signaling pathways. LIF increased muscle glucose uptake in dose (50-5,000 pM/l) and time-dependent manners with maximal effects at the 30-min time point. LIF increased Akt Ser(473) phosphorylation (P) in soleus and EDL, whereas AMPK Thr(172) P was unaffected. Incubation with parthenolide abolished LIF-induced glucose uptake and STAT3 Tyr(705) P, whereas incubation with LY-294002 and wortmannin suppressed both basal and LIF-induced glucose uptake and Akt Ser(473) P, indicating that JAK and PI 3-kinase signaling is required for LIF-stimulated glucose uptake. Incubation with rapamycin and AZD8055 indicated that mammalian target of rapamycin complex (mTORC)2, but not mTORC1, also is required for LIF-stimulated glucose uptake. In contrast to CNTF, LIF stimulation did not alter palmitate oxidation. LIF-stimulated glucose uptake was maintained in EDL from obese insulin-resistant mice, whereas soleus developed LIF resistance. Lack of SOCS3 and AMPKalpha2 did not affect LIF-stimulated glucose uptake. In conclusion, LIF acutely increased muscle glucose uptake by a mechanism potentially involving the PI 3-kinase/mTORC2/Akt pathway and is not impaired in EDL muscle from obese insulin-resistant mice.', 'The aim of the work is to analyze the relationship between consumption of glucose solution by rats and its absorption, and to use this fact for assessment of the absorptive capacity of the small intestine in non anesthetized animals in vivo. Consumption of glucose solution (200 g/L) by fasted rats was recorded in the control, and after administration of phloridzin--inhibitor of glucose active transport- or 3 hours after the restriction stress. On the mathematical model we studied the relative role of factors that can influence the temporal dynamics of glucose consumption by rats. The rate of glucose consumption was observed being decreased in the presence of phloridzin (1 mM), and be increased after the stress. The results of modeling are consistent with the experimental data and show that the rate of consumption of glucose solutions considerably more depends on the transport activity of the small intestine than on glucose concentration in the solution, or on the substrate regulation of the stomach emptying. Analysis of dynamics of consumption of glucose solution by intact rats may be considered as one of promising approaches to assessing the absorptive capacity of the small intestine under natural conditions.', 'Facilitated diffusion involves carrier substance within placenta, which acts to incr rate of transfer beyond that which would be expected... glucose is apparently transferred in this manner. ...No metabolic energy may be required, & transfer is in direction of concn gradient.', 'When excesses are given IV blood sugar values usually return near normal within an hour or two, most of excess having been eliminated through kidneys, & CA 40% dialyzes into tissues with small amt destroyed by oxidation.', 'For more Absorption, Distribution and Excretion (Complete) data for D(+)-Glucose (6 total), please visit the HSDB record page.']","['Growth of Escherichia coli on glucose in batch culture is accompanied by the excretion of acetate, which is consumed by the cells when glucose is exhausted. This glucose-acetate transition is classically described as a diauxie (two successive growth stages). Here, we investigated the physiological and metabolic properties of cells after glucose exhaustion through the analysis of growth parameters and gene expression. We found that E. coli cells grown on glucose in batch culture produce acetate and consume it after glucose exhaustion but do not grow on acetate. Acetate is catabolized, but key anabolic genes--such as the genes encoding enzymes of the glyoxylate shunt--are not upregulated, hence preventing growth. Both the induction of the latter anabolic genes and growth were observed only after prolonged exposure to low concentrations of acetate and could be accelerated by high acetate concentrations. We postulate that such decoupling between acetate catabolism and acetate anabolism might be an advantage for the survival of E. coli in the ever-changing environment of the intestine. The glucose-acetate transition is a valuable experimental model for comprehensive investigations of metabolic adaptation and a current paradigm for developing modeling approaches in systems microbiology. Yet, the work reported in our paper demonstrates that the metabolic behavior of Escherichia coli during the glucose-acetate transition is much more complex than what has been reported so far. A decoupling between acetate catabolism and acetate anabolism was observed after glucose exhaustion, which has not been reported previously. This phenomenon could represent a strategy for optimal utilization of carbon resources during colonization and persistence of E. coli in the gut and is also of significant interest for biotechnological applications.', 'When V. cholerae encounters nutritional stress, it activates (p)ppGpp-mediated stringent response. The genes relA and relV are involved in the production of (p)ppGpp, whereas the spoT gene encodes an enzyme that hydrolyzes it. Herein, we show that the bacterial capability to produce (p)ppGpp plays an essential role in glucose metabolism. The V. cholerae mutants defective in (p)ppGpp production (i.e. deltarelAdeltarelV and deltarelAdeltarelVdeltaspoT mutants) lost their viability because of uncontrolled production of organic acids, when grown with extra glucose. In contrast, the deltarelAdeltaspoT mutant, a (p)ppGpp overproducer strain, exhibited better growth in the presence of the same glucose concentration. An RNA sequencing analysis demonstrated that transcriptions of genes consisting of an operon for acetoin biosynthesis were markedly elevated in N16961, a seventh pandemic O1 strain, but not in its (p)ppGpp(0) mutant during glucose-stimulated growth. Transposon insertion in acetoin biosynthesis gene cluster resulted in glucose-induced loss of viability of the deltarelAdeltaspoT mutant, further suggesting the crucial role of acetoin production in balanced growth under glucose-rich environments. Additional deletion of the aphA gene, encoding a negative regulator for acetoin production, failed to rescue the (p)ppGpp(0) mutant from the defective glucose-mediated growth, suggesting that (p)ppGpp-mediated acetoin production occurs independent of the presence of AphA. Overall, our results reveal that (p)ppGpp, in addition to its well known role as a stringent response mediator, positively regulates acetoin production that contributes to the successful glucose metabolism and consequently the proliferation of V. cholerae cells under a glucose-rich environment, a condition that may mimic the human intestine.', 'Heterogeneity within the same tumor type has been described to be complex and occur at multiple levels. Less is known about the heterogeneity at the level of metabolism, within a tumor set, yet metabolic pathways are highly relevant to survival signaling in tumors. In this study, we profiled the glucose metabolism of several non-small cell lung carcinoma (NSCLC) cell lines and could show that, NSCLC display distinct glycolytic metabolism. Genetic and pharmacological perturbation of glycolysis was selectively toxic to NSCLCs with high rates of glycolysis. Furthermore, high expression of hexokinase-2, localized at the mitochondria, was a feature of the NSCLCs dependent on glucose catabolism. Our study provides evidence for quantitative metabolic diversity in NSCLCs and indicates that glucose metabolism provide differential prosurvival benefits to NSCLCs.', 'To observe the influence of different concentrations of bisphenol A (BPA) on glucose metabolism and lactate dehydrogenase (LDH) expression in rat Sertoli cells in vitro and investigate the mechanisms of BPA inducing male infertility. Using two-step enzyme digestion, we isolated Sertoli cells from male Wistar rats and constructed a primary Sertoli cell system, followed by immunohistochemical FasL staining. We randomly divided the Sertoli cells into a control group to be cultured in the serum-free minimal essential medium (MEM) plus dimethyl sulfoxide (DMSO) and three experimental groups to be treated with 100 nmol/L, 10 umol/L, and 1 mmol/L BPA, respectively, in the MEM plus DMSO. After 48 hours of treatment, we measured the proliferation of the cells by CCK-8 assay, determined the concentrations of metabolites by NMR spectroscopy, and detected the expression of LDH in the Sertoli cells by RT-PCR and Western blot. The purity of the isolated Sertoli cells was (96.05 +/- 1.28)% (n = 10). Compared with the control group, the 100 nmol/L, 10 umol/L, and 1 mmol/L BPA groups showed no remarkable changes in the proliferation of Sertoli cells ([98 +/- 8]%, [96 +/- 3]%, and [95 +/- 3]%, P >0.05), but the 10 umol/L and 1 mmol/L of BPA groups exhibited significantly decreased concentrations of intracellular glucose ([3.89 +/- 0.07] vs [3.36 +/- 0.24] and [3.04 +/- 0.21] pmol/cell, P <0.05) and lactate ([0.43 +/- 0.06] vs [0.29 +/- 0.05] and [0.20 +/- 0.03] pmol/cell, P <0.05). The expression of LDH mRNA was decreased with the increased concentration of BPA, while that of LDH protein reduced only in the 1 mmol/L BPA group (P <0.05). High-concentration BPA decreases the expression of LDH and alters glucose metabolism in Sertoli cells, and therefore may reduce the provision of lactate for germ cells and impair spermatogenesis.', 'For more Metabolism/Metabolites (Complete) data for D(+)-Glucose (9 total), please visit the HSDB record page.']",
4749,24750,2-(Dodecyloxy)ethanol,CCCCCCCCCCCCOCCO,,,"['Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)', 'Chemical agents injected into blood vessels and lymphatic sinuses to shrink or cause localized THROMBOSIS; FIBROSIS, and obliteration of the vessels. This treatment is applied in a number of conditions such as VARICOSE VEINS; HEMORRHOIDS; GASTRIC VARICES; ESOPHAGEAL VARICES; PEPTIC ULCER HEMORRHAGE. (See all compounds classified as Sclerosing Solutions.)']",,,
4750,24751,Poloxalene,CC1CO1.C1CO1,['Indicated to reduce viscosity in the blood before transfusions.'],"[""Poloxamer 188 (P188) exerts a protective action against oxidative stress and inflammation in tissue injury in various experimental models. In the rat model of excitotoxic injury, immediate intrathecal administration of P188 reduced neuronal loss, indicated by smaller spherical excitotoxic lesions. In a murine hind-limb model, P188 mediated a protective action against ischemia-reperfusion injury as indicated by decreased myocyte injury, preserved tissue adenosine 5'-triphosphate levels, and improved survival rates, suggesting that P188 can seal defects in cell membranes and attenuate damage induced by reactive oxygen species. P188 was shown to elicit protective effects against excitotoxic injury, and trauma-induced necrotic and apoptotic cell death in cultured neurons. In the mouse stroke models, P188 exerted a neuroprotective effect in brain ischemia-reperfusion induced acute injury by significantly reducing infarct volume and water content in brain edema and ameliorating the neurological symptoms 24 h after ischemia or reperfusion injury. P188 also significantly inhibited inflammatory, coagulation, and apoptotic responses resulting from superior mesenteric artery occlusion. In the experimental model of striatum injury in rats, P188 was shown to reduce excitotoxicity-induced tissue loss and macrophage infiltrate.""]","['Substances used on inanimate objects that destroy harmful microorganisms or inhibit their activity. Disinfectants are classed as complete, destroying SPORES as well as vegetative forms of microorganisms, or incomplete, destroying only vegetative forms of the organisms. They are distinguished from ANTISEPTICS, which are local anti-infective agents used on humans and other animals. (From Hawley&apos;s Condensed Chemical Dictionary, 11th ed) (See all compounds classified as Disinfectants.)', 'Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)', 'Agents that are used to stimulate evacuation of the bowels. (See all compounds classified as Cathartics.)']","['Following a 48-hour continuous intravenous infusion of purified P188 in healthy volunteers, the mean concentration of P188 at steady state concentration (Css) was 522 Â± 118 mg/L and the maximum concentration occurring at the end of the loading dose was approximately 909 Â± 165 mg/L. The plasma concentrations were dose-proportional.', 'Renal clearance accounted for 90% of total plasma clearance in healthy male subjects.', 'The volume of distribution at steady state (Vss) after a continuous intravenous infusion of 500 mg/kg of P188 on day 7 was approximately 2.13 mL/kg in pregnant female rats. Vss was 876 mL/kg in dogs receiving a dose of 720 mg/kg/day.', 'Following a 48-hour continuous intravenous infusion of purified P188 in healthy volunteers, the mean total body clearance was estimated to be 4.40 Â± 0.77 L/h when using the plasma concentration data only. Estimated mean renal clearance from the amount of P-188 excreted in urine was 5.21 Â± 1.28 L/h. The clearance of a single metabolite HW1 was slower than the parent compound.', 'Absorption and excretion of 14C-Poloxalene 2930 (PX), a nonionic hydrophobic surfactant of large molecular weight, were studied using bile fistula rats. Approximately half of the dose infused intraduodenally was absorbed and some of the absorbed surfactant was excreted in bile. The remainder was excreted in urine. Only trace quantities of the 14C-PX were recovered in liver and carcass at termination of the study. Two studies were also performed with 14C-PX incorporated into the diet. In the first feeding study of 7 days duration, most of the agent was excreted via the gastrointestinal tract within 72 hr of discontinuing treatment. In the second study, rats were fed dietary 14C-PX for 7, 14, or 23 days to determine whether the surfactant continued to accumulate in the body as the test period was extended. Further accumulation did occur between the 7th and 14th days but not when feeding was continued for a total of 23 days. Of the amount of 14C-PX ingested after 23 days of feeding, essentially all was excreted by the end of 7 days after discontinuing treatment. These studies indicate that despite its large molecular weight of about 3,000 some 14C-PX is absorbed. Furthermore, absorbed material is promptly excreted in bile and urine with little retained in body tissues.', 'To investigate the distribution of poloxamer 407 (Pluronic F-127), rats received 300 mg of intraperitoneal poloxamer 407 solution; blood and urine samples were taken frequently and liver and kidney homogenates were prepared and analyzed using a colorimetry assay. Clearance was 0.014 mL/min. The mean amount excreted in the urine was 76.3 mg in 24 hr. Amounts of poloxamer 407 in supernatants of liver and kidney homogenates were 15.9 and 3.1 mg, respectively.', '...The disposition and pharmacokinetics of Poloxamer 108 was studied in rats as an initial step towards understanding its behavior in man. After iv administration in rats, about 94% of 7 or 100 mg/kg doses of ethylene-14-C-labeled polymer was excreted in the urine in 3 days. About 6% of the label appeared in feces. Erythrocyte membranes were not permeable to the polymer, and only the parent compound was demonstrable in urine. Twenty hours after dosing, small residues were detectable only in the kidney, liver, small intestine and carcass. The 3rd phase of the plasma disappearance pattern was evident only at the larger dose, but plasma disappearance kinetics were independent of the dose in the used range. Most of Poloxamer 108 was eliminated rapidly in rats by renal excretion; a smaller portion probably was removed by biliary excretion.', 'A randomized, double blind, placebo controlled, dose escalation study of the toxicity and pharmacokinetics of poloxamer 188 (RheothRx) was conducted in 36 healthy male subjects (ages 19-35 yr) who received iv injections of 10-90 mg/kg/hr poloxamer or placebo. Poloxamer was eliminated primarily by renal excretion. Estimates of clearance, elimination rate constant, and apparent volume of distribution at steady state were independent of infusion rate. Steady state plasma levels increased linearly with increasing infusion rate values up to 90 mg/kg/hr. Mean plasma clearance was 1.06 mL/min/kg. ...']","['A single metabolite, HW1, with a molecular weight of approximately 16000 Daltons was detected in a pharmacokinetic study in dogs and man. HW1 was present in 10-20 and 40% of the parent compound at steady state in dogs and humans, respectively. However, it is suggested that block polymers are not metabolized and are excreted unchanged in the urine and feces, and HW1 may be a component of the higher molecular weight distribution of P188 that concentrates in the plasma due to its lower clearance rate.']","['In humans, P188 has half-life of 18 hours. The terminal plasma elimination half-life was approximately 7.65 Â± 1.10 hours in healthy volunteers receiving a 48-hour continuous intravenous infusion of purified P188.']"
4751,24752,1-(2-Butoxy-1-methylethoxy)propan-2-ol,CCCCOCC(C)OCC(C)O,,,,"['Groups of 3 female rats/time interval were administered single doses of 14C - labeled BPG in corn oil ranging from 18-22 mg/rat either orally (via gavage) or dermally (applied to a 2 cm x 3 cm area of the back and held in place for 6 hours). Following dosing, the rats were housed in metabolism cages for collection of urine, feces, CO2, and tissues for 6, 24, or 96 hours. Based on data from 96 hours collection period, amount of radioactivity absorbed following oral and dermal dosing was 58.7% and 12%, respectively. Following the oral administration, the amount of radioactivity found as percent of administered dose of BPG was 35.2%, 41%, 3.3%, and 20.2% in urine, feces, tissues, and expired CO2, respectively. Following the dermal administration, the amount of radioactivity found as percent of dose was 2.8%, 1.4%, 6.1%, and1.4% in urine, feces, tissues, and expired CO2, respectively.']",,
4752,24753,"1,3-Butadiene-1,4-diylradical",[CH-]=CC=[CH+],,,,,,
4753,24754,"Phenol, polymer with formaldehyde",[CH]C1=C(C(=CC=C1)O[CH])O,,,,,,
4754,24755,CID 24755,[CH]C([CH])C1=CC=CC=C1,,,,,,
4755,24756,"2-Propenenitrile, polymer with 1,3-butadiene and ethenylbenzene",C=CC=C.C=CC#N.C=CC1=CC=CC=C1,,,,,,
4756,24757,CID 24757,CC(=O)O.C(C(C(C(C(C=O)O)O)O)O)O.[NaH],,,,,,
4757,24758,Sodium hydride,[H-].[Na+],,,,,,
4758,24759,Hyaluronan,CC(=O)N[C@H]1[C@@H](O[C@@H]([C@H](C1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O[C@H]3[C@@H](C([C@@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)NC(=O)C)O)O)O)CO)O,"['The intra-articular preparations of hyaluronic acid are indicated for knee pain associated with osteoarthritis. Hyaluronic acid is used in cosmetic applications to prevent and reduce the appearance of wrinkles on the face, and as a dermal filler to correct facial imperfections or other imperfections on other parts of the body. It is frequently an ingredient in topical applications for wound healing and symptomatic treatment of skin irritation from various causes. Hyaluronic acid may also be indicated in ophthalmological preparations or oral capsules to treat discomfort caused by dry eyes or conjunctivitis and for its protective qualities during and before eye surgery. Finally, hyaluronic acid can be used off-label to coat the bladder for relief of interstitial cystitis symptoms.']","['HA has long-acting lubricant, shock absorbing, joint stabilizing, and water balancing properties. It is similar to the naturally occurring glycosaminoglycan (GAG) in joints. Hyaluronic acid works by acting as a lubricant and shock absorber, facilitating joint mobility and thereby reducing osteoarthritic pain.  Hyaluronic acid has antioxidative, anti-inflammatory, and analgesic effects. The water-balancing properties and viscoelasticity of hyaluronic acid are beneficial in cosmetic injections, imparting volume and reducing the appearance of imperfections and wrinkles. Due to the abovementioned properties, HA has a protective effect on the eyes and cornea.']","['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Viscoelastic solutions that are injected into JOINTS in order to alleviate symptoms of joint-related disorders such as OSTEOARTHRITIS. (See all compounds classified as Viscosupplements.)']","['There is limited information in the literature regarding the human absorption and pharmacokinetics of hyaluronic acid. When administered to rats in the oral form, hyaluronic acid is broken down to oligosaccharides by intestinal bacteria and absorbed in the colon. In pharmacokinetic studies of beagle dogs, HA was readily absorbed and rapidly excreted. When applied topically, HA with low molecular weight ranging from 20-300 kDa is absorbed through the stratum corneum, and HA with high molecular weight (1000-1400 kDa) does not penetrate the stratum corneum. The bioavailability of hyaluronic acid depends on its molecular weight.', 'There is limited information in the literature regarding the human pharmacokinetics of hyaluronic acid. Studies in rats and dogs administered a radio-labeled oral dose of HA showed 87-96% excretion the feces. Excretion of hyaluronic acid is primarily extra-renal, with some contribution from the spleen.', 'There is limited information in the literature regarding the human pharmacokinetics of hyaluronic acid. After a dermal filler injection, HA distributes rapidly into the superficial and deep dermis. Hyaluronic acid is distributed to skin of rats after intestinal metabolism into oligosaccharides.  In rats and beagle dogs receiving oral hyaluronic acid, HA accumulated in the thyroid gland, kidneys, bladder, and stomach. HA was found to be concentrated in the vertebrae, joints, and salivary glands within 4 hours after a single dose. It is suggested by pharmacokinetic studies in animals that HA distributes into the lymphatic system.', 'There is limited information in the literature regarding the human pharmacokinetics of hyaluronic acid. In a pharmacokinetic study of rabbits, maximum clearance capacity of intravenously administered hyaluronic acid was about 30 mg/day/kg.']","['Hyaluronic acid is degraded by a family of enzymes called hyaluronidases. In animals, it is metabolized into oligosaccharides by intestinal bacteria and subsequently reabsorbed in the large intestine.']","['When injected by the intra-articular route hyaluronic acid has a half-life ranging from 17 hours to 1.5 days. The half-life of hyaluronic acid is longer for purified or formulations or preparations with high molecular weight. It can vary according to the molecular weight of the administered HA, according to studies in animals. The metabolic half-life of hyaluronic acid in sheep was determined to be approximately 27 hours in pharmacokinetic studies. In sheep, HA is believed to undergo rapid elimination via the blood and liver.']"
4759,24760,CID 24760,CCCCCCCCCCCCOCCOS(=O)(=O)[O-].[Na+],,,,,,
4760,24761,2-Dodecoxyethyl hydrogen sulfate,CCCCCCCCCCCCOCCOS(=O)(=O)O,,,,,,
4761,24762,Ethylene glycol monostearate,CCCCCCCCCCCCCCCCCC(=O)OCCO,,,,"['THESE ESTERS ARE HYDROLYZED IN THE BOWEL. THE FATTY ACID IS ABSORBED & METABOLIZED; AT LEAST THE SHORTER POLYOXYETHYLENE RESIDUES ARE ALSO ABSORBED, BUT THEY ARE EXCRETED UNCHANGED IN THE URINE (NO DETECTABLE METABOLISM TO OXALIC ACID IN MAN).']",,
4762,24763,Inulin,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CO)O)O)CO[C@]3([C@H]([C@@H]([C@H](O3)CO)O)O)CO[C@]4([C@H]([C@@H]([C@H](O4)CO)O)O)CO[C@]5([C@H]([C@@H]([C@H](O5)CO)O)O)CO[C@]6([C@H]([C@@H]([C@H](O6)CO)O)O)CO[C@]7([C@H]([C@@H]([C@H](O7)CO)O)O)CO[C@]8([C@H]([C@@H]([C@H](O8)CO)O)O)CO[C@]9([C@H]([C@@H]([C@H](O9)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO[C@]1([C@H]([C@@H]([C@H](O1)CO)O)O)CO)O)O)O)O,"['Historically used in an important medical test of renal function, specifically a measure of glomerular filtration rate. Sometimes used to help relieve symptoms of diabetes mellitus - a condition characterised by hyperglycemia and/or hyperinsulinemia.']","['The inulin test is a procedure by which the filtering capacity of the glomeruli (the main filtering structures of the kidney) is determined by measuring the rate at which inulin, the test substance, is cleared from blood plasma. Inulin is one of the more suitable and accurate substance to measure because it is a small, inert polysaccharide molecule that readily passes through the glomeruli. The inulin clearance test is performed by injecting inulin, waiting for it to be distributed, and then measuring plasma and urine inulin concentrations by various assays. As nutraceutical agents inulins may have antitumor, antimicrobial, hypolipidemic and hypoglycemic actions. They may also help to improve mineral absorption and balance and may have antiosteoporotic activity.']",,"['Poorly absorbed, passes through to urine unmetabolized']",['Metabolized into carbon dioxide and methane by colonic bacteria'],['2-4 hours']
4763,24764,Hexamethyldisiloxane,C[Si](C)(C)O[Si](C)(C)C,"['Dimethicone is a colorless liquid with both cosmetic and therapeutic uses. It is used in topical creams and ointments to help distribute the active ingredients. Dimethicone is used as an anti-foaming agent, a hair and skin conditioner, and in the treatment of head lice and, as an anti-bloating/anti-flatulence agent,.']","['This drug acts as a skin protectant by helping to treat and prevent minor skin irritation due to diaper rash and seals out moisture from the diaper area. This drug temporarily protects and helps prevent chafed, chapped, cracked or windburned skin..']",,"['This drug is not believed to be absorbed when used in quantities from 1-30%.', 'Following injection of [14C]dimethicone fluid in the hind limb of rats, the radioactivity was distributed primarily in the gastrointestinal tract, and no evidence of metabolism was observed. When [14C]dimethicone was administered through i.p. injection in rats, the following distribution of radioactivity was observed at 25 days after dosing: 51% in adipose tissue, 27% in gastrointestinal tissues, and 15% in liver.', 'To examine the distribution of low molecular weight silicones in body organs, separate groups of female CD-1 mice were injected with either breast implant distillate composed primarily of hexamethylcyclotrisiloxane, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane, and tetradecamethylcycloheptasiloxane or a polydimethylsiloxane oil containing low molecular weight linear siloxanes. Mice were injected subcutaneously in the suprascapular area and killed at different times. Levels of individual low molecular weight silicones were measured in 10 different organs (brain, heart, kidney, liver, lung, mesenteric lymph nodes, ovaries, spleen, skeletal muscle, and uterus). In mice treated with the cyclosiloxane mixture and killed at 3, 6, or 9 weeks, highest levels of cyclosiloxanes were found in the mesenteric lymph nodes, ovaries, and uterus, but all organs examined contained cyclosiloxanes. In a cohort killed at 1 year, most organs contained measurable cyclosiloxanes with highest levels in mesenteric lymph nodes, abdominal fat, and ovaries. Of the individual cyclosiloxanes measured, selective retention of decamethylcyclopentasiloxane and dodecamethylcyclohexasiloxane relative to octamethylcyclotetrasiloxane was seen in all organs at all time points studied. Organs from animals receiving the linear siloxane mixture were harvested at 9, 12, and 15 weeks. ... Maximum levels in the brain, lungs, and mesenteric lymph nodes /were found/, but all other organs contained measurable levels. These data are, to the best of our knowledge, the first demonstration that after a single subcutaneous injection silicones are widely distributed throughout the body and can persist over an extended period.']","['Urine is a primary route of elimination of hexamethyldisiloxane (MM) in the form of metabolites. Accordingly, to aid in the pharmacokinetic investigations, major metabolites of MM were identified in urine collected from Fischer rats (F-344) administered (14)C-MM orally and via intravenous injection ... The structural assignments were based on GC-MS analysis of the tetrahydrofuran or methylene chloride extracts of urine containing the metabolites. Some of the metabolites in the extract required protection with trimethylsilyl groups prior to GC-MS analysis using bis(trimethylsilyl)trifluoroacetamide or highly purified hexamethyldisiloxane ... The following are among the major metabolites identified: Me2Si(OH)2; HOMe2SiCH2OH; HOCH2Me2SiOSiMe2CH2OH (predominant); HOCH2Me2SiOSiMe3; HOMe2SiOSiMe3; Me3SiOH. Besides these there were also three other metabolites- HOMe2SiOSiMe2CH2OH, 2,2,5,5- tetramethyl-2,5-disila-1,3-dioxalane and 2,2,5,5-tetramethyl-1,4-dioxa-2,5- disilacyclohexane inferred from GC-MS analyses. Their presence in the HPLC metabolite profile was not established. No parent MM was present in urine. The presence of certain metabolites such as Me2Si(OH)2 and HOMe2SiCH2OH clearly established some demethylation at the silicon-methyl bonds. Metabolites of this linear siloxane are structurally different from that obtained for cyclic siloxanes (D4 and D5) except for the commonly present Me2Si(OH)2. A mechanistic pathway for the formation of the metabolites was proposed.', 'Major metabolites of hexamethyldisiloxane (MM) a... were identified in urine collected from Fischer (F-344) rats administered (14)C-MM ... orally and via intravenous injection. ... The following are among the major metabolites identified in the case of MM: Me(2)Si(OH)(2), HOMe(2)SiCH(2)OH, HOCH(2)Me(2)SiOSiMe(2)CH(2)OH, HOMe(2)SiOSiMe(2)CH(2)-OH, HOCH(2)Me(2)SiOSiMe(3), and Me(3)SiOH. No parent MM ... was present in urine. The presence of certain metabolites such as HOMe(2)SiCH(2)OH and Me(2)Si(OH)(2) in MM ... clearly established the occurrence of demethylation at the silicon-methyl bonds. Metabolites of the linear siloxane are structurally different from that obtained for cyclic siloxane except for the commonly present Me(2)Si(OH)(2). Mechanistic pathways for the formation of the metabolites were proposed.', 'Phenyltrimethylsilane given intragastrically to rats was absorbed and eliminated in urine. Three percent of total urinary activity was shown to be from hexamethyldisiloxane.']",
4764,24765,Calcium resinate,CC(C)C1=CC2=CC[C@@H]3[C@@]([C@H]2CC1)(CCC[C@@]3(C)C(=O)[O-])C.CC(C)C1=CC2=CC[C@@H]3[C@@]([C@H]2CC1)(CCC[C@@]3(C)C(=O)[O-])C.[Ca+2],,,,,,
4765,24766,Chondroitin sulfate,CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@H]1O)OS(=O)(=O)O)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O)O)O,"['Chondroitin sulfate, used with glucosamine, is indicated to alleviate pain and inflammation from primary osteoarthritis. This supplement is reported to improve joint function and slow disease progression. Osteoarthritis is characterized by progressive structural and metabolic changes in joint tissues, mainly cartilage degradation, subchondral bone sclerosis and inflammation of synovial membrane.  Studies have proposed the potential use of chondroitin sulfate as a nutraceutical in dietary supplements.']","['In clinical trials, chondroitin sulfate has been reported a significant pain relief. Some reports have shown no slow in joint damage. The effects of chondroitin sulfate have been very controversial. One of the characteristics of chondroitin is a slow onset of action with a maximal effect attained after several months. Chondroitin sulfate has been reported to have anti-inflammatory properties by reducing the synovitis and prevent proinflammatory cytokine up-regulation in arthritis models.  It is also registered an anabolic effect of chondroitin sulfate in which it induces the synthesis of hyaluronate in synovial cells, it increases type II collagen and proteoglycan synthesis.']",,"['Chondroitin sulfate is absorbed from the gastrointestinal tract. The absorbed portion reaches a ratio of 10% as unchanged chondroitin sulfate and 90% as depolymerized low-molecular-weight derivatives. This absorption depends on the sulfation status. The bioavailability of chondroitin sulfate ranges from 10-20% following oral administration. Reports have shown a consistent accumulation of the compound in joint tissue. The steady-state is attained after 3-4 days and it takes around 3-6 months to obtain the maximal effect.  After intramuscular administration of chondroitin sulfate, the peak plasma level of 3.8 mcg/ml was reached after 90 min. When given orally, the peak plasma concentration of 4.6 mcg/ml was reached after 240 min.', 'Chondroitin sulfate is excreted in the urine as intact polymers and as partial degradation products. After intramuscular administration, about 37% of the administered dose is excreted by urine during the first 24 hours as high- and low-molecular-weight derivatives.', 'After intramuscular administration of chondroitin sulfate, the apparent volume of distribution was 0.40 ml/g. When administered orally, the apparent volume of distribution changed to 0.44ml/g.']","['Chondroitin sulfate is not metabolized by cytochrome P450. Reports have indicated the presence in plasma of mono-, oligo- and polysaccharides with a molecular weight of less of 5 kDa which are derived from the partial digestion of exogenous chondroitin sulfate. The reported degradation of chondroitin sulfate seems to be very complex and led by the formation of smaller digestion derivatives of the original form.']","['The approximate half-life of chondroitin sulfate and its derivative metabolites is 15 hours. After intramuscular administration of chondroitin sulfate in humans, the elimination half-life of the chondroitin sulfate was of 275 min. When administered orally, the elimination half-life was presented at 310 min.']"
4766,24767,CID 24767,CC(C)CCOS(=O)(=O)[O-].[Na+],,,,,,
4767,24768,Sulfuric acid hydrogen isopentyl ester,CC(C)CCOS(=O)(=O)O,,,,,,
4768,24769,Hexadimethrine Bromide,CN(C)CCCCCCN(C)C.C(CBr)CBr,,,['Coagulant substances inhibiting the anticoagulant action of heparin. (See all compounds classified as Heparin Antagonists.)'],,,
4769,24770,Polyphloretin phosphate,C1=CC(=CC=C1CCC(=O)C2=C(C=C(C=C2O)O)O)O.OP(=O)(O)O,,,['Compounds that inhibit the action of prostaglandins. (See all compounds classified as Prostaglandin Antagonists.)'],,,
4770,24771,Dimethyloxosilane,C[Si](=O)C,,,,,,
4771,24772,2-Ethenylpyridin-1-ium-1-olate,C=CC1=CC=CC=[N+]1[O-],,,,,,
4772,24773,2-[2-(4-Nonylphenoxy)ethoxy]ethanol,CCCCCCCCCC1=CC=C(C=C1)OCCOCCO,,,,,,
4773,24774,Vasotocin,CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N,,,"['Drugs that stimulate contraction of the myometrium. They are used to induce LABOR, OBSTETRIC at term, to prevent or control postpartum or postabortion hemorrhage, and to assess fetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (ABORTIFACIENTS). Oxytocics used clinically include the neurohypophyseal hormone OXYTOCIN and certain prostaglandins and ergot alkaloids. (From AMA Drug Evaluations, 1994, p1157) (See all compounds classified as Oxytocics.)', 'Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)']",,,
4774,24775,"2-{2-[4-(1,1,3,3-Tetramethylbutyl)phenoxy]ethoxy}ethanol",CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCCO,,,"['Chemical substances that are destructive to spermatozoa used as topically administered vaginal contraceptives. (See all compounds classified as Spermatocidal Agents.)', 'Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties. (See all compounds classified as Detergents.)']",,,
4775,24776,Dialdehyde starch,CC(C=O)C(CC(C=O)OC)CO,,,,,,
4776,24777,Sizofiran,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)O,,,"['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)', 'Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)']",,,
4777,24778,Ammonium 2-[2-[2-[2-(4-nonylphenoxy)ethoxy]ethoxy]ethoxy]ethyl sulphate,CCCCCCCCCC1=CC=C(C=C1)OCCOCCOCCOCCOS(=O)(=O)[O-].[NH4+],,,,,,
4778,24779,2-[2-[2-[2-(4-Nonylphenoxy)ethoxy]ethoxy]ethoxy]ethyl hydrogen sulfate,CCCCCCCCCC1=CC=C(C=C1)OCCOCCOCCOCCOS(=O)(=O)O,,,,,,
4779,24780,H-DL-xiThr-DL-Lys-DL-Pro-DL-Arg-OH,CC(C(C(=O)NC(CCCCN)C(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(=O)O)N)O,,,['Biologically active substances whose activities affect or play a role in the functioning of the immune system. (See all compounds classified as Immunologic Factors.)'],,,
4780,24781,Hymexazol,CC1=CC(=O)NO1,,,,,,
4781,24782,(Dimethylamino)ethyl p-aminobenzoate,CN(C)CCOC(=O)C1=CC=C(C=C1)N,,,,,,
4782,24783,"Acetanilide, 2-fluoro-N-methyl-2',4',5'-trichloro-",CN(C1=CC(=C(C=C1Cl)Cl)Cl)C(=O)CF,,,,,,
4783,24784,"m-ACETOTOLUIDIDE, 2-FLUORO-N-METHYL-",CC1=CC(=CC=C1)N(C)C(=O)CF,,,,,,
4784,24785,"Acetamide, N-ethyl-2-fluoro-N-1-naphthyl-",CCN(C1=CC=CC2=CC=CC=C21)C(=O)CF,,,,,,
4785,24786,"Acetanilide, 2-fluoro-N-(1-naphthylmethyl)-",C1=CC=C(C=C1)N(CC2=CC=CC3=CC=CC=C32)C(=O)CF,,,,,,
4786,24787,"Acetanilide, 2,4'-difluoro-N-methyl-",CN(C1=CC=C(C=C1)F)C(=O)CF,,,,,,
4787,24788,"2,4'-Difluoro-N-(2-hydroxyethyl)acetanilide",C1=CC(=CC=C1N(CCO)C(=O)CF)F,,,,,,
4788,24789,"Acetanilide, 4'-chloro-2-fluoro-N-(2-hydroxyethyl)-",C1=CC(=CC=C1N(CCO)C(=O)CF)Cl,,,,,,
4789,24790,"Acetanilide, 2-fluoro-N-methyl-4'-nitro-",CN(C1=CC=C(C=C1)[N+](=O)[O-])C(=O)CF,,,,,,
4790,24791,"Acetanilide, N-ethyl-2-fluoro-2',4',5'-trichloro-",CCN(C1=CC(=C(C=C1Cl)Cl)Cl)C(=O)CF,,,,,,
4791,24792,"Acetamide, 2-fluoro-N-(2-hydroxyethyl)-N-1-naphthyl-",C1=CC=C2C(=C1)C=CC=C2N(CCO)C(=O)CF,,,,,,
4792,24793,2-Fluoro-N-(2-hydroxy-1-methylethyl)-N-1-naphthylacetamide,CC(CO)N(C1=CC=CC2=CC=CC=C21)C(=O)CF,,,,,,
4793,24794,"Acetamide, 2-fluoro-N-methyl-N-2-naphthyl-",CN(C1=CC2=CC=CC=C2C=C1)C(=O)CF,,,,,,
4794,24795,2-Fluoro-N-(2-hydroxy-1-methylethyl)-N-2-naphthylacetamide,CC(CO)N(C1=CC2=CC=CC=C2C=C1)C(=O)CF,,,,,,
4795,24796,CID 24796,C(C1[C@@H]2C(C([C@H](O1)O[C@@H]3C(O[C@@H](C(C3O)O)O[C@@H]4C(O[C@@H](C(C4O)O)O[C@@H]5C(O[C@@H](C(C5O)O)O[C@@H]6C(O[C@@H](C(C6O)O)O[C@@H]7C(O[C@H](O2)C(C7O)O)CO)CO)CO)CO)CO)O)O)O,,,,,,
4796,24797,Tetrakis(4-methoxyphenyl)ethylene,COC1=CC=C(C=C1)C(=C(C2=CC=C(C=C2)OC)C3=CC=C(C=C3)OC)C4=CC=C(C=C4)OC,,,,,,
4797,24798,Barium nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Ba+2],,,,,,
4798,24799,Di(2-ethylbutyl) adipate,CCC(CC)COC(=O)CCCCC(=O)OCC(CC)CC,,,,,,
4799,24800,Dusicnan kademnaty [Czech],[N+](=O)(O)[O-].[N+](=O)(O)[O-].[Cd+2],,,,,,
4800,24801,CID 24801,CC(=NCCC1=CNC2=CC=CC=C21)S,,,,,,
4801,24802,2-(Carboxymethyl)-2-hydroxybutanedioate,C(C(=O)O)C(CC(=O)[O-])(C(=O)[O-])O,,,,,,
4802,24803,3-Methoxybutanoic acid,CC(CC(=O)O)OC,,,,,,
4803,24804,Bis(alpha-methylbenzyl)amine,CC(C1=CC=CC=C1)NC(C)C2=CC=CC=C2,,,,,,
4804,24805,4-Ethyl-1-methyloctylamine,CCCCC(CC)CCC(C)N,,,,,,
4805,24806,1-(4-Methoxy-3-methylphenyl)ethanone,CC1=C(C=CC(=C1)C(=O)C)OC,,,,,,
4806,24807,Sulfur monochloride,S(SCl)Cl,,,,,,
4807,24808,Chromium chloride (CrCl3),Cl[Cr](Cl)Cl,,,,"['In rats, brain and muscle appear to have little affinity for injected chromium (III) chloride, but there is a considerable uptake by liver, spleen and bone marrow.', '... rats absorbed from 5% to 10% of radioactive trivalent chromium (as the chloride) within 5 min after it was admin by stomach intubation. The chromium retained by the rats decr from 5% to 10% at 5 min to less than 1% at 1 hr. ... most of the quickly absorbed chromium was lost via the gastrointestinal tract.', 'The excretion and whole-body retention of various (51)Cr-chromium cmpd differed greatly in ... mouse. ... 7 days after the iv dose to mice, retained (51)Cr was ... 40% of CrCl3 ... There was high uptake of ... CrCl3 in the bone marrow ...', 'The tissue levels of chromium were followed after single intraperitoneal or subcutaneous injection of 1 mmol CrCl3/kg body wt. in Swiss male mice. Blood levels were similar after both treatment modes, with half-lives of 31-41 h. Organs not directly exposed by i.p. treatment contained similar amounts in the two groups, with kidneys > lungs > heart > brain. However, after i.p. treatment peritoneal organs (liver, spleen, pancreas and testis) had 40- to 200-fold more chromium compared with s.c. Assay of subsurface liver tissue and of testes removed via the scrotum indicated infiltration of the organs, rather than surface adsorption, of peritoneal chromium. Relative chromium concentrations after i.p. treatment were liver > pancreas = spleen > testis and after s.c. liver > spleen > testis > pancreas. Thus, s.c. treatment with CrCl3 is as effective as i.p. in terms of absorption into the blood. Treatment i.p., leading to direct uptake into peritoneal organs, is an effective way to deliver high chromium doses to these organs, but does not model likely human exposure.', 'For more Absorption, Distribution and Excretion (Complete) data for Chromium (III) chloride (12 total), please visit the HSDB record page.']","['/The investigators/ studied ... the metabolism of ... chromic chloride hexahydrate in guinea pigs for ... 60 days ... after intratracheal injection of 200 ug Cr. ... 10 min after injection, 69% of the dose remained in the lungs, & only 4% was found in the blood & ... /liver, kidneys, spleen/. By 24 hr, 45% was still in the lungs, 6% was excreted in the urine, & only a very small % was found in the other tissues. The spleen was the only tissue that showed accumulation & that occurred during the 1st 48 hr. The Cr that reached the blood was found in greater amt in the plasma than in the cells ... at the end of 30 days, 30% of Cr3+ was still in the lungs ... at 60 days ... 12% ... /Chromic chloride hexahydrate/']","['The tissue levels of chromium were followed after single intraperitoneal or subcutaneous injection of 1 mmol CrCl3/kg body wt. in Swiss male mice. Blood levels were similar after both treatment modes, with half-lives of 31-41 hr. ...']"
4808,24809,Europium chloride (EuCl3),Cl[Eu](Cl)Cl,,,,,,
4809,24810,CID 24810,O.O.O.O.O.O.[Cl-].[Cl-].[Cl-].[Fe+3],,,,,,
4810,24811,Trichlorosilane,[SiH](Cl)(Cl)Cl,,,,['The substance can be absorbed into the body by inhalation of its vapor and by ingestion.'],['... Chlorosilanes will be rapidly hydrolyzed upon contact with tissue fluids to release hydrochloric acid. /Chlorosilanes/'],
4811,24812,Indium chloride (InCl3),Cl[In](Cl)Cl,,,,"['The effects of indium sesquioxide (1312432) (IS) and indium-114-trichloride (10025828) (IT) hydrolysate aerosols were studied in rats. Rats of unspecified strain were exposed to aerosols containing 2.5 milligrams per cubic meter (mg/cu m) IS or the hydrolysis products of IT at concentrations up to 0.1mg/cu m for 30 to 180 minutes. Body burdens and urinary and fecal excretion rates were studied for up to 14 days for IS and up to 6 days for the IT hydrolysate. Gross and histopathologic studies were conducted on the animals at the end of the experiment. Autoradiographs were made of lungs and bones. Absorption of the substances was essentially complete within 24 hours of exposure, and 78 percent of the unabsorbed indium was excreted within 4 days. Small but statistically significant amounts of indium were found in the liver, kidneys, and blood. Trace amounts were found in other soft tissues. Autoradiograms showed deposits of indium and phagocytosis in the lung parenchyma and indium containing particulates in the alveoli. Accumulations of indium were found in the bone lacunae. No histopathological abnormalities were seen. The authors conclude that indium tends to accumulate in soft tissues and that the transport mechanism involves solubilized particles, not solid particulates.', '/The authors/ studied the metabolism of (114)InCl3 in rats and found that more than half of the administered dose had been absorbed or excreted 4 days after intratracheal instillation, and intramuscular and subcutaneous injections. At 30 days after administration, 33-40% of the indium dose had been eliminated via feces and urine independent of the route of administration.', '/The authors/ studied (114)In administered to mice as ionic indium chloride or as colloidal hydrated indium oxide... Ionic indium chloride concentrated primarily in the kidney while colloidal indium oxide was concentrated in the liver and reticuloendothelial system 4 days after a dose sufficient to cause the death of all animals.', '/The authors/ studied the distribution of indium trichloride after intratracheal instillation of 1.3 mg/kg bw in Fischer 344 rats. The rats were killed at different time-points up to 56 days after exposure and indium content of the lungs was determined. During the first 8 days after treatment, 87% of the indium was removed from the lung. Over the following 48 days less than 10% of the indium retained at 8 days was eliminated. It was concluded that indium chloride was capable of causing severe lung damage.', 'Ionic indium is transported in the blood bound to transferrin and has been found to be cleared within 3 days from the blood of mice given an intravenous injection.']",,"['/The authors/ studied (114)In administered to mice as ionic indium chloride or as colloidal hydrated indium oxide and reported biphasic excretion patterns for both compounds, with half-life values of 1.9 and 69 days for indium chloride and 2 and 74 days for indium oxide.', 'Mice given intravenous injections of 114 indium chloride showed a biological half life of 1.9 days for the fast phase component representing about 50% of the body burden, and 69 days for the slow phase.']"
4812,24813,Phosphorus oxychloride,O=P(Cl)(Cl)Cl,,,,"['At low concentrations the free acids resulting from the hydrolysis of phosphoryl trichloride will be neutralised quickly by body fluids. The resulting phosphate and chloride ions are natural components of food and ubiquitously found in living tissues and are not expected to pose a hazard. At high concentrations, which exceed the buffer capacity of body fluids the acids will damage the tissue at the portal of entry dependent upon concentration and duration of exposure. A systemic availability of phosphoryl trichloride or the free acids is hence not expected.']",,
4813,24814,Antimony trichloride,Cl[Sb](Cl)Cl,,,,"['In rats exposed to antimony trichloride by inhalation, a large proportion of the body burden of antimony was recovered in blood. A couple of weeks after exposure about 10% of the body burden of antimony was found in blood, and this was a higher proportion than in any other organ. ... Rabbits and dogs intratracheally exposed to antimony trichloride had less than 1% of the blood antimony concentrations found in rats.', 'Inhalation exposure of rats to trivalent (124)antimony chloride showed atypical, rapid loss from lung with somewhat longer biologic half-life (100 days) in that organ after dAY 20. ... Primary sites of antimony deposition other than lung ... /were/ whole blood, spleen, heart, and other highly vascularized organs.']",,"['Inhalation exposure of rats to trivalent (124)antimony chloride showed atypical, rapid loss from lung with somewhat longer biologic half-life (100 days) in that organ after Day 20.']"
4814,24815,Iridium tetrachloride,Cl[Ir](Cl)(Cl)Cl,,,,,,
4815,24816,Silicon tetrachloride,[Si](Cl)(Cl)(Cl)Cl,,,,,,
4816,24817,Zirconium tetrachloride,Cl[Zr](Cl)(Cl)Cl,,,,"['Deposition and retention of zirconium in lung and pulmonary lymph nodes following inhalation of zirconium oxide dust are typical of that of insol substance; however, deposition of sol zirconyl chloride in lung following inhalation of zirconium tetrachloride mist was equally great and showed similar distribution in othertissues....', 'Tracer studies of oral absorption of zirconium tetrachloride with the stable chloride as carrier, show less than 0.001% of dose passed from GI tract to blood stream.']",,
4817,24818,Niobium pentachloride,Cl[Nb](Cl)(Cl)(Cl)Cl,,,,,,
4818,24819,Phosphorus pentachloride,P(Cl)(Cl)(Cl)(Cl)Cl,,,,,,
4819,24820,Cobalt(II) fluoride,F[Co]F,,,,"['... Most of the absorption takes place in the intestine. The degree of fluoride absorption correlates with its water solubility ... A second route of absorption is through the lungs ... Fluoride is distributed widely in organs and tissues but is concentrated in bone and teeth, and the skeletal burden is related to intake and age. ... The kidneys are the major site of fluoride. Small amounts of fluoride also appear in sweat, milk, and intestinal secretions; in a very hot environment, sweat can account for nearly 50% of the total fluoride excretion. /Fluorides/', 'Bone is natural ""sink"" for fluoride ... 95-96% of body burden of fluoride is in bones & teeth. ... Fluoride is gradually excreted in urine. /fluoride/', '...Experiments demonstrated that storage of fluoride in bones occurs as result of repeated exposures to concentrations that are but slightly, if at all, irritant. /Fluoride/', 'Following ingestion, soluble fluorides are rapidly absorbed from the gastrointestinal tract at least to the extent of 97%. Absorbed fluoride is distributed throughout the tissues of the body by the blood. Fluoride concentrations in soft tissues fall to pre-exposure levels within a few hours of exposure. Fluoride exchange with hydroxyl radicals of hydroxyapatite (the inorganic constituent of bone) to form fluorohydroxyapatite. Fluoride that is not retained is excreted rapidly in urine. In adults under steady state intake conditions, the urinary concentration of fluoride tends to approximate the concentration of fluoride in the drinking water. This reflects the decreasing retention of fluoride (primarily in bone) with increasing age. Under certain conditions perspiration may be an important route of fluoride excretion. The concentration of fluoride retained in bones and teeth is a function of both the concentration of fluoride intake and the duration of exposure. Periods of excessive fluoride exposure will result in increased retention in the bone. However, when the excessive exposure is eliminated, the bone fluoride concentration will decrease to a concentration that is again reflective of intake. /Fluoride/', 'Exposure to aqueous solution of cobaltous fluoride reduced wettability & free surface energy of org layers of tooth enamel & dentine from humans or whales in vitro. It is possible that effect on wettability may contribute to anticaries effect.']",,
4820,24821,Cobalt(II) nitrate hexahydrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].O.O.O.O.O.O.[Co+2],,,,,,
4821,24822,Nobelium,[No],,,,,,
4822,24823,Ozone,[O-][O+]=O,,,"['Compounds that accept electrons in an oxidation-reduction reaction. The reaction is induced by or accelerated by exposure to electromagnetic radiation in the spectrum of visible or ultraviolet light. (See all compounds classified as Oxidants, Photochemical.)']","['EXPT IN BEAGLE DOGS, RABBITS, & GUINEA PIGS INDICATE THAT MORE THAN HALF THE OZONE INHALED IS TAKEN UP BY THE NASAL & PHARYNGEAL MUCOSA, WITH EXPOSURES TO LESS THAN 2 PPM.', '... IN MONKEYS, OZONE APPEARS TO BE ABSORBED ALONG THE ENTIRE RESPIRATORY TRACT,PENETRATING DEEPLY INTO THE PERIPHERAL, NONCILIATED AIRWAYS, & CAUSING ITS MOST CONSPICUOUS LESIONS IN THE RESPIRATORY BRONCHIOLES & ALVEOLAR DUCTS.', 'Ozone deposition velocity and ozone permeance were determined for a variety of isolated plant cuticles from the adaxial leaf surfaces. Ozone deposition velocity was lower than determined with whole plants kept in darkness. It declined continuously during exposure to the gas and showed a recovery effect after an interruption of the fumigation. It incr with the moisture content of the cuticles and decr when the ozone concn in the surrounding air was raised. The deposition velocity was much higher than cuticular ozone permeance at equiv ozone concn. Due to the ozone decay in the cuticle, ozone permeance was much lower in thick than in thincuticles. Even with the most permeable cuticles, ozone uptake under natural conditions is smaller than the flux through open stomata by a factor of at least 10,000.', 'Transpiration and ozone uptake rates were measured simultaneously in sunflower (Helianthus annuus leguminosae) leaves at different stomatal openings and various ozone concn (0, 500, 1000 and 1500 nl/l). Ozone uptake rates were proportional to the ozone concn up to 1500 nl/l. During a light-induced incr in transpiration and in carbon dioxide uptake rates, the ozone uptake rate also increased. The leaf gas phase diffusion resistance (stomatal plus boundary layer) to water vapor was calculated and converted to the resistance to ozone multiplying it by the theoretical ratio of diffusion coefficients for water vapor and ozone in air (1.67). The ozone concn in intercellular air spaces calculated from the ozone uptake rate and diffusion resistance to ozone scattered around zero (0.43 to -7.55 umol/cu m). The ozone concn in intercellular air spaces was measured directly by supplying ozone to the leaf from one side and measuring the equilibrium concn above the other side and it was found to be zero. Total leaf resistance to ozone was proportional to the gas phase resistance to water vapor with a coefficient of 1.68.', 'Transfer of ozone (O3) to forests is restricted by surface and internal resistances of foliage. O3 is efficiently absorbed through stomata. A multi-layer canopy gas and radiation exchange model (Maestro) was modified to calculate air pollutant deposition. Leaf boundary layer resistances, and stomatal resistances in the model were adjusted for gas molecular diffusivity, and leaf surface resistances and internal resistances were added. By using the proper resistances, Maestro may be used to model the deposition of O3.']","['THE /SRP: REACTION/ ... OF OZONE IS MAINLY THROUGH THE OXIDATION OF LUNG LIPIDS. /SRP: OXIDATION/ REACTION PRODUCTS THAT MAY BE EXCRETED INCL MALONALDEHYDE, ETHANE, & PENTANE.']","['Oxygen 18 was used as a tracer for inhaled ozone in mice. The amount of ozone derived oxygen in the lung was determined by measuring the amount of oxygen 18 in excess of the natural abundance level which remained covalently bound to organic constituents of lung following exposure to 1 ppm ozone for up to 60 min. The rate of disappearance of ozone derived oxygen from the lung was determined by quantifying the rate of decrease of oxygen 18 in excess of the natural abundance level in lung from mice exposed to 1 ppm ozone 18 for 45 min. With exposure at 1 ppm ozone, ozone derived oxygen accumulated in lung at a rate of 4.38 pmol/mg dry weight/min. Ozone derived oxygen had a half-life in lung of about 6 hr. At least 44 pmol of ozone reacted with lung tissue every minute of exposure to 1 ppm ozone.']"
4823,24824,Tritium,[3H][3H],,,,"['Because of the low energy and short range of the beta particles, tritium does not pose an external radiation hazard; the radiation is not sufficiently energetic to pass through skin. However, tritium is readily taken into the body, presenting an internal radiation hazard.', 'When exposed to tritiated water vapor via inhalation, people will absorb 98-99% of the activity inspired through the respiratory system. Uniform distribution throughout body fluids occurs within 90 min. Also, when exposed to such an atmosphere, tritium entering the body through the total skin area will approx equal that entering the lung. Elemental tritium (T2 or HT) is much less readily assimilated. Approx 0.004% of such activity inspired is absorbed, apparently after preliminary oxidation in the lung. Negligible amt of elemental tritium are absorbed through the skin. /Tritiated water/', 'Tritium, as tritiated water, is readily absorbed into the bloodstream from the gastrointestinal tract ... and distributes as body water. /Tritiated water/', 'The /radiation/ dose to the body if tritiated material is uniformly deposited in body water is approx 190 mrem/mCi.', 'For more Absorption, Distribution and Excretion (Complete) data for TRITIUM, RADIOACTIVE (20 total), please visit the HSDB record page.']",,"['The biological half-life of tritium in the body following intake of tritiated water has been found to range from 2.4 to 18 days among 300 individuals. /Tritiated water/', 'The body excretes tritium with a biological half life of 8-14 days (10.5 day avg), which can be reduced significantly with forced fluid intake.', 'In two chronically-exposed tritium dial painters, ...effective half-lives for tritium of two separate tritium pools ranging from 21 to 26 days for the first pool and 280 to 550 days for the second pool of tritium /were reported/. ...Biological half-lives for tritium in chronically exposed tritium dial painters of 12.1 to 13.4 days /were also reported/.']"
4824,24825,Nickel fluoride,F[Ni]F,,,,,,
4825,24826,Ferric sulfate,[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[Fe+3].[Fe+3],,,,"['The bioavailability of ferrous and ferric iron following cecal infusion was compared by assessing the hemoglobin regeneration method in ileally fistulated anemic rats. Rats were fed an iron-deficient diet (8 mg Fe/kg diet) for 14 days after recovery from surgery. The anemic rats were then divided into three groups of 11 rats. Group 1 (control) was fed an iron-adequate diet (45 mg Fe/kg diet) and infused with NaCl solution (150 mM). Group 2 and 3 were fed an iron-deficient diet and infused with ferrous sulfate [Fe(II)] suspension or ferric sulfate [Fe(III)] solution (800 ppm as Fe, pH 6.8) to provide the same amount of iron as that consumed one day before by the control group. NaCl, Fe(II) and Fe(III) were infused through the fistula as two times (1000 hr and 1800 hr) for 14 days. The volume of NaCl infused was about equal to the volume of Fe(II) suspension and Fe(III) solution infused. Hemoglobin regeneration efficiency, hematocrit, plasma iron concentration, transferrin saturation, total iron-binding capacity, iron contents in organs (liver, spleen and kidney), body weight gain and food intake were almost the same among groups.']",,
4826,24827,Ethyl 2-(hydroxymethyl)acrylate,CCOC(=O)C(=C)CO,,,,,,
4827,24828,CID 24828,CNC1=NC(=O)C2=C(N1)N=CN2,,,,,,
4828,24829,Mercury bromide (Hg2Br2),Br[Hg].Br[Hg],,,,,,
4829,24830,"mercury(I) bromide, monomer",Br[Hg],,,,,,
4830,24831,Lead(II) bromide,Br[Pb]Br,,,,,,
4831,24832,"Calcium iodide, hexahydrate",O.O.O.O.O.O.[Ca+2].[I-].[I-],,,,,,
4832,24833,Thallium sulfate,[O-]S(=O)(=O)[O-].[Tl+].[Tl+],,,"['Substances used to destroy or inhibit the action of rats, mice, or other rodents. (See all compounds classified as Rodenticides.)']","['... GAVE INTRAVENOUS THALLIUM SULFATE TO A SMALL GROUP OF RATS & SIMULATED THALLIUM KINETICS ON THE BASIS OF A THREE-COMPARTMENT MODEL. ... CONCLUDED THAT A SIGNIFICANT EXCHANGE OF THALLIUM OCCURRED BETWEEN THE TISSUES & THE INTESTINAL CONTENTS ... DESCRIBED AS AN ENTERO-ENTERAL CYCLE. ... GAVE RADIOACTIVE THALLOUS NITRATE & THALLOUS SULFATE ORALLY TO 1 PT WITH METASTATIC OSTEOGENIC SARCOMA & FOUND RATE OF EXCRETION IN URINE TO BE 3.2% PER DAY OF AMOUNT REMAINING IN BODY. THALLIUM EXCRETION IN BOTH URINE & FECES MAY PERSIST FOR MANY WEEKS IN SPITE OF LOW PLASMA LEVELS IN POISONED PATIENTS.', 'FATAL CASE ... HAD INGESTED MORE THAN 3 G THALLIUM SULFATE, PROBABLY THE HIGHEST DOSE TO BE REPORTED. TISSUE CONCN (MG/KG) WERE ... MORE THAN 20: COLON & LIVER; 10-19: STOMACH, GALLBLADDER, BONE MARROW, SMALL BOWEL; 5-9: BRAIN, LUNG, ADRENAL, SPLEEN, CEREBELLUM, KIDNEY, MUSCLE, PONS, ALL IN DESCENDING ORDER.', '/AFTER IP THALLIUM SULFATE TO ADULT MICE/ HEAVY ACCUM OF TL WAS ALSO OBSERVED IN PERI- & ENDOSTEAL LAYERS OF COMPACT BONE & IN HYALINE CARTILAGE. INTESTINES SHOWED HIGH LEVEL OF TL ... HIGHEST CONCN IN MUCOSA & CONTENTS OF LARGE INTESTINE. NO EXCRETION ... VIA BILE WAS NOTICED. LYMPH NODES & FAT & LOOSE CONNECTIVE TISSUE CONTAINED VERY LITTLE TL. THE CNS SHOWED A RELATIVELY LOW LEVEL OF (204)THALLIUM, WITH ACCUMULATION MAINLY IN THE CHOROID PLEXUSES & THE MENINGES /AFTER INTRAPERITONEAL ADMIN THALLIUM SULFATE/. NO ACCUMULATION OF THALLIUM IN THE ENDOCRINE ORGANS WAS OBSERVED.', ""IN TWO GROUPS OF 3 CASES OF THALLIUM POISONING URINE OF THE FIRST AND THIRD CASES 0.14 & 0.6 PPM OF THALLIUM WAS DETECTED. THE SECOND GROUP CONSISTED OF 3 CASES: A FIVE-YR-OLD BOY, A FIVE-YR-OLD GIRL, HER THREE-YR-OLD SISTER, & A 4TH CASE WHICH PRESUMABLY INVOLVED DIABETIC COMA, BUT THE CHILD'S URINE CONTAINED 3.84 PPM OF THALLIUM. THE URINE CONTAINED 1.52 & 0.91 PPM OF THALLIUM IN THE 5TH & 6TH CASES, RESPECTIVELY. EPIDEMIOLOGICAL INVESTIGATION REVEALED THAT THALLIUM SULFATE SOLUTION (3%) HAD BEEN USED IN HOMES IN THE DISTRICT AS A RODENTICIDE."", 'For more Absorption, Distribution and Excretion (Complete) data for THALLIUM SULFATE (7 total), please visit the HSDB record page.', 'THE RAPIDITY OF ABSORPTION FROM THE GUT OF THE RAT WAS SHOWN ... /BY OBSERVATION OF/ THALLIUM IN THE URINE WITHIN 1 HOUR OF ORAL ADMIN OF THALLOUS SULFATE.', 'Of two nonfatal human cases, from skin absorption of thallium sulfate rodenticide /in the first instance urinary thallium determination was 2.4 mg/l with a time frame of more than one month since the last exposure, and in the second instance, urinary thallium of 0.5 mg/l 6 wk after last exposure followed by 0.45 mg/l found 1 wk later/. Two weeks later thallium was not detected in the urine by the method employed.', '... GAVE INTRAVENOUS THALLIUM SULFATE TO A SMALL GROUP OF RATS & SIMULATED THALLIUM KINETICS ON THE BASIS OF A THREE-COMPARTMENT MODEL. ... CONCLUDED THAT A SIGNIFICANT EXCHANGE OF THALLIUM OCCURRED BETWEEN THE TISSUES & THE INTESTINAL CONTENTS ... DESCRIBED AS AN ENTERO-ENTERAL CYCLE. ... GAVE RADIOACTIVE THALLOUS NITRATE & THALLOUS SULFATE ORALLY TO 1 PT WITH METASTATIC OSTEOGENIC SARCOMA & FOUND RATE OF EXCRETION IN URINE TO BE 3.2% PER DAY OF AMOUNT REMAINING IN BODY. THALLIUM EXCRETION IN BOTH URINE & FECES MAY PERSIST FOR MANY WEEKS IN SPITE OF LOW PLASMA LEVELS IN POISONED PATIENTS.', 'THE DISTRIBUTION OF THALLIUM WAS DETERMINED IN 57 AUTOPSIED TISSUES, INCL BLOOD, OF A PATIENT WHO HAD BEEN ORALLY ADMIN 500 mCi THALLOUS NITRATE (TlNO3) FOLLOWED BY ... 45 MG DOSES ... THALLIUM(I) SULFATE (Tl2SO4) ... UNTIL 225 MG HAD BEEN GIVEN. THE BLOOD SHOWED A RAPID RISE WITHIN 2 HR TO A LEVEL OF 3% OF THE ADMIN RADIOISOTOPE ... TO 1.6%. SOME SPECIFIC LOCALIZATION OF THALLIUM ... WAS FOUND IN THE SCALP HAIR, KIDNEYS, HEART MUSCLE, PRIMARY BONE TUMOR, AND SPLEEN, IN THAT DECREASING ORDER. ... CLOSELY FOLLOWED BY ADRENAL MEDULLA, BONE TUMOR FROM LUNG, PANCREAS, SCALP SKIN, AND LIVER, RIB MARROW, THYROID, ADRENAL CORTEX, AND PITUITARY. ... A DIFFERENT DISTRIBUTION PICTURE WAS FOUND IN THE RAT ... INJECTED WITH 23 UG TlNO3. ... 2 DAYS AFTER DOSING, THE KIDNEYS CONTAINED THE HIGHEST CONCN FOLLOWED BY THE GUT, GONADS, AND PANCREAS. ... THESE DIFFERENCES IN LOCALIZATION OF THALLIUM SUGGEST CAUTION IN TRANSLATING RESULTS OBTAINED IN ANIMALS TO MAN.', 'For more Absorption, Distribution and Excretion (Complete) data for DITHALLIUM SULFATE (6 total), please visit the HSDB record page.']",,"['BODY BURDEN AS % OF ADMIN DOSE WAS DETERMINED IN RATS FOLLOWING ADMIN OF (204)THALLIUM ... OVER A PERIOD OF 21 DAYS. BODY CLEARANCE /OCCURRED/ ... EXPONENTIALLY WITH HALFTIME 3.3 DAYS ... AT THE END OF 21 DAYS ... 1% OF ADMIN DOSE REMAINED. ... WITH BIOLOGICAL HALF-TIME OF 3.3 DAYS ... DAILY DOSING /GIVES/ AN EQUILIBRIUM ... @ 20 DAYS. /SOLUBLE THALLIUM SALTS/', 'BODY BURDEN AS % OF ADMIN DOSE WAS DETERMINED IN RATS FOLLOWING ADMIN OF (204)THALLIUM ... OVER A PERIOD OF 21 DAYS. BODY CLEARANCE /OCCURRED/ ... EXPONENTIALLY WITH HALFTIME 3.3 DAYS ... AT THE END OF 21 DAYS ... 1% OF ADMIN DOSE REMAINED. ... WITH BIOLOGICAL HALF-TIME OF 3.3 DAYS ... DAILY DOSING /GIVES/ AN EQUILIBRIUM ... @ 20 DAYS. /SOLUBLE THALLIUM SALTS/']"
4833,24834,4-Ethoxybenzaldehyde,CCOC1=CC=C(C=C1)C=O,,,,,,
4834,24835,Eugenyl formate,COC1=C(C=CC(=C1)CC=C)OC=O,,,,,,
4835,24836,CID 24836,CC1=CC(CC(=CCC1)C)OC(=O)CC(=O)C,,,,,,
4836,24837,"Hexanoic acid, (2Z)-3,7-dimethyl-2,6-octadien-1-yl ester",CCCCCC(=O)OCC=C(C)CCC=C(C)C,,,,,,
4837,24838,Hexyl 2-methylbutanoate,CCCCCCOC(=O)C(C)CC,,,,,,
4838,24839,"2,4-Dimethylsulfolene",CC1C=C(CS1(=O)=O)C,,,,,,
4839,24840,Magnesium perchlorate,[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O.[Mg+2],,,,,,
4840,24841,Hydriodic acid,I,,,,['The iodide ion is excreted in part by the bronchial glands. ... /Hydriodic acid syrup/'],,
4841,24842,Hydrazine sulfate,NN.OS(=O)(=O)O,,,"['Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)', 'Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']","['/Following/ a single ip administration to mice, 1 mmol/kg hydrazine sulfate was distributed rapidly to most tissues with highest levels appearing in kidney. Loss from all tissues was extensive by 24 hr. Within 1st 1 to 2 hr after administration of (15)N-hydrazine sulfate, approx 20% of dose was expired as (15)N and by 48 hr another 10-15% was eliminated.']","['When hydrazine sulfate (1 mmole/kg) was injected ip in the rat, approx 15% was converted to nitrogen within the first 30 min, followed by a much slower conversion during 24 hr. The highest conversion was observed with iv doses, and lowest with sc doses.', 'The enzyme systems in rat liver and lung responsible for the oxidative metabolism of hydrazine derivatives were studied to determine whether these enzymes, cytochrome p450 and monoamine oxidase, were responsible for metabolically activating hydrazines to carcinogenic/toxic metabolites. Cytochrome p450 preferentially oxidized the nitrogen to nitrogen bond of 1,2-disubstituted hydrazines and hydrazides, while monoamine oxidase oxidized the nitrogen to nitrogen bond of all the classes of hydrazine derivatives that were tested. Oxidation of the nitrogen to nitrogen bond led to the formation of stable azo intermediates in the case of 1,2-disubstituted hydrazines and to unstable monoazo (diazene) metabolites in the case of monosubstituted hydrazines and hydrazides. /Substituted hydrazines/']",
4842,24843,Magnesium sulfate heptahydrate,O.O.O.O.O.O.O.[O-]S(=O)(=O)[O-].[Mg+2],,,,,,
4843,24844,"Calcium chloride, dihydrate",O.O.[Cl-].[Cl-].[Ca+2],,,,,,
4844,24845,Tetrafluorohydrazine,N(N(F)F)(F)F,,,,,,
4845,24846,Hydroxylammonium sulfate,[NH3+]O.[NH3+]O.[O-]S(=O)(=O)[O-],,,,,,
4846,24847,2-Propyl-1-heptanol,CCCCCC(CCC)CO,,,,,,
4847,24848,Strontium nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Sr+2],,,,"['THE ACCUMULATION & DISTRIBUTION OF (89)STRONTIUM CONTAMINATED WITH STRONTIUM NITRATE SOLUTION WERE DETERMINED IN 4 WK-OLD PIGS. STRONTIUM ACCUMULATES IN SKIN BUT PENETRATES MUCH DEEPER IN NOTICEABLE QUANTITY.', 'ORALLY ADMIN STRONTIUM NITRATE ACCUMULATED IN SKELETON OF RATS IN PROPORTION TO DOSE, AS DETERMINED IN 4- & 8-WK FEEDING TESTS. SKELETAL STORAGE AVERAGED 2.7% OF DOSE, & THE PERCENTAGE WAS UNINFLUENCED BY SEX OR AGE OR BY LEVEL FED FROM 30-1030 PPM STRONTIUM NITRATE. YOUNG (6-WK) RATS HAD 7.7 PPM STRONTIUM IN BONE ASH BEFORE ADMIN OF STRONTIUM; ADULTS HAD 11.8 PPM. THE BONE RETENTION FACTOR ... (NUMBER OF SR ATOMS/1000 CALCIUM ATOMS DIVIDED BY THE SAME RATIO FOR THE DIET), AVERAGED 0.20, INDICATING A PREFERENTIAL RETENTION OF CALCIUM TO THAT OF STRONTIUM.', 'STEP-SCAN SCINTIMETRY OF THE SACROILIAC JOINTS AND SPINE WAS PERFORMED IN PATIENTS WITH ESTABLISHED OR SUSPECTED ANKYLOSING SPONDYLITIS 2 WEEKS AFTER INJECTION OF 100 MICROCURIES OF RADIOACTIVE STRONTIUM NITRATE (85). STRONTIUM UPTAKE OF (85) STRONTIUM WAS HIGH IN CASES WITH EARLY ROENTGENOGRAPHIC CHANGES OF THE SACROILIAC JOINTS AND MINIMAL SPINAL INVOLVEMENT.']",['TRANSFORMATION OF NITRATE TO NITRITE USUALLY OCCURS WITHIN ALIMENTARY TRACT. NITRITE IS AN INTERMEDIARY PRODUCT IN REDUCTION OF NITRATE TO AMMONIA WITHIN THE RUMEN OF SHEEP & COW ... /NITRATES & NITRITES/'],
4848,24849,CID 24849,C(C(=O)O)N(CC(=O)O)CC(=O)[O-].[Na+],,,,,,
4849,24850,Aluminum Sulfate,[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[Al+3].[Al+3],"['Solutions containing 5 to 10% aluminum sulfate have been used as local applications to ulcers and to arrest foul discharges from mucous surfaces. Aluminum sulfate is also used in the preparation of aluminum acetate ear drops.  It is often purchased over the counter and is available in solid stick or powder form for minor cuts and abrasions after shaving,. Aluminum sulfate is also used as an adjuvant in vaccines.']","['Aluminum sulfate may be used as a deodorant, as well as an astringent. Aluminum sulfate is also known as an astringent. Astringents are substances that cause contraction or shrinkage of tissues and that dry up secretion.  Used as a post-shaving treatment, it can eliminate bleeding from superficial wounds,.     It has also shown in vitro anti-microbial activity.']","['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)']","['The degree of aluminum absorption depends on a number of factors, such as the aluminum salt ingested, pH (for aluminum speciation and solubility), bioavailability, as well as dietary conditions.   These facts should be taken into consideration during tissue dosimetry and response assessment to aluminum sulfate. It can be concluded that the use of currently available animal studies to develop a guideline value is inappropriate at this time  due to the above specific toxicokinetic/dynamic factors that may affect results.', 'Aluminum is excreted predominantly via the kidneys and therefore may accumulate in patients with renal failure. About 2% is excreted in bile.', 'Aluminium which is absorbed is located primarily in the heart, spleen, and bone.', 'In mammals GI absorption of ingested aluminum is poor due to transformation of aluminum salts into insoluble aluminum phosphate (AlPO4) in digestive tract, brought about by pH changes and presence of phosphate in diet. At higher doses, such as 200 mg aluminum/kg as aluminum sulfate, intestinal absorption is about 10% in rats ... .', '... No increases in urinary excretion of aluminum or in aluminum deposition in organs of rats when twice normal aluminum concentration was given as ... sulfate in food. When concentration was increased to about 15 times normal, both urinary excretion and organ deposition were enhanced.', 'In rats retention of aluminum in bone, liver, and testes ... increased with large ingested doses such as 200 mg aluminum/kg in the form of aluminum sulfate ... Level in brains of ... rats increased /SRP: to a level/ tenfold that of control. ... Excretion is mainly fecal, representing both unabsorbed ... and aluminum excreted into digestive tract from liver via bile.', 'Spring wheat plants (Triticum aestivum (L.) cvs. Kadt and WW 20299) were grown in culture and exposed to aluminum as aluminum sulfate. Aluminum uptake by roots of 9-day old plants at pH= 4.1 during 2 hr (initial uptake) could be divided into a free diffusible component and a bound fraction which was non-exchangeable with calcium. Two types of aluminum binding sites were identified: one insensitive to low temp (2 Â°C) and one existing only at 22 Â°C. At 2 Â°C and 200 uM aluminum, uptake reached approx 1.2 umol aluminum/g fresh wt within 50 min and remained at this level. At 22 Â°C, aluminum uptake did not reach equilibrium within 150 min and was characterized by a rapid uptake (0.50 umol aluminum/g fresh wt) for less than 20 min, followed by another phase at 0.19 umol Aluminum/g fresh wt/hr. The initial uptake of aluminum increased under conditions which favored leakage of phosphorus from the roots; uptake of aluminum from 50 uM aluminum was about twice as high in high phosphorus plants compared to low phosphorus plants. With 1X10-4 dinitrophenol present in the external soln, aluminum uptake increased by approx 70% at 150 and 250 uM aluminum and by approx 25% at 50 uM aluminum in both cultivars.', 'For more Absorption, Distribution and Excretion (Complete) data for ALUMINUM SULFATE (9 total), please visit the HSDB record page.']",,"['Numerous studies have actually shown that the rate of aluminum clearance in the blood decreases with time following aluminum ingestion, and therefore a single elimination half-life (t1â2) cannot depict the whole-body elimination of aluminum.']"
4850,24851,"2,3-Bis(2,3-epoxypropoxy)-1,4-dioxane",C1COC(C(O1)OCC2CO2)OCC3CO3,,,,,,
4851,24852,"1,2,4-Butanetricarboxylic acid, tri(2-ethylhexyl) ester",CCCCC(CC)COC(=O)CCC(CC(=O)OCC(CC)CCCC)C(=O)OCC(CC)CCCC,,,,,,
4852,24853,Terbium nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Tb+3],,,,,,
4853,24854,Calplus,[Cl-].[Cl-].[Ca+2],,,,,,
4854,24855,Iodine 131,[131I][131I],,,,,,
4855,24856,Aluminum potassium sulfate,[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[Al+3].[K+],"['Potassium alum is considered safe by the FDA and its use is in homepathic or OTC products. Due to its presence in several different drugs, the main indications for the use of potassium alum are:  -Constipation -Cosmetic or drug astringent, helping the shrinkage of tissues and the dry of secretions -Oral health care drug -Part of formulation in cleansing products, skin-care products, mosturizers, face powders and deodorants -Antiperspirant -Antifungal']","['The presence of potassium alum reduces swollen mucous membranes that result from inflammation of the nasal, gastrointestinal and urinary passages as well as in the presence of excessive secretions. The induction of the coagulation cascade will also stop bleeding.']","['Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund&apos;s adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)']","['Potassium alum is found in its dodecahydrate form that produces a very large molecule. This large molecule cannot be absorbed through the skin when this substance is included as an astringent agent in topical OTC. If ingested, the aluminum salts are rapidly solubilized in the stomach and then they can generate aluminum hydroxide or poorly absorbed basic aluminum salts.', 'When potassium alum is absorbed, the kidney is responsible for the elimination of the major portion of the absorbed dose. From the excretion, 0.1-0.3% of the absorbed dose is eliminated via the urine.', 'The distribution of aluminum salts in the body is influenced by increased concentrations of parathyroid hormone. It was shown, in preclinical studies, that oral administration of aluminum salts produces a distribution profile that forms deposits in kidneys, muscle, bone and gray matter.', 'Renal clearance of aluminum is approximately 5-10% of the excretion of urea or creatinine. The reduced clearance of aluminum compounds is due to the high protein binding.']","['Potassium alum does not go through a metabolic pathway. When ingested or absorbed, it will get rapidly dissolved and it will form ions that will later generate other salt derivatives.']",['Studies performed with aluminum compounds have shown a half-life of 4.5 h when administered intravenously.']
4856,24857,Radon,[Rn],,,"['Pollutants present in air which exhibit radioactivity. (See all compounds classified as Air Pollutants, Radioactive.)', 'Carcinogenic substances that are found in the environment. (See all compounds classified as Carcinogens, Environmental.)']","['Gases and vapors known to be absorbed (or excreted) by the skin include ... radon ... .', 'The presence of radon is associated with an increase in the occurrence of lung cancer due to the deposition of radioactive substances in the bronchial region.', 'Following ingestion of radon dissolved in water, greater than 90% of the absorbed radon was eliminated by exhalation within 100 minutes. By 600 minutes, only 1% of the absorbed amount remained in the body.', 'Experiments in animals have reported the retention of radon after exposure by the intraperitoneal and intravenous routes. After intravenous administration , 1.6% to 5.0% of the administered activity was retained in the animals after 120 minutes. Retention was greatest after intraperitoneal administration at 120 minutes, but by 240 minutes it was nearly the same for both routes of administration.', 'For more Absorption, Distribution and Excretion (Complete) data for Radon, radioactive (14 total), please visit the HSDB record page.']",,
4857,24858,2-(2-Methylprop-2-enyl)guanidine,CC(=C)CN=C(N)N,,,,,,
4858,24859,"Benzimidazole, 5,6-dichloro-2-nitro-",C1=C2C(=CC(=C1Cl)Cl)N=C(N2)[N+](=O)[O-],,,,,,
4859,24860,"Benzimidazole, 5-methoxy-2-nitro-",COC1=CC2=C(C=C1)N=C(N2)[N+](=O)[O-],,,,,,
4860,24861,Ferric phosphate,[O-]P(=O)([O-])[O-].[Fe+3],,,,,,
4861,24862,Ferric sodium pyrophosphate,[O-]P(=O)([O-])OP(=O)([O-])[O-].[Na+].[Fe+3],,,,,,
4862,24863,Ferrous ammonium sulfate,[NH4+].[NH4+].[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[Fe+2],,,,['The pharmacokinetics and bioavailability of iron following the oral administration of Vitaferro to normal and anemic women in their second half of pregnancy and to nonpregnant women are described. In all pregnant probands the bioavailability of the drug was about twice as high as in nonpregnant women. The parameters of elimination refer to an enhanced retention of iron during pregnancy. The drug was well resorbed and did not cause incompatibilities.'],,
4863,24864,Mercuric nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Hg+2],,,,"['FETAL UPTAKE OF METHYL MERCURY WAS GREATER THAN OF MERCURIC NITRATE AT 15 & 20 DAYS OF GESTATION. DECIDUAL TISSUE UPTAKE WAS LOW & CONSTANT FOR BOTH, YOLK SAC TOOK UP HIGHER % MERCURIC NITRATE THAN METHYL MERCURY.', '(2O3)HG-MERCURIC NITRATE WAS ADMIN TO PREGNANT HAMSTERS EARLY ON 8TH GESTATON DAY. SIGNIFICANT CONCN OF HG MEASURED 24 & 96 HR AFTER INJECTION WAS FOUND IN MATERNAL, PLACENTAL, & EMBRYONIC TISSUES.']",,"['BIOLOGICAL HALF-LIVES & ELIMINATION FROM BACTERIAL CELLS, MOSQUITO LARVAE, & GUPPIES ARE DISCUSSED FOR MERCURY COMPOUNDS INCL MERCURIC NITRATE WITH RESPECT TO TEMP, TIME, AND BUFFER & WATER CELL WASHES. HALF-LIFE DECR WHEN TEMP INCR.', 'IN FEMALE FISH (POECILIA RETICULATA) ACCUMULATION RATES OF MERCURY FROM MERCURIC NITRATE OR METHYL MERCURY CHLORIDE IN DEIONIZED WATER AT 0.1-20 NG HG/ML INCR WITH INCR HG CONCN & DECR IN PRESENCE OF COMPLEXING AGENTS. RELEASE OF MERCURIC NITRATE FROM FISH OCCURRED IN 2 STEPS WITH HALF-LIFE OF 4.2 & 67.7 DAYS. THE MERCURY RELEASED FROM MERCURIC NITRATE EXPOSED FISH IN THE 2ND STEP INCREASED WITH INCREASING EXPOSURE TIME & REPRESENTS MERCURY CONVERTED TO METHYL MERCURY IN THE FISH.']"
4864,24865,CID 24865,[137CsH],,,,,,
4865,24866,"Ammonium, N-(9,10-dihydro-9,10-ethanoanthracen-11-yl)-N,N,N',N',N'-pentamethyl-N,N'-ethylenedi-, diiodide",C[N+](C)(C)CC[N+](C)(C)C1CC2C3=CC=CC=C3C1C4=CC=CC=C24.[I-].[I-],,,,,,
4866,24867,"Dimethyl-(15-tetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaenyl)-[2-(trimethylazaniumyl)ethyl]azanium",C[N+](C)(C)CC[N+](C)(C)C1CC2C3=CC=CC=C3C1C4=CC=CC=C24,,,,,,
4867,24868,CID 24868,COC1=C2C(=C3C(=O)C=CC=C3OC2=C4C5C=COC5OC4=C1)O,,,,,,
4868,24869,5-Hydroxy-2-hexenoic acid lactone,CC1CC=CC(=O)O1,,,,,,
4869,24870,Chlorine dioxide,O=Cl[O],,,"['Chemicals especially for use on instruments to destroy pathogenic organisms. (Boucher, Clinical Dental Terminology, 4th ed) (See all compounds classified as Dental Disinfectants.)']","['The distribution and chemical fate of (36)Cl-ClO2 gas subsequent to fumigation of tomatoes or cantaloupe was investigated as were major factors that affect the formation of chloroxyanion byproducts. Approximately 22% of the generated (36)Cl-ClO2 was present on fumigated tomatoes after a 2 hr exposure to approximately 5 mg of (36)Cl-ClO2. A water rinse removed 14% of the radiochlorine while tomato homogenate contained approximately 63% of the tomato radioactivity; 24% of the radiochlorine was present in the tomato stem scar area. Radioactivity in tomato homogenate consisted of (36)Cl-chloride (>/= 80%), (36)Cl-chlorate (5 to 19%), and perchlorate (0.5 to 1.4%). In cantaloupe, 55% of the generated (36)Cl-ClO2 was present on melons fumigated with 100 mg of (36)Cl-ClO2 for a 2 hr period. Edible cantaloupe flesh contained no detectable radioactive residue (LOQ = 0.3 to 0.4 ug/g); >99.9% of radioactivity associated with cantaloupe was on the inedible rind, with <0.1% associated with the seed bed. Rind radioactivity was present as (36)Cl-chloride (approximately 86%), chlorate (approximately 13%), and perchlorate (approximately 0.6%). Absent from tomatoes and cantaloupe were (36)Cl-chlorite residues. Follow-up studies have shown that chlorate and perchlorate formation can be completely eliminated by protecting fumigation chambers from light sources.', 'After oral administration of Alcide (sodium chlorite and lactic acid) in rats, the peak plasma level was obtained in 8 hr. At 144 hr, radioactivity was highest in plasma followed by lung, kidney, skin, bone marrow, stomach, ovary, duodenum, ileum, spleen, fat, brain, liver, and carcass. Subcellular distribution revealed that 85% of the activity in the liver homogenate resided in the cytosol. 70% of total activity in plasma was located in the trichloroacetic acid supernatant, with 30% bound to the precipitated protein fraction. Urinary excretion accounted for most of the (36)chlorine eliminated.', 'One study shows that ""chlorine"" (chemical form not characterized) derived from aqueous chlorine dioxide is absorbed by the oral route, with a wide distribution and rapid and extensive elimination. In this study, groups of four rats received a single oral gavage dose of approximately 1.5 or 4.5 mg 36ClO2/kg body weight. Blood samples were collected for up to 48 hr post-administration, and at 72 hr, animals were killed, with samples taken from kidneys, lungs, small intestine, liver, spleen, thymus, bone marrow, and testes. 36Cl was found in all tissues except testes, skin, and the remaining carcass, although levels in these tissues each accounted for less than 1% of the administered dose.', 'About 40% of /a single  dose of/ 36Cl was recovered in urine, expired air, and feces, although the urine accounted for most (about 30%).', 'For more Absorption, Distribution and Excretion (Complete) data for Chlorine dioxide (6 total), please visit the HSDB record page.']","['Both chlorine dioxide and chlorite are primarily metabolized to chloride ion. At 72 hours following single oral (gavage) administration of radiolabeled chlorine dioxide in rats, chloride ion accounted for approximately 87% of the radioactivity that had been collected in the urine and 80% of the radioactivity in a plasma sample. Chlorite was the other major metabolite, accounting for approximately 11 and 21% of the radioactivity in the urine and plasma samples, respectively. Chlorate was a minor component of the radioactivity in the urine. Similarly, chloride ion accounted for approximately 85% of the radioactivity in the 72-hour urine collection of rats that had been orally administered radiolabeled chlorite; the remainder in the form of chlorite.']","['After oral administration of Alcide (sodium chlorite and lactic acid) in rats, the peak plasma level was obtained in 8 hr. The half-life for (36)Cl absorption from plasma was 8.03 hr, while the half life for (36)Cl elimination from plasma was 48.02 hr.', 'Following single gavage dosing of rats with (36)ClO2 ... peak plasma levels of (36)Cl were reached within 2 hours following dosing ... the absorption rate constant and half-time were 0.198/hour and 3.5 hours, respectively.']"
4870,24871,Chromium chloride (CrCl2),Cl[Cr]Cl,,,,,,
4871,24872,Rhodium trichloride,Cl[Rh](Cl)Cl,,,,,,
4872,24873,sec-Butylammonium chloride,CCC(C)[NH3+].[Cl-],,,,,,
4873,24874,Sec-butylamine,CCC(C)N,,,,,,
4874,24875,"13,16-Dithiaoctacosane",CCCCCCCCCCCCSCCSCCCCCCCCCCCC,,,,,,
4875,24876,CID 24876,CCCCCC(=O)[O-].[Na+],,,,,,
4876,24877,Ferric pyrophosphate,[O-]P(=O)([O-])OP(=O)([O-])[O-].[O-]P(=O)([O-])OP(=O)([O-])[O-].[O-]P(=O)([O-])OP(=O)([O-])[O-].[Fe+3].[Fe+3].[Fe+3].[Fe+3],"[""Ferric pyrophosphate is intended to be indicated for the treatment of iron loss or iron deficiency as a formulation with a milder gastrointestinal effect.   Iron deficiency appears when the dietary intake does not meet the body's requirement or when there is chronic external blood loss. During acute blood loss, body iron stores are sufficient for accelerated erythropoiesis and restoration of iron homeostasis. But when the altered homeostasis remains for weeks to months then some supplement is needed. Some causes of iron deficiency include ectoparasitism, endoparasitism, hematuria, epistaxis, hemorrhagic skin, coagulopathy, thrombocytopenia, thrombocytopathia and gastrointestinal hemorrhage.""]","['Iron supplementation typically results in increases in serum iron, transferrin-bound iron, and iron-stored in the form of ferritin in hepatocytes and macrophages. The available iron is usually used in bone marrow for the synthesis of hemoglobin.']",,"['...The aim of the present studies was to compare Fe absorption of micronised, dispersible ferric pyrophosphate (Sunactive Fe trade mark ) with that of ferrous sulfate in an infant cereal and a yogurt drink. Two separate Fe absorption studies were made in adult women (10 women/study). Fe absorption was based on the erythrocyte incorporation of stable isotopes ((57)Fe and (58)Fe) 14 days after the intake of labelled test meals of infant cereal (study 1) or yogurt drink (study 2). Each test meal was fortified with 5 mg Fe as ferrous sulfate or micronised, dispersible ferric pyrophosphate. Results are presented as geometric means. There was no statistically significant difference between Fe absorption from micronised, dispersible ferric pyrophosphate- and ferrous sulfate-fortified infant cereal (3.4 and 4.1% respectively; P=0.24) and yogurt drink (3.9 and 4.2% respectively; P=0.72).']",,
4877,24878,"Ammonium, N-(9,10-dihydro-9,10-ethanoanthracen-11-ylmethyl)-N,N,N',N',N'-pentamethyl-N,N'-ethylenedi-, diiodide",C[N+](C)(C)CC[N+](C)(C)CC1CC2C3=CC=CC=C3C1C4=CC=CC=C24.[I-].[I-],,,,,,
4878,24879,"Dimethyl-(15-tetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaenylmethyl)-[2-(trimethylazaniumyl)ethyl]azanium",C[N+](C)(C)CC[N+](C)(C)CC1CC2C3=CC=CC=C3C1C4=CC=CC=C24,,,,,,
4879,24880,"2-Naphthol, 7,8-dihydro-6-phenyl-5-(p-(2-piperidinoethoxy)phenyl)-, hydrochloride",C1CC[NH+](CC1)CCOC2=CC=C(C=C2)C3=C(CCC4=C3C=CC(=C4)O)C5=CC=CC=C5.[Cl-],,,,,,
4880,24881,"6-Phenyl-5-[4-(2-piperidin-1-ylethoxy)phenyl]-7,8-dihydronaphthalen-2-ol",C1CCN(CC1)CCOC2=CC=C(C=C2)C3=C(CCC4=C3C=CC(=C4)O)C5=CC=CC=C5,,,,,,
4881,24882,"6-Methoxy-1-phenyl-2-(3-pyridyl)-1,2,3,4-tetrahydro-1-naphthol",COC1=CC2=C(C=C1)C(C(CC2)C3=CN=CC=C3)(C4=CC=CC=C4)O,,,,,,
4882,24883,"1,3-Dichloropropene",C(C=CCl)Cl,,,"['Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['Inhalation studies with both humans and rats have shown that dichloropropene (DCP) is readily absorbed, conjugated with glutathione (GSH) via glutathione S-transferase (GST), and rapidly excreted in the urine as N-acetyl-S-(cis-3-chloroprop-2-enyl)-cysteine (3CNAC), a mercapturic acid metabolite. A study of six male volunteers exposed at 1 ppm commercial Telone II (50.6% cis-isomer, 45.2% trans-isomer) for 6 hours found the absorption of cis-DCP was 72% to 80%, while the absorption of trans-DCP was 77% to 82%. A similar percent absorption was found in rats exposed at 136 mg/cu m DCP for 3 hours. DCP does not bioaccumulate in the body. Half-lives were similar for both rats and humans for removal from the blood and for excretion of mercapturic acid metabolites. /A study/ found that the concentration of DCP in expired air and concentration in blood plateaued in the first hour of exposure and declined rapidly postexposure to nondetectable levels in less than an hour. A urinary excretion half-life of approximately 5.5 hours for DCP in rats and mice was calculated. Radio-labeled DCP, when dosed orally in rats, yielded 82% to 84% of the radioactivity in the urine within 24 hours after treatment. Most of this (14)C (92%) was present as N-acetyl-S-((Z), 3-chloroprop-2-enyl) cysteine (Z)-DCP mercapturic acid). Within 4 days, about 1% of the dose of each isomer was found in the carcass.', '... /Some/ studies have concluded that urine collection during and after exposure may be representative of exposure to dichloropropene (DCP). Urinary excretion of thioethers was measured in 12 applicators occupationally exposed to DCP and was compared to excretion of the mercapturic acid metabolites. The 8-hour time weighted average exposures to the Z-isomer and the E-isomer of DCP ranged from 0.3 to 18.9 mg/cu m over 1- to 11-hour shifts. Cumulative urinary thioether excretions and urinary postshift levels minus preshift levels correlated well with DCP exposures. Mean urinary thioether concentrations were 1.38-fold greater than the mean DCP mercapturic acid metabolite concentration, suggesting the presence of an unidentified thioether metabolite. The thioether assay correlated well with relatively high DCP exposures.', 'Studies conducted on occupational and non-occupational exposure to dichloropropene (DCP) in the Dutch flower bulb culture industry found a strong correlation between inhalation exposure and the complete cumulative urinary excretion of the mercapturic acids of DCP. A possible subclinical nephrotoxic effect of subchronic DCP exposure was noted. There was a notable decrease of glutathione and GST activity in blood, suggesting that DCP exposure may affect the glutathione conjugating capacity.', 'In /a/ personal air monitoring study of 15 applicators of dichloropropene (DCP), excretion of the DCP metabolite, 3CNAC, and excretion of the renal tubular enzyme, NAG [N-acetyl glucosaminidase], were studied. Four workers had clinically elevated NAG in all of their urine collections after baseline. Nine workers showed greater than 25% increases in NAG excretion when compared to baseline. Dichloropropene air exposure products of >700 mg/min/cu m or excretion of >1.5 mg 3CNAC/day distinguished abnormally high daily excretion of NAG. These data indicate a positive relationship between air exposure and internal exposure and a possible subclinical nephrotoxic effect in workers. In a subsequent study using these same urine samples collected during five consecutive 6- to 8-hour intervals and stored frozen for 4 years, /the authors/ analyzed the samples for albumin and retinal binding protein (RBP). Urinary excretion of albumin and RBP during the second through fifth collection intervals was not significantly increased relative to the baseline period after correction for creatinine. Within each interval, excretion of albumin and RBP was significantly correlated with each other and the 3CNAC concentrations. NAG excretion was slightly increased in nine subjects. When the 3CNAC excretion data were dichotomized into subjects excreting less than and more than 1.5 mg/day, which corresponded to low and high DCP exposures, urinary excretion of NAG and RBP was significantly lower in the low exposure than in the high exposure group. Urinary albumin excretion was similar in both groups. Urinary excretion of RBP and albumin during the baseline period correlated best with 24 hours cumulative excretion of these proteins as indicated by logistic regression analysis. Excretion of NAG during the afternoon shift correlated best with 24-hour cumulative NAG excretion. Urinary 3CNAC excretion during the next morning correlated best with its 24-hour cumulative excretion. The conclusion made was that under the conditions used by pesticide applicators, DCP has only a slight effect on the kidney.', 'For more Absorption, Distribution and Excretion (Complete) data for 1,3-DICHLOROPROPENE (12 total), please visit the HSDB record page.']","['Studies of hepatic toxicity in mice suggest that ingested 1,3-dichloropropene is biotransformed via cytochrome P-450, with metabolites inducing liver damage, and that glutathione plays an important role in the detoxification of 1,3-dichloropropene.', 'The major urinary metabolite in rats given 1,3-dichloro-2-propene was a mercapturic acid.', '(14)C-1,3-dichloropropene ((14)C-DCP) is rapidly absorbed and eliminated in both the male F344 rat and B6C3F1 mouse following oral administration of 1 or 50 mg/kg (rat) or 1 or 100 mg/kg (mouse). It is extensively metabolized in both species. Urinary excretion was the major route of elimination, accounting for 50.9-61.3 and 62.5-78.6% of the administered dose in rat and mouse, respectively. Urinary elimination half-lives ranged from 5 to 6 hr (rat) and from 7 to 10 hr (mouse). Elimination via feces or as (14)CO2 accounted for 14.5-20.5 and 13.7-17.6% of the administered dose, respectively. Metabolites arising from glutathione conjugation account for 36-55 and 48-50% of the administered dose in excreted from rats and mice, respectively. Hydrolysis of the 3-chloro moiety of DCP accounted for 24-37 and 29% of the dose administered to rats and mice, respectively. Two novel dimercapturic acid conjugates were also identified at low levels that might arise via initial hydrolysis of DCP or of epoxidation of DCP-glutathione conjugate or of DCP itself. Structural confirmation of these dimercapturates was obtained via analysis of deuterium retention from D4-DCP in the male F344 rat. Only quantitative differences are seen between the overall metabolic profile of DCP in these two species.', '1,3-Dichloropropene (1,3-DCP) is used as a soil nematocide worldwide. Technical grade 1,3-DCP is genotoxic/mutagenic and carcinogenic. /A previous study/ reported that mutagenic activity is lost after purification of 1,3-DCP samples via silica gel column chromatography. We found that mutagenicity and SOS repair in Escherichia coli, strain PM 21, are strongly reduced after purification via silica gel and that mutagenicity and induction of SOS repair depend on oxidative impurities and secondary products. Both isomers (E and Z) of 1,3-DCP are oxidized to 1,3-dichloropropene epoxide (1,3-DCP-Ox). The epoxide is subjected to rapid internal rearrangement to 2,3-dichloropropanal (2,3-DCPA), which spontaneously eliminates HCl and forms the extremely mutagenic, genotoxic, and carcinogenic 2-chloroacrolein (alpha-chloroacrolein) alpha-ClA. Thus, the genotoxic/mutagenic effects of unpurified 1,3-DCP samples mainly depend on alpha-ClA. The underlying genotoxic and mutagenic mechanism is formation of promutagenic exocyclic 1,N(2)-propanodeoxyguanosine adducts of alpha-ClA. Pure 1,3-DCP samples have only a very low S(N)1 reactivity as measured in trifluoroacetic acid solvolysis reactions, hydrolysis, and computed reactivities but possess a moderate S(N)2 reactivity as determined in alkylation tests with the nucleophiles 4-(p-nitrobenzyl)pyridine (NBP) and N-methyl-mercaptoimidazole (MMI). Evidently, the low S(N)1 reactivity is not sufficient to form necessary amounts of O(6)-alkylguanine DNA adducts required for back-mutation in Salmonella typhimurium strain TA1535. The S(N)2 reactivity may, however, lead to other DNA adducts, e.g., N7-guanine adducts, which can induce error prone repair in S. typhimurium strain TA100 and thus lead to back-mutation in this strain. Application of 1,3-DCP samples in agriculture must be considered as a mutagenic risk because the samples can be oxidized and form the extremely mutagenic alpha-ClA. As a consequence, it is questionable whether any stabilizers can prevent oxidation during application.', 'For more Metabolism/Metabolites (Complete) data for 1,3-DICHLOROPROPENE (12 total), please visit the HSDB record page.']","['Whole body: 1-2 days; [TDR, p. 518]', 'A urinary excretion half-life of approximately 5.5 hours for DCP in rats and mice was calculated.', 'In rats, the initial elimination half-life for 1,3-dichloropropene in blood ranged from 3 to 27 minutes depending on dose. 1,3-Dichloropropene mercapturic acid metabolites have urinary elimination half-lives of approximately 5 hours.', '(14)C-1,3-dichloropropene ((14)C-DCP) is rapidly absorbed and eliminated in both the male F344 rat and B6C3F1 mouse following oral administration of 1 or 50 mg/kg (rat) or 1 or 100 mg/kg (mouse). It is extensively metabolized in both species. Urinary excretion was the major route of elimination, accounting for 50.9-61.3 and 62.5-78.6% of the administered dose in rat and mouse, respectively. Urinary elimination half-lives ranged from 5 to 6 hr (rat) and from 7 to 10 hr (mouse). ...', 'Following absorption, both isomers of 1,3-dichloropropene were, at less than or equal to 300 ppm exposure levels, rapidly eliminated from the bloodstream (3-6 min half-life). In addition, data obtained in rats exposed to 300 ppm 1,3-dichloropropene revealed that this rapid elimination phase was followed by a slower elimination phase having a 33-34 min half-life. Rats exposed to 900 ppm vapors also eliminated 1,3-dichloropropene in a biphasic manner; however, in this case the blood half-life of 1,3-dichloropropene during the initial phase of excretion was 14 to 27 min.']"
4883,24884,1-(4-Nitrophenyl)ethyl nitrate,CC(C1=CC=C(C=C1)[N+](=O)[O-])O[N+](=O)[O-],,,,,,
4884,24885,Asaphan,CCOC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC2=CC=C(C=C2)N(CCCl)CCCl)NC(=O)C,,,,,,
4885,24886,"Ammonium, diethyl(4-hydroxybutyl)methyl-, iodide, ester with (cis-1,2,cis-1,3,trans-1,4)-2,4-diphenyl-1,3-cyclobutanedicarboxylic acid (2:1)",CC[N+](C)(CC)CCCCOC(=O)C1C(C(C1C2=CC=CC=C2)C(=O)OCCCC[N+](C)(CC)CC)C3=CC=CC=C3.[I-].[I-],,,,,,
4886,24887,"4-[3-[4-[Diethyl(methyl)azaniumyl]butoxycarbonyl]-2,4-diphenylcyclobutanecarbonyl]oxybutyl-diethyl-methylazanium",CC[N+](C)(CC)CCCCOC(=O)C1C(C(C1C2=CC=CC=C2)C(=O)OCCCC[N+](C)(CC)CC)C3=CC=CC=C3,,,,,,
4887,24888,"Ammonium, diethyl(2-hydroxyethyl)methyl-, iodide, ester with (cis-1,2,trans-1,3,trans-1,4)-2,4-diphenyl-1,3-cyclobutanedicarboxylic acid (2:1)",CC[N+](C)(CC)CCOC(=O)C1C(C(C1C2=CC=CC=C2)C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3.[I-].[I-],,,,,,
4888,24889,"2-[3-[2-[Diethyl(methyl)azaniumyl]ethoxycarbonyl]-2,4-diphenylcyclobutanecarbonyl]oxyethyl-diethyl-methylazanium",CC[N+](C)(CC)CCOC(=O)C1C(C(C1C2=CC=CC=C2)C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3,,,,,,
4889,24890,"Ammonium, (3-hydroxypropyl)trimethyl-, iodide, ester with (cis-1,2,trans-1,3,trans-1,4)-2,4-diphenyl-1,3-cyclobutanedicarboxylic acid (2:1)",C[N+](C)(C)CCCOC(=O)C1C(C(C1C2=CC=CC=C2)C(=O)OCCC[N+](C)(C)C)C3=CC=CC=C3.[I-].[I-],,,,,,
4890,24891,"3-[2,4-Diphenyl-3-[3-(trimethylazaniumyl)propoxycarbonyl]cyclobutanecarbonyl]oxypropyl-trimethylazanium",C[N+](C)(C)CCCOC(=O)C1C(C(C1C2=CC=CC=C2)C(=O)OCCC[N+](C)(C)C)C3=CC=CC=C3,,,,,,
4891,24892,"Ammonium, diethyl(5-hydroxypentyl)methyl-, iodide, ester with (cis-1,2,trans-1,3,trans-1,4)-2,4-diphenyl-1,3-cyclobutanedicarboxylic acid (2:1)",CC[N+](C)(CC)CCCCCOC(=O)C1C(C(C1C2=CC=CC=C2)C(=O)OCCCCC[N+](C)(CC)CC)C3=CC=CC=C3.[I-].[I-],,,,,,
4892,24893,"5-[3-[5-[Diethyl(methyl)azaniumyl]pentoxycarbonyl]-2,4-diphenylcyclobutanecarbonyl]oxypentyl-diethyl-methylazanium",CC[N+](C)(CC)CCCCCOC(=O)C1C(C(C1C2=CC=CC=C2)C(=O)OCCCCC[N+](C)(CC)CC)C3=CC=CC=C3,,,,,,
4893,24894,"Ammonium, diethyl(7-hydroxyheptyl)methyl-, iodide, ester with (cis-1,2,trans-1,3,trans-1,4)-2,4-diphenyl-1,3-cyclobutanedicarboxylic acid (2:1)",CC[N+](C)(CC)CCCCCCCOC(=O)C1C(C(C1C2=CC=CC=C2)C(=O)OCCCCCCC[N+](C)(CC)CC)C3=CC=CC=C3.[I-].[I-],,,,,,
4894,24895,"7-[3-[7-[Diethyl(methyl)azaniumyl]heptoxycarbonyl]-2,4-diphenylcyclobutanecarbonyl]oxyheptyl-diethyl-methylazanium",CC[N+](C)(CC)CCCCCCCOC(=O)C1C(C(C1C2=CC=CC=C2)C(=O)OCCCCCCC[N+](C)(CC)CC)C3=CC=CC=C3,,,,,,
4895,24896,"9-(2-((2-Chloroethyl)amino)ethylamino)-6-chloro-2-methoxyacridine, dihydrochloride",COC1=CC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)[NH2+]CC[NH2+]CCCl.[Cl-].[Cl-],,,,,,
4896,24897,"1,2-Ethanediamine, N-(6-chloro-2-methoxy-9-acridinyl)-N'-(2-chloroethyl)-",COC1=CC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NCCNCCCl,,,,,,
4897,24898,Quinacrine ethyl mustard,COC1=CC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)[NH2+]CC[NH+](CCCl)CCCl.[Cl-].[Cl-],,,,,,
4898,24899,"N',N'-bis(2-chloroethyl)-N-(6-chloro-2-methoxyacridin-9-yl)ethane-1,2-diamine",COC1=CC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NCCN(CCCl)CCCl,,,,,,
4899,24900,(p-Phenylenebis(1-methylethylene))bis(trimethylammonium) dibromide,CC(C[N+](C)(C)C)C1=CC=C(C=C1)C(C)C[N+](C)(C)C.[Br-].[Br-],,,,,,
4900,24901,Trimethyl-[2-[4-[1-(trimethylazaniumyl)propan-2-yl]phenyl]propyl]azanium,CC(C[N+](C)(C)C)C1=CC=C(C=C1)C(C)C[N+](C)(C)C,,,,,,
4901,24902,(p-Phenylenebis(1-methylethylene))bis(benzyldimethylammonium) dichloride,CC(C[N+](C)(C)CC1=CC=CC=C1)C2=CC=C(C=C2)C(C)C[N+](C)(C)CC3=CC=CC=C3.[Cl-].[Cl-],,,,,,
4902,24903,Benzyl-[2-[4-[1-[benzyl(dimethyl)azaniumyl]propan-2-yl]phenyl]propyl]-dimethylazanium,CC(C[N+](C)(C)CC1=CC=CC=C1)C2=CC=C(C=C2)C(C)C[N+](C)(C)CC3=CC=CC=C3,,,,,,
4903,24904,Imipramine pamoate,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O,,,"['Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)', 'Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)']",,,
4904,24905,5-Bromoindole,C1=CC2=C(C=CN2)C=C1Br,,,,,,
4905,24906,"1,5-Bis(methylsulfanyl)naphthalene",CSC1=CC=CC2=C1C=CC=C2SC,,,,,,
4906,24907,1-(2-(Diethylamino)ethoxy)-2-phenylbenzimidazole dihydrochloride,CC[NH+](CC)CCO[N+]1=C(NC2=CC=CC=C21)C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
4907,24908,"N,N-diethyl-2-[(2-phenyl-3H-benzimidazol-1-ium-1-yl)oxy]ethanamine",CCN(CC)CCO[N+]1=C(NC2=CC=CC=C21)C3=CC=CC=C3,,,,,,
4908,24909,Roletamide,COC1=CC(=CC(=C1OC)OC)C(=O)C=CN2CC=CC2,,,,,,
4909,24910,"(3-Iodo-6-methyl-2,4-dioxopiperidin-1-yl)acetic acid--2,2'-azanediyldi(ethan-1-ol) (1/1)",CC1CC(=O)C(C(=O)N1CC(=O)O)I.C(CO)NCCO,,,,,,
4910,24911,"2-(3-Iodo-6-methyl-2,4-dioxopiperidin-1-yl)acetic acid",CC1CC(=O)C(C(=O)N1CC(=O)O)I,,,,,,
4911,24912,Enpromate,C#CC(C1=CC=CC=C1)(C2=CC=CC=C2)OC(=O)NC3CCCCC3,,,,,,
4912,24913,Methoxy(phenyl)phosphinic acid,COP(=O)(C1=CC=CC=C1)O,,,,,,
4913,24914,CID 24914,C1=CC=C(C=C1)C2=C(OC(=C3C4=CC=CC=C4OC3=O)C2=O)O,,,,,,
4914,24915,"Butanoic acid, 1,1-dimethyl-2-phenylethyl ester",CCCC(=O)OC(C)(C)CC1=CC=CC=C1,,,,,,
4915,24916,2-Butyloctyl methacrylate,CCCCCCC(CCCC)COC(=O)C(=C)C,,,,,,
4916,24917,CID 24917,[90SrH2],,,,,,
4917,24918,Lanthanum(3+);nitric acid,[N+](=O)(O)[O-].[N+](=O)(O)[O-].[N+](=O)(O)[O-].[La+3],,,,,,
4918,24919,Lutetium(III) chloride,Cl[Lu](Cl)Cl,,,,,,
4919,24920,Lutetium nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Lu+3],,,,,,
4920,24921,Diamyl maleate,CCCCCOC(=O)C=CC(=O)OCCCCC,,,,,,
4921,24922,4-[2-(2-Hydroxyethoxy)ethoxy]-4-oxobut-2-enoic acid,C(COCCOC(=O)C=CC(=O)O)O,,,,,,
4922,24923,4-(3-Hydroxypropoxy)-4-oxobut-2-enoic acid,C(CO)COC(=O)C=CC(=O)O,,,,,,
4923,24924,Lead nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Pb+2],,,"['Elements, compounds, mixtures, or solutions that are considered severely harmful to human health and the environment. They include substances that are toxic, corrosive, flammable, or explosive. (See all compounds classified as Hazardous Substances.)']","['The retention and tissue distribution of (210)Pb were studied on 10-day-old, 150-day-old, and adult Macaca fascicularis monkeys, each age-group comprising four animals ... Lead nitrate, 10 ug lead/kg bw, containing 10 u-Ci (210)Pb/ug Pb was administered by gavage after a 12-hr fast. The (210)Pb excreted in urine and feces was monitored for 96 hr. All monkeys were necropsied 96 hr after dosing, and the (210)Pb contents of various tissues was determined. The data demonstrate that infant monkeys retain significantly more lead than adults.  Blood (210)Pb levels 96 hr after dosing did not vary significantly between age groups, and of the (210)Pb contained in blood, 98-99% was found in the cells, and 1-2% in the plasma. In the cells, 5-8% of the (210)Pb was bound to the cell membranes. The distribution between blood components did not vary significantly with age. The percentage of the lead dose excreted in urine did not vary significantly between age groups. Both the tissue Pb concn and tissue-blood Pb ratios were significantly higher in the bone structures of the young animals than in the adults. The brain:blood Pb ratio in the infants was significantly higher than in the older groups.', '... Under fasting conditions absorption of lead nitrate, lead sulfide, and lead cysteine ranged from 16 to 53%.', 'Much of an oral dose of (203)Pb lead nitrate was poorly absorbed and thus ... excreted fairly rapidly from the lactating cow. In 6 days, 95% ... excreted in ... feces, 0.2% in ... urine, and 0.02% in the milk. The biological half lives were 18 hr for the unabsorbed and 72 hr for ... absorbed (203)Pb.', 'Lead had a particular affinity for bone which, in rats 4 days after lead nitrate treatment, contained sevenfold more lead than the soft tissue.', 'For more Absorption, Distribution and Excretion (Complete) data for LEAD NITRATE (12 total), please visit the HSDB record page.']","['... Carp (Cyprinus carpio) /were held/ for 48 hr in lead nitrate concn of between 0 and 20 mg lead/L, with and without one of the three complexans, EDTA, NTA, or DTPA. The accumulation of lead in both viscera and gills was dose-related,  with the highest levels for viscera and gills being 86,000 and 4,560 mg/kg dry wt, respectively. The complexans reduced the uptake of lead at all dose levels. Concn in viscera ranged from 399 to 690 mg/kg for the three complexans, and 298 to 645 mg/kg in gills, after exposure to 20 mg/Lead (which had given the above levels without chelating agents).']","['Much of an oral dose of (203)Pb lead nitrate was poorly absorbed and thus ... excreted fairly rapidly from the lactating cow. In 6 days, 95% ... excreted in ... feces, 0.2% in ... urine, and 0.02% in the milk. The biological half lives were 18 hr for the unabsorbed and 72 hr for ... absorbed (203)Pb.']"
4924,24925,CID 24925,C[NH+](C)CCC=C1C2=CC=CC=C2CSC3=C1C=C(C=C3)F.[Cl-],,,,,,
4925,24926,CID 24926,CN(C)CCC=C1C2=CC=CC=C2CSC3=C1C=C(C=C3)F,,,,,,
4926,24927,"Strontium;2,3,4,5,6-pentahydroxyhexanoate",C(C(C(C(C(C(=O)[O-])O)O)O)O)O.[Sr+2],,,,,,
4927,24928,Calcium sulfate dihydrate,O.O.[O-]S(=O)(=O)[O-].[Ca+2],,,"['Materials used in the production of dental bases, restorations, impressions, prostheses, etc. (See all compounds classified as Dental Materials.)']",,,
4928,24929,CID 24929,[O-][Mn](=O)(=O)=O.[Na+],,,,,,
4929,24930,Chromium sulfate,[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[Cr+3].[Cr+3],,,,"['The acute and subacute toxicities of several Cr(III) and Cr(VI) compounds (chromium(3+) chloride, chromium(3+) nitrate, chromium(3+) sulfate, chromium trioxide, potassium dichromate) were determined in NZC and (CxO) mice injected ip. The distal median lethal doses (> 10 days after treatment) averaged (17.9 + or - 1.8) X 10(-6) g chromium/g body wt regardless of the oxidation state of the Cr compound injected (chromium(3+) sulfate may be an exception), but acute toxicity (3 days) was much greater with Cr(VI) compounds. Acid digests of entire male mice that were administered ip 1/6 of the distal LD50, either once or repeatedly at weekly intervals, were analyzed to determine the whole body persistence and clearance kinetics of Cr. Mice dosed once with Cr(III) retained 6.5 times more chromium at 21 days than mice treated with Cr(VI). When Cr(III) was given at weekly intervals mice accumulated 6 times more Cr by 8 wk than Cr(VI)-treated mice, though only the latter showed symptoms of chromic toxicity. Whole body Cr concentrations continued to rise with further Cr(III) treatments, but slowly declined with Cr(VI). Analyses of fecal and urinary excretion confirmed that most of the urinary Cr excretion from Cr(VI)-treated animals was much faster in both urine and feces than from mice given Cr(III). The differential storage and clearance kinetics of Cr(III) and Cr(VI) compounds may be significant in experimental Cr carcinogenesis studies and in the toxicology of Cr in workers exposed industrially to potentially carcinogenic chromium-containing dusts or aerosols.', 'Transmission electron microscopy (TEM) equipped with energy-dispersive x-ray analysis (EDX), electron spectroscopy for chemical analysis (ESCA), secondary ion mass spectrometry (SIMS), and laser microprobe for mass analysis (LAMMA) were used to follow the fate of chromium compounds deposited in the sheep tracheal lobe. Four chromium compounds were used: two chromium(VI) compounds (lead chromate and chromium trioxide) and two chromium(III) compounds (chronic oxide and chromium sulfate). Chromium trioxide is very soluble and the other three are slightly soluble. The compositions, concentrations, and sizes of particles were determined in the bronchoalveolar lavages (BAL) at d 2, 3, 5, and 30 after instillation and on the lung samples collected at d 31. The concentrations of particles in the BAL samples separated the chromium compounds in two groups where Cr2O3 and PbCrO4 (as Pb) were higher than Cr2(SO4)3, PbCrO4 (as Cr), and CrO3. The half-life for alveolar clearance of Cr2O3 and Cr2(SO4)3 has been calculated respectively at 11 and 80 d. Prismatic PbCrO4 particles break up in the lung and sustain a high concentration of isometric particles of lead chromate and another lead-containing compound in the BAL. The CrO3 instilled particles react with endogenous compounds or are transformed to insoluble hydroxyl complexes instead of diffusing very rapidly through the alveolar-capillary barrier. The alveolar clearance as measured in the BAL is not different from the control.', 'The aim of the experiment was to evaluate the diffusion rate in vitro and the skin absorption rate of trivalent and hexavalent chromium (Cr) from aqueous solution. Excretion of chromium in urine was also measured. The experiment was carried out on 47 Wistar male rats, 4-5 months old. The solutions of chromium sulfate or potassium dichromate contained 2.5, 5.0 and 10.0 mg Cr per milliliter. Exposure time was 4 hrs. It was found that diffusion rate of Cr3+ was seven-time less than of Cr2O7(2-). Absorption rates of both ions through the skin were similar. Excretion rates of chromium in urine were not different in case exposure to both xenobiotics. It can be concluded that diffusion does not play an important role in absorption of chromium through the skin. It seems that oxidation grade of chromium has no influence on the excretion rate of this metal from the organism. /Cr(III) and Cr(VI)/']",,
4930,24931,Lead(II) iodide,I[Pb]I,,,,,,
4931,24932,Palladium nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Pd+2],,,,,,
4932,24933,Uranium nitrate oxide (UO2(NO3)2),[N+](=O)(O)[O-].[N+](=O)(O)[O-].O=[U]=O,,,,"['Poorly absorbed by mouth.', '... /Uranyl nitrate is/ reported to be capable of penetrating intact skin. ...', 'Classification of uranium compounds according to transportability in the body: uranyl nitrate is highly transportable. /From table/', 'Distribution of uranium injected as uranyl nitrate in 5 terminal brain cancer patients: (% of dose) Bone: 10.0% in 2.5 days, 4.9% in 18 days, 1.4% in 74 days, 0.6% in 139 days, and 1.3% in 566 days. In kidney: 16.6% in 2.5 days, 7.2% in 18 days, 0.7% in 74 days, 1.2% in 139 days, and 0.4% in 566 days. Muscle: 1.2% in 2.5 days, 2.1% in 18 days, 0.9% in 74 days, 0.3% in 139 days, and 0.06% in 566 days. In liver: 1.8% in 2.5 days, 1.1% in 18 days, 0.2% in 74 days, 0.2% in 139 days, and 0.05% in 566 days. Blood vol: 1.0% in 2.5 days, 0.2% in 18 days, 0.005% in 74 days, 0.002% in 139 days, and 0.004% in 566 days. Urine (accumulated %): 61% in 2.5 days, 63% in 18 days, 92% in 74 days, 84% in 139 days, and 98% in 566 days. Fecal excretion negligible. /From table/', 'For more Absorption, Distribution and Excretion (Complete) data for URANYL NITRATE (11 total), please visit the HSDB record page.']",,"['The biologic half times of soluble uranium compounds (e.g., uranium hexafluoride, uranyl fluoride, uranium tetrachloride, uranyl nitrate hexahydrate) are estimated in days or weeks. Those of the less soluble compounds (e.g., uranium tetrafluoride, uranium dioxide, triuranium octaoxide) are estimated in years. /Soluble uranium compounds/']"
4933,24934,Sodium selenite,[O-][Se](=O)[O-].[Na+].[Na+],,,"['A group of chemical elements that are needed in minute quantities for the proper growth, development, and physiology of an organism. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) (See all compounds classified as Trace Elements.)']","['... Rats were depleted of endogenous natural abundance selenium by feeding a single selenium stable isotope ((82)Se-selenite) and then administered (76)Se-selenite and (77)Se-selenomethionine ((77)Se-SeMet)simultaneously. Biological samples were subjected to quantification and speciation analysis by HPLC-ICPMS. Metabolites of the labeled (76)Se and (77)Se and interaction with endogenous selenium were traced and examined without interference from the corresponding endogenous natural abundance isotopes. Differences in the distribution and metabolism among organs and between the two nutritional selenocompounds were compared under exactly identical biological and analytical conditions: (1) selenite was distributed more efficiently than SeMet in organs and body fluids except the pancreas. (2) SeMet was taken up by organs in its intact form. (3) Selenium of SeMet origin was distributed selectively in the pancreas and mostly bound to a protein together with intact SeMet. (4) Selenosugars A and B but not trimethylselenonium (TMSe) were detected in the liver. (5) Selenosugar B and TMSe were detected in the kidneys.', 'Rats were injected intraperitoneally with (75)Se sodium selenite (5 mg/kg), and it was concluded that selenium in the form of selenite accumulated in the anterior pituitary gland. The maximum selenium content was observed after 2 hours, at which time the anterior pituitary gland contained 2.9 mg/g wet weight. The selenium contact in pituitary glands from untreated rats was 0.48 mg/g wet weight.', 'With an adequate supplementation of the diet (1.0 mg/kg), 67% of a tracer dose of selenite was excreted in the urine, whereas in a state of deficiency only 6% of the same dose was excreted. /Selenite/', 'A tracer dose of selenite accumulated in red blood cells, translocated to plasma proteins, and then to the liver. Selenoprotein P seems to be involved in the transport of Se from the liver to other tissues, even though other transporters may exist and different organs may have different preferences for selenium sources. /Selenite/', 'For more Absorption, Distribution and Excretion (Complete) data for SODIUM SELENITE (16 total), please visit the HSDB record page.']","['Most dietary selenium is in the form of selenomethionine (the major dietary form of selenium) or selenocysteine, both of which are well absorbed. Other forms of selenium include selenate and selenite, which are not major dietary constituents, but are commonly used in fortified foods and dietary supplements. Two pools of reserve selenium are present in the body. The first is as selenomethionine, which is not known to have a physiological function separate from that of methionine. The second reserve pool is the selenium found in liver glutathione peroxidase. Ingested selenite, selenate, and selenocysteine are all metabolized directly to selenide, the reduced form of selenium. Selenomethionine can also be metabolized to selenide. /Selenite/', 'The addition of sodium selenite (Na2SeO3) to the drinking water of mice for 14 days resulted in the formation of dimethylselenide and also dimethyldiselenide in the breath. Exhalation seems to be a minor form of selenium elimination.', 'Selenate and selenite injected intravenously into rats were speciated by the HPLC-ICP MS method with use of an enriched stable isotope as the tracer. In dose-relation experiments, 82(Se)-enriched selenate or selenite was injected intravenously into male Wistar rats of 8 weeks of age (three rats/group) at single doses of 10, 25, 50, 100 and 200 ug/kg body weight for the selenate group, and 2, 5, 10, 25 and 50 ug/kg body weight for the selenite group. The animals were sacrificed 1 or 24 hr later, and the concentrations and distributions of selenium-82 in the liver, kidneys, serum, and urine remaining in the bladder or 24-hr urine were determined. In time-course experiments, (82)Se-enriched selenate and selenite were injected at doses of 50 and 10 ug/kg body weight, respectively, and the animals were sacrificed 5, 15, 30, 60 and 180 min later. It was suggested that selenate is directly taken up by the liver with an efficiency of approximately 1/2 compared with selenite, the latter being taken up by the liver after being metabolized to selenide in red blood cells. Although selenate and selenite were metabolized differently in the bloodstream, and also a part of only selenate was excreted directly into the urine, the selenium-82 taken up by the liver was shown to be metabolized in a manner indistinguishable between selenate and selenite. Selenium-82 of selenite origin but not of selenate origin was suggested to undergo redox reaction in the bloodstream. These results suggest that although parenteral selenate is utilized less efficiently by the body, it is utilized in the liver in a similar manner to selenite much more safely. /Selenite/', 'Metabolic pathways for Se in the body were studied for selenite and selenate, with the use of enriched (82)Se ... . The concentrations of (82)Se in organs and body fluids and the distributions of their constituents depending on the dose and time after the intravenous administration of (82)Se-selenite and -selenate to rats were determined. Selenite was taken up by red blood cells within several minutes, reduced to selenide by glutathione, and then transported to the plasma, bound selectively to albumin and transferred to the liver. Contrary to selenite, intact selenate was either taken up directly by the liver or excreted into the urine. The (82)Se of selenite origin and that of selenate origin were detected in the forms of the two Se peak materials in the liver, A and B. The former one was methylated to the latter in vivo and in vitro. The latter one was identical with the major urinary metabolite and it was identified as Se-methyl-N-acetyl-selenohexosamine (selenosugar). The chemical species-specific metabolic pathway for Se was explained by the metabolic regulation through selenide as the assumed common intermediate for the inorganic and organic Se sources and as the checkpoint metabolite between utilization for the selenoprotein synthesis and methylation for the excretion of Se. /Selenite/', 'For more Metabolism/Metabolites (Complete) data for SODIUM SELENITE (6 total), please visit the HSDB record page.']","['In humans, whole body retention studies following oral administration of sodium selenite have indicated that selenium elimination is triphasic. During the initial phase, which lasted about 1 week, elimination of selenium was rapid, with a half-life of approximately 1 day. In the second phase, which also lasted approximately 1 week, selenium elimination was slower, with a half-life of 8-9 days. In the third phase, selenium elimination was much slower, with a half-life estimated to be 115-116 days. The first two elimination phases correspond to the fecal elimination of nonabsorbed selenium and the urinary excretion of absorbed but unutilized selenium', 'Following a single, oral, 200 ug dose of sodium selenite in six male and female volunteers, the half-time was 200 to 285 hours for terminal plasma elimination and 115 to 285 days for tissues.', 'The excretion pattern of a single exposure to selenite appears to have at least two phases: a rapid initial phase with as much as 15 to 40 percent of the absorbed dose excreted in the urine the first week. There is expotential excretion of the remainder of the dose with a half life of 103 days. /Selenite/']"
4934,24935,Sodium tellurite,[O-][Te](=O)[O-].[Na+].[Na+],,,,"['The route of admin (IV, IP ... or orally) does not significantly change the pattern of soft tissue distribution of tellurium given as sodium tellurite or tellurous acid in hydrochloric acid solution. A short-term equilibrium is reached within 1-2 hr; the organs with highest concn incl the kidneys, liver, lung, thyroid, spleen, and the blood. The uptake by skeletal muscles is much slower, and in the long term, tellurium seems to accumulate in the bone.', 'Injected tellurium (IV and IP as sodium tellurite) is excreted by the rat mainly in urine (14-27% within 24 hr; 33% within one week). Fecal excretion amt to about 6% in 24 hr and 14% in one week. Tellurium is transferred to the intestine by biliary excretion. About 11-16% of IV injected tellurium (as sodium tellurite) was excreted by female dogs within 1 hr, and 23% within 6 days. About 60-80% of ingested sodium tellurite ... was rapidly eliminated by rats and swine in feces.', 'Gastrointestinal absorption of tellurites is completed within 2 hr and takes place, in rats, mainly in the duodenum and jejunum. Absorption estimates vary from 10- 15% to 25%. In swine, as in sheep, sodium tellurite is absorbed from the colon, but not from the small intestine.']","['As tellurium ranks among the rare non-essential trace elements there is only little known of its intestinal absorption and its metabolic behavior in humans. Data for risk evaluations needed for occupational medicine are based on animal experiments only. In order to investigate the metabolic behaviour of tellurium in man, tellurium in different forms was administered perorally to healthy male human volunteers. It was given as sodium tellurate, sodium tellurite, metallic colloid and intrinsically bound in cress. For the latter, cress was cultivated with tellurium-containing water in order to provide tellurium for ingestion in a form which is more equivalent to foodstuffs. After the administration the urinary excretion of tellurium was determined. Tellurium concentrations were measured in urine samples by means of graphite furnace atomic absorption spectroscopy (GFAAS). From the cumulative tellurium excretion in the first four days after the administration, a percentage intestinal absorption of 25% + or - 10% for soluble tellurium salts can be calculated. The renal tellurium excretion is faster after administration of hexavalent tellurium than after ingestion of the tetravalent form. This can explain the higher toxicity of the tetravalent tellurium compounds found in animal experiments. The introduction of tellurium to cress lowered the intestinal absorption to approximately 15%. For metallic tellurium the fractional intestinal absorption was found to be about 10%.']","['Biological half-time = about 3 weeks; [HSDB]', 'The whole-body retention of tellurium in rats after IP or IV injection of ... sodium tellurite can be described by a sum of two exponential functions with biological half-times of about 19 hr (42-49% of dose) and 13-15 days (51-58%). After gavage of the same cmpd, a third exponential term (half-time of 3-7 hr) has to be added to account for the rapid elimination of the non-absorbed fraction (70-80%). The whole-body retention model for man assumes a biological half-time of about 3 wk.']"
4935,24936,Tellurous acid,O[Te](=O)O,,,,,,
4936,24937,Thallium nitrate,[N+](=O)([O-])[O-].[Tl+],,,,"['IN /RATS GIVEN THALLIUM NITRATE/ ... EXCRETION OF (204)THALLIUM MAINTAINED SIMILAR PATTERN REGARDLESS OF ROUTE OF ADMIN. ABOUT 6% ... HAD BEEN EXCRETED IN URINE AFTER 1 DAY, EXCRETION FALLING TO ABOUT 0.5% BY 10TH DAY. ... FECAL EXCEEDED URINARY EXCRETION DURING THE 21 DAYS ... FECAL TO URINARY RATIO RISING FROM 2 TO 5.', 'A CASE IS DESCRIBED OF SEVERE POISONING WITH THALLIUM NITRATE IN AN ATTEMPT AT SUICIDE. THE PATIENT EXCRETED IN THE URINE 494.512 MG OF THALLIUM OVER A 15 WK COURSE OF TREATMENT.', 'THE DISTRIBUTION OF THALLIUM WAS DETERMINED IN 57 AUTOPSIED TISSUES, INCL BLOOD, OF A PATIENT WHO HAD BEEN ORALLY ADMIN 500 mCi THALLOUS NITRATE (TlNO3) FOLLOWED BY ... 45 MG DOSES ... THALLIUM(I) SULFATE (Tl2SO4) ... UNTIL 225 MG HAD BEEN GIVEN. THE BLOOD SHOWED A RAPID RISE WITHIN 2 HR TO A LEVEL OF 3% OF THE ADMIN RADIOISOTOPE ... TO 1.6%. SOME SPECIFIC LOCALIZATION OF THALLIUM ... WAS FOUND IN THE SCALP HAIR, KIDNEYS, HEART MUSCLE, PRIMARY BONE TUMOR, AND SPLEEN, IN THAT DECREASING ORDER. ... CLOSELY FOLLOWED BY ADRENAL MEDULLA, BONE TUMOR FROM LUNG, PANCREAS, SCALP SKIN, AND LIVER, RIB MARROW, THYROID, ADRENAL CORTEX, AND PITUITARY. ... A DIFFERENT DISTRIBUTION PICTURE WAS FOUND IN THE RAT ... INJECTED WITH 23 UG TlNO3. ... 2 DAYS AFTER DOSING, THE KIDNEYS CONTAINED THE HIGHEST CONCN FOLLOWED BY THE GUT, GONADS, AND PANCREAS. ... THESE DIFFERENCES IN LOCALIZATION OF THALLIUM SUGGEST CAUTION IN TRANSLATING RESULTS OBTAINED IN ANIMALS TO MAN.', '... GAVE RADIOACTIVE THALLOUS NITRATE & THALLOUS SULFATE ORALLY TO 1 PT WITH METASTATIC OSTEOGENIC SARCOMA & FOUND RATE OF EXCRETION IN URINE TO BE 3.2% PER DAY OF AMOUNT REMAINING IN BODY. THALLIUM EXCRETION IN BOTH URINE & FECES MAY PERSIST FOR MANY WEEKS IN SPITE OF LOW PLASMA LEVELS IN POISONED PATIENTS.', 'For more Absorption, Distribution and Excretion (Complete) data for THALLOUS NITRATE (8 total), please visit the HSDB record page.']",,['BODY BURDEN AS % OF ADMIN DOSE WAS DETERMINED IN RATS FOLLOWING ADMIN OF (204)THALLIUM ... OVER A PERIOD OF 21 DAYS. BODY CLEARANCE /OCCURRED/ ... EXPONENTIALLY WITH HALFTIME 3.3 DAYS ... AT THE END OF 21 DAYS ... 1% OF ADMIN DOSE REMAINED. ... WITH BIOLOGICAL HALF-TIME OF 3.3 DAYS ... DAILY DOSING /GIVES/ AN EQUILIBRIUM ... @ 20 DAYS. /SOLUBLE THALLIUM SALTS/']
4937,24938,Ferrous arsenate,[O-][As](=O)([O-])[O-].[O-][As](=O)([O-])[O-].[Fe+2].[Fe+2].[Fe+2],,,,,,
4938,24939,Aluminum sodium sulfate,[O-]S(=O)(=O)[O-].[O-]S(=O)(=O)[O-].[Na+].[Al+3],,,,,,
4939,24940,"Pyrophosphoric acid, copper salt",OP(=O)(O)OP(=O)(O)O.[Cu+2],,,,,,
4940,24941,CID 24941,C1=CC(=CC=C1N)S(=O)(=O)[NH-].[Na+],,,,,,
4941,24942,Copper;copper(1+);phosphoric acid,OP(=O)(O)O.[Cu+].[Cu+2],,,,,,
4942,24943,Magnesium arsenate,[O-][As](=O)([O-])[O-].[O-][As](=O)([O-])[O-].[Mg+2].[Mg+2].[Mg+2],,,,,,
4943,24944,Quinoxidine,CC(=O)OCC1=C([N+](=O)C2=CC=CC=C2N1[O-])COC(=O)C,,,,,,
4944,24945,"Pentadecane, 6-methyl-",CCCCCCCCCC(C)CCCCC,,,,,,
4945,24946,N-Butylcyclohexylamine,CCCCNC1CCCCC1,,,,,,
4946,24947,Cadmium chloride,Cl[Cd]Cl,,,,"['To investigate the relationship between cadmium (Cd) toxicity, intestinal absorption, and its distribution to various tissues in rats treated orally with minimum amounts of Cd, 14 female rats per dose group per time point were given diets consisting of 28% purified diet and 72% ordinary rice containing Cd-polluted rice (0.02, 0.04, 0.12, or 1.01 ppm of Cd) or CdCl2 (5.08, 19.8, or 40.0 ppm of Cd) for up to 8 months. At 1, 4, and 8 months after the commencement of Cd treatment, seven rats per group were euthanized for pathological examinations to determine the Cd concentrations in the liver and kidneys and metallothionein (MT) in the liver, kidneys, intestinal mucosa, serum, and urine. One week before each period of 1, 4, and 8 months, the remaining seven rats in each group were administered a single dosage of Cd(109), a tracer, to match the amounts of the designated Cd doses (about 1.2 to 2400 ug/kg body wt). They were euthanized 5 days later to determine the distribution of Cd to various tissues. No Cd-related toxic changes were observed. The concentrations of Cd in the liver and kidneys at any time point and MT in the liver, kidney, serum, and urine at 4 and 8 months increased dose-dependently, whereas MT in the intestinal mucosa did not alter markedly at any time point. The distribution rates of Cd to the liver increased dose-dependently (40% at lower doses to 60% at higher doses), whereas those to the kidney decreased dose-dependently (20% at lower doses to 10% at higher doses). The Cd retention rates 5 days after Cd(109) administration (amounts of Cd in various tissues/amounts of Cd administered) ranged from 0.2 to 1.0% at any time point. These results suggest that the distribution of Cd to the liver and kidneys after the oral administration vary depending on the dosage levels of Cd. The difference of the distribution pattern of Cd to the liver and kidney is probably due to the difference in the form of the absorbed Cd, i.e., free ion or Cd-MT complex, although not closely related to the MT in the intestinal mucosa.', 'An increased body retention of Cd in rats orally pretreated with Cd or Zn is explained by induction of hepatic and renal metallothionein. Whether intestinal absorption of Cd increases after such treatments is not clear yet. To approach this problem we measured jejunal transfer rates of Cd(109) in vitro and in vivo in pretreated rats (0.44 mmol Cd/L or 4.6 mmol Zn/L in the drinking water for 10 days) and compared them with those of untreated controls. Isolated jejunal segments were used for in vitro perfusion. In vivo perfusion was performed in anaesthetized rats with blood collected from mesenteric venules substituting corresponding losses by reinfusion of rat blood. Water and glucose transfer did not differ between controls and pretreated rats. At a luminal concentration of 5 umol Cd(109)Cl2/L, Cd and Zn pretreatment significantly increased the transfer rate of Cd(109) in vitro and in vivo similarly. The Cd(109)  transfer rates in controls in the final perfusion intervals (80-120 min) were 0.06 (pmol/cm/min) in vivo and 0.05 in vitro; the corresponding rates in Cd or Zn pretreated rats were significantly higher (P<0.05) and amounted to 0.11 and 0.18 or 0.15 and 0.23, respectively. Mucosal concentrations of Cd(109) measured at the end of the perfusion period tended to be lower in the pretreated animals than in the controls. This suggests that pretreatment with Cd or Zn reduces the amount of Cd(109) bound to the tissue leaving more Cd(109) for the transfer step. As compared to a level of mucosal metallothionein of 8 ug/g wet weight in controls, increased amounts of 67 or 52 ug/g wet weight in the Cd or Zn pretreated rats, respectively, thus did not decrease but increased transfer rates of Cd(109). Therefore, increased small intestinal transfer rates of Cd can contribute to increase the body retention of Cd seen after oral pretreatment with Cd or Zn.', 'ADULT RATS WERE INJECTED INTRAVENOUSLY WITH (109)CADMIUM CHLORIDE AND THE DISTRIBUTION OF THE ISOTOPE WITHIN THE BRAIN AND NEIGHBORING NERVOUS STRUCTURES WAS SUBSEQUENTLY STUDIED BY AUTORADIOGRAPHY. CADMIUM ACCUMULATED IN REGIONS OUTSIDE THE BLOOD-BRAIN BARRIER SUCH AS THE CHOROID PLEXUS, PINEAL GLAND AND AREA POSTREMA, BUT DID NOT APPEAR IN THE BRAIN PARENCHYMA. UPTAKE OF CADMIUM WAS OBSERVED IN THE TRIGEMINAL GANGLIA CLOSE TO THE NERVE CELLS AND IN THE OLFACTORY BULBS. IN ADDITION, CADMIUM ACCUMULATED IN THE IRIS, CILIARY BODY AND CHOROID OF THE EYE, BUT NOT IN THE OPTIC NERVES. THE DEPOSITION OF CADMIUM IN THE OLFACTORY BULBS MAY BE RELATED TO THE ANOSMIA REPORTED IN WORKERS EXPOSED TO THIS METAL.', 'CADMIUM CHLORIDE ADMIN TO RATS BY SC INJECTION OR DIRECTLY INTO LIVER IS TRANSPORTED TO TESTES. ... /ALSO, WHEN/ GIVEN SC TO RATS /IT/ APPEARED IMMEDIATELY IN PLASMA & THEN DISAPPEARED RAPIDLY; AFTER 6 DAYS ONLY 2% OF DOSE ... EXCRETED IN FECES.', 'For more Absorption, Distribution and Excretion (Complete) data for CADMIUM CHLORIDE (18 total), please visit the HSDB record page.']",,
4947,24948,Cerium nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Ce+3],,,"['Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)']",,,
4948,24949,Octyltrimethylammonium chloride,CCCCCCCC[N+](C)(C)C.[Cl-],,,,,,
4949,24950,Octyltrimethylammonium,CCCCCCCC[N+](C)(C)C,,,,,,
4950,24951,Decyltrimethylammonium chloride,CCCCCCCCCC[N+](C)(C)C.[Cl-],,,"['Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)']",,,
4951,24952,Dimethylditetradecylammonium chloride,CCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCC.[Cl-],,,,,,
4952,24953,Dimethyldimyristylammonium,CCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCC,,,,,,
4953,24954,1-Ethyl-2-nitrobenzimidazole,CCN1C2=CC=CC=C2N=C1[N+](=O)[O-],,,,,,
4954,24955,1H-Imidazole-2-carbaldehyde,C1=CN=C(N1)C=O,,,,,,
4955,24956,Calomel,Cl[Hg].Cl[Hg],,,,,,
4956,24957,"Acetic acid, fluoro-, propyl ester",CCCOC(=O)CF,,,,,,
4957,24958,Potassium sulfite,[O-]S(=O)[O-].[K+].[K+],,,,,,
4958,24959,Calcium permanganate,[O-][Mn](=O)(=O)=O.[O-][Mn](=O)(=O)=O.[Ca+2],,,,,,
4959,24960,CID 24960,CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=O)C(=C(N)O)C1=O)O)O)O)N(C)C,,,,,,
4960,24961,3-Methoxy-4-monomethylaminoazobenzene,CNC1=C(C=C(C=C1)N=NC2=CC=CC=C2)OC,,,,,,
4961,24962,Cadmium sulfate,[O-]S(=O)(=O)[O-].[Cd+2],,,,"['IN RABBITS GIVEN 60 DAILY SC INJECTIONS OF CADMIUM SULFATE, ONLY ABOUT 1% OF DOSE WAS EXCRETED IN URINE EACH DAY.', 'ABOUT 20% OF IV DOSE IN RATS WAS EXCRETED VIA FECES IN 72 HR & LITTLE ... (115)CADMIUM WAS FOUND IN URINE; DISTRIBUTION IN LIVER ... AS SULFATE WAS UNIFORM, WHEREAS IN KIDNEY THE CORTEX SHOWED HIGH ACCUM & MEDULLA CONTENT WAS LOW. PANCREAS ACCUMULATED LARGE AMT IN UNIFORM DISTRIBUTION.', 'NEARLY 70% OF (109)CD-LABELED CADMIUM SULFATE WAS FOUND IN LIVER 20 DAYS AFTER IP ADMIN TO RATS. WHEN ADMIN SMALL REPEATED DAILY DOSES, LIVER ACCUM, RATHER THAN RENEW, ITS CADMIUM SUPPLY. BILE WAS ACTUALLY INSTRUMENTAL IN REABSORPTION OF CADMIUM INTO INTESTINE.', 'WHETHER CADMIUM SULFATE WAS INJECTED SC, IP OR IM TO RATS, THE AMT OF CADMIUM EXCRETED INTO URINE WERE NEARLY SAME.', 'Copper and cadmium uptake and distribution in 2-week-old seedlings of stone pine (Pinus pinea L.), maritime pine (Pinus pinaster Ait.) and ash (Fraxinus angustifolia Vahl.) were investigated. Seedlings were grown in culture solution at increasing concentrations of CuSO4, (0.012-5 muM) and CdSO4 (0.0-5 muM). All species accumulated copper in a larger amount than cadmium. Translocation to the shoot was strongly restricted for both metals, though higher cadmium mobility within the plant could be evidenced. A strong relationship between root content and growth inhibition was detected in the roots in response to copper but not to cadmium treatments. Among species P. pinea seemed to be more tolerant to cadmium, whereas F. angustifolia was highly sensitive to both cadmium and copper. X-ray microanalysis of root tip sections showed that copper and cadmium only accumulated in the root tips of F. angustifolia, copper mostly in the cell walls of the cortex layer, cadmium in the inner compartments of the cortex cells. It is suggested that in the two Pinus species the well developed root cap plays a protecting role against metal uptake at the root-tip zone.']",,
4962,24963,Calcium nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Ca+2],,,,,,
4963,24964,Calcium thiosulfate,[O-]S(=O)(=S)[O-].[Ca+2],,,,"['REMARKABLY INERT IN VIVO, EXCEPT FOR OSMOTIC DISTURBANCES. POORLY ABSORBED FROM THE ALIMENTARY TRACT AND SO ACTS AS AN OSMOTIC CATHARTIC. /THIOSULFATE SALTS/']",,
4964,24965,Cobalt sulfate,[O-]S(=O)(=O)[O-].[Co+2],,,,"['The effects of cobalt sulfate administered to pregnant C57BI mice, OFA-SD rats, and New Zealand rabbits was studied on fetal and postnatal offspring. Cobalt concentration in the maternal blood was increased in proportion to the administered doses. Cobalt crossed the placenta and appeared in the fetal blood and amniotic fluid. Regardless of the administered dose of cobalt sulfate, cobalt concentration in the blood peaked 2 hr after administration.', 'Sheep given a single dose of hydrated cobalt sulfate were killed. ...The livers contained 400-1200 ppm of cobalt. In cattle dying after a massive overdose of hydrated cobalt sulfate livers contained 5-300 ppm, kidneys 30-200 ppm. /Hydrated cobalt sulfate/', 'Following longer-term exposure (8 weeks) to cobalt sulfate in the diet, exposed rats showed a 30-fold increase in the cobalt concentration in the myocardium, a 26-fold increase in the concentration in the soleus muscle, and a 100-fold increase in the concentration in serum compared with nonexposed controls. Long-term oral exposure of rats to cobalt chloride resulted in significantly increased levels of cobalt in the liver, kidney, muscle, brain, and testes of treated rats.', 'Cobalt metabolism and toxicology are summarized. The biological functions of cobalt are updated in the light of recent understanding of cobalt interference with the sensing in almost all animal cells of oxygen deficiency (hypoxia). Cobalt (Co(2+)) stabilizes the transcriptional activator hypoxia-inducible factor (HIF) and thus mimics hypoxia and stimulates erythropoietin (Epo) production, but probably also by the same mechanism induces a coordinated up-regulation of a number of adaptive responses to hypoxia, many with potential carcinogenic effects. This means on the other hand that cobalt (Co(2+)) also may have beneficial effects under conditions of tissue hypoxia, and possibly can represent an alternative to hypoxic preconditioning. Cobalt is acutely toxic in larger doses, and in mammalian in vitro test systems cobalt ions and cobalt metal are cytotoxic and induce apoptosis and at higher concentrations necrosis with inflammatory response. Cobalt metal and salts are also genotoxic, mainly caused by oxidative DNA damage by reactive oxygen species, perhaps combined with inhibition of DNA repair. Of note, the evidence for carcinogenicity of cobalt metal and cobalt sulfate is considered sufficient in experimental animals, but is as yet considered inadequate in humans. Interestingly, some of the toxic effects of cobalt (Co(2+)) have recently been proposed to be due to putative inhibition of Ca(2+) entry and Ca(2+)-signaling and competition with Ca(2+) for intracellular Ca(2+)-binding proteins. The tissue partitioning of cobalt (Co(2+)) and its time-dependence after administration of a single dose have been studied in man, but mainly in laboratory animals. Cobalt is accumulated primarily in liver, kidney, pancreas, and heart, with the relative content in skeleton and skeletal muscle increasing with time after cobalt administration. In man the renal excretion is initially rapid but decreasing over the first days, followed by a second, slow phase lasting several weeks, and with a significant long-term retention in tissues for several years. In serum cobalt (Co(2+)) binds to albumin, and the concentration of free, ionized Co(2+) is estimated at 5-12% of the total cobalt concentration. In human red cells the membrane transport pathway for cobalt (Co(2+)) uptake appears to be shared with calcium (Ca(2+)), but with the uptake being essentially irreversible as cobalt is effectively bound in the cytosol and is not itself extruded by the Ca-pump. It is tempting to speculate that this could perhaps also be the case in other animal cells. If this were actually the case, the tissue partitioning and biokinetics of cobalt in cells and tissues would be closely related to the uptake of calcium, with cobalt partitioning primarily into tissues with a high calcium turn-over, and with cobalt accumulation and retention in tissues with a slow turn-over of the cells. The occupational cobalt exposure, e.g. in cobalt processing plants and hard-metal industry is well known and has probably been somewhat reduced in more recent years due to improved work place hygiene. Of note, however, adverse reactions to heart and lung have recently been demonstrated following cobalt exposure near or slightly under the current occupational exposure limit. Over the last decades the use of cobalt-chromium hard-metal alloys in orthopedic joint replacements, in particular in metal-on-metal bearings in hip joint arthroplasty, has created an entirely new source of internal cobalt exposure. Corrosion and wear produce soluble metal ions and metal debris in the form of huge numbers of wear particles in nanometric size, with systemic dissemination through lymph and systemic vascular system. This may cause adverse local reactions in peri-prosthetic soft-tissues, and in addition systemic toxicity. Of note, the metal nanoparticles have been demonstrated to be clearly more toxic than larger, micrometer-sized particles, and this has made the concept of nanotoxicology a crucial, new discipline. As another new potential source of cobalt exposure, suspicion has been raised that cobalt salts may be misused by athletes as an attractive alternative to Epo doping for enhancing aerobic performance. The cobalt toxicity in vitro seems to reside mainly with ionized cobalt. It is tempting to speculate that ionized cobalt is also the primary toxic form for systemic toxicity in vivo. Under this assumption, the relevant parameter for risk assessment would be the time-averaged value for systemic cobalt ion exposure that from a theoretical point of view might be obtained by measuring the cobalt content in red cells, since their cobalt uptake reflects uptake only of free ionized cobalt (Co(2+)), and since the uptake during their 120 days life span is practically irreversible. This clearly calls for future clinical studies in exposed individuals with a systematic comparison of concurrent measurements of cobalt concentration in red cells and in serum.']",,
4965,24966,CID 24966,[NH2-].[Cl-].[Hg+2],,,,,,
4966,24967,Potassium;arsorite,[O-][As]([O-])[O-].[K+],,,,,,
4967,24968,Calgon,[O-]P1(=O)OP(=O)(OP(=O)(OP(=O)(OP(=O)(OP(=O)(O1)[O-])[O-])[O-])[O-])[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],,,,,,
4968,24969,Metaphosphoric acid (H6P6O18),OP1(=O)OP(=O)(OP(=O)(OP(=O)(OP(=O)(OP(=O)(O1)O)O)O)O)O,,,,,,
4969,24970,CID 24970,CCCCCCCCCCCC(=O)[O-].[K+],,,,,,
4970,24971,4-Nitrosobiphenyl,C1=CC=C(C=C1)C2=CC=C(C=C2)N=O,,,,,,
4971,24972,C.I. Acid yellow 54,CC1=C(C=CC(=C1)S(=O)(=O)[O-])N2C(=C(C(=N2)C)N=NC3=C(C=CC(=C3)S(=O)(=O)[O-])C(=O)[O-])[O-].[OH-].[Na+].[Na+].[Cr+3],,,,,,
4972,24973,2-{(E)-[5-Hydroxy-3-methyl-1-(2-methyl-4-sulfophenyl)-1H-pyrazol-4-YL]diazenyl}-4-sulfobenzoic acid,CC1=C(C=CC(=C1)S(=O)(=O)O)N2C(=O)C(=C(N2)C)N=NC3=C(C=CC(=C3)S(=O)(=O)O)C(=O)O,,,,,,
4973,24974,"9,10-Dimethoxy-2,3-(methylenedioxy)-13,13a-didehydro-8-berbinol",COC1=C(C2=C(C=C1)C=C3C4=CC5=C(C=C4CCN3C2O)OCO5)OC,,,,,,
4974,24975,CID 24975,C1=CC(=CC=C1N)S(=O)(=O)[N-]C2=NC=CS2.O.[Na+],,,,,,
4975,24976,Ethyl 6-cyanohexanoate,CCOC(=O)CCCCCC#N,,,,,,
4976,24977,Cyclopentyl ether,C1CCC(C1)OC2CCCC2,,,,,,
4977,24978,Calcium chlorate,[O-]Cl(=O)=O.[O-]Cl(=O)=O.[Ca+2],,,,,,
4978,24979,N-ethyl-1-phenylethanamine,CCNC(C)C1=CC=CC=C1,,,,,,
4979,24980,5-Ethylnon-3-en-2-one,CCCCC(CC)C=CC(=O)C,,,,,,
4980,24981,"Ethanol, 2-((2-methylpentyl)oxy)-",CCCC(C)COCCO,,,,,,
4981,24982,"Ethanol, 2-[[3,5-dimethyl-1-(2-methylpropyl)hexyl]oxy]-",CC(C)CC(C)CC(CC(C)C)OCCO,,,,,,
4982,24983,Europium nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Eu+3],,,,,,
4983,24984,"2,6-Dimethyl-1,4-dioxane",CC1COCC(O1)C,,,,,,
4984,24985,Dichloroethylvinylsilane,CC[Si](C=C)(Cl)Cl,,,,,,
4985,24986,"Bicyclo[2.2.1]hept-5-ene-2-carboxylic acid, ethyl ester",CCOC(=O)C1CC2CC1C=C2,,,,,,
4986,24987,"Butyric acid, 2,3-epoxy-, butyl ester",CCCCOC(=O)C1C(O1)C,,,,,,
4987,24988,N-Ethyl-3-oxobutanamide,CCNC(=O)CC(=O)C,,,,,,
4988,24989,2-(1-Ethylamyloxy)ethanol,CCCCC(CC)OCCO,,,,,,
4989,24990,"Diethyl cyclohexane-1,2-dicarboxylate",CCOC(=O)C1CCCCC1C(=O)OCC,,,,,,
4990,24991,Hex-4-en-1-yn-3-ol,CC=CC(C#C)O,,,,,,
4991,24992,Holmium chloride,Cl[Ho](Cl)Cl,,,,,,
4992,24993,CID 24993,C(CCl)O[SiH](OCCCl)OCCCl,,,,,,
4993,24994,"1,1,3-Trimethoxybutane",CC(CC(OC)OC)OC,,,,,,
4994,24995,Armentomycin,C([C@@H](C(=O)O)N)C(Cl)Cl,,,,,,
4995,24996,CID 24996,C[NH+](C)CCOC1C2=CC=CC=C2CCC3=CC=CC=C13.C(=CC(=O)[O-])C(=O)O,,,,,,
4996,24997,Deptramine,CN(C)CCOC1C2=CC=CC=C2CCC3=CC=CC=C13,,,,,,
4997,24998,"1,2-Dichloroethyl acetate",CC(=O)OC(CCl)Cl,,,,,,
4998,24999,Ethyl 6-chlorohexanoate,CCOC(=O)CCCCCCl,,,,,,
4999,25000,Cobalt nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Co+2],,,,"['The substance can be absorbed into the body by inhalation of its aerosol and by ingestion.', 'The lung retention and respiratory clearance pathway of inhaled cobalt-nitrate (CN) and cobalt-oxide (CO) aerosols labelled with cobalt-57 (Co-57) were investigated in male beagle-dogs. A gamma camera was used to measure lung retention, while lung clearance was assessed by blood and excretion analysis. Physically and chemically uniform Co-57 particles were retained similarly in the lungs, although the retention of CO particles in the 0.3 to 2.7 micron range was greatly dependent on their physicochemical properties. /In dogs/ The primary clearance pathway was dissolution of the inhaled particles. The rate of dissolution was inversely proportional to the diameter of the /cobalt nitrate or oxide/ particle; depending on particle size, particle dissolution half time ranged from 6 to 80 days. After inhalation, most of the Co-57 was identified in the lungs, followed by muscles, bone, and skin. Less than 10 percent of the initial lung burden was present in the lungs of dogs long term, with a biological half life of 400 days. Dogs exposed to CN retained 90 percent of the body burden in the lung as late as 1050 and 1500 days after exposure, while the other dogs retained only 50 to 70 percent of the body burden in the lungs at 350 and 500 days after exposure. The presence of high concentrations of Co-57 in the trachea and upper respiratory tract at the time of death of the animals confirmed the long term retention of cobalt in some tissues.', '... Accumulation was found in the liver (29% of dose, 10% kidneys, and 4.6% in the   intestines) were found following intracardiac injection of cobalt nitrate in rats.', 'Following intravenous injection of cobalt nitrate (with a 57Co tracer) in various species of animals, most of the injected dose was excreted in the urine; about 80% of the given dose was excreted in the urine within 21 days.']","['In experiments on male albino rats after subcutaneous injection of a single toxic dose it was found that cobaltous nitrate (Co(NO3)2  significantly inhibited the hexobarbital-oxidizing enzyme system, Aniline hydroxylase was significantly inhibited by Co(NO3)2. In determination of ethylmorphine demethylase activity Co(NO3)2, significantly inhibited the enzyme activity, /and/ reduced also the microsomal cytochrome P-450 content.']","['The primary clearance pathway was dissolution of the inhaled particles. The rate of dissolution was inversely proportional to the diameter of the particle; depending on particle size, particle dissolution half time ranged from 6 to 80 days. ... Less than 10 percent of the initial lung burden was present in the lungs of dogs long term, with a biological half life of 400 days.']"
5000,25001,1-But-2-enoyloxybut-2-enyl but-2-enoate,CC=CC(OC(=O)C=CC)OC(=O)C=CC,,,,,,
5001,25002,"2,6,8-Trimethylnonyl vinyl ether",CC(C)CC(C)CCCC(C)COC=C,,,,,,
5002,25003,"2,3-Dichloro-2-methylpropionaldehyde",CC(CCl)(C=O)Cl,,,,,,
5003,25004,"2,8-Dimethyl-6-(2-methylpropyl)nonan-4-ol",CC(C)CC(CC(C)C)CC(CC(C)C)O,,,,,,
5004,25005,2-Methoxyethyl bis(hydroxymethyl)carbamate,COCCOC(=O)N(CO)CO,,,,,,
5005,25006,"2,3-Dimethyl-1-pentanol",CCC(C)C(C)CO,,,,,,
5006,25007,Dysprosium nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Dy+3],,,,,,
5007,25008,"Ethene, [2-(2-ethoxyethoxy)ethoxy]-",CCOCCOCCOC=C,,,,,,
5008,25009,"Ethanol, 2-(2-((2-methylpentyl)oxy)ethoxy)-",CCCC(C)COCCOCCO,,,,,,
5009,25010,Bis(2-ethylhexyl) ether,CCCCC(CC)COCC(CC)CCCC,,,,,,
5010,25011,"1,3-Dimethoxybutane",CC(CCOC)OC,,,,,,
5011,25012,"(4S,5S,17S)-17-hydroxy-4,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one",C[C@H]1[C@@H]2CCC3C4CC[C@@H](C4(CCC3C2(CCC1=O)C)C)O,,,,,,
5012,25013,"1-(2,4-Dichlorophenyl)propan-2-yl carbamate",CC(CC1=C(C=C(C=C1)Cl)Cl)OC(=O)N,,,,,,
5013,25014,"2-Chloro-5-ethyl-7,9,10,14b-tetrahydroisoquinolino[2,1-d][1,4]benzodiazepin-6-one",CCN1C(=O)CN2CCC3=CC=CC=C3C2C4=C1C=CC(=C4)Cl,,,,,,
5014,25015,Trenbolone,C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2O,,,"['These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power. (See all compounds classified as Anabolic Agents.)']",,,
5015,25016,CID 25016,C1=CC=C(C=C1)N(C2=CC=CC=C2)C(=N)N=C([NH3+])N.[Cl-],,,,,,
5016,25017,"1,1-Diphenylbiguanide",C1=CC=C(C=C1)N(C2=CC=CC=C2)C(=N)N=C(N)N,,,,,,
5017,25018,CID 25018,C1=CC=C(C=C1)CN(C2=CC=CC=C2)C(=N)N=C([NH3+])N.[Cl-],,,,,,
5018,25019,1-Benzyl-3-(diaminomethylidene)-1-phenylguanidine,C1=CC=C(C=C1)CN(C2=CC=CC=C2)C(=N)N=C(N)N,,,,,,
5019,25020,1-Chloroaziridine,C1CN1Cl,,,,,,
5020,25021,"Anthraquinone, 1-amino-2-methoxy-",COC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)N,,,,,,
5021,25022,"Isoquinoline, 1,2,3,4-tetrahydro-2-benzyl-, hydrochloride",C1C[NH+](CC2=CC=CC=C21)CC3=CC=CC=C3.[Cl-],,,,,,
5022,25023,"2-Benzyl-1,2,3,4-tetrahydroisoquinoline",C1CN(CC2=CC=CC=C21)CC3=CC=CC=C3,,,,,,
5023,25024,Holmium trinitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Ho+3],,,,,,
5024,25025,Lanthanum ammonium nitrate,[NH4+].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[La+3],,,,,,
5025,25026,Acid Red 97,C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC(=C(C=C3)C4=C(C=C(C=C4)N=NC5=C(C=CC6=CC=CC=C65)O)S(=O)(=O)[O-])S(=O)(=O)[O-])O.[Na+].[Na+],,,,,,
5026,25027,"4,4'-Bis(2-hydroxy-1-naphthylazo)biphenyl-2,2'-disulfonic acid",C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC(=C(C=C3)C4=C(C=C(C=C4)N=NC5=C(C=CC6=CC=CC=C65)O)S(=O)(=O)O)S(=O)(=O)O)O,,,,,,
5027,25028,"(6-Amino-8a-hydroxy-1,5-dimethyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl)methyl hydrogen carbonimidate",CC1=C(C(=O)C2=C(C1=O)N3CC4C([C@@]3([C@@H]2COC(=O)N)O)N4C)N,,,,,,
5028,25029,"Bis(2,5-endomethylenecyclohexylmethyl)amine",C1CC2CC1CC2CNCC3CC4CCC3C4,,,,,,
5029,25030,"2-Ethyl-1,3,2-dioxaborolane",B1(OCCO1)CC,,,,,,
5030,25031,"(6-Fluoro-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) propanoate",CCC(=O)OC1CCC2C1(CCC3C2CC(C4=CC(=O)CCC34C)F)C,,,,,,
5031,25032,2H-chromene-3-carboxamide,C1C(=CC2=CC=CC=C2O1)C(=O)N,,,,,,
5032,25033,"ACETAMIDE, N-(1-METHYL-3-(5-NITRO-2-FURYL)-s-TRIAZOL-5-YL)-",CC(=O)NC1=NC(=NN1C)C2=CC=C(O2)[N+](=O)[O-],,,,,,
5033,25034,"ACETAMIDE, N-(4-METHYL-5-(5-NITRO-2-FURYL)-s-TRIAZOL-3-YL)-",CC(=O)NC1=NN=C(N1C)C2=CC=C(O2)[N+](=O)[O-],,,,,,
5034,25035,CID 25035,C1=CC(=CC=C1N=NC2=C(C=C(C=C2)N)N)S(=O)(=O)[O-].[Na+],,,,,,
5035,25036,"1,3-Diamino-4-(p-sulfophenylazo)benzene",C1=CC(=CC=C1N=NC2=C(C=C(C=C2)N)N)S(=O)(=O)O,,,,,,
5036,25037,Direct Yellow 27,CC1=C(C2=C(C=C1)N=C(S2)C3=CC(=C(C=C3)N=NC(C(=O)C)C(=O)NC4=CC=CC=C4OC)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+],,,,,,
5037,25038,"2-[4-[[1-(2-Methoxyanilino)-1,3-dioxobutan-2-yl]diazenyl]-3-sulfophenyl]-6-methyl-1,3-benzothiazole-7-sulfonic acid",CC1=C(C2=C(C=C1)N=C(S2)C3=CC(=C(C=C3)N=NC(C(=O)C)C(=O)NC4=CC=CC=C4OC)S(=O)(=O)O)S(=O)(=O)O,,,,,,
5038,25039,CID 25039,[NH4+].[O-]S(=O)=O,,,,,,
5039,25040,"Acetic acid, mercapto-, 1,4-butanediyl ester",C(CCOC(=O)CS)COC(=O)CS,,,,,,
5040,25041,Ammonium sulfite,[NH4+].[NH4+].[O-]S(=O)[O-],,,,,,
5041,25042,"3,3-Diethyloxetane",CCC1(COC1)CC,,,,,,
5042,25043,4-Chloro-7-nitrobenzofurazan,C1=C(C2=NON=C2C(=C1)Cl)[N+](=O)[O-],,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
5043,25044,"2,4-Dichloro-6-(4-chlorophenyl)-1,3,5-triazine",C1=CC(=CC=C1C2=NC(=NC(=N2)Cl)Cl)Cl,,,,,,
5044,25045,2-Dodecanol,CCCCCCCCCCC(C)O,,,,,,
5045,25046,5-Dodecanol,CCCCCCCC(CCCC)O,,,,,,
5046,25047,Diethyl isobutylmalonate,CCOC(=O)C(CC(C)C)C(=O)OCC,,,,,,
5047,25048,Sanochrysine,[O-]S(=O)(=S)[O-].[O-]S(=O)(=S)[O-].[Na+].[Na+].[Na+].[Au+],,,['Drugs that are used to treat RHEUMATOID ARTHRITIS. (See all compounds classified as Antirheumatic Agents.)'],,,
5048,25049,Dicobalt Octacarbonyl (stabilized with 1-5% Hexane),[CH-]=O.[CH-]=O.[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].[Co].[Co+2],,,,,,
5049,25050,Ancitabine hydrochloride,C1=CN2[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)OC2=NC1=N.Cl,,,"['Antimetabolites that are useful in cancer chemotherapy. (See all compounds classified as Antimetabolites, Antineoplastic.)']",,,
5050,25051,Ancitabine,C1=CN2[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)OC2=NC1=N,,,"['Antimetabolites that are useful in cancer chemotherapy. (See all compounds classified as Antimetabolites, Antineoplastic.)']",,,
5051,25052,CID 25052,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Mg+2],,,,,,
5052,25053,3-((2-Ethylhexyl)oxy)propionitrile,CCCCC(CC)COCCC#N,,,,,,
5053,25054,"1-Propanol, 2-[2-(2-methoxypropoxy)propoxy]-",CC(CO)OCC(C)OCC(C)OC,,,,,,
5054,25055,2-Propoxy-1-propanol,CCCOC(C)CO,,,,,,
5055,25056,"Indoline, 1-(2-(4-pyridyl)ethyl)-",C1CN(C2=CC=CC=C21)CCC3=CC=NC=C3,,,,,,
5056,25057,Piperidino disulfide,C1CCN(CC1)SSN2CCCCC2,,,,,,
5057,25058,"Benzothiazole, 2-(dimethylaminomethyl)thio-",CN(C)CSC1=NC2=CC=CC=C2S1,,,,,,
5058,25059,"2,2-Dibromo-2-cyanoacetamide",C(#N)C(C(=O)N)(Br)Br,,,,,,
5059,25060,"Ethane, 1,1-bis(p-ethylphenyl)-",CCC1=CC=C(C=C1)C(C)C2=CC=C(C=C2)CC,,,,,,
5060,25061,6-Bromohexan-2-one,CC(=O)CCCCBr,,,,,,
5061,25062,"5-amino-N-methyl-3-(5-nitrofuran-2-yl)-1,2,4-triazole-1-carboxamide",CNC(=O)N1C(=NC(=N1)C2=CC=C(O2)[N+](=O)[O-])N,,,,,,
5062,25063,CID 25063,CC[N+](CC)(CC)CCCON=CC=NOCCC[N+](CC)(CC)CC.[I-].[I-],,,,,,
5063,25064,CID 25064,CC[N+](CC)(CC)CCCON=CC=NOCCC[N+](CC)(CC)CC,,,,,,
5064,25065,"2-(1,2-Dichloroethyl)-4-methyl-1,3-dioxolane",CC1COC(O1)C(CCl)Cl,,,,,,
5065,25066,"2,4-Dihydroxy-3,3-dimethylbutyronitrile",CC(C)(CO)C(C#N)O,,,,,,
5066,25067,Bis(2-methoxyethyl) but-2-enedioate,COCCOC(=O)C=CC(=O)OCCOC,,,,,,
5067,25068,Isopropyl dodecanoate,CCCCCCCCCCCC(=O)OC(C)C,,,,,,
5068,25069,"4-(Methylformamido)-3,5-xylyl methylcarbamate",CC1=CC(=CC(=C1N(C)C=O)C)OC(=O)NC,,,,,,
5069,25070,Formamido zectran,CC1=CC(=CC(=C1NC=O)C)OC(=O)NC,,,,,,
5070,25071,4-Methylamino-3-cresyl methylcarbamate,CC1=C(C=CC(=C1)OC(=O)NC)NC,,,,,,
5071,25072,Aminomatacil,CC1=C(C=CC(=C1)OC(=O)NC)N,,,,,,
5072,25073,"CARBAMIC ACID, METHYL-, ESTER with 4'-HYDROXY-N-METHYL-o-FORMOTOLUIDIDE",CC1=C(C=CC(=C1)OC(=O)NC)N(C)C=O,,,,,,
5073,25074,4-Formamido-3-cresyl methylcarbamate,CC1=C(C=CC(=C1)OC(=O)NC)NC=O,,,,,,
5074,25075,Naringenin 7-Rhamnoglucoside,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=CC(=C4C(=O)CC(OC4=C3)C5=CC=C(C=C5)O)O)CO)O)O)O)O)O,,,,,,
5075,25076,"Alanine, 3-selenyl-",C([C@@H](C(=O)O)N)[SeH],,,,,,
5076,25077,CID 25077,C[N+](C)(C)CCCON=CC1=CC=C(C=C1)C=NOCCC[N+](C)(C)C.[I-].[I-],,,,,,
5077,25078,CID 25078,C[N+](C)(C)CCCON=CC1=CC=C(C=C1)C=NOCCC[N+](C)(C)C,,,,,,
5078,25079,(p-Phenylenebis(oxytetramethylene))bis(trimethylammonium) diiodide,C[N+](C)(C)CCCCOC1=CC=C(C=C1)OCCCC[N+](C)(C)C.[I-].[I-],,,,,,
5079,25080,Trimethyl-[4-[4-[4-(trimethylazaniumyl)butoxy]phenoxy]butyl]azanium,C[N+](C)(C)CCCCOC1=CC=C(C=C1)OCCCC[N+](C)(C)C,,,,,,
5080,25081,CID 25081,CC(=NOCC[N+](C)(C)C)C(=NOCC[N+](C)(C)C)C.[I-].[I-],,,,,,
5081,25082,CID 25082,CC(=NOCC[N+](C)(C)C)C(=NOCC[N+](C)(C)C)C,,,,,,
5082,25083,CID 25083,CC[N+](CC)(CC)CCCON=CC1=CC=C(C=C1)C=NOCCC[N+](CC)(CC)CC.[I-].[I-],,,,,,
5083,25084,CID 25084,CC[N+](CC)(CC)CCCON=CC1=CC=C(C=C1)C=NOCCC[N+](CC)(CC)CC,,,,,,
5084,25085,CID 25085,C[N+](C)(C)CCCON=C(C1=CC=CC=C1)C(=NOCCC[N+](C)(C)C)C2=CC=CC=C2.[I-].[I-],,,,,,
5085,25086,CID 25086,C[N+](C)(C)CCCON=C(C1=CC=CC=C1)C(=NOCCC[N+](C)(C)C)C2=CC=CC=C2,,,,,,
5086,25087,CID 25087,CC[N+](C)(CC)CCON=CC1=CC=C(C=C1)C=NOCC[N+](C)(CC)CC.[I-].[I-],,,,,,
5087,25088,CID 25088,CC[N+](C)(CC)CCON=CC1=CC=C(C=C1)C=NOCC[N+](C)(CC)CC,,,,,,
5088,25089,"GLYCINE, N-(m-NITROPHENYL)-",C1=CC(=CC(=C1)[N+](=O)[O-])NCC(=O)O,,,,,,
5089,25090,"2H-1-Benzopyran-3-carboxylic acid, 6-methyl-2-oxo-",CC1=CC2=C(C=C1)OC(=O)C(=C2)C(=O)O,,,,,,
5090,25091,"5-Methyl-2-(trifluoromethyl)-7,9,10,14b-tetrahydroisoquinolino[2,1-d][1,4]benzodiazepin-6-one",CN1C(=O)CN2CCC3=CC=CC=C3C2C4=C1C=CC(=C4)C(F)(F)F,,,,,,
5091,25092,CID 25092,C1CCC(C1)N=C(N)N=C([NH3+])N.[Cl-],,,,,,
5092,25093,N-cyclopentylimidodicarbonimidic diamide,C1CCC(C1)N=C(N)N=C(N)N,,,,,,
5093,25094,"2,2,2-Trichloro-N-(4,6-dichloro-1,3,5-triazine-2-yl)acetimidoyl chloride",C1(=NC(=NC(=N1)Cl)Cl)N=C(C(Cl)(Cl)Cl)Cl,,,,,,
5094,25095,"2,4-Bis[(tetrachloroethylidene)amino]-6-chloro-1,3,5-triazine",C1(=NC(=NC(=N1)Cl)N=C(C(Cl)(Cl)Cl)Cl)N=C(C(Cl)(Cl)Cl)Cl,,,,,,
5095,25096,Hydroxyzine pamoate,C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O,,,"['Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)', 'Agents, usually topical, that relieve itching (pruritus). (See all compounds classified as Antipruritics.)']",,,
5096,25097,2-Diethylaminoethyl 4-aminobenzoate; 2-(5-oxopyrrolidin-2-yl)acetic acid,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N.C1CC(=O)NC1CC(=O)O,,,,,,
5097,25098,2-(5-Oxopyrrolidin-2-yl)acetic acid,C1CC(=O)NC1CC(=O)O,,,,,,
5098,25099,Copper abietate,CC(C)C1=CC2=CC[C@@H]3[C@@]([C@H]2CC1)(CCC[C@@]3(C)C(=O)[O-])C,,,,,,
5099,25100,"Castor oil, hydrogenated",CCCCCCC(CCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCC(CCCCCC)O)OC(=O)CCCCCCCCCCC(CCCCCC)O)O,,,,,,
5100,25101,"3,4-Dihydroxy-alpha-(butylaminomethyl)benzyl alcohol",CCCCNCC(C1=CC(=C(C=C1)O)O)O,,,,,,
5101,25102,Norsolorinic acid,CCCCCC(=O)C1=C(C=C2C(=C1O)C(=O)C3=C(C2=O)C=C(C=C3O)O)O,,,,,,
5102,25103,"Tert-butyl-[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]azanium;acetate",CC(=O)[O-].CC(C)(C)[NH2+]CC(C1=CC(=C(C=C1)O)O)O,,,,,,
5103,25104,Colterol,CC(C)(C)NCC(C1=CC(=C(C=C1)O)O)O,,,,,,
5104,25105,"Isoquino(2,1-d)(1,4)benzodiazepin-6(7H)-one, 5,9,10,14b-tetrahydro-2-chloro-5-(3-(dimethylamino)propyl)-",CN(C)CCCN1C(=O)CN2CCC3=CC=CC=C3C2C4=C1C=CC(=C4)Cl,,,,,,
5105,25106,2-Methoxyethyl cyanoacetate,COCCOC(=O)CC#N,,,,,,
5106,25107,"3-Ethyl-2-[5-(3-ethyl-7-methyl-1,3-benzothiazol-2(3H)-ylidene)penta-1,3-dien-1-yl]-7-methyl-1,3-benzothiazol-3-ium iodide",CCN1C2=CC=CC(=C2SC1=CC=CC=CC3=[N+](C4=CC=CC(=C4S3)C)CC)C.[I-],,,,,,
5107,25108,"3-Ethyl-2-[5-(3-ethyl-7-methyl-1,3-benzothiazol-3-ium-2-yl)penta-2,4-dienylidene]-7-methyl-1,3-benzothiazole",CCN1C2=CC=CC(=C2SC1=CC=CC=CC3=[N+](C4=CC=CC(=C4S3)C)CC)C,,,,,,
5108,25109,"Benzamide, 2-decyloxy-N-(2-(pyrrolidinyl)ethyl)-",CCCCCCCCCCOC1=CC=CC=C1C(=O)NCCN2CCCC2,,,,,,
5109,25110,"N-phenyl-3-(3,4,5-trimethoxyphenyl)prop-2-enamide",COC1=CC(=CC(=C1OC)OC)C=CC(=O)NC2=CC=CC=C2,,,,,,
5110,25111,"Benzoic acid, 4-(2-ethoxybenzamido)-, 2-(diethylamino)ethyl ester",CCN(CC)CCOC(=O)C1=CC=C(C=C1)NC(=O)C2=CC=CC=C2OCC,,,,,,
5111,25112,"Butanamide, N-hexyl-",CCCCCCNC(=O)CCC,,,,,,
5112,25113,N-Hexylhexanamide,CCCCCCNC(=O)CCCCC,,,,,,
5113,25114,"ISOQUINOLINE, 3,4-DIHYDRO-6,7-DIMETHOXY-1-(o-FLUOROBENZYL)-, HYDROBROMIDE",COC1=C(C=C2C(=C1)CC[NH+]=C2CC3=CC=CC=C3F)OC.[Br-],,,,,,
5114,25115,"1-(2-Fluorobenzyl)-6,7-dimethoxy-3,4-dihydroisoquinoline",COC1=C(C=C2C(=C1)CCN=C2CC3=CC=CC=C3F)OC,,,,,,
5115,25116,1-Chloro-2-(phenylethynyl)benzene,C1=CC=C(C=C1)C#CC2=CC=CC=C2Cl,,,,,,
5116,25117,2-(2-Ethylbutanoylamino)-3-(4-methoxyphenyl)prop-2-enoic acid,CCC(CC)C(=O)NC(=CC1=CC=C(C=C1)OC)C(=O)O,,,,,,
5117,25118,"BENZO(b)THIOPHENE-3-ETHYLAMINE, N,N-DIMETHYL-",CN(C)CCC1=CSC2=CC=CC=C21,,,,,,
5118,25119,"6,7-Dimethyl-2-piperidinomethyl-1-tetralone hydrochloride",CC1=CC2=C(C=C1C)C(=O)C(CC2)C[NH+]3CCCCC3.[Cl-],,,,,,
5119,25120,"6,7-dimethyl-2-(piperidin-1-ylmethyl)-3,4-dihydro-2H-naphthalen-1-one",CC1=CC2=C(C=C1C)C(=O)C(CC2)CN3CCCCC3,,,,,,
5120,25121,Isophorone oxide,CC1(CC(=O)C2C(C1)(O2)C)C,,,,,,
5121,25122,Lanthanum nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[La+3],,,,,,
5122,25123,"Methanimidamide, N,N-dimethyl-N'-(2-methylphenyl)-",CC1=CC=CC=C1N=CN(C)C,,,,,,
5123,25124,"Phenethylamine, N,N-dimethyl-, hydrochloride",CN(C)CCC1=CC=CC=C1.Cl,,,,,,
5124,25125,"N,N-Dimethylphenethylamine",CN(C)CCC1=CC=CC=C1,,,,,,
5125,25126,2-Bromo-N-phenylbenzamide,C1=CC=C(C=C1)NC(=O)C2=CC=CC=C2Br,,,,,,
5126,25127,Ethyl 4-dimethylaminobenzoate,CCOC(=O)C1=CC=C(C=C1)N(C)C,,,,,,
5127,25128,"Ethanol, 2-fluoro-, nitrite",C(CF)ON=O,,,,,,
5128,25129,"ISOBUTYRIC ACID, alpha-HYDROXY-, 2-PHENYLETHYL ESTER",CC(C)(C(=O)OCCC1=CC=CC=C1)O,,,,,,
5129,25130,Cupric arsenite,O[As]([O-])[O-].[Cu+2],,,,,,
5130,25131,"Ethyl-alpha-cyano-alpha(3,5-dimethyl-4-oxacyclohexylidene)acetate",CCOC(=O)C(=C1CC(OC(C1)C)C)C#N,,,,,,
5131,25132,"4,7,7-Trimethylbicyclo[2.2.1]heptan-2-one",CC1(C2CCC1(CC2=O)C)C,,,,,,
5132,25133,Gold trichloride dihydrate,O.O.[Cl-].[Cl-].[Cl-].[Au+3],,,,,,
5133,25134,Boron tribromide,B(Br)(Br)Br,,,,,,"['Whole body (for boron taken orally): complete removed within 96 hrs; For bromide (depends on compound & route) whole body: 1 hr to 12 days; [TDR, p. 205, 214]']"
5134,25135,Boron trichloride,B(Cl)(Cl)Cl,,,,,,
5135,25136,Barium chromate,[O-][Cr](=O)(=O)[O-].[Ba+2],,,,"['Elimination of chromium from mice within 48 hr after intratracheal admin of barium chromate was only 12% of the dose. Among hexavalent chromium cmpd, barium chromate showed a low absorption rate near that of trivalent chromium cmpd. The biological half-time was 18 days. The amt of chromium distributed in the body was moderate. Chromium excretion was greater in feces than in urine ... .']",,['The biological half-time in mice was 18 days.']
5136,25137,Cesium sulfate,[O-]S(=O)(=O)[O-].[Cs+].[Cs+],,,,,,
5137,25138,Tin(II) iodide,[Sn](I)I,,,,,,
5138,25139,"2-Nonanol, 2-methyl-",CCCCCCCC(C)(C)O,,,,,,
5139,25140,4-Chloro-3-nitroanisole,COC1=CC(=C(C=C1)Cl)[N+](=O)[O-],,,,,,
5140,25141,"Aziridine, 1-(phenylsulfonyl)-",C1CN1S(=O)(=O)C2=CC=CC=C2,,,,,,
5141,25142,1-Benzyl-2-methylhydrazine,CNNCC1=CC=CC=C1,,,,,"['The enzyme systems in rat liver and lung responsible for the oxidative metabolism of hydrazine derivatives were studied to determine whether these enzymes, cytochrome p450 and monoamine oxidase, were responsible for metabolically activating hydrazines to carcinogenic/toxic metabolites. Cytochrome p450 preferentially oxidized the nitrogen to nitrogen bond of 1,2-disubstituted hydrazines and hydrazides, while monoamine oxidase oxidized the nitrogen to nitrogen bond of all the classes of hydrazine derivatives that were tested. Oxidation of the nitrogen to nitrogen bond led to the formation of stable azo intemediates in the case of 1,2-disubstituted hydrazines and to unstable monoazo (diazene) metabolites in the case of monosubstituted hydrazines and hydrazides. /Substituted hydrazines/', 'The oxidative metabolism of procarbazine, its azo, hydrazone, and two azoxy derivatives, and methylhydrazine by hepatic microsomes from phenobarbital-pretreated rats was investigated to elucidate the pathway of metabolism that resulted in methane formation from procarbazine. When incubated with microsomal reaction mixtures fortified with NADPH, all of the compounds, except the azoxy isomers, were metabolized to yield methane. A lag phase in methane formation was noted for procarbazine, but not for the other compounds. Kinetic and inhibition studies utilizing methimazole and ethylhydrazine precluded methylhydrazine as an intermediate in methane formation from procarbazine. When the azo derivative was oxidatively metabolized in the presence of liver microsomes, no hydrazone tautomer was detected. Upon monitoring the production of the azo and hydrazone metabolites formed during microsomal metabolism of procarbazine, the azo derivative was formed in sufficient quantities to account for the majority of the methane produced. In addition, small amounts of hydrazone were also detected. It was concluded that both the azo and hydrazone metabolites of procarbazine contribute to methane formation from the terminal methyl group of the hydrazine with the azo derivative being the predominant source and the hydrazone derivative being a minor source of methane. Consideration of the chemical and enzymatic pathways of procarbazine oxidation and the implication of a methyl radical intermediate in methane formation are discussed.']",
5142,25143,"1,3-Benzodioxole, 5-methoxy-6-nitro-",COC1=CC2=C(C=C1[N+](=O)[O-])OCO2,,,,,,
5143,25144,CID 25144,C1=NC2=C(NC(=NC2=N1)N)Cl,,,,,,
5144,25145,"(3R,4R,5R)-5-[1,2-bis(phenylmethoxy)ethyl]-2-ethoxy-4-phenylmethoxyoxolan-3-ol",CCOC1[C@@H]([C@H]([C@H](O1)C(COCC2=CC=CC=C2)OCC3=CC=CC=C3)OCC4=CC=CC=C4)O,,,,,,
5145,25146,Dialifor,CCOP(=S)(OCC)SC(CCl)N1C(=O)C2=CC=CC=C2C1=O,,,,"['Torak ... was almost completely metabolized when admin to dairy cow in feed (5 ppm) for 4 days. 3% of unchanged /Torak/ recovered from feces, but none was found in urine or milk. /Torak/', 'In mammals, following oral administration, dialifos is rapidly eliminated, principally in the urine, as the o-phthalic acid salt.']","['Torak ... was almost completely metabolized when admin to dairy cow in feed (5 ppm) for 4 days. 3% of unchanged ... recovered from feces. ... urinary diethyl phosphorothionate accounted for 33% of the dose; only traces of diethyl phosphate were detected. Incubation ... with beef-liver prepn ... yielded diethyl phosphorothionate ... .', '... /Torak/ was unchanged after 8 hr in presence of fresh rumen fluid ... .', 'First metabolic step is ... oxidation to the thiophosphate.']",
5146,25147,"N,N-Diethyl-1,3-dioxo-2-isoindolinebutyramide",CCN(CC)C(=O)CCCN1C(=O)C2=CC=CC=C2C1=O,,,,,,
5147,25148,"Ethylamine, 2-((6-allyl-1,4-benzodioxan-5-YL)oxy)-N-methyl-, hydrochloride",C[NH2+]CCOC1=C(C=CC2=C1OCCO2)CC=C.[Cl-],,,,,,
5148,25149,"N-methyl-2-[(6-prop-2-enyl-2,3-dihydro-1,4-benzodioxin-5-yl)oxy]ethanamine",CNCCOC1=C(C=CC2=C1OCCO2)CC=C,,,,,,
5149,25150,Cysteine hydrochloride,C(C(C(=O)O)N)S.Cl,,,,,,
5150,25151,5-((p-(Dimethylamino)phenyl)azo)isoquinoline 2-oxide,CN(C)C1=CC=C(C=C1)N=NC2=CC=CC3=C2C=C[N+](=C3)[O-],,,,,,
5151,25152,C.I. Disperse yellow 64,C1=CC=C2C(=C1)C(=O)C(C2=O)C3=NC4=CC=CC=C4C(=C3O)Br,,,,,,
5152,25153,1-Pentylpiperidine,CCCCCN1CCCCC1,,,,,,
5153,25154,Cadmium nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Cd+2],,,,"['A meta-analysis of existing scientific literature recently suggested that Cd is absorbed more efficiently by sheep if it is in the organic form in grass, than if it is added as an inorganic supplement to the diet. We tested this experimentally by feeding sheep grass from contaminated soil, compared with uncontaminated grass and with Cd added to the diet. To produce contaminated herbage, Cd nitrate was added to soil in 11 lysimeters sown with perennial ryegrass, with a further 11 lysimeters receiving no Cd to produce uncontaminated herbage. In the Cd-treated lysimeters, soil had increased exchangeable K, Mg, and Ca, leachate had increased K, Mg, Ca, Na, and P, grass had increased Cd and reduced Mg, Na, P, Mn, Fe, Cr, Al, and Ni, and there was some reduction in grass yield compared with untreated lysimeters. Grass from Cd-treated or untreated lysimeters was fed to groups of 12 ewes for 2 days, with Cd intake equated by adding Cd nitrate to the concentrate feed of ewes receiving the uncontaminated grass. The apparent absorption of Cd, Zn, Mo, Cr, and Al was increased for ewes receiving Cd-enriched grass, and apparent absorption of Cu was reduced, compared to those receiving supplementary inorganic Cd. Most of the unabsorbed Cd was excreted in feces within 4 days of feeding. The ewes consuming Cd in grass had increased B concentrations in their urine, possibly due to adverse effects of Cd on kidney function. Finally, the ewes were offered a choice of the two herbages and they ate significantly more of the uncontaminated grass. It is concluded that the apparent absorption of Cd and other heavy metals by sheep in a short-term experiment was greater when Cd was in the grass than when the Cd was added in in an inorganic form and that sheep partially avoided herbage with a high Cd concentration.']",,
5154,25155,Magnesium chlorate,[O-]Cl(=O)=O.[O-]Cl(=O)=O.[Mg+2],,,,,,
5155,25156,Zinc metaarsenite,[O-][As]=O.[O-][As]=O.[Zn+2],,,,,,
5156,25157,"Barium chloride, dihydrate",O.O.[Cl-].[Cl-].[Ba+2],,,,,,
5157,25158,"1-AZIRIDINEACETAMIDE, N,N'-(p-PHENYLENEDIMETHYLENE)BIS-",C1CN1CC(=O)NCC2=CC=C(C=C2)CNC(=O)CN3CC3,,,,,,
5158,25159,"1-Aziridineacetamide, N,N'-(1,4-cyclohexylenedimethylene)bis-",C1CC(CCC1CNC(=O)CN2CC2)CNC(=O)CN3CC3,,,,,,
5159,25160,N-Methylisatoic anhydride,CN1C2=CC=CC=C2C(=O)OC1=O,,,,,,
5160,25161,"Benzamide, 2-(allyloxy)-4-chloro-N-(2-(dimethylamino)ethyl)-",CN(C)CCNC(=O)C1=C(C=C(C=C1)Cl)OCC=C,,,,,,
5161,25162,CID 25162,C1=C(C=C(C(=O)C1=C2C=C(C=C(C2=O)[N+](=O)[O-])Cl)N(O)O)Cl,,,,,,
5162,25163,"2,2-Diethylbutyl acetate",CCC(CC)(CC)COC(=O)C,,,,,,
5163,25164,N-Hydroxy-2-naphthalenecarboxamide,C1=CC=C2C=C(C=CC2=C1)C(=O)NO,,,,,,
5164,25165,N-(2-Piperidinoethyl)-beta-tetrahydrofurfuryl-1-naphthaleneethylamine bioxalate,C1CC[NH+](CC1)CC[NH2+]CC(CC2CCCO2)C3=CC=CC4=CC=CC=C43.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
5165,25166,2-naphthalen-1-yl-3-(oxolan-2-yl)-N-(2-piperidin-1-ylethyl)propan-1-amine,C1CCN(CC1)CCNCC(CC2CCCO2)C3=CC=CC4=CC=CC=C43,,,,,,
5166,25167,N-(2-Morpholinoethyl)-beta-tetrahydrofurfuryl-1-naphthaleneethylamine bioxalate,C1CC(OC1)CC(C[NH2+]CC[NH+]2CCOCC2)C3=CC=CC4=CC=CC=C43.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
5167,25168,N-(2-morpholin-4-ylethyl)-2-naphthalen-1-yl-3-(oxolan-2-yl)propan-1-amine,C1CC(OC1)CC(CNCCN2CCOCC2)C3=CC=CC4=CC=CC=C43,,,,,,
5168,25169,N-(2-Morpholinoethyl)-beta-tetrahydrofurfuryl-1-naphthalenepropylamine bioxalate,C1CC(OC1)CC(CC2=CC=CC3=CC=CC=C32)C[NH2+]CC[NH+]4CCOCC4.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
5169,25170,N-(2-morpholin-4-ylethyl)-2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propan-1-amine,C1CC(OC1)CC(CC2=CC=CC3=CC=CC=C32)CNCCN4CCOCC4,,,,,,
5170,25171,"4-Pentenylamine, N-(2-diethylaminoethyl)-2-(1-naphthyl)-, bioxalate",CC[NH+](CC)CC[NH2+]CC(CC=C)C1=CC=CC2=CC=CC=C21.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
5171,25172,"N',N'-diethyl-N-(2-naphthalen-1-ylpent-4-enyl)ethane-1,2-diamine",CCN(CC)CCNCC(CC=C)C1=CC=CC2=CC=CC=C21,,,,,,
5172,25173,"4-Pentenylamine, 2-(1-naphthyl)-N-(2-pyrrolidinoethyl)-, bioxalate",C=CCC(C[NH2+]CCC1CCC[NH2+]1)C2=CC=CC3=CC=CC=C32.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
5173,25174,2-naphthalen-1-yl-N-(2-pyrrolidin-2-ylethyl)pent-4-en-1-amine,C=CCC(CNCCC1CCCN1)C2=CC=CC3=CC=CC=C32,,,,,,
5174,25175,"4-Pentenylamine, 2-(1-naphthyl)-N-(2-piperidinoethyl)-, bioxalate",C=CCC(C[NH2+]CC[NH+]1CCCCC1)C2=CC=CC3=CC=CC=C32.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
5175,25176,2-naphthalen-1-yl-N-(2-piperidin-1-ylethyl)pent-4-en-1-amine,C=CCC(CNCCN1CCCCC1)C2=CC=CC3=CC=CC=C32,,,,,,
5176,25177,CID 25177,CC[NH+](CC)CC[NH2+]CC(CC=CC)C1=CC=CC2=CC=CC=C21.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
5177,25178,"N',N'-diethyl-N-(2-naphthalen-1-ylhex-4-enyl)ethane-1,2-diamine",CCN(CC)CCNCC(CC=CC)C1=CC=CC2=CC=CC=C21,,,,,,
5178,25179,CID 25179,CC=CCC(C[NH2+]CCC1CCC[NH2+]1)C2=CC=CC3=CC=CC=C32.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
5179,25180,CID 25180,CC=CCC(CNCCC1CCCN1)C2=CC=CC3=CC=CC=C32,,,,,,
5180,25181,CID 25181,CC=CCC(C[NH2+]CC[NH+]1CCCCC1)C2=CC=CC3=CC=CC=C32.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
5181,25182,2-naphthalen-1-yl-N-(2-piperidin-1-ylethyl)hex-4-en-1-amine,CC=CCC(CNCCN1CCCCC1)C2=CC=CC3=CC=CC=C32,,,,,,
5182,25183,"Benzonitrile, 4-(4-phenyl-1,2,5,6-tetrahydro-1-pyridyl)-",C1CN(CC=C1C2=CC=CC=C2)C3=CC=C(C=C3)C#N,,,,,,
5183,25184,Nitraminoacetic acid,C(C(=O)O)N[N+](=O)[O-],,,,,,
5184,25185,"3,7-Dimethylnona-1,6-dien-3-ol",CCC(=CCCC(C)(C=C)O)C,,,,,,
5185,25186,"Propylamine, N,N-dimethyl-3-phenyl-, hydrochloride",C[NH+](C)CCCC1=CC=CC=C1.[Cl-],,,,,,
5186,25187,1-Dimethylamino-3-phenylpropane,CN(C)CCCC1=CC=CC=C1,,,,,,
5187,25188,2-Propenoate,C=CC(=O)[O-],,,"['Substances used to cause adherence of tissue to tissue or tissue to non-tissue surfaces, as for prostheses. (See all compounds classified as Tissue Adhesives.)']",,,
5188,25189,"2-Furanpropylamine, tetrahydro-N-(2-diethylaminoethyl)-beta-(1-naphthyl)-, biphosphate",CC[NH+](CC)CC[NH2+]CC(CC1CCCO1)C2=CC=CC3=CC=CC=C32.OP(=O)(O)[O-].OP(=O)(O)[O-],,,,,,
5189,25190,"N',N'-diethyl-N-[2-naphthalen-1-yl-3-(oxolan-2-yl)propyl]ethane-1,2-diamine",CCN(CC)CCNCC(CC1CCCO1)C2=CC=CC3=CC=CC=C32,,,,,,
5190,25191,1-Methylperylene,CC1=C2C3=CC=CC4=C3C(=CC=C4)C5=CC=CC(=C52)C=C1,,,,,,
5191,25192,"5-Methyl-3-(3-pyridyl)-1,2,4-oxadiazole",CC1=NC(=NO1)C2=CN=CC=C2,,,,,,
5192,25193,Amopyroquin hydrochloride,C1CCN(C1)CC2=C(C=CC(=C2)NC3=C4C=CC(=CC4=NC=C3)Cl)O.Cl.Cl,,,,,,
5193,25194,Amopyroquine,C1CCN(C1)CC2=C(C=CC(=C2)NC3=C4C=CC(=CC4=NC=C3)Cl)O,,,,,,
5194,25195,Leniquinsin,COC1=C(C=C(C=C1)C=NC2=C3C=C(C(=CC3=NC=C2)OC)OC)OC,,,,,,
5195,25196,4-Nitro-p-terphenyl,C1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)[N+](=O)[O-],,,,,,
5196,25197,"4-amino-5-fluoro-1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one",C1[C@@H](O[C@@H](C1O)CO)N2C=C(C(=NC2=O)N)F,,,,,,
5197,25198,8-Bromoxanthine,C12=C(NC(=O)NC1=O)N=C(N2)Br,,,,,,
5198,25199,"2-(4-Chlorophenyl)-1,3-dithiane",C1CSC(SC1)C2=CC=C(C=C2)Cl,,,,,,
5199,25200,4-Nitrophenyl diphenyl phosphate,C1=CC=C(C=C1)OP(=O)(OC2=CC=CC=C2)OC3=CC=C(C=C3)[N+](=O)[O-],,,,,,
5200,25201,"Ammonium, (6-(2-oxo-1-pyrrolidinyl)hexyl)trimethyl-, iodide",C[N+](C)(C)CCCCCCN1CCCC1=O.[I-],,,,,,
5201,25202,Trimethyl-[6-(2-oxopyrrolidin-1-yl)hexyl]azanium,C[N+](C)(C)CCCCCCN1CCCC1=O,,,,,,
5202,25203,Ammonium gluconate,C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O.N,,,,,,
5203,25204,Barium chloride,[Cl-].[Cl-].[Ba+2],,,,"['Barium forms a protein adduct in serum and is deposited in bone up to 65%. ... Barium chloride is being taken up ... by oral ingestion up to 10-30%.', 'Nasal absorption of 133-barium chloride was estimated at 60-80% of the dose at 4 hr after dosing, and alveolar absorption may be of similar magnitude.', '... In hamsters receiving (133)barium chloride by intragastric intubation, absorption was 11-32% of the dose ... .', 'When 133-Barium was injected IM into hind leg of rats for scintigraphy, barium chloride dissolved rapidly, leaving injection site within 3 days.', 'For more Absorption, Distribution and Excretion (Complete) data for Barium chloride (27 total), please visit the HSDB record page.']","['The in vivo solubility in rats of barium chloride, barium carbonate, barium sulfate, and barium fused in clay /was studied/. The chloride and the carbonate disappeared rapidly from the injection site. The sulfate dissolved more slowly; a half-life of 26 days was calculated. The fused clay was largely retained, the half-life being calculated as 1390 days.']",
5204,25205,Samarium nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Sm+3],,,,,,
5205,25206,ZINC chlorate,[O-]Cl(=O)=O.[O-]Cl(=O)=O.[Zn+2],,,,"['... CHLORATES ARE ... ABSORBED BY INGESTION OR BY INHALATION OF DUST. /CHLORATES/', 'Upon intravenous injection zinc is distributed to erythrocytes, plasma, and leukocytes; about 80% of the zinc present in the blood is found in the erythrocytes, 12-20% in the plasma, and about 3% in the leukocytes. ... There is a dynamic exchange of zinc between plasma and erythrocytes. Inhalation of dusts of zinc salts results in a transient accumulation in the lung before its absorption into the blood. There is little absorption of zinc or its salts through the skin. ... About 80% of parenterally administered zinc is excreted in the feces, suggesting an enterohepatic circulation for zinc. In humans, about 10% of the absorbed zinc is excreted in the urine, and in tropical climates about 2-3 mg zinc/day may be lost in sweat. /Soluble zinc compounds/']",,
5206,25207,"BENZOIC ACID, THIO-, S-(p-TOLYL) ESTER",CC1=CC=C(C=C1)SC(=O)C2=CC=CC=C2,,,,,,
5207,25208,Camphorquinone,CC1(C2CCC1(C(=O)C2=O)C)C,,,,,,
5208,25209,Tetradec-7-ene,CCCCCCC=CCCCCCC,,,,,,
5209,25210,Chlormerodrin,COC(CNC(=O)N)C[Hg]Cl,['Previously used as a diuretic. The radiolabeled form has been used as a diagnostic and research tool.'],['Chlormerodrin is a mercurial compound with toxic side effects. It is no longer used and has been replaced with new classes of diuretic drugs.'],,,,
5210,25211,"2,5-Diisopropyl-p-xylene",CC1=CC(=C(C=C1C(C)C)C)C(C)C,,,,,,
5211,25212,Magnesium nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Mg+2],,,,,,
5212,25213,Trolamine salicylate,C1=CC=C(C(=C1)C(=O)O)O.C(CO)N(CCO)CCO,"['Indicated for the temporary relief of aches, and pains of muscles and joints associated with backache, lumbago, strains, bruises, sprains and arthritic or rheumatic pain, pain of tendons and ligaments.']","['Trolamine salicylate is a salicylate that inhibits cyclo-oxygenase (COX) enzymes responsible for generating pro-inflammatory factors such as to induce pain and inflammation. It is thought to mediate its analgesic effect through inhibition of COX-2 enzyme, which is an induced enzyme responsible for inflammatory responses and pain in muscle and joint disorders. By inhibiting fatty acid COX enzyme, trolamine salicylate inhibits the production of prostaglandins and thromboxanes in inflammatory cells involved in generating pain and inflammation. It thereby works to temporarily reduce mild to moderate pain. In subjects with muscle soreness from exercise, administration of topical trolamine salicylate was associated with reduced duration and severity of muscule soreness compared to placebo. In subjects with osteoarthritis in hands, trolamine salicylate cream was shown to be effective in achieving temporary relief of minor pain and stiffness.']",,"['Following topical administration of 10% trolamine salicylate in healthy volunteers, salicylic acid could not be detected in serum indicating low systemic absorption.', 'Following topical administration of 10% trolamine salicylate in healthy volunteers, urinary recovery of total salicylate during the first 24 hours was 6.9 mg (p < 0.05), which is 1.4% of total dose.', 'Topical administration of 1 gram of 10% trolamine salicylate in abdominal rat skin resulted in an approximate extravascular volume of distribution (V/F) of 24.0 mL.']",,
5213,25214,"Arsenenous acid, strontium salt, tetrahydrate",O.O.O.O.[O-][As]=O.[O-][As]=O.[Sr+2],,,,,,
5214,25215,Tetrazepam,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CCCCC3,,,"['A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358) (See all compounds classified as Muscle Relaxants, Central.)']",,,
5215,25216,CID 25216,C1=CC2=C(C(=C1)O)N=CC=C2.[Cu],,,,,,
5216,25217,"p-ANISIDINE, N,N-BIS(((p-CHLOROPHENYL)THIO)METHYL)-",COC1=CC=C(C=C1)N(CSC2=CC=C(C=C2)Cl)CSC3=CC=C(C=C3)Cl,,,,,,
5217,25218,"Acetanilide, 4'-bromo-2-fluoro-N-methyl-",CN(C1=CC=C(C=C1)Br)C(=O)CF,,,,,,
5218,25219,"9,10-Bis(chloromethyl)anthracene",C1=CC=C2C(=C1)C(=C3C=CC=CC3=C2CCl)CCl,,,,,,
5219,25220,2-(Butylamino)-1-(4-nitrophenyl)ethanol,CCCCNCC(C1=CC=C(C=C1)[N+](=O)[O-])O,,,,,,
5220,25221,"4-Methylamino-3,5-xylyl methylcarbamate",CC1=CC(=CC(=C1NC)C)OC(=O)NC,,,,,,
5221,25222,4-(4-Nitrophenyl)morpholine,C1COCCN1C2=CC=C(C=C2)[N+](=O)[O-],,,,,,
5222,25223,Clortermine,CC(C)(CC1=CC=CC=C1Cl)N,,,,,,['9 to 24 hr /Clortermine hydrochloride/']
5223,25224,Haletazole tartrate,CCN(CC)CCOC1=CC=C(C=C1)C2=NC3=C(S2)C=CC(=C3)Cl.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,,,,,,
5224,25225,3-Iodo-5-nitroaniline,C1=C(C=C(C=C1[N+](=O)[O-])I)N,,,,,,
5225,25226,Diphenylmethylenemalononitrile,C1=CC=C(C=C1)C(=C(C#N)C#N)C2=CC=CC=C2,,,,,,
5226,25227,"Isophthalamic acid, 5,5'-(hexamethylenebis(carbonylimino))bis(N-propyl-2,4,6-triiodo-",CCCNC(=O)C1=C(C(=C(C(=C1I)NC(=O)CCCCCCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)C(=O)NCCC)I)I)C(=O)O)I,,,,,,
5227,25228,"Isophthalamic acid, 5,5'-(octamethylenebis(carbonylimino))bis(N-propyl-2,4,6-triiodo-",CCCNC(=O)C1=C(C(=C(C(=C1I)NC(=O)CCCCCCCCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)C(=O)NCCC)I)I)C(=O)O)I,,,,,,
5228,25229,Iocarmic acid,CNC(=O)C1=C(C(=C(C(=C1I)NC(=O)CCCCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)C(=O)NC)I)I)C(=O)O)I,,,,,,
5229,25230,"Isophthalamic acid, 5,5'-(hexamethylenebis(carbonylimino))bis(N-methyl-2,4,6-triiodo-",CNC(=O)C1=C(C(=C(C(=C1I)NC(=O)CCCCCCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)C(=O)NC)I)I)C(=O)O)I,,,,,,
5230,25231,"Isophthalamic acid, 5,5'-(decamethylenebis(carbonylimino))bis(N-methyl-2,4,6-triiodo-",CNC(=O)C1=C(C(=C(C(=C1I)NC(=O)CCCCCCCCCCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)C(=O)NC)I)I)C(=O)O)I,,,,,,
5231,25232,CID 25232,C1=CC=C(C=C1)C(C2=CC=CC=N2)C(=N)S,,,,,,
5232,25233,2-(2-(Dipropylamino)propoxy)benzophenone hydriodide,CCC[NH+](CCC)C(C)COC1=CC=CC=C1C(=O)C2=CC=CC=C2.[I-],,,,,,
5233,25234,[2-[2-(Dipropylamino)propoxy]phenyl]-phenylmethanone,CCCN(CCC)C(C)COC1=CC=CC=C1C(=O)C2=CC=CC=C2,,,,,,
5234,25235,2-(2-(Dibutylamino)propoxy)benzophenone hydriodide,CCCC[NH+](CCCC)C(C)COC1=CC=CC=C1C(=O)C2=CC=CC=C2.[I-],,,,,,
5235,25236,[2-[2-(Dibutylamino)propoxy]phenyl]-phenylmethanone,CCCCN(CCCC)C(C)COC1=CC=CC=C1C(=O)C2=CC=CC=C2,,,,,,
5236,25237,Copper;octadec-9-enoate,CCCCCCCCC=CCCCCCCCC(=O)[O-].[Cu+2],,,,,,
5237,25238,Eugenyl phenylacetate,COC1=C(C=CC(=C1)CC=C)OC(=O)CC2=CC=CC=C2,,,,,,
5238,25239,2-Phenylpropyl acetate,CC(COC(=O)C)C1=CC=CC=C1,,,,,,
5239,25240,"1,4-Benzodioxan-2-methanol, alpha-(((3-methoxypropyl)amino)methyl)-, hydrochloride",COCCC[NH2+]CC(C1COC2=CC=CC=C2O1)O.[Cl-],,,,,,
5240,25241,alpha-Isopropyl-alpha-(4-dimethylaminobutyl)-1-naphthylacetonitrile,CC(C)C(CCCCN(C)C)(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
5241,25242,Difluoroamine,N(F)F,,,,,,
5242,25243,"6,7,8,9-Tetrahydro-5H-benzocyclohepten-5-amine hydrochloride",C1CCC2=CC=CC=C2C(C1)[NH3+].[Cl-],,,,,,
5243,25244,"6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-amine",C1CCC2=CC=CC=C2C(C1)N,,,,,,
5244,25245,"2,4-Bis(dimethylamino)-6-hydrazino-1,3,5-triazine",CN(C)C1=NC(=NC(=N1)NN)N(C)C,,,,,,
5245,25246,"2,3-Dichloroisobutyric acid",CC(CCl)(C(=O)O)Cl,,,,,,
5246,25247,Mercury(I) nitrate,[N+](=O)([O-])[O-].[Hg+],,,,,,
5247,25248,"N,O-Bis(trimethylsilyl)acetamide",CC(=N[Si](C)(C)C)O[Si](C)(C)C,,,,,,
5248,25249,Stanozolol,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(CC5=C(C4)NN=C5)C,"['Stanozolol is a synthetic anabolic steroid with therapeutic uses in treating C1-inhibitor deficient hereditary angioedema. C1-inhibitor is a protease that inhibits the complement system (part of the innate immune system), a biochemical chain of reactions which assists the body in removing pathogens from the body. Stanozolol may help control attacks of hereditary angioedema.  Stanozolol can be administered orally or intramuscularly.']","['Stanozolol is a synthetic anabolic-androgenic steroid (AAS), which promotes cell growth (anabolism) and development/maintenance of masculine characteristics (androgenism).']","['Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. (See all compounds classified as Androgens.)', 'These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power. (See all compounds classified as Anabolic Agents.)']",['It is not known whether anabolic steroids are distributed into breast milk. /Anabolic steroids/'],"[""Urinary metabolites of stanozolol (17 alpha-methyl-17 beta-hydroxy-5 alpha-androst-2-eno(3,2-c)-pyrazole) following oral administration were isolated by chromatography on XAD-2 and by preparative high-performance liquid chromatography (HPLC) and identified by gas chromatography-mass spectrometry (GC/MS) with electron impact (EI)-ionisation. Stanozolol is excreted as a conjugate but is metabolized to a large extent. All identified metabolites are hydroxylated, namely at C-3' of the pyrazole ring and at C-4 beta, C-16 alpha and C-16 beta of the steroid. Less than 5% of the metabolites are found in the unconjugated urine fraction: 3'-hydroxy-stanozolol (II) and 3'-hydroxy-17-epistanozolol (III). Conjugated excreted metabolites are 3'-hydroxystanozolol (II), stanozolol (I), 4 beta-hydroxy-stanozolol (IV), 16 beta-hydroxystanozolol (V), 16 alpha-hydroxystanozolol (VI), two isomers of 3',16-dihydroxystanozolol (VII, VIII), two isomers of 4 beta, 16-dihydroxystanozolol (IX, X) and a 3',?-dihydroxystanozolol (XI). 3'-Hydroxystanozolol, 4 alpha-hydroxystanozolol, 4 beta-hydroxystanozolol, 16 alpha-hydroxy-, 16 alpha-hydroxy-17-epi- and 16 beta-hydroxystanozolol were synthesised to confirm the structural assignment of the main metabolites."", 'The equine phase I and phase II metabolism of the synthetic anabolic steroid stanozolol was investigated following its administration by intramuscular injection to a thoroughbred gelding. The major phase I biotransformations were hydroxylation at C16 and one other site, while phase II metabolism in the form of sulfate and beta-glucuronide conjugation was extensive.', 'An analytical method has been developed in order to control the illegal use of stanozolol as growth promoter in livestock. ...  Urinary metabolites were identified by mass spectrometry. Stanozolol and 16-hydroxystanozolol were detected after oral administration, while 16-hydroxystanozolol and 4,16-dihydroxystanozolol were found after subcutaneous administration.']",['24 hours']
5249,25250,Diethyl (2-chloroethyl)phosphonate,CCOP(=O)(CCCl)OCC,,,,,,
5250,25251,Ferric nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Fe+3],,,,,,
5251,25252,"2-N,4-N-diethyl-6-hydrazinyl-1,3,5-triazine-2,4-diamine",CCNC1=NC(=NC(=N1)NN)NCC,,,,,,
5252,25253,"4-N,6-N-diethyl-2-N-[(5-nitrofuran-2-yl)methylideneamino]-1,3,5-triazine-2,4,6-triamine",CCNC1=NC(=NC(=N1)NN=CC2=CC=C(O2)[N+](=O)[O-])NCC,,,,,,
5253,25254,1-Bromo-2-methylbutane,CCC(C)CBr,,,,,,
5254,25255,Citenamide,C1=CC=C2C(C3=CC=CC=C3C=CC2=C1)C(=O)N,,,,,,
5255,25256,"Furfuryl alcohol, phosphate (3:1)",C1CC(OC1)COP(=O)(OCC2CCCO2)OCC3CCCO3,,,,,,
5256,25257,"1,2-Ethanediaminium, N,N,N,N',N',N'-hexamethyl-, diiodide",C[N+](C)(C)CC[N+](C)(C)C.[I-].[I-],,,,,,
5257,25258,Dimethonium,C[N+](C)(C)CC[N+](C)(C)C,,,,,,
5258,25259,Dibutyl(3-(2-(alpha-hydroxybenzyl)phenoxy)propyl)methylammonium iodide,CCCC[N+](C)(CCCC)CCCOC1=CC=CC=C1C(C2=CC=CC=C2)O.[I-],,,,,,
5259,25260,Dibutyl[3-[2-(alpha-hydroxybenzyl)phenoxy]propyl]methylaminium,CCCC[N+](C)(CCCC)CCCOC1=CC=CC=C1C(C2=CC=CC=C2)O,,,,,,
5260,25261,2-(3-(Dimethylamino)propoxy)benzophenone hydrobromide,C[NH+](C)CCCOC1=CC=CC=C1C(=O)C2=CC=CC=C2.[Br-],,,,,,
5261,25262,[2-[3-(Dimethylamino)propoxy]phenyl]-phenylmethanone,CN(C)CCCOC1=CC=CC=C1C(=O)C2=CC=CC=C2,,,,,,
5262,25263,2-(3-(Diethylamino)propoxy)benzophenone hydrogen phosphate,CC[NH+](CC)CCCOC1=CC=CC=C1C(=O)C2=CC=CC=C2.OP(=O)(O)[O-],,,,,,
5263,25264,[2-[3-(Diethylamino)propoxy]phenyl]-phenylmethanone,CCN(CC)CCCOC1=CC=CC=C1C(=O)C2=CC=CC=C2,,,,,,
5264,25265,2-(3-(Dipropylamino)propoxy)benzophenone hydriodide,CCC[NH+](CCC)CCCOC1=CC=CC=C1C(=O)C2=CC=CC=C2.[I-],,,,,,
5265,25266,[2-[3-(Dipropylamino)propoxy]phenyl]-phenylmethanone,CCCN(CCC)CCCOC1=CC=CC=C1C(=O)C2=CC=CC=C2,,,,,,
5266,25267,2-(3-(Dibutylamino)propoxy)benzophenone hydrobromide,CCCC[NH+](CCCC)CCCOC1=CC=CC=C1C(=O)C2=CC=CC=C2.[Br-],,,,,,
5267,25268,[2-[3-(Dibutylamino)propoxy]phenyl]-phenylmethanone,CCCCN(CCCC)CCCOC1=CC=CC=C1C(=O)C2=CC=CC=C2,,,,,,
5268,25269,N-((1-(2-Benzylphenoxy)methyl)ethyl)dipropylamine hydrochloride,CCC[NH+](CCC)C(C)COC1=CC=CC=C1CC2=CC=CC=C2.[Cl-],,,,,,
5269,25270,"1-(2-benzylphenoxy)-N,N-dipropylpropan-2-amine",CCCN(CCC)C(C)COC1=CC=CC=C1CC2=CC=CC=C2,,,,,,
5270,25271,2-(2-((alpha-Methylphenethyl)amino)ethoxy)benzophenone hydrochloride,CC(CC1=CC=CC=C1)[NH2+]CCOC2=CC=CC=C2C(=O)C3=CC=CC=C3.[Cl-],,,,,,
5271,25272,Phenyl-[2-[2-(1-phenylpropan-2-ylamino)ethoxy]phenyl]methanone,CC(CC1=CC=CC=C1)NCCOC2=CC=CC=C2C(=O)C3=CC=CC=C3,,,,,,
5272,25273,"N,N-Bis(2-chloroethyl)benzylamine hydrochloride",C1=CC=C(C=C1)C[NH+](CCCl)CCCl.[Cl-],,,,,,
5273,25274,Butyrylethyleneimine,CCCC(=O)N1CC1,,,,,,
5274,25275,"Malononitrile, (1-phenylpropylidene)-",CCC(=C(C#N)C#N)C1=CC=CC=C1,,,,,,
5275,25276,"Silanamine, N-(2-phenylethyl)-1,1,1-trimethyl-",C[Si](C)(C)NCCC1=CC=CC=C1,,,,,,
5276,25277,"1H-Imidazolium, 5-((4-ethyltetrahydro-5-oxo-3-furanyl)methyl)-1,3-dimethyl-, iodide",CCC1C(COC1=O)CC2=C[N+](=CN2C)C.[I-],,,,,,
5277,25278,"4-[(1,3-Dimethylimidazol-1-ium-4-yl)methyl]-3-ethyloxolan-2-one",CCC1C(COC1=O)CC2=C[N+](=CN2C)C,,,,,,
5278,25279,Tiametonium iodide,CC[N+](C)(C)CCSCC[N+](C)(C)CC.[I-].[I-],,,,,,
5279,25280,Tiametonium,CC[N+](C)(C)CCSCC[N+](C)(C)CC,,,,,,
5280,25281,"1,1,2,3-Tetrachloropropene",C(C(=C(Cl)Cl)Cl)Cl,,,,,,
5281,25282,"N,2-Dimethyl-4-nitroaniline",CC1=C(C=CC(=C1)[N+](=O)[O-])NC,,,,,,
5282,25283,"Acetic acid, (6-hydroxy-2-naphthalenyl)oxy-",C1=CC2=C(C=CC(=C2)OCC(=O)O)C=C1O,,,,,,
5283,25284,"2-Imidazoline, 2-butyl-",CCCCC1=NCCN1,,,,,,
5284,25285,"2-Imidazoline, 2-octyl-",CCCCCCCCC1=NCCN1,,,,,,
5285,25286,"Butanoic acid, 4-(4-chloro-2-methylphenoxy)-, ethyl ester",CCOC(=O)CCCOC1=C(C=C(C=C1)Cl)C,,,,,,
5286,25287,"Cyclotetrasiloxane, heptamethylphenyl-",C[Si]1(O[Si](O[Si](O[Si](O1)(C)C)(C)C2=CC=CC=C2)(C)C)C,,,,,,
5287,25288,"Cyclotetrasiloxane, pentamethyltriphenyl-",C[Si]1(O[Si](O[Si](O[Si](O1)(C)C2=CC=CC=C2)(C)C3=CC=CC=C3)(C)C4=CC=CC=C4)C,,,,,,
5288,25289,Orthoperiodic acid,OI(=O)(O)(O)(O)O,,,,,,
5289,25290,"Glycine, N-(2-benzoyl-4-chlorophenyl)-, ethyl ester",CCOC(=O)CNC1=C(C=C(C=C1)Cl)C(=O)C2=CC=CC=C2,,,,,,
5290,25291,"DIBENZ(a,h)ACRIDINE, 14-BUTYL-",CCCCC1=C2C=CC3=CC=CC=C3C2=NC4=C1C5=CC=CC=C5C=C4,,,,,,
5291,25292,"DIBENZ(a,j)ACRIDINE, 14-ISOPROPYL-",CC(C)C1=C2C(=NC3=C1C4=CC=CC=C4C=C3)C=CC5=CC=CC=C52,,,,,,
5292,25293,Clofluperol,C1CN(CCC1(C2=CC(=C(C=C2)Cl)C(F)(F)F)O)CCCC(=O)C3=CC=C(C=C3)F,,,,,,
5293,25294,"N-p-Chlorobenzyl-N',N'-dimethyl-N-2-pyridylethylenediamine hydrochloride",C[NH+](C)CCN(CC1=CC=C(C=C1)Cl)C2=CC=CC=N2.[Cl-],,,,,,
5294,25295,Chloropyramine,CN(C)CCN(CC1=CC=C(C=C1)Cl)C2=CC=CC=N2,"['For the treatment of allergic conjunctivitis, allergic rhinitis, bronchial asthma, and other atopic (allergic) conditions.']","['Chlorpyramine is a competitive reversible H1 receptor antagonist. This inhibits vasodilation, increases in vascular permeability, and tissue edema associated with histamine release. In addition, chloropyramine has some anticholinergic properties. These effects, along with its ability to pass through the blood-brain barrier lead to side effects such as drowsiness, weakness, vertigo, fatigue, dryness in the mouth, constipation, and rarely - visual disturbances and increase of intraocular pressure.']","['Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)']",,,
5295,25296,"o-CRESOL, 4,4'-(1,2-DIETHYLETHYLENE)DI-",CC[C@H](C1=CC(=C(C=C1)O)C)[C@@H](CC)C2=CC(=C(C=C2)O)C,,,,,,
5296,25297,Samarium(3+) acetate,CC(=O)[O-].CC(=O)[O-].CC(=O)[O-].[Sm+3],,,,,,
5297,25298,1-Ethoxy-1-methoxyethane,CCOC(C)OC,,,,,,
5298,25299,"3,4-Dioxo-2,5-diphenylhexanedinitrile",C1=CC=C(C=C1)C(C#N)C(=O)C(=O)C(C#N)C2=CC=CC=C2,,,,,,
5299,25300,"Carbamic acid, ethyl-, 1,1-diphenyl-2-propynyl ester",CCNC(=O)OC(C#C)(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
5300,25301,1-(4-Chlorophenyl)-1-phenyl-2-propynyl carbamate,C#CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OC(=O)N,,,,,,
5301,25302,Strontium bromide (SrBr2),[Br-].[Br-].[Sr+2],,,,,,
5302,25303,"(4aR,5aS,8aS,15bR)-2,4a,5,5a,6,7,8,13a,15,15a,15b,16-dodecahydro4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinolin-6-ium-14-one;dihydrogen arsorate",C1C[NH+]2CC3=CCOC4CC(=O)N5C6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.O[As](=O)(O)[O-],,,,,,
5303,25304,Strontium iodide (SrI2),[Sr+2].[I-].[I-],,,,,,
5304,25305,Methacrolein diacetate,CC(=C)C(OC(=O)C)OC(=O)C,,,,,,
5305,25306,"N,N-Bis(2-chloroethyl)-p-aminophenylacetic acid",C1=CC(=CC=C1CC(=O)O)N(CCCl)CCCl,,,,,,
5306,25307,"Benzoic acid, 2-(((2-carboxyphenyl)amino)sulfonyl)-5-((4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)azo)-, disodium salt",CC1=NN(C(=O)C1N=NC2=CC(=C(C=C2)S(=O)(=O)NC3=CC=CC=C3C(=O)[O-])C(=O)[O-])C4=CC=CC=C4.[Na+].[Na+],,,,,,
5307,25308,"2-[(2-Carboxyphenyl)sulfamoyl]-5-[(3-methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl)diazenyl]benzoic acid",CC1=NN(C(=O)C1N=NC2=CC(=C(C=C2)S(=O)(=O)NC3=CC=CC=C3C(=O)O)C(=O)O)C4=CC=CC=C4,,,,,,
5308,25309,"2-Dodecenoic acid, 7,11-dichloro-3,7,11-trimethyl-, methyl ester",CC(=CC(=O)OC)CCCC(C)(CCCC(C)(C)Cl)Cl,,,,,,
5309,25310,L-Rhamnose,C[C@H]1[C@@H]([C@H]([C@H](C(O1)O)O)O)O,,,,,['L-Rhamnose is a known human metabolite of Quercitrin.'],
5310,25311,Tridecanal,CCCCCCCCCCCCC=O,,,,,,
5311,25312,"4-Heptanone, 2,6-bis(trifluoromethyl)-2,6-dihydroxy-1,1,1,7,7,7-hexafluoro-",C(C(=O)CC(C(F)(F)F)(C(F)(F)F)O)C(C(F)(F)F)(C(F)(F)F)O,,,,,,
5312,25313,alpha-Methyl-alpha-acetyloxybenzeneacetic acid,CC(=O)OC(C)(C1=CC=CC=C1)C(=O)O,,,,,,
5313,25314,N-Methyl-2-((o-methyl-alpha-phenylbenzyl)oxy)ethylamine hydrochloride,CC1=CC=CC=C1C(C2=CC=CC=C2)OCC[NH2+]C.[Cl-],,,,,,
5314,25315,Tofenacin,CC1=CC=CC=C1C(C2=CC=CC=C2)OCCNC,,,"['Drugs that bind to but do not activate CHOLINERGIC RECEPTORS, thereby blocking the actions of ACETYLCHOLINE or cholinergic agonists. (See all compounds classified as Cholinergic Antagonists.)']",,,
5315,25316,"1,6-Naphthalenediol, 2,5-bis((cyclohexylamino)methyl)-",C1CCC(CC1)NCC2=C(C3=C(C=C2)C(=C(C=C3)O)CNC4CCCCC4)O,,,,,,
5316,25317,Tris(trimethylsilyl) phosphate,C[Si](C)(C)OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C,,,,,,
5317,25318,Diphenylacetic acid 2-(diethylamino)butyl ester hydrochloride,CCC(COC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2)[NH+](CC)CC.[Cl-],,,,,,
5318,25319,"2-(Diethylamino)butyl 2,2-diphenylacetate",CCC(COC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2)N(CC)CC,,,,,,
5319,25320,Di-tert-amyl peroxide,CCC(C)(C)OOC(C)(C)CC,,,,,,
5320,25321,CID 25321,CC1=C([NH+](C=N1)C)CCC(=NN=C(N)S)C.C(#N)[S-],,,,,,
5321,25322,CID 25322,CC1=C(N(C=N1)C)CCC(=NN=C(N)S)C,,,,,,
5322,25323,1-(4-(Hydroxyamino)phenyl)ethanone,CC(=O)C1=CC=C(C=C1)NO,,,,,,
5323,25324,Decahydro-2-naphthyl acetate,CC(=O)OC1CCC2CCCCC2C1,,,,,,
5324,25325,Decahydro-2-naphthyl formate,C1CCC2CC(CCC2C1)OC=O,,,,,,
5325,25326,(2-methylpropylideneamino) N-methylcarbamate,CC(C)C=NOC(=O)NC,,,,,,
5326,25327,Diphenylacetic acid 1-((diethylamino)methyl)butyl ester hydrochloride,CCCC(C[NH+](CC)CC)OC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
5327,25328,"1-(Diethylamino)pentan-2-yl 2,2-diphenylacetate",CCCC(CN(CC)CC)OC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
5328,25329,Diphenylacetic acid 1-((diethylamino)methyl)propyl ester hydrochloride,CCC(C[NH+](CC)CC)OC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2.[Cl-],,,,,,
5329,25330,"1-(Diethylamino)butan-2-yl 2,2-diphenylacetate",CCC(CN(CC)CC)OC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
5330,25331,2-Aminoadamantane hydrochloride,C1C2CC3CC1CC(C2)C3N.Cl,,,,,,
5331,25332,2-Aminoadamantane,C1C2CC3CC1CC(C2)C3N,,,,,,
5332,25333,"2-Adamantanamine, N-methyl-, hydrochloride",CNC1C2CC3CC(C2)CC1C3.Cl,,,,,,
5333,25334,N-methyladamantan-2-amine,CNC1C2CC3CC(C2)CC1C3,,,,,,
5334,25335,"1-Aziridinepropionic acid, hexyl ester",CCCCCCOC(=O)CCN1CC1,,,,,,
5335,25336,"beta-ALANINE, N-CARBOXYMETHYL-N-NITRO-",C(CN(CC(=O)O)[N+](=O)[O-])C(=O)O,,,,,,
5336,25337,"beta-ALANINE, N,N'-(1,2-ETHANEDIYL)BIS(N-NITRO-",C(CN(CCN(CCC(=O)O)[N+](=O)[O-])[N+](=O)[O-])C(=O)O,,,,,,
5337,25338,"Cyclopropanecarboxamide, N-acetyl-",CC(=O)NC(=O)C1CC1,,,,,,
5338,25339,"2-Adamantanamine, N,N-dimethyl-, hydrochloride",CN(C)C1C2CC3CC(C2)CC1C3.Cl,,,,,,
5339,25340,"2-N,N-dimethylaminoadamantane",CN(C)C1C2CC3CC(C2)CC1C3,,,,,,
5340,25341,(1-(4-Ethoxyphenyl)butyl)diethylammonium chloride,CC[NH+](CC)C(CC(C)C1=CC=CC=C1)C2=CC=C(C=C2)OCC.[Cl-],,,,,,
5341,25342,"1-(p-Ethoxyphenyl)-N,N-diethyl-3-phenylbutylamine",CCN(CC)C(CC(C)C1=CC=CC=C1)C2=CC=C(C=C2)OCC,,,,,,
5342,25343,"1-Naphthalenepropylamine, N-(2-diethylaminoethyl)-beta-(tetrahydrofurfuryl)-, bioxalate",CC[NH+](CC)CC[NH2+]CC(CC1CCCO1)CC2=CC=CC3=CC=CC=C32.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
5343,25344,"N',N'-diethyl-N-[2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)propyl]ethane-1,2-diamine",CCN(CC)CCNCC(CC1CCCO1)CC2=CC=CC3=CC=CC=C32,,,,,,
5344,25345,N-(2-Pyrrolidinoethyl)-beta-tetrahydrofurfuryl-1-naphthalenepropylamine bioxalate,C1CC[NH+](C1)CC[NH2+]CC(CC2CCCO2)CC3=CC=CC4=CC=CC=C43.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
5345,25346,2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)-N-(2-pyrrolidin-1-ylethyl)propan-1-amine,C1CCN(C1)CCNCC(CC2CCCO2)CC3=CC=CC4=CC=CC=C43,,,,,,
5346,25347,N-(2-Piperidinoethyl)-beta-tetrahydrofurfuryl-1-naphthalenepropylamine bioxalate,C1CC[NH+](CC1)CC[NH2+]CC(CC2CCCO2)CC3=CC=CC4=CC=CC=C43.C(=O)(C(=O)[O-])O.C(=O)(C(=O)[O-])O,,,,,,
5347,25348,2-(naphthalen-1-ylmethyl)-3-(oxolan-2-yl)-N-(2-piperidin-1-ylethyl)propan-1-amine,C1CCN(CC1)CCNCC(CC2CCCO2)CC3=CC=CC4=CC=CC=C43,,,,,,
5348,25349,"4-[3-(Dimethylamino)propyl]-2-phenyl-1,4-benzothiazin-3-one",CN(C)CCCN1C2=CC=CC=C2SC(C1=O)C3=CC=CC=C3,,,,,,
5349,25350,Memotine,COC1=CC=C(C=C1)OCC2=NCCC3=CC=CC=C32,,,,,,
5350,25351,"3-Quinuclidyl 5-hydroxy-10,11-dihydro-(5H)-dibenzo(a,d)cycloheptene-5-carboxylate",C1CN2CCC1C(C2)OC(=O)C3(C4=CC=CC=C4CCC5=CC=CC=C53)O,,,,,,
5351,25352,Dinitrogen tetroxide,[N+](=O)([N+](=O)[O-])[O-],,,,,,
5352,25353,Sulfur dichloride,S(Cl)Cl,,,,,,
5353,25354,N-Propylbenzamide,CCCNC(=O)C1=CC=CC=C1,,,,,,
5354,25355,Terbufos sulfoxide,CCOP(=S)(OCC)SCS(=O)C(C)(C)C,,,,,,
5355,25356,CID 25356,CCCC1=C2C=CC(=O)C(=C2OC(=C1)O)CN3CCCCC3,,,,,,
5356,25357,CID 25357,C1CCN(CC1)CC2=C3C(=C(C=C(O3)O)C4=CC=CC=C4)C=CC2=O,,,,,,
5357,25358,"m-DIOXANE, 2-(p-BIS(2-(CHLOROETHYL)AMINO)PHENYL)-",C1COC(OC1)C2=CC=C(C=C2)N(CCCl)CCCl,,,,,,
5358,25359,CID 25359,CC1=C2C=CC(=O)C(=C2OC(=C1)O)C[NH+]3CCCCC3.[Cl-],,,,,,
5359,25360,CID 25360,CC1=C2C=CC(=O)C(=C2OC(=C1)O)CN3CCCCC3,,,,,,
5360,25361,CID 25361,CC1=C2C=CC(=O)C(=C2OC(=C1)O)C[NH+]3CCCCC3.C1=CC(=CN=C1)C(=O)[O-],,,,,,
5361,25362,CID 25362,CC1=C2C=CC(=O)C(=C2OC(=C1)O)C[NH+](C)C.C1=CC(=CN=C1)C(=O)[O-],,,,,,
5362,25363,CID 25363,CC1=C2C=CC(=O)C(=C2OC(=C1)O)CN(C)C,,,,,,
5363,25364,CID 25364,CC1=C2C=CC(=O)C(=C2OC(=C1)O)C[NH+]3CCCCC3.C1=CN=CC=C1C(=O)[O-],,,,,,
5364,25365,CID 25365,CC1=C2C=CC(=O)C(=C2OC(=C1)O)C[NH+]3CCCCC3.C1=CC=NC(=C1)C(=O)[O-],,,,,,
5365,25366,CID 25366,CCCC1=C2C=CC(=O)C(=C2OC(=C1)O)C[NH+]3CCCCC3.C1=CC(=CN=C1)C(=O)[O-],,,,,,
5366,25367,CID 25367,CCCC1=C2C=CC(=O)C(=C2OC(=C1)O)C[NH+](C)C.C1=CC(=CN=C1)C(=O)[O-],,,,,,
5367,25368,CID 25368,CCCC1=C2C=CC(=O)C(=C2OC(=C1)O)CN(C)C,,,,,,
5368,25369,CID 25369,C1CC[NH+](CC1)CC2=C3C(=C(C=C(O3)O)C4=CC=CC=C4)C=CC2=O.C1=CN=CC=C1C(=O)[O-],,,,,,
5369,25370,CID 25370,CC1=C2C=CC(=O)C(=C2OC(=C1)O)C[NH+](C)C.C1=CC=NC(=C1)C(=O)[O-],,,,,,
5370,25371,"3-Pyrroline, N-nitroso-",C1C=CCN1N=O,,,,,,
5371,25372,"Benzoic acid, 4-((2,4-diamino-6-(3-anilino-2-chloro)propylamino)pyrimidin-5-yl)azo-, ethyl ester, hydrochloride",CCOC(=O)C1=CC=C(C=C1)N=NC2=C(N=C(N=C2NCC(CNC3=CC=CC=C3)Cl)N)N.Cl,,,,,,
5372,25373,"Ethyl 4-[[2,4-diamino-6-[(3-anilino-2-chloropropyl)amino]pyrimidin-5-yl]diazenyl]benzoate",CCOC(=O)C1=CC=C(C=C1)N=NC2=C(N=C(N=C2NCC(CNC3=CC=CC=C3)Cl)N)N,,,,,,
5373,25374,"1,3,5-Tri(isopropyl)hexahydro-1,3,5-triazine",CC(C)N1CN(CN(C1)C(C)C)C(C)C,,,,,,
5374,25375,"3,4,5-Trimethylisoxazole",CC1=C(ON=C1C)C,,,,,,
5375,25376,"i-Propyl 1-methyl-1,2,5,6-tetrahydronicotinate",CC(C)OC(=O)C1=CCCN(C1)C,,,,,,
5376,25377,5-Methyl-1-(5-nitro-2-thiazolyl)-2-imidazolidinone,CC1CNC(=O)N1C2=NC=C(S2)[N+](=O)[O-],,,,,,
5377,25378,"N,N'-Bis(3-aminopropyl)ethylenediamine",C(CN)CNCCNCCCN,,,,,,
5378,25379,"5H-Dibenzo(a,d)cycloheptene-5-propylamine, 10,11-dihydro-N,N-dimethyl-, hydrochloride",C[NH+](C)CCCC1C2=CC=CC=C2CCC3=CC=CC=C13.[Cl-],,,,,,
5379,25380,"5H-DIBENZO(a,d)CYCLOHEPTENE-5-PROPYLAMINE, 10,11-DIHYDRO-N,N-DIMETHYL-",CN(C)CCCC1C2=CC=CC=C2CCC3=CC=CC=C13,,,,,,
5380,25381,Melitracen hydrochloride,CC1(C2=CC=CC=C2C(=CCCN(C)C)C3=CC=CC=C31)C.Cl,,,"['Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)']",,,
5381,25382,Melitracen,CC1(C2=CC=CC=C2C(=CCCN(C)C)C3=CC=CC=C31)C,,,"['Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. (See all compounds classified as Antidepressive Agents, Tricyclic.)']",,,
5382,25383,4'-(beta-D-Glucopyranosylamino)acetophenone,CC(=O)C1=CC=C(C=C1)N[C@H]2C(C([C@@H](C(O2)CO)O)O)O,,,,,,
5383,25384,"1-Isochromanpropylamine, N,N-dimethyl-1-phenyl-, hydrochloride",C[NH+](C)CCCC1(C2=CC=CC=C2CCO1)C3=CC=CC=C3.[Cl-],,,,,,
5384,25385,"N,N-dimethyl-3-(1-phenyl-3,4-dihydroisochromen-1-yl)propan-1-amine",CN(C)CCCC1(C2=CC=CC=C2CCO1)C3=CC=CC=C3,,,,,,
5385,25386,"1-Isochromanpropylamine, N-methyl-1-phenyl-, hydrochloride",C[NH2+]CCCC1(C2=CC=CC=C2CCO1)C3=CC=CC=C3.[Cl-],,,,,,
5386,25387,"N-methyl-3-(1-phenyl-3,4-dihydroisochromen-1-yl)propan-1-amine",CNCCCC1(C2=CC=CC=C2CCO1)C3=CC=CC=C3,,,,,,
5387,25388,"Naphthalene, 1,2,3,4-tetrahydro-1-(3-dimethylaminopropyl)-1-phenyl-, hydrochloride",C[NH+](C)CCCC1(CCCC2=CC=CC=C21)C3=CC=CC=C3.[Cl-],,,,,,
5388,25389,"N,N-dimethyl-3-(1-phenyl-3,4-dihydro-2H-naphthalen-1-yl)propan-1-amine",CN(C)CCCC1(CCCC2=CC=CC=C21)C3=CC=CC=C3,,,,,,
5389,25390,"Isoindoline, 1-(3-dimethylaminopropyl)-2-methyl-1-phenyl-, dihydrochloride",C[NH+]1CC2=CC=CC=C2C1(CCC[NH+](C)C)C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
5390,25391,"N,N-dimethyl-3-(2-methyl-1-phenyl-3H-isoindol-1-yl)propan-1-amine",CN1CC2=CC=CC=C2C1(CCCN(C)C)C3=CC=CC=C3,,,,,,
5391,25392,"Propylamine, N,N-dimethyl-3-(3-phenylindolin-3-yl)-, dihydrochloride",C[NH+]1CC(C2=CC=CC=C21)(CCC[NH+](C)C)C3=CC=CC=C3.[Cl-].[Cl-],,,,,,
5392,25393,"N,N-dimethyl-3-(1-methyl-3-phenyl-2H-indol-3-yl)propan-1-amine",CN1CC(C2=CC=CC=C21)(CCCN(C)C)C3=CC=CC=C3,,,,,,
5393,25394,"2-Indolinone, 3-(3-dimethylaminopropyl)-1-methyl-3-phenyl-, hydrochloride",CN1C2=CC=CC=C2C(C1=O)(CCC[NH+](C)C)C3=CC=CC=C3.[Cl-],,,,,,
5394,25395,3-[3-(Dimethylamino)propyl]-1-methyl-3-phenylindol-2-one,CN1C2=CC=CC=C2C(C1=O)(CCCN(C)C)C3=CC=CC=C3,,,,,,
5395,25396,"9-Anthracenepropanamine, 9,10-dihydro-N,N,10,10-tetramethyl-, hydrochloride",CC1(C2=CC=CC=C2C(C3=CC=CC=C31)CCC[NH+](C)C)C.[Cl-],,,,,,
5396,25397,"3-(10,10-dimethyl-9H-anthracen-9-yl)-N,N-dimethylpropan-1-amine",CC1(C2=CC=CC=C2C(C3=CC=CC=C31)CCCN(C)C)C,,,,,,
5397,25398,4-Amino-4-iminobut-2-enoic acid,C(=CC(=O)O)C(=N)N,,,,,,
5398,25399,"5,7-Dimethylbenz(c)acridine",CC1=CC2=C(C3=CC=CC=C3N=C2C4=CC=CC=C14)C,,,,,,
5399,25400,2-(2-Piperidinopropoxy)benzophenone hydrobromide,CC(COC1=CC=CC=C1C(=O)C2=CC=CC=C2)[NH+]3CCCCC3.[Br-],,,,,,
5400,25401,Phenyl(2-(2-(piperidin-1-yl)propoxy)phenyl)methanone,CC(COC1=CC=CC=C1C(=O)C2=CC=CC=C2)N3CCCCC3,,,,,,
5401,25402,3-Methylhex-2-ene,CCCC(=CC)C,,,,,,
5402,25403,"2,3-Dimethyl-2-pentene",CCC(=C(C)C)C,,,,,,
5403,25404,Butyl undecanoate,CCCCCCCCCCC(=O)OCCCC,,,,,,
5404,25405,"Bis(3,4-epoxybutyl) ether",C1C(O1)CCOCCC2CO2,,,,,,
5405,25406,"6-(Chloromethyl)-1,3,5-triazine-2,4-diamine",C(C1=NC(=NC(=N1)N)N)Cl,,,,,,
5406,25407,beta-Benzyl-2-indolineethanol,C1C(NC2=CC=CC=C21)C(CC3=CC=CC=C3)CO,,,,,,
5407,25408,Sodium dichromate,[O-][Cr](=O)(=O)O[Cr](=O)(=O)[O-].[Na+].[Na+],,,,"['1. Intratracheal instillation of sodium dichromate (CrVI) and chromium acetate hydroxide (CrIII) to male Wistar rats gave rise to increased chromium concentrations in whole blood, plasma and urine up to 72 hr post exposure; peak concentrations were reached at 6 hr after exposure. 2. The ratio of whole blood chromium to plasma chromium concentrations was significantly different for Cr(VI) and Cr(III) treatments. Both blood chromium and plasma chromium assays should therefore be used for the assessment of chromium exposure. 3. Chromium was also detected in peripheral lymphocytes. Cr(VI), but not Cr(III) accumulated significantly in the lymphocytes after treatment. These cells have potential to be used for biomarkers of the assessment of exposure to chromium compounds.']","['In order to understand the possible role of reactive intermediates in the formation of tissue-specific DNA damage by chromium(VI), electron paramagnetic resonance spectroscopy was used to study the in vivo formation of chromium(V) in the liver and red blood cells of 14 day chick embryos following treatment with chromium(VI). In vivo administration of sodium dichromate onto the inner shell membrane of 14 day chick embryos resulted in the formation of a persistent chromium(V) species in liver cells (g = 1.987). The intensity of the chromium(V) signal in liver cells plateaued at 70 min and persisted for 240 min after treatment with chromium(VI). The dependence of chromium(V) formation on the dose of sodium dichromate administered to the embryo was clearly different in liver versus red blood cells. Chromium(V) was detected in red blood cells only at high doses of sodium dichromate (0.50-0.60 mmol/kg), whereas chromium(V) was undetectable in red blood cells at lower doses of sodium dichromate (0.10-0.30 mmol/kg) which produced clear evidence for chromium(V) in liver. Uptake studies showed that total chromium levels in red blood cells were 10-fold greater than in liver cells, and that up to 10% of the total chromium existed as chromium(V) in liver and red blood cells in vivo. Depletion of glutathione by pretreatment of embryos with L-buthionine-S,R-sulfoximine (BSO) for 24 hr prior to treatment with a high dose of sodium dichromate (0.60 mmol/kg) caused both a decrease in the levels of chromium(V) species produced and a decrease of chromium uptake into red blood cells 50 min after treatment. At this high dose of chromium(VI), BSO pre-treatment had no effect on the level of the chromium(V) or on chromium uptake into liver cells after a 70 min incubation period. Thus, the concentration of chromium(V) inside the cell correlated with the levels of chromium taken up into the cell. Chromium(V) may be the form of chromium which is responsible for induction of DNA damage following in vivo administration of sodium dichromate.']",
5408,25409,"2-(3-Acetamido-2,4,6-triiodobenzyl)adipic acid",CC(=O)NC1=C(C=C(C(=C1I)CC(CCCC(=O)O)C(=O)O)I)I,,,,,,
5409,25410,"2-(3-Butyramido-2,4,6-triiodobenzyl)adipic acid",CCCC(=O)NC1=C(C=C(C(=C1I)CC(CCCC(=O)O)C(=O)O)I)I,,,,,,
5410,25411,CID 25411,C[N+](C)(C)CCCCC(=C(CCCC[N+](C)(C)C)I)Cl.[Cl-].[Cl-],,,,,,
5411,25412,CID 25412,C[N+](C)(C)CCCCC(=C(CCCC[N+](C)(C)C)I)Cl,,,,,,
5412,25413,CID 25413,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C(N)O)C(=O)[C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)[NH+](C)C)O.[Cl-],,,,,,
5413,25414,"3-(Cyclopentyloxy)-19-norpregna-3,5-dien-20-yn-17-ol",CC12CCC3C4CCC(=CC4=CCC3C1CCC2(C#C)O)OC5CCCC5,,,,,,
5414,25415,2-Dimethylaminoethyl 1-naphthylacetate,C[NH+](C)CCOC(=O)CC1=CC=CC2=CC=CC=C21.[Cl-],,,,,,
5415,25416,"1-Naphthalene acetic acid, dimethylaminoethyl ester",CN(C)CCOC(=O)CC1=CC=CC2=CC=CC=C21,,,,,,
5416,25417,N-Methyl-4-nitrosoaniline,CNC1=CC=C(C=C1)N=O,,,,,,
5417,25418,N-Nitrosomethylethylamine,CCN(C)N=O,,,,,"['...  Adult male Fischer 344 rats received a single i.p. or p.o. dose (4.4 mg/kg, 0.05 mmol/kg) of N-nitrosomethylethylamine, (14C)-labeled in either the methyl or ethyl group (survival time, 4 hr). DNA was analyzed by Sephasorb-HP chromatography following acid hydrolysis in 0.1 M HCl. Concentrations of 7-methylguanine in hepatic DNA were 170-200 times higher than those of 7-ethylguanine. This is approximately 2.6 times the 7-methylguanine: 7-ethylguanine ratio of 68, observed when DNA is reacted in vitro with equimolar amounts of the direct alkylating agents N-nitrosomethylurea and N-nitrosoethylurea, suggesting that hydroxylation at the alpha-position of the ethyl group of N-nitrosomethylethylamine proceeds at about 2.6 times the rate as at the methyl group. Concentrations of 7-methylguanine in liver were approximately 15 times higher than in kidney, 100 times higher than in esophagus, and 200 times higher than in lung. Addition of ethanol to the drinking water (5%) caused a slight interorgan shift in metabolism with a decrease in the 7-methylguanine ratio for liver: esophagus by 50% and an increase in the 7-methylguanine ratio for liver: kidney by 40%.', 'OThe oxidative dealkylation of ...  methylethylnitrosamine (MEN) by Sprague-Dawley rat liver microsomes was studied by a colorimetric assay for the simultaneous analysis of formaldehyde and acetaldehyde. Dealkylation in each instance followed Michaelis-Menten kinetics. ... Km values for demethylation and deethylation of MEN were intermediate between those for dimethylnitrosamine and diethylnitrosamine. ...', 'Possible relationships between structure and metabolism of nitrosamines have been investigated in the rat small intestine. Isolated segments of jejunum and ileum were perfused from the luminal side for 2 hr with a Tyrode solution containing one of four symmetrical dialkylnitrosamines with 2-5 carbon atoms per side chain, all (14)C-labeled at the alpha position, or one of two unsymmetrical nitrosamines, N-nitroso-tert-butylmethylamine and N-nitrosomethylbenzylamine, (14)C-labeled in the methyl group. Besides measurement of (14)C to intestinal tissue, the absorbed fluid (absorbate) as well as the perfusion medium and tissue homogenates were analysed by for the presence of polar metabolites to assess the intestinal metabolism of nitrosamines. Neither N-nitrosodiethylamine nor the two unsymmetrical nitrosamines were metabolized to any significant extent.', 'Ethylmethylnitrosamine has known human metabolites that include N-Nitrosoethanamine and N-Nitrosomethylamine.']",
5418,25419,Clodronic Acid,C(P(=O)(O)O)(P(=O)(O)O)(Cl)Cl,['Clodronic acid is indicated as an adjunct in the management of osteolysis from bone metastases of malignant tumors and for management of hypercalcemia of malignancy.'],"['Clodronic acid is a first generation bisphosphonate that inhibits osteoclast mediated bone resorption. It has a wide therapeutic index as a large overdose is required for significant toxicity and a long duration of action due to the slow release from bone. Patients should be counselled regarding the risk of hypocalcemia, hypovolemia, renal insufficiency, transient hyperphosphatemia, and transient hyperparathyroidism.']",['Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)'],"['Oral clodronic acid has a bioavailability of 1-2%. A 200mg intravenous dose reaches a C<sub>max</sub> of 16.1mg/L with an AUC of 44.2mg\\*h/L. A 200mg intramuscular dose reaches a C<sub>max</sub> of 12.8mg/L with an AUC of 47.5mg\\*h/L. Further pharmacokinetic data for clodronic acid are not readily available.', 'Clodronate is eliminated unchanged in the urine.', 'The renal clearance of clodronate is approximately 90mL/min.']",['Clodronate is not metabolized in humans.'],['The mean plasma half life of clodronate is 5.6h.']
5419,25420,Azidopyrimidine,CCOCCC1=C(N=C(N=C1N=[N+]=[N-])N)C2=CC=CC=C2,,,,,,
5420,25421,5-Allylfurfuryl chrysanthemate,CC(=CC1C(C1(C)C)C(=O)OCC2=CC=C(O2)CC=C)C,,,,,,
5421,25422,"2,3,4-Trimethylfuran",CC1=COC(=C1C)C,,,,,,
5422,25423,Chloramine,NCl,,,,"['Male Sprague-Dawley rats (220-240 g) were given 1.1 mg per animal [36Cl]-labelled chloramine [NH2 36Cl] orally as 3 mL of solution containing 370 mg/L chloramine. The peak plasma concentration of 36Cl (10.3 ug/L) was reached 8 hr after dosing, and the absorption and elimination half-lives were 2.5 hr and 38.8 hr, respectively. The distribution of radioactivity was highest in plasma and lowest in fat. Approximately 25% and 2% of the administered dose of radiolabelled chloramine was excreted in the urine and feces, respectively, during 120 hr of treatment. Only 0.35% of the administered dose of monochloramine was present in plasma as [36Cl] chloride 120 hr after treatment. No evidence for enzymatic intervention in the metabolism of monochloramine  was presented.', 'The effect of 15 uM monochloramine as hepatic function was investigated in isolated perfused male Sprague-Dawley rat liver. The uptake of monochloramine averaged 98%. Approximately 0.7% of the amount taken up by the liver was reduced by glutathione (GSH) and appeared in the bile in the form of GSH disulfide.']",,"['Male Sprague-Dawley rats (220-240 g) were given 1.1 mg per animal [36Cl]-labelled chloramine [NH2 36Cl] orally as 3 mL of solution containing 370 mg/L chloramine. ...The absorption and elimination half-lives were 2.5 hr and 38.8 hr, respectively.']"
5423,25424,N-Acetylpentanamide,CCCCC(=O)NC(=O)C,,,,,,
5424,25425,N-Acetylhexanamide,CCCCCC(=O)NC(=O)C,,,,,,
5425,25426,Trimethylvinylammonium bromide,C[N+](C)(C)C=C.[Br-],,,,,,
5426,25427,CID 25427,CCCCCCCCCCCCCCCCCC(=O)OCC(C1C(=O)C(=C(O1)O)O)O,,,,,,
5427,25428,CID 25428,C1=CC=C(C=C1)C2=C(C=CC(=C2)Cl)[O-].[Na+],,,,,,
5428,25429,Carbendazim,COC(=O)NC1=NC2=CC=CC=C2N1,,,"['Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice. (See all compounds classified as Antinematodal Agents.)', 'Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)', 'Chemicals that kill or inhibit the growth of fungi in agricultural applications, on wood, plastics, or other materials, in swimming pools, etc. (See all compounds classified as Fungicides, Industrial.)']","['In male rats, following a single oral admin of 3 mg/kg, 66% was eliminated in the urine within 6 hr.']","['Readily absorbed by plants. One degradation product is 2-aminobenzimidazole.', '... Two metabolites: methyl  5-hydroxy-2-benzimidazolecarbamate (5-HBC) and 2-aminobenzimidazole (2-AB) were formed very  rapidly /in rats admin 12 mg/kg iv/. Their peak concentrations in liver and kidney were 15 min after i.v. injection. Unchanged carbendazim was found in highest concentrations in blood. 5-HBC prevails in organs. 2-AB was present only in minor amounts. The extent of bioavailability in orally administered 14C-carbendazim (12 mg/kg) was about 85%. The disposition of radioactivity in  subcellular fractions was not uniform, its highest concentration was in cytosol, the lowest in microsomes. ...']","['The disappearance of (14)C-carbendazim in rat (i.v. 12 mg/kg) followed the kinetics of a two-compartment open-system model. Half-lives of the alpha-phase were 0.16 hr (liver), 0.25 hr (kidney), and of the beta-phase: 2.15 hr, 6.15 hr, respectively. Two metabolites: methyl 5-hydroxy-2-benzimidazolecarbamate (5-HBC) and 2-aminobenzimidazole (2-AB) were formed very rapidly. Their peak concentrations in liver and kidney were 15 min after i.v. injection. Unchanged carbendazim was found in highest concentrations in blood. 5-HBC prevails in organs. 2-AB was present only in minor amounts. The extent of bioavailability in orally administered 14C-carbendazim (12 mg/kg) was about 85%. The disposition of radioactivity in subcellular fractions was not uniform, its highest concentration was in cytosol, the lowest in microsomes. The elimination of (14)C-carbendazim in urine is biphasic. Half-lives of the alpha-phase were 1.4 hr (i.v.) and 2.5 hr (oral), and of the beta-phase 11.2 hr and 12.1 hr, respectively. Irrespective of the route of administration, 95% of the radioactivity in urine was composed of 5-HBC. The concentration of unchanged carbendazim in blood and of 5-HBC in urine may be of diagnostic value in acute poisoning with carbendazim.']"
5429,25430,"2-Methyl-2-propylpropane-1,3-diyl dinitrate",CCCC(C)(CO[N+](=O)[O-])CO[N+](=O)[O-],,,,,,
5430,25431,Suritozole,CN1C(=NN(C1=S)C)C2=CC(=CC=C2)F,,,,,,
5431,25432,CID 25432,C[N+]1(CCC2=CC(=C(C(=C2C1)CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CCC=CCCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-],,,,,,
5432,25433,CID 25433,C[N+]1(CCC2=CC(=C(C(=C2C1)CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CCC=CCCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C,,,,,,
5433,25434,Caffeine:Theophylline cocrystal,CN1C=NC2=C1C(=O)N(C(=O)N2C)C.CN1C2=C(C(=O)N(C1=O)C)NC=N2,,,,,,
5434,25435,"6-[4-(4-Amino-4-carboxybutyl)-3,5-bis(3-amino-3-carboxypropyl)pyridin-1-ium-1-yl]norleucine",C1=C(C(=C(C=[N+]1CCCCC(C(=O)O)N)CCC(C(=O)O)N)CCCC(C(=O)O)N)CCC(C(=O)O)N,,,,,,
5435,25436,Scillicyanoside,CC(=O)O[C@H]1C[C@@]2(C3CC[C@@]4(C=CCC[C@@]4(C3CC[C@@]2([C@H]1C5=COC(=O)C=C5)C)C=O)O[C@H]6C(C([C@@H](C(O6)CO)O)O)O)O,,,,,,
5436,25437,"3-[(3S,5R,10S,13R,14S,17R)-14-hydroxy-3-[(2S,3R,4S,5R,6S)-5-hydroxy-4-methoxy-6-methyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",C[C@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CCC4C3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)O)OC)O,,,,,,
5437,25438,"3-[(3S,5S,10R,13R,14S,17R)-3-[(2R,5S)-6-[[(3R,6S)-4,6-dihydroxy-2-methyloxan-3-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5,14-dihydroxy-10-(hydroxymethyl)-13-methyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",CC1[C@@H](C(C[C@H](O1)O)O)OCC2[C@H](C(C([C@@H](O2)O[C@H]3CC[C@@]4(C5CC[C@@]6([C@H](CC[C@@]6(C5CC[C@@]4(C3)O)O)C7=CC(=O)OC7)C)CO)O)O)O,,,,,,
5438,25439,Filipin III,CCCCCC(C1C(CC(CC(CC(CC(CC(CC(C(=CC=CC=CC=CC=CC(C(OC1=O)C)O)C)O)O)O)O)O)O)O)O,,,"['Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)', 'Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)']",,,
5439,25440,Demetric acid,CC12CCC3C(C1CCC2O)CCC4=CC(CCC34)O,,,,,,
5440,25441,CID 25441,C[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)NC(=O)C)O[C@@H]3[C@H]([C@]([C@H](O[C@@H]3OP(=O)(O)OC[C@H](C(=O)OCCC=C(C)CCC=CC(C)(C)CCC(=C)CC=C(C)CCC=C(C)C)O)C(=O)O)(C)O)OC(=O)N)CO[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)NC(=O)C)O)O[C@H]5[C@@H]([C@H]([C@H]([C@H](O5)C(=O)NC6=C(CCC6=O)O)O)O)O,,,,,,
5441,25442,gamma-Strophanthin,CC1C(C(C(C(O1)O[C@H]2C[C@H](C3([C@H]4[C@@H](CC5([C@H](CCC5(C4CCC3(C2)O)O)C6=CC(=O)OC6)C)O)CO)O)O)O)O.O.O.O.O.O.O.O.O,,,,,,
5442,25443,"3-[(1R,3S,9S,11R,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",CC1C(C(C(C(O1)O[C@H]2C[C@H](C3([C@H]4[C@@H](CC5([C@H](CCC5(C4CCC3(C2)O)O)C6=CC(=O)OC6)C)O)CO)O)O)O)O,,,,,,
5443,25444,"(2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5S,6R)-2-[(2S,3R,4S,6R)-2-[(2R,3R,4R,5R,6R)-6-[(1R,2S,3S,4R,5'R,6R,7S,8R,9S,12S,13S,15R,16R,18S)-3,15-dihydroxy-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol",C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)[C@H]([C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@@H]6[C@@]5(C[C@H]([C@@H](C6)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H](C([C@H](O8)CO)O)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O)O)C)C)O)C)OC1,,,"['Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
5444,25445,1-Menthene,CC1=C(CCCC1)C(C)C,,,,,,
5445,25446,Nimbic acid,CC1=C2C(CC1C3=COC=C3)OC4[C@@]2([C@@H]([C@@]5(C(C4C(=O)O)[C@](C=CC5=O)(C)C(=O)O)C)CO)C,,,,,,
5446,25447,Coformycin,C1[C@H](C2=C(NC=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)O,,,"['Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)', 'Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. (See all compounds classified as Antibiotics, Antineoplastic.)', 'Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)']",,,
5447,25448,CID 25448,CC1[C@]23C[C@@](O1)([C@]4([C@@]5([C@H]2N(CC5)CC=C3)C6=CC=CC=C6N4)O)C(=O)OC,,,,,,
5448,25449,alpha-Dehydrobiotin,C1[C@H]2[C@@H]([C@@H](S1)CCC=CC(=O)O)NC(=O)N2,,,,,,
5449,25450,Kalamycin; NSC 137443; U 19718,CC1C2=C(C3C(O1)OC(=O)O3)C(=O)C4=C(C2=O)C(=CC=C4)O,,,,,,
5450,25451,CID 25451,CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@@H](C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O,,,,,,
5451,25452,"Naphthalene-1,4,5,8-tetrone",C1=CC(=O)C2=C(C1=O)C(=O)C=CC2=O,,,,,,
5452,25453,CID 25453,CCCCCCCCCCCC(CC)S(=O)(=O)[O-].[Na+],,,,,,
5453,25454,Tetradecane-3-sulfonic acid,CCCCCCCCCCCC(CC)S(=O)(=O)O,,,,,,
5454,25455,CID 25455,CCCCCCCCCCCCC1=CC=C(C=C1)S(=O)(=O)O.CCCCCCCCCCCCC1=CC(=CC=C1)S(=O)(=O)O.CCCCCCCCCCCCC1=CC=CC=C1S(=O)(=O)O,,,,,,
5455,25456,3-Dodecylbenzenesulfonic acid,CCCCCCCCCCCCC1=CC(=CC=C1)S(=O)(=O)O,,,,,,
5456,25457,Dodecylbenzenesulfonic acid,CCCCCCCCCCCCC1=CC=CC=C1S(=O)(=O)O,,,"['Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics. (See all compounds classified as Surface-Active Agents.)', 'Substances used on inanimate objects that destroy harmful microorganisms or inhibit their activity. Disinfectants are classed as complete, destroying SPORES as well as vegetative forms of microorganisms, or incomplete, destroying only vegetative forms of the organisms. They are distinguished from ANTISEPTICS, which are local anti-infective agents used on humans and other animals. (From Hawley&apos;s Condensed Chemical Dictionary, 11th ed) (See all compounds classified as Disinfectants.)']","['Linear alkylbenzenesulfonic acid is absorbed through the gills and body surface of fish (carp), distributed via blood to the various tissues and organs, transported to the hepatopancreas (liver for goldfish and others), and subsequently, via bile, eliminated with the feces. /Linear alkylbenzenesulfonic acid/', '(14)C-labeled sodium dodecylbenzenesufonate (DBS) ... administered daily in the diet at a concn of 1.4 mg/kg to male rats for 5 weeks. ... From a total uptake of 1.213 + or - 0.08 mg/animal of DBS, 81.8% was excreted during the dosing period; 52.4% in feces and 29.4% in urine. Low levels of (14)C-DBS-derived residues were detected in all tissues analyzed on day 35 of the /study/. Following 1 week on normal diet only 7.8% of the nominally stored amount of (14)C was found in the excreta. Single ip injection of 0.385 mg (14)C-DBS/rat 2.26 + or - 0.15 mg/kg body weight resulted in total elimination of 94.5% within 10 days. 84.7% of the dose was eliminated the first 24 hr. All (14)C-DBS fecal and renal metabolites were ... highly polar. /Sodium dodecylbenzenesulfonate/', 'After single oral dose of /(35)S-labeled/ sodium dodecylbenzenesulfonate, rats excreted 64% and 24% of the dose in urine and feces, respectively. A similar study of repeated doses of /(14)C-labeled/ alkylbenzenesulfonate (mean molecular wt 349, a major constituent of detergents) to rhesus monkeys has shown that radioactivity did not accumulate in the tissues. /Aromatic, sulfur-containing cmpd/', 'The bioconcentration factor for (14)C alkylbenzene in bluegill sunfish (L. machrochirus) was 35. The value was significantly smaller than the predicted bioconcentration factor of 6300; the discrepancy was ascribed to metabolism. Alkylbenzene had similar patterns of tissue distribution and depuration rates when compared to its sulfonated counterpart, linear alkylbenzene sulfonate, a surfactant in laundry detergents, which had been shown to be readily metabolized.', '(14)C labelled sodium dodecylbenzene sulfonate was administered daily in the diet at a concentration of 1.4 mg/kg to male rats for 5 weeks. From the total uptake (1.213 +/- 0.08 mg/animal) of sodium dodecylbenzene sulfonate, 81.8% was excreted during the dosing period; 52.4% in feces and 29.4% in urine. Low levels of (14)C sodium dodecylbenzene sulfonate derived residues were detected in all tissues analyzed on day 35 of the experiment. Following 1 week on normal diet only 7.8% of the nominally stored amount of (14)C was found in the excreta. Single ip application of 0.385 mg (14)C sodium dodecylbenzene/rat (2.26 +/- 0.15 mg/kg body weight) resulted in a total elimination of 94.5% within 10 days. 84.7% of the dose was eliminated in the first 24 hours. All fecal and renal (14)C sodium dodecylbenzene derived activity consisted of highly polar metabolites.']",,
5457,25458,Sodium tetrapropylbenzene sulfonate,CCCCCCCCCCCCC1=CC=C(C=C1)S(=O)(=O)[O-].CCCCCCCCCCCCC1=CC(=CC=C1)S(=O)(=O)[O-].CCCCCCCCCCCCC1=CC=CC=C1S(=O)(=O)[O-].[Na+].[Na+].[Na+],,,,,,
5458,25459,Butyl-methylimino-oxidoazanium,CCCC[N+](=NC)[O-],,,,,,
5459,25460,CID 25460,C(C(C(=O)O)O)(C(=O)O)O.C(C(C(=O)O)O)(C(=O)O)O.[K+].[K+].[SbH3].[SbH3],,,,,,
5460,25461,CID 25461,CCCC[N+](CCCC)(CCCC)CCCC.C1=CC(=O)C(=O)C=C1N(O)[O-],,,,,,
5461,25462,CID 25462,C1=CC(=O)C(=O)C=C1N(O)[O-],,,,,,
5462,25463,"(6R,17S)-20-(carboxymethyl)-6-methoxy-2,5,17-trimethyldocosa-2,4,8,10,14,18,20-heptaenedioic acid",C[C@@H](CC=CCCC=CC=CC[C@H](C(=CC=C(C)C(=O)O)C)OC)C=CC(=CC(=O)O)CC(=O)O,,,,,,
5463,25464,ZINC;2-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid,C(CN(CC(=O)O)CC(=O)O)N(CCN(CC(=O)O)CC(=O)O)CC(=O)O.[Zn+2],,,,,,
5464,25465,"N-[(2S,3R,4R,5R,6R)-2-[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide",CC(C)CC=CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@H]1O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)NC(=O)C)CC([C@@H]3[C@H]([C@H]([C@@H](O3)N4C=CC(=O)NC4=O)O)O)O)O)O,,,,,,
5465,25466,ZINC potassium chromate,[OH-].[O-][Cr](=O)(=O)[O-].[O-][Cr](=O)(=O)[O-].[K+].[Zn+2].[Zn+2],,,,,,
5466,25467,"N,N'-Bis(1-phenylnonyl)ethylenediamine dihydrobromide",CCCCCCCCC(C1=CC=CC=C1)[NH2+]CC[NH2+]C(CCCCCCCC)C2=CC=CC=C2.[Br-].[Br-],,,,,,
5467,25468,"N,N'-bis(1-phenylnonyl)ethane-1,2-diamine",CCCCCCCCC(C1=CC=CC=C1)NCCNC(CCCCCCCC)C2=CC=CC=C2,,,,,,
5468,25469,Sodium antimony,[O-][Sb](=O)([O-])[O-].[Na+].[Na+].[Na+],,,,,,
5469,25470,Antimonate,[O-][Sb](=O)([O-])[O-],,,,,,
5470,25471,"16,18,20,22,24,26,28,30,32-Nonahydroxy-17,35-dimethyl-36-propan-2-yl-1-oxacyclohexatriaconta-3,5,7,9,11,13,33-heptaen-2-one",CC1C=CC(CC(CC(CC(CC(CC(CC(CC(C(C(CC=CC=CC=CC=CC=CC=CC(=O)OC1C(C)C)O)C)O)O)O)O)O)O)O)O,,,,,,
5471,25472,Aroclor 4465,C1=C(C(=CC(=C1Cl)Cl)Cl)C2=C(C(=C(C(=C2Cl)Cl)C3=C(C(=C(C=C3Cl)Cl)Cl)Cl)Cl)Cl,,,,,,
5472,25473,Bengal rose,C1=C2C(=C3C=C(C(=O)C(=C3OC2=C(C(=C1I)[O-])I)I)I)C4=C(C(=C(C(=C4Cl)Cl)Cl)Cl)C(=O)[O-].[K+].[K+],,,,,,
5473,25474,"2,3,4,5-Tetrachloro-6-(3-hydroxy-2,4,5,7-tetraiodo-6-oxo-xanthen-9-yl)benzoic acid",C1=C2C(=C3C=C(C(=O)C(=C3OC2=C(C(=C1I)O)I)I)I)C4=C(C(=C(C(=C4Cl)Cl)Cl)Cl)C(=O)O,"['Indicated as a diagnostic agent in routine ocular examinations or when superficial conjunctiva or corneal tissue change is suspected, and as an aid in the diagnosis of keratoconjunctivitis sicca, keratitis, abrasions or corrosions as well as the detection of foreign bodies.']","['Rose bengal is a staining agent that visualized ocular surfaces of both diseased and dead cells _in vivo_. It has also shown to stain healthy cultured cells, including rabbit corneal epithelial cells, in a rapid, dose-dependent manner. Various studies demonstrate the cytotoxic effects of rose bengal in different cell cultures, including smooth-muscle cells from human intestine, endothelial cells from bovinepulmonary artery, rabbit Tenon fibro-blasts, and rabbit and human corneal epithelial cells. Cellular morphological changes such as detachment, separation, loss of motility and disruption, in addition to swelling, intracytoplasmic vacuole formation and lysis have been manifested with the treatment of rose bengal, indicating that rose Bengal is not a vital dye.']",,"['No information available.', 'Rose bengal undergoes biliary excretion.', 'No information available.', 'No information available.']",['No information available.'],['Doses between 0.01 and 10 mg/kg in rat resulted in an initial biological half-life of 2 min and a terminal half-life of 100 min. The biological half-life for excretion is around 30 minutes in rats and rabbits.']
5474,25475,Aroclor 5460,C1=C(C=C(C(=C1Cl)Cl)Cl)C2=C(C=C(C(=C2Cl)Cl)C3=C(C(=CC(=C3)Cl)Cl)Cl)Cl,,,,,,
5475,25476,Angiotensina II,CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(CC3=CC=CC=C3)C(=O)O)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N,,,['Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)'],,,
5476,25477,Chrysotile Asbestos,O.O[Si]([O-])([O-])[O-].O[Si]([O-])([O-])[O-].[Mg+2].[Mg+2].[Mg+2],,,,"['.../After/ chrysotile /was fed/ to rats... the presence of fibers of the material /was noted/ in many sites in colonic epithelium and lamina propria... .', 'In studies in which chrysotile, labelled intrinsically with radioactive trace metals by neutron irridation, was injected intrapleurally into rats. ... Evidence for passage of a small amount of the fiber from the pleural cavity & lungs into such other organs as the liver /was found/; after the intrapleural inoculation ... into rats, as much as 22% of the admin dose was found later in the liver. In a similar expt ... /it was/ reported that a population of radionuclides, consistent with that expected on the basis of the labelled chrysotile, was found in the heart, lungs, diaphragm & chest muscles.', 'In cases of lung cancer without lung fibrosis, a higher concentration of asbestos fibers, mostly of the chrysotile type, was clearly demonstrated in peripheral areas of the lung. Optical and transmission electron microscopic study of lung and pleura revealed a preferential accumulation of chrysotile versus amphibole fibers in pleura; the mean length of the fibers was greater in the lung and visceral pleura than in the parietal pleura, this being particularly the case for the amphiboles. There was no relationship between the numerical concentration of fibers in lung parenchyma and that in parietal pleura. Generally, the concentration was always less in pleura than in parenchyma; however, the distribution of chrysotile microfibrils in the pleura was not homogenous, and in some areas high concentrations identical to those in the parenchyma could be observed.', ""The retention of different types of asbestos in rats following exposure to the same concentration of respirable dusts... /has been described/. For the amphiboles, there was a similar pattern with an almost proportional increase of lung dust with dose. Much less dust was found for the chrysotiles, and no increase of dust content was shown in the lungs. Dust in the lungs of animals with 6 months' exposure had been partially cleared 18 months after the inhalation period. About 74% of the amosite and crocidolite and 41% of the anthophyllite were eliminated. The elimination rate of chrysotiles could not be determined exactly, because of their low occurrence in the lung."", 'For more Absorption, Distribution and Excretion (Complete) data for Chrysotile asbestos (23 total), please visit the HSDB record page.']","['Asbestos fibers are not metabolized in the true sense of the word; however, a number of animal studies indicate that chrysotile fibers are physically altered in the lung after intratracheal injection. Following phagocytosis, chrysotile fibers were observed to decrease in size, become transparent, and, in some cases, break into fragments. ... These changes in fiber shape and size may directly impact fiber clearance and toxicity in the lung.']",['...The results showed that Canadian chrysotile is cleared from the lung with a clearance half-time of 11.4 days for the fibers longer than 20 microm. Canadian chrysotile clears in a range similar to that of glass and stone wools. It remains less biopersistent than ceramic and special purpose glasses and considerably less biopersistent than amphibole asbestos.']
5477,25478,6-Hydroxycamphor,CC1(C2CC(C1(C(=O)C2)C)O)C,,,,,,
5478,25479,CID 25479,CCCCCCCC=CC=CC(=O)[O-].CCCCCCCC=CC=CC(=O)[O-].[Bi+3],,,,,,
5479,25480,"2,4-Dodecadienoic acid",CCCCCCCC=CC=CC(=O)O,,,,,,
5480,25481,Sodium;2-hydroxybutanedioate;iron,C(C(C(=O)[O-])O)C(=O)[O-].[Na+].[Fe],,,,,,
5481,25482,1-(1-Methoxypropan-2-yloxy)propan-2-ol;2-(1-methoxypropan-2-yloxy)propan-1-ol;2-(2-methoxypropoxy)propan-1-ol,CC(CO)OCC(C)OC.CC(CO)OC(C)COC.CC(COC(C)COC)O,,,,,,
5482,25483,"1-Propanol, 2-(2-methoxy-1-methylethoxy)-",CC(CO)OC(C)COC,,,,,,
5483,25484,"2-Propanol, 1-(2-methoxy-1-methylethoxy)-",CC(COC(C)COC)O,,,,,,
5484,25485,Dipropylene glycol methyl ether,CC(CO)OCC(C)OC,,,,,,
5485,25486,Chlorinated benzoic acid,C1=CC(=C(C(=C1)Cl)C(=O)O)Cl.C1=CC(=CC=C1C(=O)O)Cl.C1=CC(=C(C=C1Cl)Cl)C(=O)O.C1=C(C=C(C(=C1Cl)C(=O)O)Cl)Cl,,,,,,
5486,25487,Ammonium iodatum,[NH4+].[I-],,,,,,
5487,25488,Azane;molybdenum;tetracosahydrate,N.N.N.N.N.N.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Mo].[Mo].[Mo].[Mo].[Mo].[Mo].[Mo],,,,,,
5488,25489,Lithium peroxide (Li2(O2)),[Li+].[Li+].[O-][O-],,,,,,
5489,25490,CID 25490,[SeH2].[TlH].[TlH],,,,,,
5490,25491,Bismuth;3-(4-phenylphenyl)prop-2-enoate,C1=CC=C(C=C1)C2=CC=C(C=C2)C=CC(=O)[O-].C1=CC=C(C=C1)C2=CC=C(C=C2)C=CC(=O)[O-].C1=CC=C(C=C1)C2=CC=C(C=C2)C=CC(=O)[O-].[Bi+3],,,,,,
5491,25492,p-Phenylcinnamic acid,C1=CC=C(C=C1)C2=CC=C(C=C2)C=CC(=O)O,,,,,,
5492,25493,"Benzyl alcohol, dichloro-",C1=CC=C(C=C1)C(O)(Cl)Cl,,,,,,
5493,25494,Undecylenic acid monoethanolamine,C=CCCCCCCCCC(=O)O.C(CO)N,,,,,,
5494,25495,Nicofuranose,C1=CC(=CN=C1)C(=O)OC[C@@H]2[C@H]([C@@H]([C@](O2)(COC(=O)C3=CN=CC=C3)O)OC(=O)C4=CN=CC=C4)OC(=O)C5=CN=CC=C5,,,['Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)'],,,
5495,25496,"5-[(3S,9S,17R)-14-hydroxy-10,13-dimethyl-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy-1,2,3,6,7,8,9,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one",CC1C(C(C(C(O1)O[C@H]2CCC3([C@H]4CCC5([C@H](CCC5(C4CCC3=C2)O)C6=COC(=O)C=C6)C)C)O)O)O,,,,,,
5496,25497,CID 25497,O.O.O.O.O.[AlH3].[AlH2]Cl,,,,,,
5497,25498,CID 25498,BBBBBBBBBB.[NH4+].[NH4+],,,,,,
5498,25499,CID 25499,BBBBBBBBBB,,,,,,
5499,25500,Nickel dihydroxide,O.O.[Ni],,,,,,
5500,25501,Sodium stannate,[O-][Sn](=O)[O-].[Na+].[Na+],,,,,,
5501,25502,Dioxido(oxo)tin,[O-][Sn](=O)[O-],,,,,,
5502,25503,Basic cupric carbonate,C(=O)([O-])[O-].[OH-].[OH-].[Cu+2].[Cu+2],,,,,,
5503,25504,Tungsten monocarbide,[C-]#[W],,,,,,
5504,25505,"Tungsten, methylidyne-",C#[W],,,,,,
5505,25506,CID 25506,CC(CN=C(S)[S-])N=C(S)[S-].[Zn+2],,,,,,
5506,25507,CID 25507,CC(CN=C(S)S)N=C(S)S,,,,,,
5507,25508,Ethylaluminum sesquichloride,CC[Al](CC)Cl.CC[Al](Cl)Cl,,,,,,
5508,25509,"(eta-1,3-Butadiene)tricarbonyliron",[CH][C][C][CH].[C-]#[O+].[C-]#[O+].[C-]#[O+].[Fe],,,,,,
5509,25510,Di-N-butylammonium tetrafluoroborate,[B-](F)(F)(F)F.CCCC[NH2+]CCCC,,,,,,
5510,25511,Methylcymantrene,CC1=C[CH-]C=C1.[C-]#[O+].[C-]#[O+].[C-]#[O+].[Mn],,,,,,
5511,25512,"5-Methyl-1,3-cyclopentadiene",CC1C=CC=C1,,,,,,
5512,25513,Pentetate calcium trisodium,C(CN(CC(=O)[O-])CC(=O)[O-])N(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Na+].[Na+].[Na+].[Ca+2],,,"['Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. (See all compounds classified as Iron Chelating Agents.)', 'Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)', 'Agents counteracting or neutralizing the action of POISONS. (See all compounds classified as Antidotes.)']",,,
5513,25514,Ammonium bromide,[NH4+].[Br-],,,,"['The biological half-life of bromide ions in human blood was studied in 10 human healthy volunteers. Br(82) labelled ammonium bromide was given orally as a water solution. The biological half-life of bromide ions was found to be about 12 days. The bromide ratio red blood cells/serum was found to be about 0.45. No bromide was found to be incorporated in fat, extracted from plasma and hemolyzed blood cells by ether. Nor was any bromide found to be incorporated in blood proteins.', 'The excretion of bromide by the urine was studied in 13 healthy voluteers who were given Br(82) ammonium bromide orally as water solution. Urine samples were collected every 2 hr approx. for 5 days. Blood and saliva bromide levels were also measured in 6 of the subjects. The biological half life of bromide was equal in blood, urine and saliva, about 12 days. Nearly all of the labelled bromide administered was found to be excreted in the urine. The mean concentration of labeled bromide in urine and saliva was about equal and 150% of the blood level. The excretion of bromide varied during the day - there was hardly any found in urine during sleep.', 'The concentration of Br-82 (in the form of NH4-82-Br containing 12 mg. bromine/mCi) in the thyroid, muscle and blood was studied in rats. The animals were injected ip with 30 uCi 82- Br in 2 mL 0.9% NaCl solution. Results of the study indicated that under normal conditions bromine is not concentrated by the thyroid. After stimulation by TSH there is an increased uptake by the gland. There was no evidence that bromine is metabolized further in the thyroid gland.', 'Single doses of an aqueous solution of Br(82)-ammonium bromide were injected into tail veins of pregnant albino mice 2 days before post-partum. The mice were sacrificed after 5 or 20 min.,1,2,4,24 or 48 hrs and the distribution of the Br(82) in the tissues of the dams and the fetuses had been studied by autoradiography. The distribution was found to be similar at the various time periods studied. The radioactivity was excreted slowly. Blood levels remained high and exceeded those recorded for most organs and tissues. Bromide gradually accumulated in the central nervous system. The level in the thyroid was relatively high but did not exceed levels in the blood. Bromide showed transplacental passage and most of the radioactive bromide was found in the bones of the fetuses, but the level was not as high as in the cartilage of the dams (which did not exceed blood levels). The following tissues accumulated bromide at higher conc. than the blood after 24 hrs: Gastric mucosa and contents, urinary bladder contents, blood-vessel walls and retina.']",,['The biological half-life of bromide ions in human blood was studied in 10 human healthy volunteers. Br(82) labelled ammonium bromide was given orally as a water solution. The biological half-life of bromide ions was found to be about 12 days.']
5514,25515,Ammonium bisulfide,[NH4+].[SH-],,,,,,
5515,25516,Ammonium fluoride,[NH4+].[F-],,,['Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)'],"['Following ingestion, soluble fluorides are rapidly absorbed from the gastrointestinal tract at least to the extent of 97%. Absorbed fluoride is distributed throughout the tissues of the body by the blood. Fluoride concentrations in soft tissues fall to pre-exposure levels within a few hours of exposure. Fluoride exchange with hydroxyl radicals of hydroxyapatite (the inorganic constituent of bone) to form fluorohydroxyapatite. Fluoride that is not retained is excreted rapidly in urine. In adults under steady state intake conditions, the urinary concentration of fluoride tends to approximate the concentration of fluoride in the drinking water. This reflects the decreasing retention of fluoride (primarily in bone) with increasing age. Under certain conditions perspiration may be an important route of fluoride excretion. The concentration of fluoride retained in bones and teeth is a function of both the concentration of fluoride intake and the duration of exposure. Periods of excessive fluoride exposure will result in increased retention in the bone. However, when the excessive exposure is eliminated, the bone fluoride concentration will decrease to a concentration that is again reflective of intake. /Fluoride/']",,
5516,25517,Ammonium Chloride,[NH4+].[Cl-],"['1. Expectorant in cough syrups. 2. The ammonium ion (NH4+) in the body plays an important role in the maintenance of acid-base balance. The kidney uses ammonium (NH4+) in place of sodium (Na+) to combine with fixed anions in maintaining acid-base balance, especially as a homeostatic compensatory mechanism in metabolic acidosis. The therapeutic effects of Ammonium Chloride depend upon the ability of the kidney to utilize ammonia in the excretion of an excess of fixed anions and the conversion of ammonia to urea by the liver, thereby liberating hydrogen (H+) and chloride (Clâ) ions into the extracellular fluid. Ammonium Chloride Injection, USP, after dilution in isotonic sodium chloride injection, may be indicated in the treatment of patients with:  (1) hypochloremic states and (2) metabolic alkalosis.']",['Systemic acidifier. In liver ammonium chloride is converted into urea with the liberation of hydrogen ions ( which lowers the pH) and chloride.'],,"['Completely absorbed within 3â6 h.  In healthy persons, absorption of ammonium chloride given by mouth was practically complete. Only 1 to 3% of the dose was recovered in the feces.', 'Excretion: Urine', 'Data not found.', 'Data not found.', 'From human incidentally exposures it was learnt that following oral administration, ammonium chloride is rapidly absorbed from the GI tract, complete absorption occurring within 3 -6 hours. Only 1 -3% of the dose was recovered in the feces. Substantial first pass metabolism occurs in the liver. For animals, after repeated oral administration, ammonium chloride enters readily the body and main targets for its toxicity are kidneys.', 'Ammonium chloride is effectively absorbed from the gastrointestinal tract ... . In healthy persons, absorption of ammonium chloride given by mouth was practically complete. Only 1 to 3% of the dose was recovered in the feces.', 'Following oral administration, ammonium chloride is rapidly absorbed from the GI tract, complete absorption occurring within 3-6 hours. However, an oral dosage form of ammonium chloride is no longer commercially available in the US.', 'Oral administration of ammonium chloride to healthy male and female volunteers at 9 mg/kg bw produced transient increases in blood ammonia in about half of the subjects. Patients with cirrhosis showed a greater and more prolonged increase over a higher baseline. This confirms substantial first pass metabolism in the liver.']","['Ammonium ion is converted to urea in the liver; chloride ion replaces bicarbonate.', 'When ammonium ion is converted to urea, liberated hydrogen ion reacts with bicarbonate and other body buffers ... chloride ion displaces bicarbonate ion; latter is converted to carbon dioxide ... chloride load to kidneys is increased and appreciable amount escapes reabsorption along with equivalent amount of cation ... and isoosmotic quantity of water.', 'The toxicity of ammonium chloride depends on the ammonia which enters the living organism and hence the cell. This substance is readily absorbed by the gastrointestinal tract, and utilized in the liver to form amino acids and proteins. When ammonium ions are converted to urea, liberated hydrogen ion reacts with bicarbonate ion to form water and carbon dioxide. The chloride ion displaces the bicarbonate ion. Chloride is loaded into the kidneys. The increased chloride concentration in the extracellular fluid produces an increased load to the renal tubules. Increase excretion of electrolytes and water causes loss of extracellular fluid and promotes the mobilization of edema fluid.', '/Ammonium chloride/ is metabolized in the liver to form urea and hydrochloric acid.', 'Male Sprague-Dawley rats gavaged with 1000 umol (15)N ammonium chloride each day for 5 days were found to excrete low, but significant amounts of excess (15)N nitrate in their urines on the five days of treatment and on the five subsequent days. A total of 0.28 + or - 0.03 umol excess (15)N nitrate (mean + or - SE) per rat was recovered which indicates that ammonia is converted to nitrate in a yield of approximately 0.0080%.']",['Unknown']
5517,25518,CID 25518,O.O.O.O.O.O.O.O.[OH-].[OH-].[O-]S(=O)(=O)[O-].[Mg+2].[Mg+2].[AlH3].[AlH3].[AlH3].[AlH3],,,,,,
5518,25519,Diammonium sulfide,[NH4+].[NH4+].[S-2],,,,"['Alkali sulfides are rapidly absorbed from intestine. It is doubtful whether skin absorbs enough to cause systemic poisoning. The sulfide radical is in part excreted by lung & kidneys & metallic sulfides (as iron sulfide) by bowel, & in part oxidized to sulfate & thiosulfate & excreted by kidneys. /Sulfides/', 'First acid dissociation constant of hydrogen sulfide is about 1x10(-7) molar so that in body fluids dissociated & undissociated hydrogen sulfide exist in about equal proportions. Undissociated acid, however, penetrates biological membranes more rapidly than the hydrosulfide anion. /Hydrogen sulfide/']",,
5519,25520,Potassium oxide (K2O),[OH-].[K+].[K+],,,,,,
5520,25521,CID 25521,CC(=CC(=O)C)O.C1C[C][C]CC[C][C]1.[Ir],,,,,,
5521,25522,"[(2R,4R,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol",COC1=CC2=C(C=CN=C2C=C1)C([C@H]3C[C@H]4CCN3C[C@@H]4C=C)O,,,,,,
5522,25523,Tricalcium silicate,[O-][Si]([O-])([O-])[O-].O=[Ca].[Ca+2].[Ca+2],,,,,,
5523,25524,Potassium hexahydroxoantimonate,[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[K+].[Sb+3],,,,,,
5524,25525,CID 25525,CC1=NN(C(=O)C1N=NC2=CC(=CC=C2)S(=O)(=O)NCCC3=CC=CC=C3)C4=CC(=C(C=C4Cl)S(=O)(=O)[O-])Cl.[Na+],,,,,,
5525,25526,"2,5-Dichloro-4-[3-methyl-5-oxo-4-({3-[(2-phenylethyl)sulfamoyl]phenyl}diazenyl)-4,5-dihydro-1H-pyrazol-1-yl]benzene-1-sulfonic acid",CC1=NN(C(=O)C1N=NC2=CC(=CC=C2)S(=O)(=O)NCCC3=CC=CC=C3)C4=CC(=C(C=C4Cl)S(=O)(=O)O)Cl,,,,,,
5526,25527,CID 25527,C1=CC(=C2C(=C1N)C(=O)C3=C(C2=O)C(=C(C=C3O)Cl)N)O.C1=CC(=C2C(=C1N)C(=O)C3=C(C2=O)C(=CC(=C3O)Cl)N)O,,,,,,
5527,25528,"9,10-Anthracenedione, 1,5-diaminochloro-4,8-dihydroxy-",C1=CC(=C2C(=C1N)C(=O)C3=C(C2=O)C(=C(C=C3O)Cl)N)O,,,,,,
5528,25529,"1,5-Diamino-4,8-dihydroxy-3-chloroanthraquinone",C1=CC(=C2C(=C1N)C(=O)C3=C(C2=O)C(=CC(=C3O)Cl)N)O,,,,,,
5529,25530,C.I. Disperse blue 60,COCCCN1C(=O)C2=C(C3=C(C(=C2C1=O)N)C(=O)C4=CC=CC=C4C3=O)N,,,,,,
5530,25531,C.I. Acid orange 67,CC1=CC=C(C=C1)S(=O)(=O)OC2=CC(=C(C=C2)N=NC3=CC=CC(=C3)NC4=C(C=C(C=C4)S(=O)(=O)[O-])[N+](=O)[O-])C.[Na+],,,,,,
5531,25532,4-[3-({2-Methyl-4-[(4-methylbenzene-1-sulfonyl)oxy]phenyl}diazenyl)anilino]-3-nitrobenzene-1-sulfonic acid,CC1=CC=C(C=C1)S(=O)(=O)OC2=CC(=C(C=C2)N=NC3=CC=CC(=C3)NC4=C(C=C(C=C4)S(=O)(=O)O)[N+](=O)[O-])C,,,,,,
5532,25533,C.I. Direct blue 80,C1=CC(=C(C=C1C2=CC(=C(C=C2)N=NC3=C4C=CC(=CC4=CC(=C3[O-])S(=O)(=O)[O-])S(=O)(=O)[O-])[O-])[O-])N=NC5=C6C=CC(=CC6=CC(=C5[O-])S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Cu+2].[Cu+2],,,,,,
5533,25534,"4,4'-[(3,3'-Dihydroxy[1,1'-biphenyl]-4,4'-diyl)bis(diazene-2,1-diyl)]bis(3-hydroxynaphthalene-2,7-disulfonic acid)",C1=CC(=C(C=C1C2=CC(=C(C=C2)N=NC3=C4C=CC(=CC4=CC(=C3O)S(=O)(=O)O)S(=O)(=O)O)O)O)N=NC5=C6C=CC(=CC6=CC(=C5O)S(=O)(=O)O)S(=O)(=O)O,,,,,,
5534,25535,C.I. Pigment Orange 36,CC(=O)C(C(=O)NC1=CC2=C(C=C1)NC(=O)N2)N=NC3=C(C=C(C=C3)Cl)[N+](=O)[O-],,,,,,
5535,25536,CID 25536,C1=CC(=NC2=C(C=C(C=C2)NC3=C(C=C(C=C3)S(=O)(=O)N)[N+](=O)[O-])S(=O)(=O)O)C=CC1=NC4=C(C=C(C=C4)S(=O)(=O)N)N(O)O,,,,,,
5536,25537,C.I. Acid yellow 49,CC1=NN(C(=C1N=NC2=CC(=C(C=C2Cl)S(=O)(=O)O)Cl)N)C3=CC=CC=C3,,,,,,
5537,25538,"2-[5-acetamido-N-(2-acetyloxyethyl)-4-[(2-bromo-3,5-dinitrophenyl)diazenyl]-2-ethoxyanilino]ethyl acetate",CCOC1=C(C=C(C(=C1)N=NC2=C(C(=CC(=C2)[N+](=O)[O-])[N+](=O)[O-])Br)NC(=O)C)N(CCOC(=O)C)CCOC(=O)C,,,,,,
5538,25539,"Calcium;2,3,4,5,6-pentahydroxyhexanoate;1,3,4,5-tetrahydroxycyclohexane-1-carboxylate",C1C(C(C(CC1(C(=O)[O-])O)O)O)O.C(C(C(C(C(C(=O)[O-])O)O)O)O)O.[Ca+2],,,,,,
5539,25540,CID 25540,C1=C(C=C(C(=C1O)O)O)C(=O)O.O.[BiH3],,,,,,
5540,25541,"Aluminum, tribromotrimethyldi-",C[Al](C)Br.C[Al](Br)Br,,,,,,
5541,25542,Bromoalumane,[AlH2]Br,,,,,,
5542,25543,Dibromoalumane,[AlH](Br)Br,,,,,,
5543,25544,Edetate Monocalcium,C(CN(CC(=O)O)CC(=O)[O-])N(CC(=O)O)CC(=O)[O-].[Ca+2],,,,,,
5544,25545,CID 25545,C(CN=C(S)[S-])N=C(S)[S-].[Ni+2],,,,,,
5545,25546,CID 25546,C(C(C(=O)[O-])[S-])(C(=O)O)[S-].[Na+].[SbH3],,,,,,
5546,25547,"Cobalt, dichlorobis(nicotinamide)-",C1=CC(=CN=C1)C(=O)N.C1=CC(=CN=C1)C(=O)N.Cl[Co]Cl,,,,,,
5547,25548,Acid blue 193,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C=C(C4=CC=CC=C43)S(=O)(=O)[O-])[O-])[O-].C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C=C(C4=CC=CC=C43)S(=O)(=O)[O-])[O-])[O-].[Na+].[Na+].[Cr+3],,,,,,
5548,25549,"(2,3,5-trimethylphenyl) N-methylcarbamate;(3,4,5-trimethylphenyl) N-methylcarbamate",CC1=CC(=C(C(=C1)OC(=O)NC)C)C.CC1=CC(=CC(=C1C)C)OC(=O)NC,,,,,,
5549,25550,"2,3,5-Trimethylphenyl methylcarbamate",CC1=CC(=C(C(=C1)OC(=O)NC)C)C,,,,"['In mice given C14 labeled preparations of trimethylphenyl methylcarbamates by gavage, each isomer formed 15-20 metabolites. Hydrolytic & nonhydrolytic metabolic routes were about equally important. With carbonyl-labeled isomers, urinary metabolites included glucuronide or sulfate conjugates; 17-35% of the radioactivity was expired as /carbon dioxide/ & 42-45% was excreted in the urine within 48 hr of admin.']","['In plants, metabolism occurs via hydroxylation of the N-methyl group & at the 3- & 4-methyl positions. All metabolites may be conjugated as glucosides.']",
5550,25551,3-Nitroquinoline,C1=CC=C2C(=C1)C=C(C=N2)[N+](=O)[O-],,,,,,
5551,25552,1-Hydroxychlordene,C1=CC(C2C1C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl)O,,,,,,
5552,25553,CID 25553,C(CN=C(S)[S-])N=C(S)[S-].[Mn+2],,,,,,
5553,25554,Ferric bromide,[Fe](Br)(Br)Br,,,,,,
5554,25555,"ACETIC ACID, (ETHYLENEDINITRILO)TETRA-, YTTRIUM complex",C(CN(CC(=O)[O-])CC(=O)[O-])N(CC(=O)O)CC(=O)[O-].[Y+3],,,,,,
5555,25556,"Acetic acid, (ethylenedinitrilo)tetra-, mercury(II) complex",C(CN(CC(=O)O)CC(=O)[O-])N(CC(=O)O)CC(=O)[O-].[Hg+2],,,,,,
5556,25557,Calcium glubionate,C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C(=O)[O-])O)O)O)O)O)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O)O.O.[Ca+2],,,,,,
5557,25558,CID 25558,C(C1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C(=O)O)O)O)O)O)O)O,,,,,,
5558,25559,Basic nickel(II) carbonate,C(=O)([O-])[O-].O.O.O.O.[Ni].[Ni].[Ni+2],,,,,,
5559,25560,2-Acetamido-5-amino-5-oxopentanoate,CC(=O)NC(CCC(=O)N)C(=O)[O-],,,,,,
5560,25561,4-Carbamoyl-2-acetamidobutanoic acid,CC(=O)NC(CCC(=O)N)C(=O)O,,,,,,
5561,25562,CID 25562,CC1=C2[C@H](C(=O)[C@]3(CC(=C[C@@H](C(C2(C)C)C[C@@H]1OC(=O)C)OC(=O)C)[C@H](C[C@@H]3O)OC(=O)[C@@H]([C@H](C4=CC=CC=C4)N(C)C)O)C)O,,,,,,
5562,25563,Iridium trichloride,Cl[Ir](Cl)Cl,,,,,,
5563,25564,"9-[4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]-2-oxiranyl]methyl]-2-oxanyl]-3-methyl-1-oxobut-2-enoxy]nonanoic acid",C[C@H]([C@H]1[C@@H](O1)C[C@H]2CO[C@H]([C@@H]([C@@H]2O)O)CC(=CC(=O)OCCCCCCCCC(=O)O)C)[C@H](C)O,,,,,,
5564,25565,Cyclochlorotine,CCC1C(=O)NC(C(=O)NC(CC(=O)NC(C(=O)N2CC(C(C2C(=O)N1)Cl)Cl)CO)C3=CC=CC=C3)CO,,,,"['ORALLY ADMIN TRITIUM-LABELED CYCLOCHLOROTINE APPEARED RAPIDLY IN THE LIVER /OF ANIMALS/, & 73% OF THE DOSE WAS EXCRETED IN THE URINE.']",,
5565,25566,N-(2-Bromopropyl)-N-ethyl-9-fluorenamine hydrobromide,CC[NH+](CC(C)Br)C1C2=CC=CC=C2C3=CC=CC=C13.[Br-],,,,,,
5566,25567,N-(2-bromopropyl)-N-ethyl-9H-fluoren-9-amine,CCN(CC(C)Br)C1C2=CC=CC=C2C3=CC=CC=C13,,,,,,
5567,25568,CID 25568,CC[C@H](C(=O)NCC=CC=C(C)[C@H]([C@@H](C)[C@H]1C(C([C@H](O1)C=CC=CC=C(C)C(=O)C2=C(N(C=CC2=O)C)O)O)O)OC)C3(C(C(C(C(O3)C=CC=CC)(C)C)O)O)O,,,,,,
5568,25569,CID 25569,CC(=O)C(=C([N-]C1=CC=CC=C1)O)[N-]N=C2C=C(C=CC2=O)S(=O)(=O)N.CC(=O)C(=NNC1=C(C=CC(=C1)S(=O)(=O)N)[O-])C(=NC2=CC=CC=C2)[O-].[Co+2],,,,,,
5569,25570,CID 25570,CC(=O)C(=NNC1=C(C=CC(=C1)S(=O)(=O)N)O)C(=O)NC2=CC=CC=C2,,,,,,
5570,25571,CID 25571,O=[Al]O[Al]=O.[AlH3].[SiH4].[Ni],,,,,,
5571,25572,Ancymidol,COC1=CC=C(C=C1)C(C2CC2)(C3=CN=CN=C3)O,,,,,,
5572,25573,CID 25573,[Li+].CC1=C2C(=CC(=C1C(=O)[O-])O)C(=O)C3=C(C2=O)C(=C(C(=C3O)O)[C@H]4[C@H]([C@@H]([C@@H](C(O4)CO)O)O)O)O,,,,,,
5573,25574,CID 25574,CC1=C2C(=CC(=C1C(=O)O)O)C(=O)C3=C(C2=O)C(=C(C(=C3O)O)[C@H]4[C@H]([C@@H]([C@@H](C(O4)CO)O)O)O)O,,,,,,
5574,25575,N-(2-Aminoethyl)-o-butoxybenzamide hydrochloride,CCCCOC1=CC=CC=C1C(=O)NCC[NH3+].[Cl-],,,,,,
5575,25576,N-(2-aminoethyl)-2-butoxybenzamide,CCCCOC1=CC=CC=C1C(=O)NCCN,,,,,,
5576,25577,N-(2-Bromoethyl)-N-ethylfluoren-9-amine hydrobromide,CC[NH+](CCBr)C1C2=CC=CC=C2C3=CC=CC=C13.[Br-],,,,,,
5577,25578,N-(2-bromoethyl)-N-ethyl-9H-fluoren-9-amine,CCN(CCBr)C1C2=CC=CC=C2C3=CC=CC=C13,,,,,,
5578,25579,"Butyramide, 4,4,4-trinitro-",C(CC([N+](=O)[O-])([N+](=O)[O-])[N+](=O)[O-])C(=O)N,,,,,,
5579,25580,CID 25580,CC(C)COC(=S)[S-].[K+],,,,,,
5580,25581,Isobutyl xanthate,CC(C)COC(=S)S,,,,,,
5581,25582,"AMMONIUM, (3-(2-(alpha-HYDROXYBENZYL)PHENOXY)PROPYL)TRIMETHYL-, TOLUENESULFONATE",CC1=CC=C(C=C1)S(=O)(=O)[O-].C[N+](C)(C)CCCOC1=CC=CC=C1C(C2=CC=CC=C2)O,,,,,,
5582,25583,3-[2-[Hydroxy(phenyl)methyl]phenoxy]propyl-trimethylazanium,C[N+](C)(C)CCCOC1=CC=CC=C1C(C2=CC=CC=C2)O,,,,,,
5583,25584,CID 25584,CCOC(=O)C1=C(C(=C2C(=CC(=O)C=C2O1)O)O)C3=CC=C(C=C3)Cl,,,,,,
5584,25585,"Isoflavone, 7-(2-(dimethylamino)ethoxy)-4'-methoxy-2-methyl-",CC1=C(C(=O)C2=C(O1)C(=CC=C2)OCCN(C)C)C3=CC=C(C=C3)OC,,,,,,
5585,25586,CID 25586,C1=CC=C(C=C1)CC(=O)[O-].[K+],,,,,,
5586,25587,CID 25587,C([C@H]([C@H]([C@@H]([C@H]([C@H](C(=O)[O-])O)O)O)O)O)O.[Na+],,,,,,
5587,25588,Glucoheptonic acid,C([C@H]([C@H]([C@@H]([C@H]([C@H](C(=O)O)O)O)O)O)O)O,,,,,,
5588,25589,Chromium carbonyl,[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].[Cr],,,,,,
5589,25590,Mafenide acetate,CC(=O)O.C1=CC(=CC=C1CN)S(=O)(=O)N,,,"['A class of compounds that reduces the secretion of H+ ions by the proximal kidney tubule through inhibition of CARBONIC ANHYDRASES. (See all compounds classified as Carbonic Anhydrase Inhibitors.)', 'Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)', 'Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)']",,,
5590,25591,CID 25591,CCCN(C(=N[N+](=O)[O-])N)N=O,,,,,,
5591,25592,1-Butyl-2-nitro-1-nitroso-guanidine,CCCCN(C(=N[N+](=O)[O-])N)N=O,,,,,,
5592,25593,CID 25593,CCCCCN(C(=N[N+](=O)[O-])N)N=O,,,,,,
5593,25594,N-[4-[4-[[4-[[4-(4-acetamidophenyl)sulfonylphenyl]iminomethyl]phenyl]methylideneamino]phenyl]sulfonylphenyl]acetamide,CC(=O)NC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(C=C2)N=CC3=CC=C(C=C3)C=NC4=CC=C(C=C4)S(=O)(=O)C5=CC=C(C=C5)NC(=O)C,,,,,,
5594,25595,"Isonicotinic acid, 2-(2-((2,4-dichlorobenzyl)carbamoyl)ethyl)hydrazide",C1=CC(=C(C=C1Cl)Cl)CNC(=O)CCNNC(=O)C2=CC=NC=C2,,,,,,
5595,25596,"Isonicotinic acid, 2-(3-phenylpropyl)hydrazide",C1=CC=C(C=C1)CCCNNC(=O)C2=CC=NC=C2,,,,,,
5596,25597,"Isonicotinic acid, 2-(2-(butylcarbamoyl)ethyl)hydrazide",CCCCNC(=O)CCNNC(=O)C1=CC=NC=C1,,,,,,
5597,25598,"ISONICOTINIC ACID, 2-(2-((p-CHLOROBENZYL)CARBAMOYL)ETHYL)HYDRAZIDE",C1=CC(=CC=C1CNC(=O)CCNNC(=O)C2=CC=NC=C2)Cl,,,,,,
5598,25599,"ISONICOTINIC ACID, 2-(2-((p-METHYLBENZYL)CARBAMOYL)ETHYL)HYDRAZIDE",CC1=CC=C(C=C1)CNC(=O)CCNNC(=O)C2=CC=NC=C2,,,,,,
5599,25600,3-(2-Aminoethyl)-1-benzothiophen-5-ol,C1=CC2=C(C=C1O)C(=CS2)CCN,,,,,,
5600,25601,"4,4,4-Trinitrobutyric acid sec-butyl ester",CCC(C)OC(=O)CCC([N+](=O)[O-])([N+](=O)[O-])[N+](=O)[O-],,,,,,
5601,25602,"BUTYRIC ACID, 4,4,4-TRINITRO-, tert-BUTYL ESTER",CC(C)(C)OC(=O)CCC([N+](=O)[O-])([N+](=O)[O-])[N+](=O)[O-],,,,,,
5602,25603,"Butyric acid, 4,4,4-trinitro-, 2,2,2-trinitroethyl ester",C(CC([N+](=O)[O-])([N+](=O)[O-])[N+](=O)[O-])C(=O)OCC([N+](=O)[O-])([N+](=O)[O-])[N+](=O)[O-],,,,,,
5603,25604,Methyl 4-nitrobutyrate,COC(=O)CCC[N+](=O)[O-],,,,,,
5604,25605,"Butyramide, N-methyl-4,4,4-trinitro-",CNC(=O)CCC([N+](=O)[O-])([N+](=O)[O-])[N+](=O)[O-],,,,,,
5605,25606,"Isophthalamic acid, 5,5'-(1,4-phenylenebis(carbonylimino))bis(N-methyl-2,4,6-triiodo-",CNC(=O)C1=C(C(=C(C(=C1I)NC(=O)C2=CC=C(C=C2)C(=O)NC3=C(C(=C(C(=C3I)C(=O)O)I)C(=O)NC)I)I)C(=O)O)I,,,,,,
5606,25607,"2,4-Dichloro-1-(trichloromethyl)benzene",C1=CC(=C(C=C1Cl)Cl)C(Cl)(Cl)Cl,,,,,,
5607,25608,"3,4-Dichlorobenzotrichloride",C1=CC(=C(C=C1C(Cl)(Cl)Cl)Cl)Cl,,,,,,
5608,25609,"1,1,2,2-Cyclopropanetetracarbonitrile, 3,3-dimethyl-",CC1(C(C1(C#N)C#N)(C#N)C#N)C,,,,,,
5609,25610,Butyloctenal,CCCCCC=C(CCCC)C=O,,,,,,
5610,25611,2-Methyl-3-heptanone,CCCCC(=O)C(C)C,,,,,,
5611,25612,9-Decen-1-OL,C=CCCCCCCCCO,,,,,,
5612,25613,trimethyl(7H-purin-8-yl)azanium;chloride,C[N+](C)(C)C1=NC2=NC=NC=C2N1.[Cl-],,,,,,
5613,25614,trimethyl(7H-purin-8-yl)azanium,C[N+](C)(C)C1=NC2=NC=NC=C2N1,,,,,,
5614,25615,CID 25615,CC(=O)CC(C1=CC(=CC=C1)I)C2=C(OC3=CC=CC=C3C2=O)O,,,,,,
5615,25616,CID 25616,CC(=O)CC(C1=CC=CC2=CC=CC=C21)C3=C(OC4=C(C3=O)C=C(C=C4)I)O,,,,,,
5616,25617,CID 25617,CC(=O)CC(C1=CC=CC=C1)C2=C(OC3=C(C2=O)C=C(C=C3)I)O,,,,,,
5617,25618,CID 25618,C1=CC=C2C(=C1)C(=CC(=N2)C=CC3=CC=C(O3)N(O)O)C(=O)N=N,,,,,,
5618,25619,"Ethanol, 2-isocyanato-, carbonate (2:1) (ester)",C(COC(=O)OCCN=C=O)N=C=O,,,,,,
5619,25620,"1-(2-Chloroethyl)-1,1-dimethylhydrazinium chloride",C[N+](C)(CCCl)N.[Cl-],,,,,,
5620,25621,"1-(2-Chloroethyl)-1,1-dimethylhydrazinium",C[N+](C)(CCCl)N,,,,,,
5621,25622,"2,2'-Dichlorobiphenyl",C1=CC=C(C(=C1)C2=CC=CC=C2Cl)Cl,,,,,,
5622,25623,4-Methoxy-4-oxobutan-1-aminium chloride,COC(=O)CCC[NH3+].[Cl-],,,,,,
5623,25624,CID 25624,CCOC(=O)CSC(=NC1=CC=C(C=C1)Cl)S,,,,,,
5624,25625,CID 25625,CCSC(=NC1=CC=CC=C1)S,,,,,,
5625,25626,CID 25626,CCOC1=CC=C(C=C1)N=C(S)SC,,,,,,
5626,25627,CID 25627,CSC(=NC1=CC=CC=C1Cl)S,,,,,,
5627,25628,CID 25628,CCSC(=NC1=CC=CC=C1Cl)S,,,,,,
5628,25629,CID 25629,CCSC(=NC1=CC(=CC=C1)Cl)S,,,,,,
5629,25630,CID 25630,C1=CC=C(C=C1)CSC(=NC2=CC(=CC=C2)Cl)S,,,,,,
5630,25631,CID 25631,C1=CC(=CC(=C1)Cl)N=C(S)SCC2=CC=C(C=C2)Cl,,,,,,
5631,25632,CID 25632,CSC(=NC1=CC(=C(C=C1)Cl)Cl)S,,,,,,
5632,25633,CID 25633,CCSC(=NC1=CC(=C(C=C1)Cl)Cl)S,,,,,,
5633,25634,CID 25634,CSC(=NC1=CC(=C(C=C1)Br)Cl)S,,,,,,
5634,25635,CID 25635,CSC(=NC1=CC=C(C=C1)[N+](=O)[O-])S,,,,,,
5635,25636,CID 25636,CCSC(=NC1=CC=C(C=C1)[N+](=O)[O-])S,,,,,,
5636,25637,CID 25637,CSC(=NC1=CC(=CC=C1)[N+](=O)[O-])S,,,,,,
5637,25638,CID 25638,CSC(=NC1=CC=CC2=CC=CC=C21)S,,,,,,
5638,25639,CID 25639,C1=CC(=C(C=C1N=C(S)SCC(=O)O)Cl)Br,,,,,,
5639,25640,p-2-Butenylphenol,CC=CCC1=CC=C(C=C1)O,,,,,,
5640,25641,4-Heptyloxyphenol,CCCCCCCOC1=CC=C(C=C1)O,,,,,,
5641,25642,Methyl 10-octadecenoate,CCCCCCCC=CCCCCCCCCC(=O)OC,,,,,,
5642,25643,"Methyl octadeca-9,11-dienoate",CCCCCCC=CC=CCCCCCCCC(=O)OC,,,,,,
5643,25644,"1,6-Hexanediol diacrylate",C=CC(=O)OCCCCCCOC(=O)C=C,,,,,"['Acrylates and methacrylates are detoxified predominantly via conjugation with glutathione via the Michael addition reaction or glutathione-S-transferase. They are also likely to be hydrolyzed via carboxylesterases. The lower molecular weight esters are rapidly metabolized and eliminated, therefore, will not likely cause cumulative toxicity. /Acrylates/']",
5644,25645,"Ammonium, trimethylenebis(benzyldimethyl-, dibromide",C[N+](C)(CCC[N+](C)(C)CC1=CC=CC=C1)CC2=CC=CC=C2.[Br-].[Br-],,,,,,
5645,25646,Trimethylenebis(benzyldimethylaminium),C[N+](C)(CCC[N+](C)(C)CC1=CC=CC=C1)CC2=CC=CC=C2,,,,,,
5646,25647,1-Methyl-4-oxonipecotic acid methyl ester hydrochloride,C[NH+]1CCC(=O)C(C1)C(=O)OC.[Cl-],,,,,,
5647,25648,Methyl 1-methyl-4-oxopiperidine-3-carboxylate,CN1CCC(=O)C(C1)C(=O)OC,,,,,,
5648,25649,CID 25649,CN1CC(C2=CC(=C(C=C21)O)N=NC(=O)N)O.C1=CC=C(C(=C1)C(=O)[O-])O.[Na+],,,,,,
5649,25650,3-(2-Hydroxybut-2-enoyloxy)propyl-trimethylazanium;chloride,CC=C(C(=O)OCCC[N+](C)(C)C)O.[Cl-],,,,,,
5650,25651,3-[(Z)-2-hydroxybut-2-enoyl]oxypropyl-trimethylazanium,C/C=C(/C(=O)OCCC[N+](C)(C)C)\O,,,,,,
5651,25652,"1-Naphthaleneacetamide, 5,6,7,8-tetrahydro-",C1CCC2=C(C1)C=CC=C2CC(=O)N,,,,,,
5652,25653,"2-Naphthaleneacetamide, 5,6,7,8-tetrahydro-",C1CCC2=C(C1)C=CC(=C2)CC(=O)N,,,,,,
5653,25654,Reproterol,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CCCNCC(C3=CC(=CC(=C3)O)O)O,,,"['Drugs that selectively bind to and activate beta-adrenergic receptors. (See all compounds classified as Adrenergic beta-Agonists.)', 'Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)']",,,
5654,25655,N-[4-(9H-xanthen-9-yl)piperazin-1-yl]fluoren-9-imine,C1CN(CCN1C2C3=CC=CC=C3OC4=CC=CC=C24)N=C5C6=CC=CC=C6C7=CC=CC=C75,,,,,,
5655,25656,CID 25656,CCCCC1CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC3C(O3)C=CC(=O)O1)O)O)O)C(=O)O)O[C@H]4C(C([C@@H](C(O4)C)O)N)O,,,,,,
5656,25657,Hex-4-en-1-yn-3-one,CC=CC(=O)C#C,,,,,,
5657,25658,"BENZYL ALCOHOL, alpha-(1-AMINOETHYL)-p-HYDROXY-, HYDROCHLORIDE",CC(C(C1=CC=C(C=C1)O)O)[NH3+].[Cl-],,,,,,
5658,25659,Nitidine chloride,C[N+]1=CC2=CC(=C(C=C2C3=C1C4=CC5=C(C=C4C=C3)OCO5)OC)OC.[Cl-],,,,,,
5659,25660,Dichloromalononitrile,C(#N)C(C#N)(Cl)Cl,,,,,,
5660,25661,alpha-(2-(Dimethylamino)ethyl)-alpha-ethylbenzyl alcohol hydrochloride,CCC(CC[NH+](C)C)(C1=CC=CC=C1)O.[Cl-],,,,,,
5661,25662,1-(Dimethylamino)-3-phenylpentan-3-ol,CCC(CCN(C)C)(C1=CC=CC=C1)O,,,,,,
5662,25663,Diallylphenylmethane,C=CCC(CC=C)C1=CC=CC=C1,,,,,,
5663,25664,Diallyl-p-aminophenylmethane hydrochloride,C=CCC(CC=C)C1=CC=C(C=C1)[NH3+].[Cl-],,,,,,
5664,25665,"4-Hepta-1,6-dien-4-ylaniline",C=CCC(CC=C)C1=CC=C(C=C1)N,,,,,,
5665,25666,"Isophthalamic acid, 5,5'-(octamethylenebis(carbonylimino))bis(N-butyl-2,4,6-triiodo-",CCCCNC(=O)C1=C(C(=C(C(=C1I)NC(=O)CCCCCCCCC(=O)NC2=C(C(=C(C(=C2I)C(=O)O)I)C(=O)NCCCC)I)I)C(=O)O)I,,,,,,
5666,25667,"2,7-Dimethyl-1,2,3,4-tetrahydronaphthalene",CC1CCC2=C(C1)C=C(C=C2)C,,,,,,
5667,25668,"Ketone, 10-(3-(dimethylamino)propyl)phenothiazin-2-YL morpholinomethyl-",CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(=O)CN4CCOCC4,,,,,,
5668,25669,Cyanofenphos,CCOP(=S)(C1=CC=CC=C1)OC2=CC=C(C=C2)C#N,,,,,,
5669,25670,Terbufos,CCOP(=S)(OCC)SCSC(C)(C)C,,,,"['A metabolism study of rats indicated that 83% of a single administration of 0.8 mg/kg terbufos was excreted in the urine in the form of metabolites and 3.5% in the feces during 168 hours. No terbufos accumulated in tissues.', 'Rapidly absorbed through skin.', 'Among 11 farmers who applied a formulated terbufos product while planting corn, ...no alkyl phosphates were detected in urine... /after an estimated respiratory dose of 0.009 mg/cu m terbufos/.']","['Metabolism occurs principally by oxidation, hydrolysis by esterases, and by transfer of portions of the molecule to glutathione.  Oxidation of organophosphorus insecticides may result in more or less toxic products.  The glutathione transferase reactions produce products, that are, in most cases, of low toxicity. Hydrolytic and transferase reactions affect both thioates and their oxons. /Organophosphorus Pesticides/', 'Biotransformation of terbufos in rat liver revealed four metabolites in the effluent prepared with a C18 cartridge after the rat liver was perfused for one hour in situ. Analysing the spectrogram of GC-IR and GC-MS, metabolite IV appeared to be an oxidative desulfuration product of terbufos with the formula C9H21O3PS2, the recovery of which in the effluent was 2.13%; metabolite I appeared to be an hydrolysate of metabolite IV with the formula C5H13O3PS, the recovery of which was 0.13%; metabolite II appeared to be an hydrolysate of terbufos with the formula C5H13O2PS2, the recovery of which was 2.65%; metabolite III appeared to be a methylate of metabolite II, with the formula C6H15O2PS2, the recovery of which was 1.42%. Relatively the recovery of terbufos was 40.8%. These results were in accord with the regular metabolic pattern in vivo of phosphorothioates with a thioether group.']",
5670,25671,"2-(3-Amino-2,4,6-triiodobenzyl)adipic acid",C1=C(C(=C(C(=C1I)N)I)CC(CCCC(=O)O)C(=O)O)I,,,,,,
5671,25672,1-(3-Aminopropyl)-4-phenylisonipecotaldehyde dihydrochloride,C1C[NH+](CCC1(C=O)C2=CC=CC=C2)CCC[NH3+].[Cl-].[Cl-],,,,,,
5672,25673,1-(3-Aminopropyl)-4-phenylpiperidine-4-carbaldehyde,C1CN(CCC1(C=O)C2=CC=CC=C2)CCCN,,,,,,
5673,25674,L-Ethionine,CCSCC[C@@H](C(=O)O)N,,,"['Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Antimetabolites.)']","['IN RAT KIDNEY RADIOACTIVITY WAS MAINLY LOCALIZED IN MEDULLA FOLLOWING INJECTION WITH (14)C-ETHIONINE, WHEREAS (14)C-METHIONINE WAS HOMOGENEOUSLY DISTRIBUTED THROUGHOUT WHOLE PARENCHYMA IN RATS.']","['S-ADENOSYLETHIONINE IS A SUGGESTED ALKYLATING METABOLITE OF CARCINOGEN ETHIONINE. /FROM TABLE/', 'ETHIONINE IS BIOACTIVATED IN LIVER TO S-ADENOSYL-L-ETHIONINE, WHICH CAN ETHYLATE MACROMOLECULES CAUSING CELL ABNORMALITIES. ADENOSYLETHIONINE IS CHEM STABLE & CAN PENETRATE TO EMBRYONIC TISSUES & CAUSE TERATOGENIC EFFECTS.', 'IN URINE OF TREATED RATS, 4 PRINCIPAL ETHIONINE EXCRETORY PRODUCTS WERE IDENTIFIED...N-ACETYLETHIONINE SULFOXIDE, S-ADENOSYLETHIONINE, ETHIONINE SULFOXIDE, & FREE ETHIONINE.']",
5674,25675,"Naphthalene, 1,2,3,4-tetrahydro-2-(p-chlorophenyl)-1-(p-(2,3-epoxypropoxy)phenyl)-",C1CC2=CC=CC=C2C(C1C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)OCC5CO5,,,,,,
5675,25676,"(1S,14S,17S)-2,9,9,17,18-pentamethyl-7-oxa-6-azapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5,10-trien-17-ol",C[C@@]1(CC[C@@H]2C1(CC[C@H]3C2CC=C4C3(CC5=C(C4(C)C)ON=C5)C)C)O,,,,,,
5676,25677,CID 25677,CCN(C1=CC=CC=C1)C(=S)[S-].[Na+],,,,,,
5677,25678,Lead(2+) ethylphenyldithiocarbamate,CCN(C1=CC=CC=C1)C(=S)S,,,,,,
5678,25679,Dysprosium citrate,C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Dy+3],,,,,,
5679,25680,"1,2,4-Tribromo-3,5,6-trichlorobenzene",C1(=C(C(=C(C(=C1Br)Cl)Br)Br)Cl)Cl,,,,,,
5680,25681,1-(3-Chlorophenyl)piperazine hydrochloride,C1CN(CCN1)C2=CC(=CC=C2)Cl.Cl,,,['Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)'],,,
5681,25682,"Ammonium, (2,5-dimethoxyphenethyl)trimethyl-, chloride",C[N+](C)(C)CCC1=C(C=CC(=C1)OC)OC.[Cl-],,,,,,
5682,25683,"2-(2,5-Dimethoxyphenyl)ethyl-trimethylazanium",C[N+](C)(C)CCC1=C(C=CC(=C1)OC)OC,,,,,,
5683,25684,Butylethylmalonic acid 2-(diethylamino)ethyl ethyl ester,CCCCC(CC)(C(=O)OCC)C(=O)OCCN(CC)CC,,,,,,
5684,25685,4-Amino-2-phenylbutanoic acid,C1=CC=C(C=C1)C(CCN)C(=O)O,,,,,,
5685,25686,"Acetic acid, (3-(N-ethylacetamido)-2,4,6-triiodophenoxy)-",CCN(C1=C(C(=C(C=C1I)I)OCC(=O)O)I)C(=O)C,,,,,,
5686,25687,"2-(3-(N-Methylacetamido)-2,4,6-triiodophenoxy)butyric acid",CCC(C(=O)O)OC1=C(C=C(C(=C1I)N(C)C(=O)C)I)I,,,,,,
5687,25688,"Acetic acid, (3-(N-methylacetamido)-2,4,6-triiodophenoxy)-",CC(=O)N(C)C1=C(C(=C(C=C1I)I)OCC(=O)O)I,,,,,,
5688,25689,"Benzenamine, 4,4'-[sulfonylbis(4,1-phenyleneoxy)]bis-",C1=CC(=CC=C1N)OC2=CC=C(C=C2)S(=O)(=O)C3=CC=C(C=C3)OC4=CC=C(C=C4)N,,,,,,
5689,25690,"Phenothiazine, 10-(2-(dimethylamino)propyl)-2-(morpholinoacetyl)-",CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(=O)CN4CCOCC4)N(C)C,,,,,,
5690,25691,CID 25691,C1=CC=C2C(=C1)N=C(N2CCC3=CC=NC=C3)S,,,,,,
5691,25692,"Methyl 4-(2-(diethylamino)acetylamino)salicylate, methiodide",CC[N+](C)(CC)CC(=O)NC1=CC(=C(C=C1)C(=O)OC)O.[I-],,,,,,
5692,25693,Diethyl-[2-(3-hydroxy-4-methoxycarbonylanilino)-2-oxoethyl]-methylazanium,CC[N+](C)(CC)CC(=O)NC1=CC(=C(C=C1)C(=O)OC)O,,,,,,
5693,25694,Conray 280,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)C(=O)NC)I.CNCC(C(C(C(CO)O)O)O)O,,,,,,
5694,25695,Phenoxyacetic acid alpha-(2-(dimethylamino)ethyl)-alpha-ethylbenzyl ester hydrochloride,CCC(CC[NH+](C)C)(C1=CC=CC=C1)OC(=O)COC2=CC=CC=C2.[Cl-],,,,,,
5695,25696,[1-(Dimethylamino)-3-phenylpentan-3-yl] 2-phenoxyacetate,CCC(CCN(C)C)(C1=CC=CC=C1)OC(=O)COC2=CC=CC=C2,,,,,,
5696,25697,Diallyl-p-methoxyphenylmethane,COC1=CC=C(C=C1)C(CC=C)CC=C,,,,,,
5697,25698,"Spiro(cyclotetrasiloxane-2,1'-(1)silaacenaphthene), 4,4,6,6,8,8-hexamethyl-",C[Si]1(O[Si](O[Si]2(CC3=CC=CC4=C3C2=CC=C4)O[Si](O1)(C)C)(C)C)C,,,,,,
5698,25699,CID 25699,CC(=O)CC(C1=CC=CC=C1I)C2=C(OC3=CC=CC=C3C2=O)O,,,,,,
5699,25700,4-Mercaptobutyric acid,C(CC(=O)O)CS,,,,,,
5700,25701,Cysteic Acid,C(C(C(=O)O)N)S(=O)(=O)O,,,,,,
5701,25702,"[(9S,14S,17S)-10,13-dimethyl-3-oxo-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] undec-10-enoate",CC12CC[C@H]3C([C@@H]1CC[C@@H]2OC(=O)CCCCCCCCC=C)CCC4=CC(=O)C=CC34C,,,,,,
5702,25703,Bis((4-(2-hydroxyethyl)-1-piperazinyl)thiocarbonyl)disulfide,C1CN(CCN1CCO)C(=S)SSC(=S)N2CCN(CC2)CCO,,,,,,
5703,25704,"[2-Bromo-1-(2,4-dichlorophenyl)ethenyl] dimethyl phosphate",COP(=O)(OC)OC(=CBr)C1=C(C=C(C=C1)Cl)Cl,,,,,,
5704,25705,"N,N'-Diphenyl-1,3,5-triazine-2,4-diamine",C1=CC=C(C=C1)NC2=NC(=NC=N2)NC3=CC=CC=C3,,,,,,
5705,25706,Pentyl 4-aminobenzoate,CCCCCOC(=O)C1=CC=C(C=C1)N,,,,,,
5706,25707,CID 25707,CC(=O)NC1C(C(C(OC1OC2=CC=CC=C2C(=O)[O-])CO)O)O.[Na+],,,,,,
5707,25708,"2-(3-Acetylamino-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-benzoic acid",CC(=O)NC1C(C(C(OC1OC2=CC=CC=C2C(=O)O)CO)O)O,,,,,,
5708,25709,"Ammonium, hexamethylenebis(dimethylpropyl-, dibromide",CCC[N+](C)(C)CCCCCC[N+](C)(C)CCC.[Br-].[Br-],,,,,,
5709,25710,Hexamethylenebis(dimethylpropylaminium),CCC[N+](C)(C)CCCCCC[N+](C)(C)CCC,,,,,,
5710,25711,"3-Methyl-1,1-diphenylurea",CNC(=O)N(C1=CC=CC=C1)C2=CC=CC=C2,,,,,,
5711,25712,[3-(Trifluoromethyl)phenyl]urea,C1=CC(=CC(=C1)NC(=O)N)C(F)(F)F,,,,,,
5712,25713,N-Hydroxy-N-methylacetamide,CC(=O)N(C)O,,,,,,
5713,25714,3-Nitro-2-naphthylamine,C1=CC=C2C=C(C(=CC2=C1)N)[N+](=O)[O-],,,,,,
5714,25715,Fonazine mesylate,CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)S(=O)(=O)N(C)C)N(C)C.CS(=O)(=O)O,,,"['Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)']",,,
5715,25716,"7,8-Dimethoxy-2,5-dimethyl-2-(4,8,12-trimethyltridecyl)chromen-6-ol",CC1=C2C=CC(OC2=C(C(=C1O)OC)OC)(C)CCCC(C)CCCC(C)CCCC(C)C,,,,,,
5716,25717,"1,2,2,3-Tetrachloropropane",C(C(CCl)(Cl)Cl)Cl,,,,,,
5717,25718,N-(2-(Benzyldithio)ethyl)decylamine hydrochloride,CCCCCCCCCC[NH2+]CCC(C1=CC=CC=C1)(S)S.[Cl-],,,,,,
5718,25719,"3-(Decylamino)-1-phenylpropane-1,1-dithiol",CCCCCCCCCCNCCC(C1=CC=CC=C1)(S)S,,,,,,
5719,25720,"DECYLAMINE, N-(2-((p-CHLOROBENZYL)DITHIO)ETHYL)-, HYDROCHLORIDE",CCCCCCCCCC[NH2+]CCC(C1=CC=C(C=C1)Cl)(S)S.[Cl-],,,,,,
5720,25721,"1-(4-Chlorophenyl)-3-(decylamino)propane-1,1-dithiol",CCCCCCCCCCNCCC(C1=CC=C(C=C1)Cl)(S)S,,,,,,
5721,25722,N-(2-((p-Nitrobenzyl)dithio)ethyl)decylamine monohydrochloride,CCCCCCCCCC[NH2+]CCCC1=C(C=C(C=C1)[N+](=O)[O-])S.[Cl-],,,,,,
5722,25723,2-[3-(Decylamino)propyl]-5-nitrobenzenethiol,CCCCCCCCCCNCCCC1=C(C=C(C=C1)[N+](=O)[O-])S,,,,,,
5723,25724,"Isonicotinic acid, 2-cyclopentylhydrazide",C1CCC(C1)NNC(=O)C2=CC=NC=C2,,,,,,
5724,25725,"Isonicotinic acid, 2-cyclooctylhydrazide",C1CCCC(CCC1)NNC(=O)C2=CC=NC=C2,,,,,,
5725,25726,alpha-Cyclopentylmandelic acid 1-methyl-3-pyrrolidinyl ester hydrochloride,C[NH+]1CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O.[Cl-],,,,,,
5726,25727,N-Methyl-3-pyrrolidinyl Cyclopentylmandelate,CN1CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O,,,,,,
5727,25728,CID 25728,C1CCC(CC1)[SnH](C2CCCCC2)C3CCCCC3.O,,,,,,
5728,25729,Tricyclohexylstannane,C1CCC(CC1)[SnH](C2CCCCC2)C3CCCCC3,,,,,,
5729,25730,"Benzoic acid, 2-(3,4-dichlorophenyl)hydrazide",C1=CC=C(C=C1)C(=O)NNC2=CC(=C(C=C2)Cl)Cl,,,,,,
5730,25731,Rubidium nitrate,[N+](=O)([O-])[O-].[Rb+],,,,,,
5731,25732,4-(Trimethylsilyl)phenol,C[Si](C)(C)C1=CC=C(C=C1)O,,,,,,
5732,25733,"4,8,12-Trioxatridecan-1-ol",COCCCOCCCOCCCO,,,,,,
5733,25734,"5H-DIBENZO(b,e)(1,4)DIAZEPIN-11-ONE, 10,11-DIHYDRO-10-(2-(DIMETHYLAMINO)ETHYL)-",CN(C)CCN1C2=CC=CC=C2NC3=CC=CC=C3C1=O,,,,,,
5734,25735,"3-[(3S,5S,10R,13R,14S,17R)-3-[(2R,5R)-6-[[(3R,6S)-4,6-dihydroxy-2-methyloxan-3-yl]oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-5,14-dihydroxy-10,13-dimethyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one",CC1[C@@H](C(C[C@H](O1)O)O)OCC2[C@H](C(C([C@@H](O2)O[C@H]3CC[C@@]4(C5CC[C@@]6([C@H](CC[C@@]6(C5CC[C@@]4(C3)O)O)C7=CC(=O)OC7)C)C)O)OC)O,,,,,,
5735,25736,Nickel nitrate,[N+](=O)([O-])[O-].[N+](=O)([O-])[O-].[Ni+2],,,,,,
5736,25737,"1,2,3,3-Tetrachlorobutane",CC(C(CCl)Cl)(Cl)Cl,,,,,,
5737,25738,Dimethyl adipimidate,COC(=N)CCCCC(=N)OC,,,"['Agents used to prevent or reverse the pathological events leading to sickling of erythrocytes in sickle cell conditions. (See all compounds classified as Antisickling Agents.)', 'Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant and Hackh&apos;s Chemical Dictionary, 5th ed, p301, p499) (See all compounds classified as Indicators and Reagents.)']",,,
5738,25739,N-Cyclopropyl-N'-phenylurea,C1CC1NC(=O)NC2=CC=CC=C2,,,,,,
5739,25740,N-Cyclopentyl-N'-phenylurea,C1CCC(C1)NC(=O)NC2=CC=CC=C2,,,,,,
5740,25741,1-(3-Chloro-4-methylphenyl)urea,CC1=C(C=C(C=C1)NC(=O)N)Cl,,,,,,
5741,25742,N-Ethyl-N-(2-hydroxyethyl)nitrosamine,CCN(CCO)N=O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,,
5742,25743,Octaethylene glycol octadecyl ether,CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCO,,,,,,
5743,25744,CID 25744,CCCCCCCCCCCCOCCOCCOCCOS(=O)(=O)[O-].[Na+],,,,,,
5744,25745,Triethylene glycol lauryl ether sulfate,CCCCCCCCCCCCOCCOCCOCCOS(=O)(=O)O,,,,,,
5745,25746,Ethylcyclooctane,CCC1CCCCCCC1,,,,,,
5746,25747,Thietane 1-oxide,C1CS(=O)C1,,,,,,
5747,25748,"[(7R,8S)-11-amino-5-ethyl-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate",CCN1C2C1[C@@]3([C@@H](C4=C(N3C2)C(=O)C(=C(C4=O)N)C)COC(=O)N)OC,,,,,,
5748,25749,Hexafluoroisopropyl methyl ether,COC(C(F)(F)F)C(F)(F)F,,,,,,
5749,25750,2-Chloro-3-(diethylamino)-1-methyl-3-oxo-1-propenyl dimethyl phosphate,CCN(CC)C(=O)C(=C(C)OP(=O)(OC)OC)Cl,,,"['Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)', 'Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)']","['The main eliminative route for phosphamidon...in rats and lactating goats was via kidneys, but small amount of several metabolites were secreted into milk of lactating goats. Only traces of unchanged /phosphamidon/ were present amongst excretory products. Desethylphosphamidon was present in urine of treated animals, whereas both phosphamidon amide and dechlorophosphamidon amide occurred in urine and milk of lactating goats. ...alpha-Chloro-nn-diethylacetoacetamide was detected in urine and in milk.', 'After ip injection of cis or trans phosphamidon-(32)P in male white rats, excreta was collected... About 60% of dose--either isomer--was recovered within 24 hr...most from urine... .', 'Phosphamidon is a systemic insecticide rapidly absorbed by the plant... In plants 50% loss occurs in about 2 days.', 'Early appearance of symptoms and steepness of acute dose-response curves (increased dosage levels produced disproportionately large increase in response) indicate that phosphamidon is rapidly and thoroughly taken up from GI tracts of birds.', 'Phosphamidon is absorbed by the respiratory and gastrointestinal tracts as well as by the skin. ...Experimental animal studies have shown that most of a radiolabelled doses of organophosphorus pesticides is rapidly excreted in expired air, urine, and feces.']","['Desethylphosphamidon was present in the urine of treated.../lactating goats/ both phosphamidon amide and dechlorophosphamidon amide occurred in the urine and milk...alpha-chloro-nn-diethylacetoacetamide was detected in urine and in milk.', 'After ip injection of cis or trans (32)P-phosphamidon in male white rats... about 60% of dose...was recovered within 24 hr after injection, most from urine. Hydrolytic products were almost entirely dimethyl phosphate, with small amount of phosphoric acid and o-demethyl phosphamidon. After foliar treatment of cotton, phosphamidon, o-demethyl phosphamidon, n-desethyl phosphamidon, hydroxyethyl phosphamidon, and dimethyl phosphate were detected externally. Internally, orthophosphate and an unknown were observed in addition to the foregoing compound. In fifth-instar tobacco budworms and bollworms, metabolism of the two isomers was similar. After injection of labeled phosphamidon.../phosphamidon, O-demethyl phosphamidon, hydroxyethyl phosphamidon, n-desethyl phosphamidon, phosphoric acid/ were observed in internal extracts /and excreta/.', 'Desethyl phosphamidon...alpha-chloroacetoacetic acid diethylamide, alpha-chloroacetoacetic acid ethylamide, dimethyl phosphoric acid, and unchanged phosphamidon were isolated from bean plants treated with (14)C-labeled phosphamidon. ...Metabolism of phosphamidon is unusual in that facile deethylation of the diethylamide moiety occurs with no demethylation at one of the methoxy groups. Environmental factors such as temperature and, to a lesser extent, light influence plant metabolism of phosphamidon to desethyl phosphamidon with increased rates at higher temperatures.', 'Rats received (32)P- and/or (14)C-labeled phosphamidon by stomach tube. .../Among metabolites found were/ vinyl hydroxyphosphamidon amide...and two compound containing only the carbon label but not further identified. Rat and rabbit liver homogenates metabolized phosphamidon... /des-n-ethyl phosphamidon and phosphamidon amide/ were found in small quantities but the hydroxy compound were not detected... .', 'For more Metabolism/Metabolites (Complete) data for PHOSPHAMIDON (6 total), please visit the HSDB record page.']",
5750,25751,Benzyl-dimethyl-(2-oxopropyl)azanium chloride,CC(=O)C[N+](C)(C)CC1=CC=CC=C1.[Cl-],,,,,,
5751,25752,Benzyl-dimethyl-(2-oxopropyl)azanium,CC(=O)C[N+](C)(C)CC1=CC=CC=C1,,,,,,
5752,25753,"2,3,5,6-Tetramethyl-4-nitroaniline",CC1=C(C(=C(C(=C1N)C)C)[N+](=O)[O-])C,,,,,,
5753,25754,"Benzenethanamine, 3,4-dimethoxy-N-(1-methyl-2-phenylethyl)-, hydrochloride",CC(CC1=CC=CC=C1)[NH2+]CCC2=CC(=C(C=C2)OC)OC.[Cl-],,,,,,
5754,25755,"N-[2-(3,4-dimethoxyphenyl)ethyl]-1-phenylpropan-2-amine",CC(CC1=CC=CC=C1)NCCC2=CC(=C(C=C2)OC)OC,,,,,,
5755,25756,1-Fluoranthenamine,C1=CC=C2C(=C1)C3=CC=CC4=C3C2=C(C=C4)N,,,,,,
5756,25757,2-Aminofluoranthene,C1=CC=C2C(=C1)C3=CC=CC4=CC(=CC2=C43)N,,,,,,
5757,25758,7-Aminofluoranthene,C1=CC2=C3C(=C1)C4=C(C3=CC=C2)C(=CC=C4)N,,,,,,
5758,25759,1-Nitrofluoranthene,C1=CC=C2C(=C1)C3=CC=CC4=C3C2=C(C=C4)[N+](=O)[O-],,,,,,
5759,25760,2-Nitrofluoranthene,C1=CC=C2C(=C1)C3=CC=CC4=CC(=CC2=C43)[N+](=O)[O-],,,"['Any substance in the air which could, if present in high enough concentration, harm humans, animals, vegetation or materials. Substances include GASES; PARTICULATE MATTER; and volatile ORGANIC CHEMICALS. (See all compounds classified as Air Pollutants.)']",,,
5760,25761,7-Nitrofluoranthene,C1=CC2=C3C(=C1)C4=C(C3=CC=C2)C(=CC=C4)[N+](=O)[O-],,,,,,
5761,25762,8-Nitrofluoranthene,C1=CC2=C3C(=C1)C4=C(C3=CC=C2)C=C(C=C4)[N+](=O)[O-],,,,,,
5762,25763,"2,6-Dibromo-4-[(2,4-dinitrophenoxy)iminomethyl]phenol",C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])ON=CC2=CC(=C(C(=C2)Br)O)Br,,,,,,
5763,25764,"N'-(p-Bromophenyl)-N,N-dimethylformamidine",CN(C)C=NC1=CC=C(C=C1)Br,,,,,,
5764,25765,"Formamidine, N'-(3-chloro-o-tolyl)-N,N-dimethyl-",CC1=C(C=CC=C1Cl)N=CN(C)C,,,,,,
5765,25766,"N,N-Dimethyl-N'-(3,4-dimethylphenyl)formamidine",CC1=C(C=C(C=C1)N=CN(C)C)C,,,,,,
5766,25767,"N'-(4-Methoxy-2-methylphenyl)-N,N-dimethylformamidine",CC1=C(C=CC(=C1)OC)N=CN(C)C,,,,,,
5767,25768,6-Thiocaffeine,CN1C=NC2=C1C(=S)N(C(=O)N2C)C,,,,,,
5768,25769,4-Bromo-3-phenylsydnone,C1=CC=C(C=C1)[N+]2=NOC(=C2Br)[O-],,,,,,
5769,25770,3-Phenyl-4-bromosydnone,C1=CC=C(C=C1)[N+]2=C(C(=O)ON2)Br,,,,,,
5770,25771,"1,4-Bis(trimethylsilyl)benzene",C[Si](C)(C)C1=CC=C(C=C1)[Si](C)(C)C,,,,,,
5771,25772,"Ammonium, benzyldimethyl(2-hydroxyethyl)-",C[N+](C)(CCO)CC1=CC=CC=C1,,,,,,
5772,25773,Pimetixene maleate,CN1CCC(=C2C3=CC=CC=C3SC4=CC=CC=C42)CC1.C(=CC(=O)O)C(=O)O,,,,,,
5773,25774,Arabinofuranosylcytosine triphosphate,C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O,,,['Compounds that inhibit cell production of DNA or RNA. (See all compounds classified as Nucleic Acid Synthesis Inhibitors.)'],,,
5774,25775,Dimethyl 2-oxoglutarate,COC(=O)CCC(=O)C(=O)OC,,,,,,
5775,25776,"2,2-Dibromo-1-(4-bromophenyl)ethanone",C1=CC(=CC=C1C(=O)C(Br)Br)Br,,,,,,
5776,25777,5-Hydroxy-2-isopropoxyphenyl methylcarbamate,CC(C)OC1=C(C=CC(=C1)O)OC(=O)NC,,,,,,
5777,25778,"1,3-Bis(2,5-dichlorophenyl)urea",C1=CC(=C(C=C1Cl)NC(=O)NC2=C(C=CC(=C2)Cl)Cl)Cl,,,,,,
5778,25779,"2-((6-Allyl-1,4-benzodioxan-5-yl)oxy)diethylamine hydrochloride",CC[NH2+]CCOC1=C(C=CC2=C1OCCO2)CC=C.[Cl-],,,,,,
5779,25780,"N-ethyl-2-[(6-prop-2-enyl-2,3-dihydro-1,4-benzodioxin-5-yl)oxy]ethanamine",CCNCCOC1=C(C=CC2=C1OCCO2)CC=C,,,,,,
5780,25781,Monoethylcholine,CC[N+](C)(C)CCO,,,,,,
5781,25782,CID 25782,CC1(CN=C(N1)S)C2=CC=CC=C2,,,,,,
5782,25783,CID 25783,CCC1(CN=C(N1)S)C2=CC=CC=C2,,,,,,
5783,25784,"1-(2-Chlorophenyl)-3-(3,4-dichlorophenyl)urea",C1=CC=C(C(=C1)NC(=O)NC2=CC(=C(C=C2)Cl)Cl)Cl,,,,,,
5784,25785,"2-(7-Oxo-2,3-dihydrofuro[3,2-g]chromen-2-yl)propyl 3-methylbut-2-enoate",CC(COC(=O)C=C(C)C)C1CC2=C(O1)C=C3C(=C2)C=CC(=O)O3,,,,,,
5785,25786,"1,4-Dihydro-2H-3,1-benzoxazin-2-one",C1C2=CC=CC=C2NC(=O)O1,,,,,,
5786,25787,"2H-3,1-Benzoxazin-2-one, 1,4-dihydro-1-phenyl-",C1C2=CC=CC=C2N(C(=O)O1)C3=CC=CC=C3,,,,,,
5787,25788,"Ethanone, 1-(2-methyl-5-phenyl-1H-pyrrol-3-YL)-",CC1=C(C=C(N1)C2=CC=CC=C2)C(=O)C,,,,,,
5788,25789,"Ammonium, hexamethylenebis(benzyldimethyl-, dibromide",C[N+](C)(CCCCCC[N+](C)(C)CC1=CC=CC=C1)CC2=CC=CC=C2.[Br-].[Br-],,,,,,
5789,25790,Benzyl-[6-(benzyl-dimethyl-ammonio)hexyl]-dimethyl-azanium,C[N+](C)(CCCCCC[N+](C)(C)CC1=CC=CC=C1)CC2=CC=CC=C2,,,,,,
5790,25791,"1,2-Dimethyl-4-nitro-1H-imidazole",CC1=NC(=CN1C)[N+](=O)[O-],,,,,,
5791,25792,"Imidazole-1-acetic acid, 2-methyl-4-nitro-, ethyl ester",CCOC(=O)CN1C=C(N=C1C)[N+](=O)[O-],,,,,,
5792,25793,3-Methyl-1-hexanol,CCCC(C)CCO,,,,,,
5793,25794,"Methanediamine, N,N'-dimethyl-N,N'-dinitro-",CN(CN(C)[N+](=O)[O-])[N+](=O)[O-],,,,,,
5794,25795,Glycerol triglycidyl ether,C1C(O1)COCC(COCC2CO2)OCC3CO3,,,,,,
5795,25796,"N-(4,6-Diamino-1,3,5-triazin-2-yl)formamide",C(=O)NC1=NC(=NC(=N1)N)N,,,,,,
5796,25797,"2,5-Diethylpyrazine",CCC1=CN=C(C=N1)CC,,,,,,
5797,25798,2-(Dimethylamino)ethanethiol hydrochloride,CN(C)CCS.Cl,,,,,,
5798,25799,Captamine,CN(C)CCS,,,,,,
5799,25800,alpha-Methylmercaptohippuronitrile,CSC(C#N)NC(=O)C1=CC=CC=C1,,,,,,
5800,25801,2-Chloro-4-(methylsulfonyl)aniline,CS(=O)(=O)C1=CC(=C(C=C1)N)Cl,,,,,,
5801,25802,"1,3-Dichloro-2-chloromethylpropene",C(C(=CCl)CCl)Cl,,,,,,
5802,25803,Febarbamate,CCCCOCC(CN1C(=O)C(C(=O)NC1=O)(CC)C2=CC=CC=C2)OC(=O)N,,,,,,
5803,25804,Carpronium chloride,C[N+](C)(C)CCCC(=O)OC.[Cl-],,,,,,
5804,25805,N-Amyl-N-methylnitrosamine,CCCCCN(C)N=O,,,"['Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (See all compounds classified as Carcinogens.)']",,"['MNAN has known human metabolites that include 2-Pentanol, 5-(methylnitrosoamino)- and N-(hydroxymethyl)-N-pentylnitrous amide.']",
5805,25806,Dimethyldinitrosoethylenediamine,CN(CCN(C)N=O)N=O,,,,,,
5806,25807,Vinylethylnitrosamine,CCN(C=C)N=O,,,,,,
5807,25808,Ethyl 4-nitroso-1-piperazinecarboxylate,CCOC(=O)N1CCN(CC1)N=O,,,,,,
5808,25809,N-Nitrosodiethanolamine diacetate,CC(=O)OCCN(CCOC(=O)C)N=O,,,,,,
5809,25810,N-Nitrosomethylaminosulfolane,CN(C1CCS(=O)(=O)C1)N=O,,,,,,
5810,25811,N-Nitrososarcosine,CN(CC(=O)O)N=O,,,,"['...N-nitrosamino acids (e.g., nitrosoproline (NPRO), nitrosohydroxyproline (NHPRO) and nitrososarcosine (NSAR)) when administered orally to rats, are excreted unchanged almost quantitatively (88-96% of the dose) in the urine and feces. ...']","['A simple and sensitive method for the quantitative estimation of endogenous N-nitrosation in rats was developed. This approach is based on the findings that N-nitroamino acids (e.g., nitrosoproline (NPRO), nitrosohydroxyproline(NHPRO) and nitrososarcosine (NSAR)) when administered orally to rats, are excreted unchanged almost quantitatively (88-96% of the dose) in the urine and feces. After sequential administration of a nitrosatable amino acid and sodium nitrite, the nitrosamino acid excreted in the urine and feces was analyzed. The amount of nitrosoproline excreted in the urine of rats was proportional to the dose of proline and to the square of the nitrite dose. Co-administration of ascorbic acid and alpha-tocopherol together with the precursors decreased the urinary nitrosoproline whereas thiocyanate increased the yield. After feeding an amino acid precursor and nitrite, the yield of nitrosamino acids, formed in vivo and excreted in the urine increased in the order: nitrosoproline < nitrososarcosine < nitrosohydroxyproline. The same order was seen when the nitrosation rates of the amino acids in vitro were compared. Evidently, N-nitrosation in vivo in rats occurs via a similar mechanism as observed in vitro. Monitoring of N-nitrosamino acids excreted in the urine and feces appears to provide a valuable index for endogenous N-nitrosation. ...']",
5811,25812,"1,1-Dimethoxynon-2-yne",CCCCCCC#CC(OC)OC,,,,,,
5812,25813,1-(2-Carbamyloxyethyl)benzotriazole,C1=CC=C2C(=C1)N=NN2CCOC(=O)N,,,,,,
5813,25814,2-Dimethylaminofluorene,CN(C)C1=CC2=C(C=C1)C3=CC=CC=C3C2,,,,,,
5814,25815,Amiphos,CC(=O)NCCSP(=S)(OC)OC,,,,,,
5815,25816,"2-tert-Butyl-4,6-dinitrophenol carbamate",CC(C)(C)C1=C(C(=CC(=C1)[N+](=O)[O-])[N+](=O)[O-])OC(=O)N,,,,,,
5816,25817,(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) (2R)-3-hydroxy-2-phenylpropanoate,CN1C2CCC1CC(C2)OC(=O)[C@@H](CO)C3=CC=CC=C3,,,,,,
5817,25818,"2,4,6-Tris((4-chlorophenyl)thio)-1,3,5-triazine",C1=CC(=CC=C1SC2=NC(=NC(=N2)SC3=CC=C(C=C3)Cl)SC4=CC=C(C=C4)Cl)Cl,,,,,,
5818,25819,"2,4,6-Tris(p-tolylthio)-1,3,5-triazine",CC1=CC=C(C=C1)SC2=NC(=NC(=N2)SC3=CC=C(C=C3)C)SC4=CC=C(C=C4)C,,,,,,
5819,25820,"3,5-Diphenyloctamethyltetrasiloxane",C[Si](C)(C)O[Si](C)(C1=CC=CC=C1)O[Si](C)(C2=CC=CC=C2)O[Si](C)(C)C,,,,,,
5820,25821,Trimethyl-[methyl-[methyl-[methyl-(methyl-phenyl-trimethylsilyloxysilyl)oxy-phenylsilyl]oxy-phenylsilyl]oxy-phenylsilyl]oxysilane,C[Si](C)(C)O[Si](C)(C1=CC=CC=C1)O[Si](C)(C2=CC=CC=C2)O[Si](C)(C3=CC=CC=C3)O[Si](C)(C4=CC=CC=C4)O[Si](C)(C)C,,,,,,
5821,25822,"Phosphinic acid, bis(chloromethyl)-, ethyl ester",C=COP(=O)(CCl)CCl,,,,,,
5822,25823,"2,5-Dichlorohexane",CC(CCC(C)Cl)Cl,,,,,,
5823,25824,"1,3,4-Thiadiazole-2-ethylamine",C1=NN=C(S1)CCN,,,,,,
5824,25825,Dodecyl nitrate,CCCCCCCCCCCCO[N+](=O)[O-],,,,,,
5825,25826,Ethylmercury;ethylmercury(1+);sulfanide,CC[Hg].CC[Hg+].[SH-],,,,,,
5826,25827,1-Aziridinecarboxanilide,C1CN1C(=O)NC2=CC=CC=C2,,,,,,
5827,25828,"1-Aziridinecarboxamide, N-methyl-",CNC(=O)N1CC1,,,,,,
5828,25829,"1,1,3-Trichloro-1-butene",CC(C=C(Cl)Cl)Cl,,,,,,
5829,25830,CID 25830,C(CN=C([NH3+])N)N=C([NH3+])N.[Cl-].[Cl-],,,,,,
5830,25831,N-(2-Guanidinoethyl)guanidine,C(CN=C(N)N)N=C(N)N,,,,,,
5831,25832,"HEXANOIC ACID, compd. with DICYCLOHEXYLAMINE (1:1)",CCCCCC(=O)O.C1CCC(CC1)NC2CCCCC2,,,,,,
5832,25833,Pent-2-enenitrile,CCC=CC#N,,,,,,
5833,25834,"Phosphorothioic acid, O,O-diethyl S-(phenylmethyl) ester",CCOP(=O)(OCC)SCC1=CC=CC=C1,,,,,,
5834,25835,6-Methyltridecane,CCCCCCCC(C)CCCCC,,,,,,
5835,25836,"Acetic acid, thiocyanato-, hexyl ester",CCCCCCOC(=O)CSC#N,,,,,,
5836,25837,CID 25837,CC(=O)N=C1C=C2C(=CC1=[N+](O)[O-])C3=CC=CC=C3C2=O,,,,,,
5837,25838,"3-{[4-O-(6-Deoxyhexopyranosyl)hexopyranosyl]oxy}-5,14-dihydroxy-19-oxobufa-20,22-dienolide",C[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@@H](O[C@@H]([C@H]([C@H]2O)O)O[C@H]3CC[C@@]4(C5CC[C@@]6([C@H](CC[C@@]6(C5CC[C@@]4(C3)O)O)C7=COC(=O)C=C7)C)C=O)CO)O)O)O,,,,,,
5838,25839,CID 25839,C[C@H]1C=CC=C(C(=O)N=C2C(=CNN3CCN(CC3)C)C(=C4C(=C2O)C(=C(C5=C4C(=O)[C@](O5)(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,,,,,,
5839,25840,2-Bromo-4-nitroaniline,C1=CC(=C(C=C1[N+](=O)[O-])Br)N,,,,,,
5840,25841,"2-(Diamino-1,3,5-triazin-2-yl)acetonitrile",C(C#N)C1=NC(=NC(=N1)N)N,,,,,,
5841,25842,Tributyllead chloride,CCCC[Pb](CCCC)(CCCC)Cl,,,,,,
5842,25843,"Phosphorothioic acid, O-(4-amino-3-methylphenyl) O,O-dimethyl ester",CC1=C(C=CC(=C1)OP(=S)(OC)OC)N,,,,,,
5843,25844,CID 25844,CC1=C(C=CC(=C1)OP(=O)(OC)S)N,,,,,,
5844,25845,CID 25845,CCCCCCCCC=CCCCCCCCC(=O)[O-].CCCCCCCCC=CCCCCCCCC(=O)[O-].[Cr+2],,,,,,
5845,25846,"1-Aziridinecarboxamide, N-cyclohexyl-",C1CCC(CC1)NC(=O)N2CC2,,,,,,
5846,25847,BENZO(a)PYRENE-6-CARBOXALDEHYDE,C1=CC=C2C(=C1)C3=C4C(=C2C=O)C=CC5=CC=CC(=C54)C=C3,,,,,,
5847,25848,"N,N-Dimethyl-2-((2-methyl-1-o-tolylcyclohexyl)oxy)ethylamine hydrochloride",CC1CCCCC1(C2=CC=CC=C2C)OCC[NH+](C)C.[Cl-],,,,,,
5848,25849,"N,N-dimethyl-2-[2-methyl-1-(2-methylphenyl)cyclohexyl]oxyethanamine",CC1CCCCC1(C2=CC=CC=C2C)OCCN(C)C,,,,,,
5849,25850,"N,N-Dimethyl-2-((2-ethyl-1-o-tolylcyclohexyl)oxy)ethylamine hydrochloride",CCC1CCCCC1(C2=CC=CC=C2C)OCC[NH+](C)C.[Cl-],,,,,,
5850,25851,"2-[2-ethyl-1-(2-methylphenyl)cyclohexyl]oxy-N,N-dimethylethanamine",CCC1CCCCC1(C2=CC=CC=C2C)OCCN(C)C,,,,,,
5851,25852,"Ethylamine, N,N-dimethyl-2-((2-ethyl-1-(o-ethylphenyl)cyclohexyl)oxy)-, hydrochloride",CCC1CCCCC1(C2=CC=CC=C2CC)OCC[NH+](C)C.[Cl-],,,,,,
5852,25853,"2-[2-ethyl-1-(2-ethylphenyl)cyclohexyl]oxy-N,N-dimethylethanamine",CCC1CCCCC1(C2=CC=CC=C2CC)OCCN(C)C,,,,,,
5853,25854,"ETHYLAMINE, 2-((1-o-CUMENYL-2-METHYLCYCLOHEXYL)OXY)-N,N-DIMETHYL-, HYDROCHLORIDE",CC1CCCCC1(C2=CC=CC=C2C(C)C)OCC[NH+](C)C.[Cl-],,,,,,
5854,25855,"N,N-dimethyl-2-[2-methyl-1-(2-propan-2-ylphenyl)cyclohexyl]oxyethanamine",CC1CCCCC1(C2=CC=CC=C2C(C)C)OCCN(C)C,,,,,,
5855,25856,"ETHYLAMINE, 2-((1-o-CUMENYL-2-ETHYLCYCLOHEXYL)OXY)-N,N-DIMETHYL-, HYDROCHLORIDE",CCC1CCCCC1(C2=CC=CC=C2C(C)C)OCC[NH+](C)C.[Cl-],,,,,,
5856,25857,"2-[2-ethyl-1-(2-propan-2-ylphenyl)cyclohexyl]oxy-N,N-dimethylethanamine",CCC1CCCCC1(C2=CC=CC=C2C(C)C)OCCN(C)C,,,,,,
5857,25858,"Ethylamine, 2-((1-o-cumenyl-2-isopropylcyclohexyl)oxy)-N,N-dimethyl-, hydrochloride",CC(C)C1CCCCC1(C2=CC=CC=C2C(C)C)OCC[NH+](C)C.[Cl-],,,,,,
5858,25859,"N,N-dimethyl-2-[2-propan-2-yl-1-(2-propan-2-ylphenyl)cyclohexyl]oxyethanamine",CC(C)C1CCCCC1(C2=CC=CC=C2C(C)C)OCCN(C)C,,,,,,
5859,25860,"Methacrylic acid, carbomethoxymethyl ester",CC(=C)C(=O)OCOCC=O,,,,,,
5860,25861,"4,2'-Dihydroxychalcone",C1=CC=C(C(=C1)C(=O)C=CC2=CC=C(C=C2)O)O,,,,,,
5861,25862,"2',4',3-Trihydroxy-4-methoxychalcone",COC1=C(C=C(C=C1)C=CC(=O)C2=C(C=C(C=C2)O)O)O,,,,,,
5862,25863,Procion blue MX-R,C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3NC4=CC(=C(C=C4)S(=O)(=O)O)NC5=NC(=NC(=N5)Cl)Cl)S(=O)(=O)O)N,,,,,,
5863,25864,N-Cyclopropyl-1-methylhexylamine,CCCCCC(C)NC1CC1,,,,,,
5864,25865,"Hexylamine, N-cyclopropyl-N,1-dimethyl-",CCCCCC(C)N(C)C1CC1,,,,,,
5865,25866,N-Cyclopropylbenzylamine,C1CC1NCC2=CC=CC=C2,,,,,,
5866,25867,"N,N'-Bis(dimethylaminomethylene)hexamethylenediamine",CN(C)C=NCCCCCCN=CN(C)C,,,,,,
5867,25868,4-Amino-1-butanol,C(CCO)CN,,,,,,
5868,25869,2-Amino-3-hexanol,CCCC(C(C)N)O,,,,,,
5869,25870,"1-NAPHTHALENEACETONITRILE, alpha,alpha-BIS(3-(DIMETHYLAMINO)PROPYL)-",CN(C)CCCC(CCCN(C)C)(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
5870,25871,"1-NAPHTHALENEACETONITRILE, alpha,alpha-BIS(3-(DIETHYLAMINO)PROPYL)-",CCN(CC)CCCC(CCCN(CC)CC)(C#N)C1=CC=CC2=CC=CC=C21,,,,,,
5871,25872,"1-Pyrrolidinevaleronitrile, alpha-1-naphthyl-",C1CCN(C1)CCCC(C#N)C2=CC=CC3=CC=CC=C32,,,,,,
5872,25873,alpha-(3-Piperidinopropyl)-1-naphthaleneacetonitrile,C1CCN(CC1)CCCC(C#N)C2=CC=CC3=CC=CC=C32,,,,,,
5873,25874,2-Naphthalen-1-yl-5-piperidin-1-yl-2-propan-2-ylpentanenitrile,CC(C)C(CCCN1CCCCC1)(C#N)C2=CC=CC3=CC=CC=C32,,,,,,
5874,25875,5-Morpholin-4-yl-2-naphthalen-1-ylpentanenitrile,C1COCCN1CCCC(C#N)C2=CC=CC3=CC=CC=C32,,,,,,
5875,25876,alpha-Isopropyl-alpha-(3-morpholinopropyl)-1-naphthaleneacetonitrile,CC(C)C(CCCN1CCOCC1)(C#N)C2=CC=CC3=CC=CC=C32,,,,,,
5876,25877,"2-(Diethylamino)-2',6'-dimethylthioacetanilide hydrochloride",CC[NH+](CC)CC(=O)NC1=C(C=CC=C1SC)SC.[Cl-],,,,,,
5877,25878,"N-[2,6-bis(methylsulfanyl)phenyl]-2-(diethylamino)acetamide",CCN(CC)CC(=O)NC1=C(C=CC=C1SC)SC,,,,,,
5878,25879,Beryllium dihydroxide,[Be+2].[OH-].[OH-],,,,,,
5879,25880,"14-Hydroxy-3-oxocarda-1,4,20(22)-trienolide",C[C@]12CCC3C([C@]1(CCC2C4=CC(=O)OC4)O)CCC5=CC(=O)C=C[C@]35C,,,,,,
5880,25881,"2-(Cyclobutylamino)-3',4'-dihydroxy-acetophenone hydrochloride",C1CC(C1)[NH2+]CC(=O)C2=CC(=C(C=C2)O)O.[Cl-],,,,,,
5881,25882,"2-(Cyclobutylamino)-1-(3,4-dihydroxyphenyl)ethanone",C1CC(C1)NCC(=O)C2=CC(=C(C=C2)O)O,,,,,,
5882,25883,"1-Octadecanamine, N-(1-methylethyl)-",CCCCCCCCCCCCCCCCCCNC(C)C,,,,,,
5883,25884,"GUANIDINE, (p-METHYLBENZYL)-",CC1=CC=C(C=C1)CN=C(N)N,,,,,,
5884,25885,CID 25885,COC1=C(C=C(C=C1)CC[NH2+]C(=N)[NH3+])OC.[O-]S(=O)(=O)[O-],,,,,,
5885,25886,"2-[2-(3,4-Dimethoxyphenyl)ethyl]guanidine",COC1=C(C=C(C=C1)CCN=C(N)N)OC,,,,,,
5886,25887,"3,4,5-Trimethoxyphenylacetonitrile",COC1=CC(=CC(=C1OC)OC)CC#N,,,,,,
5887,25888,"2-Imidazoline, 2-(5,6,7,8-tetrahydro-1-naphthyl)-",C1CCC2=C(C1)C=CC=C2C3=NCCN3,,,,,,
5888,25889,"1,3,5-Triazine-2,4-diamine, 1-(3,4-dichlorophenyl)-1,6-dihydro-6,6-dimethyl-",CC1(N=C(N=C(N1C2=CC(=C(C=C2)Cl)Cl)N)N)C,,,,,,
5889,25890,3-Hydroxybenzo(a)pyrene,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C(C=CC(=C54)C=C3)O,,,,,,
5890,25891,1-Hydroxybenzo(a)pyrene,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=C(C=C5)O)C=C3,,,,,,
5891,25892,"Benzo(a)pyrene-7,8-dihydrodiol",C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C=CC(C5O)O)C=C2,,,,,"['7,8-Dihydrobenzo[a]pyrene-7,8-diol has known human metabolites that include Benzo(a)pyrene diol epoxide.']",
5892,25893,8-Hydroxybenzo[a]pyrene,C1=CC2=C3C(=C1)C=CC4=C3C(=CC5=C4C=CC(=C5)O)C=C2,,,,,,
5893,25894,12-Methylbenz(a)anthracene-7-carboxaldehyde,CC1=C2C(=C(C3=CC=CC=C13)C=O)C=CC4=CC=CC=C42,,,,,,
5894,25895,"2,10-Dimethylacridinium methyl sulfate",CC1=CC2=CC3=CC=CC=C3[N+](=C2C=C1)C.COS(=O)(=O)[O-],,,,,,
5895,25896,"2,10-Dimethylacridin-10-ium",CC1=CC2=CC3=CC=CC=C3[N+](=C2C=C1)C,,,,,,
5896,25897,4-Amino-10-methylacridinium chloride,C[N+]1=C2C(=CC3=CC=CC=C31)C=CC=C2N.[Cl-],,,,,,
5897,25898,10-Methylacridin-10-ium-4-amine,C[N+]1=C2C(=CC3=CC=CC=C31)C=CC=C2N,,,,,,
5898,25899,Propyl 5-(dimethylamino)-2-naphthalen-1-yl-2-propan-2-ylpentanoate,CCCOC(=O)C(CCCN(C)C)(C1=CC=CC2=CC=CC=C21)C(C)C,,,,,,
5899,25900,Propan-2-yl 5-(dimethylamino)-2-naphthalen-1-yl-2-propan-2-ylpentanoate,CC(C)C(CCCN(C)C)(C1=CC=CC2=CC=CC=C21)C(=O)OC(C)C,,,,,,
5900,25901,"1,2-Dichloro-3-(3-iodoprop-2-ynoxy)benzene",C1=CC(=C(C(=C1)Cl)Cl)OCC#CI,,,,,,
5901,25902,1-Methylbenzotriazole,CN1C2=CC=CC=C2N=N1,,,,,,
5902,25903,2-((1-(4-Chlorophenyl)cyclohexyl)oxy)ethyl(diethyl)ammonium chloride,CC[NH+](CC)CCOC1(CCCCC1)C2=CC=C(C=C2)Cl.[Cl-],,,,,,
5903,25904,Clofenciclan,CCN(CC)CCOC1(CCCCC1)C2=CC=C(C=C2)Cl,,,,,,
5904,25905,1-(Phenylthio)anthraquinone,C1=CC=C(C=C1)SC2=CC=CC3=C2C(=O)C4=CC=CC=C4C3=O,,,,,,
5905,25906,"Anthraquinone, 2-(phenylthio)-",C1=CC=C(C=C1)SC2=CC3=C(C=C2)C(=O)C4=CC=CC=C4C3=O,,,,,,
5906,25907,Melarsonyl potassium,C1=CC(=CC=C1NC2=NC(=NC(=N2)N)N)[As]3SC(C(S3)C(=O)[O-])C(=O)[O-].[K+].[K+],,,,,,
5907,25908,Melarsonyl,C1=CC(=CC=C1NC2=NC(=NC(=N2)N)N)[As]3SC(C(S3)C(=O)O)C(=O)O,,,,,,
5908,25909,CID 25909,CC(C)(C[SnH](CC(C)(C)C1=CC=CC=C1)CC(C)(C)C2=CC=CC=C2)C3=CC=CC=C3.CC(C)(C[SnH](CC(C)(C)C1=CC=CC=C1)CC(C)(C)C2=CC=CC=C2)C3=CC=CC=C3.O,,,,,,
5909,25910,Tris(2-methyl-2-phenylpropyl)stannane,CC(C)(C[SnH](CC(C)(C)C1=CC=CC=C1)CC(C)(C)C2=CC=CC=C2)C3=CC=CC=C3,,,,,,
5910,25911,Synepirin 500,CCCCC(CC)CN1C(=O)C2C(C1=O)C3(CCC2(C=C3)C)C(C)C,,,,,,
5911,25912,Chlorbromuron,CN(C(=O)NC1=CC(=C(C=C1)Br)Cl)OC,,,,"['WHEN ... ADMIN ORALLY TO RATS /(14)C-LABELED/, IT WAS OBSERVED THAT TOTAL RADIOACTIVITY WAS RAPIDLY & EFFICIENTLY ELIM IN URINE & FECES. ... 90% OR MORE OF RADIOACTIVITY APPLIED WAS ACCOUNTED FOR IN EXCRETA WITHIN 72 HR AFTER ADMIN.', 'Dermal absorption is not significant.']","['WHEN ... (14)C-CHLORBROMURON ... /WAS/ ADMIN TO RATS, NO MORE THAN 0.1-2% OF RADIOACTIVITY APPLIED WAS ACCOUNTED FOR BY CO2 IN EXPIRED AIR ... NEITHER THE UNCHANGED HERBICIDES NOR THEIR METABOLITES HAVE BEEN DECARBOXYLATED TO ANY MAJOR EXTENT IN THESE ANIMALS. ... NO SIGNIFICANT METABOLITES OF ANILINE ... /OBSERVED IN/ EXCRETA OR TISSUES ...', 'THE RATE OF ABSORPTION, TRANSLOCATION, & SUBSEQUENT METABOLISM OF CHLORBROMURON DIFFERS WITH PLANT SPECIES THUS AFFECTING THE END METABOLITES OBSERVED.', 'CHLORBROMURON HAS BEEN SHOWN TO UNDERGO 3-STEP DEGRADATION PROCESS IN PLANTS. FIRST 2 STEPS ARE DEMETHYLATION TO A MONOMETHYL THEN TO A DEMETHYL INTERMEDIATE. THIRD STEP IS DEAMINATIVE-DECARBOXYLATION THAT PRODUCES ANILINE MOLECULE.', 'Ring hydroxylation of /chlorbromuron/ in animal tissues /has been/ described.']",
5912,25913,1-Pentadecene,CCCCCCCCCCCCCC=C,,,,,,
5913,25914,N-Ethyl-n-butylamine,CCCCNCC,,,,,,
5914,25915,2-Ethyl-5-methylpyrazine,CCC1=NC=C(N=C1)C,,,,,,
5915,25916,"3-Ethyl-2,5-dimethylpyrazine",CCC1=NC(=CN=C1C)C,,,,,,
5916,25917,Isopropyl cyanoacetate,CC(C)OC(=O)CC#N,,,,,,
5917,25918,Isobutyl cyanoacetate,CC(C)COC(=O)CC#N,,,,,,
5918,25919,Allyl cyanoacetate,C=CCOC(=O)CC#N,,,,,,
5919,25920,Hexyl cyanoacetate,CCCCCCOC(=O)CC#N,,,,,,
5920,25921,1-Dimethylamino-4-isopropyl-4-(1-naphthyl)-5-iminooctane,CCCC(=N)C(CCCN(C)C)(C1=CC=CC2=CC=CC=C21)C(C)C,,,,,,
5921,25922,2-(p-Propoxyphenyl)acetohydroxamic acid,CCCOC1=CC=C(C=C1)CC(=O)NO,,,,,,
5922,25923,3-Isopropylcyclobutanecarboxylic acid,CC(C)C1CC(C1)C(=O)O,,,,,,
5923,25924,"N,N-Dipentyl-4-pentyloxy-1-naphthamidine hydrochloride",CCCCC[NH+](CCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCCCCC.[Cl-],,,,,,
5924,25925,"4-pentoxy-N,N-dipentylnaphthalene-1-carboximidamide",CCCCCN(CCCCC)C(=N)C1=CC=C(C2=CC=CC=C21)OCCCCC,,,,,,
5925,25926,"ACRIDINE, 9-(p-DIMETHYLAMINOANILINO)-",CN(C)C1=CC=C(C=C1)NC2=C3C=CC=CC3=NC4=CC=CC=C42,,,,,,
5926,25927,"Indole, 3-(2-(dimethylamino)ethyl)-1-methyl-",CN1C=C(C2=CC=CC=C21)CCN(C)C,,,,,,
